patient_text,eligibility_text,title,label
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically proven unifocal or multifocal, supratentorial, pure or mixed anaplastic
             oligodendroglioma

               -  Prior suspected or proven low-grade glioma allowed if current histologic proof of
                  pure or mixed anaplastic oligodendroglioma

          -  Tumor must contain an unequivocal (at least 25%) oligodendroglial element and have 2
             or more anaplastic features, 1 of which must be frequent mitoses or endothelial
             proliferation

               -  For mixed tumors, the non-oligodendroglial element must be astrocytic and the
                  oligodendroglial or astroglial component may be anaplastic

          -  No evidence of spinal drop metastasis or spread to noncontiguous meninges

               -  MRI of spine not required for asymptomatic patients and patients not excluded
                  based on pathologic evidence of local meningeal infiltration by underlying tumor

          -  No tumor that is predominantly located in the posterior fossa (i.e., brainstem or
             cerebellum)

          -  No spinal cord tumors

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Platelet count at least 150,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2 times normal

          -  Serum glutamate oxaloacetate transaminase (SGOT) no greater than 2 times normal

          -  Alkaline phosphatase no greater than 2 times normal

        Renal:

          -  Creatinine no greater than 1.5 times normal

        Pulmonary:

          -  No chronic lung disease unless diffusion capacity of lung for carbon monoxide (DLCO)
             is at least 60% predicted

        Other:

          -  No active infection

          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or
             carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No concurrent steroids as antiemetics

          -  Concurrent steroids allowed to control central nervous system (CNS) symptoms due to
             tumor-associated or radiotherapy-associated cerebral edema

        Radiotherapy:

          -  No prior radiotherapy to brain or head/neck

        Surgery:

          -  Prior surgery allowed",Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed anaplastic astrocytoma Standard maximum
        resection or stereotactic biopsy required within 4 weeks prior to therapy

        PATIENT CHARACTERISTICS: Age: Over 16 Performance status: ECOG/ZUBROD/WHO 0-2 Life
        expectancy: At least 8 weeks Hematopoietic: WBC greater than 4,000 Platelets greater than
        100,000 Hematocrit greater than 30% Hepatic: Bilirubin less than 2 mg/dl Renal: Creatinine
        less than 1.5 mg/dl Creatinine clearance greater than 70 ml/min BUN less than 40 mg/dl
        Other: No major medical illness

        PRIOR CONCURRENT THERAPY: No anticancer drugs between surgery and protocol treatment No
        steroids after 10 days following surgery (may be resumed occasionally during radiotherapy)",Radiation Therapy in Treating Patients With Brain Cancer,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed supratentorial * grade I/II glioma,
        including: Diffuse fibrillary astrocytoma No pilocytic astrocytoma No mixed tumor with
        ependymoma elements * Supratentorial sites include: Frontal, temporal, parietal, or
        occipital lobes Thalamus, basal ganglia, or midbrain Lateral or third ventricles Pons,
        medulla, or optic chiasm tumors allowed only if secondary to eligible tumor More than 1
        separate tumor allowed Diagnosis based on surgical biopsy or subtotal resection Measurable
        or evaluable disease on T2-weighted MRI required

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC
        greater than 3,500/mm3 Platelet count greater than 130,000/mm3 Hemoglobin greater than 9
        g/dL Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) AST less than 2 times
        ULN Alkaline phosphatase less than 2 times ULN Renal: Creatinine less than 1.5 times ULN
        Other: No active or uncontrolled infection No second malignancy within 3 years except:
        Nonmelanomatous skin cancer In situ cervical cancer No pregnant or nursing women Negative
        pregnancy test required within 7 days prior to entry Effective contraception required of
        fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: At least 1 week since prior steroids OR Stable steroid dose
        for at least 1 week prior to study Radiotherapy: No prior cranial or head and neck
        irradiation Surgery: See Disease Characteristics",Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma,0
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Biopsy proven glioblastoma multiforme or anaplastic astrocytoma
        Central pathologic review at Dartmouth-Hitchcock Medical Center, including assay for tumor
        p53 expression No anaplastic oligodendroglioma No mixed oligodendroastrocytoma Recurrent or
        progressive disease following radiotherapy documented by CT or MRI within 2 weeks of entry

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100%
        Hematopoietic: WBC at least 3,000 ANC at least 1,500 Platelets at least 100,000 Hepatic:
        Bilirubin no greater than 1.0 mg/dL AST/ALT no greater than 2.5 times normal Renal:
        Creatinine no greater than 1.5 mg/dL Other: No documented sensitivity to E. coli-derived
        products No major medical or psychiatric illness that would interfere with therapy or
        compliance with scheduled follow-up No pregnant or nursing women Adequate contraception
        required of fertile patients

        PRIOR CONCURRENT THERAPY: No prior taxanes or topoisomerase I inhibitors At least 4 weeks
        since chemotherapy (6 weeks since nitrosoureas) At least 4 weeks since radiotherapy",Combination Chemotherapy for Patients With Brain Cancer,2
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignancy expressing GD2, including, but not limited to:

               -  Medulloblastoma/primitive neuroectodermal tumor of the CNS

               -  Malignant glioma

               -  Neuroblastoma

               -  Retinoblastoma

               -  Ependymoma

               -  Sarcoma

               -  Melanoma

               -  Small cell lung carcinoma

               -  Other tumor types must have GD2 expression confirmed by immunohistochemical
                  staining

          -  Cerebrospinal fluid or leptomeningeal disease that is refractory to conventional
             therapy or for which no conventional therapy exists

          -  Prior measurable human anti-mouse monoclonal antibody titer allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  3 and over

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 50,000/mm^3

        Hepatic:

          -  Bilirubin less than 3 mg/dL

        Renal:

          -  Creatinine less than 2 mg/dL

          -  Blood urea nitrogen less than 30 mg/dL

        Other:

          -  May have active malignancy outside the central nervous system

          -  No obstructive hydrocephalus

          -  No CNS grade 3 or 4 toxicity as a consequence of prior treatments

          -  No life threatening infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Prior monoclonal antibody treatment allowed

        Chemotherapy:

          -  Prior chemotherapy allowed

          -  Must have recovered from all hematopoietic and neurologic side effects of prior
             chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Prior radiotherapy allowed

          -  At least 6 weeks since prior cranial or spinal irradiation

        Surgery:

          -  Not specified",Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed malignant glioma - Recurrent glioblastoma
        - Anaplastic astrocytoma - Mixed anaplastic glioma For recurrent glioblastoma: Required
        documented progression must include an increase in tumor size of at least 25% or appearance
        of new lesion For anaplastic astrocytoma or mixed anaplastic glioma: Must have measurable,
        contrast enhancing disease on postoperative CT or MRI scan No postoperative radiation or
        chemotherapy If patients have received prior brachytherapy or stereotactic radiosurgery,
        they must have confirmation of true progressive disease rather than radiation necrosis by
        PET scanning or biopsy

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count
        at least 1,800/mm3 Platelet count at least 125,000/mm3 Hemoglobin at least 9 g/dL
        (transfusion allowed) Hepatic: Bilirubin less than 1.5 mg/dL SGOT less than 2.0 times upper
        limit of normal Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than
        70 mL/min Cardiovascular: No uncontrolled arrhythmias or conduction defects No unstable or
        newly diagnosed angina pectoris No New York Heart Association class II-IV heart disease No
        congestive heart failure No major problems with edema (e.g., severe Cushing's syndrome,
        residual leg swelling from deep-vein thrombosis) No recent coronary artery disease No
        poorly controlled hypertension (diastolic greater than 110 mmHg and systolic greater than
        180 mmHg) Pulmonary: DLCO greater than 80% of expected value Other: HIV negative No major
        psychiatric illness No other prior malignancy except adequately treated basal cell or
        squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer
        from which the patient is currently in complete remission, or any other cancer from which
        the patient has been free of disease for 5 years Not pregnant or nursing Adequate
        contraception required of all fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy: No
        prior nitrosourea or temozolomide No more than 1 prior chemotherapy regimen allowed for
        patients with glioblastoma At least 6 weeks since mitomycin or procarbazine and recovered
        At least 4 weeks since other prior chemotherapy and recovered No other concurrent
        chemotherapy Endocrine therapy: If receiving steroids, must be on a stable steroid dose for
        at least 72 hours prior to study No other concurrent endocrine therapy Radiotherapy: At
        least 6 weeks since radiotherapy No greater than 10-20% of marrow irradiated in prior
        radiotherapy No other concurrent radiotherapy Surgery: Surgery allowed",Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically proven recurrent anaplastic oligodendroglioma or
        anaplastic mixed oligoastrocytoma following primary surgery and radiation therapy Tumors
        for anaplastic mixed oligoastrocytoma must contain at least 25% oligodendroglial elements
        Tumors must be clinically aggressive for patients with only 1 anaplastic feature Prior low
        grade oligodendrogliomas or oligoastrocytomas undergoing repeat biopsy following clinical
        or radiological progression are eligible Bidimensionally measurable and progressive lesions
        by CT or MRI

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not
        specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at
        least 100,000/mm3 Hepatic: Not specified Renal: Creatinine normal Other: Not pregnant or
        nursing Fertile patients must use effective contraception No prior malignancies except
        curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer No other
        serious illness or medical condition No active uncontrolled infection No history of
        neurologic or psychiatric disorder

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks
        since chemotherapy No more than 1 prior chemotherapy regimen No prior camptothecin
        derivatives Endocrine therapy: At least 2 weeks on stable steroid therapy, if necessary
        Radiotherapy: At least 2 months since prior radiotherapy No prior radiation therapy for
        recurrent disease Surgery: At least 6 weeks since prior surgery (except biopsy only) Prior
        surgery for recurrent disease allowed (including stereotactic biopsy or partial resection)
        Other: No concurrent experimental drugs or anticancer therapy",Topotecan in Treating Patients With Recurrent Brain Tumors,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed unifocal or multifocal supratentorial WHO grade II
             astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic), oligodendroglioma, or
             oligoastrocytoma

          -  Patients with neurofibromatosis are eligible

          -  No other low-grade histologies, including:

               -  Pilocytic astrocytoma

               -  Subependymal giant cell astrocytoma of tuberous sclerosis

               -  Subependymoma

               -  Pleomorphic xanthoastrocytoma

               -  Presence of a neuronal element such as ganglioglioma

               -  Dysneuroembryoplastic epithelial tumor

          -  No presence of any high-grade glioma, including:

               -  Anaplastic astrocytoma

               -  Glioblastoma multiforme

               -  Anaplastic oligodendroglioma

               -  Anaplastic oligoastrocytoma

          -  No tumors in nonsupratentorial or other locations including optic chiasm, optic
             nerve(s), pons, medulla, cerebellum, or spinal cord

          -  No evidence of spread to spinal meninges or noncontiguous cranial meninges (i.e.,
             leptomeningeal gliomatosis)

          -  No gliomatosis cerebri

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Hematopoietic:

          -  For high-risk patients:

               -  Granulocyte count at least 1,500/mm^3

               -  Platelet count normal

        Hepatic:

          -  Bilirubin no greater than 2 times normal

          -  SGOT or SGPT no greater than 4 times normal

          -  Alkaline phosphatase no greater than 2 times normal

        Renal:

          -  Creatinine no greater than 2 times normal

        Pulmonary:

          -  No chronic lung disease (unless DLCO at least 60%)

        Neurological:

          -  Neurologic function score no greater than 3

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or
             nonmelanoma skin cancer

          -  No active infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy to the head or neck (unless brain is clearly excluded, such as
             radiotherapy for localized vocal cord cancer)

        Surgery:

          -  Not specified",Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed supratentorial anaplastic
        oligodendroglioma or anaplastic oligoastrocytoma not requiring immediate radiotherapy Newly
        diagnosed, progressive, or recurrent disease Bidimensionally measurable disease At least
        1.5 cm2 by MRI

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life
        expectancy: More than 12 weeks Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet
        count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin less than 1.5
        times upper limit of normal (ULN) SGOT/SGPT less than 2.5 times ULN Alkaline phosphatase
        less than 2 times ULN Renal: BUN less than 1.5 times ULN Creatinine less than 1.5 times ULN
        Other: Neurologically stable No nonmalignant systemic disease No acute infection treated
        with intravenous antibiotics No frequent vomiting No medical condition (e.g., partial bowel
        obstruction) that would interfere with oral medication intake No other prior or concurrent
        malignancy except surgically cured carcinoma in situ of the cervix or basal cell or
        squamous cell carcinoma of the skin No AIDS-related illness HIV negative Not pregnant or
        nursing Negative pregnancy test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: No more than 1 prior biologic therapy No
        concurrent biologic therapy No concurrent growth factors (e.g., epoetin alfa) Chemotherapy:
        No more than 1 prior chemotherapy regimen No other concurrent chemotherapy Endocrine
        therapy: Must be on stable dose of steroids for at least 1 week prior to study Concurrent
        steroids allowed Radiotherapy: See Disease Characteristics No concurrent radiotherapy
        Surgery: At least 2 weeks since prior surgical resection (newly diagnosed patients must be
        enrolled within 28 days of surgery or biopsy) Recovered from prior major surgery Other: No
        other concurrent investigational drugs",Temozolomide in Treating Patients With Anaplastic Oligodendroglioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed progressive, primary, intracranial, supratentorial, low-grade
             glioma including:

               -  Astrocytoma

               -  Oligodendroglioma

               -  Mixed glioma

               -  Optic pathway glioma*

               -  Pontine glioma* NOTE: *Biopsy not required

          -  Patients with optic pathway glioma must also meet the following criteria:

               -  Progressive loss of vision as defined by doubling of octaves

               -  Visual acuity loss not explained by other causes

               -  Increase in proptosis of greater than 3 mm

               -  Increase in diameter of optic nerve of at least 2 mm on neuroimaging

               -  Increase in distribution of tumor involving optic tracts or optic radiations as
                  indicated by CT scan or MRI

        PATIENT CHARACTERISTICS:

        Age:

          -  4 and over

        Performance status:

          -  Karnofsky 70-100%

        Life expectancy:

          -  More than 12 weeks

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  SGOT and SGPT less than 2.5 times ULN

          -  Alkaline phosphatase less than 2 times ULN

        Renal:

          -  Creatinine less than 1.5 times ULN

          -  BUN less than 1.5 times ULN

        Other:

          -  Must be neurologically stable

          -  No systemic disease

          -  No acute infection requiring IV antibiotics

          -  No frequent vomiting

          -  No other medical condition that would interfere with oral medication (e.g., partial
             bowel obstruction)

          -  No other prior or concurrent malignancies except:

               -  Surgically cured carcinoma in situ of the cervix

               -  Basal or squamous cell skin cancer

          -  HIV negative

          -  No AIDS-related illness

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent biologic therapy (growth factors or epoetin alfa)

        Chemotherapy:

          -  At least 6 weeks since prior chemotherapy unless evidence of disease progression

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 6 weeks since prior radiotherapy unless evidence of disease progression

          -  No concurrent radiotherapy

        Surgery:

          -  At least 3 weeks since prior surgery unless evidence of disease progression

          -  Recovered from all prior surgery

        Other:

          -  No other concurrent investigational drugs",Temozolomide in Treating Patients With Progressive Low-Grade Glioma,0
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed incurable adult anaplastic astrocytoma

          -  Evidence of progressive or recurrent tumor by MRI scan performed within 2 weeks prior
             to study entry

          -  Must have received and failed standard therapy

          -  Tumor must be at least 5 mm

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  WBC at least 2000/mm^3

          -  Platelet count at least 50,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT and SGPT no greater than 5 times upper limit of normal

          -  No hepatic failure

        Renal:

          -  Creatinine no greater than 2.5 mg/dL

          -  No history of renal conditions that contraindicate high dosages of sodium

        Cardiovascular:

          -  No uncontrolled hypertension

          -  No history of congestive heart failure

          -  No history of other cardiovascular conditions that contraindicate high dosages of
             sodium

        Pulmonary:

          -  No serious lung disease such as severe chronic obstructive pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 4 weeks after study

          -  No active infection

          -  No other serious concurrent disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy and recovered

          -  No concurrent immunomodulating agents

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No concurrent antineoplastic agents

        Endocrine therapy:

          -  Concurrent corticosteroids allowed

        Radiotherapy:

          -  At least 8 weeks since prior radiotherapy and recovered

        Surgery:

          -  Fully recovered from any prior surgery

        Other:

          -  Prior cytodifferentiating agent allowed

          -  No prior antineoplaston therapy",Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma,2
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed low-grade astrocytoma that has progressed,
             recurred, or persisted after initial therapy, including radiotherapy

          -  Previously treated with at least 1 prior standard therapy (e.g., radiotherapy,
             chemotherapy, immunotherapy, or cytodifferentiating agent)

          -  Measurable tumor by MRI scan performed within two weeks prior to study entry

          -  Tumor must be at least 5 mm

          -  No brain stem tumors

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  More than 2 months

        Hematopoietic:

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 50,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT and SGPT no greater than 5 times upper limit of normal

          -  No hepatic failure

        Renal:

          -  Creatinine no greater than 2.5 mg/dL

          -  No renal insufficiency

          -  No history of renal conditions that contraindicate high dosages of sodium

        Cardiovascular:

          -  No uncontrolled hypertension

          -  No chronic heart failure

          -  No history of congestive heart failure

          -  No history of other cardiovascular conditions that contraindicate high dosages of
             sodium

        Pulmonary:

          -  No severe lung disease (e.g., chronic obstructive pulmonary disease)

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 4 weeks after study
             participation

          -  No other concurrent serious disease

          -  No active infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior immunotherapy and recovered

          -  No concurrent immunomodulating agents

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No concurrent antineoplastic agents

        Endocrine therapy:

          -  Concurrent corticosteroids allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 8 weeks since prior radiotherapy and recovered

        Surgery:

          -  Must recover from prior surgery

        Other:

          -  No prior antineoplastons",Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma,2
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed diagnosis of anaplastic astrocytoma

          -  Tumor subtotally resected or biopsied prior to therapy

          -  Evidence of residual tumor by MRI scan performed within two weeks prior to study entry

          -  No brain stem tumors

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  More than 2 months

        Hematopoietic:

          -  WBC at least 1,500/mm^3

          -  Platelet count at least 50,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic:

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT and SGPT no greater than 5 times upper limit of normal

          -  No hepatic failure

        Renal:

          -  Creatinine no greater than 2.5 mg/dL

          -  No renal failure

        Cardiovascular:

          -  No prior congestive heart failure

          -  No coronary artery disease

          -  No myocardial infarction within the past year

          -  No angina requiring medication

          -  No uncontrolled hypertension

        Pulmonary:

          -  No moderate to severe chronic obstructive pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 4 weeks after study
             participation

          -  No active infection

          -  No other concurrent serious disease

          -  No other prior malignancy except carcinoma in situ of the cervix or superficial
             nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy

          -  No concurrent immunomodulating agents

        Chemotherapy:

          -  No prior myelosuppressive chemotherapy

        Endocrine therapy:

          -  Concurrent corticosteroids for cerebral edema allowed

        Radiotherapy:

          -  No prior myelosuppressive radiotherapy

          -  No concurrent radiotherapy

        Surgery:

          -  See Disease Characteristics

          -  Recovered from any prior surgery

        Other:

          -  No prior cytodifferentiating agents

          -  No prior antineoplaston therapy

          -  No other concurrent antineoplastic agents",Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma,2
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically proven primary malignant gliomas including the
        following: Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic
        oligodendroglioma Anaplastic infiltrating glioma Mixed malignant gliomas Must show evidence
        of tumor recurrence or progression on at least 2 serial enhanced MRI scans Must have
        measurably enhancing residual disease on MRI or CT scan of brain

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 60-100% Life
        expectancy: Greater than 8 weeks Hematopoietic: Absolute granulocyte count at least
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGPT less than 2 times institutional
        normal Alkaline phosphatase less than 2 times institutional normal Bilirubin less than 1.5
        mg/dL Renal: BUN less than 1.5 times institutional normal OR Creatinine less than 1.5 times
        institutional normal Other: No active infection Not pregnant or nursing Fertile patients
        must use effective contraception 1 month before, during, and 1 month after study No other
        disease that will obscure toxicity or alter drug metabolism No other concurrent medical
        illness

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        procarbazine No prior isotretinoin At least 4 weeks since prior chemotherapy (6 weeks for
        nitrosoureas) and recovered Endocrine therapy: Not specified Radiotherapy: Prior
        radiotherapy allowed Surgery: Not specified Other: No concurrent tetracyclines",Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed, newly diagnosed, anaplastic astrocytoma
        No oligodendrogliomas or oligoastrocytomas

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: WBC at least 3500/mm3 Platelet count at least 130,000/mm3 Hepatic:
        Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 2
        times ULN Renal: Creatinine no greater than 0.5 mg/dL Other: Not pregnant or nursing
        Fertile patients must use effective contraception No uncontrolled infection No concurrent
        malignant disease or major medical problem except superficial skin cancers

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 5 years
        since prior chemotherapy Endocrine therapy: Concurrent corticosteroids allowed
        Radiotherapy: At least 5 years since prior radiotherapy Surgery: Not specified",Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma,2
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed anaplastic astrocytoma or anaplastic
        oligoastrocytoma in first relapse Recurrence or progression at least 6 months from initial
        diagnosis Must have received maximally feasible surgical resection and fractionated
        external beam radiotherapy Must have received no more than 1 prior systemic cytotoxic
        chemotherapy regimen for initial disease Bidimensionally measurable disease by MRI scan
        (stable dose of corticosteroids for at least 7 days prior to scan)

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3
        Platelet count at least 75,000/mm3 Hemoglobin at least 9 g/dL Hepatic: AST no greater than
        3 times upper limit of normal (ULN) Bilirubin less than 1.5 times ULN Renal: Creatinine no
        greater than 2 mg/dL OR Creatinine clearance at least 40 mL/min Other: Not pregnant or
        nursing Negative pregnancy test Fertile patients must use effective contraception during
        and for 3 months after the study No known allergy to etoposide No other acute or chronic
        medical illness or psychiatric disorder

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior epoetin alfa,
        filgrastim (G-CSF), or sargramostim (GM-CSF) and recovered No concurrent immunotherapy
        Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy (2
        weeks since vincristine; 6 weeks since nitrosoureas or mitomycin) and recovered No prior
        leflunomide (SU101) therapy No other concurrent chemotherapy Endocrine therapy: No
        concurrent hormonal therapy (except medroxyprogesterone acetate for appetite stimulation)
        Radiotherapy: See Disease Characteristics No more than 1 prior course of radiotherapy At
        least 8 weeks since prior radiotherapy and recovered No prior interstitial radiotherapy or
        implanted carmustine wafers Prior radiosensitizer(s) concurrent with radiotherapy or used
        as neoadjuvant therapy allowed No concurrent radiotherapy Surgery: See Disease
        Characteristics No more than 2 prior surgical resections At least 1 week since prior
        surgery or biopsy for anaplastic astrocytoma No concurrent surgery (including resection,
        stereotactic surgery, or interstitial implants) Other: At least 4 weeks since prior
        investigational agents No other concurrent investigational agents",Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse,0
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically proven recurrent glioblastoma or anaplastic
        astrocytoma Stereotactically accessible, enhancing mass no greater than 50 mL total volume
        by MRI No significant mass effect Recent craniotomy allowed No anaplastic oligodendroglioma
        No tumors of the brainstem, cerebellum, or both hemispheres No diffuse subependymal or CSF
        disease If on stable or increasing dose of steroid, must have evidence of increasing
        contrast enhancement by MRI or CT scan Prior external beam radiotherapy required

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: Absolute neutrophil count greater than 1500/mm3
        Platelet count greater than 100,000/mm3 Hemoglobin greater than 9.5 g/dL Hepatic: Bilirubin
        less than 2 mg/dL AST and ALT less than 2 times upper limit of normal (ULN) PT/PTT no
        greater than ULN Renal: Creatinine less than 2 mg/dL Other: Not pregnant Negative pregnancy
        test Fertile patients must use effective contraception No systemic diseases to cause
        unacceptable anesthetic/operative risk No active infection requiring treatment No
        unexplained febrile illness

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent blood or platelet transfusions
        Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy: See Disease
        Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior
        radiotherapy Surgery: See Disease Characteristics Medically able to undergo surgery Other:
        No other concurrent investigational agents",IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma,0
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed unresectable glioblastoma multiforme (GBM),
             recurrent GBM, or recurrent anaplastic astrocytoma (AA)

          -  MRI scan documenting gadolinium enhanced tumor volume of at least 5 cm3, but no
             greater than 60 cm^3

               -  Recurrent GBM and AA must be documented by MRI after the most recent treatment
                  and before any planned surgical debulking

          -  At least 5 days since prior surgical debulking

          -  No planned resection of newly diagnosed GBM before or during study

          -  No bilateral noncontiguous gadolinium enhancing tumors

          -  No satellite lesions greater than 1.5 cm from anticipated location of interstitial
             catheter tip

          -  No more than 2 satellite lesions

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Platelet count at least 100,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  WBC at least 3,000/mm^3

        Hepatic:

          -  Hepatitis B surface antigen negative

          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)

          -  SGOT and SGPT no greater than 3 times ULN

          -  Alkaline phosphatase no greater than 3 times ULN

          -  Lactic dehydrogenase no greater than 3 times ULN

          -  Prothrombin time no greater than 1.5 times ULN

        Renal:

          -  Creatinine clearance at least 50 mL/min

        Cardiovascular:

          -  No significant unstable cardiovascular disease

          -  No New York Heart Association class III/IV heart disease

          -  No evidence of myocardial infarction within the past 3 months

        Other:

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Human antichimeric antibody (HACA) titer no greater than 48 ng/mL

          -  No anatomical or physiological considerations that would preclude study participation

          -  No active autoimmune disease, active infection, or traumatic injury requiring
             treatment

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 4 weeks since prior intravenous chemotherapy or Gliadel wafers

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 8 weeks since prior external beam or gamma knife radiotherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  At least 30 days since prior investigational treatment",Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed brain tumors

               -  Grade III or IV disease:

                    -  Glioblastoma multiforme

                    -  Anaplastic astrocytoma

                    -  Anaplastic oligodendroglioma

                    -  Anaplastic pleomorphic xanthoastrocytoma

                    -  Anaplastic or malignant oligoastrocytoma

                    -  Gemistocytic astrocytoma

                    -  Malignant glioma

               -  Grade II glial tumors in unfavorable locations (i.e., imaging evidence of
                  gliomatosis cerebri and/or bithalamic involvement)

               -  Diffuse pontine gliomas with greater than 2/3 involvement of the pon

        PATIENT CHARACTERISTICS:

        Age:

          -  3 to 21

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 2,500/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin greater than 8.0 g/dL

        Hepatic:

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT/SGPT less than 5 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Other:

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Prior corticosteroids allowed

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  No more than 28 days since prior definitive surgery for brain tumor

        Other:

          -  Concurrent anticonvulsants allowed",Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically proven glioblastoma multiforme, anaplastic
        astrocytoma, or anaplastic mixed glioma Progressive or recurrent disease following
        radiotherapy (54-64 Gy) and/or chemotherapy Tumor recurrence must have anatomic
        characteristics that allow safe and reasonable surgical intervention Measurable disease by
        serial MR or CT imaging No Li-Fraumeni syndrome or known germline defect in p53 gene No
        radiographically or surgically proven gliomatosis cerebri No tumors requiring immediate
        excision due to impending neurologic decline

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count
        at least 1,000/mm3 Platelet count at least 100,000/mm3 Hematocrit at least 25% Hepatic:
        Bilirubin less than 1.5 mg/dL SGOT and SGPT less than 2.5 times upper limit of normal (ULN)
        PT or PTT no greater than ULN Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular:
        No uncontrolled hypertension No uncontrolled or unstable angina pectoris No uncontrolled
        cardiac dysrhythmia Other: Not pregnant or nursing Negative pregnancy test Fertile patients
        must use effective contraception during and for 6 months after study HIV negative No other
        active malignancy within the past 5 years except curatively treated basal or squamous cell
        skin cancer or carcinoma in situ of the cervix No uncontrolled or serious concurrent
        infection or other serious medical illness that would preclude study therapy No viral
        syndrome diagnosed within 2 weeks prior to study No other underlying medical condition that
        would increase risk of study or obscure interpretation of adverse results No active
        adenoviral infection

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy
        and recovered No concurrent biologic therapy Chemotherapy: See Disease Characteristics No
        more than 1 prior chemotherapy regimen At least 3 weeks since prior chemotherapy (6 weeks
        for nitrosoureas) and recovered No prior interstitial chemotherapy such as Gliadel wafer
        implantation for present brain tumor No concurrent chemotherapy Endocrine therapy: At least
        3 weeks since prior hormonal therapy and recovered No concurrent hormonal therapy
        Radiotherapy: See Disease Characteristics No prior brachytherapy for present brain tumor At
        least 3 months since other prior radiotherapy and recovered No concurrent radiotherapy
        Surgery: See Disease Characteristics No prior radiosurgery for present brain tumor At least
        3 weeks since other prior oncologic surgery No other concurrent oncologic surgery Other: No
        other concurrent investigational drugs",Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically proven recurrent or progressive malignant glioma of one of the
             following types:

               -  Anaplastic oligodendroglioma or oligoastrocytoma

               -  Anaplastic astrocytoma

               -  Glioblastoma multiforme (stratum closed to accrual 11/30/01)

          -  Patients who have failed radiotherapy are eligible

          -  Measurable disease by CT scan or MRI

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 70-100%

        Life expectancy:

          -  At least 12 weeks

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin greater than 10 g/dL

        Hepatic:

          -  SGOT or SGPT less than 3 times upper limit of normal (ULN)

          -  Alkaline phosphatase less than 2 times ULN (if greater than 2 times ULN then a gamma
             glutamyl transferase test must be performed)

        Renal:

          -  BUN less than 1.5 times ULN

          -  Creatinine less than 1.5 times ULN

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception

          -  No other serious concurrent infection or other medical illness that would preclude
             study entry

          -  No frequent vomiting or partial bowel obstruction

          -  HIV negative

          -  No AIDS-related illness

          -  No other concurrent malignancy except carcinoma in situ of the cervix or basal cell
             skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent epoetin alfa

        Chemotherapy:

          -  At least 6 weeks since other prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 3 months since prior radiotherapy (exceptions allowed for
             recurrent/progressive disease at discretion of primary investigator)

        Surgery:

          -  Recovered from prior surgery

        Other:

          -  No other concurrent investigational agents

          -  Concurrent anticonvulsant therapy allowed",Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically proven unifocal anaplastic astrocytoma or mixed gliomas, including the
             following:

               -  Anaplastic astrocytoma

               -  Mixed oligodendroglial/astrocytic tumors

                    -  Oligodendroglial component must be no greater than 25%

          -  No vascular proliferation and necrosis

          -  Increased cellularity, pleomorphism, and nuclear atypia allowed

          -  No tumor predominantly located in the posterior fossa (i.e., brainstem or cerebellum)

          -  Patients with prior biopsy proven low grade astrocytoma who now have anaplastic
             astrocytoma and have had no prior radiotherapy or chemotherapy also eligible

          -  Study therapy must begin within 6 weeks of diagnosis

          -  No spinal cord tumors, spinal drop metastases, or metastases to noncontiguous meninges

               -  Pathologic evidence of local meningeal infiltration by underlying tumor allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 1 year

        Hematopoietic:

          -  Hemoglobin at least 10 g/dL

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 150,000/mm^3

        Hepatic:

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) less than 2 times ULN

          -  Alkaline phosphatase less than 2 times ULN

        Renal:

          -  Blood urea nitrogen no greater than 25 mg/dL

          -  Creatinine less than 1.5 times normal

        Pulmonary:

          -  No pre-existing lung disease that, in the investigator's opinion, would preclude
             administration of carmustine or lomustine or completion of therapy

        Other:

          -  No other major medical illness or psychiatric impairment that would preclude study
             compliance

          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or
             carcinoma in situ of the cervix

          -  No known hypersensitivity to 1 of the components of carmustine, lomustine,
             temozolomide, dacarbazine, or any other nitrosourea

          -  No active infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy

        Chemotherapy:

          -  See Disease Characteristics

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to brain or head and neck

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent anticancer treatment for anaplastic astrocytoma until a recurrence
             is detected",Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Biopsy and x-ray confirmed primary osteopetrosis

          -  Presence of anemia and/or cranial nerve compression

        --Prior/Concurrent Therapy--

          -  Biologic therapy: No prior/concurrent bone marrow transplantation No prior interferon
             gamma No other investigational biologic agents

          -  Chemotherapy: No prior/concurrent chemotherapeutic agents for bone marrow
             transplantation

          -  Endocrine therapy: Prior/concurrent corticosteroid as supportive therapy allowed

          -  Radiotherapy: Not specified

          -  Surgery: At least 5 days since major surgery

          -  Other: Prior/concurrent calcitriol as supportive therapy allowed Prior/concurrent
             transfusion as supportive therapy allowed Prior/concurrent dietary therapy allowed

        --Patient Characteristics--

          -  Age: 2 months to 10 years

          -  Performance status: Not specified

          -  Life expectancy: At least 6 months

          -  Hematopoietic: Not specified

          -  Hepatic: Bilirubin less than 2 mg/dL

          -  Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 50 mL/min

          -  Pulmonary: No uncorrected airway obstruction

          -  Other: No active infection requiring intravenous antibiotics No known seizure disorder
             not related to hypocalcemia No uncorrected hydrocephalus No MRI evidence of cerebral
             atrophy Must maintain or gain body weight No sleep apnea No thrombocytopenia No
             massive splenomegaly","Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis",1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically proven supratentorial malignant primary glioma, including:

               -  Glioblastoma multiforme

               -  Anaplastic astrocytoma

               -  Anaplastic oligodendroglioma

               -  Anaplastic mixed oligoastrocytoma

               -  Malignant astrocytoma not otherwise specified

               -  Benign or malignant meningiomas, including brain and spinal meningiomas

          -  Patients with meningiomas are excluded from phase II portion of study

          -  Must have shown unequivocal evidence of tumor recurrence or progression by CT scan or
             MRI

          -  Must have failed prior radiotherapy

          -  Must have prestudy contrast MRI or contrast CT scan of brain on stable steroid dose
             within the past 14 days

               -  Must be on stable (unchanged) dose of steroids for at least 5 days before scans

          -  Phase II:

               -  Must have completed radiotherapy at least 2 months prior to enrollment

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  More than 8 weeks

        Hematopoietic:

          -  WBC at least 2,300/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 8 g/dL (transfusion allowed)

        Hepatic:

          -  SGOT less than 2.5 times upper limit of normal

          -  Bilirubin normal

          -  No significant active hepatic disease

        Renal:

          -  Creatinine less than 1.5 mg/dL OR

          -  Creatinine clearance at least 60 mL/min

          -  No significant active renal disease

        Cardiovascular:

          -  No uncompensated coronary artery disease on ECG or physical examination

          -  No history of myocardial infarction or severe/unstable angina within the past 6 months

          -  No deep venous or arterial thrombosis within the past 3 months

        Pulmonary:

          -  No pulmonary embolism within the past 3 months

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 2 months after study

          -  No other serious concurrent illness

          -  No significant active psychiatric disease

          -  No diabetes mellitus with severe peripheral vascular disease

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No serious active infection

          -  No other concurrent disease that would obscure toxic effects or dangerously alter drug
             metabolism

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 3 weeks since prior biologic therapy (e.g., interferon) and recovered

          -  No concurrent immunotherapy

        Chemotherapy:

          -  Phase I:

               -  No more than 2 prior chemotherapy regimens for recurrent disease

          -  Phase II:

               -  No more than 1 prior chemotherapy regimen for recurrent disease

          -  At least 2 weeks since prior vincristine

          -  At least 6 weeks since prior nitrosoureas

          -  At least 3 weeks since prior procarbazine

          -  Recovered from prior chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  See Disease Characteristics

          -  At least 3 weeks since prior endocrine therapy (e.g., tamoxifen) and recovered

        Radiotherapy:

          -  See Disease Characteristics

          -  No concurrent radiotherapy

        Surgery:

          -  Recovered from prior surgery

          -  Recent prior resection of recurrent or progressive tumor allowed

        Other:

          -  No other concurrent investigational agents",SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed recurrent or progressive glioblastoma
        multiforme, anaplastic astrocytoma, or gliosarcoma Resistant to nitrosourea (defined as
        progressive or recurrent disease within 8 weeks of receiving nitrosourea) Measurable
        residual disease by MRI or CT scan

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3
        Platelet count at least 100,000/mm3 Hemoglobin greater than 10 g/dL Hepatic: Bilirubin
        normal SGOT no greater than 2.5 times upper limit of normal Renal: Creatinine no greater
        than 1.5 mg/dL BUN no greater than 25 mg/dL Pulmonary: DLCO greater than 80% predicted
        Other: Not pregnant or nursing Fertile patients must use effective contraception during and
        for 2 months after study

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics At least 4 weeks since prior chemotherapy At least 6 weeks since prior
        nitrosourea, procarbazine, or mitomycin and recovered No prior nitrosourea greater than
        1,200 mg/m2 Endocrine therapy: Concurrent stable dose corticosteroids allowed if on for at
        least two weeks prior to study Radiotherapy: At least 4 weeks since prior radiotherapy
        Surgery: Not specified",Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant glioma

               -  Glioblastoma

               -  Gliosarcoma

               -  High-grade glioma

               -  Anaplastic astrocytoma

               -  Anaplastic mixed oligoastrocytoma

               -  Anaplastic oligodendroglioma

               -  Anaplastic ependymoma

          -  Must have completed radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  More than 3 months

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  SGOT/SGPT less than 3 times ULN

          -  Alkaline phosphatase less than 2 times ULN

        Renal:

          -  BUN less than 1.5 times ULN

          -  Creatinine less than 1.5 times ULN

        Pulmonary:

          -  Pulmonary function test with diffusion greater than 50 OR

          -  Clearance by the pulmonary service

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No AIDS-related illness

          -  No nonmalignant systemic disease that would preclude study

          -  No acute infection requiring IV antibiotics

          -  No psychiatric condition that would preclude study compliance

          -  No frequent vomiting or medical condition that would interfere with oral medication
             intake (e.g., partial bowel obstruction)

          -  No other prior or concurrent malignancy except surgically cured carcinoma in situ of
             the cervix or basal cell or squamous cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy

          -  No prior biologic therapy

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 2 weeks since prior radiotherapy

        Surgery:

          -  Not specified",Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma,2
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","Inclusion Criteria:

          -  Histologically confirmed supratentorial grade IV astrocytoma

               -  Glioblastoma multiforme

          -  Subtotal resection or biopsy with measurable and contrast-enhancing disease on the
             postoperative, pretreatment MRI/CT scan

          -  Performance status - Karnofsky 60-100%

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 9.0 g/dL

          -  Bilirubin normal

          -  Creatinine normal

          -  Creatinine clearance at least 60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No serious concurrent infection or medical illness that would jeopardize ability to
             receive protocol chemotherapy with reasonable safety

          -  No other prior malignancy within the past 5 years except curatively treated carcinoma
             in situ or basal cell skin cancer

          -  No grade 2 or greater pre-existing sensory neuropathy

          -  No history of allergy to platinum compounds or to antiemetics appropriate for
             administration in conjunction with protocol chemotherapy

          -  Mini mental score at least 15

          -  No prior immunotherapy for glioblastoma multiforme

          -  No prior biologic therapy for glioblastoma multiforme, including:

               -  Immunotoxins

               -  Immunoconjugates

               -  Antiangiogenesis compounds

               -  Antisense

               -  Peptide receptor antagonists

               -  Interferons

               -  Interleukins

               -  Tumor infiltrating lymphocytes

               -  Lymphokine activated killer cells

               -  Gene therapy

          -  No concurrent filgrastim (G-CSF)

          -  No prior chemotherapy for glioblastoma multiforme

          -  No prior hormonal therapy for glioblastoma multiforme

          -  Prior glucocorticoid therapy for glioblastoma multiforme allowed

          -  Must be maintained on a stable (lowest required dose) corticosteroid regimen for at
             least 5 days before and during study

          -  No concurrent dexamethasone as an antiemetic

          -  No prior radiotherapy for glioblastoma multiforme

          -  Recovered from immediate postoperative period

          -  At least 10 days since prior anticonvulsant drug that induces hepatic metabolic
             enzymes

          -  No other concurrent investigational agents",Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed recurrent primary malignant glioma

               -  Anaplastic astrocytoma

               -  Glioblastoma multiforme

               -  Anaplastic oligodendroglioma

               -  Gliosarcoma

               -  Anaplastic mixed oligoastrocytoma

          -  Measurable disease by MRI or CT

          -  No immediate radiotherapy required

          -  Neurologically stable for at least 2 weeks prior to study

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Greater than 12 weeks

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  SGOT and SGPT less than 2.5 times ULN

          -  Alkaline phosphatase less than 2 times ULN

        Renal:

          -  Blood urea nitrogen and creatinine less than 1.5 times ULN

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No other nonmalignant systemic disease

          -  No acute infection treated with IV antibiotics

          -  No frequent vomiting or other condition that would preclude oral medication
             administration (e.g., partial bowel obstruction)

          -  No other prior malignancies except surgically cured carcinoma in situ of the cervix or
             basal or squamous cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No more than 1 prior biologic therapy regimen

        Chemotherapy:

          -  No more than 1 prior chemotherapy regimen

          -  At least 6 weeks since prior chemotherapy, unless evidence of disease progression

          -  No prior failure of irinotecan or temozolomide

        Endocrine therapy:

          -  Concurrent corticosteroids allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 6 weeks since prior radiotherapy, unless evidence of disease progression

        Surgery:

          -  At least 3 weeks since prior surgery, unless evidence of disease progression, and
             recovered

        Other:

          -  No concurrent immunosuppressive agents",Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed high-grade malignant glioma of one of the following subtypes:

               -  Glioblastoma

               -  Anaplastic astrocytoma

               -  Anaplastic oligoastrocytoma

               -  Gliomatosis cerebri

          -  No disseminated disease or primary spinal cord malignancies

          -  Measurable intracranial residual disease by MRI

        PATIENT CHARACTERISTICS:

        Age:

          -  3 and over

          -  Under 22 at time of diagnosis

        Performance status:

          -  Karnofsky 50-100% if over 10 years of age

          -  Lansky 50-100% if 10 years of age or under

        Life expectancy:

          -  At least 8 weeks

        Hematopoietic:

          -  Absolute neutrophil count at least 1,000/mm^3

          -  Platelet count at least 100,000/mm^3 (transfusion independent)

          -  Hemoglobin at least 8.0 g/dL (RBC transfusions allowed)

        Hepatic:

          -  Bilirubin no greater than 1.5 times normal for age

          -  SGPT no greater than 2.5 times normal for age

          -  Albumin at least 2 g/dL

        Renal:

          -  Creatinine no greater than 1.5 times normal for age OR

          -  Creatinine clearance or radioisotope glomerular filtration rate at least lower limit
             of normal for age

        Pulmonary:

          -  No dyspnea at rest

          -  No exercise intolerance

          -  Pulse oximetry at least 94%

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No uncontrolled infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy

          -  No concurrent prophylactic hematopoietic growth factors

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Prior corticosteroid therapy allowed

          -  No concurrent corticosteroids as antiemetic

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  No more than 31 days since prior maximal neurosurgical procedure

        Other:

          -  No concurrent phenobarbital or cimetidine",Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS: Histologically confirmed supratentorial malignant primary glioma
        Glioblastoma multiforme (closed to accrual as of 05/31/2001) Gliosarcoma (closed to accrual
        as of 05/31/2001) Anaplastic astrocytoma Anaplastic oligodendroglioma Mixed malignant
        gliomas Original histological diagnosis of low-grade glioma allowed if a subsequent
        histological diagnosis of malignant glioma is confirmed Prior treatment for no more than 2
        prior relapses allowed Disease progression documented by at least 2 pre-study brain scans
        Recent prior tumor resection of recurrent or progressive tumor allowed if recovered from
        the effects of prior surgery

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life
        expectancy: More than 8 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3
        Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL (may be transfusion
        dependent) Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) SGOT less than
        2 times ULN Renal: Creatinine less than 1.5 mg/dL Creatinine clearance at least 60 mL/min
        Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective
        barrier contraception during and for at least 2 months after study Able to swallow capsules
        No active infection No disease or other serious concurrent medical illness that would
        preclude study

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 week since prior interferon At least
        1 week since prior thalidomide Chemotherapy: Recovered from prior chemotherapy At least 4
        weeks since prior cytotoxic therapy (2 weeks for vincristine, 3 weeks for procarbazine, or
        6 weeks for nitrosoureas) Endocrine therapy: At least 1 week since prior tamoxifen Prior
        steroids allowed if on stable or decreasing dose for at least 5-7 days before baseline MRI
        If steroid dose is increased between date of baseline MRI and initiation of study drug, a
        new baseline MRI is required Radiotherapy: Not specified Surgery: See Disease
        Characteristics No concurrent surgery Other: At least 1 week since any prior noncytotoxic
        agents (e.g., isotretinoin) No other concurrent anticancer therapy, including other
        investigational drugs",Fenretinide in Treating Patients With Recurrent Malignant Glioma,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed glioblastoma multiforme or anaplastic
             astrocytoma

               -  Residual tumor on postoperative MRI

          -  Bidimensionally measurable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 65

        Performance status:

          -  Karnofsky or Lansky 70-100% OR

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,000/mm^3

          -  Hemoglobin at least 8 g/dL (transfusion allowed)

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  SGPT no greater than 3 times ULN

        Renal:

          -  Age 5 years and under: Creatinine less than 1.2 mg/dL

          -  Age over 5 to 10 years: Creatinine less than 1.5 mg/dL

          -  Age over 10 to 15 years: Creatinine less than 1.8 mg/dL

          -  Age over 15 years: Creatinine less than 2.4 mg/dL

        Cardiovascular:

          -  No myocardial infarction within the past 6 months

        Other:

          -  No other concurrent serious medical condition that would preclude study

          -  Able to tolerate oral medications

          -  No prior malignancy for which patient received prior chemotherapy or spinal
             irradiation

          -  No history of severe allergic reaction to platinum-containing compounds

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 72 hours since prior filgrastim (G-CSF)

        Chemotherapy:

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Concurrent steroids for tumor-related cerebral edema allowed

          -  No concurrent corticosteroids for solely antiemetic purposes

        Radiotherapy:

          -  No prior or concurrent radiotherapy

        Surgery:

          -  Recovered from prior surgery

          -  No concurrent surgery","Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma",1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically proven, newly diagnosed, supratentorial, grade IV astrocytoma
             (glioblastoma multiforme)

               -  Incompletely resected disease

          -  Must have measurable and contrast enhancing tumor on the postoperative MRI/CT scan

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  Transaminases no greater than 4 times upper limit of normal

        Renal:

          -  Creatinine no greater than 1.7 mg/dL

        Other:

          -  No other serious concurrent infection or medical illness that would preclude study
             therapy

          -  No other active malignancy within the past 5 years except curatively treated carcinoma
             in situ of the cervix or basal cell skin cancer

          -  No psychosis requiring ongoing therapy with antipsychotic medication

          -  Mini mental score at least 15

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy or biologic agents (including immunotoxins, immunoconjugates,
             antisense compounds, peptide receptor antagonists, interferons, interleukins, tumor
             infiltrating lymphocytes, lymphokine activated killer cells, or gene therapy) for
             glioblastoma multiforme

          -  No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF] or sargramostim
             [GM-CSF])

        Chemotherapy:

          -  No prior chemotherapy for glioblastoma multiforme

        Endocrine therapy:

          -  No prior hormonal therapy for glioblastoma multiforme

          -  Prior glucocorticoids allowed

          -  Concurrent corticosteroids allowed if on stable dose (no increase within the past 5
             days)

        Radiotherapy:

          -  No prior radiotherapy for glioblastoma multiforme

        Surgery:

          -  See Disease Characteristics

          -  Recovered from immediate postoperative period

        Other:

          -  Greater than 10 days since prior anticonvulsants that induce hepatic metabolic enzymes
             (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or felbamate)

          -  No other concurrent investigational agents",Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Part I:

               -  Histologically confirmed, newly diagnosed glioblastoma multiforme or anaplastic
                  astrocytoma (closed to accrual 12/19/2000)

          -  Parts I and II:

               -  Histologically confirmed astrocytic, oligodendroglial, or mixed glial tumor

                    -  Grade III or higher

                    -  Recurrent or progressive after radiotherapy

          -  Evaluable residual disease by contrast-enhanced MRI or CT scan

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

        Hepatic:

          -  SGOT no greater than 2.5 times upper limit of normal

          -  Bilirubin normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

          -  BUN no greater than 25 mg/dL

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 2 months after study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 6 weeks since prior biologic therapy and recovered

        Chemotherapy:

          -  At least 2 weeks since prior chemotherapy (including but not limited to topotecan) and
             recovered

               -  Patients in trials with one of the following treatment combinations are allowed
                  to enroll 6 weeks after receiving carmustine (BCNU):

                    -  BCNU on day 1

                    -  BCNU on day 1 and topotecan on days 1, 8, 15, 22, 29, and 36

                    -  BCNU on day 1 and irinotecan on days 1, 8, 15, and 22

        Endocrine therapy:

          -  Patients on corticosteroids must be on a stable dose for at least 2 weeks before study

          -  At least 6 weeks since other prior endocrine therapy and recovered

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 6 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified","Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma",2
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed supratentorial glioblastoma multiforme (with areas of
             necrosis) by surgical biopsy or excision within 4 weeks of study

          -  Tumor and/or any associated edema limited to one hemisphere and unifocal

          -  No gross invasion of a ventricular surface

          -  Tumor accessible

          -  No other astrocytoma

          -  No multifocal or recurrent malignant glioma

          -  No disease below the tentorium or beyond the cranial vault

        PATIENT CHARACTERISTICS:

        Age:

          -  Adult

        Performance status:

          -  Zubrod 0-1

        Life expectancy:

          -  At least 8 weeks

        Hematopoietic:

          -  Hemoglobin at least 10 g/dL (transfusion allowed)

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  Serum glutamic-oxaloacetic transaminase (SGOT) or Serum glutamic-pyruvic transaminase
             (SGPT) no greater than 2 times normal

        Renal:

          -  Blood Urea Nitrogen (BUN) no greater than 25 mg/dL

          -  Creatinine no greater than 1.5 mg/dL

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No hypersensitive or idiosyncratic reaction to bleomycin

          -  No other prior malignancies within the past 2 years except nonmelanomatous skin cancer
             or carcinoma in situ of the cervix or urinary bladder

          -  No other major medical illness or psychiatric impairment that would preclude study
             participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for glioblastoma multiforme

          -  No prior radiosensitizer for glioblastoma multiforme

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy to the head or neck resulting in overlapping radiotherapy fields

        Surgery:

          -  See Disease Characteristics

          -  Recovered from prior surgery",Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme,1
"Patient is a 45-year-old man with a history of anaplastic astrocytoma of the spine complicated by severe lower extremity weakness and urinary retention s/p Foley catheter, high-dose steroids, hypertension, and chronic pain. The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation. Complicated by progressive lower extremity weakness and urinary retention. Patient initially presented with RLE weakness where his right knee gave out with difficulty walking and right anterior thigh numbness. MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma. Therapy included field radiation t10-l1 followed by 11 cycles of temozolomide 7 days on and 7 days off. This was followed by CPT-11 Weekly x4 with Avastin Q2 weeks/ 2 weeks rest and repeat cycle.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant tumors

               -  Anaplastic astrocytoma

               -  Oligodendroglioma

               -  Germ cell tumor

               -  Medulloblastoma

               -  Primary neuroectodermal tumor

               -  Esthesioneuroblastoma

               -  CNS lymphoma (primary or systemic disease)

          -  Multifocal intracranial disease allowed

          -  No extraneural metastases (except controlled systemic lymphoma)

          -  Pretreatment considerations based on tumor type

               -  Anaplastic astrocytoma:

                    -  Recurrent disease

                    -  Any treatment at diagnosis allowed (carmustine dose limited to 480 mg/m2)

                    -  Chemotherapy not required at recurrence

               -  Oligodendroglioma:

                    -  Disease response (at least minor) to conventional chemotherapy OR

                    -  Recurrent disease

               -  Esthesioneuroblastoma:

                    -  Attempted complete surgical resection

                    -  Disease progression after radiotherapy

                    -  Response to chemotherapy regimen comprising cyclophosphamide, etoposide, and
                       cisplatin

               -  CNS lymphoma:

                    -  Disease refractory to methotrexate OR

                    -  Failure after initial treatment with methotrexate OR

                    -  Considered at high risk for disease relapse despite initial response

          -  Radiographic or pathological confirmation of recurrent disease required

          -  Not eligible for other high priority national or institutional clinical studies

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG or Zubrod 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine less than 1.5 times normal

        Cardiovascular:

          -  LVEF at least 45%

        Pulmonary:

          -  DLCO at least 60% predicted OR

          -  Approval of pulmonologist

        Other:

          -  Not pregnant or nursing

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent anticancer hormonal therapy

          -  No concurrent steroids as antiemetics

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No concurrent barbiturates or acetaminophen

          -  Participation in other concurrent supportive care or gene therapy trials allowed",Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer,1
"48 M with a h/o HTN hyperlipidemia, bicuspid aortic valve, and tobacco abuse who presented to his cardiologist on [**2148-10-1**] with progressive SOB and LE edema. TTE revealed severe aortic stenosis with worsening LV function. EF was 25%. RV pressure was 41 and had biatrial enlargement. Noted to have 2+ aortic insufficiency with mild MR. He was sent home from cardiology clinic with Lasix and BB (which he did not tolerate), continued to have worsening SOB and LE edema and finally presented here for evaluation.
During this admission repeat echo confirmed critical aortic stenosis showing left ventricular hypertrophy with cavity dilation and severe global hypokinesis, severe aortic valve stenosis with underlying bicuspid aortic valve, dilated ascending aorta, mild pulmonary artery systolic hypertension. The patient underwent a preop workup for valvular replacement with preop chest CT scan and carotid US (showing moderate heterogeneous plaque with bilateral 1-39% ICA stenosis). He also underwent a cardiac cath with right heart cath to evaluate his pulm art pressures which showed no angiographically apparent flow-limiting coronary artery disease.","Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol
        between the 60th and 90th percentiles.",Asymptomatic Carotid Artery Plaque Study (ACAPS),0
"48 M with a h/o HTN hyperlipidemia, bicuspid aortic valve, and tobacco abuse who presented to his cardiologist on [**2148-10-1**] with progressive SOB and LE edema. TTE revealed severe aortic stenosis with worsening LV function. EF was 25%. RV pressure was 41 and had biatrial enlargement. Noted to have 2+ aortic insufficiency with mild MR. He was sent home from cardiology clinic with Lasix and BB (which he did not tolerate), continued to have worsening SOB and LE edema and finally presented here for evaluation.
During this admission repeat echo confirmed critical aortic stenosis showing left ventricular hypertrophy with cavity dilation and severe global hypokinesis, severe aortic valve stenosis with underlying bicuspid aortic valve, dilated ascending aorta, mild pulmonary artery systolic hypertension. The patient underwent a preop workup for valvular replacement with preop chest CT scan and carotid US (showing moderate heterogeneous plaque with bilateral 1-39% ICA stenosis). He also underwent a cardiac cath with right heart cath to evaluate his pulm art pressures which showed no angiographically apparent flow-limiting coronary artery disease.","Patients undergoing evaluation for CAD who show at least two myocardial segments with wall
        motion abnormalities on a baseline echocardiogram will be offered to participate in this
        study.

        Patients will be adults older than 21 years of age.

        No pre-menopausal patients who are lactating, are pregnant or potentially pregnant as
        judged by history, physical examination, ultrasound or urine pregnancy test.

        No one with unstable angina.

        No subjects with recent myocardial infarction (less than 1 month).

        No one with frequent ectopy which precludes adequate imaging acquisition.

        No subjects with significant hypertension (systolic blood pressure greater than 170 mm Hg).

        No hypotension with basal sitting systolic arterial pressure less than 100 mm HG confirmed
        30 minutes later.

        No subjects with sinus tachycardia greater than or equal to 100 beats/minute.

        No atrial fibrillation.

        No inadequate two-dimensional echocardiographic windows.",Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle,0
"48 M with a h/o HTN hyperlipidemia, bicuspid aortic valve, and tobacco abuse who presented to his cardiologist on [**2148-10-1**] with progressive SOB and LE edema. TTE revealed severe aortic stenosis with worsening LV function. EF was 25%. RV pressure was 41 and had biatrial enlargement. Noted to have 2+ aortic insufficiency with mild MR. He was sent home from cardiology clinic with Lasix and BB (which he did not tolerate), continued to have worsening SOB and LE edema and finally presented here for evaluation.
During this admission repeat echo confirmed critical aortic stenosis showing left ventricular hypertrophy with cavity dilation and severe global hypokinesis, severe aortic valve stenosis with underlying bicuspid aortic valve, dilated ascending aorta, mild pulmonary artery systolic hypertension. The patient underwent a preop workup for valvular replacement with preop chest CT scan and carotid US (showing moderate heterogeneous plaque with bilateral 1-39% ICA stenosis). He also underwent a cardiac cath with right heart cath to evaluate his pulm art pressures which showed no angiographically apparent flow-limiting coronary artery disease.",No eligibility criteria,Balloon Valvuloplasty Registry,2
"48 M with a h/o HTN hyperlipidemia, bicuspid aortic valve, and tobacco abuse who presented to his cardiologist on [**2148-10-1**] with progressive SOB and LE edema. TTE revealed severe aortic stenosis with worsening LV function. EF was 25%. RV pressure was 41 and had biatrial enlargement. Noted to have 2+ aortic insufficiency with mild MR. He was sent home from cardiology clinic with Lasix and BB (which he did not tolerate), continued to have worsening SOB and LE edema and finally presented here for evaluation.
During this admission repeat echo confirmed critical aortic stenosis showing left ventricular hypertrophy with cavity dilation and severe global hypokinesis, severe aortic valve stenosis with underlying bicuspid aortic valve, dilated ascending aorta, mild pulmonary artery systolic hypertension. The patient underwent a preop workup for valvular replacement with preop chest CT scan and carotid US (showing moderate heterogeneous plaque with bilateral 1-39% ICA stenosis). He also underwent a cardiac cath with right heart cath to evaluate his pulm art pressures which showed no angiographically apparent flow-limiting coronary artery disease.","Inclusion criteria for probands: Onset of hypertension by age 60 years and the presence of
        at least one additional hypertensive sibling who was willing to participate. Hypertension
        was defined according to systolic BP 140 or diastolic BP 90 in at least two different
        evaluations, or treatment for hypertension. Volunteers with type 1 diabetes or renal
        failure were excluded.

        Inclusion criteria for subsequent recruits: Criteria as indicated in Study Population
        Description (i.e., criteria based on familial relationships, hypertension and
        antihypertensive medication status).",Family Blood Pressure Program - HyperGEN,0
"48 M with a h/o HTN hyperlipidemia, bicuspid aortic valve, and tobacco abuse who presented to his cardiologist on [**2148-10-1**] with progressive SOB and LE edema. TTE revealed severe aortic stenosis with worsening LV function. EF was 25%. RV pressure was 41 and had biatrial enlargement. Noted to have 2+ aortic insufficiency with mild MR. He was sent home from cardiology clinic with Lasix and BB (which he did not tolerate), continued to have worsening SOB and LE edema and finally presented here for evaluation.
During this admission repeat echo confirmed critical aortic stenosis showing left ventricular hypertrophy with cavity dilation and severe global hypokinesis, severe aortic valve stenosis with underlying bicuspid aortic valve, dilated ascending aorta, mild pulmonary artery systolic hypertension. The patient underwent a preop workup for valvular replacement with preop chest CT scan and carotid US (showing moderate heterogeneous plaque with bilateral 1-39% ICA stenosis). He also underwent a cardiac cath with right heart cath to evaluate his pulm art pressures which showed no angiographically apparent flow-limiting coronary artery disease.",All participants related to a patient with familial combined hyperlipidemia,Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia,0
"48 M with a h/o HTN hyperlipidemia, bicuspid aortic valve, and tobacco abuse who presented to his cardiologist on [**2148-10-1**] with progressive SOB and LE edema. TTE revealed severe aortic stenosis with worsening LV function. EF was 25%. RV pressure was 41 and had biatrial enlargement. Noted to have 2+ aortic insufficiency with mild MR. He was sent home from cardiology clinic with Lasix and BB (which he did not tolerate), continued to have worsening SOB and LE edema and finally presented here for evaluation.
During this admission repeat echo confirmed critical aortic stenosis showing left ventricular hypertrophy with cavity dilation and severe global hypokinesis, severe aortic valve stenosis with underlying bicuspid aortic valve, dilated ascending aorta, mild pulmonary artery systolic hypertension. The patient underwent a preop workup for valvular replacement with preop chest CT scan and carotid US (showing moderate heterogeneous plaque with bilateral 1-39% ICA stenosis). He also underwent a cardiac cath with right heart cath to evaluate his pulm art pressures which showed no angiographically apparent flow-limiting coronary artery disease.",No eligibility criteria,Racial Differences in the Coronary Microcirculation,0
A 32 yo woman who presents following a severe 'exploding' headache. She and her husband report that yesterday she was in the kitchen and stood up and hit her head on the corner of a cabinet. The next morning she developed a sudden 'exploding' headache. She came to the hospital where head CT showed a significant amount of blood in her right ventricle. NSGY evaluated her for spontaneous intraventricular hemorrhage with a concern for an underlying vascular malformation. Cerebral angiogram was done which showed abnormal vasculature with a draining vein from L temporal lobe penetrating deep white matter consistent with AVM. The patient did continue to have a headaches but they were improving with pain medication. The patient refused PT evaluation but was ambulating independently without difficulty. She was discharged to home with her husband on [**2155-12-6**].,"Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
A 32 yo woman who presents following a severe 'exploding' headache. She and her husband report that yesterday she was in the kitchen and stood up and hit her head on the corner of a cabinet. The next morning she developed a sudden 'exploding' headache. She came to the hospital where head CT showed a significant amount of blood in her right ventricle. NSGY evaluated her for spontaneous intraventricular hemorrhage with a concern for an underlying vascular malformation. Cerebral angiogram was done which showed abnormal vasculature with a draining vein from L temporal lobe penetrating deep white matter consistent with AVM. The patient did continue to have a headaches but they were improving with pain medication. The patient refused PT evaluation but was ambulating independently without difficulty. She was discharged to home with her husband on [**2155-12-6**].,"-  INCLUSION CRITERIA:

        Adult greater than or equal to 18 years with known or suspected spinal AVM and capacity to
        provide written informed consent.

        Child ages 4-18 with known or suspected spinal AVM and with parent/guardian informed
        consent.

        EXCLUSION CRITERIA:

        Unable to tolerate MRI and/or spinal arteriography.

        Child less than 4 years.",Evaluation and Treatment of Patients Spinal Blood Vessel Abnormalities,1
A 32 yo woman who presents following a severe 'exploding' headache. She and her husband report that yesterday she was in the kitchen and stood up and hit her head on the corner of a cabinet. The next morning she developed a sudden 'exploding' headache. She came to the hospital where head CT showed a significant amount of blood in her right ventricle. NSGY evaluated her for spontaneous intraventricular hemorrhage with a concern for an underlying vascular malformation. Cerebral angiogram was done which showed abnormal vasculature with a draining vein from L temporal lobe penetrating deep white matter consistent with AVM. The patient did continue to have a headaches but they were improving with pain medication. The patient refused PT evaluation but was ambulating independently without difficulty. She was discharged to home with her husband on [**2155-12-6**].,"Patients will be drawn from among those referred to the NINDS Epilepsy Research Branch.

        No patients with evidence for a progressive neurological disorder.

        No subjects with metal hardware in the cranial cavity, cardiac pacemakers, indwelling
        medication pumps, cochlear implants, intracardiac lines, significant intracranial masses or
        evidence of increased intracranial pressure.

        Women must not be pregnant.",Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy,0
A 32 yo woman who presents following a severe 'exploding' headache. She and her husband report that yesterday she was in the kitchen and stood up and hit her head on the corner of a cabinet. The next morning she developed a sudden 'exploding' headache. She came to the hospital where head CT showed a significant amount of blood in her right ventricle. NSGY evaluated her for spontaneous intraventricular hemorrhage with a concern for an underlying vascular malformation. Cerebral angiogram was done which showed abnormal vasculature with a draining vein from L temporal lobe penetrating deep white matter consistent with AVM. The patient did continue to have a headaches but they were improving with pain medication. The patient refused PT evaluation but was ambulating independently without difficulty. She was discharged to home with her husband on [**2155-12-6**].,"-  INCLUSION CRITERIA:

        To be eligible for entry into the study, a candidate must meet the following criteria:

        Patient with a confirmed diagnosis of Chiari I malformation who has a family member with
        syringomyelia or Chiari I malformation, or

        Family member of a patient with a confirmed diagnosis of Chiari I malformation, AND

        There are at least two family members diagnosed with Chiari I malformation.

        If an adult, able to give informed consent; if a minor, has an adult who is legally
        responsible for the subject and who is able to give consent.

        EXCLUSION CRITERIA:

        A candidate will be excluded if he/she:

        Has a contraindication to MRI scanning.

        Is unable to comprehend the risks of the testing.

        Is less than one year of age.

        Cannot undergo MRI scanning without sedation.",Genetic Analysis of the Chiari I Malformation,0
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine or systemic chemoprophylaxis for PCP.

          -  Preventive therapy for steroid-associated ulcers and any other therapies required to
             manage steroid toxicity (e.g., insulin).

        Patients must have:

          -  Documented initial episode or relapse of acute cryptococcal meningitis. (NOTE:
             Patients must be untreated for this episode except for administration of a test dose
             of 1 g or less amphotericin B.)

          -  Acute cryptococcal meningitis with cerebrospinal fluid opening pressure >= 250 mm H2O
             prior to receipt of antifungal therapy for this episode.

          -  Documented HIV infection OR a diagnosis of AIDS based on a documented AIDS-defining
             opportunistic infection.

          -  Ability to begin therapy within 8 hours after the pre-entry lumbar puncture.

          -  Consent of parent or guardian if less than 18 years of age.

        NOTE:

          -  Comatose patients eligible provided informed consent can be provided by guardian or
             next of kin.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Concurrent CNS disease such as another infection or neoplasm that would interfere with
             assessment of response.

          -  Prison incarceration.

        Concurrent Medication:

        Excluded:

          -  Acetazolamide, mannitol, urea preparations, and other corticosteroids during the first
             72 hours of the study.

          -  Treatment or prophylaxis with other systemic antifungal agents at any time.

          -  Antiretroviral therapy during the first 72 hours of the study.

        Prior Medication:

        Excluded within 7 days prior to study entry:

          -  Corticosteroids, mannitol, urea preparations, acetazolamide, or more than 24 hours of
             phenytoin.",Dexamethasone in Cryptococcal Meningitis,0
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","Patients with a histologic diagnosis of small noncleaved cell (undifferentiated) (SNCL),
        lymphoblastic (LL), and large cell lymphoma (LCL) who were treated according to National
        Cancer Institute Pediatric Branch non-Hodgkin's lymphoma protocols 74-0, 75-6, 76-5, 77-04,
        85-C-67, and 89-C-41A, and who have been in continuous remission for one year or longer
        following completion of treatment.

        Patients who have relapsed and been successfully re-treated are not excluded, except for
        patients with lymphoblastic lymphoma who have been re-treated according to acute
        lymphoblastic leukemia protocols.",Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors,1
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","-  INCLUSION CRITERIA:

        Screening FOR SUSPECTED PTLDS:

        Age greater than or equal to 13 years old, suspect of suffering from Lyme disease

        Post-Treatment Lyme Disease Syndrome (PTLDS): For the purposes of this study, PTLDS is
        defined as occurring in male or female patients age 13 and above who have been diagnosed
        with confirmed or probable Lyme disease per CDC definition
        (https://wwwn.cdc.gov/nndss/conditions/lyme-disease/case-definition/2017/). Studyphysician
        will review history to confirm probable cases. They have received recommended antibiotic
        therapy and have persistent or relapsing symptoms and/or signs for at least six months
        after therapy. They also should have no other documented explanation for their signs and
        symptoms.

        Lyme arthritis controls: For the purposes of this study, Lyme arthritis is defined as
        occurring in an otherwise healthy male or female aged 18 and above who have intermittent
        episodes of arthritis involving one or few joint, without any other cause being documented,
        and have positive serum antibodies to B.burgdorferi confirmed by Western blot according to
        the CDC criteria.

        Recovered Controls: For the purposes of this study, a recovered control is defined as an
        otherwise healthy male or female aged 18 and above who has had Lyme disease, fulfilling the
        CDC Lyme Disease National Surveillance Case Definition and who had received accepted
        antibiotic treatment for Lyme disease (at least 3 months since the end of antibiotic
        therapy before protocol evaluation) and who are currently asymptomatic.

        Seropositive Controls: For the purposes of this study, a serpositive control is defined as
        an otherwise healthy male or female aged 18 and above who has positive serum IgG antibody
        to B.burgdorferi by Western blot according to the CDC criteria and are asymptomatic and who
        recall no episodes of disease compatible with Lyme infection and have not received
        antibiotic therapy for Lyme disease.

        OspA vaccinated control: For the purposes of this study, a OspA vaccinated control is
        defined as an otherwise healthy male or female aged 18 and above who has received at least
        two doses of the OspA vaccine for Lyme disease (Lymerix [R]). These controls may have a
        positive ELISA for B.burgdorferi but a negative (or unreadable) IgG western blot.

        Multiple sclerosis controls: For the purposes of this study, a multiple sclerosis control
        is defined as an otherwise healthy male or female aged 18 and above with
        relapsing-remitting or progressive multiple sclerosis as defined by the Clinical Trial
        Committee of the National Multiple Sclerosis Society and no evidence of prior exposure to
        B.burgdorferi as indicate by negative history for Lyme disease and negative Western blot
        for B.burgdorferi in the serum by the CDC criteria. Patients should have a Kurtzke or
        Expanded Disability Status Scale (EDSS) between 1 to 5.

        Healthy Volunteers: For the purpose of this study, a healthy volunteer is defined as
        healthy male or female, age 18 and above, with no history compatible with Lyme disease and
        negative serological testing to B.burgdorferi by the CDC criteria.

        All study participants must agree to allow their samples to be used for future research.

        EXCLUSION CRITERIA:

        General exclusion criteria:

        Age less than 18 (less than 13 for patients with PTLDS).

        Weight less than 70 Lb (35 kg).

        Pregnancy or lactation.

        Women with childbearing potential who are sexually active with a male partner and unwilling
        to use effective contraception during the evaluation and treatment phases of the protocol.

        Clinically significant laboratory abnormalities including positive test for syphilis (RPR),
        HBsAg, anti-HCV, anti-HIV.

        Chronic medication use will be evaluated in a case-by-case basis.

        Not able to understand all of the requirements of the study or unable to give informed
        consent and/or comply with all aspects of the evaluation.

        EXCLUSION CRITERIA FOR PTLDS PATIENTS AND LYME ARTHRITIS CONTROLS:

        In addition to the general exclusion criteria, these individuals will be excluded for:

          1. Use of immunosuppressive drugs such as systemic (but not topical or inhalant) steroids
             and cytotoxic agents.

          2. History of any recognized autoimmune disease such as rheumatoid arthritis, vasculitis,
             systemic erythematous lupus, etc.

          3. Serious pre-existing or concurrent chronic medical or psychiatric illnesses other than
             Lyme disease.

          4. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness that might produce neurologic deficit (such as
             cerebrovascular disease).

          5. Use of systemic antibiotics in the previous month.

          6. Use of immunomodulators such as interferons.

          7. Chronic medication use will be evaluated in a case-by-case basis.

          8. Patients will be excluded from this protocol if they are judged by the principal
             investigator as having a significant impairment in their capacity for judgment and
             reasoning that compromise their ability to make decisions in their best interest.

        EXCLUSION CRITERIA FOR RECOVERED, SEROPOSITIVE, OSPA VACCINATED AND HEALTHY VOLUNTEERS
        CONTROLS:

        In addition to the above applicable exclusion criteria (general exclusion criteria and
        exclusion criteria for PTLDS patients and Lyme arthritis controls), these individuals will
        be excluded for:

        1. Pre-existing or concurrent serious chronic medical or psychiatric illness.

        EXCLUSION CRITERIA FOR MULTIPLE SCLEROSIS CONTROLS:

        In addition to the above general exclusion criteria, these individuals will be excluded
        for:

          1. Pre-existing or concurrent serious psychiatric or chronic medical illness besides
             Multiple Sclerosis.

          2. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness, besides Multiple Sclerosis, that might produce
             neurologic deficit (such as cerebrovascular disease).

          3. Previously received total lymphoid irradiation (TLI) or cladribine.

          4. Has used of immunoactive medications (excluding beta-interferon) in the three months
             preceding the study.

          5. In the three months prior to the study initiation, was given such investigational
             treatments as plasmapheresis, hyperbaric oxygen, gangliosides, Copolymer 1, etc.

        ELIGIBILITY OF SPECIAL POPULATIONS:

        Children: Children 13 years and older are eligible to participate in the PTLDS cohort
        because the condition under study can affect children. T, and this age was selected as
        appropriate for the children to provide assent to and comply with the study procedures.
        Children younger than 13 will be excluded from the PTLDS cohort, and no children will be
        enrolled in the other study cohorts.

        Pregnant and lactating women: Pregnant and lactating women are excluded from study
        participation. An enrolled participant who becomes pregnant during the study will be
        withdrawn

        Adults who lack capacity to consent: Adults who lack decision-making capacity to provide
        informed consent are excluded at screening, and enrolled adult participants who permanently
        lose the ability to consent during study participation will be withdrawn.

        NIH staff members: NIH staff may be enrolled if they meet eligibility criteria. Neither
        participation nor refusal to participate as a subject in the research will have an effect,
        either beneficial or adverse, on the participant s employment or position at NIH. Every
        effort will be made to protect participant information, but such information may be
        available in medical records and may be available to authorized users outside of the study
        team in both an identifiable and unidentifiable manner.","A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations",0
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","Inclusion Criteria

        Patient must have AIDS related complex (ARC) as defined by Walter Reed stages, be
        ambulatory, and be able to give informed consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients with unstable disease characterized by the following are excluded:

          -  Hospitalization within the past 14 days.

          -  Major opportunistic infection, current or past.

          -  An active infection of onset during the past 30 days, as evidenced by symptoms, signs,
             or laboratory abnormalities such as:

          -  Temperature = or > 100.5 degrees F.

          -  Night sweats.

          -  Weight loss = or > 10 percent of body weight.

          -  Diarrhea (3 or more bowel movements/day).

          -  Persistent cough, shortness of breath, or dyspnea on exercise.

          -  Abnormal chest x-ray suggesting pneumonia or increased arterial-alveolar (A-a)
             gradient.

          -  Altered mental status, seizures, or focal neurologic signs.

          -  Abnormal computerized tomography (CT) scan or magnetic resonance imaging (MRI)
             suggestive of toxoplasmosis, peripheral mononuclear leukocytes, lymphoma, or other
             focal abnormality of the central nervous system (CNS).

          -  Abnormal cerebrospinal fluid (CSF) suggestive of cryptococcal, mycobacterial, or other
             meningitis. (The decision to perform invasive tests, such as lumbar puncture,
             specialized microbiological tests such as bone marrow culture for Mycobacteria or
             Histoplasma capsulatum, or specialized radiological tests such as CT scan or MRI
             should be based on clinical assessment of the patient.)

          -  Kaposi's sarcoma.

          -  Lymphoma; malignancy requiring chemotherapy.

          -  Dementia.

          -  Requiring hemodialysis or renal insufficiency or failure.

          -  Leukopenia.

          -  Thrombocytopenia.

        Patients with the following are excluded:

          -  Unstable disease.

          -  Kaposi's sarcoma.

          -  Lymphoma; malignancy requiring chemotherapy.

          -  Dementia.

          -  Major opportunistic infection, current or past.

          -  Anemia (hemoglobin less than 9.5 g/dl).

        Prior Medication:

        Excluded within 1 month of study entry:

          -  Ribavirin or zidovudine (AZT) or other antivirals.

          -  Immunomodulating agents.",Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo),0
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS: Newly diagnosed undifferentiated nonlymphoblastic non-Hodgkin's
        lymphoma (Burkitt's or non-Burkitt's) Newly diagnosed large cell lymphoma with CNS
        involvement Recurrent non-Hodgkin's lymphoma L-3 and B-cell leukemia included At least 1 of
        the following required: LDH at least 500 IU/liter (old method) or 2,000 IU/liter (new
        method) Bone marrow involvement (greater than 5% lymphoblasts) CNS involvement
        (lymphoblasts on CSF cytospin or intracranial mass on CT or MRI scan)

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: Not
        specified Hepatic: Not specified Renal: Not specified

        PRIOR CONCURRENT THERAPY: Prior therapy allowed for non-Hodgkin's lymphoma No prior therapy
        for all other diseases",Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","Inclusion Criteria:

          -  Pathologically documented EBV antigen positive lymphoproliferative disease, lymphoma,
             or other EBV-associated malignancy OR

          -  Severely immunocompromised patients who develop blood levels of EBV DNA exceeding 500
             copies/ml DNA, and are therefore at high risk for developing an EBV LPD

        It is expected that five types of patients afflicted with EBV-associated lymphomas or
        lymphoproliferative diseases will be referred and will consent to participate in this
        trial. These are:

          1. Patients developing or at risk for EBV lymphomas or lymphoproliferative disorders
             following an allogeneic marrow transplant.

          2. Patients developing or at risk for EBV lymphomas or lymphoproliferative disorders
             following an allogeneic organ transplant.

          3. Patients with AIDS developing EBV lymphomas or lymphoproliferative diseases as a
             consequence of the profound acquired immunodeficiency induced by HIV.

          4. Patients who develop EBV lymphomas or lymphoproliferative diseases as a consequence of
             profound immunodeficiencies associated with a congenital immune deficit or acquired as
             a sequela of anti-neoplastic or immunosuppressive therapy.

          5. Patients who develop other EBV-associated malignancies without pre-existing immune
             deficiency, including: EBV+ Hodgkin's and Non- Hodgkin's disease, EBV+ nasopharyngeal
             carcinoma, EBV+ hemophagocytic lymphohistiocytosis, or EBV+ leiomyosarcoma.

        Exclusion Criteria:

        The following patients will be excluded from this study:

          -  Moribund patients who, by virtue of heart, kidney, liver, lung, or neurologic
             dysfunction not related to lymphoma, are unlikely to survive the 6-8 weeks required
             for in vitro generation and expansion of the EBV-specific T cells to be used for
             therapy and the subsequent 3 weeks required to achieve an initial assessment of the
             effects of infusions of EBV-specific T cells.

          -  Pregnancy does not constitute a contraindication to infusions of EBV-specific T cells.","Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignancy (solid tumor or lymphoma)

          -  No history of brain metastases

        PATIENT CHARACTERISTICS:

          -  Age: 18 and over

          -  Life expectancy: At least 12 weeks

          -  Performance status: ECOG 0-2

          -  WBC at least 4,000/mm3

          -  Absolute neutrophil count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

          -  Bilirubin less than 1.5 mg/dL

          -  Creatinine normal

          -  No history of seizure disorder Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas and mitomycin)
             and recovered

          -  At least 4 weeks since prior radiotherapy and recovered",Penclomedine in Treating Patients With Solid Tumors or Lymphoma,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS: Histologically confirmed B-cell non-Hodgkin's lymphoma (low,
        intermediate, or high grade categories) A new classification scheme for adult non-Hodgkin's
        lymphoma has been adopted by PDQ. The terminology of ""indolent"" or ""aggressive"" lymphoma
        will replace the former terminology of ""low"", ""intermediate"", or ""high"" grade lymphoma.
        However, this protocol uses the former terminology.

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: BUN no greater than
        1.5 times upper limit of normal (ULN) Creatinine no greater than 1.5 times ULN Other: No
        known allergies to mouse proteins No second primary malignancy within past 5 years other
        than adequately treated in situ carcinoma of the cervix or uterus, or basal or squamous
        cell carcinoma of the skin Not pregnant or nursing Effective contraception required of all
        fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior exposure to mouse antibodies other
        than technetium Tc 99m LL2 monoclonal antibody Chemotherapy: Not specified Endocrine
        therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: At least 1
        month since any other prior investigational therapy No concurrent participation in another
        protocol involving medical devices or investigational agents",Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS: Histologically confirmed B-cell non-Hodgkin's lymphoma (low,
        intermediate, or high grade categories) Must have been treated with chemotherapy and/or
        radiotherapy with evidence of minimal residual disease by conventional diagnostic
        modalities A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by
        PDQ. The terminology of ""indolent"" or ""aggressive"" lymphoma will replace the former
        terminology of ""low"", ""intermediate"", or ""high"" grade lymphoma. However, this protocol uses
        the former terminology.

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: BUN no greater than
        1.5 times upper limit of normal (ULN) Creatinine no greater than 1.5 times ULN Other: No
        known allergies to mouse proteins No second primary malignancy within past 5 years other
        than adequately treated in situ carcinoma of the cervix or uterus, or basal or squamous
        cell carcinoma of the skin Not pregnant or nursing Effective contraception required of all
        fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior exposure to mouse antibodies other
        than LymphoScan Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified
        Radiotherapy: See Disease Characteristics Surgery: Not specified Other: At least 1 month
        since any other prior investigational therapy No concurrent participation in another
        protocol involving medical devices or investigational agents",Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS:

          -  Histologically or cytologically proven HIV-associated B cell non-Hodgkin's lymphoma,
             including:

          -  Diffuse large B cell lymphoma

          -  Intermediate grade diffuse large cell lymphoma

          -  High grade large cell immunoblastic lymphoma

          -  Burkitt's lymphoma

          -  High grade B cell lymphoma, Burkitt's like (small noncleaved lymphoma)

          -  No primary CNS lymphoma (parenchymal brain or spinal cord tumor)

          -  Evaluable disease HIV documentation may be serologic (ELISA or western blot), culture,
             or quantitative PCR or bDNA assay Tumors must be CD20 positive (greater than 50% cells
             express CD20)

          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.
             The terminology of ""indolent"" or ""aggressive"" lymphoma will replace the former
             terminology of ""low"", ""intermediate"", or ""high"" grade lymphoma. However, this protocol
             uses the former terminology.

        PATIENT CHARACTERISTICS:

          -  Age: Over 18

          -  Performance status: Karnofsky 70-100%

          -  Absolute neutrophil count greater than 1,000/mm3*

          -  Platelet count greater than 75,000/mm3*

             * Unless cytopenias are secondary to lymphoma

          -  Bilirubin less than 2.0 mg/dL (unless secondary to hepatic infiltration with lymphoma
             or isolated hyperbilirubinemia associated with the use of indinavir)

          -  SGOT or SGPT less than 7 times upper limit of normal

          -  Creatinine less than 2.0 mg/dL (unless due to lymphoma)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No acute, active HIV-associated opportunistic infection requiring antibiotics

          -  Mycobacterium avium complex allowed

          -  No concurrent malignancy except carcinoma in situ of the cervix, nonmetastatic
             nonmelanomatous skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy

        PRIOR CONCURRENT THERAPY:

          -  Prior or concurrent epoetin alfa or filgrastim (G-CSF) allowed

          -  No prior colony stimulating factor therapy within 24 hours prior to chemotherapy

          -  No prior chemotherapy for HIV-associated non-Hodgkin's lymphoma

          -  At least 1 year since prior cyclophosphamide or doxorubicin

          -  No prior radiotherapy for HIV-associated non-Hodgkin's lymphoma

          -  Chronic therapy with myelosuppressive agents allowed

          -  Concurrent antiretroviral therapy, antifungal medications, and antibiotics allowed",Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma,1
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS:

          -  Histologically proven aggressive non-Hodgkin's lymphoma and registered to front-line
             CALGB protocols (e.g, CLB-59903, 59909, 10002, and 50103)

               -  Diffuse small cleaved cell lymphoma

               -  Diffuse mixed small and large cell lymphoma

               -  Diffuse large cell lymphoma

               -  Diffuse large cell immunoblastic lymphoma

               -  Small noncleaved cell lymphoma

               -  Mantle cell lymphoma OR

          -  Previously entered on similar curative CALGB protocols (CLB-8852, CLB-8854, and
             CLB-9351) with blocks or unstained slides of initial diagnosis available

        PATIENT CHARACTERISTICS:

        Age:

          -  18 years and older",Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS:

          -  Diagnosed hematologic malignancy that is eligible for an active allogeneic bone marrow
             transplantation protocol and leukemia, lymphoma, myeloma, and aplastic anemia
             treatment protocols

          -  HLA-identical or one antigen-mismatched related donor

        PATIENT CHARACTERISTICS:

        Age:

          -  10 to 65

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No known sensitivity to E. coli derivatives

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics",Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS: Histologically confirmed CD20+ B-cell non-Hodgkin's lymphoma No
        relapsed intermediate or high grade disease eligible for bone marrow or stem cell
        transplant Intermediate or high grade disease must have received a prior anthracycline
        containing regimen Low grade disease (with or without prior therapy) felt to be incurable
        with standard therapy allowed No CNS involvement by lymphoma A new classification scheme
        for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of ""indolent"" or
        ""aggressive"" lymphoma will replace the former terminology of ""low"", ""intermediate"", or
        ""high"" grade lymphoma. However, this protocol uses the former terminology.

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At
        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count
        at least 75,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 3 times
        upper limit of normal (ULN) AST/ALT less than 3 times ULN Renal: Creatinine no greater than
        2 times ULN Cardiovascular: No New York Heart Association class III or IV heart disease No
        history of angina Other: Not pregnant or nursing Negative pregnancy test Fertile patients
        must use effective contraception HIV negative No uncontrolled infection No autoimmune
        related phenomena No peptic ulcer disease

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior rituximab No
        prior interleukin-12 No other concurrent immunotherapy Chemotherapy: See Disease
        Characteristics No prior fludarabine or 2-chlorodeoxyadenosine unless CD4 count normal
        Recovered from prior chemotherapy No concurrent chemotherapy Endocrine therapy: No
        concurrent steroid therapy Radiotherapy: No concurrent radiotherapy Surgery: Not specified",Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","-  Documented leptomeningeal metastases

          -  Carcinomatous meningitis that is previously untreated or failed prior therapy OR

          -  Lymphomatous meningitis

          -  Systemic disease that is responding or stable on current therapy not eligible if
             discontinuing therapy would be deleterious

          -  Age 18 and over

          -  Karnofsky Performance Status 60-100%

          -  Life expectancy of at least 6 weeks

          -  Absolute neutrophil count greater than 1,500/L

          -  Platelet count greater than 100,000/L

          -  Creatinine no greater than 2.0 mg/dL

          -  No congestive heart failure

          -  No unstable angina

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No contraindication to diagnostic sampling of CSF via lumbar puncture or reservoir

          -  No medical conditions that would interfere with absorption of oral medication (e.g.,
             malabsorption, obstruction, or frequent vomiting)

          -  No uncontrolled infection

          -  Prior neuroaxis chemotherapy (lumbar puncture, reservoir, or systemic) allowed

          -  No other concurrent chemotherapy for other sites of disease

          -  No prior radiotherapy to areas of measurable meningeal disease unless there is clear
             radiographic progression in these areas

          -  No prior radiotherapy to greater than 30% of bone marrow

          -  Prior radiotherapy to the neuroaxis allowed

          -  No concurrent radiotherapy for other sites of disease or for progressive disease

          -  Recovered from any prior recent therapy",Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma,1
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","Inclusion Criteria:

          -  Patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma or
             peripheral T-cell lymphoma

               -  Indolent B-cell lymphoma will include Waldenstrm's macroglobulinemia,
                  lymphoplasmacytoid lymphoma small lymphocytic lymphoma, marginal zone lymphoma,
                  and follicular small cleaved-cell or mixed cell lymphoma; patients with prior or
                  concurrent evidence of transformation to large cell lymphoma or with follicular
                  large cell lymphoma are ineligible

               -  Peripheral T-cell lymphoma will include all entities described in the REAL
                  classification; patients with B-cell ALCL are ineligible; patients with cutaneous
                  T-cell lymphoma and all its variants and/or histologic transformation of
                  cutaneous T-cell lymphoma are not eligible for this protocol, because they will
                  be instead eligible for a separate protocol

               -  Relapsed peripheral T-cell lymphomas include all those achieving and maintaining
                  a complete or partial response during initial therapy; refractory includes those
                  achieving all other responses during initial therapy; since the response rate of
                  indolent B-cell lymphomas to up-front therapy exceeds 90% this distinction is not
                  meaningful there

          -  No more than 2 prior chemotherapy and one prior immunotherapy regimens; if
             chemoimmunotherapy was used, the limit will be 3 prior regimens

          -  Performance status =< 2 Zubrod

          -  Staging work-up within 3 weeks and bidimensionally measurable disease

          -  No anti-cancer treatment within the past three weeks

          -  ANC >= 1,000/ul; may be included if in the judgment of the study chairman lower counts
             are explained by marrow or splenic involvement by lymphoma

          -  Platelets >= 100,000/ul; may be included if in the judgment of the study chairman
             lower counts are explained by marrow or splenic involvement by lymphoma

          -  Bilirubin =< 1.5 x normal

          -  SGPT =< 2.5 x normal values

          -  Estimated endogenous creatinine clearance > 50 ml/min

          -  HIV negative; the patients are excluded because the expected opportunistic infections
             will render study toxicity difficult to interpret; in addition the possible effects of
             506U78 on CD4 cells may be dangerous to these patients; furthermore, indolent B-cell
             lymphomas and aggressive peripheral T-cell lymphomas are extremely rare in the setting
             of HIV infection

          -  No active CNS disease

          -  No other malignancy within the last 5 years, except basal cell carcinoma of the skin
             or in-situ cervical carcinoma treated with curative intent

          -  Females must not be pregnant or breast feeding and must be practicing adequate
             contraception; this is because 506U78 may be harmful to the developing fetus and
             nursing newborn or infant

          -  No preexisting sensory or motor neuropathy of grade  2, no history of seizures

          -  No prior stem cell or bone marrow transplantation; no prior 506U78

          -  All patients, including women or members of a minority that fulfill criteria for study
             entry will be eligible for treatment; no one fulfilling all these criteria for entry
             will be denied treatment solely on the basis of sex or minority status

          -  Patients with medical, psychiatric, or social conditions that make compliance with
             treatment or follow-up unlikely are not eligible

          -  No history of symptomatic cardiac dysfunction or pericardial effusion",506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma,1
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS:

          -  One of the following histologically confirmed diagnoses

               -  High grade non-Hodgkin's lymphoma:

                    -  Immunoblastic or small noncleaved cell lymphoma (Burkitt's or non-Burkitt's)
                       in complete or partial remission after initial therapy

                    -  Localized (stage I or Zeigler stage A) small noncleaved (Burkitt's or
                       non-Burkitt's) after relapse or incomplete response to initial therapy

                    -  Lymphoblastic lymphoma in second or greater complete or partial response

                    -  High risk lymphoblastic lymphoma in first complete remission or after
                       initial therapy (high risk factors include stage IV disease, LDH greater
                       than 2 times normal, and 2 or more extranodal sites)

               -  Intermediate grade non-Hodgkin's lymphoma:

                    -  Diffuse large cell lymphoma

                    -  Diffuse mixed cell lymphoma

                    -  Diffuse small cleaved cell lymphoma

                    -  Follicular large cell lymphoma

                    -  In second or greater complete or partial remission OR

                    -  High risk in first complete remission or after initial therapy

                         -  High risk features include:

                              -  No complete response after 12 weeks of initial combination
                                 chemotherapy

                              -  Bulky disease (greater than 10 cm nodal masses or mediastinal
                                 disease involving greater than 1/3 of the chest diameter

                              -  Malignant pleural effusion

                              -  Liver involvement

                              -  LDH greater than 2 times upper limit of normal at diagnosis

                              -  At least 2 extranodal sites

               -  Low grade non-Hodgkin's lymphoma:

                    -  Follicular small cleaved cell lymphoma

                    -  Follicular mixed cell lymphoma

                    -  Diffuse small lymphocytic lymphoma

                    -  In first or greater complete response OR

                    -  Following initial treatment if complete response is not achieved

                    -  In second or greater complete or partial response if treated at diagnosis
                       without clinical symptoms necessitating treatment

               -  T-cell lymphoma (nonlymphoblastic, intermediate, or high grade lymphomas) after
                  initial therapy whether or not complete response is achieved

               -  Hodgkin's lymphoma

                    -  Stage I and II disease treated with primary radiotherapy and failure of at
                       least one combination chemotherapy regimen

                    -  Stage III and IV disease with failure on mechlorethamine, vincristine,
                       procarbazine, and prednisone (MOPP)-like regimen, alternative noncross
                       resistant regimen (e.g., doxorubicin, bleomycin, vinblastine, and
                       dacarbazine [ABVD]), or a combination (e.g., MOPP-ABV)

                    -  High risk features allowed including:

                         -  Failure to achieve initial complete remission with MOPP and/or ABVD and
                            crossover or hybrid therapy

                         -  Relapse within 6 months after initial therapy

                         -  Relapse after initial radiotherapy with complete response longer than 1
                            year since initial therapy and subsequent failure on MOPP and/or ABVD
                            or hybrid

                    -  Bulky mediastinal disease after initial therapy and residual mass of at
                       least 5 cm with other features of persisting disease (e.g., Gallium scan
                       positive, high LDH, enlarging on serial x-rays, or positive biopsy)

          -  No HIV or HTLV-1 associated lymphomas

          -  No resistant or refractory lymphoma (no partial response following up to 3 courses of
             combination chemotherapy)

          -  No active ischemic or degenerative CNS disease NOTE: A new classification scheme for
             adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of ""indolent"" or
             ""aggressive"" lymphoma will replace the former terminology of ""low"", ""intermediate"", or
             ""high"" grade lymphoma. However, this protocol uses the former terminology.

        PATIENT CHARACTERISTICS:

        Age:

          -  70 and under

        Performance status:

          -  Age 65-70 years:

               -  Karnofsky 80-100%

          -  Under 65 years:

               -  ECOG 0-1 (2 allowed if symptoms are directly related to lymphoma)

        Life expectancy:

          -  Greater than 8 weeks

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No prior or current chronic liver disease

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST and alkaline phosphatase less than 2 times normal

        Renal:

          -  Age 65-70 years:

               -  Creatinine clearance greater than 60 mL/min (if creatinine at least 1.5 mg/dL)

          -  Under 65 years:

               -  Creatinine no greater than 1.5 mg/dL OR

               -  Creatinine clearance greater than 50 mL/min

        Cardiovascular:

          -  LVEF at least 45% by MUGA

          -  No symptoms of cardiac disease

          -  No active ischemic heart disease

          -  No uncontrolled hypertension

        Pulmonary:

          -  Age 65-70 years:

               -  If history of smoking or respiratory symptoms, spirometry and DLCO must be
                  greater than 50% of predicted

          -  All ages:

               -  No obstructive airway disease

               -  No resting hypoxemia (PO_2 less than 80)

               -  DLCO at least 50% of predicted

        Other:

          -  No poorly controlled diabetes

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  Must have prior chemotherapy to attempt to achieve complete response

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No radiotherapy to residual disease prior to transplantation

        Surgery:

          -  Not specified

        Other:

          -  Concurrent IV antibiotic therapy allowed for fever or signs of infection",Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","-  INCLUSION CRITERIA:

          -  Age 18 years or older.

          -  ECOG performance status less than or equal to 3.

        At least one of the following:

          -  Exposure risk to HIV, KSHV, or HPV

          -  HIV seropositive

          -  KSHV seropositive

          -  EBV seropositiv

          -  HTLV-1 seropositive

        NOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if patients have
        previously been seropositive or have had a disease associated with KSHV (KS, primary
        effusion lymphoma [PEL], or KSHV-multicentric Castleman s disease), this is sufficient to
        meet this criterion for eligibility.

          -  Malignancy, Castleman's disease, or skin lesions with appearance of Kaposi's sarcoma

          -  Cervical or anal intraepithelial lesion

        EXCLUSION CRITERIA:

        Inability to provide informed consent.","Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer",1
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS: Diagnosis of intermediate grade B-cell CD20+ non-Hodgkin's
        lymphoma Failed to achieve initial complete response (CR) after at least 2 courses of
        standard chemotherapy OR Relapsed after CR and not eligible for autologous bone marrow
        transplant Measurable disease defined as one of the following: Bidimensionally measurable
        disease at least 2 cm in diameter by radiograph or CT scan Enlarged spleen extending at
        least 2 cm below the costal due to lymphomatous involvement Enlarged liver with focal
        lesions on CT scan or biopsy proven lesions Lymphomatous hepatic involvement must be biopsy
        proven for the liver to be sole area of measurable disease No evidence of CNS involvement A
        new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The
        terminology of ""indolent"" or ""aggressive"" lymphoma will replace the former terminology of
        ""low"", ""intermediate"", or ""high"" grade lymphoma. However, this protocol uses the former
        terminology.

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not
        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3* Platelet count at
        least 100,000/mm3* *unless there is bone marrow involvement with lymphoma Hepatic:
        Bilirubin less than 3 mg/dL AST/ALT less than 2 times normal Renal: Creatinine less than
        2.1 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: LVEF greater than
        45% by MUGA or echocardiogram Other: No prior malignancy within the past 10 years except
        squamous cell carcinoma or basal cell carcinoma of the skin or cervical cancer No evidence
        of infection HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients
        must use effective contraception

        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior rituximab",Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma,1
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following:

               -  Chronic myelogenous leukemia

                    -  Philadelphia chromosome-positive OR

                    -  Molecular evidence of bcr/abl gene rearrangement

               -  Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses,
                  myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia,
                  paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia

                    -  Confirmed by cytochemistry, immunophenotyping, and/or chromosomal
                       abnormalities

               -  Multiple myeloma

               -  Hereditary immunodeficiency disorders

                    -  Confirmed by immunologic determination

               -  Sickle cell anemia or beta-thalassemia

                    -  Confirmed by hemoglobin electrophoresis

               -  Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic
                  leukodystrophy)

                    -  Confirmed by metabolic testing

               -  Other non-malignant conditions

          -  Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation

        PATIENT CHARACTERISTICS:

        Age:

          -  65 and under

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified",Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer,2
"This is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma. Pericardial fluid was kappa light chain restricted CD10 positive monotypic B cells expressing FMC-7, CD19, CD20, and myc rearrangement consistent with Burkitt's Lymphoma. A subsequent lumbar puncture and bone marrow biopsy were negative for any involvement which made this a primary cardiac lymphoma. A cardiac MRI showed a mass that was 3cm x 1cm on the lateral wall of the right atrium adjacent to the AV junction.
Past Medical History:
1. Rare migraines
2. HTN
3. Obesity
4. PCOS/infertility
5. Viral encephalitis/meningitis-->ICH-->seizure/stroke ([**2137**]) =- from severe sinus infxn, caused mild non-focal residual deficits
6. CSF leak w/ meningitis s/p lumbar drain placement
7. R LE DVT s/p IVC filter placement
8. Knee surgery","DISEASE CHARACTERISTICS:

          -  Clinically and/or histologically confirmed hematologic malignancy or genetic disorder

               -  Chronic myelogenous leukemia

                    -  Typical blood and marrow morphology

                    -  Presence of Philadelphia chromosome OR

                    -  Molecular evidence of bcr/abl rearrangement if Philadelphia
                       chromosome-negative

               -  Acute myeloid leukemia, acute lymphocytic leukemia, myelodysplasia, or lymphoma

                    -  High risk of relapse or progressive disease

                    -  Typical clinical features and morphology in blood, marrow, lymph node, or
                       other tissue by cytochemistry, immunophenotyping, and/or chromosomal
                       abnormalities

               -  Multiple myeloma

                    -  Typical marrow morphology, radiographic findings, and paraprotein

               -  Aplastic anemia

                    -  Typical marrow and blood findings

               -  Genetic disorder including storage disease (e.g., adrenoleukodystrophy),
                  hemoglobinopathies (e.g., thalassemia), or severe immunodeficiency

          -  Unwilling to undergo conventional high-dose chemoradiotherapeutic conditioning prior
             to allogeneic stem cell transplantation OR

          -  Presence of other medical disorder which precludes high-dose chemoradiotherapeutic
             conditioning (e.g., cardiac disease or infection)

          -  Syngeneic twin, HLA-identical, or 1 or 2 HLA antigen-mismatched family member or
             unrelated donor

        PATIENT CHARACTERISTICS:

        Age:

          -  1 to 80

        Performance status:

          -  Karnofsky 50-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No other serious medical or psychiatric illness that would preclude study compliance

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Disease Characteristics

        Chemotherapy:

          -  See Disease Characteristics

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  Not specified",Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders,2
"74M hx of CAD s/p CABG, EF 60% prior CVA (no residual deficits), HTN, HL, DMII, Moderate to Severe PVD was referred to cardiology for evaluation of PVD, and on examination patient was found to have carotid bruits. Upon further review of symptoms the pt reports + Occasional dizziness, no prior syncope occasional HA, Denies CP/SOB. No sensory or motor defects. He recalls that he might have had a stroke 10-15 years ago without any residual deficit. Prior to CABG he only had diaphoresis.
Further review of systems is notable for absence of chest pain, dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, palpitations, syncope or presyncope. He underwent Carotid U/S that showed significant bilateral carotid stenosis, L>R. Angiography revealed an 80% stenosis of the R ICA and a 90% L ICA stenosis. Cerebral angiography further revealed patent right ACA and MCA and patent left ACA and left MCA.
Past Medical History:
CAD s/p CABG in [**2154**] ([**Hospital1 112**])
Prior CVA
Bilateral carotid artery disease
Anemia
PVD
Hypertension
Diabetes c/b retinopathy and peripheral neuropathy
Cataracts s/p surgery
Thyroid nodule
Colon polyps s/p resection
Intermittent Lower back pain
Proteinuria
s/p right elbow fracture as a child
Arthritis","Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol
        between the 60th and 90th percentiles.",Asymptomatic Carotid Artery Plaque Study (ACAPS),2
"74M hx of CAD s/p CABG, EF 60% prior CVA (no residual deficits), HTN, HL, DMII, Moderate to Severe PVD was referred to cardiology for evaluation of PVD, and on examination patient was found to have carotid bruits. Upon further review of symptoms the pt reports + Occasional dizziness, no prior syncope occasional HA, Denies CP/SOB. No sensory or motor defects. He recalls that he might have had a stroke 10-15 years ago without any residual deficit. Prior to CABG he only had diaphoresis.
Further review of systems is notable for absence of chest pain, dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, palpitations, syncope or presyncope. He underwent Carotid U/S that showed significant bilateral carotid stenosis, L>R. Angiography revealed an 80% stenosis of the R ICA and a 90% L ICA stenosis. Cerebral angiography further revealed patent right ACA and MCA and patent left ACA and left MCA.
Past Medical History:
CAD s/p CABG in [**2154**] ([**Hospital1 112**])
Prior CVA
Bilateral carotid artery disease
Anemia
PVD
Hypertension
Diabetes c/b retinopathy and peripheral neuropathy
Cataracts s/p surgery
Thyroid nodule
Colon polyps s/p resection
Intermittent Lower back pain
Proteinuria
s/p right elbow fracture as a child
Arthritis","Inclusion Criteria:

          -  TIA or non-severe stroke within 90 days prior to randomization (including day 90)

          -  Modified Rankin score of < 3

          -  High grade stenosis (50 to 99 percent) of a major intracranial artery (carotid artery,
             MCA stem (M1), vertebral artery,and basilar artery) documented by conventional
             angiography within 90 days prior to randomization (including day 90)

          -  TIA or stroke is attributed to high grade intracranial stenosis

          -  Age > 40 years

          -  Patient is able to follow an outpatient protocol(requiring monthly blood tests and
             clinic visits every four months for the duration of the study) and is available by
             telephone

          -  Patient understands the purpose and requirements of the study, can make him/herself
             understood, and has provided informed consent

        Exclusion Criteria:

          -  Extracranial carotid stenosis (> 50 percent) ipsilateral to stenosis of the
             intracranial carotid artery or MCA (ie.tandem stenoses, either of which could have
             caused patient's symptoms)

          -  Isolated stenosis of the anterior cerebral artery, posterior cerebral artery, MCA
             division, or a distal branch of the MCA

          -  Intracranial or extracranial arterial dissection, Moya Moya disease, vasculitis,
             radiation induced vasculopathy, fibromuscular dysplasia

          -  Presence of any of the following unequivocal cardiac sources of embolism: chronic or
             paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis,
             intracardiac clot or vegetation, myocardial infarction within three months, dilated
             cardiomyopathy, left atrial spontaneous echo contrast

          -  A contraindication to the use of either warfarin or aspirin e.g. active peptic ulcer
             disease, active bleeding diathesis, platelets < 100,000*, hematocrit < 30*, clotting
             factor abnormality that increases the risk of bleeding, alcohol or substance abuse,
             severe gait instability, cerebral hemorrhage, systemic hemorrhage within the past
             year, severe liver impairment (SGOT > 3x normal*, cirrhosis), allergy to aspirin or
             warfarin, uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic
             pressure > 115mm Hg), positive stool guaiac that is not attributable to hemorrhoids,
             creatinine > 3.0*

          -  Indication for intravenous heparin beyond randomization

          -  A severe neurological deficit that renders the patient incapable of living
             independently

          -  Dementia or psychiatric problem that prevents the patient from following an outpatient
             program reliably

          -  Co-morbid conditions that may limit survival to less than five years

          -  Pregnancy or female in age range of childbearing potential who is not using
             contraception

          -  Enrollment in another study that would conflict with the current study

          -  Excluded because difficult to measure percent stenosis of these small arteries,
             lesions are uncommon, and prognosis of patients - With these lesions is unknown * on
             most recent test done within 90 days prior to randomization, including day 90",Aspirin Or Warfarin To Prevent Stroke,1
"74M hx of CAD s/p CABG, EF 60% prior CVA (no residual deficits), HTN, HL, DMII, Moderate to Severe PVD was referred to cardiology for evaluation of PVD, and on examination patient was found to have carotid bruits. Upon further review of symptoms the pt reports + Occasional dizziness, no prior syncope occasional HA, Denies CP/SOB. No sensory or motor defects. He recalls that he might have had a stroke 10-15 years ago without any residual deficit. Prior to CABG he only had diaphoresis.
Further review of systems is notable for absence of chest pain, dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, palpitations, syncope or presyncope. He underwent Carotid U/S that showed significant bilateral carotid stenosis, L>R. Angiography revealed an 80% stenosis of the R ICA and a 90% L ICA stenosis. Cerebral angiography further revealed patent right ACA and MCA and patent left ACA and left MCA.
Past Medical History:
CAD s/p CABG in [**2154**] ([**Hospital1 112**])
Prior CVA
Bilateral carotid artery disease
Anemia
PVD
Hypertension
Diabetes c/b retinopathy and peripheral neuropathy
Cataracts s/p surgery
Thyroid nodule
Colon polyps s/p resection
Intermittent Lower back pain
Proteinuria
s/p right elbow fracture as a child
Arthritis","Inclusion Criteria:

          -  Symptomatic patients with recent neurological events (TIA or non-disabling stroke)
             with an associated carotid stenosis greater than or equal to 50% by angiography or
             greater than or equal to 70% by ultrasound or greater than or equal to 70% by Computed
             Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA) are eligible for
             randomization.

          -  Asymptomatic patients with no recent (in the last 6 months) neurological events
             referable to the study with artery and carotid stenosis (patients with symptoms beyond
             180 days are considered asymptomatic) greater than or equal to 60% by angiography or
             greater than or equal to 70% by ultrasound or greater than or equal to 80% by CTA or
             MRA are eligible for randomization.

        Exclusion Criteria:

          -  Conditions that: (1) interfere with the evaluation of endpoints, (2) are known to
             interfere with the completion of CEA or CAS, or (3) affect the likelihood of survival
             for the study period (4 years). Chronic atrial fibrillation and/or anti-coagulation or
             episodic atrial fibrillation within the last 6 months.",Carotid Revascularization Endarterectomy Versus Stenting Trial,2
"74M hx of CAD s/p CABG, EF 60% prior CVA (no residual deficits), HTN, HL, DMII, Moderate to Severe PVD was referred to cardiology for evaluation of PVD, and on examination patient was found to have carotid bruits. Upon further review of symptoms the pt reports + Occasional dizziness, no prior syncope occasional HA, Denies CP/SOB. No sensory or motor defects. He recalls that he might have had a stroke 10-15 years ago without any residual deficit. Prior to CABG he only had diaphoresis.
Further review of systems is notable for absence of chest pain, dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, palpitations, syncope or presyncope. He underwent Carotid U/S that showed significant bilateral carotid stenosis, L>R. Angiography revealed an 80% stenosis of the R ICA and a 90% L ICA stenosis. Cerebral angiography further revealed patent right ACA and MCA and patent left ACA and left MCA.
Past Medical History:
CAD s/p CABG in [**2154**] ([**Hospital1 112**])
Prior CVA
Bilateral carotid artery disease
Anemia
PVD
Hypertension
Diabetes c/b retinopathy and peripheral neuropathy
Cataracts s/p surgery
Thyroid nodule
Colon polyps s/p resection
Intermittent Lower back pain
Proteinuria
s/p right elbow fracture as a child
Arthritis","Inclusion criteria

          -  Patients with type 2 diabetes mellitus (DM), defined by medical record diagnosis,
             fasting glucose >140 mg/dl, or the use of diabetes medications

          -  Had a myocardial infarction (MI) any time in the past, a coronary angiogram within the
             previous year, or an exercise perfusion scan (stress thallium study) within one year

          -  Patients with CAD group, defined by the following criteria: documented prior MI,
             PTCA/stent, CABG, or >75% stenosis in any vessel by coronary angiography.

          -  Patients without CAD group, defined as: the absence of a prior MI and <50% stenosis in
             all vessels by coronary angiography within the past year, or the combination of a
             normal exercise perfusion scan and the absence of a prior MI or any interventional
             cardiac procedures.

        Exclusion criteria

          -  MI or cardiac procedures within the past 3 months

          -  Diagnoses of cancer, severe congestive heart failure (ejection fraction < 20%), kidney
             or liver disease, pancreatitis, other gastrointestinal conditions,

          -  Laboratory values of creatinine levels > 1.3, abnormal liver function tests, abnormal
             CBC, fasting TG > 400 mg/dl, urine protein > 2+ on urinalysis or > 1000 mg/24 h,
             abnormal thyroid function tests, body mass index (BMI) > 34 for men and > 37 for women
             or BMI < 20 for both sexes

          -  Age < 35 or > 75 years","Diabetes, Lipoproteins and Accelerated Vascular Disease",2
"Patient is a 55yo woman with h/o ESRD on HD and peritoneal dialysis who presented with watery, non bloody diarrhea and weakness. She has a history of 2 prior C diff infections, the most recent just 1 month ago. Recent antibx use in the last month on prior admission. Was also txd for Cdiff at that time for 14 d. course with po vanco. Pt was initially admitted to the ICU and was septic on pressors (levophed) until the morning of [**8-26**] with leukocytosis but no fever. C diff assay positive on admission, and pt had leukocytosis consistent with C diff. Patient was placed on Vanco po, Flagyl IV and Flagyl po initially, and when patient improved she was transitioned to Vanco oral and Flagyl oral on [**8-29**]. Patient was treated with Vanco for an extended course of 6 weeks given her recurrent C diff. Pt was also encouraged to take probiotics and to bleach her home when she was discharged.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage IV melanoma that is recurrent or progressing and
             unlikely to respond to existing therapy

          -  Measurable disease by MRI or CT scan

               -  Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary,
                  inguinal, or femoral areas and at least 0.5 cm in other locations

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  WBC at least 2,000/mm3

          -  Platelet count at least 50,000/mm3

        Hepatic:

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT and SGPT no greater than 5 times the upper limit of normal

          -  No hepatic insufficiency

        Renal:

          -  Creatinine no greater than 2.5 mg/dL

          -  No renal insufficiency

          -  No renal conditions that contraindicate high dosages of sodium

        Cardiovascular:

          -  No chronic heart failure

          -  No uncontrolled hypertension

          -  No history of congestive heart failure

          -  No other cardiovascular conditions that contraindicate high dosages of sodium

        Pulmonary:

          -  No severe lung disease, such as chronic obstructive pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 4 weeks after study

          -  No serious medical or psychiatric disorders

          -  No active infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy and recovered

          -  No concurrent immunomodulating agents

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No concurrent antineoplastic agents

        Endocrine therapy:

          -  Concurrent corticosteroids allowed

        Radiotherapy:

          -  At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors
             who have received radiotherapy to some, but not all, tumors may be admitted earlier
             than 8 weeks)

        Surgery:

          -  Recovered from prior surgery

        Other:

          -  Prior cytodifferentiating agent allowed

          -  No prior antineoplaston therapy",Antineoplaston Therapy in Treating Patients With Stage IV Melanoma,0
"Patient is a 55yo woman with h/o ESRD on HD and peritoneal dialysis who presented with watery, non bloody diarrhea and weakness. She has a history of 2 prior C diff infections, the most recent just 1 month ago. Recent antibx use in the last month on prior admission. Was also txd for Cdiff at that time for 14 d. course with po vanco. Pt was initially admitted to the ICU and was septic on pressors (levophed) until the morning of [**8-26**] with leukocytosis but no fever. C diff assay positive on admission, and pt had leukocytosis consistent with C diff. Patient was placed on Vanco po, Flagyl IV and Flagyl po initially, and when patient improved she was transitioned to Vanco oral and Flagyl oral on [**8-29**]. Patient was treated with Vanco for an extended course of 6 weeks given her recurrent C diff. Pt was also encouraged to take probiotics and to bleach her home when she was discharged.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage IV adenocarcinoma or transitional cell carcinoma of the
             kidney that is unlikely to respond to existing therapy

          -  Measurable disease by MRI or CT scan

          -  Tumor must be more than 2 cm for lymph nodes in head, neck, axillary, inguinal, or
             femoral areas and at least 0.5 cm for other locations

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 50,000/mm^3

        Hepatic:

          -  No hepatic insufficiency

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT and SGPT no greater than 5 times upper limit of normal

        Renal:

          -  No renal insufficiency

          -  Creatinine no greater than 2.5 mg/mL

          -  No history of renal conditions that contraindicate high dosages of sodium

        Cardiovascular:

          -  No known chronic heart failure

          -  No uncontrolled hypertension

          -  No history of congestive heart failure

          -  No history of other cardiovascular conditions that contraindicate high dosages of
             sodium

        Pulmonary:

          -  No severe lung disease, such as chronic obstructive pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 4 weeks after study
             participation

          -  Not a high medical or psychiatric risk

          -  No concurrent nonmalignant systemic disease that would preclude therapy

          -  No active infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy

          -  No concurrent immunomodulatory agents

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No concurrent antineoplastic agents

        Endocrine therapy:

          -  Concurrent corticosteroids allowed

        Radiotherapy:

          -  At least 8 weeks since prior radiotherapy and recovered

        Surgery:

          -  Recovered from prior surgery

        Other:

          -  Prior cytodifferentiating agents allowed

          -  No prior antineoplastons",Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer,0
"Patient is a 55yo woman with h/o ESRD on HD and peritoneal dialysis who presented with watery, non bloody diarrhea and weakness. She has a history of 2 prior C diff infections, the most recent just 1 month ago. Recent antibx use in the last month on prior admission. Was also txd for Cdiff at that time for 14 d. course with po vanco. Pt was initially admitted to the ICU and was septic on pressors (levophed) until the morning of [**8-26**] with leukocytosis but no fever. C diff assay positive on admission, and pt had leukocytosis consistent with C diff. Patient was placed on Vanco po, Flagyl IV and Flagyl po initially, and when patient improved she was transitioned to Vanco oral and Flagyl oral on [**8-29**]. Patient was treated with Vanco for an extended course of 6 weeks given her recurrent C diff. Pt was also encouraged to take probiotics and to bleach her home when she was discharged.","Inclusion Criteria:

          -  Major depression assessed by Structured Clinical Interview for DSM-IV Axis I Disorders
             (SCID; First et al, 1995)

          -  Minimum score greater than or equal to 20 on the 17-item Hamilton Depression (HAM-D)
             Scale at screen and at baseline

          -  GAF of 60 or less (moderate symptoms) at screen and at baseline

          -  HAM-D cannot decrease by 25% or more between screening and baseline

          -  Capacity to give informed consent and to follow study procedures.

          -  Abstinence or effective method of contraception throughout the study

        Exclusion Criteria:

          -  Scores greater than 2 on the ""suicide"" item of HAM-D, or history of suicide attempt(s)
             in the past 12 months

          -  Current suicidal or homicidal risk, as determined by the investigator

          -  Women of childbearing age who are pregnant, planning pregnancy in the next 6 months,
             breast-feeding, or not using medically acceptable means of birth control (hormonal
             treatment such as birth control pill, injection or implant, IUD, or double barrier of
             condom and diaphragm together is acceptable; primary use of condom, sponge or
             diaphragm alone (single barrier) is not acceptable because these may carry a higher
             rate of failure when used alone

          -  Clinically significant liver disease (such as hepatitis, cirrhosis, etc); or
             clinically significant elevation of liver enzyme tests (two times the upper limit of
             normal; asymptomatic Gilbert's syndrome is not an exclusion). 4. Serious or unstable
             medical illness. 5. History of seizure disorder (other than febrile).

          -  Any of the following DSM-IV diagnoses by SCID: current (within past 6 months) alcohol
             or other substance abuse disorder; schizophrenia, schizo-affective, or other psychotic
             disorder; bipolar disorder; current panic disorder or obsessive compulsive disorder;
             history of psychotic features of affective disorder (mood congruent or incongruent)

          -  Clinical or laboratory evidence of untreated or unstable thyroid disorder

          -  Failed to respond to at least two adequate antidepressant trials (defined as 6 weeks
             or more treatment with either greater than or equal to 150 mg imipramine, or tricyclic
             equivalent), or greater than or equal to 60 mg of phenelzine, or MAOI equivalent, or
             greater than or equal to 100 mg of sertraline, or its SSRI equivalent

          -  Have taken sertraline or any form of hypericum during this current episode of
             depression at any dose level, daily, for at least one month, within the past 6 months

          -  Current (within past 6 months) use of other prescription or non-prescription drugs,
             including anticonvulsants and other medications with significant psychotropic
             properties, antiretroviral medications, cyclosporine, digoxin, coumadin, dietary
             supplements, natural remedies, and botanical preparations (eg, hypericum, kava,
             valerian)

          -  Have had other investigational drugs within 30 days or other psychotropic medication
             within 21 days of baseline (6 weeks for fluoxetine)

          -  Known allergy or hypersensitivity to the study medications

          -  Positive drug urine screen

          -  Have been in psychotherapy for 2 months or less at the time of enrollment into the
             study

          -  Receiving psychotherapies which are specifically designed to treat depression, eg,
             interpersonal psychotherapy during the study period

          -  Mental retardation or cognitive impairment, or any disorder that might interfere with
             their ability to consent or follow study procedures and requirements",Treatment of Major Depression With St. John's Wort (Hypericum),0
"Patient is a 55yo woman with h/o ESRD on HD and peritoneal dialysis who presented with watery, non bloody diarrhea and weakness. She has a history of 2 prior C diff infections, the most recent just 1 month ago. Recent antibx use in the last month on prior admission. Was also txd for Cdiff at that time for 14 d. course with po vanco. Pt was initially admitted to the ICU and was septic on pressors (levophed) until the morning of [**8-26**] with leukocytosis but no fever. C diff assay positive on admission, and pt had leukocytosis consistent with C diff. Patient was placed on Vanco po, Flagyl IV and Flagyl po initially, and when patient improved she was transitioned to Vanco oral and Flagyl oral on [**8-29**]. Patient was treated with Vanco for an extended course of 6 weeks given her recurrent C diff. Pt was also encouraged to take probiotics and to bleach her home when she was discharged.",No eligibility criteria,Genetic Analysis of Human Hypertensive End Stage Renal Disease (H-ESRD),0
"60 yo M with Hep C cirrhosis, grade II esophageal varices, recent admission for UGIB [**2-9**] NSAID gastritis, referred for admission throught the ED by hepatology clinic for new slurred speech and tangential thought process. Patient also describes new imbalance leading to a fall during which he may have hit his head on. Per last liver clinic note has been off ETOH for a year (corroborated with pt), utox was negative for alocohol. CT was within normal limits, and neuro evaluation determined this was not ischemic infart. Patient was given a presumptive diagnosis of hepatic encephalopathy and started on lactulose. Liver function tests showed a striking increase in his total and direct bilirubin since last visit. Another worrisome feature was the increase in the patient's AFP. This could be progression of cirrhosis as he failed interferon twice. He is to follow-up as an outpatient to work this up.
Past Medical History:
HCV Cirrhosis (tx with interferon x2 with no response)
Portal Gastropathy
Grade II Esophageal varices
HTN
Recent admission [**4-/2150**]: UGIB [**2-9**] non-steroidal induced
gastritis","INCLUSION CRITERIA:

        Subjects selected will be between the ages of 12 and 18 years.

        All subjects must score within normal limits on measures of threshold sensitivity, speech
        recognition in quiet, middle ear function and TEOAEs to be included in the study.

        Group A subjects must be identified as having learning or attention problems in school and
        show show reduced scores on speech-in-noise tasks.

        Group B subjects must demonstrate speech-in-noise scores within normal limits.

        Groups will be matched for sex, age and handedness.

        EXCLUSION CRITERIA:

        Subjects will be excluded for history of voice disorders, autism, stuttering, aphasia,
        multiple sclerosis, traumatic brain injury, severe language disorders and psychiatric
        disorders.

        Children who are being treated for hyperactivity disorder will be excluded.

        Children who are taking medication prescribed for hyperactivity, anxiety or depression may
        be excluded.

        Children younger than 12 will be excluded.",Testing a Possible Cause of Reduced Ability of Children to Process Speech in Noise,0
"60 yo M with Hep C cirrhosis, grade II esophageal varices, recent admission for UGIB [**2-9**] NSAID gastritis, referred for admission throught the ED by hepatology clinic for new slurred speech and tangential thought process. Patient also describes new imbalance leading to a fall during which he may have hit his head on. Per last liver clinic note has been off ETOH for a year (corroborated with pt), utox was negative for alocohol. CT was within normal limits, and neuro evaluation determined this was not ischemic infart. Patient was given a presumptive diagnosis of hepatic encephalopathy and started on lactulose. Liver function tests showed a striking increase in his total and direct bilirubin since last visit. Another worrisome feature was the increase in the patient's AFP. This could be progression of cirrhosis as he failed interferon twice. He is to follow-up as an outpatient to work this up.
Past Medical History:
HCV Cirrhosis (tx with interferon x2 with no response)
Portal Gastropathy
Grade II Esophageal varices
HTN
Recent admission [**4-/2150**]: UGIB [**2-9**] non-steroidal induced
gastritis","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Orthostatic hypotension due to autonomic nervous system
        failure, i.e.: Fall in systolic blood pressure (supine to standing) of at least 15 mm Hg
        AND Symptoms of dizziness, lightheadedness, unsteadiness with a severity of 4.5 or less on
        a 10 point scale in 2 of 3 evaluations over a 3 day period --Prior/Concurrent Therapy-- No
        concurrent sympathomimetics or alpha-receptor agonists or antagonists No concurrent drug
        with significant smooth muscle relaxant or constrictive properties e.g., calcium channel
        blockers At least 30 days since other prior investigational agents --Patient
        Characteristics-- Hepatic: No coagulopathy Renal: No acute nephritis or chronic renal
        failure Cardiovascular: No sustained supine hypertension greater than 180/110 mm Hg No
        congestive heart failure No myocardial infarction within the last 6 months No uncontrolled
        arrhythmia (ventricular tachycardia or second or third degree heart block not treated with
        pacemaker) No unstable angina pectoris No history of cerebral vascular accident Other: No
        pheochromocytoma No thyrotoxicosis No seizure disorder Not pregnant or nursing Negative
        pregnancy test Fertile patients must use effective contraception",Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension,0
"60 yo M with Hep C cirrhosis, grade II esophageal varices, recent admission for UGIB [**2-9**] NSAID gastritis, referred for admission throught the ED by hepatology clinic for new slurred speech and tangential thought process. Patient also describes new imbalance leading to a fall during which he may have hit his head on. Per last liver clinic note has been off ETOH for a year (corroborated with pt), utox was negative for alocohol. CT was within normal limits, and neuro evaluation determined this was not ischemic infart. Patient was given a presumptive diagnosis of hepatic encephalopathy and started on lactulose. Liver function tests showed a striking increase in his total and direct bilirubin since last visit. Another worrisome feature was the increase in the patient's AFP. This could be progression of cirrhosis as he failed interferon twice. He is to follow-up as an outpatient to work this up.
Past Medical History:
HCV Cirrhosis (tx with interferon x2 with no response)
Portal Gastropathy
Grade II Esophageal varices
HTN
Recent admission [**4-/2150**]: UGIB [**2-9**] non-steroidal induced
gastritis","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Biopsy proven primary biliary cirrhosis (PBC); Disproportionate
        increase in alkaline phosphatase; Positive antimitochondrial antibody test OR Symptoms
        consistent with PBC, e.g.: pruritus, fatigue, malaise, jaundice, elevated bilirubin

        No clinically advanced PBC, i.e.: bilirubin greater than 10 mg/dL or albumin less than 2.5
        g/dL, determined by 2 analyses 10 weeks apart; bleeding esophageal varices or congestive
        gastropathy; chronic hepatic encephalopathy; chronic ascites

        --Prior/Concurrent Therapy-- No concurrent drugs associated with chronic liver disease

        --Patient Characteristics--

        Hematopoietic: WBC at least 2500 Platelets at least 100,000 (unless due to hypersplenism);
        Hematocrit at least 30%

        Renal: No renal disease that could cause liver dysfunction

        Other: No history of alcohol abuse; No other medical illness that might cause liver
        dysfunction, e.g., severe cardiac failure; No pregnant women",Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis,0
"60 yo M with Hep C cirrhosis, grade II esophageal varices, recent admission for UGIB [**2-9**] NSAID gastritis, referred for admission throught the ED by hepatology clinic for new slurred speech and tangential thought process. Patient also describes new imbalance leading to a fall during which he may have hit his head on. Per last liver clinic note has been off ETOH for a year (corroborated with pt), utox was negative for alocohol. CT was within normal limits, and neuro evaluation determined this was not ischemic infart. Patient was given a presumptive diagnosis of hepatic encephalopathy and started on lactulose. Liver function tests showed a striking increase in his total and direct bilirubin since last visit. Another worrisome feature was the increase in the patient's AFP. This could be progression of cirrhosis as he failed interferon twice. He is to follow-up as an outpatient to work this up.
Past Medical History:
HCV Cirrhosis (tx with interferon x2 with no response)
Portal Gastropathy
Grade II Esophageal varices
HTN
Recent admission [**4-/2150**]: UGIB [**2-9**] non-steroidal induced
gastritis","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Clinical diagnosis of cirrhosis with portal hypertension or portal-systemic shunting

        --Prior/Concurrent Therapy--

          -  No concurrent therapy for hepatic encephalopathy

        --Patient Characteristics--

          -  Age: Under 65

          -  Performance status: Not specified

          -  Hematopoietic: Not specified

          -  Hepatic: See Disease Characteristics

          -  Renal: Not specified

          -  Other: No alcohol intake within 1 month prior to entry No requirement for beta
             blockers No requirement for corticosteroids Not in intercontinental travel",Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis,1
"60 yo M with Hep C cirrhosis, grade II esophageal varices, recent admission for UGIB [**2-9**] NSAID gastritis, referred for admission throught the ED by hepatology clinic for new slurred speech and tangential thought process. Patient also describes new imbalance leading to a fall during which he may have hit his head on. Per last liver clinic note has been off ETOH for a year (corroborated with pt), utox was negative for alocohol. CT was within normal limits, and neuro evaluation determined this was not ischemic infart. Patient was given a presumptive diagnosis of hepatic encephalopathy and started on lactulose. Liver function tests showed a striking increase in his total and direct bilirubin since last visit. Another worrisome feature was the increase in the patient's AFP. This could be progression of cirrhosis as he failed interferon twice. He is to follow-up as an outpatient to work this up.
Past Medical History:
HCV Cirrhosis (tx with interferon x2 with no response)
Portal Gastropathy
Grade II Esophageal varices
HTN
Recent admission [**4-/2150**]: UGIB [**2-9**] non-steroidal induced
gastritis","Inclusion Criteria:

          -  Age at entry at least 18 years.

          -  Positive for Hepatitis C.

          -  Previous treatment with any interferon or interferon and ribavirin for at least 3
             months.

          -  Documented non-response to treatment with interferon.

          -  A liver biopsy demonstrating significant liver scarring.

        Exclusion Criteria:

          -  No other liver disease.

          -  No unstable major medical diseases or conditions.

          -  No major complications of cirrhosis.

          -  No recent abuse of alcohol or illicit drugs.",Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,2
"60 yo M with Hep C cirrhosis, grade II esophageal varices, recent admission for UGIB [**2-9**] NSAID gastritis, referred for admission throught the ED by hepatology clinic for new slurred speech and tangential thought process. Patient also describes new imbalance leading to a fall during which he may have hit his head on. Per last liver clinic note has been off ETOH for a year (corroborated with pt), utox was negative for alocohol. CT was within normal limits, and neuro evaluation determined this was not ischemic infart. Patient was given a presumptive diagnosis of hepatic encephalopathy and started on lactulose. Liver function tests showed a striking increase in his total and direct bilirubin since last visit. Another worrisome feature was the increase in the patient's AFP. This could be progression of cirrhosis as he failed interferon twice. He is to follow-up as an outpatient to work this up.
Past Medical History:
HCV Cirrhosis (tx with interferon x2 with no response)
Portal Gastropathy
Grade II Esophageal varices
HTN
Recent admission [**4-/2150**]: UGIB [**2-9**] non-steroidal induced
gastritis","Inclusion Criteria

        All of the following criteria must be met:

          -  Gestation age (GA) at birth >= 28 weeks

          -  Discharged to home care with parent or other guardian who has legal authority to give
             informed consent

          -  Greater than 10th percentile for GA at birth using the scales according to Lubchenco,
             Hansman, and Boyd from Pediatrics 1966 volume 37 and Battaglia and Lubchenco in the
             Journal of Pediatrics 1967 volume 71

          -  Jewelry in pierced body parts can be removed

          -  Mothers > 17 years old

          -  Recruited within 60 days of EDC (estimated date of conception)

        Two or more of the following must be met:

          -  Intrapartum distress as determined by placental abruption, thick meconium staining of
             amniotic fluid, sustained fetal bradycardia of heart rate < 100 beats/min, or late or
             absent heart rate variability

          -  Profound metabolic or mixed academia as determined by umbilical artery pH < 7.0, base
             deficit of > 10 mEq/L or pH < 7.1 and base excess greater than 14 mmol/L within 72
             hours of birth, Apgar score < 5 at 5 minutes or beyond, or need for positive pressure
             ventilation resuscitation for > 1 min after birth

          -  Neonatal neurological manifestations such as seizures during hospital stay, lethargy,
             hypotonia or hypertonia, stupor, flaccidity, or decerebration

          -  Multiple organ system dysfunction

          -  Abnormal EEG, CT scan, or MRI consistent with hypoxic or ischemic brain insult

        Exclusion Criteria:

          -  Infants of substance abusing mothers (ISAM)

          -  Intrauterine growth retardation (IUGR)

          -  Infants requiring extracorporeal membrane oxygenation (ECMO) in the neonatal period

          -  Hearing or visual impairment

          -  Congenital cyanotic heart disease with cyanosis and requiring PGE infusion. Children
             with minimum cardiac structural anomalies (e.g., PDA or VSD or peripheral pulmonary
             stenosis) will not be excluded from the study.

          -  Congenital abnormalities of the central nervous system such as congenital
             hydrocephalus

          -  Grade IV intraventicular hemorrhage requiring ventriculo-peritoneal shunt (VP shunt)

          -  Trisomy 13, 18, or 21, or Fragile X

          -  Metabolic encephalopathy from inborn errors of metabolism (e.g. PKU, OTC)

          -  Metal or wire mesh implants, pacemaker implants, cochlear implants, orthopedic
             surgical wires or implants

          -  Status epilepticus

          -  Ventilator dependent at discharge

          -  Infectious meningitis

          -  Encephalitis with radiological evidence of severe cortical or severe hemispheric
             destruction

          -  Silastic catheters, broviacs, or Hickman port home TPA

          -  Infants who may not be available for the duration of the study

          -  Any infant who in the opinion of investigator has no potential to benefit from the
             intervention (e.g., children with prenatal herpes meningitis, severe cortical
             destruction, mother does not follow up with the intervention or with the follow-up
             appointments)",Home Stimulation for Brain-Asphyxiated Infants,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Antihypertensive agents.

        Concurrent Treatment:

        Allowed:

          -  Blood products.

          -  Ventilatory support.

        Prior Medication:

        Required:

          -  At least 7 days trimethoprim / sulfamethoxazole or parenteral pentamidine.

          -  Allowed:

          -  Myelosuppressive or nephrotoxic agents including zidovudine, but must be discontinued
             during trial.

        No improvement in ventilatory status, defined as no change or a decrease in arterial or
        alveolar difference ((A-a) DO2) in the 72 hours prior to entry. (A-a) DO2 should be
        determined on room air, or receiving an FiO2 of 100 percent for 10 minutes via a tightly
        fitting non-rebreathing mask, or at an FiO2 of 100 percent for 10 minutes if the patient is
        being ventilated. Intolerance to TMP / SMX is defined as one or more of the following:

          -  Platelets < 50000 platelets/mm3 or absolute neutrophil count (polys + bands) = or <
             500 cells/mm3 on at least two occasions = or > 12 hours apart.

          -  Blistering rash, mucosal involvement, generalized maculopapular eruption or
             intolerable pruritus.

          -  Transaminase > 5 x ULN or = or > 300 IU if baseline abnormal.

          -  Daily temperature = or > 103 degrees F beginning after the 5th day of treatment and
             persisting for at least 3 days and not responsive to antipyretic therapy, with no
             other discernible cause.

          -  Any other severe or life-threatening adverse reaction to TMP / SMX that, in the
             investigator's opinion, makes continued or recurrent treatment with TMP / SMX
             inadvisable (approved on a case-by-case basis by the NIAID clinical monitor).

          -  Intolerance to pentamidine is defined as one or more of the following:

          -  Platelets < 50000 platelets/mm3 or absolute neutrophil count (polys + bands) < 550
             cells/mm3 on at least two occasions = or > 12 hours apart.

          -  Serum creatinine > 3.0 mg/dl.

          -  Systolic blood pressure < 90 mm requiring supportive therapy.

          -  Symptomatic hypoglycemia with blood glucose = or < 40 or hyperglycemia requiring
             therapy.

          -  Pancreatitis with laboratory confirmation (abnormal amylase and/or lipase).

          -  Any other severe or life-threatening adverse reaction to pentamidine that, in the
             investigator's opinion, makes continued or recurrent treatment with pentamidine
             inadvisable (approved on a case-by-case basis by the NIAID clinical monitor).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reactions due to trimetrexate.

          -  Patients with less severe adverse reactions may be enrolled if, in the opinion of the
             investigator, they do not prohibit rechallenge with the drug.

        Concurrent Medication:

        Excluded:

          -  Myelosuppressive or nephrotoxic agents.

          -  Other investigational drugs including high-dose steroids (exceeding physiologic
             replacement doses).

        Patients with the following are excluded:

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reactions due to trimetrexate.

          -  Patients with less severe adverse reactions may be enrolled if, in the opinion of the
             investigator, they do not prohibit rechallenge with the drug.",A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","-  INCLUSION CRITERIA:

        A. ALPS Natural History sample size and demographics:

        Study size: up to 1000 patients, patients, relatives and normal controls.

        Sex Distribution: Male and female

        Age range: All ages acceptable

        B. Eligibility Criteria for Natural History Study:

          1. To be considered as having ALPS, patients must elevated TCR alpha/beta+ CD4-8-
             peripheral blood DNT cells (equal to or greater than 1.5 percent of total lymphocytes
             or 2.5 percent of CD3+ lymphocytes) in the setting of normal or evalted lymphocyte
             counts.

          2. A history of chronic (greater than 6 months) non-malignant, non-infectious
             lymphadenopathy and/or splenomegaly.

          3. Willingness to allow blood, tissue and other samples to be stored.

          4. Patients with RALD (RAS associated leukoproliferative disorders) who present with
             autoimmunity, lymphadenopathy and/or splenomegaly, with elevated or normal DNT s and
             somatic mutations in NRAS and KRAS

        C. Eligibility Criteria for Screening potential patients:

          1. A history of chronic (greater than 6 months) lymphadenopathy and/or splenomegaly.

          2. Willingness to allow blood, tissue and other samples to be stored.

        D. Screening criteria for ALPS Relatives:

          1. Extended family members of an ALPS patient are eligible for genetic screening to
             determine if they carry the mutation found in their family.

          2. Willingness to allow blood, tissue and other samples to be stored.

        E. Eligibility of special populations:

        1. Women who are pregnant or breast feeding are eligible to enroll as probands or
        relatives. However, certain obstetric issues may pose a safety risk for travel and
        evaluation here. Eligibility for this group will be determined on a case by case basis by
        the PI. This protocol is not actively seeking women who are pregnant

        F. 1. Apheresis will be done only on healthy volunteers or patients with ALPS who have
        adequate peripheral venous access. Women of childbearing age must have a negative pregnancy
        test within 24 hours of the procedure and must not be breast-feeding.

        EXCLUSION CRITERIA:

        1. Any condition that the Principal Investigator deems to be non-conducive to the research
        goals of the study.",Study of Autoimmune Lymphoproliferative Syndrome (ALPS),0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","-  INCLUSION CRITERIA:

        Diagnosis of chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) will be
        made according to the World Health Organization (WHO) diagnostic classification. A
        lymphocyte count in excess of 5000/mcl is typically found in the leukemic variant but is
        not a pre-requisite for a diagnosis of SLL. Low, Intermediate or High-Risk Category of
        CLL/SLL, using the Modified Three-Stage Rai Staging System as follows:

        Risk Category: Low Risk

        Rai Stage: 0

        Clinical Features: Elevated blood and marrow lymphocyte numbers only (L). (lymphocytes
        greater than 5000/microl in blood, and lymphocytes greater than 30 percent in marrow).

        Risk Category: Intermediate Risk

        Rai Stage: I

        Clinical Features: L + enlarged lymph nodes (LN)

        Risk Category: Intermediate Risk

        Rai Stage: II

        Clinical Features: L + enlarged spleen or liver

        Risk Category: High Risk

        Rai Stage: III

        Clinical Features: L + anemia (Hemoglobin less than 11 gm/dl)

        Risk Category: High Risk

        Rai Stage: IV

        Clinical Features: L + thrombocytopenia (platelets less than 100,000/microl)

        Patients in the modified Rai high risk group and select patients in the intermediate risk
        group will undergo treatment with Rituximab Fludarabine. To meet treatment criteria
        patients in the intermediate risk group should have evidence of active disease as
        demonstrated by at least one of the following criteria:

          1. massive or progressive splenomegaly or lymphadenopathy;

          2. presence of weight loss greater than 10% over the preceding 6 months;

          3. constitutional symptoms of extreme fatigue, night sweats or recurrent fever of greater
             than 100 degrees F (documented fevers must be occurring without evidence of specific
             infection), and bone pain;

          4. progressive lymphocytosis with an increase of greater than 50% over a 2 month period,
             or an anticipated doubling time of less than 6 months;

          5. chronic infections either increased number or prolonged infections;

          6. other high risk prognostic indicators such as excess elevation of
             beta-2-microglobulin, cluster differentiation 38 (CD38) expression and adverse
             cytogenetics may be used to better appraise the risk in each individual patient.

        Patients with a diagnosis of CLL/SLL who do not meet the eligibility criteria for receiving
        Rituximab and Fludarabine (are not intermediate- or high-risk CLL/SLL), can enroll on the
        protocol for the purpose of donating cellular products. Such patients will not receive
        rituximab and fludarabine chemotherapy. At a later date, if it is documented that the
        patient does meet the criteria, then the patient may receive Rituximab and Fludarabine
        (after discussion with the Principal Investigator).

        In a limited number of cases, patients with low-risk CLL/SLL may be initiated on Rituximab
        and Fludarabine treatment. For example, individuals who are candidates for bone marrow
        transplantation may be started on Rituximab Fludarabine as an induction regimen prior to
        transplantation. Additionally, some low-risk patients may be started on Rituximab and
        Fludarabine for psychological reasons (patient insistence on starting chemotherapy prior to
        disease progression). However, it must be stressed that low-risk CLL/SLL patients will be
        discouraged from initiating therapy except in these specific cases.

        Age greater than or equal to 18 years of age.

        Patients must have received no prior cytotoxic or monoclonal antibody therapy.

        Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

        Required initial laboratory tests: Blood urea nitrogen (BUN) and Creatinine values must be
        less than or equal to 1.5 times the normal values; alternatively, patients with creatinine
        clearance of greater than 50 ml per minute will also be eligible. Aspartate
        aminotransferase (AST) and alanine aminotransferase (ALT) values must be less than or equal
        to 2.0 times normal values; patients with laboratory values greater than these levels may
        be enrolled on the protocol (after a specific approval from the Principal Investigator) if
        the values are due to a known, pre-existing liver disease. Bilirubin must be less than or
        equal to 2.0 mg/dl unless due to Gilbert's disease.

        The patient must be competent to sign an informed consent, and sign the protocol consent
        form.

        EXCLUSION CRITERIA:

        Patients must not be pregnant or breastfeeding.

        Patients with active autoimmune hemolytic anemia (AIHA)) grade III or higher (transfusion
        or steroids indicated) or immune thrombocytopenia (ITP) grade III or higher (platelets less
        than 50,000/microL) shall not be enrolled. Patients with a history of prior therapy to
        control either AIHA or ITP will be eligible, provided they do not require maintenance
        corticosteroids, and have not received monoclonal antibody therapy in the past 6 months.
        Patients developing AIHA or ITP on protocol may be managed as medically indicated on
        protocol but will generally not undergo fludarabine/rituximab treatment until resolution of
        hemolysis or thrombocytopenia to less than grade III.

        Any patient with a medical condition that requires chronic use of corticosteroids shall not
        be enrolled.",Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis,1
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","MDS of RA & RAEB sub-types.

        No current treatment and off other treatments for at least two weeks.

        ECOG performance status less than or equal to 2.

        No MDS of FAB sub-group' refractory anemia with ring sideroblasts' (RARS).

        No transforming to acute leukemia (FAB sub-group RAEB-Tie.; greater than 20% blasts in
        marrow aspirate).

        No hypoplastic marrow without one major or two minor criteria as outlined in table 3 of the
        appendix.

        No one being treatment with growth factors or cyclosporine within four weeks prior to entry
        to protocol.

        No previous treatment with ATG.

        No ECOG performance status of greater than 2.

        No active uncontrolled infection.

        No women which current pregnancy, or unwilling to take oral contraceptives if of
        childbearing potential.

        No patients for whom bone marrow transplant is indicated as primary therapy.

        No one age less than 18 years.

        Must be able to give informed consent.

        No HIV positive patients.

        No active malignant disease (excluding basal cell carcinoma).

        No one with serum creatine greater than 2mg/dl.

        No patients who are moribund or patients with concurrent hepatic, renal, cardiac,
        metabolic, or any disease of such severity that death within 7-10 days is likely.",A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","Inclusion Criteria

        Patients must have:

          -  HIV seropositivity by Western blot.

          -  Advanced ARC or AIDS as defined by CDC.

          -  Cytopenia defined as total peripheral leukocyte count of < 3,000 cells/mm3 or platelet
             count of < 100,000 cells/mm3 or serum hemoglobin < 10 g/dl.

          -  Anticipated life expectancy = or > 6 months.

          -  Ambulatory.

          -  Willing to sign informed consent.

          -  Willing to forego use of any other investigational therapies except ddI.

        Prior Medication:

        Allowed > 2 weeks prior to study entry:

          -  zidovudine.

          -  Allowed > 4 weeks prior to study entry:

          -  systemic cytotoxic chemotherapy; investigational drugs; medications known to be
             myelosuppressive as ganciclovir, trimethoprim/sulfamethoxazole or dapsone.

          -  Allowed > 6 weeks prior to study entry:

          -  other hemopoietic growth factor treatment as GM-CSF, EPO.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Active opportunistic infection.

          -  Symptoms of CNS disease referable to HIV infection.

          -  Dementia or altered mental status that would prohibit giving and understanding
             informed consent.

        Systemic chemotherapy.

          -  Investigational therapies other than ddI.

          -  Medications with known myelosuppressive effects such as ganciclovir,
             trimethoprim/sulfamethoxazole or dapsone or AZT.

          -  Other hematopoietic growth factor treatments as GM-CSF, G-CSF, or EPO.

        Prophylactic therapy for pneumocystis or oral thrush.

          -  ddI.

          -  Corticosteroids or topical corticosteroid creams.

        Patients may not have:

          -  Life expectancy < 6 months.

          -  Active drug or alcohol abuse.

          -  Active opportunistic infections.

          -  Treatment with any other investigational drugs except ddI within 4 weeks of study
             entry.

          -  Dementia or altered mental state that prohibits giving informed consent.

          -  Symptoms of CNS disease referable to HIV infection.

          -  Major surgery within 4 weeks of study entry.

          -  History of major pulmonary or cardiac disease.

          -  History of any prior malignancy other than Kaposi's sarcoma or noninvasive
             subcutaneous carcinoma.

          -  Documented allergic disorder such as asthma, history of anaphylaxis, atopy, serum
             sickness, or bronchospasm.

        Not allowed within 2 weeks prior to study entry:

          -  zidovudine (AZT).

          -  Not allowed within 4 weeks prior to study entry:

          -  systemic cytotoxic chemotherapy; investigational drugs other than ddI; medications
             known to be myelosuppressive as ganciclovir, trimethoprim/sulfamethoxazole or dapsone.

          -  Not allowed within 6 weeks prior to study entry:

          -  other hematopoietic growth factor treatment as GM-CSC, G-CSF, EPO.

        Radiation therapy or major surgery within 4 weeks of study entry.

        Active drug or alcohol abuse.","A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia",0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","Exclusion Criteria

        Co-existing Condition:

        Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal
        dysfunction, or gastric ulceration are excluded.

        Concurrent Medication:

        Excluded:

          -  Systemic corticosteroids.

          -  Cytotoxic immunosuppressive agents.

          -  Radiotherapy.

        Critically ill patients or those with CDC-defined AIDS are excluded.

        Prior Medication:

        Excluded within 1 month of study entry:

          -  Immunotherapy.

        Patients with persistent generalized lymphadenopathy (PGL).",A Study of Isoprinosine in Patients With Lymph Node Disease,1
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","DISEASE CHARACTERISTICS:

          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL) requiring therapy and meeting
             the following criteria:

               -  Previously untreated disease

               -  Peripheral blood morphology, excluding other leukemia and low-grade lymphoma in
                  leukemic phase

               -  Cell markers: CD5+, CD23+, SmIg (weak), CD79b-, FMC7-

               -  Persistent lymphocytosis (greater than 10,000/mm^3)

               -  At least 40% bone marrow infiltration

          -  Stage 0 or I progressive disease indicated by at least one of the following:

               -  Persistent rise in lymphocyte count with doubling time less than 12 months

               -  Downward trend in hemoglobin and/or platelet count

               -  At least 50% increase in size of liver and/or spleen and/or lymph nodes

               -  Appearance of lymphadenopathy, hepatomegaly, or splenomegaly

               -  Constitutional symptoms caused by disease

                    -  Pyrexia

                    -  Night sweats

                    -  Weight loss OR

          -  Stage II or III

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)*

          -  SGOT/SGPT no greater than 2 times ULN* NOTE: * Unless due to CLL

        Renal:

          -  Creatinine clearance at least 30 mL/min

        Other:

          -  No other cancer or life-threatening disease

          -  Not pregnant

          -  Fertile patients must use effective contraception during and for 6 months after study
             therapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  No concurrent corticosteroids (e.g., dexamethasone) as antiemetics

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified",Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia,1
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","DISEASE CHARACTERISTICS: Histologically proven hepatocellular carcinoma OR Elevation of
        alpha fetoprotein (AFP) (greater than 400 ng/mL) in the presence of a space occupying
        lesion in the liver with known chronic liver disease Lesion must be easily biopsied
        Unresectable disease Bidimensionally measurable disease by radiography OR Evaluable disease
        with elevated AFP Okuda stage I disease Tumor size less than 50% of liver No ascites
        Albumin greater than 3 g/dL Bilirubin less than 2 mg/dL OR Okuda stage II disease Bilirubin
        as in stage I If ascites present, albumin must be greater than 3 g/dL

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 12 weeks Hematopoietic: Hemoglobin at least 9.0 g/dL Neutrophil count at least
        1,500/mm3 Platelet count at least 80,000/mm3 Hepatic: See Disease Characteristics SGOT/SGPT
        no greater than 4 times upper limit of normal Any cause of underlying liver disease
        including hepatitis B or C allowed Renal: Creatinine no greater than 2.0 mg/dL
        Cardiovascular: No poor cardiac function No myocardial infarction within the past 6 months
        No poorly controlled arrhythmia No congestive heart failure LVEF at least 45% by MUGA
        Other: No active hepatic encephalopathy No other active malignancies except curatively
        treated nonmelanoma skin cancer or carcinoma in situ of the cervix HIV negative No
        immunodeficiency Not pregnant or nursing Negative pregnancy test Fertile patients must use
        effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy,
        including interferon Chemotherapy: No prior systemic or intra arterial doxorubicin At least
        6 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: Not
        specified Surgery: See Disease Characteristics Other: At least 4 weeks since prior
        investigational therapy",Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","DISEASE CHARACTERISTICS:

          -  Histologic or cytologic diagnosis of indolent lymphoma as defined by International
             Working Formulation categories A-C or diagnosis of Waldenstrom's macroglobulinemia, or
             chronic lymphocytic leukemia

          -  Lymphoma must be stage III, IV, or recurrent (no primary CNS lymphoma or lymphomatous
             meningitis)

          -  Waldenstrom's macroglobulinemia must have at least one of the following:

               -  IGM greater than 3,000 mg/dL

               -  Hemoglobin less than 10.0 g/dL

               -  Bone marrow involvement greater than 30% lymphocytes

               -  At least 2 cm lymphadenopathy

               -  Serum viscosity greater than 3.0

          -  Chronic lymphocytic leukemia must be intermediate or high risk stages I-IV and have
             progressed on fludarabine therapy unless patient cannot tolerate fludarabine

               -  Intermediate risk group must have at least one indication of active disease:

                    -  Presence of any one of the disease related B symptoms: 10% or more loss of
                       body weight over the preceding 6 month period, extreme fatigue, fever above
                       100 degrees F without evidence of infection, or night sweats

                    -  Massive (greater than 6 cm below left costal margin) or progressive
                       splenomegaly

                    -  Massive (greater than 10 cm in longest diameter) or progressive
                       lymphadenopathy

                    -  Progressive lymphocytosis with an increase of 50% over a 2 month period or
                       anticipated doubling time of less than 12 months

                    -  Evidence of progressive marrow failure as manifested by the development or
                       worsening of anemia and/or thrombocytopenia

                    -  Autoimmune anemia and/or thrombocytopenia poorly responsive to
                       corticosteroid therapy

          -  Intolerance, relapse, or failure following prior fludarabine allowed

          -  Measurable or evaluable disease

          -  No untreated immediate life threatening tumor complications

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  CALGB 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

          -  WBC at least 4,000/mm^3*

          -  Absolute granulocyte count at least 1,500/mm^3*

          -  Platelet count at least 100,000/mm^3*

          -  Hemoglobin at least 9 g/dL* NOTE: *Unless documented bone marrow involvement

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  SGOT no greater than 2.5 times upper limit of normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance at least 60 mL/min

        Other:

          -  No prior malignancy except adequately treated basal or squamous cell skin cancer,
             carcinoma in situ of the cervix, well differentiated stage IA prostate cancer, or any
             other cancer from which the patient has been disease free for five years

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior autologous bone marrow or stem cell transplantation

        Chemotherapy:

          -  See Disease Characteristics

          -  No more than 2 prior systemic regimens for treatment of lymphoma

          -  No chemotherapy for treatment of any other prior malignancy

          -  At least 4 weeks since chemotherapy and recovered

          -  Prior fludarabine therapy allowed

        Endocrine therapy:

          -  See Disease Characteristics

        Radiotherapy:

          -  Prior radiotherapy allowed (index lesion cannot be within prior radiotherapy field)

        Surgery:

          -  Recovered from prior surgery","Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia",2
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","DISEASE CHARACTERISTICS: Diagnosis of B-cell chronic lymphocytic leukemia manifested by all
        of the following: Minimum threshold peripheral lymphocyte count of at least 5,000/mm3 Small
        to medium sized peripheral blood lymphocytes with no greater than 55% prolymphocytes Bone
        marrow aspirate and biopsy containing at least 30% lymphoid cells Immunophenotypic and
        biopsy evaluation of peripheral blood lymphocytes demonstrating monoclonality of B
        lymphocytes B-cell markers with CD5 antigen (e.g., T-1, T-101) in the absence of other pan
        T-cell markers (e.g., CD3, CD2) Expression of CD19, CD20, and CD23 B cell surface markers
        B-cell expression of kappa or lambda light chains Active disease with at least one of the
        following criteria: One or more disease related symptoms: At least 10% weight loss within
        the past 6 months Fever greater than 100.5 F for at least 2 weeks without evidence of
        infection Night sweats without evidence of infection Evidence of progressive marrow failure
        as manifested by the development of or worsening of anemia (hemoglobin less than 11.0 g/dL)
        and/or thrombocytopenia (platelet count less than 100,000/mm3) (i.e., any stage III or IV
        disease) Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroid
        therapy Massive (i.e., greater than 6 cm below the left costal margin) or progressive
        splenomegaly (i.e., a greater than 50% increase over two months) Massive (i.e., greater
        than 10 cm in longest diameter) or progressive lymphadenopathy (i.e., a greater than 50%
        increase over two months) Progressive lymphocytosis with an increase of greater than 50%
        over a 2 month period (unrelated to corticosteroids) or an anticipated doubling time of
        less than 6 months No marked hypogammaglobulinemia or the development of a monoclonal
        protein in the absence of any criteria for active disease Previously treated with at least
        a fludarabine or cladribine based regimen and a prior alkylating agent with evidence of
        recurrent or progressive disease

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: See Disease Characteristics Platelet count at least 75,000/mm3
        Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater
        than 1.5 times ULN (unless due to hemolysis or chronic lymphocytic leukemia) Renal:
        Creatinine no greater than 1.5 times ULN Cardiovascular: No New York Heart Association
        class III or IV heart disease No myocardial infarction within the past month Other: No
        uncontrolled infection HIV negative No other active malignancy Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy: See Disease
        Characteristics No concurrent corticosteroids Radiotherapy: At least 4 weeks since prior
        radiotherapy Surgery: At least 4 weeks since prior major surgery",Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia,2
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","Inclusion Criteria include:

          -  Metastatic disease as evidenced by soft tissue and/or bony metastases.

          -  Baseline PSA value of at least 5 ng/mL. All subjects must have stable or rising PSA.

          -  Tumor progression after hormonal therapy.

          -  Hormonal therapy consisting of castration by orchiectomy or LHRH agonists for
             treatment of prostate cancer. Castration levels of testosterone (< 50 ng/dL) must be
             documented for all subjects including subjects who underwent orchiectomy as therapy
             for cancer of the prostate.

          -  A subject is eligible if he initially responded to antiandrogen withdrawal (> 25%
             decrease in PSA) but at the time of registration demonstrated tumor progression. A
             subject is eligible if he failed to respond to antiandrogen withdrawal.

          -  Subjects have no cancer-related pain and do not regularly require analgesics for
             cancer-related pain.

          -  ECOG Performance Status of 0 or 1.

          -  Life expectancy of at least 16 weeks.

          -  Adequate hematologic, renal, and liver function.

        Exclusion Criteria include:

          -  Visceral organ metastases (e.g., liver, lung, brain) or cytologically positive
             effusions (e.g., pleural effusions or ascites).

          -  Metastatic disease expected to be in need of radiation therapy within 4 months.

          -  Concurrent therapy with experimental agents.

          -  Systemic corticosteroids at doses greater than 40 mg hydrocortisone per day for any
             reason other than treatment of prostate cancer within the previous 6 months without
             prior approval.

        Please note that there are additional eligibility criteria. The study center will determine
        if you meet all of the criteria.",Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","DISEASE CHARACTERISTICS: Histologically or cytologically confirmed refractory, progressive,
        B-cell chronic lymphocytic leukemia Failed prior first line therapy of chlorambucil or
        fludarabine (or their equivalent) Progressive disease as defined by at least one of the
        following: Greater than 50% increase in the sum of the products of at least 2 lymph nodes
        on two consecutive determinations 2 weeks apart (at least one lymph node must be greater
        than 2 cm) Appearance of new palpable lymph nodes At least a 50% increase in size of
        previously palpable liver or spleen Appearance of palpable hepatomegaly or splenomegaly not
        previously present At least a 50% increase in the absolute lymphocyte count to at least
        5,000/mm3 Transformation to an aggressive histology (e.g., Richter's or prolymphocytic
        leukemia) High risk OR Intermediate risk with active disease, as defined by the following:
        Greater than 10% weight loss Extreme fatigue Fevers greater than 100.5 Fahrenheit for
        greater than 2 weeks without infection Night sweats Splenomegaly greater than 6 cm
        Lymphadenopathy greater than 10 cm Lymphocytosis with a doubling time less than 6 months

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG or Zubrod 0-2 Life
        expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no
        greater than 2.5 times upper limit of normal (ULN) ALT and AST no greater than 2.5 times
        ULN Renal: Creatinine no greater than 2.0 mg/dL Other: Not pregnant Negative pregnancy test
        Fertile patients must use effective contraception during and for 2 weeks after study

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
        specified",Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","INCLUSION CRITERIA

        Adults and children 18 years of age or greater will be studied.

        Enrolled in a primary stem cell transplant protocol that has been approved by the IRB.

        Potential subjects are people donating PBSC concentrates for HLA-compatible relatives as
        part of IRB approved protocols or donating PBSCs for laboratory investigations.

        EXCLUSION CRITERIA

        Donors who cannot remain in the Bethesda area for an additional 4 to 5 days following their
        donations will be excluded from the third ultrasound.",Spleen Size in Peripheral Blood Stem Cell Donors,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","DISEASE CHARACTERISTICS: Diagnosis of intermediate grade B-cell CD20+ non-Hodgkin's
        lymphoma Failed to achieve initial complete response (CR) after at least 2 courses of
        standard chemotherapy OR Relapsed after CR and not eligible for autologous bone marrow
        transplant Measurable disease defined as one of the following: Bidimensionally measurable
        disease at least 2 cm in diameter by radiograph or CT scan Enlarged spleen extending at
        least 2 cm below the costal due to lymphomatous involvement Enlarged liver with focal
        lesions on CT scan or biopsy proven lesions Lymphomatous hepatic involvement must be biopsy
        proven for the liver to be sole area of measurable disease No evidence of CNS involvement A
        new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The
        terminology of ""indolent"" or ""aggressive"" lymphoma will replace the former terminology of
        ""low"", ""intermediate"", or ""high"" grade lymphoma. However, this protocol uses the former
        terminology.

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not
        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3* Platelet count at
        least 100,000/mm3* *unless there is bone marrow involvement with lymphoma Hepatic:
        Bilirubin less than 3 mg/dL AST/ALT less than 2 times normal Renal: Creatinine less than
        2.1 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: LVEF greater than
        45% by MUGA or echocardiogram Other: No prior malignancy within the past 10 years except
        squamous cell carcinoma or basal cell carcinoma of the skin or cervical cancer No evidence
        of infection HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients
        must use effective contraception

        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior rituximab",Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma,0
"This is a 57-year-old gentleman with CLL and large cell transformation. He presented with his disease back in [**10/2119**] with an elevated white count and LDH. He was without any splenomegaly or any cytopenias at that time. He did have some bulky lymphadenopathy. He then completed four cycles of FCR therapy, which he completed back in 09/[**2119**]. He had an excellent response to therapy and was monitored off treatment for approximately two years. He then presented in [**7-/2122**] with a rising white count, approximately 50% lymphocytes, and a mildly elevated LDH. He also had some mild worsening palpable lymphadenopathy. He then received four cycles of PCR, but did not have much in the way of response and his treatment regimen was switched to R-CVP of which he received two cycles. He did again not have a significant response, though continued to have an excellent performance status, and he was ultimately switched to Campath therapy. He did have resolution of his lymphocytosis, and his white count has come down nicely, but did not have much in the way of response in terms of reducing his bulky lymphadenopathy. He then eventually had developed an enlarging left cervical node which was biopsied and was found to have Richter's transformation.","Inclusion Criteria:

          -  Diagnosis of one of the following:

               -  Confirmed chronic lymphocytic leukemia (CLL), meeting the following criteria:

                    -  Peripheral blood lymphocytosis greater than 5,000/mm^3

                    -  Co-expression of the CD5, CD19, CD20, and CD23 surface antigens

                    -  Clonal kappa and lambda light chain expression

                    -  Dim surface immunoglobulin expression

               -  Small lymphocytic lymphoma

          -  Relapsed or refractory disease

               -  Must have received at least 1 prior regimen containing fludarabine

               -  Meets one of the following criteria:

                    -  Recurrence of lymphocytosis greater than 5,000/mm^3 or an increase in lymph
                       node volume greater than 50% after achieving complete (CR) or partial
                       response (PR)

                    -  Never achieved a CR or PR after receiving at least 2 courses of fludarabine
                       IV for 5 days at a dose of 25 mg/m^2/day

          -  No other lymphoproliferative diseases or diseases due to transformation of CLL (e.g.,
             prolymphocytic leukemia or Richter's syndrome)

          -  No known CNS disease

          -  Performance status - Karnofsky 60-100%

          -  At least 12 weeks

          -  See Disease Characteristics

          -  Bilirubin < 2.0 times upper limit of normal (ULN)*

          -  SGOT < 2.5 times ULN*

          -  Creatinine < 1.5 times ULN

          -  No history of cardiac arrhythmia

          -  No myocardial infarction within the past 6 months

          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma
             in situ of the cervix

          -  No active serious infection uncontrolled by antibiotics

          -  No pre-existing neurotoxicity grade 3 or greater

          -  No other medical condition that would preclude study participation

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Female patients must use 2 effective methods (at least 1 highly active method) of
             contraception 4 weeks before, during, and for 4 weeks after study participation and
             male patients must use effective barrier contraception during and for 4 weeks after
             study participation

          -  At least 4 weeks since prior biologic therapy and recovered

          -  No concurrent growth factors (epoetin alfa, filgrastim [G-CSF], or sargramostim
             [GM-CSF])

          -  See Disease Characteristics

          -  No more than 3 prior chemotherapy regimens

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No other concurrent chemotherapy

          -  At least 4 weeks since prior radiotherapy and recovered

          -  No concurrent radiotherapy

          -  Recovered from any prior investigational agents

          -  No other concurrent investigational agents",Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer,0
"41 year old man with history of severe intellectual disability, CHF, epilepsy presenting with facial twitching on the right and generalized shaking in at his NH which required 20 mg valium to cease seizure activity. Per outside medical patient was felt to have focal epilepsy with secondary generalization, likely due to anoxic brain injury at birth, and probably related to the atrophic changes seen on MRI, particularly in the left temporal lobe.
The patient first developed seizures at age 13 found by family to have a generalized convulsion. He had a second seizure two years after his first episode. He was maintained on Dilantin and phenobarbital. The patient went 20 years without another seizure. He was recently tapered off Dilantin, and it was felt that perhaps this medication was necessary to maintain him seizure free. The patient had no further events during the hospital course and was back at his baseline at the time of discharge. Full EEG reports are pending at the time of dictation.
Past Medical History:
Epilepsy as above, CHF, depression","INCLUSION CRITERIA:

        Patients with partial seizures, infantile spasms and Lennox-Gastaut syndrome will be
        selected.

        EXCLUSION CRITERIA:

        Evidence of a structural lesion as cause for epilepsy.

        Degenerative or metabolic disease.

        Inability to comply with the protocol.",Metabolic Abnormalities in Children With Epilepsy,1
"41 year old man with history of severe intellectual disability, CHF, epilepsy presenting with facial twitching on the right and generalized shaking in at his NH which required 20 mg valium to cease seizure activity. Per outside medical patient was felt to have focal epilepsy with secondary generalization, likely due to anoxic brain injury at birth, and probably related to the atrophic changes seen on MRI, particularly in the left temporal lobe.
The patient first developed seizures at age 13 found by family to have a generalized convulsion. He had a second seizure two years after his first episode. He was maintained on Dilantin and phenobarbital. The patient went 20 years without another seizure. He was recently tapered off Dilantin, and it was felt that perhaps this medication was necessary to maintain him seizure free. The patient had no further events during the hospital course and was back at his baseline at the time of discharge. Full EEG reports are pending at the time of dictation.
Past Medical History:
Epilepsy as above, CHF, depression","Age 5 to 60 at entry to protocol.

        History of partial or Complex Partial Epilepsy for two or more years.

        Patients should be on a stable anti-convulsant regimen defined as unchanged medicines and
        dose modifications lower than 20% in the last month. Blood levels of anti-convulsants will
        be measured at the beginning of the study, prior to stimulation and after the study to
        assure that the type and dose of medication will remain constant.

        Seizures not completely responsive to medical treatment (1 or more seizures per week for at
        least 6 months) and patients have failed at least two anti-convulsant regimens in the past.

        The patients have a localized seizure focus.

        Epilepsy refractory to medical treatments.

        No pregnant women (will be tested with urine pregnancy test).

        No severe coronary disease.

        No metal anywhere in the cranium except the mouth.

        No intracardiac lines.

        No increased intracranial pressure as expressed by the presence of papilledema.

        No cardiac pacemakers.

        Must not be taking neuroleptic or antidepressant medications.

        No progressive neurologic disease.",Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy,1
"41 year old man with history of severe intellectual disability, CHF, epilepsy presenting with facial twitching on the right and generalized shaking in at his NH which required 20 mg valium to cease seizure activity. Per outside medical patient was felt to have focal epilepsy with secondary generalization, likely due to anoxic brain injury at birth, and probably related to the atrophic changes seen on MRI, particularly in the left temporal lobe.
The patient first developed seizures at age 13 found by family to have a generalized convulsion. He had a second seizure two years after his first episode. He was maintained on Dilantin and phenobarbital. The patient went 20 years without another seizure. He was recently tapered off Dilantin, and it was felt that perhaps this medication was necessary to maintain him seizure free. The patient had no further events during the hospital course and was back at his baseline at the time of discharge. Full EEG reports are pending at the time of dictation.
Past Medical History:
Epilepsy as above, CHF, depression","DISEASE CHARACTERISTICS:

          -  Malignant solid tumor or lymphoma refractory to standard therapy or for which no
             therapy of proven benefit exists

          -  No leukemia

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

          -  Age: 18 and over

          -  Performance status: Karnofsky 70-100%

          -  Life expectancy: At least 3 months

          -  WBC at least 3,500/mm3

          -  Absolute neutrophil count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

          -  Hemoglobin at least 9 g/dL

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST/ALT less than twice normal (unless due to disease)

          -  PT and PTT normal

          -  Creatinine no greater than 1.5 mg/dL

          -  Creatinine clearance at least 60 mL/min

          -  No history of congestive heart failure requiring medical therapy

          -  No clinically significant or life threatening cardiac arrhythmia

          -  No history of significant pulmonary disease or lymphangitic lung disease

          -  No hypersensitivity to cyclosporine or cremophore

          -  No history of manifest or latent porphyria or hypersensitivity to barbiturates (for
             parts of study using phenobarbital)

          -  No history of inflammatory bowel disease requiring therapy

          -  No chronic diarrhea syndrome or paralytic ileus

          -  No medical or psychiatric condition that precludes informed consent

          -  Not pregnant

          -  Effective contraception required of fertile women

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior biologic therapy

          -  At least 2 weeks since prior colony stimulating factors

          -  At least 4 weeks since prior chemotherapy (at least 6 weeks since nitrosoureas or
             mitomycin)

          -  No prior bleomycin or irinotecan

          -  At least 4 weeks since prior radiotherapy to greater than 25% of bone marrow

          -  Minimum time interval between prior therapy and eligibility shortened by 2 weeks when
             phenobarbital is administered

          -  Concurrent use of medications that affect the central nervous or cardiovascular
             systems (e.g., anticonvulsants, calcium channel blockers, oral contraceptives) must be
             approved by the Principal Investigator",Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma,0
"41 year old man with history of severe intellectual disability, CHF, epilepsy presenting with facial twitching on the right and generalized shaking in at his NH which required 20 mg valium to cease seizure activity. Per outside medical patient was felt to have focal epilepsy with secondary generalization, likely due to anoxic brain injury at birth, and probably related to the atrophic changes seen on MRI, particularly in the left temporal lobe.
The patient first developed seizures at age 13 found by family to have a generalized convulsion. He had a second seizure two years after his first episode. He was maintained on Dilantin and phenobarbital. The patient went 20 years without another seizure. He was recently tapered off Dilantin, and it was felt that perhaps this medication was necessary to maintain him seizure free. The patient had no further events during the hospital course and was back at his baseline at the time of discharge. Full EEG reports are pending at the time of dictation.
Past Medical History:
Epilepsy as above, CHF, depression","Inclusion Criteria

          1. Patients with left ventricular dusfunction

          2. Patients with non-ischemic cardiomyopathy

        Exclusion Criteria

        1. Patients not at high risk for sudden cardiac death (SCD)",Prognostic Significance of T Wave Alternans,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  physiologic replacement doses of steroids.

          -  Pneumocystis carinii pneumonia (PCP) in patient who is HIV positive by ELISA, HIV
             culture, or p24 antigenemia, or is a member of a risk group for HIV infection.

          -  Failed at least 4 but not > 14 full days' therapy with either
             sulfamethoxazole/trimethoprim (SMX/TMP) or parenteral pentamidine. Patients must have
             received therapy with only one of the two conventional agents prior to enrollment.

          -  Patients in whom an unequivocal diagnosis of this episode of PCP has been or can be
             established by morphologic confirmation of three or more typical Pneumocystis carinii
             organisms in sputum, bronchoalveolar lavage fluid, or lung tissue obtained by
             transbronchial or open lung biopsy within 15 days prior to study entry.

          -  Patients in whom no significant improvement in arterial-alveolar oxygen pressure
             (defined as a decrease of at least 15mm Hg) is observed in the 24 hours prior to
             entry.

          -  Patient is willing to have maximal medical support, including pressors, invasive
             monitoring, and/or mechanical ventilation, during at least the first 7 days of
             protocol therapy if such support is necessary. Continuation of maximal medical support
             beyond 7 days is at discretion of investigator and patient.

          -  Patients with history of hypersensitivity less severe than type I may be enrolled if,
             in opinion of investigator, these adverse effects do not prohibit rechallenge with the
             drug.

        Prior Medication:

        Required:

          -  At least 4 full days but no greater than 14 full days of parenteral and/or oral
             therapy with sulfamethoxazole/trimethoprim (SMX/TMP) or pentamidine.

        Allowed:

          -  Zidovudine (AZT).

        Exclusion Criteria

        Co-existing Condition:

        Excluded:

          -  Patients with history of type I hypersensitivity (urticaria, angioedema, anaphylaxis),
             exfoliative dermatitis, or other life-threatening reaction secondary to trimetrexate,
             sulfamethoxazole/trimethoprim, or pentamidine.

          -  Presence of any process that, in the opinion of investigator, would be adversely and
             seriously affected by steroid therapy.

          -  Failure to meet inclusion criteria.

        Concurrent Medication:

        Excluded:

          -  Zidovudine (AZT).

          -  Myelosuppressive agents.

          -  Nephrotoxic agents.

          -  AZT may be resumed at completion of study.

        Excluded:

          -  Patients with history of type I hypersensitivity (urticaria, angioedema, anaphylaxis),
             exfoliative dermatitis, or other life-threatening reaction secondary to trimetrexate,
             sulfamethoxazole/trimethoprim, or pentamidine.

          -  Presence of any process that, in the opinion of investigator, would be adversely and
             seriously affected by steroid therapy.

          -  Failure to meet inclusion criteria.

        Prior Medication:

        Excluded within 4 days of study entry:

          -  Any other investigational agent.

          -  Excluded within 14 days of study entry:

          -  Steroids (other than physiologic replacement doses).",Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Patients must have:

          -  HIV antibody positive.

          -  CD4 cell counts less than 500/mm3.

          -  Adequate general health.

          -  No significant deterioration in performance status within the past month.

          -  Prior treatment with a stable regimen of antiretroviral medication for at least 4
             weeks prior to study.

        Prior Medication:

        Required:

          -  Stable regimen of antiretroviral medication for at least 4 weeks prior to study entry.

        Allowed:

          -  Aerosolized pentamidine for PCP prophylaxis.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Intercurrent infection.

          -  Clinically significant abnormality on EKG.

          -  Known hypersensitivity to quinolines.

          -  Known hemoglobin M abnormality.

          -  Known NADH methemoglobin reductase deficiency.

          -  Positive test for G6PD deficiency.

          -  Fever.

        Prior Medication:

        Excluded:

          -  Other systemic medication (other than AZT, ddC, ddI, methadone, acyclovir, and NSAIDs)
             within 3 days prior to study entry.",Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Concurrent Medication:

        Required:

          -  Antiretroviral therapy during study treatment only in patients with CD4 count < 500
             cells/mm3 (per 12/30/94 amendment).

        Allowed:

          -  G-CSF for a second occurrence of grade 3 or 4 neutropenia (per 12/30/94 amendment).

          -  Nonsteroidal anti-inflammatory agents including acetaminophen for drug-related fevers.

          -  Systemic steroids for no more than 1 week in any 30-day period.

          -  PCP prophylaxis with TMP/SMX, dapsone, or inhaled pentamidine, if patient has a
             history of PCP or a CD4 count < 250 cells/mm3.

        Allowed only in patients with CD4 count < 100 cells/mm3:

          -  Maintenance doses of ganciclovir, pyrimethamine/sulfa and TMP/SMX for stable,
             well-controlled opportunistic infections.

          -  Non-myelosuppressive treatment IND medications.

        Prior Medication: Required: PER AMENDMENT 11/20/95:

          -  Stable dose of antiretroviral therapy required for at least 21 days prior to study
             entry for all patients. (Changed from - Stable dose of antiretroviral therapy for at
             least 21 days prior to study entry in patients with CD4 count < 500 cells/mm3 (per
             12/30/94 amendment).

        Patients must have:

          -  AIDS-related Kaposi's sarcoma.

          -  PER AMENDMENT 11/20/95: CD4 lymphocyte count >= 100 but < 500 cells/mm3. (Changed from
             - HIV infection.)

          -  PER AMENDMENT 11/20/95: All Patients will receive antiretroviral therapy. (Changed
             from - Current antiretroviral therapy IF CD4 count < 500 cells/mm3 (per 12/30/94
             amendment).)

          -  No active opportunistic infections requiring induction therapy.

          -  Consent of parent or guardian if less than 18 years of age.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Other active malignancies (except basal cell carcinoma of the skin and in situ
             cervical cancer).

          -  Alteration in mental status that may prevent compliance.

          -  Cardiac functional capacity of Class II or worse OR regional wall abnormalities or
             abnormal ejection fraction on two-dimensional echocardiogram, if performed.

        Concurrent Medication:

        Excluded:

          -  Chemotherapy, interferons, or immune modulators for Kaposi's sarcoma.

          -  Myelosuppressive agents such as induction doses of ganciclovir, Fansidar
             (pyrimethamine/sulfadoxine), or any other investigational drugs (with the exception of
             non-myelosuppressive treatment IND medications in specific patients).

          -  GM-CSF or erythropoietin (except for a second grade 3/4 neutropenia or anemia).

          -  G-CSF.

        Patients with the following prior conditions are excluded:

          -  History of myocardial infarction or significant arrhythmias.

          -  History of symptomatic hypoglycemia.

        Prior Medication:

        Excluded:

          -  Systemic therapy (including chemotherapy, interferons, and immune modulators) for
             Kaposi's sarcoma within 4 weeks prior to study entry.",A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine for PCP prophylaxis.

        PER AMENDMENT 4/3/96:

          -  History of treatment limiting toxicity to pyrimethamine. Patients with a history of
             treatment limiting toxicity to both pyrimethamine and sulfonamides will be assigned to
             receive atovaquone plus clarithromycin.

        Patients must have:

          -  Documented HIV infection or diagnosis of AIDS (except for CD4 count < 200 cells/mm3).

          -  Toxoplasmic encephalitis.

          -  Ability to give informed consent or legal designee who could give consent.

        PER AMENDMENT 4/3/96:

          -  NOTE - A history of treatment limiting toxicity to both pyrimethamine and sulfonamides
             will result in the patient being enrolled in the atovaquone plus clarithromycin arm.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Coma.

          -  Opportunistic infection that requires either acute or maintenance treatment with
             disallowed medications.

          -  Any infections or neoplasms of the central nervous system other than Toxoplasma, HIV
             encephalopathy, or syphilis.

          -  Unable to take oral study drugs.

          -  Malabsorption (i.e., three or more episodes of diarrhea per day that has caused >= 10
             percent loss of body weight over the past 4 weeks).

          -  Positive CSF or serum for Cryptococcus antigen or culture (a positive serum antigen
             only is acceptable, provided patient received prior antifungal therapy and is on
             maintenance, and the likelihood of recurrence is low).

          -  Malignancy requiring use of cytotoxic chemotherapy.

          -  Medical or social condition that would adversely affect study participation or
             compliance.

        Concurrent Medication:

        Excluded:

          -  Trimethoprim-sulfamethoxazole.

          -  Primaquine.

          -  Sulfonamides.

          -  Antifolates.

          -  Dapsone.

          -  Clarithromycin (except for patients in the cohort to receive this drug).

          -  Azithromycin.

          -  Clindamycin.

          -  Other macrolides.

          -  Gamma interferon.

          -  Metoclopramide.

          -  G-CSF or GM-CSF.

        Excluded in patients receiving clarithromycin as study drug:

          -  Terfenadine, astemizole, or any other long-acting, non-sedating antihistamines.

        PER AMENDMENT 4/3/96:

          -  Cisapride - may increase GI motility and may increase drug absorption.

        Patients with the following prior conditions are excluded:

          -  History of treatment-limiting toxicity to atovaquone.

          -  Receipt of > 96 hours (per amendment) of treatment prior to study entry for the
             current episode of toxoplasmic encephalitis.",Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Recommended:

          -  Standard immunizations. Should repeat MMR 3 months after discontinuing study.

          -  Benadryl and/or aspirin.

          -  Pneumocystis carinii pneumonia prophylaxis.

          -  Systemic ketoconazole and acyclovir, or oral nystatin for acute therapy.

          -  Aerosol ribavirin for short-term treatment of RSV.

        Concurrent Treatment:

        Allowed:

          -  Blood transfusion.

        Patients must have the following:

          -  Parent or guardian available to give written informed consent.

          -  Protocol requires prior Institutional Review Board (IRB) approval before any subject
             is entered into study.

        Prior Medication:

        Allowed:

          -  Gammaglobulin, intravenous (IV) or intramuscular (IM).

          -  Immunoglobulin, IV (IVIG).

          -  Maternal antiretroviral treatment during pregnancy.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.

          -  Presence of serious acute infection requiring parenteral treatment at time of study
             entry.

        Concurrent Medication:

        Excluded:

          -  Prophylaxis for oral candidiasis or otitis media or other infections.

          -  Immunoglobulin therapy (except single dose or for hypogammaglobulinemia).

          -  Ketoconazole, acyclovir, or nystatin for prophylaxis.

        Patients with the following are excluded:

          -  Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.

          -  Presence of serious acute infection requiring parenteral treatment at time of study
             entry.

        Prior Medication:

        Excluded:

          -  Antiretroviral treatment or experimental treatment within 2 weeks of entry.",The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Vincristine, vinblastine, bleomycin, or interferon for Kaposi's sarcoma.

          -  Erythropoietin.

          -  Didanosine by exemption for 10 patients.

          -  Barbiturates.

          -  Coumarin-type anticoagulants.

          -  Oral contraceptives.

          -  Digoxin.

          -  Methadone.

          -  Narcotics.

          -  Acyclovir.

          -  Acetaminophen.

          -  Sulfonamides.

          -  Trimethoprim / sulfamethoxazole.

          -  Pentamidine for Pneumocystis carinii pneumonia (PCP) or PCP prophylaxis.

          -  Topical antifungals.

          -  Pyrimethamine.

          -  Ganciclovir.

          -  AZT.

          -  Stress doses of steroids in patients with adrenal insufficiency.

        Concurrent Treatment:

        Allowed:

          -  Dose reduction or interruption of myelosuppressive therapy and transfusion to maintain
             hemoglobin of 7 or more g/dl.

          -  Radiation therapy.

        Patient must:

          -  Show laboratory evidence of HIV infection and disseminated histoplasmosis.

          -  Be oriented to person, place, and time.

          -  Be able to give written informed consent (appropriate consent must be obtained from a
             parent or legal guardian for patients under 18 years of age).

        Allowed:

          -  Abnormal liver function tests in Grade 3 toxicity range if liver biopsy shows evidence
             that histoplasmosis caused these abnormalities.

          -  Mucocutaneous candidiasis.

        Prior Medication:

        Allowed:

          -  Amphotericin B or ketoconazole for pulmonary histoplasmosis at least 3 months prior to
             study entry.

          -  Azidothymidine (AZT).

          -  Vincristine, vinblastine, bleomycin, or interferon for mucocutaneous Kaposi's sarcoma.

          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Severely ill, or at risk of dying from histoplasmosis within the first week of
             treatment, as indicated by systolic blood pressure less than 90 mm Hg , or PO2 less
             than 60.

          -  Active CNS lesions, malignancies, or infections other than MAI.

          -  Severe malabsorption syndrome (persistent diarrhea more than 4 weeks duration with at
             least 4 loose stools per day accompanied by a 10 percent or greater weight loss).

          -  Requiring cytotoxic therapy for malignancies.

          -  Any systemic fungal infection other than histoplasmosis.

          -  Systemic Mycobacterium avium intracellulare.

          -  Receiving treatment for other acute opportunistic infections whose signs and symptoms
             have not yet resolved or stabilized.

          -  History of allergy to or intolerance of imidazoles or azoles.

        Concurrent Medication:

        Excluded:

          -  All other systemic antifungal agents.

          -  Investigational drugs not specifically allowed.

          -  Oral hypoglycemics.

          -  Rifamycins.

          -  Phenytoin.

          -  Carbamazepine.

          -  Steroids in excess of physiologic replacement doses not specifically allowed.

          -  Cytotoxic chemotherapy.

          -  Discouraged:

          -  Antacids.

          -  Sucralfate.

          -  H2 blockers.

        Patients with the following are excluded:

          -  Severely ill, or at risk of dying from histoplasmosis within the first week of
             treatment.

          -  Active CNS infections, malignancies or lesions not documented to be caused by
             histoplasmosis, which would interfere with assessment of response.

          -  Unable to take oral medications reliably.

          -  Severe malabsorption syndrome.

          -  Requiring cytotoxic therapy for malignancies.

          -  Any systemic fungal infection other than histoplasmosis.

          -  Systemic Mycobacterium avium intracellulare.

          -  Receiving treatment for other acute opportunistic infections whose signs and symptoms
             have not yet resolved or stabilized.

        Prior Medication:

        Excluded for greater than 1 week within the last 3 months:

          -  Fluconazole.

          -  Itraconazole.

          -  SCH 39304.

          -  Amphotericin B greater than 1.5 mg/kg, or any other antifungal for this episode of
             disseminated histoplasmosis.

        Patients who the investigator feels would be undependable with regard to adherence to the
        protocol.","A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS",0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Patient must:

          -  Have Pneumocystis carinii pneumonia (PCP) that has not been treated for current
             episode. PCP must be documented by observation of > 1 cluster of organisms in sputum,
             bronchial secretion, or lung tissue.

          -  Have clinical symptoms of respiratory disease or radiologic abnormalities.

        Exclusion Criteria

          -  Patient cannot have significant emotional disorder.

        Concurrent Medication: Excluded:

          -  Drugs likely to be bone marrow toxic.

          -  Investigational drugs.

        Prior Medication: Excluded:

          -  Three patients in each group cannot have had zidovudine (AZT) for at least 2 months
             prior to administration of trimetrexate.",A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Acetaminophen:

          -  650 mg prescribed as necessary for temperature > 38.7 degrees C. Acetaminophen should
             not be prescribed as a standing order for more than 48 hours.

        Prior Medication:

        Allowed:

          -  Zidovudine (AZT) as long as such therapy is suspended prior to randomization and not
             reinstituted until therapy for the acute episode is completed and the patient's white
             blood cell count is acceptable.

          -  Other myelosuppressive therapies which may be handled in the same manner as AZT.

          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP).

          -  Unequivocal diagnosis of Pneumocystis carinii pneumonia (PCP) by morphologic
             confirmation of three or more typical P. carinii organisms in sputum, bronchoalveolar
             lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3
             days before or after randomization. If morphologic confirmation is not possible prior
             to therapy, patients may be randomized if the investigator believes there is a high
             suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be
             established within 6 days of randomization, the patient will be withdrawn from study
             therapy. Resting (A-a) DO2 < 30 torr on room air. Patient, parent, guardian, or person
             with power of attorney gives informed consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients will be excluded for the following reasons:

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reaction secondary to antibiotics
             containing sulfa, trimethoprim, or trimetrexate.

          -  History of life-threatening pentamidine toxicity.

        Concurrent Medication:

        Excluded:

          -  Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia
             (PCP).

          -  Disalcid.

          -  Aspirin.

          -  Acetaminophen q4h as a standing order for more than 48 hours.

        Prior Medication:

        Excluded within 14 days of study entry:

          -  Systemic steroids exceeding physiological replacement.

          -  Other investigational drugs including ganciclovir.

          -  Excluded within 6 weeks of study entry:

          -  Another antiprotozoal regimen for this episode for therapy of active Pneumocystis
             carinii pneumonia (PCP).

          -  Patients who are unable to have arterial blood gas analysis (ABG's) on room air.

          -  Patients for whom a liter of intravenous fluid (5 percent dextrose in water) per 24
             hours, which is required to maintain blinding, would be medically inadvisable.",Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Acetaminophen 650 mg prescribed as necessary for temperature > 38.7 degrees C.
             Acetaminophen q4h should not be prescribed as a standing order for more than 48 hours.

        Prior Medication:

        Allowed:

          -  Zidovudine as long as such therapy is suspended prior to randomization and not
             reinstituted until therapy for the acute episode is completed.

          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP).

          -  Unequivocal diagnosis of Pneumocystis carinii pneumonia (PCP) by morphologic
             confirmation of three or more typical P. carinii organisms in sputum, bronchoalveolar
             lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3
             days before or after randomization. If morphologic confirmation is not possible prior
             to therapy, patients may be randomized if the investigator believes there is a high
             suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be
             established within 6 days of randomization, the patient will be withdrawn from study
             therapy.

          -  Resting alveolar-arterial oxygen differences = or > 30 mm Hg on room air.

        Exclusion Criteria

        Patients with the following are excluded:

          -  Inability to have alveolar blood gas analysis on room air.

          -  Medically unable to receive a liter of intravenous fluid (5 percent dextrose in water)
             per 24 hours. This procedure is required in order to maintain blinding.

        Prior Medication:

        Excluded within 14 days of study entry:

          -  Systemic steroids exceeding physiological replacement.

          -  Other investigational drugs.

          -  Excluded within 6 weeks of study entry:

          -  Antiprotozoal regimen for this episode consisting of pentamidine, eflornithine, DFMO,
             or dapsone, for therapy of active Pneumocystis carinii pneumonia (PCP)

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reaction secondary to antibiotics
             containing sulfa, trimethoprim, or trimetrexate.

          -  History of life-threatening pentamidine toxicity.

          -  Requirement for treatment with agents that are known to be myelosuppressive or
             nephrotoxic during the period of acute Pneumocystis carinii pneumonia (PCP) therapy.

          -  Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia
             (PCP); disulcid; aspirin; acetaminophen q4h for more than 48 hours.",Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","INCLUSION CRITERIA:

        Diagnosis: Wegener's granulomatosis.

        Age: 10-80 years.

        Qualifications to eligibility:

        Prior documentation of vasculitis based on clinical characteristics and histopathological
        and/or angiographic evidence of vasculitis. Patients will be eligible for this study
        regardless of whether they are currently receiving immunosuppressive therapies. Failure to
        respond to prior therapy with other cytotoxic agents or toxicity from such agents, in the
        setting of persistent disease, will constitute one reason for eligibility for this study.

        In the absence of histopathological and/or angiographic evidence of vasculitis, patients
        with the following criteria will also be eligible:

        A. Positive C-ANCA (done at the NIH), and

        B. Glomerulonephritis as evidenced by the presence of red blood cell casts and proteinuria
        or renal biopsy showing necrotizing glomerulonephritis in the absence of positive
        immunofluorescence for immunoglobulin and complement, and

        C. One or more of the following:

        Inflammatory sinusitis with histopathological evidence of granulomatous inflammation and
        negative special stains for mycobacteria and fungi. Sinusitis must be present for at least
        3 months and have failed to respond to at least 2 weeks of antibiotic therapy directed
        against likely pathogens (H. influenza, S. pneumonia, and upper respiratory tract anaerobic
        bacteria);

        Pulmonary nodule or infiltrates in a patient in the absence of infection.

        Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater
        than or equal to 3 (Appendix I) or if begun on immunosuppressive therapy at an outside
        institution, a history of a Vasculitis Disease Activity Index greater than or equal to 3
        during the past 6 months.

        EXCLUSION CRITERIA:

        Evidence of infection by gram stain and/or culture specimens. In those instances in which
        infection cannot be ruled out by gram stain and culture of secretions or collections of
        fluid in involved organs, it may be necessary to obtain a biopsy of the affected tissue for
        microbiological and histopathological studies.

        Recent (within four weeks) increase in GC or cytotoxic drug therapy.

        Patients who are pregnant or nursing infants will not be eligible. Fertile women should
        have a negative pregnancy test within one week prior to study entry and should be using
        effective means of birth control.

        Processes that would predispose to enhanced risk of MTX toxicity: acute or chronic liver
        disease, alcohol abuse (greater than 14 oz of 100 proof liquor or equivalent per week),
        active peptic ulcer disease, and inability to comply with study guidelines.

        Serological evidence of infection with human immunodeficiency virus (a serological
        determination will be performed within two weeks of study entry).",Steroids and Methotrexate to Treat Systemic Vasculitis,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","INCLUSION CRITERIA:

        Selected patients should have PM, IBM or DM.

        Specifically they should have a) proximal muscle weakness; b) no evidence of clinical,
        histological or family history of another neuromuscular illness; c) elevation of muscle
        enzymes during the course of the disease; d) typical skin rash in case of DM; and e)
        diagnostic muscle biopsy.

        Suitable candidates for IVIg should be patients with active, bonefide disease who:

          1. have been treated with steroids but had: a) no response or incomplete response (as
             defined by continued muscle weakness) to high-dose therapy or b) a good response to
             steroids but inability to taper the dose without a flare of disease activity or c)
             unacceptable steroid side effects such as gastrointestinal hemorrhages, osteonecrosis,
             hyperglycemia, extreme weight gain etc., and

          2. have been treated with one immunosuppressive drug (such as azathioprine, Methotrexate,
             Cyclophosphamide, Cyclosporine) but without benefit or with unacceptable side effects.

        EXCLUSION CRITERIA:

        Pregnant or nursing women (confirmed by a screening pregnancy test).

        Critically ill patients such as those requiring intravenous pressors for maintenance of
        cardiac output due to severe cardiomyopathy, patients with respiratory insufficiency and
        patients with severe muscle weakness requiring help for basic self care.

        Children below age 18.

        Patients with severe renal or hepatic disease, severe COPD or coronary artery disease or
        other systemic medical problems often seen when PM or DM is associated with severe cases of
        lupus, rheumatoid arthritis or scleroderma.

        Patients with known allergic reaction to IVIg.

        Serum IgA less than 11mg/dl.",Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Subjects include children and adults from birth to 80 years of age.

        Participants must have histologic evidence of an increased mast cell number in at least one
        organ system.

        Must be willing to be seen at the NIH according to protocol guidelines.

        Routine medical care must be available through their referral physician.

        Patients with mastocytosis now followed at the NIH on protocol 88-I-0190 will be continued
        on this study.",Characteristics of Mast Cells in Mastocytosis,2
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Primary Sjogren's Syndrome; symptoms of dry eyes and dry mouth; 6 week period off disease
        modifying agents, such as antimalarials or steroids.

        No males.

        No females with childbearing potential.

        No patients with hypersensitivity to thalidomide.

        No confounding medical illness or abnormal laboratory test that in the judgment of the
        investigators would pose added risk for study participants.",Pilot Study of Thalidomide to Treat Sjogren's Syndrome,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","-  SUBJECT INCLUSION CRITERIA:

        Healthy Volunteers must:

          1. Be 18-70 years of age

          2. Be healthy

          3. Have adequate peripheral venous access

          4. Have normal renal function (creatinine less than or equal to 1.5mg/dL; less than or
             equal to 1 plus proteinuria)

          5. Have normal hepatic function (bilirubin less than or equal to 1.5 mg/dL)

          6. Have normal hematologic function (WBC greater than or equal to 3000/mm(3);
             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to
             175,000; hemoglobin greater than or equal to 12.5 g/dL)

        Patients must:

          1. Be 18-70 years of age

          2. Have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis
             (applicable to systemic mastocytosis patients only) or other allergic, hematologic, or
             immunologic condition

          3. Have adequate peripheral venous access or be willing to have a central line placed.

          4. First be admitted as inpatients under an existing NIH protocol

          5. Have preserved renal function (creatinine less than or equal to 2 mg/dL; less than or
             equal to 2 plus proteinuria)

          6. Have preserved hepatic function (bilirubin less than or equal to 1.5 mg/dL)

          7. Have preserved hematologic function (WBC greater than or equal to 3000/mm(3);
             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to
             175,000; hemoglobin greater than or equal to 12.5 g/dL)

        All female subjects of childbearing potential:

          1. May be enrolled if using effective contraception

          2. Have a negative serum or urine pregnancy test determined within 72 hours before
             beginning Plerixafor or G-CSF administration

        SUBJECT EXCLUSION CRITERIA:

        All subjects must not meet any of the following criteria:

        Healthy Volunteers and patients must not:

          1. Have active bacterial, fungal or viral infections

          2. Have viral screens positive for HIV or hepatitis B or C

          3. Be pregnant or lactating

          4. Have a history of autoimmune disease such as rheumatoid arthritis, vasculitis,
             pyoderma gangrenosum or similar disorder

          5. Have any condition, which in the judgment of the investigator, might place the subject
             at undue risk

        Healthy Volunteers with any of the following will be excluded:

          1. Splenomegaly, pulmonary fibrosis and other related conditions

          2. Use of any investigative drugs within the past 12 months

          3. Have a significant coagulation disorder

        Systemic Mastocytosis and Mast Cell Related Condition Patients with any of the following
        will be excluded:

          1. Patients taking any other growth factors, cytokines or investigative drugs

          2. Patients who are hemodynamically unstable (blood pressure systolic of lower than 105
             or diastolic lower than 65)",Study of Mast Cell Precursors,1
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","General: Age equal to or greater than 18.

        Access to a primary medical care provider outside of the NIH.

        Able to give informed consent.

        No history of malignancy or autoimmune disease such as rheumatoid arthritis, vasculitis,
        pyoderma gangrenosum, psoriasis.

        No use of systemic corticosteroids within the past month.

        No use of local corticosteroids at the proposed blistering site within the past month.

        No evidence of current acute infection.

        INR less than or equal to 1.5, PTT less than or equal to 40, platelet count greater than or
        equal to 100,000/mm(3).

        No personal or family history of keloid formation.

        Blood glucose less than or equal to 160.

        No use of any investigative drugs within the past month.

        No allergy to lidocaine.

        Healthy volunteers must not have a history of atopic dermatitis, mastocytosis or chronic
        urticaria.

        Mastocytosis: Histologic evidence of mast cell hyperplasia in at least one organ system.

        Atopic Dermatitis: Must have at least 3 major and 3 minor criteria.

        No history of mastocytosis.",Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals,1
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","INCLUSION CRITERIA:

        Documentation of Wegener's Granulomatosis (WG) based on clinical characteristics and
        histopathological evidence of vasculitis.

        Patient with a positive C- or P-ANCA and glomerulonephritis as evidenced by the presence of
        red blood cell casts and proteinuria or renal biopsy showing necrotizing glomerulonephritis
        in the absence of positive immunofluorescence for immunoglobulin and complement will also
        be eligible.

        Patients must be of the ages of 18-80 years.

        Patients on the CYC to MTX protocol (#95-I-0091) who experience a relapse of disease while
        on MTX maintenance therapy. Relapse is defined by a Vasculitis Disease Activity Index of
        greater than or equal to 3. Patients from outside the NIH will also be eligible if they
        have been treated with a CYC to MTX regimen identical to that used in #95-I-0091 and
        experience a relapse of disease while on MTX maintenance therapy. If treatment for this
        relapse has already been commenced at the outside institution with daily CYC and
        glucocorticoid, patients will still be eligible if there is a history of a Vasculitis
        Disease Activity Index greater than or equal to 3 at the time of CYC and glucocorticoid
        initiation. Patients who experience a relapse of disease after MTX has been stopped or
        while tapering the MTX dose (following 2 years of maintenance therapy) will not be
        eligible.

        Patients with active disease who have a contraindication to MTX therapy will be eligible.
        Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater
        than or equal to 3.

        Patients with inactive disease who have a contraindication to CYC and. Evidence of active
        disease as defined by a Vasculitis Disease Activity Index of greater than or equal to 3.

        Patients with inactive disease on MTX while on the CYC to MTX protocol (95-I-0091) or the
        MTX protocol (90-I-0086) who develop an contraindication necessitating discontinuation of
        MTX. Patients from outside the NIH will also be eligible if they similarly develop a
        contraindication to MTX while on treatment.

        Patients with inactive disease on the CYC protocol (#76-I-0041 or 76-I-0042) who develop a
        contraindication necessitating CYC discontinuation and also have a contraindication to
        receiving MTX. Patients from outside the NIH will also be eligible if they similarly
        develop a contraindication to CYC while on treatment and cannot receive MTX.

        Patients with inactive disease who are receiving treatment with CYC and prednisone in a
        manner similar to #76-I-0042 will be eligible if they have a contraindication to receiving
        MTX and have been in remission for less 3 months.

        EXCLUSION CRITERIA:

        Evidence of active infection which, in the judgment of the investigator, is of greater
        danger to the patient than the underlying vasculitis. In those instances in which infection
        cannot be ruled out by gram stain and culture of secretions or collections of fluid in
        involved organs, it may be necessary to obtain a biopsy of the affected tissue for
        microbiological and histopathological studies.

        Patients who are pregnant or who are nursing infants will not be eligible. Fertile women
        must have a negative pregnancy test within one week prior to study entry and must be using
        an effective means of birth control.

        Patients with active disease who are eligible for the CYC to MTX protocol (#95-I-0091) or
        the MTX protocol (#90-I-0086).

        Active peptic ulcer disease.

        Serological evidence of infection with human immunodeficiency virus. A serological
        determination will be performed within two weeks of beginning study participation.

        Inability to comply with study guidelines.

        Creatinine clearance less than 25ml/min.",Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Female gender only, ages 18 to 75.

        Patients should have documented primary Sjogren's syndrome as determined by protocol
        84-D-0056. The diagnosis of primary Sjogren's syndrome will be based on the presence of all
        three of the following:

        Salivary gland abnormalities;

        Lacrimal gland abnormalities;

        Serologic abnormalities.

        Controls should have no signs or symptoms of Sjogren's syndrome, and negative serologic
        testing reconfirmed within 2 weeks of the OGTT.

        Willingness to: a) participate in phase I and II of the protocol; b) follow the guidelines
        set to prepare for the OGTT; and c) modify current medical therapy if necessary.

        Must be able to comply with protocol procedures.

        No patients with ""incomplete"" Sjogren's syndrome, i.e., with less than three positive
        findings as described above.

        No presence of physical or mental conditions that may interfere with the protocol. These
        include the following diseases and conditions:

        (Present at time of phase I/II): significant disruption of sleep-wake pattern (i.e., less
        than 4 hours of continuous sleep, on the night before the OGTT only), BMI less than 18 or
        equal to/greater than 30, anemia with Hgb less than 10 gm/dl, use of tobacco or alcohol;

        (Within the past 6 weeks): acute weight change (greater than 5%), use of contraceptives
        -BCP-, Depoprovera or Norplant), irregular menstrual cycle, lactation, blood drawing in
        excess of 50 ml, use of recreational drugs, modification of estrogen replacement therapy;

        (Within the past 6 months): chronic pattern of weight change (greater than 10%), eating
        disorders, uncontrolled hypo/hyperthyroidism, breast cancer, lymphoma or other malignancy,
        pregnancy, treatment for depression, insulinoma, VIPoma, pheochromocytoma, atrophic
        gastritis, active tuberculosis or treatment for it;

        (A history of): HIV+, sarcoidosis, secondary Sjogren's syndrome, bleeding diathesis, organ
        transplant, severe neuroendocrine, renal, cardiovascular, pulmonary or gastrointestinal
        disease (e.g., renal insufficiency, unstable angina, heart failure, severe emphysema,
        Crohn's disease), diabetes mellitus, acromegaly and mental retardation.

        No contraindications to OGTT. These include:

        Hospital inpatient status, acute illness, immobilization, starvation, severe emotional
        distress within one week of the OGTT;

        Low carbohydrate diet (less than 150 g/day) for 3 days preceding the OGTT;

        Pregnancy;

        Therapy which impairs glucose tolerance: e.g., niacin, thiazide diuretics, phenytoin,
        excess thyroxine or psychotropic drugs within 1 month of phase I, oral contraceptives
        within 6 weeks of phase I, glucocorticoid treatment within the past 6 months (or one year
        if treatment lasted over 2 weeks), Beta blockers/agonists (e.g., terbutaline) within 2 days
        of phase I;

        Diabetes mellitus;

        Glucose intolerance.

        Subjects may not take medications that can affect somatostatin levels, such as
        antidepressants, benzodiazepines, neuromodulators (e.g., cholinergic, alpha/beta
        adrenergic), oral contraceptives (BCP), steroid hormones (with the exception of estrogen
        replacement therapy -ERT-, for which subjects will be matched), immunomodulators,
        anticonvulsants (e.g., carbamazepine), cimetidine -Tagamet (Registered Trademark)-, herbal
        remedies (because of their variable substance content). Subjects may not take drugs
        affecting gastrin secretion: antacids (e.g., Maalox (Registered Trademark), Mylanta
        (Registered Trademark), H(2) receptor antagonists (e.g., famotidine -Pepcid (Registered
        Trademark)-, ranitidine -Zantac (Registered Trademark)-), cathecolamines, atropine,
        haloperidol. To become eligible, subjects should be able to safely discontinue these
        medications at least one month prior to phase I. Antacids, H(2) antagonists and
        neuromodulators (e.g., Salagen) may be discontinued 2 days prior to phase I.

        Patients cannot have take experimental drugs within 1 month of the beginning of the
        protocol.",The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion Criteria

        Patients must have the following:

          -  Clinical diagnosis of acute mild to moderate Pneumocystis carinii pneumonia.

          -  Dose-limiting intolerance to TMP / SMX or inadequate response to TMP / SMX.

          -  Willingness and ability to give informed consent. The clinical condition of the
             patient and appropriate physiologic criteria should be used in evaluating patients for
             therapy with 566C80. Patients who are rapidly progressing in disease severity or have
             severe disease as evidenced by sustained tachypnea (e.g., sustained respiratory rate >
             30 breaths/minute), rapid deterioration in (A-a)DO2 and chest radiograph may not be
             appropriate candidates for oral therapy, including 566C80. Therapy with parenteral
             pentamidine should be undertaken in these cases. Treatment with IV trimetrexate or
             primaquine / clindamycin should be considered for these patients unless the patient is
             known to have dose-limiting intolerance to these agents. Patients with severe PCP who
             are intolerant and/or unresponsive to therapy with TMP / SMX and parenteral
             pentamidine may enroll in the 566C80 open-label compassionate plea protocol.

        Exclusion Criteria

        Patients with the following prior conditions are excluded: History of serious or
        dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable
        to the drug.",A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia,1
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","DISEASE CHARACTERISTICS: Histologically or clinically proven chronic graft versus host
        disease (GVHD) that has failed to respond to at least 1 month of treatment with the
        following: Steroids (greater than 0.5 mg/kg/day) AND Cyclosporine or a cytotoxic agent
        (azathioprine or mercaptopurine) OR Other experimental treatment (such as chloroquine) All
        allogeneic bone marrow or peripheral blood stem cell transplantation patients eligible
        regardless of underlying disease for which transplantation was performed if: At least 45
        days since prior transplantation No relapse of underlying disease No loss of donor
        hematopoiesis Patients with a rapid deterioration of GVHD that is considered life
        threatening if not controlled are eligible after receiving high dose steroids (greater than
        1 mg/kg/day) for at least 10 days

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,300/mm3
        Platelet count at least 75,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than
        2 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use
        effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: No
        other concurrent cytotoxic drugs Endocrine therapy: Concurrent steroids allowed but must be
        tapered to less than 0.5 mg/kg/day of prednisone or equivalent prior to starting study drug
        (if symptomatic flare develops during taper, patients may continue on the lowest dose
        thought to produce stabilization) Radiotherapy: Not specified Surgery: Not specified Other:
        Concurrent cyclosporine and other nonmyelosuppressive drugs allowed No concurrent
        myelosuppressive agents (azathioprine, mercaptopurine)",Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Confirmed diagnosis of hereditary angioedema (HAE) based upon C4 antigenic level,
             positive family history, and C1 inhibitor (C1INH) antigenic level (Type I HAE) or
             functional level (Type II HAE)

          -  Functional C1 within normal levels if diagnosis of acquired C1INH is possible

          -  Negative family history will not exclude as long as patient meets all other criteria,
             has normal C1 level, and has no evidence of acquired C1INH deficiency

          -  History of symptoms of HAE including episodic swelling, abdominal pain, and/or
             respiratory difficulty

          -  Experiencing a minimum of 1-2 HAE episodes within 6 weeks

        --Prior/Concurrent Therapy--

          -  Endocrine therapy: Anabolic steroids allowed as long as dose has not been changed in
             at least 30 days

          -  Other: No concurrent and at least 1 week since prior aspirin, nonsteroidal
             antiinflammatory agents, dipyridamole, Coumadin-like drugs, or any other medication
             having an effect on coagulation or platelets

        --Patient Characteristics--

          -  Hematopoietic: No clinically significant history of hematologic disease

          -  Hepatic: No clinically significant history of hepatic disease

          -  Renal: No clinically significant history of renal disease

          -  Cardiovascular: No clinically significant history of cardiac disease or hypertension

          -  Pulmonary: No clinically significant history of pulmonary disease

          -  Other: No contraindication to the use of inhaled or subcutaneous heparin No drug
             allergy that would interfere with the study No clinically significant history of:
             Malignancy Diabetes mellitus Neurologic disease Immunologic disease Bleeding disorder
             Infirmity No history of drug abuse, alcoholism, psychosis, or other
             psychological/psychiatric disorder",Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations,0
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","-  INCLUSION CRITERIA: PATIENT

        Ages greater than or equal to 2 to 80.

        Wt greater than 40 kg.

        Patients with systemic mastocytosis proven by a bone marrow biopsy and one of the
        following:

        Category I disease with poor prognosis secondary to extensive bone marrow involvement of
        mast cells (i.e. greater than 50 percent of the bone marrow cavity replaced by mast cells)
        and evidence of a bone marrow failure state defined as presence of one of the following for
        greater than or equal to 2 months:

          -  Neutrophil count less than 500/ mm3.

          -  Platelet count less than 20,000/mm3.

          -  Dependency on transfusion of RBC or platelets.

        Category II disease with an associated hematologic disorder:

          -  Myelodysplastic syndromes.

          -  Myeloproliferative states except essential thrombocytosis or polycythemia vera.

          -  Increased blasts in peripheral blood or bone marrow greater than 10 percent.

          -  Bone marrow failure states as described above.

        Category III disease with enlarged peripheral lymph nodes with histopathological evidence
        of the replacement of the entire lymph node architecture with mast cells and/or
        accompanying peripheral eosinophilia. We also consider aggressive systemic mastocytosis
        with local tissue invasion as category III disease.

        Category IV disease with mast cell leukemia, characterized by the presence of malignant
        mast cells in the peripheral blood, which constitute greater than 10 percent of the
        nucleated cells.

        No major organ dysfunction precluding transplantation.

        DLCO greater than or equal to 65 percent predicted.

        Left ventricular ejection fraction of greater than or equal to 40%.

        ECOG performance status of 0 or 1.

        Life expectancy of more than 3 months.

        HLA-identical sibling available as donor.

        Patients or their parent(s)/responsible guardian(s) must be able to comprehend the
        investigational nature of the study and be willing to sign an informed consent.

        INCLUSION CRITERIA: DONOR

        HLA identical family donor, (only HLA identical).

        Weight greater than or equal to 18 kg.

        Age less than or equal to 80 years old.

        Informed consent given.

        EXCLUSION CRITERIA: PATIENT (Any of the following)

        Pregnant or lactating

        Age less than 2 or age greater than 80 years.

        Weight less than or equal to 40 kg.

        ECOG performance status of 2 or more.

        Psychiatric disorder or mental deficiency severe as to make compliance with the BMT
        treatment unlikely, and making informed consent impossible.

        Major anticipated illness or organ failure incompatible with survival from PBSC transplant.

        DLCO less than 65 percent predicted.

        Left ventricular ejection fraction less than 40%.

        Baseline GFR less than 50ml/min: measured or calculated by the following formula: GFR =
        {(140-age) x body weight in kg}/72 x serum creatinine (for females, multiply by 0.85).

        Serum bilirubin greater than 4 mg/dl, transaminases greater than 5 times the upper limit of
        normal.

        Other malignant diseases liable to relapse or progress within 5 years.

        Life expectancy of less than 3 months.

        EXCLUSION CRITERIA: DONOR (Any of the following)

        Pregnant or lactating.

        Donor unfit to receive G-CSF and undergo apheresis (Uncontrolled hypertension, history of
        congestive heart failure or unstable angina, thrombocytopenia).

        HIV positive. Donors who are positive for HBV, HCV or HTLV-1 may be used if the
        risk-benefit ratio is considered acceptable by the patient and investigator.

        Weight greater than 18 kg.

        Age greater than 2 or less than 80 years.",Stem Cell Transplantation to Treat Systemic Mastocytosis,1
"Pt is a 22yo F otherwise healthy with a 5 yr history of the systemic mastocytosis, with flares normally 3/year, presenting with flushing and tachycardia concerning for another flare. This is patient's 3rd flare in 2 months, while still on steroid taper which is new for her. She responded well to 125 mg IV steroids q 8 hrs and IV diphenydramine in addition to her continuing home regimen. CBC was at her baseline, w/normal differential. Serum tryptase revealed a high value at 84. The patient failed aspirin challenge due to adverse reaction. She was stabilized on IV steroids and IV benadryl and transferred back to the medical floor. She continued on her home histamine receptor blockers and was transitioned from IV to PO steroids and benadryl and observed overnight and was discharged on her home meds, prednisone taper, GI prophylaxis with PPI, Calcium and vitamin D, and SS bactrim for PCP.","Inclusion:

        A diagnosis of systemic lupus erythematosus",Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus,0
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","-  INCLUSION CRITERIA:

        In order to be eligible to participate in this study, an individual must meet all of the
        following criteria:

          1. Male or female, adults or children >= 6 months+.

          2. Patients with known or suspected thyroid nodules and/or thyroid cancer.

          3. At risk family members of patients who have a genetic susceptibility to developing
             thyroid cancer.

        EXCLUSION CRITERIA:

        An individual who meets any of the following criteria will be excluded from participation
        in this study:

        1. Serious underlying medical conditions that restrict diagnostic testing or therapy such
        as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma
        requiring intervention before thyroid cancer is addressed.",Studies on Tumors of the Thyroid,2
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","-  INCLUSION CRITERIA

        Subjects selected for this study will be patients with Zollinger-Ellison syndrome who are
        being evaluated under the protocol entitled ""Diagnostic evaluation of patients with
        suspected abnormalities of gastric secretion"" (80-DK-123). To be entered into the study a
        patient must meet each of 3 criteria:

          1. histologically proven gastrinoma;

          2. evidence of metastatic tumor by one or more of angiography, ultrasound, computerized
             axial tomography, bone scan or octreoscan;

          3. progression of tumor size during the preceding 6 months as assessed by repeated
             imaging studies.

        EXCLUSION CRITERIA

        For treatment with interferon-(alpha):

          1. Congestive heart failure

          2. Proteinuria, 3 + or greater

          3. Creatinine clearance less than 30 ml/min

          4. Platelet count less than 30 x 10(9)/1

          5. White blood count less than 4 x 10(9)/1

          6. Bilirubin greater than 3 mg/dl

          7. Positive test for HIV antibody

          8. Pregnancy

        For treatment with octreotide:

        1. Presence of cholelithiases",Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer,0
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","INCLUSION CRITERIA

        Patients must satisfy the following criteria:

        The patient must have a biopsy proven diagnosis of carcinoma of the oral cavity,
        oropharynx, hypopharynx, nasopharynx, larynx, maxillary sinus. Squamous cell,
        lymphoepithelioma, transitional cell and undifferentiated histologies will be included.

        We will accept AJCC stages III-IV for all the sites, except base of tongue, nasopharynx,
        and maxillary sinus where we will accept stage II patients as well.

        Patients must have no surgical option or have refused surgery.

        Patients with evidence of distant metastasis not confined to the region of the head and
        neck will be excluded.

        All patients will be evaluated by either the NIH or National Naval Medical Center (NNMC)
        Otolaryngology-head and neck surgery center.

        Patients must have had no prior radiotherapy to the head and neck region and no prior
        treatment with chemotherapy for their head and neck cancers.

        Patients must have a performance status of less then or equal to 2 (ECOG Criteria).

        Patients must have an absolute granulocyte count of greater than or equal to 2000/mm(3) and
        a platelet count of greater than or equal to 100,000/mm(3).

        Patients should have adequate hepatic and renal function as indicated by a serum bilirubin
        of less than or equal to 2.0 mg/dl and SGOT of less than or equal to 4.0 times the upper
        limit of the institutional norm and a serum creatinine of less than or equal to 1.5 mg/dl.

        No other serious concurrent medical or psychiatric illness which would jeopardize the
        ability of the patient to receive with reasonable safety the chemotherapy and radiation
        therapy outlined in this protocol is allowed.

        No other active, concomitant malignancy other than curatively treated carcinoma in situ of
        the cervix or basal cell carcinoma of the skin is allowed.

        Patients must be at least 18 years old.

        Signed informed consent: Each patient must be aware of the neoplastic nature of his/her
        disease and willingly consent after being informed of the procedure to be followed, the
        experimental nature of the therapy, alternatives, potential benefits, side effects, risks,
        and discomforts.

        Pregnant women and nursing mothers are ineligible.

        Eligible patients of childbearing potential should use contraception.

        Patients will be registered on the protocol by telephone. An authorized physician will
        telephone information concerning a potential candidate for this protocol to the Orkand
        personnel in their Central Clinical Data Management Registration Office at (301) 402-1732
        between the hours of 8:30 am to 5:00 pm Monday through Friday.",A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer,1
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","Patients greater than or equal to 18 years of age, with well-differentiated, non-medullary
        thyroid cancer, including papillary (including follicular-variant), follicular, and Hurthle
        cell.

        Patients who recently have undergone a total or near-total thyroidectomy and are scheduled
        to undergo initial 131I diagnostic studies and ablation.

        Patients must have evidence of residual thyroid tissue after thyroid surgery confirmed by
        ultrasound or other imaging technique (e.g., a technetium [Tc 99] pertechnetate or thallium
        scan).

        Patients who have undergone thyroidectomy or other thyroid surgery at least 6 weeks prior
        to enrollment.

        All patients who have been sustained on maintenance THST for at least 4 weeks, but not
        longer than 12 weeks after thyroidectomy.

        All patients who have confirmed serum TSH levels less than or equal to 0.5 mU per liter
        within 7 days prior to the first Thyrogen dose, and prior to randomization.

        Female patients of childbearing age must have a negative serum human chorionic gonadotropin
        (HCG) pregnancy test prior to entering the study and within 5 days of any 131I
        administration and must be following an approved method of contraception.

        Patients who are committed to following the protocol requirements as evidenced by providing
        written informed consent.

        Patients for whom a 131I scan is currently contraindicated because withdrawal from THST is
        not an option due to pituitary dysfunction or other compelling medical reasons are
        excluded.

        Patients should not have a concurrent major medical disorder (e.g., documented cardiac
        disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver
        disease or advanced pulmonary disease) who may be too ill to adequately comply with the
        requirements of this study.

        Patients with non-thyroidal conditions known to effect 131I uptake (e.g., congestive heart
        failure, renal failure) are excluded.

        Patients should not have undergone any intravenous water soluble radiographic contrast
        administration within the previous 4 weeks.

        Patients should not have received intrathecal or cholecystographic iodinated contrast agent
        administration within 3 months prior to enrollment.

        Patients should not be taking drugs that affect thyroid or renal function (e.g., renal
        drugs, lithium, or corticosteroids).

        Patients should not be participating in another investigational drug study or in such a
        study within 30 days of their enrollment in this study.

        No patients with a recent history of alcoholism or drug abuse, severe emotional behavioral
        or psychiatric problems who, in the opinion of the investigator, would not be able to
        comply with the requirements of this study.",Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,2
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","DISEASE CHARACTERISTICS: Biopsy-proven squamous cell carcinoma of one of the following
        sites: Hypopharynx Larynx Oral cavity Oropharynx At least 1 of the following high-risk
        factors required: Histologic extracapsular nodal extension Histologic involvement of 2 or
        more regional lymph nodes Microscopically positive mucosal margins Complete resection of
        all visible and palpable disease Therapy must begin within 8 weeks of tumor-related surgery
        Bilateral resections may or may not be performed simultaneously Eligibility window begins
        with first definitive surgery Neck dissection not required for T4 N0, truly midline
        supraglottic tumors No tumors of the lip, nasopharynx, or sinuses No synchronous or
        concurrent head and neck tumors No evidence of distant metastasis Concurrent registration
        on Fixed Tumor Repository Study allowed

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100%
        Hematopoietic: WBC at least 3,500 Platelets at least 100,000 Hepatic: Not specified Renal:
        Creatinine clearance greater than 50 mL/min Other: No medical contraindication to protocol
        therapy No second malignancy within 5 years No pregnant or nursing women

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head
        and neck region Surgery: See Disease Characteristics",Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery,0
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer Bidimensionally
        measurable disease of any of the following types required: Bidimensionally measurable lung
        lesions on chest X-ray, CT scan, or MRI Palpable and quantifiable lymph nodes at least 2 x
        2 cm Abdominal mass at least 2 x 2 cm quantifiable by CT scan Bidimensionally measurable
        liver metastases at least 2 x 2 cm Palpable hepatomegaly if liver edge is clearly defined
        and extends at least 5 cm below the costal margin of the xiphoid process Unacceptable as
        measurable disease: Diffuse lung infiltration or unidimensionally measurable hilar lesions
        Pelvic mass of indefinite dimension Bone metastases Pleural effusion or ascites No brain
        metastases Must have failed or progressed on prior therapy or relapsed less than 12 months
        after therapy discontinuation Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 16 and over Sex: Female Menopausal status: Not specified
        Performance status: SWOG 0-2 Life expectancy: At least 6 months Hematopoietic: Granulocyte
        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGOT no greater than
        2.5 times upper limit of normal Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no
        greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No
        history of congestive heart failure, myocardial infarction within past 6 months,
        ventricular arrhythmia, or ischemic heart disease requiring medication If necessary,
        ejection fraction at least 50% by MUGA Other: Not pregnant or nursing Negative pregnancy
        test Fertile patients must use effective contraception No other prior malignancies in past
        5 years other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ
        of the cervix No other serious illnesses or active infections No seizure disorder requiring
        anticonvulsant therapy

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:
        See Disease Characteristics No more than 2 prior chemotherapy regimens for metastatic
        disease One prior adjuvant chemotherapy regimen for metastatic disease allowed At least 4
        weeks since prior chemotherapy No other concurrent chemotherapy Endocrine therapy: One
        prior regimen of hormonal therapy for metastatic disease allowed At least 3 weeks since
        prior hormonal therapy and recovered No concurrent hormonal or corticosteroid therapy
        Radiotherapy: At least 4 weeks since prior radiotherapy to less than 25% bone marrow No
        concurrent radiotherapy Surgery: At least 4 weeks since prior surgery and recovered No
        concurrent surgery Other: At least 4 weeks since any prior treatment directed at the tumor
        and recovered No other concurrent anticancer or investigational therapy No concurrent
        participation on another therapeutic clinical trial",Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer,0
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","DISEASE CHARACTERISTICS: Histologically confirmed recurrent, refractory, or second primary
        squamous cell cancer of the head and neck that is incurable with surgery or radiotherapy
        Any N, Any M, single or multiple tumor(s) Locally accessible, discrete tumor(s) by CT or
        MRI scan Must be considered incurable with surgery or radiotherapy, for example: Distant
        disease (e.g., lung and/or liver metastases) OR Cervical disease fixed to surrounding
        structures (e.g., carotid artery or prevertebral fascia) OR Metastases in the site of prior
        radiotherapy OR Not suitable for anesthesia or reconstructive surgery OR Multiple cutaneous
        metastases

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: No disease exacerbated by light, including systemic lupus erythematosus,
        psoriasis, porphyria, actinic reticuloid, or xeroderma pigmentosum Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 30 days
        since prior chemotherapy (6 weeks since nitrosoureas) Endocrine therapy: Concurrent steroid
        therapy allowed Radiotherapy: At least 30 days since prior radiotherapy to the head and
        neck Surgery: At least 30 days since prior surgery and recovered Other: At least 30 days
        since prior light activated therapy or medication (e.g.,PUVA or Accutane) No prior
        photodynamic therapy At least 30 days since prior experimental drugs","Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy",2
"A 75 yo M w/ metastatic papillary thyroid cancer s/p XRT 19 sessions who presented with 2 days of worsening dysphagia for solids, poor oral intake, weight loss 20 pounds over last several weeks and some lethargy.
Papillary thyroid cancer dx w/ right neck mass
--s/p neck mass resection; unable to perform thyroidectomy
--high bleed risk, proximity to trachea and recurrent laryngeal nerve and large tumor size
--s/p XRT to neck 
--s/p RAI ablation
--Metastatic to lymph nodes and adrenal glands
* s/p hernia repair
* s/p tonsillectomy","DISEASE CHARACTERISTICS: Radiologically confirmed persistent or metastatic follicular or
        papillary thyroid cancer following total thyroidectomy and radioiodine ablation therapy
        Metastatic disease confirmed histologically or cytologically or by elevated thyroglobulin
        levels No radioiodine uptake by whole body scanning Stable iodine contamination from
        radiologic contrast material within the past 10 months allowed, if absence of current
        contamination demonstrated by less than 80 micrograms of iodine in a 24 hour urine
        collection

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
        least 100,000/mm3 Hepatic: SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN)
        Bilirubin no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN OR
        Creatinine clearance at least 50 mL/min Other: Not pregnant or nursing Negative pregnancy
        test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: At least 4 weeks since prior levothyroxine Any prior therapy for
        restoration of radioiodine uptake allowed, if unsuccessful and did not exceed treatment
        schedules planned for this study",Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer,2
"34 year old woman with Marfan's syndrome and known severe mitral valve prolapse with regurgitation, who was planned for a MV repair but was lost to follow-up. She remains symptomatic and is now prepared to undergo mitral valve repair/replacement surgery. EF of 65% on TTE. 
Past Medical History:
Marfans Syndrome
MVP with severe mitral regurgitation
Gastric reflux disease
History of gestational diabetes mellitus
Hypertension with pregnancy
Obesity
c-section x 2
laser eye surgery
cataract surgery
foot surgery (shorten bone length)","18 - 65 years of age.

        Patients with severe aortic regurgitation and patients with severe mitral regurgitation.

        Patients will discontinue medications 48 hours prior to the study.

        Women must not be pregnant.

        Patients must not have an associated valvular heart disease (i.e., patients with aortic
        regurgitation will be excluded if there is coexistent mitral valve disease; patients with
        mitral regurgitation will be excluded if there is coexistent aortic valve disease).

        Patients must not have any form of cardiomyopathy.

        Patients must not have coronary artery disease.

        Patients must not have ventricular ectopy during baseline conditions (i.e., couplets,
        frequent PVc's [greater than 6/min], early coupling [""R-on-T"" phenomenon], ventricular
        bigeminy) that might potentially predispose the patient for the development of dangerous
        dysrhythmia during dobutamine infusion.

        Patients must not have a history of cardiac arrest or ventricular tachycardia.

        Patients must not have a history of congestive heart failure.

        Patients must not have hypotension (i.e., systolic blood pressure less than 100 mmHg).

        Patients must not have a systolic blood pressure greater than 200 mmHg.

        Patients must not have a left atrial size of greater than 100 mm.

        Patients must not have atrial fibrillation.

        Patients must not have sinus tachycardia greater than or equal to 100 beats/min.

        Patients must not have esophageal disease.

        Patients must not have any other medical condition that , at the discretion of the
        physician in charge, may increase the risk of the procedure.",Investigation of Heart Function in Patients With Heart Valve Defects,2
"34 year old woman with Marfan's syndrome and known severe mitral valve prolapse with regurgitation, who was planned for a MV repair but was lost to follow-up. She remains symptomatic and is now prepared to undergo mitral valve repair/replacement surgery. EF of 65% on TTE. 
Past Medical History:
Marfans Syndrome
MVP with severe mitral regurgitation
Gastric reflux disease
History of gestational diabetes mellitus
Hypertension with pregnancy
Obesity
c-section x 2
laser eye surgery
cataract surgery
foot surgery (shorten bone length)","INCLUSION CRITERIA:

        Individuals and their family members will be offered enrollment if they have a suspected or
        established diagnosis of Marfan, Stickler, Ehlers-Danlos, or a closely related syndrome.

        Personal or family history of one or more of the following features in a pattern suggestive
        of a heritable connective tissue disorder:

        Marfanoid body habitus;

        Aortic dilatation and/or dissection;

        Ectopia lentis, detached retina, vitreous degeneration and/or early onset high myopia;

        Posterior cleft palate; joint laxity and/or dislocation;

        Premature osteoarthritis;

        Skin fragility, striae, easy bruisability and/or hyperextensibility;

        Pectus excavatum or carinatum;

        Scoliosis, spondylolisthesis, and/or dural ectasia;

        High frequency sensorineural hearing loss.

        EXCLUSION CRITERIA:

        Inability to provide informed consent.",Study of Heritable Connective Tissue Disorders,2
"62 yo male with hx of CVA, neurogenic bladder with indwelling suprapubic catheter with multiple prior admissions for UTIs, altered mental status, and urosepsis presents to the hospital in urosepsis now resolved after treatment with vanc/meropenem. Per CT there is a non-obstructing stone in the L ureter, no evidence of urethral strictures. Significant leaking around suprapubic cath site. Started on ditropan changed over to detrol. Urologist not concerned with leaking and will f/u with pt next week.
s/p CVA
Neurogenic bladder s/p suprapubic cath
Recurrent UTIs with Klebsiella/Pseudomonas
Non-hodgkins Marginal Zone Lymphoma of the left orbit Dx in 03
(s/p R-CHOP x 6 cycles)
Bells Palsy
BPH
Hypertension
Partial Bowel obstruction s/p colostomy
Hepatitis C
Cryoglobulinemia
SLE with transverse myelitis, anti-dsDNA Ab+
Insulin Dependant Diabetic
Fungal Esophagitis Stage IV?
Urinary Tract Infections-pseudomonas & enterococcus","Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the female breast which is inoperable,
             recurrent or metastatic

          -  HER-2/neu status must be known at the time of protocol registration; HER-2/neu
             assessment will be based on FISH analysis of either the primary tumor or a metastatic
             site; a scoring of 0 or 1+ by immunohistochemistry (IHC) is considered negative; 2+ is
             considered negative unless confirmed by FISH positivity, in which case it should be
             considered positive; 3+ by IHC is considered positive; for centers using FISH only, a
             positive FISH assay by itself is sufficient to determine HER-2 positivity

          -  Patients with the following prior therapy are eligible:

               -  Patients with 0-1 prior chemotherapy regimens for metastatic or locally advanced
                  breast cancer, with the following exception: no prior taxane for
                  metastatic/locally advanced breast cancer

               -  Patients with 0-1 prior chemotherapy regimens in the adjuvant setting; if
                  adjuvant regimen included a taxane, patient must have been disease free for at
                  least 12 months from completion of adjuvant therapy until relapse

               -  Patients must be > 2 weeks from prior surgery, other than simple biopsy or
                  placement of venous access device; patients must be > 4 weeks from prior
                  chemotherapy; patients must be >6 weeks from nitrosoureas, melphalan, or
                  mitomycin

                    -  Patients must be > 4 weeks from prior hormonal therapy unless tumor
                       measurements document clear progression while on treatment; if progression
                       is documented and toxicity from hormonal regimen has resolved, patients may
                       be placed on study > 1 week from prior hormonal therapy

          -  Prior Herceptin therapy is not allowed

          -  Patients with central nervous system metastases are eligible only if the patient has
             completed cranial irradiation at least 6 months prior, is currently asymptomatic, and
             is not currently receiving corticosteroids for this condition; patients with
             leptomeningeal carcinoma (carcinomatous meningitis) are not eligible

          -  MESURABLE DISEASE: Any mass reproducibly measurable in two perpendicular dimensions,
             examples include:

               -  Pulmonary nodules

               -  Hepatic lesions

               -  Skin nodules (if two measurements can be assigned)

               -  Lymph nodes

          -  The following lesions do not qualify as measurable:

               -  Central nervous system (CNS) lesions

               -  Bone disease only; lytic lesions should be documented and followed

               -  Lymphangitic pulmonary metastases (patients with lymphangitic metastases are
                  eligible if there are other sites of metastatic disease which can be measured)

               -  Lesions which have been irradiated unless there is definite documentation of
                  progression since radiotherapy

          -  A baseline assessment of left ventricular ejection fraction within 8 weeks of
             registration is required (echocardiogram or resting multi gated acquisition scan
             [MUGA] (radionuclide cineangiography [RNCA]) nuclear scintigraphy); patients with a
             left ventricular ejection fraction (LVEF) < 45% are ineligible

          -  Granulocytes >= 1500/ul

          -  Platelet count >= 100,000/ul

          -  Creatinine =< 2.0 mg/dl

          -  Bilirubin within institutional normal limits

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])","Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic",0
"62 yo male with hx of CVA, neurogenic bladder with indwelling suprapubic catheter with multiple prior admissions for UTIs, altered mental status, and urosepsis presents to the hospital in urosepsis now resolved after treatment with vanc/meropenem. Per CT there is a non-obstructing stone in the L ureter, no evidence of urethral strictures. Significant leaking around suprapubic cath site. Started on ditropan changed over to detrol. Urologist not concerned with leaking and will f/u with pt next week.
s/p CVA
Neurogenic bladder s/p suprapubic cath
Recurrent UTIs with Klebsiella/Pseudomonas
Non-hodgkins Marginal Zone Lymphoma of the left orbit Dx in 03
(s/p R-CHOP x 6 cycles)
Bells Palsy
BPH
Hypertension
Partial Bowel obstruction s/p colostomy
Hepatitis C
Cryoglobulinemia
SLE with transverse myelitis, anti-dsDNA Ab+
Insulin Dependant Diabetic
Fungal Esophagitis Stage IV?
Urinary Tract Infections-pseudomonas & enterococcus","DISEASE CHARACTERISTICS:

          -  Histologically or cytologically proven HIV-associated B cell non-Hodgkin's lymphoma,
             including:

          -  Diffuse large B cell lymphoma

          -  Intermediate grade diffuse large cell lymphoma

          -  High grade large cell immunoblastic lymphoma

          -  Burkitt's lymphoma

          -  High grade B cell lymphoma, Burkitt's like (small noncleaved lymphoma)

          -  No primary CNS lymphoma (parenchymal brain or spinal cord tumor)

          -  Evaluable disease HIV documentation may be serologic (ELISA or western blot), culture,
             or quantitative PCR or bDNA assay Tumors must be CD20 positive (greater than 50% cells
             express CD20)

          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.
             The terminology of ""indolent"" or ""aggressive"" lymphoma will replace the former
             terminology of ""low"", ""intermediate"", or ""high"" grade lymphoma. However, this protocol
             uses the former terminology.

        PATIENT CHARACTERISTICS:

          -  Age: Over 18

          -  Performance status: Karnofsky 70-100%

          -  Absolute neutrophil count greater than 1,000/mm3*

          -  Platelet count greater than 75,000/mm3*

             * Unless cytopenias are secondary to lymphoma

          -  Bilirubin less than 2.0 mg/dL (unless secondary to hepatic infiltration with lymphoma
             or isolated hyperbilirubinemia associated with the use of indinavir)

          -  SGOT or SGPT less than 7 times upper limit of normal

          -  Creatinine less than 2.0 mg/dL (unless due to lymphoma)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No acute, active HIV-associated opportunistic infection requiring antibiotics

          -  Mycobacterium avium complex allowed

          -  No concurrent malignancy except carcinoma in situ of the cervix, nonmetastatic
             nonmelanomatous skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy

        PRIOR CONCURRENT THERAPY:

          -  Prior or concurrent epoetin alfa or filgrastim (G-CSF) allowed

          -  No prior colony stimulating factor therapy within 24 hours prior to chemotherapy

          -  No prior chemotherapy for HIV-associated non-Hodgkin's lymphoma

          -  At least 1 year since prior cyclophosphamide or doxorubicin

          -  No prior radiotherapy for HIV-associated non-Hodgkin's lymphoma

          -  Chronic therapy with myelosuppressive agents allowed

          -  Concurrent antiretroviral therapy, antifungal medications, and antibiotics allowed",Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma,0
"62 yo male with hx of CVA, neurogenic bladder with indwelling suprapubic catheter with multiple prior admissions for UTIs, altered mental status, and urosepsis presents to the hospital in urosepsis now resolved after treatment with vanc/meropenem. Per CT there is a non-obstructing stone in the L ureter, no evidence of urethral strictures. Significant leaking around suprapubic cath site. Started on ditropan changed over to detrol. Urologist not concerned with leaking and will f/u with pt next week.
s/p CVA
Neurogenic bladder s/p suprapubic cath
Recurrent UTIs with Klebsiella/Pseudomonas
Non-hodgkins Marginal Zone Lymphoma of the left orbit Dx in 03
(s/p R-CHOP x 6 cycles)
Bells Palsy
BPH
Hypertension
Partial Bowel obstruction s/p colostomy
Hepatitis C
Cryoglobulinemia
SLE with transverse myelitis, anti-dsDNA Ab+
Insulin Dependant Diabetic
Fungal Esophagitis Stage IV?
Urinary Tract Infections-pseudomonas & enterococcus","Inclusion Criteria:

          -  Histologically confirmed transitional cell carcinoma (TCC) of the urothelium,
             including the bladder, urethra, ureter, or renal pelvis

               -  No pure adenocarcinomas, pure squamous cell carcinomas, small cell carcinoma, or
                  only small foci of TCC (less than 10% of tumor specimen)

               -  Locally advanced (T4b) TCC of the bladder

               -  Metastatic (N2 or N3 or M1)TCC of the urothelium

               -  HER2 expression (3+) as determined by immunohistochemistry or gene amplification
                  by fluorescent in situ hybridization

          -  Must not be a candidate for potentially curative surgery or radiotherapy

          -  Measurable disease

               -  At least 1 unidimensionally measurable lesion of at least 20 mm by conventional
                  techniques OR at least 10 mm by spiral CT scan

               -  The following lesions are considered nonmeasurable:

                    -  Bone lesions

                    -  Leptomeningeal disease

                    -  Ascites

                    -  Pleural/pericardial effusion

                    -  Lymphangitis cutis/pulmonis

                    -  Abdominal masses not confirmed and followed by imaging techniques

                    -  Cystic lesions

                    -  Primary bladder masses

          -  Relapsed from or failed to achieve a complete or partial response after 1 prior
             systemic chemotherapy regimen for TCC, including cisplatin, carboplatin, paclitaxel,
             docetaxel, or gemcitabine

               -  Prior adjuvant or neoadjuvant chemotherapy is considered 1 prior chemotherapy
                  regimen

               -  Prior single-agent chemotherapy as a radiosensitizer is not considered a prior
                  systemic chemotherapy regimen

          -  No known brain metastases

          -  Performance status - CTC 0-2

          -  More than 12 weeks

          -  Absolute neutrophil count at least 1,000/mm^3

          -  Platelet count at least 75,000/mm^3

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)

          -  AST no greater than 2 times ULN

          -  Creatinine clearance at least 30 mL/min

          -  Ejection fraction at least 50% (or lower limit of normal) by echocardiogram or MUGA

          -  No history of ongoing congestive heart failure

          -  No active cardiac ischemia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other prior malignancy within the past 5 years except adequately treated basal cell
             or squamous cell skin cancer or carcinoma in situ of the cervix

          -  HIV negative

          -  No known autoimmune disease

          -  No prior trastuzumab (Herceptin)

          -  At least 14 days since prior radiotherapy

          -  At least 30 days since prior chemotherapy

          -  Prior doxorubicin allowed provided cumulative dose is no greater than 300 mg/m^2

          -  Prior epirubicin allowed provided cumulative dose is no greater than 600 mg/m^2

          -  No concurrent chemotherapy

          -  No concurrent hormonal therapy except:

               -  Steroids given for adrenal failure

               -  Hormones administered for nondisease-related conditions (e.g., insulin for
                  diabetes)

               -  Intermittent dexamethasone as an antiemetic or for sensitivity reactions to study
                  drug

          -  No concurrent palliative radiotherapy

          -  Prior radiotherapy allowed provided treated area is not only site of measurable
             disease

          -  At least 14 days since prior surgery","Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium",0
"62 yo male with hx of CVA, neurogenic bladder with indwelling suprapubic catheter with multiple prior admissions for UTIs, altered mental status, and urosepsis presents to the hospital in urosepsis now resolved after treatment with vanc/meropenem. Per CT there is a non-obstructing stone in the L ureter, no evidence of urethral strictures. Significant leaking around suprapubic cath site. Started on ditropan changed over to detrol. Urologist not concerned with leaking and will f/u with pt next week.
s/p CVA
Neurogenic bladder s/p suprapubic cath
Recurrent UTIs with Klebsiella/Pseudomonas
Non-hodgkins Marginal Zone Lymphoma of the left orbit Dx in 03
(s/p R-CHOP x 6 cycles)
Bells Palsy
BPH
Hypertension
Partial Bowel obstruction s/p colostomy
Hepatitis C
Cryoglobulinemia
SLE with transverse myelitis, anti-dsDNA Ab+
Insulin Dependant Diabetic
Fungal Esophagitis Stage IV?
Urinary Tract Infections-pseudomonas & enterococcus",No eligibility criteria,Adolescent Blood Pressure Variation and Ventricular Mass,0
"62 yo male with hx of CVA, neurogenic bladder with indwelling suprapubic catheter with multiple prior admissions for UTIs, altered mental status, and urosepsis presents to the hospital in urosepsis now resolved after treatment with vanc/meropenem. Per CT there is a non-obstructing stone in the L ureter, no evidence of urethral strictures. Significant leaking around suprapubic cath site. Started on ditropan changed over to detrol. Urologist not concerned with leaking and will f/u with pt next week.
s/p CVA
Neurogenic bladder s/p suprapubic cath
Recurrent UTIs with Klebsiella/Pseudomonas
Non-hodgkins Marginal Zone Lymphoma of the left orbit Dx in 03
(s/p R-CHOP x 6 cycles)
Bells Palsy
BPH
Hypertension
Partial Bowel obstruction s/p colostomy
Hepatitis C
Cryoglobulinemia
SLE with transverse myelitis, anti-dsDNA Ab+
Insulin Dependant Diabetic
Fungal Esophagitis Stage IV?
Urinary Tract Infections-pseudomonas & enterococcus","DISEASE CHARACTERISTICS:

          -  One of the following histologically confirmed diagnoses

               -  High grade non-Hodgkin's lymphoma:

                    -  Immunoblastic or small noncleaved cell lymphoma (Burkitt's or non-Burkitt's)
                       in complete or partial remission after initial therapy

                    -  Localized (stage I or Zeigler stage A) small noncleaved (Burkitt's or
                       non-Burkitt's) after relapse or incomplete response to initial therapy

                    -  Lymphoblastic lymphoma in second or greater complete or partial response

                    -  High risk lymphoblastic lymphoma in first complete remission or after
                       initial therapy (high risk factors include stage IV disease, LDH greater
                       than 2 times normal, and 2 or more extranodal sites)

               -  Intermediate grade non-Hodgkin's lymphoma:

                    -  Diffuse large cell lymphoma

                    -  Diffuse mixed cell lymphoma

                    -  Diffuse small cleaved cell lymphoma

                    -  Follicular large cell lymphoma

                    -  In second or greater complete or partial remission OR

                    -  High risk in first complete remission or after initial therapy

                         -  High risk features include:

                              -  No complete response after 12 weeks of initial combination
                                 chemotherapy

                              -  Bulky disease (greater than 10 cm nodal masses or mediastinal
                                 disease involving greater than 1/3 of the chest diameter

                              -  Malignant pleural effusion

                              -  Liver involvement

                              -  LDH greater than 2 times upper limit of normal at diagnosis

                              -  At least 2 extranodal sites

               -  Low grade non-Hodgkin's lymphoma:

                    -  Follicular small cleaved cell lymphoma

                    -  Follicular mixed cell lymphoma

                    -  Diffuse small lymphocytic lymphoma

                    -  In first or greater complete response OR

                    -  Following initial treatment if complete response is not achieved

                    -  In second or greater complete or partial response if treated at diagnosis
                       without clinical symptoms necessitating treatment

               -  T-cell lymphoma (nonlymphoblastic, intermediate, or high grade lymphomas) after
                  initial therapy whether or not complete response is achieved

               -  Hodgkin's lymphoma

                    -  Stage I and II disease treated with primary radiotherapy and failure of at
                       least one combination chemotherapy regimen

                    -  Stage III and IV disease with failure on mechlorethamine, vincristine,
                       procarbazine, and prednisone (MOPP)-like regimen, alternative noncross
                       resistant regimen (e.g., doxorubicin, bleomycin, vinblastine, and
                       dacarbazine [ABVD]), or a combination (e.g., MOPP-ABV)

                    -  High risk features allowed including:

                         -  Failure to achieve initial complete remission with MOPP and/or ABVD and
                            crossover or hybrid therapy

                         -  Relapse within 6 months after initial therapy

                         -  Relapse after initial radiotherapy with complete response longer than 1
                            year since initial therapy and subsequent failure on MOPP and/or ABVD
                            or hybrid

                    -  Bulky mediastinal disease after initial therapy and residual mass of at
                       least 5 cm with other features of persisting disease (e.g., Gallium scan
                       positive, high LDH, enlarging on serial x-rays, or positive biopsy)

          -  No HIV or HTLV-1 associated lymphomas

          -  No resistant or refractory lymphoma (no partial response following up to 3 courses of
             combination chemotherapy)

          -  No active ischemic or degenerative CNS disease NOTE: A new classification scheme for
             adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of ""indolent"" or
             ""aggressive"" lymphoma will replace the former terminology of ""low"", ""intermediate"", or
             ""high"" grade lymphoma. However, this protocol uses the former terminology.

        PATIENT CHARACTERISTICS:

        Age:

          -  70 and under

        Performance status:

          -  Age 65-70 years:

               -  Karnofsky 80-100%

          -  Under 65 years:

               -  ECOG 0-1 (2 allowed if symptoms are directly related to lymphoma)

        Life expectancy:

          -  Greater than 8 weeks

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No prior or current chronic liver disease

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST and alkaline phosphatase less than 2 times normal

        Renal:

          -  Age 65-70 years:

               -  Creatinine clearance greater than 60 mL/min (if creatinine at least 1.5 mg/dL)

          -  Under 65 years:

               -  Creatinine no greater than 1.5 mg/dL OR

               -  Creatinine clearance greater than 50 mL/min

        Cardiovascular:

          -  LVEF at least 45% by MUGA

          -  No symptoms of cardiac disease

          -  No active ischemic heart disease

          -  No uncontrolled hypertension

        Pulmonary:

          -  Age 65-70 years:

               -  If history of smoking or respiratory symptoms, spirometry and DLCO must be
                  greater than 50% of predicted

          -  All ages:

               -  No obstructive airway disease

               -  No resting hypoxemia (PO_2 less than 80)

               -  DLCO at least 50% of predicted

        Other:

          -  No poorly controlled diabetes

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  Must have prior chemotherapy to attempt to achieve complete response

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No radiotherapy to residual disease prior to transplantation

        Surgery:

          -  Not specified

        Other:

          -  Concurrent IV antibiotic therapy allowed for fever or signs of infection",Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma,2
"62 yo male with hx of CVA, neurogenic bladder with indwelling suprapubic catheter with multiple prior admissions for UTIs, altered mental status, and urosepsis presents to the hospital in urosepsis now resolved after treatment with vanc/meropenem. Per CT there is a non-obstructing stone in the L ureter, no evidence of urethral strictures. Significant leaking around suprapubic cath site. Started on ditropan changed over to detrol. Urologist not concerned with leaking and will f/u with pt next week.
s/p CVA
Neurogenic bladder s/p suprapubic cath
Recurrent UTIs with Klebsiella/Pseudomonas
Non-hodgkins Marginal Zone Lymphoma of the left orbit Dx in 03
(s/p R-CHOP x 6 cycles)
Bells Palsy
BPH
Hypertension
Partial Bowel obstruction s/p colostomy
Hepatitis C
Cryoglobulinemia
SLE with transverse myelitis, anti-dsDNA Ab+
Insulin Dependant Diabetic
Fungal Esophagitis Stage IV?
Urinary Tract Infections-pseudomonas & enterococcus","Criteria:

          -  No concurrent radiotherapy

          -  No prior angioplasty

          -  No concurrent chemotherapy

          -  No concurrent oral or IV corticosteroids for more than 2 consecutive weeks or orally
             inhaled corticosteroids for more than 4 consecutive weeks during any 6 month period of
             the study

          -  Chronic nasally inhaled steroids allowed provided patient agrees to use mometasone or,
             in countries where mometasone is not available, fluticasone

          -  No prior coronary bypass surgery

          -  At least 30 days since prior investigational medication

          -  No other prior malignancy within the past 5 years except:

          -  No prior pelvic radiotherapy

          -  Histologically proven superficial transitional cell carcinoma of the bladder at high
             risk for recurrence, meeting 1 of the following staging criteria:

          -  Stage Ta (grade 3 OR multifocal OR at least 2 occurrences, including current tumor,
             within the past 12 months)

          -  Stage T1 (any grade)

          -  Stage Tis

          -  Patients with Ta or T1 lesions must have undergone complete transurethral resection of
             bladder tumor within the past 9 months

          -  No carcinoma involving the prostatic urethra or upper urinary tract

          -  Must have received the following prior to randomization:

          -  Induction course of BCG comprising 6 weekly intravesical doses (at least 4 doses if
             BCG intolerant)

          -  Additional induction courses of BCG allowed

          -  Maintenance course of BCG comprising 3 weekly doses (at least 1 dose if BCG
             intolerant)

          -  No evidence of disease by cystoscopy (with or without biopsy) and bladder cytology
             prior to initiation of maintenance BCG

          -  Concurrent interferon allowed

          -  Zubrod 0-2 or ECOG 0-2

          -  WBC at least 3,000/mm^3

          -  Hemoglobin at least lower limit of normal

          -  Platelet count at least 125,000/Mm^3

          -  No significant bleeding disorder

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGOT and SGPT no greater than 1.5 times ULN

          -  No chronic or acute hepatic disorder

          -  Creatinine no greater than 1.5 times ULN

          -  No chronic or acute renal disorder

          -  Normal kidneys and ureters on imaging study within the past 9 months

          -  No active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)

          -  No active pancreatitis

          -  No esophageal, gastric, pyloric channel, or duodenal ulceration that was diagnosed or
             treated within the past 30 days

          -  No history of cardiovascular disease, including any of the following conditions:

          -  Stroke

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other medical or psychological condition that would preclude study participation

          -  No hypersensitivity or adverse reactions to sulfonamides, cyclooxygenase (COX)-2
             inhibitors, salicylates, or other NSAIDs

          -  Nonmelanomatous skin cancer cured by excision

          -  Carcinoma in situ of the cervix

          -  Stage 0 chronic lymphocytic leukemia

          -  Other malignancy for which patient has no current evidence of disease, has received no
             therapy within the past 6 months, has no concurrent or planned therapy, and has an
             expected disease-free survival of at least 5 years

          -  No concurrent immunotherapy

          -  At least 2 weeks since prior aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
             except cardioprotective dose (no greater than 100 mg/day) of aspirin

          -  No concurrent chronic NSAIDs except oral cardioprotective dose (no greater than 100
             mg/day) of aspirin

          -  Concurrent chronic use is defined as a frequency of at least 3 times per week for more
             than 2 consecutive weeks per year

          -  No other concurrent investigational drug

          -  No other concurrent systemic therapy

          -  No concurrent lithium or fluconazole

          -  No other concurrent hormonal therapy except hormone replacement (i.e., estrogen or
             thyroid hormone replacement)

          -  Myocardial infarction

          -  Angina

          -  Congestive heart failure",Celecoxib in Treating Patients With Bladder Cancer,0
"70 y/o with COPD on 2.5-3.5L O2 at baseline, OSA and obesity hypoventilation syndrome, dCHF, discharged [**2132-8-24**] now presents with agitation and altered mental status with hypoxia and O2 sats 70s on BipAp with 5L. Pt agitated then somnolent at initial presentation. Daughter reported increased agitation and altered mental status x 2-3 days with O2 sats 60s-70s at home. Daughter has also noted increased LE edema and weight gain which prompted a phone call to her PCP and increased lasix dose from 80daily to 100mg daily with some mild improvement in edema. She has had decreased appetite, PO intake, energy level at home with difficulty with ADLs. No recent history of fever, cough, chills, sputum production, CP, abd pain, or other complaints other than chronic right thigh pain last 1-2 months. Daughter also reports med compliance and compliance with BiPap at night.
Past Medical History:
- CAD; s/p 4 vessel CABG in [**2119**]
- CHF; EF 55%, mild AS
- obesity hypoventilation syndrome
- obstructive sleep apnea
- DM2
- ventricular tachycardia; s/p ICD in [**2127**]
- hypothyroidism
- schizophrenia
- COPD
- Pneumona treated in [**4-7**] at [**Hospital1 **]","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of adult respiratory distress syndrome (ARDS) with sepsis

        ARDS characterized by: hypoxemia refractory to supplemental oxygen therapy, diffuse
        pulmonary infiltrates, no cardiogenic cause of pulmonary edema, and reduced pulmonary
        compliance

        Sepsis characterized by: Two or more of the following: Fever or hypothermia; Tachycardia;
        Tachypnea; WBC greater than 12,000/mm3 or less than 4,000/mm3 or immature neutrophils;
        Hypotension; Clinical suspicion of infection; Inadequate organ perfusion or organ
        dysfunction as demonstrated by: Acute deterioration in mental acuity (excluding sedatives
        or other nonsepsis causes) OR Unexplained metabolic acidosis OR Oliguria for greater than 2
        hours OR Unexplained coagulopathy (elevated PT or PTT or platelet count decreased to less
        than 50% of baseline within 24 hours or less than 100,000/mm3) OR Acute elevation of
        bilirubin to greater than 2.0 mg/dL AND elevation of alkaline phosphatase, SGOT, or SGPT

        No sepsis with unstable BP

        --Prior/Concurrent Therapy--

        At least 30 days since prior enrollment in investigational trial; No other concurrent
        enrollment in investigational trial

        --Patient Characteristics--

        Hematopoietic: See Disease Characteristics; No uncontrolled hemorrhage (transfusion of 4 or
        more units required within past 24 hours); No chemotherapy induced neutropenia (granulocyte
        count less than 1000/mm3)

        Hepatic: No severe liver disease with portal hypertension

        Renal: No anuria (urine output less than 50 mL/day)

        Cardiovascular: No cardiogenic shock

        Neurologic: No recent stroke, head trauma, or increased intracranial pressure; No other
        serious neurologic disorder

        Other: Not pregnant; No acquired immune deficiency syndrome; No immunosuppressed transplant
        patients; No severe burns; No irreversible underlying condition with rapidly fatal course;
        No marked obesity; No recent history of diarrhea",Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis,1
"70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient.
Past Medical History:
1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago
2. Mitral valve prolapse
3. Atrial fibrillation
4. Hyperlipemia
5. Hypertension
6. Chronic kidney disease (SCr 2.1 in [**3-17**])
7. Hypothyroidism? (TSH 10 in [**3-17**])
8. Anemia (HCT 30.7 in [**3-17**])","Patients greater than or equal to 18 years of age, with well-differentiated, non-medullary
        thyroid cancer, including papillary (including follicular-variant), follicular, and Hurthle
        cell.

        Patients who recently have undergone a total or near-total thyroidectomy and are scheduled
        to undergo initial 131I diagnostic studies and ablation.

        Patients must have evidence of residual thyroid tissue after thyroid surgery confirmed by
        ultrasound or other imaging technique (e.g., a technetium [Tc 99] pertechnetate or thallium
        scan).

        Patients who have undergone thyroidectomy or other thyroid surgery at least 6 weeks prior
        to enrollment.

        All patients who have been sustained on maintenance THST for at least 4 weeks, but not
        longer than 12 weeks after thyroidectomy.

        All patients who have confirmed serum TSH levels less than or equal to 0.5 mU per liter
        within 7 days prior to the first Thyrogen dose, and prior to randomization.

        Female patients of childbearing age must have a negative serum human chorionic gonadotropin
        (HCG) pregnancy test prior to entering the study and within 5 days of any 131I
        administration and must be following an approved method of contraception.

        Patients who are committed to following the protocol requirements as evidenced by providing
        written informed consent.

        Patients for whom a 131I scan is currently contraindicated because withdrawal from THST is
        not an option due to pituitary dysfunction or other compelling medical reasons are
        excluded.

        Patients should not have a concurrent major medical disorder (e.g., documented cardiac
        disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver
        disease or advanced pulmonary disease) who may be too ill to adequately comply with the
        requirements of this study.

        Patients with non-thyroidal conditions known to effect 131I uptake (e.g., congestive heart
        failure, renal failure) are excluded.

        Patients should not have undergone any intravenous water soluble radiographic contrast
        administration within the previous 4 weeks.

        Patients should not have received intrathecal or cholecystographic iodinated contrast agent
        administration within 3 months prior to enrollment.

        Patients should not be taking drugs that affect thyroid or renal function (e.g., renal
        drugs, lithium, or corticosteroids).

        Patients should not be participating in another investigational drug study or in such a
        study within 30 days of their enrollment in this study.

        No patients with a recent history of alcoholism or drug abuse, severe emotional behavioral
        or psychiatric problems who, in the opinion of the investigator, would not be able to
        comply with the requirements of this study.",Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,0
"70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient.
Past Medical History:
1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago
2. Mitral valve prolapse
3. Atrial fibrillation
4. Hyperlipemia
5. Hypertension
6. Chronic kidney disease (SCr 2.1 in [**3-17**])
7. Hypothyroidism? (TSH 10 in [**3-17**])
8. Anemia (HCT 30.7 in [**3-17**])","DISEASE CHARACTERISTICS:

          -  Histologically or cytologically proven adenocarcinoma of the exocrine pancreas
             excluding periampullary cancer

          -  Resectable malignancy must be located in a region that can be encompassed by a
             radiation port of 20 x 20 cm

          -  No evidence of extranodal metastatic disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Bilateral renal function as demonstrated by excretory urogram (IVP) or abdominal CT
             scan with contrast OR

          -  Greater than 2/3 of one functioning kidney must be shielded during radiation therapy

        Other:

          -  Must have adequate oral nutrition (greater than 1200 calories daily)

          -  Greater than 5 years since prior malignancy except:

               -  Squamous cell skin cancer

               -  Basal cell skin cancer

               -  In situ cervical cancer

          -  Not pregnant or lactating

          -  Patients of reproductive potential must use effective birth control

          -  No cystic neoplasms of the pancreas

          -  No islet cell, periampullary or cholangiocarcinoma

          -  No Federal Medical Center inmates

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for this disease

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiation therapy for this disease

          -  No prior radiation therapy to the abdomen

        Surgery:

          -  Celiotomy and standardized exploration for resectability required",Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas,2
"70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient.
Past Medical History:
1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago
2. Mitral valve prolapse
3. Atrial fibrillation
4. Hyperlipemia
5. Hypertension
6. Chronic kidney disease (SCr 2.1 in [**3-17**])
7. Hypothyroidism? (TSH 10 in [**3-17**])
8. Anemia (HCT 30.7 in [**3-17**])","1. Patients with histologically documented untreated squamous cell carcinoma or
             adenocarcinoma of the thoracic esophagus (below 20 cm) or gastro-esophageal junction
             and with less than 2 cm distal spread into the gastric cardia were eligible.

          2. No evidence of distant metastatic disease by history and physical examination

          3. Upper endoscopy with biopsy, computed tomography (CT) of the chest and upper abdomen,
             and pulmonary function studies are required.

          4. Bone scan is required for alkaline phosphatase more than 3X the institutional normal
             value.

          5. Bronchoscopy is required if the primary tumor was adjacent to the trachea or left main
             stem bronchus.

          6. Patients are required to have:

               -  granulocyte counts 1,800/mL

               -  platelet count  100,000/mL

               -  creatinine clearance  50 mL/min

          7. Esophageal ultrasound (EUS) and preresection staging by thoracoscopy (ts) and
             laparoscopy/minilaparotomy (ls), including biopsy of celiac axis and lesser curvature
             are recommended

          8. Tumors must be considered surgically resectable (T1-3, NX), including regional
             thoracic lymph node (N1) metastases.

          9. Patients with supraclavicular lymph nodes measuring  1.5 cm by CT (not palpable) are
             eligible.

         10. Patients with lymph node metastases to levels 15 to 20 (predominantly celiac axis and
             paracardial nodes) 1.5 cm by CT.

         11. Patients may not have previously received chemotherapy or radiation therapy for this
             tumor or any radiation therapy that would overlap the radiation fields required for
             this malignancy.

         12. Patients with previous malignancies are eligible if more than 5 years had elapsed from
             diagnosis without evidence of tumor recurrence.

         13. There can be no other serious illness that would limit survival to less than 2 years,
             or psychiatric condition that would prevent compliance with treatment or informed
             consent. Patients with uncontrolled or severe cardio- vascular disease,pulmonary
             disease, oractive infections are excluded.

         14. Pregnant patients are excluded.

         15. Informed consent is required for all patients.",Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus,0
"70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient.
Past Medical History:
1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago
2. Mitral valve prolapse
3. Atrial fibrillation
4. Hyperlipemia
5. Hypertension
6. Chronic kidney disease (SCr 2.1 in [**3-17**])
7. Hypothyroidism? (TSH 10 in [**3-17**])
8. Anemia (HCT 30.7 in [**3-17**])","Inclusion Criteria:

          -  Major depression assessed by Structured Clinical Interview for DSM-IV Axis I Disorders
             (SCID; First et al, 1995)

          -  Minimum score greater than or equal to 20 on the 17-item Hamilton Depression (HAM-D)
             Scale at screen and at baseline

          -  GAF of 60 or less (moderate symptoms) at screen and at baseline

          -  HAM-D cannot decrease by 25% or more between screening and baseline

          -  Capacity to give informed consent and to follow study procedures.

          -  Abstinence or effective method of contraception throughout the study

        Exclusion Criteria:

          -  Scores greater than 2 on the ""suicide"" item of HAM-D, or history of suicide attempt(s)
             in the past 12 months

          -  Current suicidal or homicidal risk, as determined by the investigator

          -  Women of childbearing age who are pregnant, planning pregnancy in the next 6 months,
             breast-feeding, or not using medically acceptable means of birth control (hormonal
             treatment such as birth control pill, injection or implant, IUD, or double barrier of
             condom and diaphragm together is acceptable; primary use of condom, sponge or
             diaphragm alone (single barrier) is not acceptable because these may carry a higher
             rate of failure when used alone

          -  Clinically significant liver disease (such as hepatitis, cirrhosis, etc); or
             clinically significant elevation of liver enzyme tests (two times the upper limit of
             normal; asymptomatic Gilbert's syndrome is not an exclusion). 4. Serious or unstable
             medical illness. 5. History of seizure disorder (other than febrile).

          -  Any of the following DSM-IV diagnoses by SCID: current (within past 6 months) alcohol
             or other substance abuse disorder; schizophrenia, schizo-affective, or other psychotic
             disorder; bipolar disorder; current panic disorder or obsessive compulsive disorder;
             history of psychotic features of affective disorder (mood congruent or incongruent)

          -  Clinical or laboratory evidence of untreated or unstable thyroid disorder

          -  Failed to respond to at least two adequate antidepressant trials (defined as 6 weeks
             or more treatment with either greater than or equal to 150 mg imipramine, or tricyclic
             equivalent), or greater than or equal to 60 mg of phenelzine, or MAOI equivalent, or
             greater than or equal to 100 mg of sertraline, or its SSRI equivalent

          -  Have taken sertraline or any form of hypericum during this current episode of
             depression at any dose level, daily, for at least one month, within the past 6 months

          -  Current (within past 6 months) use of other prescription or non-prescription drugs,
             including anticonvulsants and other medications with significant psychotropic
             properties, antiretroviral medications, cyclosporine, digoxin, coumadin, dietary
             supplements, natural remedies, and botanical preparations (eg, hypericum, kava,
             valerian)

          -  Have had other investigational drugs within 30 days or other psychotropic medication
             within 21 days of baseline (6 weeks for fluoxetine)

          -  Known allergy or hypersensitivity to the study medications

          -  Positive drug urine screen

          -  Have been in psychotherapy for 2 months or less at the time of enrollment into the
             study

          -  Receiving psychotherapies which are specifically designed to treat depression, eg,
             interpersonal psychotherapy during the study period

          -  Mental retardation or cognitive impairment, or any disorder that might interfere with
             their ability to consent or follow study procedures and requirements",Treatment of Major Depression With St. John's Wort (Hypericum),0
"70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient.
Past Medical History:
1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago
2. Mitral valve prolapse
3. Atrial fibrillation
4. Hyperlipemia
5. Hypertension
6. Chronic kidney disease (SCr 2.1 in [**3-17**])
7. Hypothyroidism? (TSH 10 in [**3-17**])
8. Anemia (HCT 30.7 in [**3-17**])","Inclusion criteria for probands: Onset of hypertension by age 60 years and the presence of
        at least one additional hypertensive sibling who was willing to participate. Hypertension
        was defined according to systolic BP 140 or diastolic BP 90 in at least two different
        evaluations, or treatment for hypertension. Volunteers with type 1 diabetes or renal
        failure were excluded.

        Inclusion criteria for subsequent recruits: Criteria as indicated in Study Population
        Description (i.e., criteria based on familial relationships, hypertension and
        antihypertensive medication status).",Family Blood Pressure Program - HyperGEN,2
"70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient.
Past Medical History:
1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago
2. Mitral valve prolapse
3. Atrial fibrillation
4. Hyperlipemia
5. Hypertension
6. Chronic kidney disease (SCr 2.1 in [**3-17**])
7. Hypothyroidism? (TSH 10 in [**3-17**])
8. Anemia (HCT 30.7 in [**3-17**])","Patients must have regionally confined histologically or cytologically proven
        adenocarcinoma of the pancreas or Ampulla of Vater. Tumors must overexpress HER2 as
        demonstrated by greater than or equal to 2+ immunohistochemical staining of the biopsy
        specimen.

        Patients must sign an informed consent.

        Patients must have an ECOG performance status of less than or equal to 2.

        Patients should have a serum creatinine less than 1.5 mg/dl or creatinine clearance greater
        than 60 ml/hr; SGOT and SGPT less than 4 times the upper limit of normal.

        Patients must have an ANC greater than 2000/mm(3) and platelets greater than 100,000/mm(3).

        Patients must be at least 18 years of age.

        Patients of all racial and gender groups will be included.

        Patients must not have received any prior gemcitabine, radiotherapy, or Herceptin therapy
        for pancreatic cancer.

        Patients cannot receive concurrent hormonal or immunotherapy treatment for pancreatic
        cancer.

        Patients cannot receive any anti-tumor therapy within 30 days of protocol eligibility and
        must have recovered from any prior treatment related toxicity.

        Patients must not have evidence of distant metastases (e.g., peritoneal, carcinomatosis,
        liver metastases).

        No concurrent second malignancy other than non-melanoma skin cancer or cervical carcinoma
        in situ.

        Must not have medical conditions that preclude undergoing surgery or receiving therapy or
        follow up, or have psychiatric disease which would prevent adequate informed consent or
        render receiving this therapy unsafe.

        No patients with an LV ejection fraction less than the lower limit of normal as determined
        at the Clinical Center, NIH.

        Women must not be pregnant or nursing due to the unknown effects of this therapy on the
        unborn or nursing child.

        Must not have received prior abdominal or pelvic radiation.

        Must not have recent myocardial infarction (less than 6 months prior), unstable angina, or
        congestive heart failure (NYHA class III or IV).

        Must not have active diseases which make the patient more susceptible to infection,
        including but not limited to AIDS, hepatitis, history of autoimmune disorders, because the
        experimental treatment being evaluated in this protocol may be unsafe in the absence of an
        intact immune system.","Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas",2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","Inclusion Criteria

        Concurrent Medication: Required:

          -  PCP prophylaxis with Bactrim, dapsone, or aerosolized pentamidine.

          -  Oral candidiasis prophylaxis with fluconazole, ketoconazole, or clotrimazole oral
             troches.

          -  Antiretroviral agent available by therapy IND.

          -  MAI prophylaxis with rifabutin (in patients with CD4 counts < 100 cells/mm3).

        Patients must have:

          -  HIV infection.

          -  Primary CNS lymphoma with NO systemic involvement.

        Prior Medication:

        Allowed:

          -  Prior corticosteroids.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Concomitant malignancy other than Kaposi's sarcoma, curatively treated carcinoma in
             situ of the cervix, or squamous or basal cell carcinoma of the skin.

          -  Active uncontrolled infection.

          -  Renal failure, active nonmalignant duodenal ulcer, uncontrolled diabetes mellitus, or
             other serious medical conditions that would preclude aggressive cytotoxic chemotherapy
             administration.

          -  Active heart disease (congestive heart failure or heart block greater than first
             degree on EKG).

        Concurrent Medication:

        Excluded:

          -  Any investigational agent other than antiretroviral agents available by therapy IND.

        Patients with the following prior conditions are excluded:

          -  No prior malignancy other than Kaposi's sarcoma, curatively treated carcinoma in situ
             of the cervix, or squamous cell or basal cell carcinoma of the skin.

          -  No new infectious complications within the past 2 weeks that require a change in
             antibiotics.

          -  History of myocardial infarction within the past 3 months.

        Prior Medication:

        Excluded:

          -  Prior chemotherapy other than for Kaposi's sarcoma.",Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma,0
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","INCLUSION CRITERIA:

        Documentation of WG based on clinical characteristics and histopathological evidence of
        vasculitis. Patients with a positive C- or P-ANCA and glomerulonephritis as evidence by the
        presence of red blood cell casts and proteinuria or renal biopsy showing necrotizing
        glomerulonephritis in the absence of positive immunofluorescence for immunoglobulin and
        complement will also be eligible.

        Age 10-80 years.

        Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater
        than or equal to 3 or if begun on CTX and glucocorticoid at an outside institution, a
        history of a Vasculitis Disease Activity Index greater than or equal to 3 at the time of
        therapy initiation.

        EXCLUSION CRITERIA:

        Evidence of active systemic infection which, in the judgement of the investigator, is of
        greater danger to the patient than the underlying vasculitis. In those instances in which
        infection cannot be ruled out by gram stain and culture of secretions or collections of
        fluid in involved organs, it may be necessary to obtain a biopsy of the affected tissue for
        microbiological and histopathological studies.

        Patients who are pregnant or who are nursing infants will not be eligible. Fertile women
        must have a negative pregnancy test within one week prior to study entry and must be using
        an effective means of birth control.

        Processes associated with an increased risk of MTX toxicity: acute or chronic liver
        disease, past history of alcohol abuse (greater than 14 oz. of 100 proof liquor or
        equivalent per week), ongoing alcohol use of any volume that cannot be discontinued upon
        entry into the study.

        Serological evidence of infection with human immunodeficiency virus, hepatitis C, or a
        positive hepatitis B surface antigen. A serological determination will be performed within
        two weeks of beginning study participation.

        Inability to comply with study guidelines.",Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides,0
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","-  INCLUSION CRITERIA - PATIENT:

        Ages 55-71 years.

        Chronic myelogenous leukemia (CML): chronic phase.

        Acute lymphoblastic leukemia (ALL), all patients in complete or partial remission.

        Acute myelogenous leukemia (AML): AML in first complete or partial remission. Exceptions:
        AML with good risk karyotypes: AML M3 t(5;17), AML M4Eo (inv. 16), AML t(8;21). All AML in
        second or subsequent complete remission.

        Myelodyplastic syndromes: refractory anemia with excess of blasts (less than 10%) or early
        transformation to acute leukemia or Chronic myelomonocytic leukemia.

        Chronic lymphocytic leukemia (CLL) with bulky or progressive disease despite prior
        treatment with chemotherapy which includes purine analogs.

        Mantle cell lymphoma.

        Relapsed or progressive non-Hodgkins lymphoma, failing standard treatment approaches and
        unsuitable for autologous stem cell transplantation.

        No major organ dysfunction precluding transplantation.

        DLCO greater than or equal to 40% predicted.

        Left ventricular ejection fraction: greater than 30% predicted.

        ECOG performance status of 0-2.

        INCLUSION CRITERIA - DONOR:

        HLA identical family donor, up to 75 years old.

        Fit to receive G-CSF and give peripheral blood stem cells (normal blood count,
        normotensive, no history of stroke, no history of severe heart disease).

        Informed consent given.

        EXCLUSION CRITERIA:

        Patient or donor pregnant or lactating.

        Patient age less than 55, greater than 71 years.

        ECOG performance status of 3 or more. Psychiatric disorder or mental deficiency of the
        patient or the donor sufficiently severe as to make compliance with the BMT treatment
        unlikely, and making informed consent impossible.

        Major anticipated illness or organ failure incompatible with survival from BMT.

        DLCO less than 40% predicted.

        Left ventricular ejection fraction less than 30% predicted.

        Serum creatinine greater than 2.5 mg/dl.

        Serum bilirubin greater than 4 mg/dl, transaminases greater than 5 times the upper limit of
        normal.

        HIV positive (donor or recipient). Donors who are positive for HBV, HCV, or HTLV will be
        used at the discretion of the investigator.

        Other malignant diseases liable to relapse or progress within 5 years.

        Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of
        heart failure or unstable angina, platelet count less than 90,000/cu mm).",Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults,0
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Newly diagnosed, active multiple myeloma of any stage requiring treatment

               -  Smoldering myeloma (Durie-Salmon stage I) must have a 25% or greater increase in
                  M component levels and/or Bence-Jones protein excretion or development of
                  symptoms

          -  Quantifiable M component of IgG, IgA, IgD, IgE, and/or urinary kappa or lambda light
             chain (Bence-Jones protein) excretion required

               -  Plasmacytosis of at least 30% allowed for non-secretory disease or secretory
                  disease without quantifiable protein

               -  IgM peaks excluded

          -  Evaluation of siblings as potential allogeneic bone marrow transplant donors required
             for patients 55 years of age and younger (As of 8/1/97, permanently closed)

               -  HLA followed by DR and MLC testing required

          -  Renal failure, even on dialysis, eligible provided:

               -  Cause is attributed to myeloma (Bence-Jones protein or hypercalcemia)

               -  Duration does not exceed 2 months

          -  If medically appropriate, the following conditions should be treated prior to
             registration:

               -  Pathologic fractures

               -  Pneumonia at diagnosis

               -  Hyperviscosity with shortness of breath

        PATIENT CHARACTERISTICS:

        Age:

          -  70 and under

        Performance status:

          -  SWOG 0-2 (SWOG 3 or 4 based solely on bone pain allowed)

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  See Disease Characteristics

        Cardiovascular:

          -  Normal ejection fraction by ECHO or MUGA

          -  No myocardial infarction within 6 months

          -  No unstable angina

          -  No difficult to control congestive heart failure

          -  No uncontrolled hypertension

          -  No difficult to control arrhythmias

          -  No history of chronic cerebral vascular accident

        Pulmonary:

          -  No history of chronic obstructive or restrictive pulmonary disease

          -  Pulmonary function studies and DLCO at least 50% of predicted except for demonstrated
             myeloma involvement on bronchoscopy and/or open lung biopsy

        Other:

          -  No uncontrolled diabetes

          -  No significant comorbid medical condition

          -  No uncontrolled, life-threatening infection

          -  No prior malignancy within 5 years except adequately treated nonmelanoma skin cancer
             or carcinoma in situ of the cervix

          -  No prior malignancy treated with cytotoxic drugs used on this protocol

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy except local radiotherapy provided the following cumulative dose
             limits for prior dose plus potential TBI dose on protocol are not exceeded:

               -  Less than 5,000 cGy to bone

               -  Less than 4,000 cGy to mediastinum, heart, small bowel, brain, and spinal cord

               -  Less than 2,000 cGy to the liver

               -  Less than 1,500 cGy to the kidney and lungs

        Surgery:

          -  Not specified","SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma",2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS: Multiple myeloma confirmed by bone marrow plasmacytosis and with
        measurable M-component in the serum or urine by immunoelectrophoresis or immunofixation No
        Stage I myeloma No smoldering multiple myeloma Refractory to or in first relapse following
        an initial response to VAD (vincristine/doxorubicin/dexamethasone), with relapse defined as
        any of the following: 50% increase above the lowest remission level of serum or urine
        M-protein while on therapy 25-50% increase above the lowest remission level of serum or
        urine M-protein associated with either: Hypercalcemia (greater than 11 mg/dl) Hb decrease
        of 2 g/dl attributable to increasing marrow plasmacytosis Appearance of new lytic lesions
        Calcium no greater than 11 mg/dl No myeloma meningitis No plasma cell leukemia

        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: ECOG 0-2 Hematopoietic: WBC
        greater than 500 (after G-CSF) Platelets greater than 25,000 Hepatic: Bilirubin no greater
        than 2.0 mg/dl Renal: Creatinine no greater than 2.0 mg/dl Cardiovascular: No NYHA class
        II-IV disease Pulmonary: DLCO at least 50% of predicted FVC at least 75% of predicted FEV1
        at least 60% of predicted Other: No uncontrolled infection No active fungal infection No
        fever No prior malignancy within 5 years except: Basal cell skin cancer In situ carcinoma
        of the cervix No pregnant or nursing women

        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological response modifiers allowed
        Chemotherapy: No time limit between cytotoxic therapy and protocol treatment Prior
        cumulative melphalan dose less than 300 mg Endocrine therapy: Corticosteroids for
        hypercalcemia allowed Radiotherapy: Prior radiotherapy allowed Prior pelvic radiotherapy
        allowed, but patients with such therapy are unlikely to have adequate PBSC harvested
        Surgery: Not specified","High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse",2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Primary amyloidosis diagnosed by appropriate amyloid stains or electromicroscopy of
             abdominal fat, bone marrow, or other target tissues

               -  Pathology reviewed by Temple University

          -  Amyloidosis secondary to any stage of multiple myeloma allowed provided plasma cell
             concentration in bone marrow is less than 15%

          -  No amyloidosis secondary to rheumatoid arthritis or chronic infection

          -  No familial amyloidosis

        PATIENT CHARACTERISTICS:

        Age:

          -  16 to 65

        Performance status:

          -  Karnofsky 80-100%

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Liver function tests less than twice normal

          -  No active liver disease

        Renal:

          -  Creatinine clearance greater than 50 mL/min

          -  Nephrotic syndrome allowed

        Cardiovascular:

          -  Cardiac evaluation required in patients with left ventricular ejection fraction less
             than 45% by echocardiogram or MUGA

          -  No poorly controlled hypertension

        Pulmonary:

          -  FEV_1 and DLCO greater than 50% of predicted, or pulmonary evaluation required

          -  No chronic obstructive pulmonary disease

        Other:

          -  No history of serious coagulopathy, hemorrhage, or bleeding

          -  No active infection

          -  No other serious comorbid disease (e.g., poorly controlled diabetes)

          -  No pregnant women

          -  Adequate contraception required of fertile women

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  More than 12 monthly cycles of prior alkylating agent chemotherapy discouraged

        Endocrine therapy:

          -  Corticosteroids discontinued at least 6 weeks prior to transplantation

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  Not specified",High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis,2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","Inclusion:

          -  Patient must have a diagnosis of multiple myeloma confirmed by the presence of:

          -  Bone marrow plasmacytosis with >10% abnormal plasma cells or multiple biopsy-proven
             plasmacytomas, and at least one of the criteria below must be documented:

               1. Myeloma protein in the serum

               2. Myeloma protein in the urine (free monoclonal light chain)

               3. Radiologic evidence of osteolytic lesions (generalized osteoporosis qualifies
                  only if the bone marrow aspirate contains >20% plasma cells)

          -  Patients must have no active infection during the prior seven days and be off all
             antibiotics for the prior seven days.

          -  Patients cannot have received radiotherapy during the preceding ten days.

          -  Primary therapy for multiple myeloma must start within three days after entry to this
             study. For purposes of eligibility for this study, myelosuppressive chemotherapy or
             high-dose dexamethasone based regimens are acceptable as primary therapy. The
             high-dose dexamethasone regimen must include, at a minimum, dexamethasone 40 mg per
             day days 1-4, 9-12, 17-20 for the first cycle and 40 mg per day on days 1-4 of the
             second cycle.

          -  Patients who are to receive dexamethasone alone or dexamethasone with thalidomide are
             among those eligible for this protocol.

          -  Patients must have a serum creatinine <5.0 mg/dl and not require dialysis at the time
             of study entry. If patients require dialysis after enrollment, they can continue on
             the protocol using the adjusted medication guidelines

          -  Written informed consent must be obtained prior to entry.

        Exclusion:

        - Patients with smoldering myeloma, history of hypersensitivity to fluoroquinolones or
        trimethoprim, bone marrow transplant or autologous stem cell rescue planned during the
        first two months of treatment, patients taking theophylline, or patients previously treated
        with chemotherapy or high-dose dexamethasone",Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy,0
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Multiple myeloma of any stage confirmed by:

               -  Bone marrow plasmacytosis with at least 10% plasma cells, sheets of plasma cells,
                  or biopsy proven plasmacytosis

               -  Myeloma (M) protein in serum and/or urine

          -  Measurable disease by at least one of the following:

               -  Serum M-component at least 1.0 g/dL by electrophoresis

                    -  Baseline measurement by nephelometry also, if used to follow response

               -  Urine M-protein excretion greater than 200 mg/24 hours by electrophoresis

          -  The following are not considered measurable but are followed for response:

               -  Lytic bone lesions

               -  Bone marrow plasmacytosis

               -  Anemia

               -  Serum beta 2-microglobulin

          -  Objective evidence of progression by at least one of the following:

               -  Increased serum M-protein (by electrophoresis unless M-spike less than 1.5 g/dL)

                    -  At least 50% above lowest remission level or by at least 2 g/dL

                    -  To more than 1.0 g/dL if sole protein indication of relapse

                    -  Nephelometry may be used instead of electrophoresis

               -  Increased urine M-protein

                    -  To 50% above lowest level OR by 2 g/24 hours

                    -  To greater than 200 mg/24 hours

               -  Definite new lytic bone lesions or at least a 50% increase in size of existing
                  lesions (discussion with ECOG Study Chairman required if sole indication of
                  progression)

               -  Increase in serum or urine M-protein by 25% to under 50% (as above) plus one of
                  the following:

                    -  Serum calcium greater than 12 mg/dL without other cause

                    -  Hemoglobin decreased by more than 2.0 g/dL not attributed to chemotherapy,
                       interferon therapy, or a myelodysplastic syndrome

                         -  Less than 11 g/dL in men

                         -  Less than 10 g/dL in women

                    -  At least a 50% increase in bone marrow plasmacytosis

          -  Failure of prior cytotoxic therapy defined by one of the following:

               -  Never responded

               -  Relapsed within 2 months of last treatment

               -  Relapsed 2-12 months after last treatment following initial response

          -  Adequate prior chemotherapy required, e.g.:

               -  At least 2 courses of combination chemotherapy (e.g., VBMCP, VBAP, MP)

                    -  Prior vincristine, doxorubicin, and dexamethasone (VAD) allowed

                         -  No demonstrated resistance to VAD

                         -  At least 3 months since prior VAD

                    -  Cumulative doxorubicin dose no more than 250 mg/m2

                    -  Prior autologous peripheral blood stem cell transplant allowed if performed
                       prior to development of drug resistance

                         -  No prior allogeneic transplant

          -  No smoldering myeloma, localized plasmacytoma, or monoclonal gammopathy of
             undetermined significance (MGUS)

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-3

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  Absolute neutrophil count at least 1,000/mm^3

          -  Platelet count at least 50,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  AST less than 1.5 times ULN

          -  No chronic or active hepatitis or cirrhosis

        Renal:

          -  Creatinine less than 3.0 mg/dL

        Cardiovascular:

          -  Ejection fraction at least 50%

          -  No history of congestive heart failure

          -  No overt angina despite medication

          -  No myocardial infarction within 2 months

          -  No poorly controlled hypertension (i.e., pressure 200/110 or higher despite
             medication)

          -  No arrhythmia requiring therapy (i.e., sustained atrial or ventricular arrhythmia or
             multifocal premature ventricular contraction)

               -  Digoxin to control ventricular rate of atrial fibrillation that has been chronic
                  for more than 1 month allowed

        Neurologic:

          -  No peripheral neuropathy with weakness

          -  No cerebellar disease with ataxia

        Gastrointestinal:

          -  Adequate gastrointestinal function to allow absorption of PSC 833

          -  No active peptic ulcer

        Other:

          -  No hypersensitivity to PSC 833 or cyclosporine

          -  No active infection

          -  HIV negative

          -  No uncontrolled diabetes mellitus

          -  No second malignancy within the past 5 years except curatively treated nonmelanomatous
             skin cancer, carcinoma in situ of the cervix, or other localized cancer treated with
             surgery alone

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other serious medical problem unless sufficiently stabilized

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Prior biologic therapy (e.g., interferon) allowed

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 3 weeks since other prior chemotherapy (including plicamycin)

        Endocrine therapy:

          -  At least 2 weeks since high dose steroids (at least 100 mg/m2/day of prednisone or at
             least 40 mg/day of dexamethasone (including steroids for hypercalcemia)

        Radiotherapy:

          -  At least 2 weeks since prior radiotherapy except limited radiotherapy to a single bone
             lesion

        Surgery:

          -  At least 4 weeks since prior major surgery

        Other:

          -  No concurrent anticoagulants

          -  No concurrent drugs known to modulate cyclosporine blood concentrations",Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma,2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed recurrent or persistent multiple myeloma at least 6 months
             following allogeneic bone marrow transplantation (BMT) from an HLA identical sibling

          -  Must meet one of following criteria to be considered persistent, recurrent, or
             progressive disease:

               -  Residual detectable disease 6-12 months after BMT, as determined by the M protein
                  level or bone marrow involvement, without further evidence of clinical or
                  laboratory improvement on 2 consecutive measurements 4 weeks apart

               -  Complete response not achieved 12 or more months after BMT and there is no
                  evidence of progressive improvement

               -  At least 25% increase of serum paraprotein (greater than 1.0 g/dL) as measured on
                  two occasions or a 50% increase in urinary light chain excretion (greater than
                  150 mg/day) as measured on 2 occasions

               -  A 10% increase in plasma cells in the bone marrow

          -  Disease in complete response but with recurrence of M protein and 10% point increase
             in myeloma cells in the marrow allowed

          -  No lytic lesions alone or new soft tissue plasmacytoma as sole evidence of progression

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  More than 4 weeks

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin no greater than 2.0 times upper limit of normal

        Renal:

          -  Not specified

        Other:

          -  No active infection

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Must have received prior allogeneic bone marrow transplantation from an HLA A;B;DR
             genotypically matched sibling donor

          -  No concurrent interferon therapy for relapsed disease

        Chemotherapy:

          -  At least 4 weeks since cyclosporine, methotrexate, azathioprine, or other graft versus
             host disease (GVHD) prophylaxis/treatment without evidence of flare of GVHD

          -  At least 4 weeks since prior chemotherapy for relapsed disease

        Endocrine therapy:

          -  Must be receiving a dose no greater than 0.25 mg/kg prednisone for at least 4 weeks
             prior to registration without flare of GVHD

          -  No prior prednisone dose greater than 0.25 mg/kg in the past 4 weeks

          -  Must receive concurrent prednisone of a dose no greater than 0.25 mg/kg

          -  Concurrent corticosteroids allowed

        Radiotherapy:

          -  Concurrent palliative radiotherapy allowed if evidence of other evaluable disease
             other than irradiated bony sites

        Surgery:

          -  Not specified",Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation,2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","-  INCLUSION CRITERIA - Recipients:

        Group A: Subjects at high risk for transplant related complications and mortality as
        defined below:

        Ages 10 to 75 (both inclusive) with a history of one of the following:

          -  Treatment with dose intensive chemotherapy and/or radiotherapy

          -  Previous history of allo/auto transplant

          -  History of multiple myeloma or extramedullary plasmacytoma

          -  Chronic disease or co-morbid medical condition including subjects with symptoms or
             signs of significant pulmonary disease, hepatic disease, kidney disease, cardiac
             disease or disease of other organ systems which would result in increased risk of
             morbidity or death from a standard myeloablative transplant.

        Diseases to be included:

          -  CML chronic phase

          -  Acute lymphoblastic leukemia (ALL), all subjects in complete or partial remission.

          -  AML: AML in first complete or partial remission Exceptions: AML with good risk
             karyotypes: AML M3 t(15:17), AML M4Eo (inv. 16), AML t(8;21). All AML in second or
             subsequent complete remission.

          -  MDS: refractory anemia with excess blasts (RAEB), or chronic myelomonocyte leukemia
             (CMML).

          -  Myeloproliferative diseases associated with either cytopenia or uncontrolled
             proliferation.

          -  CLL or small lymphocytic lymphoma (SLL) with bulky or progressive disease despite
             prior treatment with chemotherapy which includes purine analogs.

          -  NHL

        A) Intermediate or high grade relapsed or progressive despite treatment with standard
        therapy ineligible for autologous PBSC transplant.

        B) NHL intermediate or high grade relapsing despite prior autologous transplant.

        C) Low grade follicular or small lymphocytic lymphoma (1) high risk patients who have
        relapsed following conventional chemotherapy, (2) relapsed following autologous marrow or
        PBSC transplant, or (3) chemo resistant disease.

        D) Mantle cell lymphoma

        E) NHL intermediate or high grade with concurrent BCL2 and MYC translocations who are at
        high risk for relapsed and who have low survival with conventional chemotherapy.

          -  HD, relapsed after prior autologous transplant or after 2 or more combination
             chemotherapy regimens and ineligible for autologous PBSC transplant.

          -  EBV driven lymphoproliferative disorders progressing despite standard therapies.

          -  MM: MM subjects must be between the ages of 8 and 65 (both inclusive)

          -  Mycosis fungoides, which has been shown to be amenable to allogeneic stem cell
             transplants.

        Group B: (Closed to enrollment Oct 2010) Subjects with hematologic diseases associated with
        reasonable longevity, shown to be curable by allogeneic BMT but where concern for a high
        procedural mortality with conventional BMT may delay or prevent such treatment.

        Ages 8 to 80 (both inclusive) with a history of one of the following

          -  PNH associated with either life-threatening thrombosis, cytopenia, transfusion
             dependence or recurrent and debilitating hemolytic crisis.

          -  Aplastic anemia or PRCA (acquired or congenital) in subjects associated with
             transfusion dependence and/or neutropenia who are not candidates for or who have
             failed immunosuppressive therapy

          -  RA or RARS MDS subjects who have associated transfusion dependence and/or neutropenia.

        Ability to comprehend the investigational nature of the study and provide informed consent.
        The procedure will be explained to subjects age 8-17 years with formal consent being
        obtained from parents or legal guardian.

        Availability of HLA identical or single HLA locus mismatched family donor

        INCLUSION CRITERIA - Donor:

        HLA identical or single HLA mismatched family donor

        Age greater than or equal to 2 up to 80 years old

        Weight greater than or equal to 18 kg

        Ability of donor or guardian of donor to comprehend the investigational nature of the study
        and provide informed consent.

        EXCLUSION CRITERIA - Recipient - any of the following:

        Pregnant or lactating

        Group A: age less than 10 or greater than 75 (multiple myeloma age less than 8 or greater
        than 65);

        Group B: Age less than 8 or greater than 80 years.

        ECOG performance status of 3 or more (See NIH Bone and Marrow Consortium Supportive Care
        Guidelines for Allogeneic Hematopoietic Stem Cell Transplant Recipients -
        http://intranet.cc.nih.gov/bmt/_pdf/ECOG_Karnofsky_Lansky_Scales.pdf)

        Psychiatric disorder or mental deficiency severe as to make compliance with the BMT
        treatment unlikely and making informed consent impossible

        Major anticipated illness or organ failure incompatible with survival from PBSC transplant

        Diffusion capacity of carbon monoxide (DLCO) less than 40% predicted.

        Left ventricular ejection fraction: less than 30%.

        Serum creatinine greater than 2.5 mg/dl or creatinine clearance less than 50 cc/min by 24
        hr urine collection

        Serum bilirubin greater than 4 mg/dl, transaminases greater than 5x upper limit of normal,

        Other malignant diseases liable to relapse or progress within 5 years.

        EXCLUSION CRITERIA - Donor - any of the following:

        Pregnant or lactating

        Donor unfit to receive G-CSF and undergo apheresis (uncontrolled hypertension, history of
        congestive heart failure or unstable angina, thrombocytopenia)

        HIV positive donor. Donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or
        human T-cell lymphotropic virus (HTLV I/II) will be used at the discretion of the
        investigator following counseling and approval from the recipient",Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow,2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Histologically proven stage I-III multiple myeloma

               -  Less than 18 months since diagnosis

               -  Smoldering myeloma allowed if there is evidence of progressive disease requiring
                  therapy

                    -  At least 25% increase in M protein levels or Bence Jones excretion

                    -  Hemoglobin no greater than 10.5 g/dL

                    -  Hypercalcemia

                    -  Frequent infections

                    -  Rise in serum creatinine above normal on 2 separate occasions

               -  Nonquantifiable monoclonal proteins allowed if other criteria for multiple
                  myeloma or smoldering myeloma are met

          -  Response/status after induction therapy:

               -  Responding or stable disease AND no greater than 40% myelomatous involvement of
                  bone marrow

          -  No Waldenstrom's macroglobulinemia

        PATIENT CHARACTERISTICS:

        Age:

          -  65 and under

        Performance status:

          -  Karnofsky 80-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  Serum glutamic axaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase
             (SGPT) less than 2.5 times upper limit of normal

          -  Hepatitis B antigen or hepatitis C ribonucleaic acid (RNA) negative

        Renal:

          -  See Disease Characteristics

          -  Creatinine no greater than 1.4 mg/dL

          -  Creatinine clearance greater than 65 mL/min

        Cardiovascular:

          -  Cardiac ejection fraction at least 50% by multigated acquisition scan (MUGA) or
             echocardiogram

        Pulmonary:

          -  Forced-expiratory volume in one second (FEV_1) greater than 60% of normal

          -  Diffusing capacity for carbon monoxide (DLCO) greater than 50% of predicted lower
             limit

        Other:

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Human immunodeficiency virus (HIV) negative

          -  No other medical or psychosocial problems that would increase patient risk

          -  No other malignancy within past 5 years except nonmelanomatous skin cancer or
             carcinoma in situ of the cervix

          -  No known hypersensitivity to filgrastim (G-CSF) or Escherechi coli-derived proteins

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  No more than 3 prior chemotherapy regimens

          -  At least 4 weeks since prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

        Surgery:

          -  Not specified","Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma",1
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Diagnosed active multiple myeloma defined by:

               -  Lytic disease

               -  Anemia

               -  Hypercalcemia

               -  Secondary renal insufficiency

               -  More than 400 mg/24 hours of urinary protein excretion

               -  Symptomatic hyperviscosity

          -  If previously treated, refractory to no more than 1 regimen

          -  Primary amyloidosis without subsequent multiple myeloma allowed

               -  Abnormal renal function allowed if due to primary disease

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  See Disease Characteristics

          -  Creatinine clearance greater than 50 mL/min if no renal impairment

        Cardiovascular:

          -  No cardiac function that would preclude study

          -  LVEF greater than 45%

        Pulmonary:

          -  No pulmonary function that would preclude study

          -  FVC greater than 60% predicted

          -  DLCO greater than 50% predicted

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No greater than 18 months of prior alkylator exposure

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  See Disease Characteristics

          -  No more than 3 prior treatment regimens allowed",Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.",No eligibility criteria,Genetic Analysis of Human Hypertensive End Stage Renal Disease (H-ESRD),0
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","INCLUSION CRITERIA:

          -  MDS of refractory anemia (RA), refractory anemia with ring sideroblasts (RARS) &
             refractory anemia with excess blasts (RAEB) sub-types

          -  Off all other treatments (except G-CSF (granulocyte colony stimulating factor), and
             transfusion support and related medications) for at least four weeks.

          -  G-CSF can be used before, during and after the protocol treatment for patients with
             documented neutropenia (less than 500/uL) as long as they meet the criteria for anemia
             and/or thrombocytopenia as stated above.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less

          -  High or intermediate predicted probability of response

        EXCLUSION CRITERIA:

          -  MDS of FAB sub-group chronic myelomonocytic leukemia (CMML)

          -  Transformation to acute leukemia (FAB sub-group RAEB-T, ie., greater than 20% blasts
             in marrow aspirate)

          -  Hypoplastic marrow without one major or two minor criteria

          -  Treatment with growth factors (except for G-CSF) or cyclosporine within 4 weeks prior
             to entry to protocol

          -  ECOG performance status of greater than 2

          -  Active uncontrolled infection

          -  Current pregnancy, or unwilling to take oral contraceptives if of childbearing
             potential

          -  Patients for whom bone marrow transplant is indicated as standard therapy (age less
             than fifty-five with a fully-matched sibling donor)

          -  Age less than18 years

          -  Not able to give informed consent

          -  HIV positive patients

          -  Active malignant disease (excluding basal cell carcinoma)

          -  Serum creatinine greater than 2mg/dl

          -  Patients who are moribund or patients with concurrent hepatic, renal, cardiac,
             metabolic, or any disease of such severity that death within 3 months is likely

          -  Low predicted probability of response",Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia,0
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed multiple myeloma

               -  M-protein by serum protein electrophoresis or urine protein electrophoresis

               -  Quantitative determination of immunoglobulin

               -  Bone marrow biopsy and aspirate with a plasma cell count greater than 10%

               -  Refractory or chemoresistant disease defined as failure to respond (less than 50%
                  reduction in M protein level) or progression within 2 months after receiving at
                  least 2 chemotherapy regimens including:

                    -  Alkylating based regimen (melphalan) in combination with steroids
                       (prednisone) or other chemotherapy regimens (e.g., vincristine, bleomycin,
                       melphalan, cyclophosphamide, and prednisone or vincristine, carmustine,
                       doxorubicin, and prednisone)

                    -  Vincristine, doxorubicin, and dexamethasone (VAD) regimen

                    -  Pulse therapy with high dose steroids alone

                    -  High dose alkylating agent and autologous stem cell transplantation

                    -  Allogeneic bone marrow transplantation

               -  Plateau phase defined as M protein in the serum or urine for more than 6 weeks
                  despite response to prior therapy

                    -  Must have received at least 2 of the chemotherapy regimens listed above or
                       equivalent regimens

               -  Recurrent disease defined as progression more than 2 months after initial therapy
                  and failure to respond (less than 50% reduction or progression in M protein
                  levels) to 1 chemotherapy regimen listed above or other salvage regimens (e.g.,
                  high-dose cyclophosphamide or topotecan)

                    -  Must have received VAD or other equivalent chemotherapy regimen

                    -  Should be considered for autologous or allogenic transplantation

                    -  Prior local radiotherapy allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 2,000/mm^3*

          -  Platelet count at least 50,000/mm^3* NOTE: *Unless attributable to bone marrow
             infiltration by multiple myeloma

        Hepatic:

          -  Bilirubin less than 3 mg/dL

          -  Transaminases less than 2.5 times upper limit of normal (ULN)

        Renal:

          -  Creatinine less than 1.5 times ULN OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No cardiac arrhythmias including recurrent supraventricular arrhythmia, any type of
             sustained ventricular arrhythmia, or conduction block (atrioventricular block grade II
             or III, left bundle branch block)

          -  Ejection fraction at least 30%

          -  No uncontrolled ischemic heart disease

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 4 months
             after study

          -  HIV negative

          -  No grade 3 or higher neurological disorder, including seizure disorders

          -  No underlying medical condition that would preclude study

          -  No other active malignancy except adequately treated basal or squamous cell carcinoma
             of the skin or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Disease Characteristics

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 2 weeks since prior chemotherapy

        Endocrine therapy:

          -  See Disease Characteristics

          -  Concurrent steroid treatment allowed except for primary treatment of myeloma

        Radiotherapy:

          -  See Disease Characteristics

          -  Concurrent local radiotherapy for pain or symptom control allowed provided the pain or
             symptom is not related to disease progression

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent ascorbic acid supplements

          -  No other concurrent investigational drug or therapy

          -  Concurrent bisphosphonates allowed",Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma,1
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","-  INCLUSION CRITERIA: Collection of plasma in recipient:

        Patients with Immunoglobulin G (IgG) or Immunoglobulin A (IgA) multiple myeloma.

        Patients have siblings.

        Human leukocyte antigen (HLA) typing of recipient and donor(s) initiated.

        Viral antibody screening initiated.

        INCLUSION CRITERIA: Recipient:

        Patients with IgG or IgA multiple myeloma.

        Patients must have achieved at least a partial remission following initial conventional
        chemotherapy regimen or after autologous stem cell transplantation. Patients who have
        undergone tandem autologous stem transplants are eligible if they meet all other
        eligibility criteria. Patients who have achieved at least a partial remission to initial
        (primary) conventional chemotherapy will be encouraged to proceed to autologous
        transplantation, but will also be eligible for this protocol.

        Patients 18-75 years of age. The upper age limit was chosen as it is felt that the
        toxicities would exceed potential benefit in this older population.

        Karnofsky performance status greater than or equal to 80%.

        Life expectancy greater than 6 months.

        Left ventricular ejection fraction has to be greater than 50% by either multi-gated
        acquisition scan (MUGA) or 2-D echo.

        Carbon monoxide diffusing capacity (DLCO) greater than 50% of the expected value when
        corrected for hemoglobin (Hb)(96).

        Creatinine less than or equal to 1.5 mg/dl and a creatinine clearance greater than or equal
        to 50 ml/min.

        Direct bilirubin less than or equal to 2.0 mg/dl serum glutamic oxaloacetic transaminase
        (SGOT) less than 4x top normal.

        M-protein: the concentration in the harvested plasma must be greater than 70% of the total
        Ig of the corresponding isotype.

        Patients must be human immunodeficiency virus (HIV)-negative. There is the theoretical
        possibility that the degree of immune suppression associated with the treatment may result
        in progression of HIV infection. Patients may be Hepatitis B core antigen positive, but
        surface antigen negative and without evidence of active infection. Patients must be
        Hepatitis C negative.

        Not pregnant or lactating. Patients of childbearing potential must use an effective method
        of contraception. The effects of the chemotherapy, the subsequent transplant and the
        medications used after the transplant are highly likely to be harmful to a fetus. The
        effects upon breast milk are also unknown and may potentially be harmful to the infant.

        Consenting first degree relative matched at 6/6 or 5/6 HLA antigens, this may include a
        mismatch at the D locus.

        Ability to give informed consent.

        INCLUSION CRITERIA: Donor:

        Age 18-75 years. As the potential cerebrovascular and cardiac complications may potentially
        increase with age, age 75 has been chosen arbitrarily as the upper age limit. However, if
        it is determined after initial accrual of patients in this upper age range that this
        procedure is relatively safe, the age range may be extended.

        No physical contraindications to stem cell donation (i.e. severe atherosclerosis,
        auto-immune disease, cerebrovascular accident, active malignancy (97). Patients with severe
        atherosclerosis by history will receive a cardiology consult and be judged eligible on a
        case by case basis.

        Donors must be HIV-negative, hepatitis B surface antigen (HBsAg-), and Hepatitis C antibody
        negative. This is to prevent the possible transmission of these infections to the
        recipient.

        Not pregnant or lactating. Donors of childbearing potential must use an effective method of
        contraception. The effects of cytokine administration on a fetus are unknown and may be
        potentially harmful. The effects upon breast milk are also unknown and may potentially be
        harmful to the infant.

        Normal cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) numbers as
        defined by Clinical Center standards.

        Ability to give informed consent.","Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma",2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","Inclusion Criteria:

          -  Patients aged > 49 years and < 75 years with non-Hodgkin lymphoma (NHL), chronic
             lymphocytic leukemia (CLL) and multiple myeloma who are not eligible for a curative
             autologous transplantation or who have failed prior autologous transplantation;
             patients with NHL and CLL must have failed prior therapy with an alkylating agent
             and/or fludarabine, or be at high risk of relapse; patients with multiple myeloma must
             have stage II or III disease and received prior chemotherapy

          -  Patients < 50 years of age with NHL, CLL or multiple myeloma at high risk of regimen
             related toxicity through prior autologous transplant or through pre-existing medical
             conditions

          -  Patients < 75 years of age with other malignant diseases treatable by allogeneic bone
             marrow transplant (BMT) whom through pre-existing chronic disease affecting kidneys,
             liver, lungs, and heart are considered to be at high risk for regimen related toxicity
             using standard high dose regimens; the following diseases are the likely candidates:

               -  Myelodysplastic syndromes

               -  Myeloproliferative syndromes

               -  Acute Leukemia with < 10% blasts

               -  Amyloidosis

               -  Hodgkin's disease

               -  Renal cell carcinoma

          -  Patients with other malignancies declining standard allografts may be approved for
             transplant following presentation and approval by the Fred Hutchinson Cancer Research
             Center (FHCRC) chimerism group

          -  DONOR:

               -  Human leukocyte antigen (HLA) genotypically or phenotypically identical related
                  donor

               -  Donor must consent to granulocyte colony-stimulating factor (G-CSF)
                  administration and leukopheresis

               -  Donor must have adequate veins for leukopheresis or agree to placement of central
                  venous catheter (femoral, subclavian)

               -  Age < 75 years

        Exclusion Criteria:

          -  Eligible for a high-priority curative autologous transplant

          -  Patients with rapidly progressive aggressive NHL unless in minimal disease state

          -  Active central nervous system (CNS) involvement with disease

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment

          -  Females who are pregnant

          -  Patients who are human immunodeficiency virus (HIV) positive

          -  Cardiac ejection fraction < 40%

          -  Severe defects in pulmonary function testing (defects are currently categorized as
             mild, moderate and severe) as defined by the pulmonary consultant, or receiving
             supplementary continuous oxygen

          -  Total bilirubin > 2 x the upper limit of normal

          -  Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic
             transaminase (SGOT) 4 x the upper limit of normal

          -  Karnofsky score < 50

          -  Patients with poorly controlled hypertension

          -  Patients with renal failure are eligible, however patients with renal compromise
             (serum creatinine greater than 2.0) will likely have further compromise in renal
             function and may require hemodialysis (which may be permanent) due to the need to
             maintain adequate serum cyclosporine levels

          -  DONOR:

               -  Identical twin

               -  Age less than 12 years

               -  Pregnancy

               -  Infection with HIV

               -  Inability to achieve adequate venous access

               -  Known allergy to G-CSF

               -  Current serious systemic illness","Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer",2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS: Histologically proven multiple myeloma Initial diagnosis must have
        been confirmed by one of the following prior to initial treatment for multiple myeloma:
        Biopsy of an osteolytic lesion or soft tissue tumor composed of plasma cells Bone marrow
        aspirate and/or biopsy demonstrating at least 10% plasmacytosis Bone marrow containing less
        than 10% plasma cells but with at least 1 bony lesion and the M-protein criteria outlined
        below Measurable serum M-component of IgG, IgA, IgD, or IgE at initial diagnosis OR If only
        light chain disease (urine M-protein only) present, then the urinary excretion of light
        chain (Bence Jones) protein must have been at least 1.0 g/24 hours at time of initial
        diagnosis Must have undergone autologous stem cell transplantation within 1 year of
        beginning initial chemotherapy for multiple myeloma Must be randomized 60-100 days after
        autologous stem cell infusion No evidence of progressive disease

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: At
        least 6 months Hematopoietic: See Disease Characteristics Granulocyte count at least
        1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: AST and/or ALT no greater than 1.5
        times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN Renal:
        Creatinine no greater than 3 times ULN Cardiovascular: No uncontrolled hypertension Other:
        Not pregnant or nursing Negative pregnancy test Fertile female patients must use 2
        effective methods of contraception (1 barrier and 1 hormonal) during and for 1 month after
        study Fertile male patients must use effective barrier contraception during and for 1 month
        after study No other medical condition that would preclude long term use of prednisone or
        thalidomide No other malignancy within the past 5 years except adequately treated squamous
        cell or basal cell skin cancer or carcinoma in situ of the cervix No diabetes with end
        stage organ damage No history of gastric ulceration or bleeding No avascular necrosis of
        the hips No peripheral neuropathy causing symptomatic dysfunction Sensory symptoms induced
        by vincristine allowed No demonstrated hypersensitivity to thalidomide or its components No
        other major medical illness that would increase risk or preclude study No employment that
        prohibits the use of sedatives (due to known effect of thalidomide)

        PRIOR CONCURRENT THERAPY: Biologic: See Disease Characteristics No prior thalidomide
        Chemotherapy: See Disease Characteristics Endocrine: Not specified Radiotherapy: Not
        specified Surgery: Not specified Other: No other concurrent anticancer treatment No other
        concurrent investigational therapy",Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,1
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed multiple myeloma OR

          -  Primary systemic amyloidosis resulting in significant organ dysfunction and decreased
             quality of life

          -  Complete or partial response after standard chemotherapy

          -  Primary refractory or relapsed multiple myeloma after first-line treatment with
             standard chemotherapy

          -  Ineligible for higher priority national or institutional clinical studies

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin less than 2 times normal

        Renal:

          -  Creatinine less than 2.5 mg/dL or on stable hemodialysis

        Cardiovascular:

          -  LVEF at least 45%

        Pulmonary:

          -  DLCO at least 60% of predicted OR

          -  Approval by pulmonologist

        Other:

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Concurrent participation in gene therapy trials allowed

        Chemotherapy:

          -  See Disease Characteristics

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent steroids as antiemetics during chemotherapy

          -  No concurrent anticancer hormonal therapy

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No concurrent barbiturates or acetaminophen during chemotherapy

          -  Concurrent participation in supportive care trials allowed",Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis,1
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following:

               -  Chronic myelogenous leukemia

                    -  Philadelphia chromosome-positive OR

                    -  Molecular evidence of bcr/abl gene rearrangement

               -  Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses,
                  myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia,
                  paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia

                    -  Confirmed by cytochemistry, immunophenotyping, and/or chromosomal
                       abnormalities

               -  Multiple myeloma

               -  Hereditary immunodeficiency disorders

                    -  Confirmed by immunologic determination

               -  Sickle cell anemia or beta-thalassemia

                    -  Confirmed by hemoglobin electrophoresis

               -  Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic
                  leukodystrophy)

                    -  Confirmed by metabolic testing

               -  Other non-malignant conditions

          -  Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation

        PATIENT CHARACTERISTICS:

        Age:

          -  65 and under

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified",Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer,2
"64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis (involvement of lungs, tongue, bladder, heart), on hemodialysis for ESRD who represents for malaise, weakness, and generalized body aching x 2 days. She was admitted last week with hypercalcemia and treated with pamidronate 30mg, calcitonin, and dialysis. Patient was Initially treated with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. With relapse of her myeloma, she received thalidomide velcade and thalidomide, which were eventually also held due to worsening edema and kidney function.","DISEASE CHARACTERISTICS: Newly diagnosed multiple myeloma (diagnosis within 12 months of
        study) and scheduled to undergo autologous peripheral blood stem cell transplantation Prior
        diagnosis of monoclonal gammopathy of undetermined significance (MGUS) or smoldering
        myeloma (SMM) allowed if the criteria for diagnosis of multiple myeloma was met within 12
        months of study Serum or urinary M-protein confirmation of diagnosis (IgA, IgD, IgG, IgE,
        or light chain proteins) At least 10% plasma cells in bone marrow Must have received
        induction therapy without disease progression or relapse after initial response Prior
        induction therapy must have been completed no more than 6 months before stem cell
        collection and no more than 9 months before transplantation Must have undergone stem cell
        mobilization with cyclophosphamide IV and filgrastim (G-CSF) The following diagnoses are
        excluded: Non-secretory multiple myeloma IgM myeloma Solitary bone or extramedullary
        plasmacytoma Symptomatic MGUS or SMM Symptomatic indolent multiple myeloma

        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater than 2
        mg/dL SGPT no greater than 2 times upper limit of normal No clinical evidence of
        amyloidosis involving the liver Renal: Creatinine no greater than 2.0 mg/dL Creatinine
        clearance at least 30 mL/min No clinical evidence of amyloidosis involving the kidney
        Cardiovascular: LVEF at least 50% No evidence of amyloidosis on echocardiogram No
        uncontrolled arrhythmia No symptomatic cardiac disease Pulmonary: FEV1 at least 60% OR FVC
        at least 60% OR DLCO at least 60% No symptomatic pulmonary disease No clinical evidence of
        amyloidosis involving the lungs Other: HIV negative No cord compression No other concurrent
        illness that would preclude survival No clinical evidence of amyloidosis involving the
        autonomic nervous system or gastrointestinal tract No known allergy to vitamin C Not
        pregnant or nursing Negative pregnancy test Fertile patients must use effective
        contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior
        thalidomide for myeloma No prior peripheral blood stem cell or bone marrow transplantation
        No concurrent thalidomide No concurrent interferon Chemotherapy: See Disease
        Characteristics No prior clarithromycin for myeloma No more than 2 courses of prior
        induction therapy containing an alkylating agent Endocrine therapy: No concurrent
        dexamethasone Radiotherapy: No prior radiotherapy to more than 20% of bone marrow No
        greater than 30 Gy to the spinal cord Surgery: Not specified Other: At least 28 days since
        prior bisphosphonates No prior new or experimental agents for myeloma No concurrent
        experimental therapies No concurrent bisphosphonates",Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,1
"This is a 78 year-old male with h/o BPH s/p multiple urological procedures, including s/p Suprapubic prostatectomy. He was noted to have low urine output and bladder scan showed 360cc residual. It was impossible for staff to pass a foley. Urology was consulted, performed a flexible cystoscopy in the ICU and found severe 2cm bulbar urethral stricture. They were able to pass small catheter through and left in place. The patient leaked around the catheter, the catheter eventually came out but he continued to have good urine output and post-void bladder scans were performed q4h to ensure he did not have high residual volume. Urology suggested that when patient is stable he will have to be taken to the OR to have the stricture surgically fixed.","Category I: Individuals and family members with established diagnoses of hereditary
        malignancies where the disease gene is known, specifically von Hippel Lindau or HPRC.

        Category II: Individuals and family members with malignant disorders where the disease gene
        is not yet known, specifically hereditary forms of Type II papillary renal cancer, clear
        cell renal carcinoma, renal oncocytoma or chromophobe renal carcinoma or Birt Hogg Dube
        syndrome.

        Category III: Malignant diseases of suspected, but not proven genetic etiology, including
        families with more than one individual affected by the same or related cancers.",Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples,0
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.","Men, women, and children in cardiac arrest for which CPR was initiated in ten minutes or
        less from the time of arrest.",Evaluation of SC-V Versus Conventional CPR,0
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.","Men & women with VF, VT with syncope, or VT without syncope, but with ejection fraction
        less than or equal to .40 & systolic blood pressure less than 80 mm Hg, chest pain , or
        near syncope.",Antiarrhythmics Versus Implantable Defibrillators (AVID),2
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.","Group 1:

        HCM patients, aged grater than 20 years of either gender who received DDD pacemakers at the
        NIH at least 4 years ago, for relief of LVOT obstruction and drug-refractory symptoms.

        Group 2:

        HCM patients selected from Group 1 who at the follow-up cardiac catheterization are
        demonstrated to have either (1) no significant LVOT obstruction (less than 30mm HG at rest
        and less than 50mm HG with Isuprel); or (2) a substantial reduction of the LVOT obstruction
        (greater than 50% reduction in LVOT gradient).

        Patient who have developed a heart block will be excluded from group 2.

        Females must have a negative pregnancy test.",Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy,0
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.","Patients of either gender, aged 18-80 years.

        NYHA functional class III/IV, or syncope, or greater than or equal to 2 presyncope despite
        verapamil and/or Beta-blocker therapy.

        LV outflow tract gradient greater than or equal to 30 mm Hg at rest or greater than or
        equal to 50 mm Hg following isoproterenol infusion to a heart rate of greater than 100 bpm.

        No patients with mid-cavity obstructive HCM.

        No patients with LV septal wall thickness less than 15 mm estimated by echocardiography.

        No patients with greater than 50 percent luminal narrowing in a major coronary artery
        vessel.

        No patients with chronic atrial fibrillation.

        No patients with a positive pregnancy test.",A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy,0
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.","INCLUSION CRITERIA:

        Children of either gender, aged 4 to 18 years.

        Obstructive HCM defined as LV hypertrophy, and an LV intra-cavitary pressure gradient
        measured at cardiac catheterization of greater than or equal to 30 mm Hg at rest or greater
        than or equal to 50 mm Hg following isoproterenol infusion to a heart rate of greater than
        or equal to 100 beats per minute.

        Cardiac symptoms (chest discomfort, dyspnea, lightheadedness or presyncope, syncope,
        cardio-respiratory arrest, palpitations, excessive fatigue); and/or exercise duration which
        is less than 10th percentile predicted for age/gender despite a trial of a beta-blocker
        therapy and a trial of verapamil therapy.

        EXCLUSION CRITERIA:

        Other systemic diseases that prevent assessment by exercise tests and cardiac
        catheterization.

        Chronic atrial fibrillation.

        Positive pregnancy test: A negative urine pregnancy test will be required before each
        cardiac catheterization, electrophysiologic study and thallium study. Pregnant or lactating
        subjects may not participate in the study due to potential teratogenic effects of
        radiation.",Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle,0
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.",No eligibility criteria,Identifying High Risk Patients With Syncope,2
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.",No eligibility criteria,Triggers of Ventricular Arrhythmias (TOVA) Study,2
"65 yo man with history of CAD and prior MI, HLD, HTN, ventricular tachycardia, and syncope was admitted earlier today evaluation of syncope and ventricular arrhythmias. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device. It was interrogated at the OSH and per report the monitor read from yesterday: 40 seconds of VT and then bradycardia with a rate of 39 shortly thereafter corresponding with his symptoms. Overnight, the patient went into monomorphic VT on telemetry. The patient was found to be unresponsive. CPR was initiated, unclear if the patient had a pulse. Within one minute the patient returned to sinus rhythm. The patient does not report any symptoms prior to this episode. Currently, the patient feels presyncope and nausea, but denies chest pain. Patient is to be transferred to the CCU for catheterization and EPS.","Inclusion Criteria

          1. Patients with left ventricular dusfunction

          2. Patients with non-ischemic cardiomyopathy

        Exclusion Criteria

        1. Patients not at high risk for sudden cardiac death (SCD)",Prognostic Significance of T Wave Alternans,2
"A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted.  Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted.  Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted.  Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.","INCLUSION CRITERIA:

        Male or female patients, 18 years of age or older.

        Newly diagnosed patients with acromegaly, or previously untreated.

        Presence of a pituitary tumor greater than 10 mm at greatest diameter (macroadenoma).

        Lack of suppression of GH to less than 2.0 ng/mL using a regular GH RIA, or less than one
        ng/mL using a two-site immunoradiometric or chemiluminescent GH assay, after oral
        administration of 100 g of glucose.

        IGF-1 levels above the upper limits of normal (adjusted for age and gender).

        Demonstrated tolerance to a test dose of s.c. Sandostatin Injection.

        Demonstrated responsiveness to a 100 ug s.c. Sandostatin Injection test dose, as evidenced
        by suppression of mean 4HR GH to less than 5 ng/mL, or to greater than 50 % of the baseline
        value.

        Patients who are able to provide written informed consent.

        EXCLUSION CRITERIA:

        Patients demonstrating intolerance to a s.c. Sandostatin (octreotide acetate) test dose.

        Patients who have received any prior treatment for their acromegaly, including
        radiotherapy, octreotide, bromocriptine, lanreotide, or prior surgery.

        Female patients who are pregnant or lactating, or are of childbearing potential and not
        practicing a medically acceptable method of birth control.

        Patients with compression of the optic chiasm significant enough to cause visual field
        defects on automated testing.

        Patients who require surgery for relief of any neurologic signs or symptoms associated with
        their tumor.

        Patients with symptomatic cholelithiasis.

        Patients who have congestive heart failure (NYHA Class III and IV), unstable angina,
        sustained ventricular tachycardia, ventricular fibrillation, or a history of acute
        myocardial infarction within the three months preceding study entry.

        Patients with liver disease such as cirrhosis, chronic active hepatitis or chronic
        persistent hepatitis, or persistent ALT, AST, or alkaline phosphatase 2X greater than upper
        limit of normal; or direct bilirubin more than 10% greater than upper limit of normal.

        Patients with abnormal clinical laboratory values considered by the Investigator or the
        Sponsor's Medical Monitor to be clinically significant and which could affect the
        interpretation of the study results.

        Patients who have any current or prior medical condition that may interfere with the
        conduct of the study or of the evaluation of its result in the opinion of the Investigator
        or Sponsor's Medical Monitor.

        Patients who have a history of alcohol or drug abuse in the six month period prior to Visit
        1.

        Patients who have received any investigational drug within one month prior to Visit 1, or
        who plan to take an investigational drug during the study.

        Patients with any mental impairment limiting their ability to comply with all study
        requirements.

        Patients who, for any reason, will be unable to complete the entire study.",Sandostatin LAR Depot vs. Surgery for Treating Acromegaly,1
"A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted.  Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Active acromegaly with growth hormone (GH) hypersecretion
        confirmed within 1 month prior to entry, i.e.: Somatomedin C elevated GH not below 2 ng/mL
        on standard 100 g oral glucose tolerance test Postmenopausal and hypogonadal women eligible
        Volunteers aged 18 to 30 recruited for up to 3 stimulation tests Weight within 15% of ideal
        Physical exam normal No history of disease No requirement for medication No medical or
        mental contraindication to protocol participation, including heavy alcohol or tobacco use
        No pregnant women --Prior/Concurrent Therapy-- Not specified --Patient Characteristics--
        Age: 18 to 65 Hematopoietic: No anemia Hepatic: No hepatic disease Renal: No renal disease
        Cardiovascular: No uncontrolled hypertension No heart disease Other: No requirement for
        replacement gonadal steroids, glucocorticoids, or thyroxine No mental illness No heavy
        alcohol use No tobacco use No drug abuse No medical contraindication to protocol therapy",Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly,2
"A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted.  Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of hypogonadotropism

        Men: Small testes, abnormal semen analysis, and subnormal plasma testosterone levels
        without an elevation in gonadotropin levels

        Women: Amenorrhea and subnormal plasma estradiol levels, or lack of cornification of the
        vaginal mucosa without an elevation in gonadotropin levels OR Hypothalamic amenorrhea in
        normally estrogenized women with amenorrhea or oligomenorrhea and normal plasma free
        testosterone and gonadotropin levels

        Patients with hyperprolactinemia eligible only if hypogonadotropism persists after
        correction of hyperprolactinemia by dopamine agonist therapy

        --Prior/Concurrent Therapy-- At least 2 months since sex hormone treatment

        --Patient Characteristics--

        Other:

          -  Not pregnant

          -  No chronic systemic, metabolic, or endocrine disease",Leuprolide in Treating Adults With Hypogonadotropism,1
"A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted.  Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of acromegaly and treated with transsphenoidal surgery

        Biochemically and histologically confirmed growth hormone secreting tumor

        OR

        Healthy volunteers

        --Prior/Concurrent Therapy--

        Surgery:

          -  See Disease Characteristics

          -  Greater than 6 months since prior surgery

        Other: At least 1 month since prior bromocriptine or octreotide

        --Patient Characteristics--

        Performance status: Ambulatory

        Hepatic: No active hepatic disease

        Renal: No active renal disease

        Other:

          -  No diabetes mellitus

          -  No glucose intolerance

          -  Hypopituitarism allowed if on stable doses of replacement therapy",Measurement of Outcome of Surgical Treatment in Patients With Acromegaly,1
"A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted.  Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.","Autoimmune thrombocytopenia purpura: platelet count less than 20,000/mm3 Adequate or
        increased marrow megakaryocytes Presence of detectable platelet associated immunoglobulins
        not due to alloreactive antibodies or posttransfusion purpura Prior response to
        immunosuppressive therapy Platelet count chronically less than 20,000/mm3 with petechial
        bleeding or less than 50,000/mm3 with other bleeding OR Any history of life threatening
        hemorrhage Refractory to conventional therapy for at least 21 days Splenectomy At least 1
        additional immunosuppressive therapy applied after splenectomy OR Controlled on
        conventional therapy but at price of unacceptable toxicity: Serious steroid related
        toxicity Absolute neutrophil count less than 500/mm3 25% of time, pure red blood cell
        transfusion dependent or other toxicities (e.g., hemorrhagic cystitis) that are a
        consequence of chronic or cytotoxic therapy Unable to wean from chronic daily or
        intermittent cytotoxic therapy

        Autoimmune hemolytic anemia or pure red cell aplasia, AIHA: Hemolytic anemia Hemoglobin
        less than 10.0 g/dL without transfusion Hemolysis as evidenced by both: Sustained
        reticulocytosis (greater than 125,000/mm3) without evidence of active bleeding or
        increasing hemoglobin Laboratory evidence of hemolysis Positive direct antiglobulin test or
        equivalent immune adherence test No evidence for paroxysmal nocturnal hemoglobinuria
        Negative Ham's test and sucrose hemolysis. For PRCA: Anemia due to selective decrease in
        marrow erythroid precursors Hemoglobin less than 10.0 g/dL without transfusion Severe
        reticulocytopenia (less than 20,000/mm3 despite anemia) Severely decreased marrow erythroid
        precursors Positive marrow coculture with serum or cells or response to immunosuppression
        No evidence for PNH Negative Ham's test and sucrose hemolysis Severe disease: Chronic
        (i.e., greater than 1 year) Transfusion dependent or untransfused hemoglobin less than 8.0
        g/dL Ferritin greater than 2,000 or evidence of organ dysfunction due to iron overload
        Refractory to conventional therapy after all 3 of the following: High dose steroids (at
        least 1 mg/kg) for at least 21 days Splenectomy (except cold reactive antibodies) 1
        additional immunosuppressive therapy OR Controlled on conventional therapy but at price of
        unacceptable toxicity

        Rheumatoid arthritis: Morning stiffness for at least 6 weeks Arthritis of 3 or more joint
        areas Arthritis of hand joints Symmetric arthritis Rheumatoid nodules Serum rheumatoid
        factor Radiographic changes Active rheumatoid disease as evidenced by all of the following:
        Elevated Westergren erythrocyte sedimentation rate Minimum of 16 swollen or tender joints
        using the 28 joint count method Must be at high risk for developing deforming joint disease
        as defined by at least 2 of the following: High titer IgM-IgG rheumatoid factor
        Radiographic evidence of erosive arthritis developing within the first 24 months of
        clinical disease Functional class II or III Refractory to conventional therapy after 12
        months of: Methotrexate used in combination with cyclosporine, hydroxychloroquine, or
        sulfasalazine OR Intramuscular gold therapy (total dose greater than 1.0 g and duration at
        least 6 months) OR Controlled on conventional therapy but at price of unacceptable toxicity

        Juvenile rheumatoid arthritis: Under 16 years of age at onset Arthritis in 1 or more joints
        as defined by swelling or effusion, or presence of 2 or more of the following: Limitation
        of range of motion Tenderness or pain on motion Increased heat Duration of disease 6 weeks
        or longer Onset type defined by type of disease in first 6 months: Polyarthritis (i.e., 5
        or more inflamed joints) Oligoarthritis (i.e., less than 5 inflamed joints) Systemic (i.e.,
        arthritis with characteristic fever) Exclusion of other forms of juvenile arthritis Active
        disease evidenced by 1 of the following: Minimum of 2 swollen or tender joints using the 71
        joint count method Endocardial or myocardial disease, or serositis Anemia or thrombocytosis
        of chronic disease High risk for developing deforming joint disease or evidence of
        potential life threatening involvement for at least 1 internal organ system Radiographic
        evidence of erosive arthritis developing within first 24 months of clinical disease
        Functional class II or III Endocardial, myocardial, pericardial, and/or pleural disease
        Hemoglobin less than 10.0 g/dL or platelet count greater than 600,000/mm3 Refractory to
        conventional therapy after 12 months of methotrexate used in combination with
        hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, or cyclophosphamide OR
        Controlled on conventional therapy but at price of unacceptable toxicity

        Systemic lupus erythematosus: Malar rash Discoid rash Photosensitivity Oral ulcers
        Arthritis Serositis Renal disorder Neurologic disorder Hematologic disorder Immunologic
        disorder Antinuclear antibody Must have at least 4 of 7 variables on the lupus activity
        scale measured Evidence of potential life threatening involvement of at least 1 internal
        organ system Endocardial and/or myocardial disease Central nervous system disease Pulmonary
        parenchymal disease Renal disease defined as WHO III, IV or V and a high activity and low
        chronicity index Immune mediated cytopenias Refractory to conventional therapy after
        attempts to control disease with at least 2 drugs, including prednisone and 1 of the
        following: Azathioprine Cyclophosphamide (greater than 500 mg/m2 monthly for 6 months)
        Cyclosporine OR Controlled on conventional therapy but at price of unacceptable toxicity

        Vasculitis Definitive diagnosis of 1 of the following forms: Churg-Strauss syndrome Giant
        cell arteritis Henoch-Schonlein purpura Hypersensitivity vasculitis Polyarteritis nodosa
        Takayasu arteritis Wegener's granulomatosis Evidence of active disease defined as
        reversible manifestations of the underlying inflammatory process Must have 1 or more of the
        following: Elevated Westergren erythrocyte sedimentation rate Elevated C reactive protein
        Decrease serum complement levels Evidence of potential life threatening involvement of at
        least 1 internal organ system Endocardial and/or myocardial disease Central nervous system
        disease Pulmonary parenchymal disease Renal disease defined as WHO III, IV or V and a high
        activity and low chronicity index Immune mediated cytopenias Refractory to conventional
        therapy (i.e., failed or relapsed within 6 months) after attempts to control disease with
        at least 2 drugs, including prednisone and 1 of the following: Methotrexate Azathioprine
        Cyclophosphamide Cyclosporine OR Controlled on conventional therapy but at price of
        unacceptable toxicity

        Performance status: ECOG 0-1 ECOG 2 allowed provided symptoms directly related to
        autoimmune disease Hepatic: No history of severe, prior or ongoing chronic liver disease
        Bilirubin less than 2.0 mg/dL AST less than 2 times upper limit of normal (ULN) Alkaline
        phosphatase less than 2 times ULN Renal: Creatinine less than 2.5 mg/dL OR Creatinine no
        greater than 2 times normal baseline for age in pediatric patients Cardiovascular: No
        symptoms of cardiac disease No active ischemic heart disease Ejection fraction greater than
        45% by MUGA No uncontrolled hypertension Pulmonary: FEV1/FVC at least 60% OR Resting PO2 at
        least 80 mm Hg DLCO greater than 50% predicted O2 saturations greater than 94% in children
        unable to perform PFTs Neurologic: No active or ongoing ischemic or degenerative CNS
        disease not attributable to underlying disease Other: Not pregnant No poorly controlled
        diabetes HIV negative",Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases,0
"The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.",No eligibility criteria,Minneapolis Children's Blood Pressure Study,0
"The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.",No eligibility criteria,Epidemiology of Insulin and Dehydroepiandrosterone Sulfate and Coronary Heart Disease Mortality,0
"A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by  his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a  history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister.  He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.",Patients with asthma; specific eligibility criteria vary for each study.,Asthma Clinical Research Network (ACRN),2
"A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by  his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a  history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister.  He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.","Male or nonpregnant, non-breastfeeding females age 12-85 years.

        Diagnosis of persistent asthma for greater than 1 year and currently being treated with
        short acting beta-2 agonist only.

        FEV1 50-80% of predicted (must be demonstrated at Day 10 and Day 0). Patients will be
        stratified into 50-70% or 71-80% cohort at Day 10.

        Increase of greater than or equal to 15% over baseline FEV1 approximately 15-20 minutes
        after beta-2 agonist inhalation (2-4 puffs of albuterol via MDI or the nebulized
        equivalent) documented at baseline.

        Positive prick skin test to at least two allergens (defined as wheal 3 mm greater than
        control and erythema greater than control).

        History of asthma symptoms (wheezing, shortness of breath, cough, chest tightness, or
        nighttime awakening) on least 3 of the last 7 days.

        Fulfillment of washout criteria by not using any of the medications listed below for the
        specified times prior to Day 0 of the study drug treatment:

        Parenteral corticosteroids for 4 weeks;

        Oral corticosteroids for 4 weeks;

        Inhaled corticosteroids for 4 weeks;

        Cromolyn sodium (Intal), nedocromil (Tilade) for 4 weeks;

        Theophylline, zileuton (Zyflo), zafirlukast (Accolate), or montelukast (Singulair) for 4
        weeks;

        Astemizole (Hismanal) for 12 weeks;

        Terfenadine (Seldane), or fexofenadine (Allegra) for 6 days;

        Cetirizine (Zyrtec) for 6 days;

        Hydroxyzine (Atarax, Vistaril) for 6 days;

        Azelastine (Astelin) nasal spray for 6 days; and

        Salmeterol (Serevent) for 9 days.

        No clinically significant abnormality in chemistry, hematology, urinalysis: serum
        creatinine less than or equal to 1.7 mg/dL; total bilirubin less than or equal to 1.5
        mg/dL; AST (SGOT), ALT (SGPT) less than or equal to 2 times laboratory's upper limit of
        normal.

        No clinically significant abnormality in EKG within 1 month prior to enrollment.

        No clinically significant abnormality in CXR (other than changes consistent with asthma)
        within 1 year prior to enrollment.

        Nonsmoker, for at least 2 years with a smoking history of no more than 10 pack years (e.g.,
        one pack per day for 10 years).

        Agreement to use medically accepted contraception throughout the study, if sexually active,
        except females who are postmenopausal for greater than or equal to 2 years.

        Agreement not to donate blood or blood products throughout the study.

        Demonstrated ability to follow proper technique in the use of the AERx system.

        A written, signed, and witnessed consent form.

        No desensitization therapy within 3 months prior to Day 0 of study drug treatment.

        No use of any investigational or non-approved drug therapy within 30 days prior to Day 0 of
        study drug treatment.

        No occurrence of acute asthma exacerbation requiring emergency room treatment within 6
        weeks of Day 0 of study drug treatment.

        No occurrence of acute asthma exacerbation requiring hospitalization within 12 months of
        Day 0 of study drug treatment.

        No occurrence of respiratory infection which affects asthma within 4 weeks prior to Day 0
        of study drug treatment.

        No history of endotracheal intubation for asthma-related exacerbation within 15 years prior
        to Day 0 of study drug treatment.

        No presence of significant medical conditions (including obesity affecting respiratory
        function, congestive heart failure, myocardial infarction, unstable angina, uncontrolled
        hypertension, severe pulmonary disease, history of cancer [other than resected cutaneous
        basal or squamous cell carcinoma], insulin-dependent diabetes, autoimmune disease, or known
        HIV infection).

        No previous enrollment in a study of soluble IL-4 receptor.

        No history of alcohol abuse, drug abuse, or psychiatric illness that would interfere with
        ability to comply with protocol requirements or give informed consent.

        No patients experiencing hypersensitivity to soluble IL-4R.",Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma,1
"A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by  his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a  history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister.  He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.","DISEASE CHARACTERISTICS: Histologically or cytologically proven diagnosis of cancer
        FEV-1/FVC at least 80% of predicted OR FEV-1/FVC less than 80% AND improvement in FEV-1
        less than 15% after using a bronchodilator Maximum inspiratory pressure no greater than -50
        cm of water Oximetry at least 90% Rating of dyspnea ""moderate"" or ""severe"" on verbal rating
        scale (VRS) of ""none, mild, moderate, or severe"" to describe ""usual breathlessness"" when
        walking over the past 24 hours Score for pain of ""none"" or ""mild"" on a VRS of ""none, mild,
        moderate, or severe"" for ""unusual pain"" over the past 24 hours

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Not specified Life
        expectancy: Greater than 10 days Hematopoietic: Hemoglobin at least 8.5 g/dL Hepatic:
        AST/ALT no greater than 2 times upper limit of normal (ULN) No liver disease Renal:
        Creatinine no greater than 2 times ULN No kidney disease Cardiovascular: No acute
        congestive heart failure Greater than 3 months since prior myocardial infarction No
        coronary artery disease where cardiac stimulation might prove harmful (i.e., no unstable
        angina) No uncontrolled hypertension Pulmonary: See Disease Characteristics Other: Folstein
        Mini-Mental Status Exam score of at least 24 Able (i.e., sufficiently fluent) and willing
        to complete quality of life questionnaire and other assessments in either English or French
        No history of clinically significant allergy or intolerance to theophylline, aminophylline,
        or other methylxanthines No active peptic ulcer disease No uncontrolled hyperthyroidism

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 14 days
        since prior chemotherapy No concurrent chemotherapy Endocrine therapy: At least 2 months
        since prior initiation of hormonal therapy Hormones as appetite stimulant allowed if
        received for more than 2 weeks No concurrent oral contraceptives Concurrent steroids
        allowed if taken for at least 1 week prior to study Concurrent inhaled or oral
        corticosteroids allowed if taken for at least 1 week prior to study No concurrent
        initiation of a new hormonal manipulation Radiotherapy: At least 28 days since prior
        radiotherapy that includes the lung in the treatment field No concurrent radiotherapy that
        includes the lung in the treatment field Surgery: Not specified Other: No concurrent
        digitalis glycosides, lithium, coumarin anticoagulants, other xanthines, cimetidine,
        quinolone antibiotics (e.g, ciprofloxacin and norfloxacin), macrolide antibiotics (e.g.,
        erythromycin), fluvoxamine, and calcium channel blockers Concurrent nebulized or inhaled
        cromolyn, nedocromil, beta2-agonists, ipratropium, opioids, benzodiazepines, oxygen, and
        diuretics allowed if dose is stable for more than 1 week prior to study No concurrent
        paracentesis (i.e., thoracentesis) No concurrent blood transfusion",Theophylline in Treating Cancer Patients With Shortness of Breath,0
"The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed:
IPSS score : 15
Post-void residual: 70 mL
Prostate volume (TRUS): 60 mL
Prostate-specific antigen (PSA) level: 3.2 ng/mL
10 mL/sec of maximum flow rate when urine volume was 130 mL
He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.5 g/dl
WBC: 135000 /mm3
Plt: 350000 /ml
PT: 11 second
PTT: 35 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","POPULATION CHARACTERISTICS:

        Regional advanced postradiation fibrosis of the neck, chest wall, pelvis, or extremities
        causing measurable impairment of specific function, i.e.: Decreased range of motion,
        Weakness, Sensory deficit, Pain requiring narcotics, Significantly altered activities of
        daily living.

        None of these conditions present either before or during radiotherapy or attributed to
        surgery or chemotherapy.

        Patients with prostate cancer allowed if prostate-specific antigen (PSA) is less than 4.0
        ng/mL and the last 3 PSA values were stable or decreasing. Abnormal bone scan or film
        acceptable if consistent with degenerative disease.

        No recurrent or metastatic cancer.

        No concurrent second cancer.

        PRIOR/CONCURRENT THERAPY: At least 3 months since pentoxifylline.

        PATIENT CHARACTERISTICS:

        Age: 18 and over.

        Performance status: Karnofsky 70%-100% (unrelated to postradiation fibrosis).

        CARDIOVASCULAR:

        No symptomatic coronary artery disease with frequent anginal episodes necessitating any of
        the following during past 6 months: Coronary artery bypass, Angioplasty, Pacemaker
        placement, Thrombolytic treatment.

        No chronic cardiac failure with persistent hemodynamic abnormality and ejection fraction
        less than 40%.

        No coagulation, platelet, or vascular disorder that threatens to cause bleeding.

        OTHER:

        No intolerance to pentoxifylline or other xanthines (e.g., caffeine, theophylline,
        theobromine).

        No seizure disorder.

        No peptic ulcer disease.

        Willing to undergo serial evaluations (excluding biopsies, laser Doppler, MRI) by NCI
        rehabilitation specialist for documentation and grading of functional disability.

        No pregnant or nursing women.

        Adequate contraception encouraged in fertile women.",Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis,0
"The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed:
IPSS score : 15
Post-void residual: 70 mL
Prostate volume (TRUS): 60 mL
Prostate-specific antigen (PSA) level: 3.2 ng/mL
10 mL/sec of maximum flow rate when urine volume was 130 mL
He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.5 g/dl
WBC: 135000 /mm3
Plt: 350000 /ml
PT: 11 second
PTT: 35 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS: Previously untreated adenocarcinoma of the prostate T1b-c or T2a-b
        with a Gleason score more than 5 and PSA greater than 4 ng/mL OR Any T3 PSA under 70 ng/mL
        within 3 weeks prior to entry and at least 10 days after prostate biopsy No biopsy proven
        regional nodal involvement No distant metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100%
        Hematopoietic: White blood cell (WBC) count of at least 4,000/mm3 Platelet count at least
        100,000/mm3 Hemoglobin at least 11 g/dL Hepatic: Not specified Renal: Not specified Other:
        No major medical or psychiatric illness that would preclude study No other malignancy
        within the past 5 years

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior or
        concurrent chemotherapy Endocrine therapy: Prior hormonal therapy allowed Radiotherapy: No
        prior pelvic irradiation Surgery: No prior prostatectomy or cryosurgery for prostate cancer",Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer,0
"The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed:
IPSS score : 15
Post-void residual: 70 mL
Prostate volume (TRUS): 60 mL
Prostate-specific antigen (PSA) level: 3.2 ng/mL
10 mL/sec of maximum flow rate when urine volume was 130 mL
He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.5 g/dl
WBC: 135000 /mm3
Plt: 350000 /ml
PT: 11 second
PTT: 35 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","-  Inclusion Criteria:

          -  patients must have prostate specific antigen (PSA) only androgen dependent
             adenocarcinoma of the prostate. All patients must have failed definitive therapy
             (radical prostatectomy, radiation therapy with external beam or brachytherapy,or
             cryosurgery).

          -  Patients must have a negative Computerized Tomography (CT) scan and Bone Scan for
             metastatic prostate cancer.

          -  Patients must have histopathological documentation of prostate cancer. Every attempt
             should be made to have slides and blocks reviewed at National Cancer Institute (NCI)
             Pathology laboratory. The review of pathology by the NCI will not delay enrollment.

          -  Patients must have progressive prostate cancer. Two consecutively rising PSAs above
             the nadir post-definitive therapy and an absolute value greater than 1.0 ng/ml
             separated by at least 2 weeks.

          -  Patients must have a life expectancy of more than 12 months.

          -  Patients must have a performance status of 0 to 2 according to the Eastern Cooperative
             Oncology Group (ECOG) criteria.

          -  Hematological eligibility parameters (within 2 weeks of starting therapy):

        Granulocyte count greater than or equal to 1,000/mm^3. Platelet count greater than or equal
        to 75,000/mm^3.

        - Biochemical eligibility parameters (within 2 weeks of starting therapy): If the
        creatinine is greater than 2.0 mg/dL obtain a 24 hour urine collection.

        Creatinine clearance must be greater than 40 mL/min. Hepatic function:

        bilirubin (total) less than or equal to 1 mg/dL upper limit of normal; Alanine
        aminotransferase (ALT) less than 2.5 times upper limit of normal.

          -  Exception: Patients with Clinical Gilbert's Syndrome may have total bilirubin less
             than or equal to 2.5 mg/dL.

          -  Patients must not have other concurrent malignancies (within the past 2 years) with
             the exception of nonmelanoma skin cancer and Rai Stage 0 chronic lymphoma leukemia),
             in situ carcinoma of any site, or life threatening illnesses, including untreated
             infection (must be at least 1 week off intravenous antibiotic therapy before beginning
             thalidomide).

          -  Patients with a history of unstable or newly diagnosed angina pectoris, recent
             myocardial infarction (within 6 months of enrollment), New York class II-IV congestive
             heart failure, chronic obstructive lung disease requiring oxygen therapy, uncontrolled
             seizure activity or by medical judgement of the physician, are not eligible.

          -  Patients must be able to understand and sign an informed consent document.

          -  Patients must be willing to travel from their home to the NIH or the participating
             institution (Louisiana State Univ., Univ. of Washington, Columbia University,Wayne
             State, University of Minnesota, University of Pittsburgh, Holy Cross)for follow-up
             visits (due to sedation associated with thalidomide). It is preferred that patients
             not drive the first 3 days of taking daily dosing,or if sedation appears to be a
             continuing complication).

          -  Patients must be greater than or equal to 18 years of age.

          -  Male patients must be counseled about the possibility that thalidomide may be present
             in semen. Men must use a latex condom every time they have sexual intercourse with
             women during therapy and for 8 weeks after discontinuing thalidomide, even if they
             have had a successful vasectomy.

          -  Patients may enroll as a late entry if the following criteria are met: Have received
             leuprolide or goserelin within 3 months of starting study,have a PSA within two weeks
             of hormonal injection and have a bone scan without metastasis within 8 weeks of
             enrollment.

          -  Patients with Rai Stage of Chronic Lymphocytic Leukemia (lymphocytosis only) will be
             eligible.

          -  Exclusion Criteria:

          -  Patients that have received leuprolide, diethylstilbestrol (DES), flutamide,
             bicalutamide, PC stands for prostate cancer and SPES is the Latin word for
             hope)PC-SPES, goserelin, cytotoxic chemotherapy, finasteride and/or nilutamide within
             the past year (or currently) are not eligible. Patients that received these agents for
             adjuvant or neoadjuvant therapy at the time of definitive therapy are eligible.
             Exception: Patients enrolled under late entry criteria, who have received
             leuprolide/goserelin within 3 months of starting study are eligible.

          -  Patients with National Cancer Institute (NCI)/Cancer Therapy Evaluation Program (CTEP)
             grade 2 or greater peripheral neuropathy of any cause that is clinically detectable,
             patients receiving anti-convulsive medications, and patients with a history of
             seizures within the past 10 years will not be eligible for this study.

          -  Patients who are receiving sedative/hypnotic agents (i.e. benzodiazepines) which
             cannot be discontinued, will not be eligible for this study. Patients who have had a
             surgical orchiectomy will not be eligible for this study.

          -  Patients who received a systemic chemotherapy for prostate cancer will not be
             eligible.

          -  Patients with a confirmed psychiatric history of a major depression consistent with
             American Psychiatric Association Diagnostic and Statistical Manual (DSM IIIR
             criteria), confirmed by a psychiatrist will not be eligible.",Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer,0
"The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed:
IPSS score : 15
Post-void residual: 70 mL
Prostate volume (TRUS): 60 mL
Prostate-specific antigen (PSA) level: 3.2 ng/mL
10 mL/sec of maximum flow rate when urine volume was 130 mL
He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.5 g/dl
WBC: 135000 /mm3
Plt: 350000 /ml
PT: 11 second
PTT: 35 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS: Histologically proven locally recurrent organ-confined prostate
        cancer after external beam radiotherapy, radiation seed implants, or cryosurgery. Gleason
        score of at least 6. Prostate specific antigen values (PSA) of at least 1.0 ng/mL with 2
        consecutive rises in PSA at least 2 weeks apart, of which the second increase is greater
        than the first, after achieving a nadir. Must have at least 3 recorded PSA values over a
        minimum of the last 3 months to determine the slope. Patients must have declined additional
        conventional treatment or be ineligible for conventional treatment of their prostate
        cancer. No metastasis by bone scan. No significant central nervous system (CNS) disease.

        PATIENT CHARACTERISTICS: Age: 18 and over. Performance status: Karnofsky 80-100% OR Eastern
        Cooperative Oncology Group (ECOG) 0 or 1. Life expectancy: Not specified. Hematopoietic:
        White blood cell count (WBC) greater than 3,000/mm3. Platelet count greater than
        100,000/mm3. Hemoglobin greater than 9.0 g/dL. Hepatic: Bilirubin normal. Serum glutamic
        oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) less than 3
        times upper limit of normal. Albumin greater than 3 g/dL. Prothrombin time (PT) and partial
        thromboplastin time (PTT) normal. Hepatitis B surface antigen negative. Renal: Creatinine
        normal. Cardiovascular: No uncontrolled hypertension. No significant cardiovascular
        disease, e.g.: History of ventricular dysfunction; Congestive heart failure; Symptoms of
        coronary artery disease; History of any ventricular arrhythmia; Prior myocardial
        infarction. Other: HIV negative. Fertile patients must use effective double-barrier
        contraception during and for 3 months after study participation. No active autoimmune
        disease. No active infection requiring IV antibiotics. No uncontrolled diabetes mellitus.
        No significant psychiatric disorder that would preclude study. No other malignancy within
        the past 5 years except adequately treated basal cell or squamous cell skin cancer.

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior Leuvectin. Chemotherapy: At least 3
        weeks since prior chemotherapy (6 weeks for mitomycin or hydroxyurea). Endocrine therapy:
        No prior hormonal therapy for prostate cancer. Radiotherapy: See Disease Characteristics.
        At least 3 weeks since prior radiotherapy. Surgery: At least 1 month since prior
        intrathoracic or intra-abdominal surgery. At least 2 weeks since other prior major surgery.
        Other: At least 10 days since prior anticoagulants or non-steroidal anti-inflammatory
        agents. No neoadjuvant or other concurrent anticancer drug therapy. No concurrent
        immunosuppressive drugs. No other concurrent experimental therapy.",Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"INCLUSION CRITERIA

        Women of any age with clinical stage II breast cancer who met the following criteria:

        Patients with stage II breast cancer will include primary tumor less than or equal to 5 cm
        in size with axillary lymph nodes which are clinically ([N0 or N1] [T1N1, T2N0, T2N1]).

        Patients will be staged according to the 1986 AJCC TMM classification.

        Patients with bilateral breast cancer will be eligible provided at least one tumor is
        invasive and classified as stage I or II, and neither breast is stage III.

        Histologic sections of the breast tumor must be classified as an invasive primary breast
        neoplasm of epithelial origin.

        Patients must be geographically accessible for follow-up and willing to return for the
        follow-up at the NCI.

        Patients must be mentally competent to understand and give informed consent for the
        protocol.

        Estrogen receptor (ER) status can include ER positive, negative, or unknown.

        Patients with prior cancers may be eligible as long as they have received curative therapy
        and have had no evidence of recurrence for greater than or equal to 10 years.

        EXCLUSION CRITERIA

        Patients will be excluded from this protocol for the following reasons:

        Advanced local disease or distant metastases (stage III or IV).

        Previous therapy to the breast other than excisional biopsy.

        Pregnancy.

        Unwillingness to use birth control during chemotherapy.

        Chronic disease such as heart, lung, liver, kidney, blood or metabolic disorders which may
        render the patient a poor risk for surgery or chemotherapy. Specifically, liver function -
        SGOT, SGPT, alkaline phosphatase and total bilirubin should be less than 1.5 x the upper
        limits of normal. Renal function - creatinine should be less than 1.7 and/or creatinine
        clearance should be greater than 45 ml/min. If there is any history of cardiac disease,
        patients must have a normal ejection fraction on MUGA scan and no angina.",Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial,2
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"POPULATION CHARACTERISTICS:

        Women and men at increased risk for the development of breast cancer by at least one of the
        following criteria:

        Histologically documented ductal carcinoma in situ (DCIS), including DCIS with minimal
        invasion or microinvasion.

        Histologically documented lobular neoplasia, including lobular hyperplasia and lobular
        carcinoma in situ (LCIS).

        Histologically documented atypical ductal hyperplasia in postmenopausal women.

        Histologically documented atypical ductal hyperplasia in premenopausal women with 1
        first-degree relative (mother or sister) diagnosed with breast cancer.

        Histologically documented atypical ductal hyperplasia in premenopausal women with 3 or more
        relatives diagnosed with breast cancer provided at least 1 is a second-degree relative.

        3 or more first- or second-degree relatives diagnosed with breast or ovarian cancer with at
        least 1 diagnosed with breast cancer.

        2 or more premenopausal (under age 50) first-degree relatives diagnosed with breast cancer.

        1 or more first-degree relatives diagnosed with breast cancer if at least 1 relative in the
        extended pedigree had ovarian cancer.

        3 or more relatives with breast cancer with at least 1 first-degree relative diagnosed with
        premenopausal breast cancer.

        Previously diagnosed Stage I breast cancer with surgery and/or radiotherapy only (without
        prior adjuvant chemo- or hormonal therapy).

        Positive for the BRCA1/BRCA2 gene.

        No history of other invasive breast cancer.

        No evidence of malignancy on breast and gynecologic exams.

        Participants with a family history of breast cancer will be seen in consultation by the
        Family Studies Branch, NCI.

        PRIOR/CONCURRENT THERAPY:

        Mastectomy or lumpectomy plus radiotherapy required prior to entry for patients with DCIS.
        Patients with DCIS who have participated in protocol NCI-MB-348 eligible.

        No participation in any other breast cancer prevention study involving pharmacologic
        intervention.

        No prior chemotherapy or hormonal therapy for invasive breast cancer.

        At least 3 months since estrogen or progesterone replacement therapy or hormonal
        contraceptives.

        PATIENT CHARACTERISTICS:

        Age: 35 and over.

        Performance status: Ambulatory.

        Life expectancy: At least 10 years.

        Hematopoietic: Complete blood count normal.

        Hepatic:

        Bilirubin normal.

        Alkaline phosphate normal.

        AST normal.

        PT, PTT normal.

        No history of bleeding disorder.

        No history of chronic hepatitis or cirrhosis.

        Renal:Creatinine less than 1.5 mg/dL.

        Cardiovascular:

        No history of deep venous thrombosis.

        No history of pulmonary embolus.

        Other:

        No allergy to any study medication.

        Capable of tolerating multiple diagnostic procedures.

        No history of abnormal vaginal bleeding. Hysterectomy for vaginal bleeding of benign
        etiology allowed.

        No history of retinal disease, macular degeneration, or night blindness.

        No medical or psychiatric risk due to nonmalignant systemic disease that would preclude
        study participation.

        No history of malignancy except: Curatively treated nonmelanomatous skin cancer. Curatively
        treated in situ cervical carcinoma. Hodgkin's disease treated more than 5 years ago.

        No pregnant women.

        Adequate contraception required of fertile patients during and for 12 months after
        fenretinide and for 2 months after tamoxifen.",A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed stage I or IIA breast carcinoma that is
             considered operable

          -  No prior axillary clearance or biopsy

          -  Complete excisional biopsy of primary tumor without axillary clearance or biopsy
             allowed

          -  Suspicious manifestations of metastatic disease (e.g., hot spots on bone scan or
             skeletal pain of unknown cause) must be proven benign

          -  No bilateral breast cancer (any mass in contralateral breast must be proven benign by
             biopsy)

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  60 and over

        Sex:

          -  Female

        Menopausal status

          -  Postmenopausal

        Performance status:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 4,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.1 mg/dL

          -  AST less than 60 U/L

        Renal:

          -  Creatinine less than 1.3 mg/dL

        Cardiovascular:

          -  Normal cardiac function

          -  No history of congestive heart failure

        Other:

          -  No nonmalignant systemic disease that would preclude protocol therapy or prolonged
             follow-up

          -  No psychiatric or addictive disorder that would preclude protocol therapy or informed
             consent

          -  No other prior or concurrent malignancy except nonmelanomatous skin cancer or
             adequately treated carcinoma in situ of the cervix

          -  Geographically accessible for follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy for breast cancer

        Chemotherapy:

          -  No prior chemotherapy for breast cancer

        Endocrine therapy:

          -  No prior endocrine therapy for breast cancer

        Radiotherapy:

          -  No prior radiotherapy for breast cancer

        Surgery:

          -  See Disease Characteristics",Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"DISEASE CHARACTERISTICS: Adenocarcinoma of the breast with 1 or more histologically proven
        positive axillary nodes OR Adenocarcinoma of the breast with negative axillary nodes or
        adverse prognostic factors such that the patient is at high risk for recurrence and node
        negative lesion is characterized by the following features: Tumor at least 1 cm Poorly
        differentiated, SBR grade III, or MSBR grade V and/or lymphatic/vascular invasion
        Pathologic review by experienced breast pathologist recommended if grade is unspecified and
        lymphatic/vascular invasion is absent Disease considered potentially curable and treated by
        1 of the following: Complete surgical removal of the breast plus axillary node dissection
        Partial surgical removal of the breast plus axillary node dissection, with the intention of
        giving breast irradiation following completion of an adjuvant chemotherapy regimen Regional
        nodal or chest wall irradiation not prohibited but strongly discouraged No evidence of
        residual tumor in the axilla following dissection No microscopic evidence of residual tumor
        at the resection margins following total mastectomy Further excision highly recommended if
        there is microscopic residual disease present at partial mastectomy margins If further
        excision is not undertaken, a radiotherapy boost to the tumor bed is required in addition
        to breast irradiation given following protocol chemotherapy Disease clinically staged prior
        to surgery as T1-T3a, N0-2, M0 No clinical T4 disease, i.e.: No extension to the chest wall
        No edema (including peau d'orange) No skin ulceration No satellite skin nodules confined to
        the same breast No inflammatory carcinoma Disease pathologically staged following surgery
        as TNM stage I, II, or III (T0-4; N0-2; M0) T4 allowed only with dermal involvement on
        pathology assessment No evidence of metastatic disease beyond the homolateral axillary
        nodes on pre-chemotherapy chest x-ray, bone scan (with radiographs of suspicious areas),
        and abdominal ultrasound (required only if bilirubin, alkaline phosphatase, or AST/ALT are
        elevated) Simultaneous bilateral breast carcinoma allowed Complete tumor resection on both
        breasts required Axillary dissection on both sides must meet criteria as above if both
        sides are clinically node-positive Axillary dissection on the second side optional if the
        axilla is clinically negative at the time of surgery and the other side is node-positive
        Adjuvant chemotherapy must begin within 14 weeks of initial pathologic diagnosis Hormone
        receptor status: Any receptor level allowed (values must be available if biochemical method
        used; immunocytochemical assay permitted)

        PATIENT CHARACTERISTICS: Age: Not specified Sex: Female Menopausal status: Pre- or
        perimenopausal, i.e., meeting at least 1 of the following criteria: Normal menstruation
        Amenorrhea for less than 1 year (up to 3 years in patients under age 52) Biochemical
        evidence of ovarian function Hysterectomy without bilateral oophorectomy in patients under
        age 56 Premenopausal women no greater than age 50 who were started on replacement hormone
        therapy before amenorrhea are eligible Performance status: ECOG 0-2 prior to chemotherapy
        Hematopoietic: WBC at least 3,000/mm3 Polymorphs and bands at least 1,500/mm3 Platelet
        count at least 100,000/mm3 Hepatic: (unless abdominal ultrasound indicates liver
        metastasis) Alkaline phosphatase no greater than 2 times normal AST and/or ALT no greater
        than 2 times normal Renal: Not specified Other: No history of serious underlying medical
        illness or psychiatric or addictive disorder No second malignancy within 5 years except:
        Curatively treated nonmelanomatous skin cancer Curatively treated endometrium, colon, or
        thyroid cancer or carcinoma in situ of the cervix No plan for pregnancy during the 5-year
        study period Fertile women must use effective contraception (other than oral contraception)
        Accessible for treatment and follow-up

        PRIOR CONCURRENT THERAPY: Biologic therapy: Colony-stimulating factors allowed (use must be
        documented) Chemotherapy: No prior chemotherapy No concurrent other cytotoxic therapy
        Endocrine therapy: Adjuvant tamoxifen (20 mg po daily) allowed up to 2 weeks before or
        during adjuvant chemotherapy provided drug is discontinued at randomization No long-term
        prednisone or other hormones Radiotherapy: See Disease Characteristics Surgery: See Disease
        Characteristics",Tamoxifen in Treating Women With High-Risk Breast Cancer,2
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"1. Required Tumor Parameters

             1.1 Patients with operable, histologically confirmed adenocarcinoma of the female
             breast and positive lymph nodes. Node positivity may be determined by either an
             axillary node dissection or a positive sentinel node finding by immunohistochemistry
             or histology. This includes any patient with one or more positive lymph nodes whose
             tumors are T0, T1, 2 or 3 and N1, N2, MO. Patients with metaplastic carcinoma are
             eligible. Bilateral disease does not exclude patients from entry.

             1.2 Tumors that are locally advanced at diagnosis are not eligible. This is left to
             investigator judgment. Patients with tumors fixed to the chest wall, peau d'orange
             skin changes, skin ulcerations, or clinical inflammatory changes (T4 disease) are
             excluded from this study. Dermal lymphatic involvement noted on pathology without
             clinical inflammatory changes will not exclude a patient from this study.

             1.3 Patients with any ERP/PgR status are eligible.

          2. Prior treatment:

             2.1 <84 days from mastectomy or within 84 days of axillary dissection if the patient's
             most extensive breast surgery was a breast sparing procedure.

             2.2 Surgical resection margins - All tumor should be removed by either a modified
             radical mastectomy or a segmental mastectomy. Node dissection: patients may have had
             either an axillary node dissection or sentinel lymph node biopsy before beginning
             treatment on protocol.

               -  Mastectomy: There should be no evidence of gross or microscopic tumor at the
                  surgical resection margins noted in the final surgery or pathology reports for
                  patients who have had a modified radical mastectomy. Patients with close margins
                  (tumor < 1 mm from margin) are eligible.

               -  Segmental mastectomy (lumpectomy): Although clear margins are preferable, DCIS or
                  LCIS at the surgical resection margin will not render a patient who has undergone
                  a segmental mastectomy ineligible for this study. Invasive tumor at the final
                  resection margin will render a patient ineligible.

             2.3 No prior chemotherapy.

             2.4 No prior radiation therapy for this malignancy. Patients who received radiation to
             the breast for DCIS are eligible. Patients who have had segmental mastectomy will be
             treated with radiotherapy according to standard procedures in the treating physician's
             institution after completion of all chemotherapy. Patients who have had modified
             radical mastectomy may also receive radiotherapy at the discretion of the treating
             physician according to institutional guidelines.

             2.5 Patients may receive up to four weeks of tamoxifen therapy for this malignancy and
             still be eligible for study entry. Patients who received tamoxifen for purposes of
             chemoprevention (e.g., Breast Cancer Prevention Trial) or for other indications
             (including previous breast cancer) are eligible. Tamoxifen therapy should be
             discontinued before the patient is enrolled on this study.

          3. Age > 18. There is no upper age limit for enrollment on this study.

          4. Required initial laboratory data:

               -  Granulocyte count > 1000/mm3

               -  Platelet count > 100,000/mm3

               -  Bilirubin within upper limits of normal",Combination Chemotherapy in Treating Patients With Breast Cancer,2
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive adenocarcinoma of the breast

               -  Confined to the breast and ipsilateral axilla on clinical exam

                    -  Stage I, II, or IIIA (cT1-3, N0-1, M0)

          -  At least one axillary lymph node with evidence of tumor on histologic exam

               -  Sentinel node biopsy allowed if followed by axillary dissection

               -  No suspicious palpable nodes in the contralateral axilla or palpable
                  supraclavicular or infraclavicular nodes, unless proven on biopsy to not be
                  involved with tumor

          -  No bilateral malignancy or mass in the opposite breast, unless mass is histologically
             proven to be benign

          -  Must have undergone either a prior total mastectomy and axillary dissection (modified
             radical mastectomy) OR

          -  Prior lumpectomy and axillary dissection

               -  Patients must receive radiotherapy after randomization (not before) AND after
                  chemotherapy

               -  Margins must be clear

               -  No ipsilateral lymph nodes that are fixed to one another or to other structures
                  (N2 disease) and/or any positive nonaxillary lymph nodes (intramammary nodes are
                  considered axillary nodes)

               -  No histologically evident invasive tumor or ductal carcinoma in situ

               -  No diffuse tumors by mammography that would not be surgically amenable to
                  lumpectomy

               -  No other dominant mass in the ipsilateral breast remnant unless one of the
                  following is true:

                    -  Histologically benign

                    -  Surgically removed with clear margins if malignant

          -  No ulceration, erythema, infiltration of the skin or underlying chest wall (complete
             fixation), peau d'orange, or skin edema of any magnitude

               -  Tethering or dimpling of the skin or nipple inversion allowed

          -  No metastatic disease

               -  Skeletal pain allowed if bone scan negative for metastases

          -  Hormone receptor status:

               -  Estrogen and progesterone status determined

        PATIENT CHARACTERISTICS:

        Age:

          -  greater than or equal to 18 years

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 10 years, excluding diagnosis of cancer

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3 (may be less, if in the opinion of the
             investigator, this represents an ethnic or racial variation)

          -  Platelet count at least 100,000/mm^3* NOTE: *If platelet count is above the upper
             limit of normal (ULN), significant underlying hematologic disorders must be excluded

        Hepatic:

          -  Bilirubin no greater than ULN

          -  Alkaline phosphatase less than 2.5 times ULN*

          -  SGOT less than 1.5 times ULN*

          -  No nonmalignant systemic hepatic disease that would preclude study participation NOTE:
             *Alkaline phosphatase and SGOT cannot both be greater than ULN

        Renal:

          -  Creatinine no greater than normal

          -  No nonmalignant systemic renal disease that would preclude study participation

        Cardiovascular:

          -  No nonmalignant systemic cardiovascular disease that would preclude study
             participation

          -  LVEF at least lower limit of normal (LLN) by MUGA or echocardiogram

          -  No active cardiac disease that would preclude use of doxorubicin or docetaxel,
             including the following:

               -  Any prior myocardial infarction

               -  Angina pectoris requiring anti-anginal medication

               -  History of congestive heart failure

               -  Cardiac arrhythmia requiring medication

               -  Severe conduction abnormality

               -  Valvular disease with documented cardiac function compromise

               -  Cardiomegaly on chest x-ray or ventricular hypertrophy on EKG, unless LVEF at
                  least LLN

               -  Poorly controlled hypertension (diastolic greater than 100 mm/Hg)

               -  Hypertension well controlled by medication allowed

        Other:

          -  No grade 2 or greater peripheral neuropathy

          -  No other prior malignancy within the past 5 years except:

               -  Effectively treated squamous cell or basal cell skin cancer

               -  Surgically treated carcinoma in situ of the cervix

               -  Segmentally resected lobular carcinoma in situ of the ipsilateral or
                  contralateral breast

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception

          -  No nonmalignant systemic disease that would preclude study participation

          -  No diabetes with morning fasting blood glucose of 200 mg/dL or greater

          -  No psychiatric or addictive disorders that would preclude informed consent

          -  No contraindication to corticosteroids that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for breast cancer

        Chemotherapy:

          -  No prior chemotherapy for breast cancer

          -  No prior anthracyclines or taxanes

          -  No other concurrent investigational chemotherapy

        Endocrine therapy:

          -  No prior hormonal therapy for breast cancer

          -  No concurrent hormonal birth control methods or other hormonal therapy

          -  No concurrent raloxifene, including for osteoporosis

          -  Concurrent low-dose topical estrogen in the form of conjugated estrogen ring or
             conjugated estrogen vaginal cream (dose no more than 0.3 mg or 1/8 of an applicator
             applied vaginally 3 times a week) allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy for this malignancy

        Surgery:

          -  See Disease Characteristics

          -  No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy,
             mastectomy, sentinel node biopsy, axillary dissection, or re-excision of lumpectomy
             margins)

        Other:

          -  No prior systemic therapy for this malignancy

          -  No concurrent medications that alter cardiac conduction (e.g., digitalis, beta
             blockers, or calcium-channel blockers) for cardiac arrhythmia, angina, or congestive
             heart failure (allowed if administered for other reasons [e.g., hypertension])

          -  Concurrent bisphosphonates allowed","Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes",2
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"DISEASE CHARACTERISTICS:

          -  Resectable invasive adenocarcinoma of the breast, confirmed by 1 of the following:

               -  Histologically confirmed by core or open biopsy

               -  Confirmed by fine needle aspiration cytology AND positive clinical breast
                  examination and ultrasound or mammography

          -  Clinically negative lymph nodes

               -  No positive ipsilateral axillary lymph nodes

               -  No prior removal of ipsilateral axillary lymph nodes

               -  No suspicious palpable nodes in the contralateral axilla or palpable
                  supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy

          -  No ulceration, erythema, infiltration of the skin or underlying chest wall (complete
             fixation), peau d'orange, or skin edema of any magnitude

               -  Tethering or dimpling of the skin or nipple inversion allowed

          -  No bilateral malignancy or mass in the opposite breast that is suspicious for
             malignancy, unless proven nonmalignant by biopsy

          -  No diffuse tumors or multiple malignant tumors in different quadrants of the breast

          -  No other prior breast malignancy except lobular carcinoma in situ

          -  No prior or concurrent breast implants

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  18 years and older

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 10 years (excluding diagnosis of cancer)

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No hepatic systemic disease

        Renal:

          -  No renal systemic disease

        Cardiovascular:

          -  No cardiovascular systemic disease

        Other:

          -  No prior malignancy within past 5 years except:

               -  Effectively treated squamous cell or basal cell skin cancer

               -  Surgically treated carcinoma in situ of the cervix

               -  Surgically treated lobular carcinoma in situ of the ipsilateral or contralateral
                  breast

          -  No concurrent psychiatric or addictive disorder

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for this cancer

        Chemotherapy:

          -  No prior chemotherapy for this cancer, including neoadjuvant chemotherapy

        Endocrine therapy:

          -  No prior hormonal therapy for this cancer

        Radiotherapy:

          -  No prior radiotherapy for this cancer

        Surgery:

          -  See Disease Characteristics

          -  No prior breast reduction surgery

          -  Prior excisional biopsy or lumpectomy allowed",Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"DISEASE CHARACTERISTICS:

          -  Postmenopausal women at increased risk for developing invasive breast cancer, who meet
             one of the following criteria:

               -  At least 12 months since spontaneous menstrual bleeding

               -  Prior documented hysterectomy and bilateral salpingo-oophorectomy

               -  At least 55 years of age with prior hysterectomy with or without oophorectomy

               -  Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of
                  ovaries unknown with documented follicle-stimulating hormone level demonstrating
                  elevation in postmenopausal range

          -  Histologically confirmed lobular carcinoma in situ treated by local excision only OR a
             minimum projected 5 year probability of invasive breast cancer of at least 1.66%,
             using Breast Cancer Risk Assessment Profile

          -  No clinical evidence of malignancy on physical exam within the past 180 days

          -  No evidence of suspicious or malignant disease on bilateral mammogram within the past
             year

          -  No bilateral or unilateral prophylactic mastectomy

          -  No prior invasive breast cancer or intraductal carcinoma in situ

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  35 and over

        Sex:

          -  Female

        Menopausal status:

          -  See Disease Characteristics

        Performance status:

          -  No restricted normal activity for a significant portion of each day

        Life expectancy:

          -  At least 10 years

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm^3

          -  Complete blood count and differential normal

          -  Platelet count normal

        Hepatic:

          -  SGOT or SGPT normal

          -  Bilirubin normal

          -  Alkaline phosphatase normal

        Renal:

          -  Creatinine normal

        Cardiovascular:

          -  No cerebral vascular accident, transient ischemic attack, atrial fibrillation, or
             uncontrolled hypertension

          -  No deep vein thrombosis

        Pulmonary:

          -  No pulmonary embolus

        Other:

          -  No other prior malignancy within the past 5 years except basal cell or squamous cell
             skin cancer or carcinoma in situ of the cervix

          -  No concurrent nonmalignant disease that would preclude administration of tamoxifen or
             raloxifene

          -  No clinical depression, psychiatric condition, or addictive disorder

          -  No uncontrolled diabetes

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  At least 3 months since prior estrogen or progesterone replacement therapy, oral
             contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin
             inhibitors, or antiandrogens

          -  At least 3 months since prior tamoxifen, raloxifene, or other selective
             estrogen-receptor modulators of less than 3 months duration

          -  Concurrent Estring allowed

        Radiotherapy:

          -  No prior breast radiotherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No prior systemic adjuvant therapy for breast cancer

          -  No other participation in a cancer prevention or osteoporosis prevention study
             involving pharmacologic intervention(s)

               -  NSABP-P-1 patients who received placebo are eligible

          -  No concurrent warfarin or cholestyramine

          -  Concurrent calcitonin or nonhormonal medication (e.g., cholecalciferol, fluoride, or
             bisphosphonates) allowed",Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"Eligibility Criteria:

          -  Women with a diagnosis of breast cancer established by tissue obtained by needle
             biopsy or incisional biopsy.

          -  There must be a residual measurable breast and/or axillary mass after biopsy.

          -  Clinical stage T1, N1-3, Mo or T2-4, N0-3, Mo. T2N0 lesions < 4cm in maximum dimension
             are eligible only if breast conservation is not feasible or practical without
             preoperative tumor shrinkage.

          -  Patients must be willing to undergo a mastectomy or breast sparing procedure plus
             axillary lymph node dissection.

          -  There must be no evidence of systemic metastases.

          -  No prior chemotherapy. Patients may have received up to 14 days of tamoxifen. 3.1.7
             Patients > 18years are eligible.

          -  ECOG performance status 0-1.

          -  Normal hematologic function defined as white blood cell count > 3500/111 or neutrophil
             count > 1500411 and platelets >100,000/4

          -  Normal renal function defined as serum creatinine <1.5 mg/di.

          -  Adequate hepatic function. Bilirubin must be < institutional upper limit of normal
             (ULN). Transaminases (SGOT and/or SGPT) may be up to 2.5 X institutional ULN if
             alkaline phosphatase is < ULN, or alkaline phosphatase may be up to 4 X ULN if
             transaminases are < ULN. However, patients who have both transaminase elevation > 1.5
             X ULN and alkaline phosphatase > 2.5 X ULN are not eligible for this study (due to
             decreased clearance of docetaxel and increased risk of toxicity).

          -  Patients with prior CIS of cervix or nonmelanoma skin cancers are eligible. Patients
             with prior DCIS or LCIS of breast are eligible if not previously treated with
             radiation or chemotherapy. Patients with prior malignancies including contralateral
             breast cancers treated with curative intent more than 5 years before enrollment are
             eligible.

          -  Patients must have signed informed consent.

        Exclusion Criteria:

          -  Patients with a prior history of malignancy other than those mentioned in section
             3.1.12 are ineligible.

          -  Patients must not have severe concurrent medical or psychiatric illness (i.e. no
             severe diabetes mellitus, poorly controlled ischemic heart disease or congestive heart
             failure, or severe chronic obstructive or restrictive pulmonary disease).

          -  The interval between initial diagnosis of breast cancer and the start of treatment
             must not be greater than 8 weeks.

          -  Due to anticipated toxicities to an unborn fetus, and excretion of chemotherapy in
             breast milk, patients must not be pregnant or lactating and must use effective
             contraception during treatment.

          -  No history of hypersensitivity reaction to preparation containing polysorbate 80,
             3.2.6 Patients must not have peripheral neuropathy grade 2 or higher.

          -  Patients must not have had prior radiation to >25% of bone marrow",Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of cystic fibrosis (CF) with mild to moderate lung disease; FVC at least 60%
        predicted; Schwachman-Kulczycki score at least 65; Sweat chloride greater than 60 mEq/L

        All CF genotypes allowed

        No sputum colonization with Burkholderia cepacia or another multiply resistant organism

        No recurrent or intermittent hemoptysis; At least 1 year since significant hemoptysis
        requiring transfusion or embolization OR Coughing of greater than 30 mL of blood more often
        than once a week

        --Prior/Concurrent Therapy--

        At least 30 days since hospitalization or home intravenous antibiotic therapy for pulmonary
        exacerbation

        No concurrent investigational drugs or therapy

        --Patient Characteristics--

        Other: No concurrent cigarette smoking; Not pregnant or nursing; Negative pregnancy test;
        Fertile patients must use effective contraception",Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"Inclusion Criteria

          -  Histologically confirmed stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV
             primary carcinoma of the breast

               -  Fine needle aspiration, core needle biopsy, or incisional biopsy allowed

               -  No excisional biopsy

               -  Any of the following:

                    -  Tumor size 2, Nodes 1 (T2N1) or tumor size 3 nodes 0 (T3N0)

                    -  Any T with N2 (including axillary lymph nodes matted to one another) or N3

                    -  Any T4, including inflammatory breast cancer

                    -  Adjuvant patients with at least 4 positive lymph nodes and HER-2
                       overexpressing tumor

                    -  Supraclavicular or infraclavicular positive lymph nodes without distant
                       metastases

                    -  Distant metastases with measurable disease in breast or lymph nodes

          -  Synchronous bilateral primary breast cancer allowed if the more serious cancer meets
             entry criteria

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

        Age: Not specified

        Sex: Female

        Menopausal status: Not specified

        Performance status: Not specified

        Life expectancy: Not specified

        Hematopoietic:

        White cell count > 3000 / mm3 Platelet count > 100,000 / mm3

        Hemoglobin > 9 mg / dl Bilirubin < 1.5 x normal Creatinine < 1.5 x normal left ventricular
        ejection fraction (LVEF) normal by resting nuclear ventriculogram Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception

        Exclusions

        Prior malignancies except:

        Effectively treated squamous cell or basal cell skin cancer Carcinoma in situ of the cervix
        that has been curatively treated by surgery alone Nonbreast malignancy from which patient
        has been disease-free for 5 years and is at low risk of recurrence","Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer",2
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"-  INCLUSION CRITERIA - Annual Follow-up Study:

        To participate in the Annual Follow-up Study, a woman must:

        Be at least 25 years of age (or 5 years younger than the age at diagnosis of the youngest
        family member with a tumor associated with the Breast-Ovarian Cancer Syndrome) and less
        than 56 years of age.

        Must be:

        A known BRCA1 or BRCA2 deleterious mutation carrier

        OR

        A first- or second- degree relative of an individual known to carry a deleterious BRCA1 or
        BRCA2 mutation

        OR

        A first- or second- degree relative of an individual with a tumor associated with the
        Breast-Ovarian Cancer Syndrome in a family with a known BRCA mutation.

        Have undergone genetic counseling and risk assessment.

        Agree to release of genetic test result for stratification purposes, whether or not she has
        chosen to receive individual test results for clinical decision-making.

        Have an ECOG performance status of 0-1.

        Be able to provide informed consent.

        Have at least one non-irradiated breast.

        EXCLUSION CRITERIA - Annual Follow-up Study:

        Any of the following will result in exclusion from the Annual Follow-up Study:

        Pregnancy or lactation within 6 months of enrollment.

        Abnormal CA-125 level.

        Bilateral breast cancer, ovarian (any stage) or breast cancer (Stage IIB or worse) unless
        relapse free for 5 years prior to the time of enrollment.

        Patients with DCIS, Stage I and Stage II breast cancer are eligible provided that it has
        been at least 6 months from the completion of primary therapy (surgery, radiation, and
        chemotherapy as applicable). Tamoxifen and aromatase inhibitor adjuvant therapy is allowed.

        Patients with DCIS, Stage I and Stage II breast cancer who have had a local relapse after
        primary treatment are not eligible unless they have been relapse free for 5 years prior to
        the time of enrollment.

        History of other invasive cancer unless relapse free for 5 years prior to the time of
        enrollment. Non-Melanoma skin cancer or cervical carcinoma in situ are excepted.

        Previous bilateral mastectomy or bilateral radiation therapy.

        Weigh over 136 kilograms.

        Allergy to gadolinium.

        Allergy to lidocaine or Marcaine (bupivacaine). (excluded from breast duct lavage only).

        Subareolar or other surgery of the breast to be studied which might disrupt the ductal
        systems. For example, papilloma resection, biopsy or fine needle aspirations (FNAs) within
        2 cm of the nipple might disrupt the ductal systems. Biopsies or FNAs greater than 2 cm
        from the nipple are acceptable. (Excluded from ductal lavage only)

        A breast implant or prior silicone injections in the breast to be studied. (Exclude from
        breast ductal lavage only)

        Active infections or inflammation in a breast to be studied. (breast ductal lavage only)

        Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would
        preclude informed consent or ability to participate in clinical research.",Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"-  ELIGIBILITY CRITERIA:

        Inclusion Criteria - Menstrual Cycle Study:

        To participate in the Menstrual Cycle Pilot Study, a woman must:

        Must be at least 25 years of age (or 5 years younger than the age at diagnosis of the
        youngest family member with a tumor associated with the Breast-Ovarian Cancer Syndrome) and
        less than 46 years of age.

        Must be premenopausal as determined by menstrual history (no change in menstrual pattern in
        prior 6 months) and an FSH level less than 15 mIU/ml obtained on the third day of the
        menstrual cycle.

        Have undergone genetic counseling and risk assessment.

        Must be a known mutation carrier or be a first- or second-degree relative of an individual
        with a tumor associated with the Breast-Ovarian Cancer Syndrome in a family with a known
        BRCA mutation.

        Agree to release of genetic test result for stratification purposes, whether or not she has
        chosen to receive individual test results for clinical decision-making.

        Be willing to use non-hormonal methods of contraception until completion of the 3 month
        follow-up studies.

        Have an ECOG performance status of 0-1.

        Be able to provide informed consent.

        Exclusion Criteria - Menstrual Cycle Study:

        Any of the following will result in exclusion from the Menstrual Cycle Pilot Study:

        A history of menstrual cycle irregularities over the previous 6 months, including history
        of cycles less than 26 days or more than 35 days.

        Steroid therapy, use of selective estrogen receptor modulators (SERMs) or hormonal agents
        (including tamoxifen, raloxifene, estrogen, DHEA, anabolic steroids, oral contraceptives,
        depoprovera, progestin IUD, oral progestins, norplant, or drugs to induce ovulation) within
        6 months prior to study entry and must agree not to use these compounds until completion of
        the three-month follow-up study.

        Pregnancy or lactation within 12 months of enrollment.

        History of infertility with a suspected ovarian etiology or persistent ovarian cyst.

        Abnormal CA-125 level.

        History of invasive cancer except for non-melanoma skin cancer or cervical carcinoma in
        situ.

        Creatinine greater than 2.

        Previous bilateral mastectomy, bilateral radiation therapy to the breast, or oophorectomy.

        History of DCIS or LCIS .

        Weight over 136 kilograms.

        Allergy to gadolinium.

        Allergy to lidocaine or Marcaine (bupivacaine) (excluded from breast duct lavage only).

        Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would
        preclude informed consent or ability to participate in clinical research.

        Inclusion Criteria - Training Cohort:

        To participate in the Training Cohort a volunteer must:

          -  Be female and at least 18 years and less than 51 years of age.

          -  Have at least one breast considered eligible for study.

          -  Provide evidence (either films or radiologist's report) of a mammogram done within the
             12 months prior to enrollment showing low or no suspicion of carcinoma in at least one
             breast. (Mammograms will not be provided to participants as part of the training
             cohort.)

          -  Have a physical examination of the breast to be studied consistent with low or no
             suspicion of carcinoma at the time of enrollment.

          -  Provide the name of a primary care physician to whom the results of breast duct lavage
             cytologies can be sent.

          -  Have signed the informed consent for breast duct lavage.

        Exclusion Criteria - Training Cohort:

        Any of the following will exclude a potential participant from the Training Cohort:

          -  Pregnancy or lactation within the past 12 prior to enrollment.

          -  Subareolar or other surgery of the breast to be studied (papilloma resection, biopsy
             or fine needle aspirations which might disrupt the ductal systems within 2 cm of the
             nipple. (Biopsies of fine needle aspirations of the breast greater than or equal to 2
             cm from the nipple are acceptable.)

          -  A breast implant or prior silicone injections in the breast to be studied.

          -  Radiation therapy to a breast to be studied.

          -  Active infections or inflammation in a breast to be studied.

          -  Chemotherapy or a selective estrogen receptor modifier (e.g., tamoxifen or raloxifen)
             taken within 12 months prior to enrollment.

          -  A known allergy to lidocaine, prilocaine or Marcaine (bupivacaine).",Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study,0
The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using well women multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.,"Eligibility

          -  Patients must have undergone either a total mastectomy or a lumpectomy with either an
             axillary dissection or sentinel node biopsy. If any sentinel node is histologically
             positive by H & E, or histologically suspicious on H & E and confirmed positive by
             immunohistochemistry (IHC), then the patient must have a completion axillary
             dissection.

          -  The tumor must be invasive adenocarcinoma on histologic examination with clinical
             assessment T1-3, N0-1, M0.

          -  Patients must not be participating in any other clinical trials of systemic therapy
             for early-stage breast cancer. Patients may participate in the following radiation
             therapy trials:

               -  Node-positive patients may participate in the National Cancer Institute of Canada
                  Clinical Trials Group protocol MA.20, provided the requirements of the B-34
                  protocol continue to be met. (Node-negative B-34 patients may not participate in
                  MA.20.)

               -  Node-positive mastectomy patients may participate in Southwest Oncology Group
                  protocol S9927, provided the requirements of the B-34 protocol continue to be
                  met.

          -  Patients must have an analysis of both estrogen and progesterone receptors on the
             primary tumor performed prior to randomization. Tumors will be defined as ER or
             progesterone receptor (PgR) positive if: 1) the Dextran-coated charcoal or
             sucrose-density gradient method shows them to have greater than or equal to 10 fmol/mg
             cytosol protein, or 2) if using individual laboratory criteria they can be shown to be
             positive by the enzyme immunoassay method (EIA) or immunocytochemical assay. ""Marginal
             or borderline,"" results (i.e., those not definitively negative) will also be
             considered positive.

          -  At the time of randomization, the patient must have had the following within the past
             3 months: history and physical exam, a bone scan, thoracic and lumbar spine x-rays,
             and a chest x-ray. Within the past 12 months patients must have had a gynecologic exam
             (for women who have a uterus and who will be taking tamoxifen) and a bilateral
             mammogram.

          -  At the time of randomization:

               -  the postoperative absolute neutrophil count (ANC) must be greater than or equal
                  to 1500/mm3 (or less than 1500/mm3 if, in the opinion of the investigator, this
                  represents an ethnic or racial variation of normal);

               -  the postoperative platelet count must be greater than or equal to 100,000;

               -  there must be postoperative evidence of adequate hepatic function, i.e.,

               -  total bilirubin at or below the upper limit of normal (ULN) for the laboratory;
                  and

               -  alkaline phosphatase less than 2.5 x the ULN; and

               -  the serum glutamate oxaloacetate transaminase (SGOT)/ aspartate transaminase
                  (AST) less than 1.5 x the ULN;

               -  there must be postoperative evidence of adequate renal function (serum creatinine
                  within or less than the laboratory's normal range).

          -  Serum albumin and serum calcium must be within normal limits.

          -  A patient with skeletal pain is eligible for inclusion in the study if bone scan
             and/or roentgenological examination fails to disclose metastatic disease. Suspicious
             findings must be confirmed as benign by x-ray, MRI, or biopsy.

          -  Patients with prior nonbreast malignancies are eligible if they have been disease-
             free for greater than or equal to 5 years before randomization and are deemed at low
             risk for recurrence by their treating physicians. Patients with squamous or basal cell
             carcinoma of the skin that has been effectively treated, carcinoma in situ of the
             cervix that has been treated by surgery only, or lobular carcinoma in situ (LCIS) of
             the ipsilateral or contralateral breast treated by hormone therapy and/or surgery only
             are eligible, even if these were diagnosed within 5 years before randomization.

          -  Patients must have a Zubrod performance status of 0, 1, or 2.

          -  Special conditions for eligibility of lumpectomy patients: Irradiation and surgery.
             Patients treated by lumpectomy and axillary node dissection (or no axillary dissection
             if sentinel node biopsy is negative) to be followed by breast radiation therapy must
             meet all the eligibility criteria in addition to the following:

               -  Generally, lumpectomy should be reserved for tumors less than 5 cm. However, at
                  the investigator's discretion, patients treated with lumpectomy for tumors
                  greater than or equal to 5 cm are eligible.

               -  The margins of the resected specimen must be histologically free of invasive
                  tumor and ductal carcinoma in situ (DCIS). For patients in whom pathologic
                  examination demonstrates tumor present at the line of resection, additional
                  operative procedures may be performed to obtain clear margins. This is
                  permissible even if axillary dissection has been performed. Patients in whom
                  tumor is still present at the resected margins after re-excision(s) must undergo
                  total mastectomy to be eligible.

        Ineligibility.

          -  Significant non-malignant bone disease that is likely to interfere with the
             interpretation of bone x-rays.

          -  Ulceration, erythema, infiltration of the skin or the underlying chest wall (complete
             fixation), peau d'orange, or skin edema of any magnitude. (Tethering or dimpling of
             the skin or nipple inversion should not be interpreted as skin infiltration. Patients
             with these conditions are eligible.)

          -  Ipsilateral lymph nodes that on clinical examination are found to be fixed to one
             another or to other structures (cN2 disease).

          -  Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or
             infraclavicular nodes, unless there is biopsy evidence that these are not involved
             with tumor.

          -  Prior therapy for breast cancer, including irradiation, chemotherapy, biotherapy,
             and/or hormonal therapy, with the exception of tamoxifen. Tamoxifen may be given as
             adjuvant therapy before study entry, but only if it was started within 28 days before
             randomization. Patients who started tamoxifen within 28 days before randomization and
             who are being considered for chemotherapy must have their tamoxifen stopped at the
             start of chemotherapy.

          -  Prior history of breast cancer, except LCIS.

          -  Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement
             therapy, etc. (These patients are eligible only if this therapy is discontinued prior
             to randomization.) Exceptions: patients may use low-dose estrogen vaginal creams or
             Estring for symptomatic vaginal dryness, raloxifene (or other selective estrogen
             receptor modulators [SERMs]) for the prevention of osteoporosis, and
             luteinizing-hormone-releasing hormone (LHRH) agonists/antagonists for the purpose of
             medical ovarian ablation as a component of adjuvant therapy for the breast cancer.

          -  Patients currently taking alendronate (Fosamax) or other bisphosphonates or
             calcitonin to treat or prevent osteoporosis are not eligible.

          -  Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
             preclude a patient from being subjected to any of the treatment options or would
             prevent prolonged follow-up.

          -  Psychiatric or addictive disorders that would preclude obtaining informed consent.

          -  Pregnancy or lactation at the time of proposed randomization. This protocol excludes
             pregnant or lactating women because the effects of clodronate on such women have not
             been studied fully.

          -  Bilateral malignancy or a mass or mammographic abnormality in the opposite breast
             suspicious for malignancy unless there is biopsy proof that the mass is not malignant.

          -  Special conditions for ineligibility of lumpectomy patients: Irradiation and surgery.
             The following patients will also be ineligible:

               -  Patients with diffuse tumors (as demonstrated on mammography) that would not be
                  considered surgically amenable to lumpectomy.

               -  Patients treated with lumpectomy in whom there is another clinically dominant
                  mass or mammographically suspicious abnormality within the ipsilateral breast
                  remnant. Such a mass must be biopsied and demonstrated to be histologically
                  benign prior to randomization or, if malignant, must be surgically removed with
                  clear margins.

               -  Patients in whom the margins of the resected specimen are involved with invasive
                  tumor or ductal carcinoma in situ (DCIS). Additional surgical resections to
                  obtain free margins are allowed. Patients in whom tumor is still present after
                  the additional resection(s) must undergo mastectomy to be eligible.",Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer,2
"A 45-year-old woman was referred to the emergency department with abdominal pain lasting about 4 days accompanied by nausea and 2 episodes of vomiting. The pain is localized to the epigastric region and radiates to the right upper quadrant. The pain is worsening after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and two C/sections. She has 2 children, and she is menopausal. She doesn't smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. On palpation, she experiences epigastric tenderness  and  tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones and biliary sludge. The largest gallstone is 0.7cm. Surgery consultation recommends elective cholecystectomy.","DISEASE CHARACTERISTICS: Histologically or cytologically proven non-small cell lung cancer
        Squamous cell lung cancer Large cell lung cancer Adenocarcinoma lung cancer Mixture of
        above Locally advanced disease for which the patient declined aggressive treatment or that
        is unsuitable for aggressive curative treatment due to at least one of the following:
        Performance status of ECOG 2 or 3 Otherwise unexplained weight loss greater than 10% in the
        last 6 months Bulky disease that cannot be irradiated safely to high doses Inability to
        tolerate chemotherapy Cytologically positive pleural effusion OR Clinically or
        radiologically proven metastatic disease for which palliative chemotherapy is not planned
        in the first 38 days after radiotherapy No more than one brain metastasis allowed One of
        the following symptoms identified as the index symptom: Loss of appetite Nausea Vomiting
        Cough Coughing up blood Chest pain Shortness of breath Difficulty swallowing Fatigue Must
        have symptoms related to intrathoracic lung cancer that are amenable to radiation
        palliation

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-3 Life expectancy:
        Greater than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: Fluent in English or French No loss of sight or other inability to
        complete questionnaires or diary Not pregnant No concurrent terminal illness No other
        active malignancy that is causing symptoms or is expected to progress in the next 3 months

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 30 days
        since prior chemotherapy and failed No planned chemotherapy within 38 days after study
        treatment Endocrine therapy: Not specified Radiotherapy: No planned laser therapy within 38
        days after study treatment Surgery: At least 30 days since prior surgery and failed Other:
        No planned photodynamic therapy or sclerotherapy within 38 days after study treatment",Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer,0
"A 45-year-old woman was referred to the emergency department with abdominal pain lasting about 4 days accompanied by nausea and 2 episodes of vomiting. The pain is localized to the epigastric region and radiates to the right upper quadrant. The pain is worsening after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and two C/sections. She has 2 children, and she is menopausal. She doesn't smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. On palpation, she experiences epigastric tenderness  and  tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones and biliary sludge. The largest gallstone is 0.7cm. Surgery consultation recommends elective cholecystectomy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Histologically diagnosed severe preeclampsia at risk for eclamptic convulsions with
             the following criteria:

          -  Blood pressure greater than 160/110 mmHg OR Mean arterial pressure of 126 mmHg

          -  Proteinuria greater than 5 g/24 hr

          -  Epigastric pain OR Right upper quadrant pain AST/ALT greater than 70 U/L

          -  Severe headache and/or scotomata

          -  Thrombocytopenia as evidenced by: Platelet count less than 100,000/mm3 Disseminated
             intravascular coagulation Microangiopathic hemolytic anemia Oliguria (less than 400
             mL/day or 30 mL/hr)

          -  Pulmonary edema

        --Prior/Concurrent Therapy--

          -  No prior/concurrent magnesium sulfate or dihydropyridine agents

          -  No other concurrent antiseizure medications

        --Patient Characteristics--

          -  Age: Not specified

          -  Performance status: Not specified

          -  Hematopoietic: See Disease Characteristics

          -  Hepatic: See Disease Characteristics

          -  Renal: No severe renal failure See Disease Characteristics

          -  Cardiovascular: No history of angina or myocardial infarction No cardiac dysfunction
             No history or sign of congestive cardiac failure No arrhythmia with ventricular rate
             less than 60 bpm See Disease Characteristics

          -  Pulmonary: See Disease Characteristics

        --Other:--

          -  No severe mental or physical disorder that may affect therapy

          -  Not allergic to drugs with chemical structure similar to nimodipine or magnesium
             sulfate

          -  No evidence of fetal distress or fetal anomalies",Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia,0
"A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","INCLUSION CRITERIA:

        Age above 18 years, male or female.

        Serum alanine or asparate aminotransferase activities that are above the upper limit of
        normal (ALT greater than 41 or AST greater than 31 U/L) on an average of three
        determinations taken during the previous 6 months. The mean of the three determinations
        will be defined as ""baseline"" levels.

        Presence of anti-HCV and HCV RNA in serum tested at least once during the previous six
        months.

        Evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a
        histology activity index of at least 6 (out of a maximum of 22).

        Written informed consent.

        EXCLUSION CRITERIA:

        If previously treated with interferon or ribavirin, must not have a lack of sustained
        virological response as shown by the presence of HCV RNA in serum six months after stopping
        therapy. Patients must not have received the combination of alpha interferon and ribavirin
        in the past.

        Decompensated liver disease, as marked by bilirubin greater than 4 mg%, albumin less than
        3.0 gm%, prothrombin time greater than 2 sec prolonged, or history of bleeding esophageal
        varices, ascites or hepatic encephalopathy. Patients with ALT levels greater than 1000 U/L
        (greater than 25 times ULN) will not be enrolled but may be followed until three
        determinations are below this level.

        Pregnancy or, in women of child-bearing potential or spouses of such women, inability to
        practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or
        use of condoms and spermacide, or birth control pills, or an intrauterine device.

        Significant systemic or major illnesses other than liver disease, including congestive
        heart failure, renal failure (creatinine clearance less than 50 ml/min), organ
        transplantation, serious psychiatric disease or depression, and angina pectoris.

        Pre-existing anemia (hematocrit less than 36% for men and less than 34% for women) or known
        history of hemolytic anemia.

        Antiviral or immunosuppressive therapy within the last 6 months.

        Evidence of another form of liver disease in addition to viral hepatitis (e.g., autoimmune
        liver disease, Wilson's disease, alcoholic liver disease, hemochromatosis,
        alpha-1-antitrypsin deficiency).

        Any evidence of coronary artery disease or cerebral vascular disease, including
        abnormalities on exercise stress testing in patients with defined risk factors who will be
        screened for evidence of underlying coronary artery disease.

        Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one
        year.

        Evidence of hepatocellular carcinoma; either alphafetoprotein (AFP) levels greater than 50
        ng/ml (normal is less than 9 ng/ml) and /or ultrasound (or other imaging study)
        demonstrating a mass suggestive of liver cancer.

        Clinical gout.",Combination Drug Therapy for Patients With Hepatitis C,2
"A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","-  INCLUSION CRITERIA:

        Age above 18 years, male or female.

        Elevated alanine (ALT) or asparate (AST) aminotransferase activities averaging at least
        twice the upper limit of normal on three determinations taken at least one month apart
        during the previous 6 months. The mean of these three determinations will be defined as
        ""baseline"" ALT and AST levels.

        Presence of anti-HCV and HCV RNA in serum tested at least once during the previous six
        months.

        Evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a
        histology activity index of at least 6 (out of a maximum of 22).

        Contraindications to the use of alpha interferon, either in the form of specific
        contraindications to its use (depression, psychiatric illness, neurological impairment,
        severe thrombocytopenia, autoimmune disease), or the history of severe side effects or
        intolerance during a previous course of alpha interferon, or lack of a sustained
        virological (sustained lost of HCV RNA from serum for more than six months after stopping
        treatment) response to an adequate course (6 months) of the combination of alpha interferon
        and ribavirin or (after September 1, 2003) the combination of peginterferon and ribavirin.

        Written informed consent.

        INCLUSION CRITERIA FOR PATIENTS IN 98-DK-0003:

        An important group of patients who were enrolled in the current study, were patients who
        participated in the Clinical Research Protocol 98-DK-0003 (Combination of alpha interferon
        with long-term ribavirin for patients with chronic hepatitis C) and who did not have a
        sustained virological response to this treatment. These patients were eligible to enroll
        into the current study once they had finished the therapy and follow up period in that
        trial. These patients fit the inclusion criteria listed above with one exception: some
        patients were receiving ribavirin monotherapy as a part of their participation in
        98-DK-0003. These patients were eligible to be immediately enrolled into this study without
        a medication-free period in between.

        EXCLUSION CRITERIA:

        Pregancy or, in women of childbearing potential, inability to practice adequate
        contraception. Men with spouses or sexual partners of childbearing potential also be
        excluded if they are unable to practice adequate contraception.

        Significant systemic illnesses other than liver disease, including a history of congestive
        heart failure, cerebral vascular disease, renal failure (creatinine clearance less than 50
        ml/min), and angina pectoris.

        Patients with an abnormal stress test or carotid untrasound will not be enrolled into this
        study.

        Pre-existing anemia (hematocrit less than 32%) or known history of hemolytic anemia.

        Interferon or immunosuppressive therapy within the last 6 months.

        Evidence of another form of liver disease in addition to viral hepatitis, such as
        autoimmune or alcoholic liver disease.

        Active or recent (within one year) alcohol or drug abuse or psychiatric illness that is
        likely to interfere with compliance and requirements for safety monitoring during this
        study.",Long-Term Therapy With Ribavirin for Chronic Hepatitis C,2
"A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","Patients with chronic hepatitis C.

        Age 18 to 70 years, male or female.

        HCV infection indicated by the presence of anti-HCV (by ELISA and recombinant immunoblot
        assay [RIBA]).

        Written informed consent.

        Women must not be pregnant.

        Patients must not have significant systemic illnesses other than liver disease, including
        congestive heart failure, renal failure, uncontrolled diabetes mellitus.

        Patients must not have antiviral or immunosuppressive therapy within the last 6 months.

        Patients must not have HIV infection.

        Patients must not have contraindications to liver biopsy (mainly clotting abnormality
        (coumadin therapy, platelet count less than 50,000/cubic millimeter, prothrombin time more
        than 4 seconds beyond control)).",History of Hepatitis C in Volunteer Blood Donors,2
"A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","Inclusion Criteria

        Patients must have the following symptoms and conditions:

          -  Treatment naive.

          -  Recent HIV infection.

          -  Baseline laboratory values within acceptable ranges.

          -  Written, informed consent from parent or legal guardian for patients < 18 years old.

          -  Available for follow-up for at least 96 weeks.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions and symptoms are excluded:

          -  Documentation of other cause for previously mentioned clinical conditions.

          -  Intractable diarrhea.

          -  Signs and symptoms of bilateral peripheral neuropathy >= Grade 2.

          -  Inability to tolerate oral medication.

          -  Hemophilia, other bleeding disorder, or no accessible tonsillar or lymph node tissue.

        Patients with the following prior conditions are excluded:

        History of acute or chronic pancreatitis. 1. Use of potent neurotoxic drugs is not
        permitted.

          -  No other anti-HIV therapy allowed.

          -  Nelfinavir should not be administered concurrently with rifampin or rifabutin,
             terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), triazolam
             (Halcion), and midazolam (Versed).

             1. Any prior antiretroviral therapy.

          -  Prior vaccination with a candidate HIV therapeutic vaccine.

          -  Previous therapy with agents with significant systemic myelosuppressive, neurotoxic,
             pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or
             the expected need for such therapy at the time of enrollment.

          -  Previous therapy with rifampin or rifabutin, terfenadine (Seldane), astemizole
             (Hismanal), cisapride (Propulsid), triazolam (Halcion), and midazolam (Versed) within
             14 days prior to study entry or at any time while on study.

        Active alcohol or substance abuse.","A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection",0
"A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Pathologically confirmed primary sclerosing cholangitis (PSC) meeting the following
        criteria:

          -  Chronic cholestatic disease for at least 6 months

          -  Liver biopsy within the past 6 months compatible with the diagnosis of PSC Intra
             and/or extrahepatic biliary duct obstruction, beading, or narrowing

        OR

        Pathologically confirmed primary biliary cirrhosis (PBC) that is experiencing suboptimal
        response to ursodeoxycholic acid and meeting the following criteria:

          -  Chronic cholestatic liver disease for at least 6 months

          -  Positive antimitochondrial antibody

          -  No biliary obstruction by ultrasound, CT, or cholangiography

          -  Prior liver biopsy compatible with diagnosis of PBC

          -  Received ursodeoxycholic acid for at least 6 months

        --Prior/Concurrent Therapy--

        Biologic therapy:

          -  At least 3 months since prior D-penicillamine

          -  No planned transplantation for at least 1 year

        Chemotherapy:

          -  At least 3 months (6 months for PBC) since prior cyclosporin, colchicine,
             azathioprine, or methotrexate

          -  At least 6 months since prior chlorambucil (PBC only)

        Endocrine therapy: At least 3 months (6 months for PBC) since prior corticosteroids

        Surgery: No prior intraductal stones or operations on the biliary tree except
        cholecystectomy (PSC only)

        Other:

          -  At least 3 months since prior pentoxifylline, ursodeoxycholic acid, or nicotine (PSC
             only)

          -  At least 6 months since prior chenodeoxycholic acid (PBC only)

        --Patient Characteristics--

        Life expectancy: At least 3 years

        Hematopoietic: Not specified

        Hepatic:

          -  Alkaline phosphatase at least 2 times upper limits of normal

          -  No chronic hepatitis B infection

          -  No hepatitis C infection

          -  No autoimmune hepatitis

          -  Bilirubin no greater than 4 mg/dL (PBC only)

        Cardiovascular: No severe cardiopulmonary disease

        Other:

          -  No concurrent advanced malignancy

          -  At least 3 months since prior inflammatory bowel disease requiring specific treatment
             except maintenance therapy (PSC only)

          -  No anticipated need for transplantation within 1 year

          -  Not pregnant

          -  No liver disease of other etiology such as:

        Chronic alcoholic liver disease

        Hemochromatosis

        Wilson's disease

        Congenital biliary disease

        Cholangiocarcinoma

        No recurrent ascending cholangitis requiring hospitalization more than 2 times per year
        (PSC only)

        At least 1 year since prior active peptic ulcer

        No recurrent variceal bleeds

        No spontaneous encephalopathy

        No diuretic-resistant ascites",Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis,0
"A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.",Persistent infection with mild hepatitis that is non-progressive.,Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies,0
"A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","-  INCLUSION CRITERIA:

        Patients who have recovered from past HCV exposure (positive anti-HCV but negative HCV
        viremia and absent liver disease).

        Patients with asymptomatic HCV infection (positive anti-HCV and HCV viremia, but
        persistently normal or minimally elevated ALT and normal or mild disease on liver biopsy).

        Patients with active liver disease (positive anti-HCV and HCV viremia, persistently
        elevated ALT and/or moderate disease on liver biopsy).

        Patients with active extrahepatic manifestations of HCV infection (cryoglobulinemia,
        glomerulonephritis, vasculitis, etc.).

        Patients with rapidly progressive, severe liver disease and/or hepatocellular carcinoma.

        Patients who have undergone or are undergoing treatment.

        Patients from a single-source outbreak of HCV infections (in which the viral factors should
        be identical and the patients are often from a homogeneous population with less genetic
        variability).

        HCV infected family members and twins.

        Patients with other forms of liver disease including HBV infection, primary biliary
        cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, hemochromatosis, and
        Wilson's Disease, as well as normal volunteers.

        EXCLUSION CRITERIA:

        Adult subjects with a Hct of less than 30 or pediatric subjects less than 25 will be
        excluded.

        Children with HCV infection younger than 2 years of age will be excluded.

        Unaffected healthy volunteers who are minors are not eligible for this study.",Genetics of Hepatitis C Virus Infection,0
"The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow:
BP: 135/80
RR: 25/min
HR: 75 bpm
BMI: 40
O2sat: 90%",Men and women who were cigarette smokers and between the ages of 35 and 60.,Lung Health Study (LHS) I and III,2
"The patient is a 33-year-old woman complained of fatigue, weight gain and abnormal spotting between menses. No hirsutism or nipple discharge was detected. Her BMI was 34. Her lab results were remarkable for high TSH level (13 mU/L) and low free T4 level (0.2 ng/dl). Her anti-TPO levels were extremely high (120 IU/ml). She was diagnosed with Hashimoto's thyroiditis. Her aunt, brother and mother have the same disease. After  starting 250 mcg Levothyroxine per day, her symptoms improved significantly and her periods are normal. She is still overweight with BMI of 31. Her most recent thyroid profile revealed all results except for anti-TPO within the normal range:
TSH: 2.35 mU/L
Free T4: 2.7 ng/dl
Anti-TPO: 75 IU/ml","-  INCLUSION CRITERIA:

        The categories of subjects eligible to participate in this study include:

          1. Patients with known or suspected thyroid abnormalities (e.g. hypothyroidism,
             hyperthyroidism, extreme iodine deficiency, and inherited forms of hypothyroidism
             resulting from abnormalities in the expression of genes coding for the TSH- beta
             subunit, Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS.

          2. Patients with thyroid function test (TFT) abnormalities due to:

               -  Non-thyroidal illness

               -  Abnormalities of serum TH binding proteins leading to euthyroid hyperthyroxinemia
                  or hypotriiodothyronemia.

               -  Genetic deficiency of thyroxine-binding globulin (TBG).

               -  Antibodies to mouse immunoglobulins leading to an artifactual elevation in the
                  TSH ultrasensitive (""3rd generation"") assay which may mimic ""inappropriate""
                  secretion of TSH.

        Inclusion and exclusion criteria for each group of subjects are given below.

        Patients with known or suspected thyroid abnormalities will be eligible to p rticipate if
        the individual meets all of the following criteria:

          1. Stated willingness to comply with all study procedures and availability for the
             duration of the study.

          2. Male or female, aged 6 months+.

        Hyperthyroid states include but are not restricted to:

          1. Graves' disease (GD) thought to result from thyroid-stimulating immunoglobulins
             (TSIg's), a subclass of which also stimulate eye muscle and fatty tissue producing
             exophthalmos (Graves' ophthalmopathy), as well as the skin in the pretibial area
             causing pretibial myxedema (Graves' dermopathy);

          2. Subacute thyroiditis (SAT), a painful inflammation thought to result from viral
             infection with Coxsackie, as well as other viruses;

          3. Silent thyroiditis, a painless inflammation thought to result from autoimmune attack
             of thyrocytes by antimicrosomal antibodies directed against thyroid peroxidase (TPO),
             as well as antithyroglobulin(anti-Tg) antibodies;

          4. Single or multiple hyperfunctioning thyroid nodules of unknown etiology, probably
             resulting from the activation of certain thyroid oncogenes and/or growth factors, such
             as the thyrotropin (TSH) receptor (TSHR) and the a-subunit of the G protein (Ga);

          5. Iodide-induced hyperthyroidism of unknown etiology;

          6. Surreptitious administration of thyroid hormone (TH), usually present in patients with
             underlying psychiatric disease or occasionally related to patients with obesity and
             other eating disorders

          7. Trophoblastic neoplasms, thought to result from high levels of hCG secretion, which,
             because of its structural similarity to TSH, causes ""spillover"" of action at the TSHR
             level;

          8. ""Inappropriate"" secretion of TSH, which may be present either in patients with TSH-
             producing pituitary tumors (TSHomas) or from a non-neoplastic cause, i.e. pituitary
             resistance to the action of thyroid hormone (3,4).

        Hypothyroid states include but are not restricted to:

          1. Primary (or thyroidal) hypothyroidism, usually resulting from auto-antibodies to
             thyroid proteins, such as antimicrosomal antibodies to TPO usually associated with
             lymphocytic (Hashimoto's) thyroiditis (HT) or atrophic thyroiditis, or blocking
             antibodies to the TSHR, usually in the context of non-goitrous hypothyroidism;

          2. Secondary (or pituitary) hypothyroidism, usually resulting from tumors of the
             pituitary of non-thyrotropic origin such, as growth hormone (GH)-secreting tumors or
             prolactinomas;

          3. Tertiary (or hypothalamic) hypothyroidism, usually resulting from a deficiency in the
             hypothalamic hormone thyrotropin-releasing hormone (TRH), either of unknown etiology
             or secondary to a pituitary tumor;

          4. Bio-inactive TSH, either relating to an endogenous abnormality of hypothalamic
             hormones or secondary to pituitary tumors (and usually related to abnormal
             glycosylation patterns of the TSH molecule);

          5. Generalized resistance to thyroid hormone (RTH), a disease which has been shown to be
             due to abnormalities in the TH receptor, c-erbA-beta (or TR- beta).

        The above are the principal disorders under study, but we may also investigate other
        abnormalities, such as extreme iodine deficiency, and inherited forms of hypothyroidism
        resulting from abnormalities in the expression of genes coding for the TSH- beta subunit,
        Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS (among others).

        EXCLUSION CRITERIA:

        There are no exclusion criteria for subjects with known or suspected thyroid abnormalities.",Evaluation of Patients With Thyroid Disorders,2
"The patient is a 33-year-old woman complained of fatigue, weight gain and abnormal spotting between menses. No hirsutism or nipple discharge was detected. Her BMI was 34. Her lab results were remarkable for high TSH level (13 mU/L) and low free T4 level (0.2 ng/dl). Her anti-TPO levels were extremely high (120 IU/ml). She was diagnosed with Hashimoto's thyroiditis. Her aunt, brother and mother have the same disease. After  starting 250 mcg Levothyroxine per day, her symptoms improved significantly and her periods are normal. She is still overweight with BMI of 31. Her most recent thyroid profile revealed all results except for anti-TPO within the normal range:
TSH: 2.35 mU/L
Free T4: 2.7 ng/dl
Anti-TPO: 75 IU/ml","Patients greater than or equal to 18 years of age, with well-differentiated, non-medullary
        thyroid cancer, including papillary (including follicular-variant), follicular, and Hurthle
        cell.

        Patients who recently have undergone a total or near-total thyroidectomy and are scheduled
        to undergo initial 131I diagnostic studies and ablation.

        Patients must have evidence of residual thyroid tissue after thyroid surgery confirmed by
        ultrasound or other imaging technique (e.g., a technetium [Tc 99] pertechnetate or thallium
        scan).

        Patients who have undergone thyroidectomy or other thyroid surgery at least 6 weeks prior
        to enrollment.

        All patients who have been sustained on maintenance THST for at least 4 weeks, but not
        longer than 12 weeks after thyroidectomy.

        All patients who have confirmed serum TSH levels less than or equal to 0.5 mU per liter
        within 7 days prior to the first Thyrogen dose, and prior to randomization.

        Female patients of childbearing age must have a negative serum human chorionic gonadotropin
        (HCG) pregnancy test prior to entering the study and within 5 days of any 131I
        administration and must be following an approved method of contraception.

        Patients who are committed to following the protocol requirements as evidenced by providing
        written informed consent.

        Patients for whom a 131I scan is currently contraindicated because withdrawal from THST is
        not an option due to pituitary dysfunction or other compelling medical reasons are
        excluded.

        Patients should not have a concurrent major medical disorder (e.g., documented cardiac
        disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver
        disease or advanced pulmonary disease) who may be too ill to adequately comply with the
        requirements of this study.

        Patients with non-thyroidal conditions known to effect 131I uptake (e.g., congestive heart
        failure, renal failure) are excluded.

        Patients should not have undergone any intravenous water soluble radiographic contrast
        administration within the previous 4 weeks.

        Patients should not have received intrathecal or cholecystographic iodinated contrast agent
        administration within 3 months prior to enrollment.

        Patients should not be taking drugs that affect thyroid or renal function (e.g., renal
        drugs, lithium, or corticosteroids).

        Patients should not be participating in another investigational drug study or in such a
        study within 30 days of their enrollment in this study.

        No patients with a recent history of alcoholism or drug abuse, severe emotional behavioral
        or psychiatric problems who, in the opinion of the investigator, would not be able to
        comply with the requirements of this study.",Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,1
"The patient is a 33-year-old woman complained of fatigue, weight gain and abnormal spotting between menses. No hirsutism or nipple discharge was detected. Her BMI was 34. Her lab results were remarkable for high TSH level (13 mU/L) and low free T4 level (0.2 ng/dl). Her anti-TPO levels were extremely high (120 IU/ml). She was diagnosed with Hashimoto's thyroiditis. Her aunt, brother and mother have the same disease. After  starting 250 mcg Levothyroxine per day, her symptoms improved significantly and her periods are normal. She is still overweight with BMI of 31. Her most recent thyroid profile revealed all results except for anti-TPO within the normal range:
TSH: 2.35 mU/L
Free T4: 2.7 ng/dl
Anti-TPO: 75 IU/ml","INCLUSION CRITERIA:

          -  Women between the ages of 18 and 45 years, who have their reproductive organs.

          -  Excellent health other than a three month history of pelvic pain and documented
             endometriosis at laparoscopy. Chronic medications may be acceptable at the discretion
             of the internist associate investigator (LN). Use of antidepressants, medications for
             migraines and headaches, allergy medications, and treatment of bowel symptoms such as
             irritable bowel disease will be allowed.

          -  Do not desire pregnancy for the duration of the study.

          -  Are using abstinence, mechanical (condoms, diaphragms) or sterilization methods of
             contraception and are willing to continue using them throughout the study.

          -  Willing and able to give informed consent.

          -  Willing and able to comply with study requirements.

          -  Less than grade III overweight or BMI less than 40 kg/m(2).

        EXCLUSION CRITERIA:

          -  Women with other causes of chronic pelvic pain including infectious, gastrointestinal,
             musculoskeletal, neurologic or psychiatric.

          -  Significant abnormalities in the physical or laboratory examination including renal
             and liver function more than twice the normal range.

          -  Hysterectomy or bilateral salpingo-oophorectomy.

          -  Pregnancy.

          -  Lactation.

          -  Use of hormonal contraception, selective estrogen receptor modulators, progestins,
             estrogens, steroids, or ovulation induction in the last 3 months.

          -  Other medical or surgical treatment for endometriosis in the last 6 months.

          -  Untreated abnormal pap smear or other gynecologic condition.

          -  History of venous thrombosis events including deep vein thrombosis, pulmonary
             embolism, and retinal vein thrombosis.

          -  Allergy to study drug.

          -  History of stroke, complicated migraine, or documented transient ischemic attack.

          -  Manic depressive illness or untreated major depression.",The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis,0
"The patient is a 33-year-old woman complained of fatigue, weight gain and abnormal spotting between menses. No hirsutism or nipple discharge was detected. Her BMI was 34. Her lab results were remarkable for high TSH level (13 mU/L) and low free T4 level (0.2 ng/dl). Her anti-TPO levels were extremely high (120 IU/ml). She was diagnosed with Hashimoto's thyroiditis. Her aunt, brother and mother have the same disease. After  starting 250 mcg Levothyroxine per day, her symptoms improved significantly and her periods are normal. She is still overweight with BMI of 31. Her most recent thyroid profile revealed all results except for anti-TPO within the normal range:
TSH: 2.35 mU/L
Free T4: 2.7 ng/dl
Anti-TPO: 75 IU/ml","Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of malignancy, with evidence
             of metastatic disease (evaluable disease is adequate), who have not responded to
             standard therapy, who have relapsed, or for whom such therapy is not available

          -  Patients must have a tumor that has been shown to express CEA by immunohistochemical
             techniques or have had an elevated serum CEA > 10 at any point during their disease
             course

          -  Patients must have an anticipated survival of at least 6 months

          -  Patients must be fully informed about their illness and the investigational nature of
             the study protocol (including foreseeable risks and possible side effects), and must
             sign an informed consent

          -  Patients must be ambulatory, with an ECOG performance status of 0 or 1, and must be
             maintaining a reasonable state of nutrition, consistent with weight maintenance

          -  WBC >= 3,000/mm^3

          -  ANC >= 1500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Bilirubin =< 2 x upper limit of normal

          -  SGOT and SGPT =< 4 x upper limit of normal

          -  All patients should have an initial urine analysis; the initial urine analysis for
             eligibility is: proteinuria grade 0, hematuria grade 0, and no abnormal sediment; any
             positive protein including trace values should be evaluated by a 24-hour urine; any
             other abnormality in the sediment or the presence of hematuria should be evaluated by
             a nephrologist for evidence of underlying renal pathology; patients may be eligible if
             the underlying cause of the abnormality is determined to be non-renal

          -  Normal creatinine is defined by creatinine =< 1.5 mg/dL OR creatinine clearance >= 60
             ml/min

          -  At least 6 patients must be HLA-A2 positive for each of cohorts 3, 6, and 7; once the
             HLA-A2 positive quota of 6 has been met, enrollment to that cohort may close at the
             discretion of the principal investigator; there are no HLA phenotype restrictions for
             cohorts 1,2,4, and 5, although phenotyping will be performed on all patients

          -  Vaccinia-nave patients may be enrolled to any cohort

               -  There must be no history of allergy or untoward reaction to prior vaccination
                  with vaccinia virus, for patients on cohorts 4, 5, 6, or 7

          -  Patients for all cohorts should have no evidence of immunocompromise or autoimmunity
             as defined by:

               -  HIV negative by serologic testing; this requirement is due to the potential for
                  an unacceptable high risk of systemic viremia, if live virus vaccine were to be
                  administered to an immunocompromised individual; while similar constructs have
                  been given to HIV positive patients, concern is high for toxicity, particularly
                  with vaccinia

               -  No other diagnosis (past or present) of:

                    -  Altered immune function, including immunodeficiency or history of
                       immunodeficiency; eczema; history of eczema, or other eczematoid skin
                       disorders; or those with acute, chronic or exfoliative skin conditions (e.g.
                       atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other
                       open rashes or wounds; this requirement is due to a potential unacceptable
                       high risk of systemic viremia, if study vaccine were to be administered to
                       an immunocompromised individual

                    -  Any autoimmune disease such as, Addison's disease, Hashimoto's thyroiditis,
                       or systemic lupus erythematous, Sjogren syndrome, scleroderma, myasthenia
                       gravis, Goodpasture syndrome active Grave's disease; this requirement is due
                       to the potential risks of autoimmunity

               -  No prior radiation to > 50% of all nodal groups

               -  No concurrent use of systemic steroids, except for physiologic doses for systemic
                  steroid replacement or local (topical, nasal, or inhaled) steroid use

          -  Patients must have recovered from the reversible side effects of prior therapy

          -  Patients must be willing and able to travel to Georgetown University Hospital for
             treatment and follow-up during therapy and at least monthly thereafter until there is
             evidence of disease progression

          -  Patients must be able to avoid close household contact (close household contacts are
             those who share housing or have close physical contact) with persons with active or a
             history of eczema or other eczematoid skin disorders; those with other acute, chronic
             or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella
             zoster, severe acne, or other open rashes or wounds) until condition resolves;
             pregnant or nursing women; children under 5 years of age; and immunodeficient or
             immunosuppressed persons (by disease or therapy), including HIV infection

        Exclusion Criteria:

          -  Recent major surgery (within 21 days)

          -  Frequent vomiting or severe anorexia

          -  Pregnant or lactating women; this requirement is due to an unacceptable high risk of
             CEA antibody transfer, which may be potentially harmful to the developing fetus or
             infant; (NOTE: women and men enrolled in the study are to practice an effective method
             of birth control for at least six months after their last treatment on protocol)

          -  Serious intercurrent medical illness which would interfere with the ability of the
             patient to carry out the treatment program, including, but not limited to,
             inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active
             diverticulitis

          -  The following therapies are prohibited and may not be administered to patients being
             treated on this protocol: chemotherapy, hormonal therapy, biologic therapy, and
             immunotherapy

          -  Patients must have recovered completely from any reversible toxicity associated with
             their most recent therapy; typically this is 3-4 weeks for patients who most recently
             received cytotoxic therapy except for the nitrosoureas and mitomycin C for which 6
             weeks is needed for recovery

          -  Patients with clinically active brain metastasis, uncontrolled seizure disorders,
             encephalitis, or multiple sclerosis

          -  Patients can not have any history (past or present) of allergy to eggs or egg products

          -  Patients with history of receiving CEA-containing vaccines are excluded from
             enrollment into any of the 8 actual study cohorts; however, patients with metastatic
             disease who have progressed (as defined by objective response criteria for solid
             measurable tumor; tumor marker elevation alone is not sufficient) on a CEA-containing
             vaccine, may be enrolled to this study as they arise if they meet the patient
             eligibility criteria, but will be added-in outside of the eight established cohorts,
             at the currently established safe dose level; additionally, these patients will
             receive only the rF-CEA(6D)-TRICOM vaccine (possibly along with GM-CSF if cohort 7 is
             the currently established safe dose level), but otherwise will be treated according to
             the protocol as any other patient on study; such additional patients will not count
             toward study accrual, determination of primary immunologic endpoints, or the
             determination of the MTD",Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer,0
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"INCLUSION CRITERIA:

        The normal volunteers are obtained through the NIH volunteer program or are NIH employees.
        Normal volunteers are in excellent health and are receiving no chronic medications.

        We now routinely test patients with hypocortisolism or hypercortisolism in our clinic and
        ward.",Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency,0
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"DISEASE CHARACTERISTICS: Previously untreated, histologically proven invasive carcinoma of
        the cervix Eligible histologies: Squamous Adenocarcinoma Adenosquamous Eligible stages:
        Bulky stage IB, i.e.: Exophytic lesions 4 cm or greater in diameter OR Cervix expanded to 4
        cm or greater and presumed clinically to result from cancer No extension beyond cervix
        clinically and by IVP or CT with contrast

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-2 Hematopoietic: WBC
        at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than
        1.5 times normal AST no greater than 3 times normal Alkaline phosphatase no greater than 3
        times normal Renal: Creatinine no greater than 2.0 mg/dL Other: No septicemia or severe
        infection No other concurrent malignancy within the past 5 years except curatively treated
        nonmelanomatous skin cancer and prior malignancy therapy does not contraindicate current
        protocol therapy Suitability for radical hysterectomy and lymphadenectomy required

        PRIOR CONCURRENT THERAPY: No prior therapy for cervical cancer No prior pelvic irradiation",Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer,2
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"DISEASE CHARACTERISTICS: Histologically proven stage IV or recurrent squamous cell,
        adenosquamous, or adenocarcinoma of the uterine cervix including: Lung, liver, lymph node,
        or skin metastases OR Retroperitoneal disease OR Other advanced measurable disease OR
        Positive paraaortic lymph nodes Measurable disease that is beyond the scope of conventional
        radiation therapy or surgery, or recurrent after radiation therapy or surgery Measurable,
        recurrent disease within a previously irradiated field must have increased in size by 100%
        on at least 2 successive scans, MRI, or physical examinations

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not
        specified Hematopoietic: WBC at least 3,000/mm3 OR Absolute neutrophil count at least
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times
        the upper limit of normal (ULN) AST and ALT no greater than 2 times ULN Renal: Creatinine
        no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: No New
        York Heart Association class III/IV heart disease No uncontrolled congestive heart failure
        or angina Pulmonary: No chronic obstructive pulmonary disease Gastrointestinal: No evidence
        of active gastrointestinal bleeding No active peptic ulcer disease No inflammatory bowel
        disease Other: Normal diet required No known active infections HIV negative AIDS-related
        complex (ARC) negative No substance abuse or psychiatric problems No evidence of autoimmune
        disease No other prior invasive malignancy except resected basal cell or squamous cell skin
        cancer Not pregnant or nursing Negative pregnancy test Fertile patients must use effective
        contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: 1 prior biologic therapy allowed At least 4
        weeks since prior biologic therapy Chemotherapy: 1 prior adjuvant chemotherapy regimen
        allowed 1 prior chemotherapy regimen for advanced disease allowed At least 4 weeks since
        prior chemotherapy No concurrent chemotherapy Endocrine therapy: No concurrent steroid
        therapy No concurrent megestrol acetate Radiotherapy: See Disease Characteristics No
        concurrent radiotherapy Surgery: See Disease Characteristics At least 2 weeks since prior
        surgery",Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix,1
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"DISEASE CHARACTERISTICS: Histologically proven stage IB or IIA cervical cancer Squamous
        cell carcinoma Adenosquamous cell carcinoma Adenocarcinoma Pelvic and/or common iliac or
        para-aortic lymph node involvement Undergone a radical hysterectomy, complete pelvic
        lymphadenectomy, and resection of any enlarged common iliac or para-aortic lymph nodes No
        clear cell carcinoma or small cell carcinoma with neuroendocrine differentiation Resectable
        disease

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: WBC at least 3500/mm3 Platelet count at least 100,000/mm3 Hepatic:
        Bilirubin no greater than 14.6 mg/dL Renal: Creatinine no greater than 1.356 mg/dL
        Creatinine clearance at least 60 mL/min Pulmonary: Maximum breathing capacity at least 30
        L/min FEV1 at least 1.0 L No signs of respiratory insufficiency Other: No potentially
        active site of infection (e.g., fistula or abscesses) No prior or concurrent second
        malignancy except adequately treated basal cell carcinoma of the skin

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: Not specified Radiotherapy: No preoperative external radiotherapy
        Surgery: See Disease Characteristics",Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer,1
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"Inclusion Criteria:

          -  Cytologically confirmed atypical glandular cells of undetermined significance (AGUS)

          -  Must be scheduled to undergo complete histologic examination of the cervix by cone
             biopsy using loop electrosurgical excision procedure with an endocervical curettage,
             excisional cone biopsy with or without endocervical curettage, or hysterectomy within
             6 months of the initial cytologic diagnosis of AGUS

          -  No history of endometrial hyperplasia

          -  No history of cancer of the endometrium, vagina, or cervix

          -  HIV negative

          -  No pregnant patients who are at high risk for excessive bleeding or preterm labor if a
             cone biopsy is performed

          -  No prior cytotoxic chemotherapy for vaginal and/or cervical cancer

          -  No prior radiotherapy to the vagina or cervix

          -  No concurrent radiotherapy to the vagina or cervix

          -  No prior hysterectomy",Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer,1
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"DISEASE CHARACTERISTICS: Diagnosis of abnormal Pap test, as indicated by one of the
        following: Atypical squamous cells of undetermined significance (ASCUS) Low grade squamous
        intraepithelial lesion (LGSIL) High grade squamous intraepithelial lesion (HGSIL) Visible
        lesion on cervix by colposcopy

        PATIENT CHARACTERISTICS: Age: Any age Performance status: ECOG 0-4 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:
        Pregnant or nursing women allowed

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: Not specified Radiotherapy: No prior pelvic irradiation Surgery: No
        prior total hysterectomy",Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results,2
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"Inclusion Criteria

        Women may be eligible for this study if they:

          -  Are HIV-positive.

          -  Are at least 13 years of age and menstruating.

          -  Are willing to enroll in another drug study.

          -  Have written consent of a parent or guardian if under 18 years.

          -  This study has been changed to increase enrollment. Women who are starting HAART-based
             therapy prescribed by a personal physician or participating in an antiretroviral trial
             are all eligible.

          -  Intend to start antiretroviral therapy within 14 days of study entry.

        Exclusion Criteria

        Women will not be eligible for this study if they:

          -  Have been on anti-HIV treatment for more than 14 days.

          -  Are abusing drugs or alcohol.

          -  Are receiving medication that affects the immune system, fights HPV, or is
             investigational, except for anti-HIV drugs provided by coenrolling in a Phase II or
             III trial with approval of a study chair within 30 days of study entry, including but
             not limited to systemic interferons and interleukins, thalidomide, systemic cidofovir,
             and HPV vaccines. This study has been changed. The following medications are no longer
             excluded: thymopentin, hydroxyurea, granulocyte colony-stimulating factor (G-CSF and
             filgrastim), and GM-CSF (sargramostim).

          -  Have cervical cancer or a history of cervical cancer.

          -  Have had a hysterectomy (removal of the uterus).

          -  Participated in HPV trials at any time.

          -  Use imiquimod inside the vagina.

          -  Are taking corticosteroid treatment in large doses.",The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women,1
The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and   four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.,"DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed stage IIB-IVA carcinoma of the cervix

               -  Adenocarcinoma

               -  Squamous cell carcinoma

               -  Mixed cell histology

               -  No small cell anaplastic histology

          -  No para-aortic lymph node involvement

               -  No indication for para-aortic radiotherapy

          -  No distant metastases

          -  No CNS disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  More than 3 months

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 7.0 mmol/L (approximately 11 g/dL)

          -  Epoetin alfa and/or transfusion allowed

        Hepatic:

          -  Not specified

        Renal:

          -  Glomerular filtration rate at least 60 mL/min

        Cardiovascular:

          -  No myocardial infarction within the past 6 months

          -  No unstable angina

          -  No congestive heart failure with expected inability to tolerate fluid load

          -  No cerebrovascular accident within the past 6 months

        Other:

          -  No pacemaker and/or metal implants

          -  No active uncontrolled infection

          -  No compromised immune status

          -  No psychosis

          -  No other prior malignancy except nonmelanoma skin cancer

          -  No mental or other physical inability that would preclude study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy

        Surgery:

          -  No prior surgery","Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer",1
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","High Risk Protocol: Patients with small non-cleaved (Burkitt or Burkitt-like) or diffuse
        large cell lymphomas except those with:

        a) Minimal extra-abdominal tumor as the sole site of disease and a serum LDH less than 1.5
        times the upper limit of normal (NIH patients, less than 350 U/L) or except those with b)
        completely resected small, localized abdominal mass (involved segmental lymph nodes
        permitted) and a serum LDH level less than 1.5 times upper limit of normal (NIH patients
        less than 350 U/L).

        All patients with small non-cleaved (Burkitt or Burkitt-like) or diffuse large cell
        lymphomas with a serum LDH level greater than 1.5 times the upper limit of normal (NIH
        patients, greater than 350 U/L), regardless of the clinically documented extent of disease.

        All patients with small non-cleaved (Burkitt or Burkitt-like) or diffuse large cell
        lymphomas with testicular involvement.

        Low risk protocol: Patients with small non-cleaved (Burkitt or Burkitt-like) or diffuse
        large cell lymphomas with a) minimal extra-abdominal disease as the sole site of disease
        and a serum LDH less than 1.5 times the upper limit of normal (NIH patients, less than 350
        U/L) or b) completely resected small, localized abdominal mass (involved segmental lymph
        nodes permitted for gastrointestinal disease) and a serum LDH level less than 1.5 times the
        upper limit of normal (NIH patients, less than 350 U/L).

        No patients with lymphoblastic lymphomas, low grade or follicular lymphomas.

        No patients with peripheral T cell lymphomas that do not fall into the category of
        anaplastic large cell lymphoma.

        No patients with a previously documented lymphoma or histological evidence of co-existing
        lymphoma of other histology.

        No patients who have been previously treated with chemotherapy or radiotherapy.

        No patients with HIV infection.

        No patients above the age of 60 years.

        No patients with a history of inherited or non-HIV acquired immunodeficiency syndromes.",Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","DISEASE CHARACTERISTICS:

        Biopsy proven squamous cell carcinoma of the following head and neck sites:

        Hypopharynx Oral cavity Larynx Oropharynx Nasal cavity Unknown primary Paranasal sinus

        Histologically proven poorly-differentiated carcinoma of the following head and neck sites:

        Hypopharynx Oral cavity Larynx Oropharynx Nasal cavity Paranasal sinus Stage III/IV (T0-4
        N1-3 M0-2) disease

        PATIENT CHARACTERISTICS:

        WBC at least 3,000/mm3 Bilirubin no greater than 2.0 mg/dL AST no greater than 100 U/L
        Creatinine no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min (patients in
        Group N2-N3) No second malignancy within 5 years except curatively treated nonmelanomatous
        skin carcinoma No prior RT or chemotherapy, except prior radiotherapy to primary tumor
        allowed Not pregnant or nursing. Negative pregnancy test required Effective contraception
        required of fertile women Subjects with unknown primary cancers who had metastatic cervical
        lymph nodes are eligible Signed informed consent previously approved by the Institutional
        Review Board.",Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","Inclusion Criteria

          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Adequate organ function as defined by a white blood cell (WBC) count of 4,000/L; a
             platelet count of 100,000/L; a Hemoglobin level of 10 g/dL; a serum creatinine of 1.5
             mg/dL or creatinine clearance of 60 mL/min; and a direct bilirubin level of 1.5 mg/dL.

          -  Forced expiratory volume at 1 second more than 2.0 L or 75% of predicted for height
             and age from pre-enrollment pulmonary function testing.

          -  No history or evidence of cardiac disease on ECG

          -  No prior systemic treatment for RCC, but patients may have received prior locoregional
             radiation therapy to solitary resectable metastases, which must have undergone
             surgical resection before enrollment.

          -  No prior history of invasive malignancy in the past 5 years

          -  Human immunodeficiency virus (HIV) negative

          -  Female patients must not be pregnant or planning to become pregnant

        Exclusion criteria

         Age younger than 16",Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","Inclusion Criteria:

          -  Previously treated non-Hodgkin's lymphoma (all histologies except lymphoblastic and
             Burkitt's lymphoma) or Hodgkin's disease

          -  Maximum of 4 previous treatment regimens

          -  Measurable disease

          -  No CNS involvement

          -  Performance status - Zubrod 0-1

          -  Performance status - Karnofsky 80-100%

          -  At least 12 weeks

          -  Platelet count at least 75,000/mm^3

          -  Absolute neutrophil count greater than 1500/mm^3

          -  Lymphocyte count greater than 500/mm^3

          -  Hemoglobin at least 8.0 g/dL

          -  Bilirubin less than 1.5 mg/dL

          -  SGOT/SGPT less than 2 times normal

          -  Creatinine no greater than 1.6 mg/dL

          -  Creatinine clearance at least 60 mL/min

          -  No severe cardiovascular disease including active ischemic heart disease, congestive
             heart failure, or major arrhythmias

          -  No severe pulmonary disease including dyspnea with moderate to severe exertion

          -  HIV negative

          -  No active infection

          -  Not pregnant or nursing

          -  Fertile patients must use adequate contraception

          -  No clinically significant autoimmune disease (e.g. rheumatoid arthritis)

          -  No clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer

          -  No prior allogeneic bone marrow or stem cell transplant

          -  At least 3 weeks since prior biologic therapy for lymphoma

          -  At least 3 weeks since prior chemotherapy for lymphoma

          -  No concurrent steroid therapy

          -  At least 3 weeks since prior endocrine therapy for lymphoma

          -  At least 3 weeks since prior radiotherapy for lymphoma

          -  At least 2 weeks since prior surgery",Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","DISEASE CHARACTERISTICS: Histologically proven high risk Ewing's family of tumors: Ewing's
        sarcoma of bone Extraosseous Ewing's sarcoma Peripheral neuroepithelioma Must have one of
        the following characteristics: Metastatic disease at diagnosis Primary tumor of the
        humerus, femur, or trunk Bulky (greater than 8 cm) tumor Elevated LDH prior to biopsy (at
        least 900 IU/mL)

        PATIENT CHARACTERISTICS: Age: 3 to 60 Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: Granulocyte count at least 500/mm3 Platelet count at least
        75,000/mm3 Hemoglobin at least 8 g/dL (transfusion allowed) Hepatic: Bilirubin no greater
        than 1.5 mg/dL SGOT or SGPT no greater than 3 times normal Renal: BUN less than 30 mg/dL
        Creatinine no greater than 1.5 times normal for age OR Creatinine clearance at least 70
        mL/min Cardiovascular: Ejection fraction at least 50% OR Fractional shortening at least 29%
        Other: Not pregnant or nursing Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
        specified",Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","DISEASE CHARACTERISTICS: Diagnosis of non-Hodgkin's lymphoma, Hodgkin's disease, breast
        cancer, or other solid tumors with eligibility for FHCRC/PSOC protocols involving
        autologous peripheral blood stem cell transplantation No evidence of bone marrow disease No
        pericardial effusion, pleural effusion, or ascites No CNS involvement Hormone receptor
        status: Not specified

        PATIENT CHARACTERISTICS: Age: 70 and under Menopausal status: Not specified Performance
        status: Not specified Life expectancy: Not specified Hematopoietic: Absolute neutrophil
        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater
        than 2.5 times upper limit of normal (ULN) SGOT no greater than 2.5 times ULN Renal:
        Creatinine no greater than 2.0 mg/dL No medically unmanageable, severe hypokalemia
        Cardiovascular: No history of atrial arrhythmia or congestive heart failure No history of
        thromboembolic disease, except successfully treated catheter related thrombosis LVEF at
        least 45% Other: No active infection requiring systemic antibiotics HIV negative No known
        allergy to murine or E. coli proteins No documented prior anaphylactic reaction to
        interleukin-11 or filgrastim (G-CSF) No papilledema No history of Factor V Leiden defect,
        factor II, antithrombin III, Protein C or Protein S deficiencies Not pregnant or nursing
        Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: No
        prior cumulative dose of doxorubicin greater than 300 mg/m2 At least 3 weeks since prior
        chemotherapy Endocrine therapy: No concurrent estrogen supplementation Radiotherapy: No
        prior radiotherapy to the pelvic area Surgery: Not specified Other: No chronic diuretic
        therapy At least 1 week since prior aspirin or anticoagulants except low dose
        anticoagulation to prevent catheter thrombosis","Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors",0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Clinically diagnosed E. coli-associated diarrhea-associated hemolytic uremic syndrome
             (HUS)

          -  Diarrheal prodrome within 7 days before onset of disease

          -  No HUS associated with the following: Hereditary Post-bone marrow transplantation
             Streptococcus pneumoniae infection

          -  No prior catastrophic complications

        --Patient Characteristics--

          -  Hematopoietic: Thrombocytopenia less than 140,000/mm3 Fragmented red blood cells

          -  Renal: Renal involvement (hematuria, proteinuria, or azotemia) No underlying
             glomerular disease

          -  Other: HIV negative No pre-existing structural abnormality or dysmotility syndrome of
             the gastrointestinal tract No inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis)",Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome,2
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Diagnosis of stable, persistent lactic acidemia Venous lactate at least 3 mM under
             basal conditions defined as: At least 4 hours postprandial No concurrent illness

        OR

          -  Diagnosis of cerebral lactic acidemia with elevated lactic acid in CSF but not in the
             blood

          -  No organic acidemias or defective gluconeogenesis

        --Patient Characteristics--

          -  Hematopoietic: Hemoglobin at least 7 mg/dL

          -  Hepatic: Bilirubin no greater than 3 times upper limit of normal (ULN) AST, ALT, or
             GGT no greater than 10 times ULN

          -  Renal: Creatinine no greater than 2 mg/dL

          -  Cardiovascular: Ejection fraction at least 25%

          -  Other: No hypoglycemia (blood sugar less than 50 mg/dL at no greater than 12 hours
             fasting) No severe peripheral neuropathy interfering with normal activities of living",Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","Inclusion Criteria:

          -  Minimum weight of 40 kg.

          -  Diagnosis of WG, excluding infections, malignancies, systemic autoimmune disorders,
             and other forms of vasculitis that may mimic WG.

          -  At least two of the five modified American College of Rheumatology (ACR) criteria for
             a diagnosis of WG. The modified ACR criteria are: (1) nasal or oral inflammation,
             defined as the development of painful or painless oral ulcers or purulent or bloody
             nasal discharge; (2) abnormal chest radiograph, defined as the presence of nodules,
             fixed infiltrates, or cavities; (3) active urinary sediment, defined as microscopic
             hematuria (> 5 red blood cells per high-power field) or red blood cell casts; (4)
             granulomatous inflammation on biopsy, defined as histologic changes showing
             granulomatous inflammation within the wall of an artery or in the perivascular or
             extravascular area (artery or arteriole); and (5) positive serum ELISA for ANCAs
             (anti-neutrophil cytoplasmic antibodies) directed at PR-3.

          -  Birmingham Vasculitis Activity Score (BVAS) score 3 or greater within 28 days of
             randomization. This may include either the presence of one or more major items (3
             points each) or the presence of three or more minor items (1 point each).

          -  Willingness and ability, with the assistance of a caregiver if necessary, to comply
             with treatment and followup procedures.

          -  Willingness of men and women of childbearing potential to practice an adequate method
             of birth control during the study and for 3 months afterwards.

          -  Willingness to limit alcohol consumption to one alcoholic drink per week while taking
             methotrexate.

          -  Willingness to refrain from breast-feeding during the study and for 3 months
             afterwards.

          -  Collection of all baseline data within 14 days prior to randomization.

          -  Signed consent statement.

        Exclusion Criteria:

          -  Presence of an active systemic infection.

          -  White blood cell count less than 4,000/mm cubed or a platelet count less than
             120,000/mm cubed.

          -  Creatinine greater than 2.0 mg/dL secondary to non-WG causes (e.g., hypertensive
             nephropathy) for a patient with limited disease.

          -  Known acute or chronic liver disease.

          -  History of multiple sclerosis or other neurological symptoms suggesting a
             demyelinating syndrome.

          -  Current evidence of malignancy or malignancy diagnosed within 5 years of study entry.
             Patients with squamous or basal cell carcinomas of the skin may be enrolled if they
             have received curative surgical treatment.

          -  Positive serum pregnancy test for women of childbearing potential.

          -  Previous treatment with specific therapies directed against tumor necrosis factor,
             e.g., etanercept or infliximab.",Etanercept for Wegener's Granulomatosis,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","Inclusion Criteria:

          -  Patients must have:

               -  AML, ALL, or high-risk MDS (RAEB or RAEB-t) that has:

                    -  Not responded (no CR) to initial induction chemotherapy, or

                    -  Recurred after an initial CR of < 1 year, or

                    -  Recurred after an initial CR of > 1 year and failed to respond to an initial
                       reinduction attempt, or

                    -  Recurred more than once, or

               -  Chronic myeloid leukemia in myeloid blast phase

                    -  Patients with CML blast phase may receive BMS-214662 as their first therapy
                       for blast phase or after failing other treatments for blast phase

               -  Patients with refractory or relapsed acute promyelocytic leukemia are eligible
                  provided they have failed an ATRA-containing regimen

          -  Performance status of =< 0-2

          -  Signed informed consent indicating that patients are aware of the investigational
             nature of this study in keeping with the policies of the hospital

          -  Patients must have been off chemotherapy for the 4 weeks prior to entering this study
             and recovered from the toxic effects of that therapy; patients with evidence of
             rapidly progressive disease (i.e., absolute peripheral blood blast count >= 5 x 10^9/L
             and increasing by >= 1 x 10^9/L/24 hours) may receive treatment before 4 weeks from
             the previous treatment providing they have recovered from all toxic effects of that
             therapy; use of hydroxyurea on patients with rapidly proliferative disease is allowed
             up to 24 hours prior to the start of therapy

          -  Bilirubin =< 1.5 mg/dL

          -  Creatinine =< 1.5 mg/dL or creatinine clearance >= 60 mL/hr

          -  Patients who are likely to benefit from allogeneic bone marrow transplantation (i.e.,
             age < 60 years of physiological age with histocompatible donor) should be excluded
             from this study unless such therapy is not feasible

        Exclusion Criteria:

          -  Pregnant and nursing females will be excluded; patients of childbearing potential
             should practice effective methods of contraception

          -  Patients with prolonged QTc interval on EKG are excluded","BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia",0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","PATIENTS WITH NORMAL ADRENAL GLANDS:

        Patients with normal adrenal glands will be recruited from those studied under NCI
        protocols.

        They will not have taken suppressive doses of glucocorticoids for 12 months, and will not
        have any known adrenal pathology, either of the cortex or medulla.

        They will not have Von-Hippel Lindau syndrome.

        PATIENTS WITH ACTH-INDEPENDENT CUSHING'S SYNDROME:

        Will be aged 18 or older;

        Will have plasma ACTH levels of 10 pg/mL or less;

        Will have an outside physician who will follow them after surgery.

        Must not weigh greater than 380 pounds. These patients are unable to undergo CT scans.

        Must not have a CT scan showing normal or atrophic bilateral adrenal glands.

        Must not have a CRH test showing a response as defined above. The diagnosis of these
        patients will need further evaluation.

        Must not have any condition that would preclude surgery, including advanced heart failure,
        significant coronary artery disease, severe pulmonary disease.

        Must not have a hematocrit less than 30 or research blood withdraw greater than 450 mL in
        the previous six weeks.

        Must not be pregnant.

        Must not have a history of angina or known coronary artery disease, because these patients
        are at risk for exacerbation during the vasopressin test.

        The SF-36 questionnaire will only be given to individuals who speak and read English
        fluently. Patients may participate in the remainder of the study, however, if they do not
        meet this criterion.",Study of Cushing's Syndrome Not Related to ACTH Production,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed supratentorial glioblastoma multiforme by surgical biopsy or
             resection within 5 weeks of study

          -  Postoperative residual contrast enhancing tumor and resection tumor cavity together no
             greater than 60 mm in maximum diameter

          -  No well-differentiated or anaplastic astrocytomas or multifocal glioma

          -  No tumors originating in the brainstem

          -  No residual tumor within 10 mm of optic chiasm

          -  No recurrent glioblastoma multiforme

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Zubrod 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Hemoglobin greater than 9 g/dL

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL

          -  Serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate
             transaminase (SGOT) less than 2 times normal

        Renal:

          -  Creatinine less than 1.8 mg/dL

          -  Blood urea nitrogen (BUN) less than 30 mg/dL

        Pulmonary:

          -  Chest x-ray normal OR

          -  Diffusion capacity of lung for carbon monoxide (DLCO) greater than 60% predicted

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Neurologic functional status 0-3

          -  No other prior malignancy within the past 5 years except carcinoma in situ of the
             cervix or bladder, ductal carcinoma in situ of the breast, or nonmelanomatous skin
             cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Concurrent steroids allowed

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics

        Other:

          -  Concurrent anticonvulsants allowed",Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme,0
"A 17 year old boy  complains of vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset. Physical exam was remarkable for pallor, jaundice, and diffuse abdominal tenderness. Lab results were as follows:
Hemoglobin: 9.7 g/dL
Platelet: 110,000 /cu.mm
Creatinine: 3.6 mg/dL
blood urea nitrogen (BUN): 73 mg/dL
direct bilirubin: 2.4 mg/dL
lactate dehydrogenase (LDH): 881 IU/L (normal: 110-265 IU/L)
Peripheral blood smear showed a moderate number of schistocytes and helmet cells.  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 were found in stools. 
He has no other underlying disease and he is not on any medications.","-  INCLUSION CRITERIA:

        Aggressive CD20 positive Diffuse Large B-cell lymphoma confirmed by Laboratory of
        Pathology, NCI. Note: Participants with aggressive B-cell lymphoma of the plasmablastic
        lymphoma sub-type who do not have surface CD20 expression, are also eligible.

        HIV + serology.

        All stages (I-IV) of disease.

        ECOG Performance status 0-4

        NHL previously untreated with cytotoxic chemotherapy; however, participants may be entered
        if they have had prior cyclophosphamide for an urgent problem at diagnosis (e.g. epidural
        cord compression, superior vena cava syndrome) and/or a single dose of intrathecal
        methotrexte (MTX) at the time of the pre-treatment diagnostic lumbar puncture

        Age greater than or equal to 18 years

        Laboratory tests (unless impairment due to respective organ involvement by tumor):

          -  Creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than or
             equal to 50 ml/min

          -  Bilirubin less than 2.0 mg/dl, or total bilirubin less than or equal to 4.5 mg/dl with
             direct fraction less than or equal to 0.3 mg/dl in participants for whom these
             abnormalities are felt to be due to protease inhibitor therapy

          -  AST and ALT less than or equal to 3x ULN (AST and ALT less than or equal to 6x ULN for
             participants on hyperalimentation for whom these abnormalities are felt to be due to
             the hyperalimentation)

          -  ANC greater than or equal to 1000/mm(3)

          -  Platelet greater than or equal to 75,000/mm(3) (unless impairment due to ITP)

        Ability of participant to provide informed consent.

        EXCLUSION CRITERIA:

        Previous rituximab

        Pregnancy or nursing.

        - Doxorubicin, etoposide, vincristine and cyclophosphamide are teratogenic and may be
        excreted in milk.

        Current clinical heart failure or symptomatic ischemic heart disease.

        Serious underlying medical condition or infection other than HIV that would contraindicate
        SC-EPOCH-R.

          -  Examples include, but are not limited to:

          -  Severe AIDS-related wasting

          -  Sever intractable diarrhea

          -  Active inadequately treated opportunistic infection of the CNS

          -  Primary CNS lymphoma

        Primary CNS lymphoma",EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection,0
A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine  this  year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.,"Inclusion Criteria

        Patients may be eligible for the main study if they:

          -  Became infected with HIV within the last 120 days.

          -  Are at least age 16 and have written consent of a parent or guardian if under 18.

          -  Are willing to practice abstinence or use barrier methods of birth control, such as
             condoms.

          -  Are available for at least 72 weeks.

          -  Patients may be eligible for 1 of the 2 substudies if they:

          -  Are at least age 16 and have written consent of a parent or guardian if under 18.

          -  Have had HIV infection for more than 1 year and have a CD4 cell count greater than 500
             cells/mm3, or do not have HIV infection but are at risk of getting HIV because of
             their lifestyle, such as sexual activity or injection drug use.

          -  Have never had hepatitis B infection or a hepatitis B vaccine and they are available
             for 28 weeks (hepatitis B vaccine substudy only).

          -  Have not received a tetanus shot in the past 5 years, have never had an allergic
             reaction to a tetanus shot, and are available for 8 weeks (tetanus shot substudy
             only).

        Exclusion Criteria

        Patients will not be eligible for the main study if they:

          -  Have taken anti-HIV drugs for more than 7 days for the treatment of HIV. However,
             anti-HIV drugs taken to help prevent HIV are acceptable.

          -  Have certain types of cancer.

          -  Are receiving an experimental treatment.

          -  Are pregnant or breast-feeding.

          -  Are allergic to study drugs.

          -  Have taken certain medications that may interfere with the study.

          -  Patients will not be eligible for 1 of the 2 substudies if they:

          -  Are receiving an experimental treatment.

          -  Are pregnant or breast-feeding.",Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV,0
A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine  this  year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.,"-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine  this  year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.,"Inclusion Criteria:

          1. Women age 18 to 55 years

          2. Regular menstrual cycles of 21- to 35-days duration

          3. Pathologic stages I to II breast cancer, in whom all gross disease-including ductal
             carcinoma in situ-was surgically removed either in a one-stage or two-stage procedure.

          4. required serum be drawn within 1 calendar day of the lumpectomy/mastectomy for women
             who underwent a one-stage procedure and within 1 calendar day of each stage for women
             who underwent a two-stage procedure.

        Exclusion Criteria:

          1. Lactation within the past 3 months

          2. galactorrhea

          3. neoadjuvant therapy

          4. previous breast cancer, and history of any cancer (except squamous or basal cell skin
             carcinoma) in which the patient was not disease-free for at least 10 years",Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer,0
A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine  this  year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.,"Inclusion Criteria:

        Volunteers may be eligible for this trial if they:

          -  Are able to and have given informed consent.

          -  Are able to understand and comply with all study procedures and to complete study
             diary.

          -  Are aged 18 to 49 years.

          -  Are female, and are not pregnant.

          -  Are available for all study visits.

        Exclusion Criteria:

        Volunteers will not be eligible for this trial if they:

          -  Are allergic to eggs or egg products.

          -  Have a current chronic medical condition for which influenza vaccine is normally
             recommended.

          -  Have received experimental vaccines or medications within 30 days of study entry.

          -  Have received parenteral immunoglobulin within 30 days of study entry.",Half-Dose Flu Vaccine Study in Healthy Adults,2
A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine  this  year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.,"-  ELIGIBILITY CRITERIA:

        Inclusion Criteria - Menstrual Cycle Study:

        To participate in the Menstrual Cycle Pilot Study, a woman must:

        Must be at least 25 years of age (or 5 years younger than the age at diagnosis of the
        youngest family member with a tumor associated with the Breast-Ovarian Cancer Syndrome) and
        less than 46 years of age.

        Must be premenopausal as determined by menstrual history (no change in menstrual pattern in
        prior 6 months) and an FSH level less than 15 mIU/ml obtained on the third day of the
        menstrual cycle.

        Have undergone genetic counseling and risk assessment.

        Must be a known mutation carrier or be a first- or second-degree relative of an individual
        with a tumor associated with the Breast-Ovarian Cancer Syndrome in a family with a known
        BRCA mutation.

        Agree to release of genetic test result for stratification purposes, whether or not she has
        chosen to receive individual test results for clinical decision-making.

        Be willing to use non-hormonal methods of contraception until completion of the 3 month
        follow-up studies.

        Have an ECOG performance status of 0-1.

        Be able to provide informed consent.

        Exclusion Criteria - Menstrual Cycle Study:

        Any of the following will result in exclusion from the Menstrual Cycle Pilot Study:

        A history of menstrual cycle irregularities over the previous 6 months, including history
        of cycles less than 26 days or more than 35 days.

        Steroid therapy, use of selective estrogen receptor modulators (SERMs) or hormonal agents
        (including tamoxifen, raloxifene, estrogen, DHEA, anabolic steroids, oral contraceptives,
        depoprovera, progestin IUD, oral progestins, norplant, or drugs to induce ovulation) within
        6 months prior to study entry and must agree not to use these compounds until completion of
        the three-month follow-up study.

        Pregnancy or lactation within 12 months of enrollment.

        History of infertility with a suspected ovarian etiology or persistent ovarian cyst.

        Abnormal CA-125 level.

        History of invasive cancer except for non-melanoma skin cancer or cervical carcinoma in
        situ.

        Creatinine greater than 2.

        Previous bilateral mastectomy, bilateral radiation therapy to the breast, or oophorectomy.

        History of DCIS or LCIS .

        Weight over 136 kilograms.

        Allergy to gadolinium.

        Allergy to lidocaine or Marcaine (bupivacaine) (excluded from breast duct lavage only).

        Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would
        preclude informed consent or ability to participate in clinical research.

        Inclusion Criteria - Training Cohort:

        To participate in the Training Cohort a volunteer must:

          -  Be female and at least 18 years and less than 51 years of age.

          -  Have at least one breast considered eligible for study.

          -  Provide evidence (either films or radiologist's report) of a mammogram done within the
             12 months prior to enrollment showing low or no suspicion of carcinoma in at least one
             breast. (Mammograms will not be provided to participants as part of the training
             cohort.)

          -  Have a physical examination of the breast to be studied consistent with low or no
             suspicion of carcinoma at the time of enrollment.

          -  Provide the name of a primary care physician to whom the results of breast duct lavage
             cytologies can be sent.

          -  Have signed the informed consent for breast duct lavage.

        Exclusion Criteria - Training Cohort:

        Any of the following will exclude a potential participant from the Training Cohort:

          -  Pregnancy or lactation within the past 12 prior to enrollment.

          -  Subareolar or other surgery of the breast to be studied (papilloma resection, biopsy
             or fine needle aspirations which might disrupt the ductal systems within 2 cm of the
             nipple. (Biopsies of fine needle aspirations of the breast greater than or equal to 2
             cm from the nipple are acceptable.)

          -  A breast implant or prior silicone injections in the breast to be studied.

          -  Radiation therapy to a breast to be studied.

          -  Active infections or inflammation in a breast to be studied.

          -  Chemotherapy or a selective estrogen receptor modifier (e.g., tamoxifen or raloxifen)
             taken within 12 months prior to enrollment.

          -  A known allergy to lidocaine, prilocaine or Marcaine (bupivacaine).",Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Inclusion Criteria:

          -  Patient must be ambulatory and relatively good health. Even if unable to work at least
             able to partially care care for self and not demented.

          -  May have been alcoholic or drug abuser 6 months previous.

          -  Unspecified

          -  CD4 Unspecified.

        Exclusion Criteria:

          -  Non ambulatory patients or those requiring extensive help in self care are excluded.

          -  Non ambulatory patients or those requiring extensive help in self care are excluded.

          -  Current alcohol or drug abuse.

          -  Unspecified",Antidepressant Treatment of AIDS Related Depression.,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Inclusion Criteria

        You may be eligible for this study if you:

          -  Are an HIV-positive woman over 13 years old (need consent if under 18).

          -  Have lost weight over the past 12 months.

          -  Are able to eat almost enough to maintain your current weight.

          -  Agree to practice abstinence or use effective methods of birth control.

          -  Are on a stable anti-HIV drug regimen or have not been on any anti-HIV drug regimen
             for the past 30 days.

        Exclusion Criteria

        You will not be eligible for this study if you:

          -  Are allergic to nandrolone.

          -  Have a history of cervical cancer, diabetes, cardiomyopathy or congestive heart
             failure, or are taking certain medications.

          -  Have an active opportunistic (HIV-associated) infection or another major illness
             within 30 days of study entry.

          -  Have an abnormal PAP smear.

          -  Have difficulty eating (are on tube-feeding, for example).

          -  Have severe nausea, vomiting, or diarrhea.

          -  Have Kaposi's sarcoma (unless stable) or are receiving chemotherapy or radiation for
             any type of cancer.

          -  Are pregnant or breast-feeding.",A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are at least 18 years old.

          -  Have sex with or share injection drugs with a person who is thought to have early HIV
             infection, or if they have recently become HIV-positive.

          -  Can provide written consent.

          -  Are available for a follow-up period of at least 4 weeks.",The Biology of HIV Transmission,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","-  INCLUSION CRITERIA:

        The subjects of this study will be women who meet the following criteria:

          -  history within the last two years of at least six months with menstrually-related mood
             or behavioral disturbances of at least moderate severity - that is, disturbances that
             are distinct in appearance and associated with a notable degree of subjective
             distress;

          -  a 30% increase in mean negative mood ratings (relative to the range of the scale
             employed) in the premenstrual week compared with the week following the end of menses
             in at least two of three cycles;

          -  age 18 to 50;

          -  not pregnant and in good medical health;

          -  regular menses.

        For subjects with recurrent brief depression:

          -  dysphoric mood or loss of interest or pleasure;

          -  duration less than two weeks;

          -  four of the following symptoms: poor appetite or significant weight loss (when not
             dieting) or increased appetite or significant weight gain; insomnia or hypersomnia;
             psychomotor agitation or retardation; loss of interest or pleasure in usual
             activities, or decrease in sexual drive; loss of energy; fatigue; feelings of
             worthlessness, self-reproach, or excessive or inappropriate guilt; diminished ability
             to think or concentrate, slowed thinking, or indecisiveness;

          -  impairment in usual occupational activities;

          -  at least one-two episodes per month over one year.

        Age-matched women without mood and behavioral disorders will be recruited.

        EXCLUSION CRITERIA for all study participants:

          -  Subjects should have no general medical illness that is primary (i.e., appears to be
             causing the mood disorder);

          -  Current antidepressant therapy (since this is a screening protocol for subsequent
             treatment and physiologic evaluation studies in which participants must be untreated).
             Antidepressants will not be withheld from participants who need or want them;

          -  Current alcohol or substance use or dependence (excluding nicotine) of sufficient
             magnitude to require independent, concurrent treatment intervention (e.g., antabuse or
             opiate treatment, but not including self-help groups).

          -  Pregnant or lactating women

          -  Subjects who are unable to provide informed consent

          -  NIMH employees/staff and their immediate family members will be excluded from the
             study per NIMH policy.",Study of Premenstrual Syndrome and Premenstrual Dysphoria,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","INCLUSION CRITERIA:

        Patients over the age of 2 who are enrolled in 91-DK-0085, ""Studies of Hyperparathyroidism
        and Related Disorders"", or patients who are undergoing parathyroid localization as part of
        routine patient care while enrolled in other Clinical protocols will be considered for the
        study.

        EXCLUSION CRITERIA:

        Patients will be excluded if:

        There is any contraindication to arteriography.

        The Patient is pregnant.",Using X-Ray Dye to Locate Hidden Parathyroid Tumors,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","-INCLUSION CRITERIA:

        i. Normal Language Development, Hearing and Cognition

        ii. The following screening tests previously published with norms were found to have a good
        distribution for determining normal functioning in adolescents and adults as all subjects
        did not hit ceiling and all had scores greater than or equal to the 80th percentile. These
        tests are being used to ensure that subjects affected with stuttering or FPPD do not have
        other disorders such as hearing loss, language delay, or mental retardation.

        Peabody Picture Vocabulary Test III (PPVT-III)

        Expressive Vocabulary Test (EVT)

        Oral Speech Mechanism Screening Examination

        Revised Token Test; Token test for Children

        Test of Non verbal intelligence (TONI-2)

        Digit Span subtest of the WICS-R

        Audiometric Screening

        Goldman Fristoe Test of Articulation

        WUG Test of Morphological Encoding

        Test of Auditory Comprehension of Language (TACL)

        Khan-Lewis Phonological Analysis

        INCLUSION CRITERIA FOR IDENTIFYING AND QUANTIFYING STUTTERING:

        The Stuttering Severity Index -3 (Riley, 1981) has been found to be accurate for
        identifying and assessing the severity of stuttering during conversational speech. For the
        inclusion of a stuttering subject we require:

        i. A total overall score of 11 or greater between 3 and 17 years,

        ii. A total overall score of 18 or greater from age 18 and above.

        INCLUSION CRITERIA FOR IDENTIFYING FPPD:

        i. A family history of an autosomal dominant pattern of inheritance of the speech disorder
        over several generations with persistence into adulthood in some cases,

        ii. Speech symptoms during conversational speech include: deletion of final consonants;
        syllable reduction and syllable deletion; deletion of grammatical markers such as copulas,
        auxiliaries, prepositions, connectives; poor ability to self-correct; poor awareness of
        errors; and consonant cluster reduction.

        iii. Greater than 9% discourse errors during analysis of a sample of 300 syllables.

        iv. A discrepancy of 30 points (1 and 1/2 Standard Deviations) between receptive (the
        higher score) and expressive percentile score on the PPVT III and Expressive Vocabulary
        Test.

        v. For subjects greater than 7 years of age, a phonological process rating of 3 or more for
        any phonological process on the Khan-Lewis Phonological Analysis. For subjects less than 7
        years of age, a phonological process rating of 3 or more on 2 phonological processes on the
        Khan-Lewis Phonological Analysis. Finally, any subjects with a non developmental
        phonological process error will be identified as potentially having FPPD.

        EXCLUSION CRITERIA:

        i. Anyone with a hearing loss will be excluded from participation during the diagnostic
        testing.

        ii. Children with delayed language, more than 1 year delay from norms on receptive and
        expression language testing will be excluded.

        iii. Language impairment: scores more than 2 standard deviations below the age appropriate
        score on the standardized language tests listed under the inclusion criteria.

        iv. Cognitive impairment: scores more than 2 standard deviations below the age appropriate
        score on the standardized cognitive tests listed under the inclusion criteria.

        v. Bilingual non-native English speakers - Studies have demonstrated that brain
        organization for speech and language may differ in bilingual persons. It is hypothesized
        that this may alter speech motor learning and thus kinematic data from non-native English
        speakers would differ from native English speakers. Therefore, only native-American English
        speakers, with only one language spoken in the home, will be included.",Characteristics of Idiopathic Familial Speech Disorders,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.",People over the age of 50 who have lost their spouse within the last three months.,Consequences of Conjugal Bereavement in Adults,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","-  INCLUSION CRITERIA - DEPRESSED WOMEN:

        The patient is a woman 21 to 45 years old on the date of the initial screening.

        The patient is not postmenopausal.

        She must be willing to practice an acceptable method of birth control, as appropriate (IUD,
        oral contraceptives, diaphragm, condoms, hormonal implants/injection, with the exception of
        subdermal levonorgestrel, sterilization) and have a negative serum pregnancy test at
        screening.

        Women currently on estrogen/progestin contraceptive therapy must have been on a stable
        regimen of estrogen/progestin for at least 6 months prior to enter the study.

        The patient understands the procedures and the risks of the study and has been informed
        that, alternatively, she may freely elect to be treated with the currently available
        treatments by her physician.

        The patient voluntarily agrees to participate in the study.

        INCLUSION CRITERIA RELATED TO THE PSYCHIATRIC STATUS:

        The patient had at least one episode of major depression within the last 3 years (DSM-IV).
        In addition, the subject has a past history (prior to the last 3 years) of at least one
        major depressive episode lasting more than 2 weeks.

        With the exception of depression, the patient is in good health, based on medical history,
        physical examination, and laboratory screening evaluation.

        The patient has a physician; either a family doctor, a psychiatrist, a psychotherapist, or
        another qualified health care professional who can provide medical treatment for
        depression. If the subject is not receiving any medical care for depression, a member of
        the NIH team will help the patient identify one and will work closely with this
        professional during the study.

        The patient can be on pharmacological antidepressant therapy, as medically indicated and
        prescribed by her primary physician or health professional. It is not a requirement of this
        study for subjects to stop antidepressant treatment, unless it is medically indicated for
        reasons such as the medication is ineffective, not well tolerated, or the patient no longer
        needs such treatment. This decision will be based upon their physician's evaluation.

        Patients starting a new antidepressant medication(s) should be on this treatment for 4-6
        weeks prior to enrollment.

        Carbamazepine, valproic acid or thyroid hormones used as adjunctive therapy for treatment
        of depression are allowed.

        Women with a current or recent (within the past 3 years) history of alcohol or drug abuse
        are eligible if, in the opinion of the principal investigator, this condition is not likely
        to impair patient compliance or if the participation in the study does not pose additional
        risks to the subject.

        INCLUSION CRITERIA RELATED TO THE BONE STATUS:

        The patient has spinal anatomy suitable for dual-energy x-ray absorptiometry (DEXA)
        densitometry of the lumbar spine, with no evidence of vertebral fractures in at least three
        vertebrae. Significant scoliosis, bony trauma, osteoarthritis, and sequelae of orthopedic
        procedures that result in anatomy unsuitable for accurate bone densitometry, must be absent
        from the lumbar spine.

        The patient has osteopenia or osteoporosis, as indicated by a bone mineral density at the
        spine that is between 1.5 and 5 standard deviations below peak bone mass, or history of an
        osteoporotic vertebral or hip fracture. Patients whose eligibility is based only on a
        prevalent vertebral fracture will have the fracture confirmed by a radiologist.

        EXCLUSION CRITERIA - DEPRESSED WOMEN:

        GENERAL EXCLUSION CRITERIA:

        The patient is, in the opinion of the investigator, mentally or legally incapacitated such
        that informed consent cannot be obtained.

        Pregnancy or breast-feeding.

        Menopause.

        The patient plans to move within the next 12 months to a location which could impair a
        continued follow-up.

        The patient has a history of or evidence for an illness or has significant abnormalities on
        prestudy clinical or laboratory evaluations, which, in the opinion of the principal
        investigator, might complicate the interpretation of the data or pose additional risk to
        the subject.

        The patient has any of the following medical conditions: any malabsorption syndrome,
        significant genitourinary, renal (serum creatinine greater than or equal to 1.6 mg/dL),
        hepatic, or pulmonary disease; uncontrolled hypertension; uncontrolled diabetes mellitus;
        decompensated heart failure; clinically significant arrhythmias; unstable angina, any
        immunodeficiency syndrome including AIDS.

        The patient has received any drug of investigation within 30 days of the start of the
        study.

        The use of subdermal levonorgestrel and similar preparations.

        EXCLUSION CRITERIA RELATED TO THE PSYCHIATRIC STATUS:

        The patient does not have an outside care provider for treatment of depression.

        The patient is judged to be at suicidal risk, as clinically evident or indicated by a score
        of 4 at the Hamilton Scale, question 3 (suicide), or by reports of suicidal intent during
        SCID-IV interview.

        The patient has a history suggesting potential for self-harm or violence towards others.

        The patient currently has psychotic depression (e.g. hallucinations, delusions).

        The patient has schizoaffective disorder.

        Patients with a diagnosis of active anorexia nervosa, bulimia or any other eating disorder
        are not eligible.

        Patients with a diagnosis of bipolar disorders type 1 or type 2 or any psychotic disorder
        other than psychotic depression are not eligible.

        Women with a current or recent (within the past 3 years) history of alcohol or drug
        dependence are not eligible.

        EXCLUSION CRITERIA RELATED TO THE BONE STATUS OR THE USE OF ALENDRONATE:

        The patient is affected by severe osteoporosis, as indicated by a history of recurrent
        non-traumatic fractures and/or a BMD value which is below 4 SD the peak bone mass at the
        spine and/or the hip.

        The patient has a history of recent major upper gastrointestinal (GI) (esophagus, stomach,
        duodenum) mucosal erosive disease. As defined by (1) significant upper GI bleeding within
        the last year resulting in hospitalization and/or transfusion. (2) Recurrent ulcer disease
        documented by radiographic or endoscopic means (two episodes in the last two years, or any
        documented ulcer in the preceeding 3 months). (3) Uncontrolled dyspepsia currently treated
        on a daily basis. (4) Esophageal or gastric variceal disease or (5) esophageal stricture,
        achalasia, or severe esophageal motor dysfunction. (This only applies to Group C and D)

        The patient has a history of cancer with the following exceptions: (1) superficial basal or
        squamous cell carcinoma of the skin that was treated, and (2) other malignancies treated at
        least 10 years ago without any evidence of recurrence.

        The patient has a history of, or evidence for, metabolic bone disease (other than low bone
        mineral density) including, but not limited to uncontrolled hyper- or hypocalcemia, hyper-
        or hypoparathyroidism, Paget's disease of bone, osteomalacia, or osteogenesis imperfecta.
        Patients with surgically cured hyperparathyrodism due to parathyroid adenoma (at least one
        year prior to randomization) are eligible for inclusion in the trial. Patients with
        well-controlled hyper- or hypothyrodism, as indicated by clinical evaluation and normal
        plasma TSH level are eligible for inclusion in the trial.

        The patient has received treatment prior to enrollment in the study that might have
        influenced bone turnover including:

        Beginning a regimen (for more than 2 consecutive weeks) within the last 6 months, of any
        estrogen preparation including mixed estrogen agonist/antagonist, (e.g., tamoxifen or
        raloxifene) or progestins.

        Having used within the last 6 months any of the following: anabolic steroids (including
        DHEA and other weaker analogs), calcitonin, calcitriol, alfacalcidol, excess vitamin A
        (greater than 10,000 units/day) or vitamin D (greater than 1,000 units/day), cyclosporine,
        or anticonvulsivants.

        The patient is on a thyroid hormone for treatment of a thyroid condition, unless the
        patient has received a stable dose for the last 6 weeks prior to study enrollment, and is
        euthyroid, as documented by an ultrasensitive TSH serum assay.

        The patient is on fluoride at a dose greater than 1 mg/day any time (fluoride taken greater
        than 3 months ago for less than 1 week is acceptable).

        The patient has a history of glucocorticoid treatment for more than 1 month, within 6
        months prior to study start (patients who received therapeutic glucocorticoids in the past
        must be considered unlikely to need glucocorticoid treatment during the course of the
        study).

        Any previous treatment with bisphophonates for more than 2 weeks.

        The patient's screening 25-hydroxyvitamin D level is less than 15 ng/mL unless 24-h urine
        calcium and serum PTH, calcium, and alkaline phosphatase are all within the normal range.

        The patient is not able to stand or sit upright for at least 30 minutes.

        The patient has a body weight greater than 137 kg, due to limitations in the accuracy of
        DEXA measurements above this body weight.

        EXCLUSION CRITERIA RELATED TO THE EXERCISE (COOPER) TEST:

        Subjects on beta-blockers will not be eligible to participate in the 12-min test.

        INCLUSION CRITERIA - HEALTHY CONTROL WOMEN:

        Healthy control women must be of good physical health; specifically, no history of any
        DSM-IV diagnoses, including but not limited to depression and anorexia nervosa.

        They also must have normal bone density, no history of osteoporotic fractures, and be
        willing to be on a valid contraceptive method.

        EXCLUSION CRITERIA - HEALTHY CONTROL WOMEN:

        Control women should not have any of the risk factors for bone loss such as smoking,
        alcohol abuse, dietary imbalances unless the risk factor is present only to a mild extent.",Bone Loss in Premenopausal Women With Depression,0
"The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Participants must be female gender.

        Participants age must be 45-70 years inclusive.

        Participants FSH must be greater than 20 mlU/mL assay (this is a two-site immunofluorescent
        assay, Abbott Labs, post-menopausal range greater than 20).

        Participants must have12 month or greater history of amenorrhea.

        No current use of any sex steroid hormone replacement therapy (including selective estrogen
        receptor modulators) including transdermal, injectable, vaginal and oral preparations and
        willingness to abstain from such use during the study.

        Participants BMI 19-30.

        Participants must have a normal mammogram and pap smear at study entry.

        Participants must be able and willing to maintain a minimum daily intake of 1000 mg calcium
        from dietary sources and/or supplements for the duration of the study.

        Participants must have a normal pro-time and PTT at screening visit.

        Participants must be able to read and speak English fluently so as to allow accurate
        self-administration of medication, recording of symptoms and unassisted completion of
        weekly questionnaire.

        Participants must be in good health. Chronic medication use, except for glucocorticoid use
        or sex hormone replacement therapy, may be acceptable at the discretion of the principal
        investigator. Interval use of over-the-counter counter drugs, other than aspirin or NSAIDs,
        is acceptable but must be recorded.

        Particippants hemoglobin must be greater than 10 g/dL.

        Participants must be willing and able to self-administer daily medication, to complete
        self-administered questionnaires, to record daily symptoms and to return to the Clinical
        Center for weekly follow-up appointments for a minimum of 8 continuous weeks.

        Participants with a history of diabetes mellitus type I or II are not eligible.

        Participants with a history of malignancy within the past 5 years are not eligible.

        Participants must not have a current use (within 90 days of study entry) of drugs that
        affect bone turnover and mineral metabolism such as bisphophonates, parathyroid hormone,
        hydrochlorothiazide and calcitonin.

        Participants with triglyceride level of 500 mg/ml or greater at initial visit are not
        eligible.

        Participants must not use cholesterol-lowering medication currently or within 6 weeks of
        study entry.

        Participants with tobacco use currently or within 90 days of study entry are not eligible.

        Participants with a history of diseases that alter mineral metabolism such as
        hyperparathyroidism, chronic renal insufficiency and hemodialysis are not eligible.

        Participants requiring ongoing anti-inflammatory medication (e.g., aspirin, NSAIDs) whether
        prescribed or over the counter are not eligible.

        Participants with current use of anticoagulants (e.g. Warfarin, heparin), anti-platelet
        drugs or history of bleeding disorder are not eligible.

        Participants must not use OTC herbal or alternative treatments for hot flashes or other
        menopausal symptoms, such as DHEA, soy protein supplements, or other phytoestrogens within
        two months of study entry, and unwillingness to abstain from these products during the
        study.

        Participants must not use drugs that affect the frequency of intensity of hot flashes such
        as clonidine or SSRI's within 2 months of study entry.

        Participants must not have ischemic heart disease (e.g. angina, myocardial infarction or
        congestive heart failure).

        Participants must not have significant abnormalities in the history, physical or laboratory
        examination.

        Participants must not a history of venous thromboembolic events including deep vein
        thrombosis (DVT), pulmonary embolism, retinal vein thrombosis.

        Participants must not a history of stroke, complicated migraine, documented transient
        ischemic attack or uncontrolled hypertension.

        Participants must not absence of the uterus (hysterectomy).",Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause,2
"The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment.
She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment.
She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment.
She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.","Females with a diagnosis of Primary Sjogren's Syndrome.

        No history of breast cancer.",DHEA Treatment for Sjogren's Syndrome,0
"The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment.
She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.","Primary Sjogren's Syndrome; symptoms of dry eyes and dry mouth; 6 week period off disease
        modifying agents, such as antimalarials or steroids.

        No males.

        No females with childbearing potential.

        No patients with hypersensitivity to thalidomide.

        No confounding medical illness or abnormal laboratory test that in the judgment of the
        investigators would pose added risk for study participants.",Pilot Study of Thalidomide to Treat Sjogren's Syndrome,0
"The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment.
She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment.
She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.","Clinical diagnosis of classical or hypermobile EDS based on history and physical
        examination by a study investigator.

        Subjectively suffer from chronic pain (defined as pain occurring at least weekly).

        Must agree to not seek mind-body therapy or other similar interventions outside of this
        study during the time under investigation.

        Able to give informed consent.

        No minors (under 18 years of age).

        Not currently using formal mind-body or similar therapy for treatment of chronic pain.

        No major surgical procedure within 90 days or intending to undergo such a procedure during
        the time course of this study.

        Not decisionally impaired subjects.

        No previous diagnosis or hospitalization for a psychotic condition(s). Specifically, no
        history of illness involving altered perception of reality. Psychiatric diagnoses such as
        depression or anxiety will not exclude participation.",Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome,0
"The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment.
She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.","-  Acute intermittent porphyria

          -  Variegate porphyria and hereditary coproporphyria eligible but analyzed separately",Study of Nutritional Factors in Porphyria,0
"The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg.  She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
Her cardiac assessment is normal. Her joints and ROM are within  normal.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg.  She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
Her cardiac assessment is normal. Her joints and ROM are within  normal.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,1
"The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg.  She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
Her cardiac assessment is normal. Her joints and ROM are within  normal.",Stratified random sample based on risk severity obtained during phone interview,Prevalence of Sleep Apnea in Women,2
"The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg.  She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
Her cardiac assessment is normal. Her joints and ROM are within  normal.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Obese women with chronic anovulation due to polycystic ovary syndrome (PCOS)

        Must have oligoamenorrhea and hyperandrogenemia

        --Prior/Concurrent Therapy--

        At least 2 months since prior standard therapy (including over the counter drugs) At least
        2 months since prior investigational agents

        --Patient Characteristics--

        Hematopoietic: Hematocrit greater than 38%

        Hepatic: Liver function normal No clinically significant hepatic disease

        Renal: No clinically significant renal disease Creatinine less than 1.4 mg/dL No
        proteinuria

        Cardiovascular: No clinically significant cardiac disease

        Pulmonary: No clinically significant pulmonary disease

        Hormonal: Thyroid function normal Prolactin normal Fasting 17 alpha-hydroxy progesterone
        less than 200 mg/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency

        Other: Not pregnant Negative pregnancy test Fertile patients must use effective
        contraception No diabetes mellitus No clinically significant neurologic, psychiatric,
        infectious, neoplastic, or metabolic disease No clinically significant malignant disease
        except nonmelanomatous skin cancer At least 1 year since any prior drug abuse or alcoholism",Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome,2
"The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg.  She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
Her cardiac assessment is normal. Her joints and ROM are within  normal.","INCLUSION CRITERIA:

        All ethnic groups

        Males and females

        Age greater than 14 years

        Clinically-significant lipodystrophy, identified by the study physician during the physical
        examination as an absence of fat outside the range of normal variation and/or identified as
        a disfiguring factor by the patient.

        Circulating leptin levels less than 4.0 ng/ml in females and less than 3.0 ng/ml in males
        as measured by Linco assay on at least 2 occasions.

        Presence of at least one of the following metabolic abnormalities:

        Presence of diabetes as defined by the 1997 ADA criteria: a) fasting plasma glucose greater
        than or equal to 126 mg/dL, or b) 2 hour plasma glucose greater than or equal to 200 mg/dL
        following a 75 gram oral glucose load, or c) diabetic symptoms with a random plasma glucose
        greater than or equal to 200 mg/dL.

        Fasting insulin greater than 30 micrograms/ml;

        Fasting hypertriglyceridemia greater than 200 mg/dl.

        EXCLUSION

        General: Pregnant women, women in their reproductive years who do not use an effective
        method of birth control, women currently nursing or lactating within 6 weeks of having
        completed nursing, and persons who are unable to provide informed consent will be excluded
        from the study.

        Exclusions for underlying disease likely to increase side effects or to hinder objective
        data collection:

        Known liver disease due to causes other than non-alcoholic steatohepatitis

        Current alcohol or substance abuse

        Psychiatric disorder impeding competence or compliance

        Active tuberculosis

        Use of anorexiogenic drugs

        Other condition which in the opinion of the clinical investigators would impede completion
        of the study

        Subjects who have a known hypersensitivity to E. Coli derived proteins",Leptin to Treat Lipodystrophy,0
"The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg.  She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
Her cardiac assessment is normal. Her joints and ROM are within  normal.",- BMI 25-40 kg/m2 inclusive,Effectiveness of Atkins Diet for Weight Loss,2
"The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg.  She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
Her cardiac assessment is normal. Her joints and ROM are within  normal.","-  INCLUSION CRITERIA:

        Based on the Inclusion Criteria outlined below, patients will accrue to one of the cohorts
        of the trial.

        Cohort- chemotherapy regimens allowed. Cohort Status

        Cohort 1

        Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome)-2 or fewer. Closed to
        accrual

        Cohort 2

        Peripheral T-cell Lymphoma, unspecified, or Anaplastic large cell lymphoma (T and null
        cell) Primary Cutaneous Type -2 or fewer. Open and accruing

        Cohort 3

        Cutaneous T-cell Lymphomas or Peripheral T-cell Lymphoma-More than 2. Closed to accrual

        Cohort 4

        Other Mature T cell Lymphomas-Any number. Open and accruing

        Cohort 5

        Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome)-2 or fewer-Cohort 5 is a
        replicate cohort, identical to #1

        Cohort 6

        Peripheral T-cell Lymphoma (PTCL), unspecified, or Anaplastic large cell lymphoma (T and
        null cell) Primary Cutaneous Type-More than 2. Patients with PTCL in cohort 3 migrated to
        this cohort

        Cohort 7

        Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome) Prior vorinostat
        required-Any number

        Patients with cutaneous T-cell lymphoma [CTCL (mycosis fungoides or Sezary syndrome) stage
        IB to IVB are eligible. Patients with stage IB and IIA should be refractory to, intolerant
        to, or have reached a six-month or longer response plateau on at least two prior therapies
        from the following list: psoralen plus ultraviolet A irradiation (PUVA), ultraviolet B
        (UVB), electron beam therapy (EBT), photophoresis, interferon, systemic cytotoxic
        chemotherapy, topical nitrogen mustard, or topical carmustine (BCNU). One qualifying prior
        treatment must have been topical nitrogen mustard, topical carmustine or a phototherapy
        (UVB, PUVA or EBT). Topical steroids, systemic retinoids or biologicals do not qualify.
        Patients with stage IB or IIA who are not candidates for topical nitrogen mustard, topical
        carmustine or phototherapy (UVB, PUVA or EBT) are eligible for enrollment. Patients may not
        have received more than two systemic cytotoxic chemotherapy regimens. Steroids, retinoids,
        and biologic agents, will not be considered as systemic cytotoxic chemotherapy.
        Radiolabeled monoclonal antibody therapy is considered equivalent to a systemic cytotoxic
        chemotherapy regimen and must be counted toward the two prior systemic cytotoxic regimens.
        Patients with stage IIB-IVB who have had no more than 2 prior systemic cytotoxic
        chemotherapeutic regimens are eligible. There is no restriction regarding number of prior
        topical therapies, skin irradiation, or non-cytotoxic systemic therapies (i.e. PUVA,
        retinoids or biologic, with the exception of radiolabeled monoclonal antibody therapy) in
        this patient group. After 24 patients were enrolled in this arm, the arm was closed, and a
        replicate arm constituted of this same patient population was opened (Cohort 5).

        Patients with peripheral T-cell lymphoma (PTCL), unspecified, or anaplastic large cell
        lymphoma, T and null cell, primary cutaneous type, as defined by the Revised European
        American Lymphoma (REAL)/World Health Organization (WHO) classification (16-18), who have
        experienced disease progression after receiving prior standard treatment and who have had
        no more than 2 prior systemic cytotoxic chemotherapeutic regimens are eligible.

        Patients with cutaneous T cell lymphoma (Mycosis fungoides or Sezary Syndrome) or
        peripheral T cell lymphoma as defined above who have received more than 2 prior systemic
        therapies and who have experienced disease progression will be included in a third and
        independent arm. This arm of the protocol was closed to accrual for CTCL with Amendment H.

        Patients with mature T cell lymphomas not included above will be enrolled in a fourth arm.
        These include but are not exclusively limited to: Enteropathy-type T cell lymphoma;
        Hepatosplenic T-cell lymphoma; Subcutaneous panniculitis-like T cell lymphoma;
        Angioimmunoblastic T-cell lymphoma; Anaplastic large cell lymphoma. Patients must have
        experienced disease progression after receiving prior standard treatment. There will be no
        limit on the number of prior regimens. Primitive T cell neoplasms and T cell leukemias will
        not be enrolled.

        Patients with peripheral T-cell lymphoma, unspecified, or anaplastic large cell lymphoma, T
        and null cell, primary cutaneous type, as defined by the REAL/WHO classification (16-18),
        who have experienced disease progression after receiving prior standard treatment and who
        have had more than 2 prior systemic cytotoxic chemotherapeutic regimens are eligible for
        enrollment to a sixth arm of the trial.

        Patients with cutaneous T cell lymphoma (Mycosis fungoides or Sezary Syndrome) or
        peripheral T cell lymphoma as defined in #1 who have received any number of prior systemic
        therapies and who have previously been treated with vorinostat will be included in a third
        and independent arm. Patients can be enrolled in this arm if they received prior vorinostat
        and experienced disease progression, subsequent relapse, or had to discontinue to agent due
        to toxicity.

        Disease that is measurable by radiographic imaging, assessing skin lesions, or by
        quantitating Sezary cell count.

        Patients must:

        be age greater than or equal to 18 years

        have a performance status of Eastern Cooperative Oncology Group (ECOG) 0-2

        have no serious or intercurrent illness and have a life expectancy of greater than 12 weeks

        give written informed consent

        female patients of childbearing potential must have a negative pregnancy test within 4
        weeks and must use effective contraception

        sexually active males must use effective contraception

        Laboratory values (performed less than or equal to 14 days prior to registration):

        absolute neutrophil count greater than or equal to 1000/microliter, platelets greater than
        or equal to l00,000/microliter, bilirubin (total and direct) less than or equal to 1.5x
        upper limit of normal, and aspartate aminotransferase (AST) less than or equal to 3x upper
        limit of normal, unless impairment is due to organ involvement by lymphoma, creatinine less
        than or equal to 1.5x upper limit of normal, or documented creatinine clearance of greater
        than or equal to 60mL/min

        Cardiac studies (performed within 4 weeks of registration):

        Ejection fraction of greater than 50% by Echocardiogram or Cardiac magnetic resonance
        imaging (MRI), or greater than or equal to 45% by multi-gated acquisition scan (MUGA) Scan.

        A stable dose (greater than 1 month) of corticosteroids administered for symptom management
        will not preclude enrollment. Tapering will be initiated following administration of
        depsipeptide.

        EXCLUSION CRITERIA:

        Patients with unconfirmed diagnosis, or with B-cell lymphomas will be excluded.

        Prior or concurrent malignancies that have not been curatively treated.

        Known central nervous system (CNS) lymphoma.

        Chemotherapy within 4 weeks, 6 weeks for nitrosoureas or mitomycin C.

        Biologics, Immunotherapy within 2 weeks.

        Human Immunodeficiency virus (HIV) seropositivity.

        Pregnant or breast-feeding patients.

        Major surgery within 21 days.

        Uncontrolled infection or uncontrolled medical illness.

        Patients having received prior histone deacetylase (HDAC) inhibitor therapy for T cell
        lymphoma will be excluded except for patients eligible to enroll in cohort 7.

        Patients with the following cardiac risk factors will be excluded from the study:

        Patients with known cardiac abnormalities such as:

        Congenital long QT syndrome

        Corrected QT interval (QTc) interval greater than 480 milliseconds

        Patients who have had a myocardial infarction within 12 months of study entry.

        Patients who have active coronary artery disease as, e.g. angina as defined by Canadian
        Class II-IV

        Patients with an electrocardiography (ECG) recorded at screening showing evidence of
        cardiac ischemia (ST depression of greater than or equal to 2 mm).

        Any patient in whom coronary artery disease is suspected should be referred for a
        cardiology consultation and if active myocardial ischemia is demonstrated the patient
        should be excluded. If a noninvasive imaging study is equivocal, it may be necessary to
        proceed to coronary angiography.

        Patients with congestive heart failure that meets New York Heart Association (NYHA) Class
        II to IV definitions and/or ejection fraction less than 45% by MUGA scan or less than 50%
        by echocardiogram and/or MRI.

        Patients with a history of sustained ventricular tachycardia (VT), ventricular fibrillation
        (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic
        implantable cardioverter defibrillator (AICD). Patients with a history of arrhythmia should
        have Holter monitoring and evaluation by cardiology.

        Patients with dilated, hypertrophic, or restrictive cardiomyopathy from prior treatment or
        other causes (in doubt, see ejection fraction criteria above). Patients with left
        ventricular hypertrophy should be discussed with the Principal Investigator or Study
        Chairman.

        Patients with uncontrolled hypertension, i.e., systolic blood pressure (SBP) greater than
        or equal to 160 mm Hg or diastolic blood pressure (DBP) greater than or equal to 95 mm Hg.

        Patients with cardiac arrhythmia requiring anti-arrhythmic medication other than beta
        blocker or calcium channel blocker. Patients in whom digitalis cannot be discontinued are
        excluded from study.

        Patients with Mobitz II second degree heart block who do not have a pacemaker. Patients
        with first degree or Mobitz I second degree heart block, bradyarrhythmias or sick sinus
        syndrome require Holter monitoring and evaluation by cardiology.

        Patients with other cardiac disease may be excluded at the discretion of the principal
        investigator (PI) following consultation with cardiology.",Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma,0
"The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.","Inclusion Criteria

        Patient must:

          -  Have Pneumocystis carinii pneumonia (PCP) that has not been treated for current
             episode. PCP must be documented by observation of > 1 cluster of organisms in sputum,
             bronchial secretion, or lung tissue.

          -  Have clinical symptoms of respiratory disease or radiologic abnormalities.

        Exclusion Criteria

          -  Patient cannot have significant emotional disorder.

        Concurrent Medication: Excluded:

          -  Drugs likely to be bone marrow toxic.

          -  Investigational drugs.

        Prior Medication: Excluded:

          -  Three patients in each group cannot have had zidovudine (AZT) for at least 2 months
             prior to administration of trimetrexate.",A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP,0
"The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Acetaminophen 650 mg prescribed as necessary for temperature > 38.7 degrees C.
             Acetaminophen q4h should not be prescribed as a standing order for more than 48 hours.

        Prior Medication:

        Allowed:

          -  Zidovudine as long as such therapy is suspended prior to randomization and not
             reinstituted until therapy for the acute episode is completed.

          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP).

          -  Unequivocal diagnosis of Pneumocystis carinii pneumonia (PCP) by morphologic
             confirmation of three or more typical P. carinii organisms in sputum, bronchoalveolar
             lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3
             days before or after randomization. If morphologic confirmation is not possible prior
             to therapy, patients may be randomized if the investigator believes there is a high
             suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be
             established within 6 days of randomization, the patient will be withdrawn from study
             therapy.

          -  Resting alveolar-arterial oxygen differences = or > 30 mm Hg on room air.

        Exclusion Criteria

        Patients with the following are excluded:

          -  Inability to have alveolar blood gas analysis on room air.

          -  Medically unable to receive a liter of intravenous fluid (5 percent dextrose in water)
             per 24 hours. This procedure is required in order to maintain blinding.

        Prior Medication:

        Excluded within 14 days of study entry:

          -  Systemic steroids exceeding physiological replacement.

          -  Other investigational drugs.

          -  Excluded within 6 weeks of study entry:

          -  Antiprotozoal regimen for this episode consisting of pentamidine, eflornithine, DFMO,
             or dapsone, for therapy of active Pneumocystis carinii pneumonia (PCP)

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reaction secondary to antibiotics
             containing sulfa, trimethoprim, or trimetrexate.

          -  History of life-threatening pentamidine toxicity.

          -  Requirement for treatment with agents that are known to be myelosuppressive or
             nephrotoxic during the period of acute Pneumocystis carinii pneumonia (PCP) therapy.

          -  Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia
             (PCP); disulcid; aspirin; acetaminophen q4h for more than 48 hours.",Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,0
"The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.","Inclusion Criteria

        Patients must have:

          -  HIV infection.

          -  CD4 count <= 200 cells/mm3 or <= 15 percent of total lymphocytes OR a history of prior
             PCP.

          -  History of intolerance to trimethoprim and/or sulfonamides.

          -  No active pneumocystosis. Patient or guardian must sign informed consent. Pregnant
             patients are eligible at the clinician's discretion. Patients who do not meet required
             laboratory values may be eligible at the discretion of the clinician.

        Exclusion Criteria

        Concurrent Medication:

        Excluded:

          -  Any medication with potential anti-PCP activity.

        Patients with the following prior conditions are excluded:

          -  Treatment-limiting reaction to pentamidine or dapsone.",A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides,0
"The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.","Patients with clinically definite and/or laboratory-supported definite diagnosis of MS.

        Patients must have had a minimum of 6 monthly MRI scans prior to randomization according to
        a standardized MRI protocol and fulfill the pre-defined MRI criteria of disease activity:
        mean of at least 0.5 total gadolinium-enhancing lesion in the 6 monthly scans immediately
        preceding randomization.

        No evidence of relapse for at least 30 days prior to entry.

        One or more relapses in the 2 years preceding randomization.

        Expanded Disability Status Scale (EDSS) score less than or equal to 7.0.

        Male or female aged 18 to 55 years.

        Females must be either post-menopausal, surgically incapable of bearing children, or
        practicing a medically accepted method of birth control.

        Patients willing and able to give informed consent according to national legal
        requirements.","Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)",2
"The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension.  She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension.  She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension.  She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension.  She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","DISEASE CHARACTERISTICS: Histologically proven stage IIB, IIIA, IIIB, and IVA squamous cell
        carcinoma of the cervix Bidimensionally measurable disease No bilateral hydronefrosis

        PATIENT CHARACTERISTICS: Age: Any age Performance status: WHO 0-2 Life expectancy: At least
        12 weeks Hematopoietic: Hemoglobin at least 10 g/dL Leukocytes at least 4,000/mm3 Platelet
        count at least 75,000/mm3 Hepatic: Bilirubin less than 1.25 times upper limit of normal
        (ULN) AST less than 1.25 times ULN Renal: BUN less than 30 mg/dL AND Creatinine less than
        1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: No prior or other concurrent
        malignancies, other than properly treated basal cell skin cancer

        PRIOR CONCURRENT THERAPY: Not specified",Docetaxel in Treating Patients With Advanced Cancer of the Cervix,0
"The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension.  She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Mild or moderate generalized myasthenia gravis Grade 2 or 3
        myasthenia gravis according to a modified Osserman groups system Ocular myasthenia gravis
        alone or myasthenia gravis in crisis not eligible Must have elevated acetylcholine receptor
        antibody titer No evidence of thymoma on chest CT or MRI No immunoglobulin-A deficiency
        less than 5 mg/dL Group 1: Patients who have not received other immunosuppressive therapy
        in the past, including intravenous immunoglobulin Group 2: Patients considered
        steroid-dependent

        Considered steroid-dependent if demonstrated improvement following initiation of
        corticosteroid therapy but continue to have generalized weakness on examination despite
        receiving 20 mg of prednisone (or equivalent) every other day and experience unacceptable
        symptoms on lower doses Prednisone and other immunosuppressive drug doses must not have
        changed within last 4 weeks May have had other immunosuppressive medication (azathioprine,
        cyclosporine, cyclophosphamide) or have received plasma exchange if these treatments were
        not initiated in the 2 months prior to study enrollment Must be receiving immunosuppressive
        medication for at least 3 months prior to study

        --Prior/Concurrent Therapy-- Endocrine therapy: Corticosteroid must be maintained at a
        constant dose during study Surgery: No thymectomy in the last 3 months Other: No
        plasmapheresis in the last 2 months --Patient Characteristics-- Age: 15 and over Weight: No
        greater than 80% above ideal body weight Hepatic: SGOT, SGPT, and alkaline phosphatase no
        greater than 1.5 times upper limit of normal (ULN) Renal: BUN no greater than ULN
        Creatinine no great than ULN Neurology: No history of relevant chronic degenerative,
        psychiatric, or neurologic disorder, other than myasthenia gravis, that can produce
        weakness or fatigue No altered consciousness, dementia, or abnormal mental status
        Pulmonary: Forced vital capacity at least 50% of predicted Not at high risk for aspiration
        Other: No active thyroid gland dysfunction as manifested by abnormal thyroid function tests
        or the need for current thyroid replacement Normal thyroid function tests required No other
        major relevant chronic or debilitating illnesses within 6 months of study Not pregnant or
        nursing Adequate contraception required of all fertile patients",Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis,2
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,2
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","Biopsy proven advanced cancer, for whom no better therapy exists.

        Enrollment of patients with breast cancer, lymphoma, renal cell cancer or ovarian cancer
        are encouraged.

        Patients with a life expectancy of at least 16 weeks, and a performance status (Karnofsky
        Scale) of 70% or greater. No rapidly growing disease.

        Patients with prior therapy.

        WBC greater than 3,000/mm(3) and AGC greater than 1000/mm(3); platelets greater than
        100,000/mm(3).

        Creatinine clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than
        90 u/L; SGPT less than 100 u/L.

        Patients must sign an informed consent and have geographic accessibility to return for
        follow up and treatment.

        No history of brain metastases.

        No patients currently receiving treatment with the following agents or any other agent
        known to significantly interact with cyclosporine, and the treatment cannot be discontinued
        , or changed to another therapeutically equivalent allowable drug: acetazolamide,
        barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole,
        nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil,
        tamoxifen, progesterone, quinine, quinidine, or amiodarone.

        No patients with a history of coronary artery disease with angina pectoris or history of
        congestive heart failure.

        No patients with a history of cardiac disease, other than angina pectoris or congestive
        heart failure, including patients with arrhythmias or conduction system abnormalities will
        be considered on an individual basis.

        No patients with symptomatic peripheral neuropathy (grade 2 or greater).

        No patients with a positive serology for HIV.

        No patients who are pregnant or unwilling to practice adequate contraception.

        No patients with prior bone marrow transplantation or extensive irradiation resulting in
        compromised bone marrow reserve.",A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833,0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","Patients who are seropositive, documented by a licensed ELISA with a confirmatory Western
        blot assay for HIV with greater than or equal to 500 CD4+ cells/mm(3) at the time of
        screening who also meet either of the 2 following criteria:

        During acute infection there is no lower limit for the CD4 count (acute infection is
        defined for this protocol as the 6 month period after diagnosis of HIV seropositivity in a
        patient with documented negative HIV serology within the 6 months prior to diagnosis of HIV
        seropositivity) OR;

        If there is a history of CD4 count less than 300 cells/mm(s) at any point after initial HIV
        seropositive diagnosis patient will not be eligible, unless this count was during the time
        of acute infection.

        Ambulatory status, and ability and willingness to give informed consent.

        Must be over 18 years old and have an estimated life expectancy of more than 12 months.

        Hgb greater than or equal to 12 g/dl for men and 11 gm/dl for women.

        ANC greater than or equal to 1000/mm(3).

        Creatinine greater than or equal to 1.5 mg/dl or creatinine clearance greater than 50
        ml/min.

        LFT: AST and ALT less than or equal to 3x upper limit of normal IU/ml for enrollment.
        Alkaline phosphatase less than or equal to 2.5x ULN.

        Bilirubin within normal limits, except for known Gilbert's Syndrome or if patient is on
        protease inhibitor therapy. For patients on protease inhibitor therapy, direct bilirubin
        less than or equal to 0.3 mg/dl and indirect bilirubin less than or equal to 4.5 mg/dl.

        Patients must be willing to comply with a medical regimen of highly active antiretroviral
        therapy, and must be on a stable antiretroviral regimen for a minimum of 4 weeks prior to
        the first vaccination.

        Patients should not be receiving antiretroviral therapy or should not have received
        antiretroviral therapy within 6 months.

        Patients without actual or suspected allergies to any component of vaccine.

        No prior vaccines for HIV.

        Patients should not have received treatment with the following meds at study entry or
        within preceding 3 months - agents with immunomodulating activity, parenteral therapies,
        HIV drugs, vaccines, interferons, corticosteroids, any growth factors.

        No prior Aids defining OI.

        No active life threatening infection.

        No severe malabsorption.

        No evidence of Kaposi Sarcoma or other tumor - likely to require cytotoxic antitumor
        therapy within 6 months of entering study. Must complete acute therapy for infections at
        least 14 days prior to entry.

        No pregnancy. Female patients of child bearing potential must have a negative pregnancy
        test prior to vaccine administration. Males and females must agree to use effective birth
        control methods during the course of vaccination.

        No patients in whom there is a medical contraindication or potential problems in complying
        with the requirements of the protocol.",Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection,0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","Must have been diagnosed with osteosarcoma by the age of 25 years.

        Patient must have a biopsy proven osteosarcoma and either: a) active tumor with no
        available standard therapy options; b) metastatic osteosarcoma at diagnosis, has completed
        therapy and has no evidence of active disease; or, c) is status-post any surgery for
        recurrent osteosarcoma, either local or metastatic recurrence, and is free of disease by CT
        scan.

        Measurable disease not required.

        Patients with serum creatinine &lte; 2.0 mg/dL or creatinine clearance &gte; 40 ml/min per
        1.73m(2) (if serum creatinine is &gte; 2.0 mg/dL).

        Patients with normal thyroid function.

        Patients with total bilirubin, SGOT and SGPT < twice the upper limit of normal.

        Patients with normal direct bilirubin only if total direct bilirubin is abnormal.

        Patients with bone marrow criteria: ANC>1500/mm(3) and platelet count >100,000/mm(3).

        Patients without a history of insulin-dependent diabetes mellitus or current insulin
        requirement. Fasting morning blood glucose <150 mg/dL.

        Patients with ECOG performance status of 0, 1 or 2 and a life expectancy of at least 8
        weeks.

        Patients not on chemotherapy or radiation therapy within the past 2 weeks and recovered
        from the acute side effects of prior anti-neoplastic therapy.

        Patients with documented negative HIV serology within the past 6 months.

        Post-menarcheal patients must have documented negative urine and serum pregnancy test
        (B-HCG); when indicated, patient must be willing to take oral contraceptives or other
        appropriate contraceptives to avoid pregnancy during the period of treatment.

        Patient, parent or guardian must give informed consent.

        No pregnant or lactating women.

        No women of child-bearing potential who are unable or unwilling to use appropriate
        contraceptives during the period of treatment.

        No patients with uncorrected hypothyroidism.

        No patients with insulin-dependent diabetes mellitus or fasting blood glucose &gte; 150
        mg/dL.

        No patients with HIV infection.

        No patients with a history of thromboembolic events who require prophylaxis for
        thromboembolic events with anticoagulants once entry into Cohort III has begun.

        Patients with a history of symptomatic gallbladder disease must have had a cholecystectomy.",A Phase I Study of OncoLAR (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma,0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","DISEASE CHARACTERISTICS:

        Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous
        Ewing's sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma,
        primitive sarcoma of bone, and ectomesenchymoma.

        Confirmed presence of tumor-specific infusion protein by documented RT-PCR which
        corresponds to one of the tumor specific peptides available for vaccination.

        Measurable tumor.

        No prior or current CNS metastases.

        PRIOR/CONCURRENT THERAPY:

        ARM A PATIENTS:

        May be enrolled on the protocol for the first phase in the absence of RT PCR documentation
        of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides
        available for vaccination. However, RT PCR documentation at the time of tumor recurrence
        must occur prior to administration of immunotherapy. At time of initial tumor diagnosis,
        prior to any cytoreductive therapy.

        ARM B PATIENTS:

        Tumor recurrence occurring during or after receiving at least first line cytoreductive
        therapy for ESFT and AR. No more than two post-recurrence salvage regimens unless
        peripheral CD4+T cell number is greater than 400 cells per millimeter cubed.

        At least 6 weeks since any treatments and recovered from all acute toxic effects from time
        in which immunotherapy will be started for this study.

        No concurrent estrogen therapy during immunotherapy section of study.

        PATIENT CHARACTERISTICS:

        Age: 2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).

        Weight: Greater than 15 kg (at time of apheresis).

        Performance status: ECOG 0-2.

        Life expectancy: At least 8 weeks.

        Hematopoietic:

        ANC greater than 100,000/mm(3).

        Hemoglobin greater than 9.0 g/dL.

        Platelet count greater than 50,000/mm(3).

        Hepatic:

        Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).

        Transaminases less than 3 times normal (unless related to involvement by tumor).

        Renal:

        Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.

        Cardiovascular:

        No major disorder of cardiovascular system.

        Cardiac ejection fraction greater than 40%.

        Pulmonary:

        No major disorder of pulmonary system.

        OTHER:

        Not pregnant or nursing.

        HIV negative.

        Hepatitis B or C negative.

        No patients requiring daily oral corticosteroid therapy.

        If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre
        syndrome, ineligible to receive influenza vaccine.","A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer",0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","Children between ages of 4 years and 18 years.

        Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC)
        Definition.

        Availability of a parent or guardian to provide Informed Consent.

        Child is not critically ill or clinically unstable.

        No CDC categories N1 and A1 (1994 revised classification for HIV infection in children less
        than 13 years of age) and the CDC 1993 revised HIV classification and expanded AIDS
        surveillance definition for adolescents and adults.

        Non-presence of an active opportunistic infection requiring acute intervention at the time
        of entry (e.g. CMV, aspergillosis, cryptococcosis, Candida, etc.). Patients receiving
        treatment for an infection that requires prolonged treatment must have been stable on
        therapy for at least 30 days prior to study entry.

        No administration of chemotherapeutic agents, investigational agents or use of
        immunomodulating agents such as IVIG, corticosteroids, interferons, pentoxifylline,
        G-CSF/GM-CSF, erythropoeitin, growth hormone and other growth factors within one month of
        enrollment.

        None of the following laboratory abnormalities within 2 weeks of study entry:

        Total WBC count less than 1500/mm(3) or an absolute neutrophil count less than 750/mm(3);

        Hemoglobin less than 8.0 g/dl;

        Platelet count less than 75,000/mm(3);

        Creatinine greater than 2.0 x normal;

        Creatinine clearance less than or equal to 50 mL/min/m(2);

        Total bilirubin greater than 2 x normal;

        SGOT/SGPT greater than 5 x normal;

        Serum amylase pancreatic isoenzyme greater than 90 U/L (2 x upper limit of normal for
        adult). Serum amylase pancreatic isoenzyme should be obtained only if total serum amylase
        is greater than 180 U/L.

        No history of clinical pancreatitis and/or elevation in serum amylase pancreatic isoenzyme
        of greater than 180 U/L.

        No history of peripheral neuropathy of Grade II or greater severity.

        No previous treatment with ritonavir, indinavir, nelfinavir, nevirapine or stavudine.
        Patients may have received treatment with ritonavir, indinavir, nelfinavir for less than 4
        weeks.

        Ability to swallow tablets.

        No child for whom the volume of research blood required for study evaluation exceeds the
        maximum volume of research blood allowable (3 ml/kg in a single blood withdrawal and 7
        ml/kg in a 6-week period). This would be applicable to a child less than 16.5 kg.

        No patients who refuse or cannot have leukapheresis done.

        Sexually active post-menarchal females must be willing to use a barrier method of
        contraception or be willing to remain sexually abstinent.","A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine",0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","Must be 18 years old or greater.

        ECOG performance status of 0-1.

        Individuals without a history of cancer are eligible, as are those with a history of
        cancer. Individuals with a history of cancer (excluding non-melanomatous skin cancer ) will
        need to submit their pathology slides for review in the Laboratory of Pathology, NCI.

        Must be able to understand and give informed consent.

        Life expectancy greater than 6 months.

        Hgb greater than or equal to 8.0gm/dl, platelets greater than or equal to
        100,000/microliters, ANC greater than or equal to 1000/microliters, creatinine less than or
        equal to 2.0/mg/dl, SGPT and SGOT less than or equal to 147 and 168 U/L, total bilirubin
        less than or equal to 2 mg/dl (patients with a higher level of bilirubin due to a familial
        defect in bilirubin metabolism will be considered on an individual basis).

        No history of breast cancer.

        No pregnant or breast feeding subjects.

        Must not be HIV positive.

        No history of venous thrombosis within the past year.

        No medical conditions, which, in the opinion of the investigators would jeopardize either
        the patient or the integrity of the data obtained.

        No patients who are currently receiving active therapy for neoplastic disorders. However,
        patients with prostate cancer who are on an LHRH agonist (e.g., Lupron or Zoladex), or who
        have undergone surgical castration, are eligible for study.

        No patients who are on estrogen therapy.

        No patients taking hormonal forms of contraception.

        No patients with a known soy intolerance.","A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor",0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Cystic fibrosis-associated liver disease, defined by at least one of the following
             criteria: (1) Documented increase in serum concentrations of any of the liver enzymes
             (at least once in the preceding year) ALT at least twice normal AST at least 1.5 times
             normal Alkaline phosphatase at least 1.5 times normal GGT at least 1.5 times normal
             (2) Persistent hepatomegaly of more than 6 months duration defined by percussed liver
             span greater than 1 SEM for age (3) Splenomegaly, defined as a palpable spleen greater
             than 2.0 cm below the left costal margin (4) Abnormalities of ultrasound scan
             (increased size, dishomogeneous echogenicity, nodular liver, irregular margins,
             splenomegaly) within 6 months prior to study entry

          -  Patients enrolled in the first part of the study (objective I) are eligible to
             participate in the second part (objective II)

        --Prior/Concurrent Therapy--

          -  At least 3 months since prior ursodiol

          -  At least 3 months since treatment with drug with choleretic properties or effects that
             influence bile acid metabolism

        --Patient Characteristics--

          -  Hepatic: No decompensated cirrhosis No hepatic neoplasm or cholelithiasis

          -  Pulmonary: No significantly impaired pulmonary function with FEV1 less than 50%

          -  Other: At least 15 kg body weight No severely compromised clinical or nutritional
             state",Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis,0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Biopsy proven primary biliary cirrhosis (PBC); Disproportionate
        increase in alkaline phosphatase; Positive antimitochondrial antibody test OR Symptoms
        consistent with PBC, e.g.: pruritus, fatigue, malaise, jaundice, elevated bilirubin

        No clinically advanced PBC, i.e.: bilirubin greater than 10 mg/dL or albumin less than 2.5
        g/dL, determined by 2 analyses 10 weeks apart; bleeding esophageal varices or congestive
        gastropathy; chronic hepatic encephalopathy; chronic ascites

        --Prior/Concurrent Therapy-- No concurrent drugs associated with chronic liver disease

        --Patient Characteristics--

        Hematopoietic: WBC at least 2500 Platelets at least 100,000 (unless due to hypersplenism);
        Hematocrit at least 30%

        Renal: No renal disease that could cause liver dysfunction

        Other: No history of alcohol abuse; No other medical illness that might cause liver
        dysfunction, e.g., severe cardiac failure; No pregnant women",Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis,0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Infants diagnosed with herpes simplex virus infection involving the central nervous
             system with or without evidence of viral dissemination to other organs (i.e., skin,
             liver, or lungs) HSV-1 or HSV-2 isolated from cutaneous lesions from any site (skin,
             oropharynx, cerebrospinal fluid (CSF), urine, etc.) OR Must have positive CSF
             polymerase chain reaction (PCR) if no cutaneous skin lesions are present and viral
             cultures are negative No infection limited to skin, eyes, or mouth Evidence of CNS
             involvement includes one or more of the following: Abnormal CSF indices for term
             infants (WBC greater than 22/mm3 and protein greater than 115 mg/dL) Abnormal CSF
             indices for preterm infants (WBC greater than 25/mm3 and protein greater than 220
             mg/dL) Abnormal neuroimaging study (CT with contrast, MRI with gadolinium, or head
             ultrasound) Disseminated disease is defined as one or more of the following: SGPT at
             least 2.5 times upper limit of normal Pneumonia/pneumonitis Necrotizing enterocolitis
             Disseminated intravascular coagulopathy

          -  Birth weight at least 800 grams

        --Prior/Concurrent Therapy--

          -  No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or
             famciclovir for longer than 120 hours or 5 days

        --Patient Characteristics--

          -  Renal: Creatinine no greater than 1.5 mg/dL

          -  Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage

          -  Other: No infants known to be born to HIV positive women",Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System,0
"A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed.
Vital signs are reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are  detected in the heart and lung auscultation. Her liver and spleen are normal on palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Infants diagnosed with herpes simplex virus infection limited to skin, eyes, and mouth;
        HSV-1 or HSV-2 isolated from cutaneous lesions, conjunctivae, or oropharynx (presence of
        skin lesions not required); normal CSF indices: WBC less than 22/mm3 and protein less than
        115 mg/dL for term infants OR WBC less than 25/mm3 and protein less than 220 mg/dL for
        preterm infants; no evidence of CNS involvement by CT with contrast, MRI with gadolinium,
        or head ultrasound; no visceral dissemination (normal liver function tests, normal chest
        x-ray, etc.); negative CSF PCR result

        Birth weight at least 800 grams

        --Prior/Concurrent Therapy--

        No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or
        famciclovir for longer than 120 hours or 5 days; no prior prophylactic acyclovir for risk
        of herpes simplex virus infection

        --Patient Characteristics--

        Renal: Creatinine no greater than 1.5 mg/dL

        Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage

        Other: No infants known to be born to HIV-positive women","Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth",0
"The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty  chewing that started 6 years ago and is  worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and  Bisphosphonate will be started as first-line therapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Confirmed diagnosis of hereditary angioedema (HAE) based upon C4 antigenic level,
             positive family history, and C1 inhibitor (C1INH) antigenic level (Type I HAE) or
             functional level (Type II HAE)

          -  Functional C1 within normal levels if diagnosis of acquired C1INH is possible

          -  Negative family history will not exclude as long as patient meets all other criteria,
             has normal C1 level, and has no evidence of acquired C1INH deficiency

          -  History of symptoms of HAE including episodic swelling, abdominal pain, and/or
             respiratory difficulty

          -  Experiencing a minimum of 1-2 HAE episodes within 6 weeks

        --Prior/Concurrent Therapy--

          -  Endocrine therapy: Anabolic steroids allowed as long as dose has not been changed in
             at least 30 days

          -  Other: No concurrent and at least 1 week since prior aspirin, nonsteroidal
             antiinflammatory agents, dipyridamole, Coumadin-like drugs, or any other medication
             having an effect on coagulation or platelets

        --Patient Characteristics--

          -  Hematopoietic: No clinically significant history of hematologic disease

          -  Hepatic: No clinically significant history of hepatic disease

          -  Renal: No clinically significant history of renal disease

          -  Cardiovascular: No clinically significant history of cardiac disease or hypertension

          -  Pulmonary: No clinically significant history of pulmonary disease

          -  Other: No contraindication to the use of inhaled or subcutaneous heparin No drug
             allergy that would interfere with the study No clinically significant history of:
             Malignancy Diabetes mellitus Neurologic disease Immunologic disease Bleeding disorder
             Infirmity No history of drug abuse, alcoholism, psychosis, or other
             psychological/psychiatric disorder",Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations,0
"The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty  chewing that started 6 years ago and is  worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and  Bisphosphonate will be started as first-line therapy.","-  INCLUSION CRITERIA:

        Patients must be referred to the NIH with a diagnosis or a suspicion of Hyper IgE syndrome.
        Family members of probands and patients referred for other immune syndromes that
        demonstrate some of the characteristics of HIES may also be evaluated under this protocol.
        Male and female patients will be accepted. An inclusion age range will be constructed to
        accommodate at-risk infants born into affected families as well as to be able to examine
        the members of extended families. The extent of evaluation will be tailored to the patient
        s needs, age, and conditions. The cutaneous manifestations of Hyper IgE syndromes are often
        present at birth and need management from that time on.

        EXCLUSION CRITERIA:

        Coronary CTA will not be performed on any patient with contraindication to IV contrast
        media. This includes patients with 1) creatinine value of >1.3 mg/dl, 2) history of
        multiple myeloma, 3) Use of metformin-containing products less than 24 hours prior to
        contrast media, and 4) history of significant allergic reaction to CT contrast agents
        despite the use of premedication.

        Subjects with a medical, psychiatric, or social condition which, in the opinion of the
        investigator, would place undue burden on the subject, NIH resources, or increase risk of
        participation, may be excluded.",Study of Clinical Features and Genetics of Hyperimmunoglobulin E Recurrent Infection,0
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","Men, ages 35-57. One or more of three risk factors--hypertension, hypercholesterolemia, and
        cigarette smoking.

        Free from coronary heart disease.",Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT),0
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","-  INCLUSION CRITERIA:

               1. Patients 2 years and older, will be eligible for participation if they have a
                  disorder that, in the judgment of the treating physician, might be amenable to
                  treatment with BTX.

               2. Applicable disorders include but are not limited to dystonia, hemifacial spasm,
                  blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual
                  dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia.

        EXCLUSION CRITERIA:

          1. Women who are planning on becoming pregnant, are pregnant or breastfeeding, for the
             duration of the condition.

          2. Subjects who require treatment with an aminoglycoside antibiotic, until treatment is
             complete.

          3. For laryngeal injections, subjects must have a paradoxical vocal fold movement with
             intermittent stridor due to either gastroesophageal reflux or emotional disorders.",Botulinum Toxin for the Treatment of Involuntary Movement Disorders,2
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","-  Any volunteer of any age from birth to old age who is deemed medically fit to
             participate and is willing to provide their informed consent will be included in the
             study.",Human Movement Database,1
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","INCLUSION CRITERIA:

        Patients may be included on this protocol if they have an identifiable neurological
        disorder or represent a diagnostic puzzle. These disorders would include patients with
        Parkinson's disease, Alzheimer's disease, multiple system atrophy, progressive supranuclear
        palsy, restless legs syndrome, other cognitive and movement disorders, and diagnostic
        puzzles.

        Patients 18-90 years of age, inclusive, are eligible.",Diagnosis and Natural History Study of Patients With Neurological Conditions,2
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","-  INCLUSION CRITERIA:

        Individuals age 18 or over from families in which an autosomal dominant form of Parkinson's
        disease is apparently being inherited.

        The diagnosis must be supported by accepted clinical criteria: tremor, bradykinesia, and
        responsiveness to L-DOPA.

        Unaffected family members will also be enrolled.

        Subjects must give consent.

        Parkinson's disease may be associated with dementia.

        Decisionally-impaired individuals will be enrolled.",Genetic Analysis of Parkinson's Disease,1
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","All patients will have parkinsonism of undetermined etiology.

        Males and females between the ages of 18 and 85 are eligible for the study.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risks, specifically those who have the following: a history of
        convulsive, hepatic, or renal disorders; currently receiving treatment for myocardial
        infarction, arrhythmia or cardiac failure; and pregnant women or anyone not practicing an
        effective means of birth control.",Intravenous Levodopa for the Diagnosis of Parkinson's Disease,1
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","All patients will carry a diagnosis of idiopathic Parkinson's Disease based on the presence
        of a characteristic clinical history and neurologic findings. Most will have relatively
        advanced disease with associated motor response complications.

        Males and females between the ages of 18-75.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risk.

        No patients with baseline QTc prolongation (greater than 440 msec).

        No pregnant women nor those not practicing effective means of birth control.",Treatment of Parkinson's Disease With Eliprodil,1
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","All patients will carry a diagnosis of Huntington's disease confirmed by DNA testing.

        Patients will have mild to moderate disease with associated significant chorea.

        Ability to comply with study requirements and to report on their condition by telephone.

        Males and females between the ages of 18 and 82.

        No patients with the presence or history of any medical condition that can reasonably be
        expected to subject the patient to unwarranted risk.

        No patients with renal impairment (serum creatinine exceeding the upper limit of normal).

        No patients with a history of intolerance to previous exposure to amantadine.

        No patients with an MMSE of less than 18/30.

        No patients receiving other anti-chorea therapies (such as Haldol). Those receiving other
        anti-chorea therapies must stop taking these medications for at least 4 weeks prior to the
        study to be eligible.

        No pregnant women.

        Patients must practice effective means of birth control.",Treatment of Huntington's Chorea With Amantadine,1
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","All patients will carry a diagnosis of Parkinson's Disease based on the presence of a
        characteristic clinical history and neurological findings. Symptom severity will range from
        Hoehn & Yahr stage II-IV.

        Males and females between the ages 30-76 are eligible for the study.

        Initial emphasis will be on patients who are taking few or no other medications than
        levodopa for their Parkinson's disease.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risk.

        No patients with a history of significant cardiac (myocardial infarction within 12 months
        prior to study, dysrhythmia; QTc intervals greater than 440 msec).

        No patients who are convulsive, hepatic, or with renal disorders (exceeding the upper limit
        of normal values for LFT's and creatinine respectively).

        No patients with evidence of other serious medical illness, a history of alcohol or drug
        abuse, those who have participated in an investigational trial within 28 days prior to
        study, and pregnant or nursing women or anyone not practicing effective means of birth
        control.",Treatment of Parkinson's Disease With a Transdermal Skin Patch,2
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","Males and females between the ages of 30 and 75 are eligible for the study. All will carry
        the diagnosis of idiopathic Parkinson's disease based on the presence of a characteristic
        clinical history and neurological findings. All will have relatively advanced disease
        (Hoehn and Yahr Stages II to IV) with levodopa-associated motor response complications,
        including wearing-off fluctuations and peak-dose dyskinesias.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risk.

        No clinically significant laboratory abnormalities including liver enzyme elevations more
        than three times the upper limit of normal, or neutropenia (WBC less than 4000).

        No parkinson's disease patients exhibiting diphasic or end-of-dose dyskinesias or disabling
        dystonia.

        Since LY300164 is an inhibitor of CP4503A4, patients receiving certain drugs metabolized by
        that pathway will not be included.

        No patients who are unable to be treated with levodopa/carbidopa alone or a single,
        relatively short-acting dopamine agonist.

        No patients who require additional treatment with amantadine or other concomitant
        medications.

        No pregnant women or those not practicing effective means of birth control since the
        influence of any investigational compound on the unborn child and reproductive organs is
        unknown.",Study of LY300164 for the Treatment of Parkinson's Disease,1
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","Inclusion Criteria:

          -  The subjects must have the three cardinal features of PD: slowness of movement,
             resting tremor and rigidity. The signs of PD must be greater on one side.

        Exclusion Criteria:

          -  Disorders that mimic PD.

          -  Other serious medical problems.",Parkinson's Disease Treatment With Coenzyme Q10,0
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","Inclusion Criteria:

          -  Early, mild PD, not requiring medications

          -  Age 30 or older

          -  Duration from time of diagnosis of PD: less than 2 years

          -  Hoehn & Yahr Stage 1 or 2

          -  Exposure to levodopa or dopamine agonist of 14 days or less",Timing of Levodopa Treatment in Parkinson's Disease,1
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","Patients must discontinue all hypertensive therapy two weeks prior to entering this study.

        Patient with a serum cholesterol value of 240 mg/dl or greater.

        Patients must discontinue all lipid-lowering agents 1 month prior to entering this study.

        No patients with evidence of active liver disease (e.g. ALT greater than 1.5 times the
        upper limit of normal).

        No history of diabetes, peripheral vascular disease, coagulopathy, or any other disease
        predisposing to vasculitis or Raynaud's phenomenon.

        No women with childbearing potential unless they use an effective contraceptive method.",Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol,0
"A 57-year old farmer was diagnosed with Parkinson's disease a year ago. He experiences slowness of movement and tremors. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with planting and taking care of their farm animals before his diagnosis. The patient complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is on Levodopa and Trihexyphenidyl. He stated his medications help with shaking and slow movement. But he still has difficulty initiating movements, stiffness and slowness in general. He is an alert and cooperative man who doesn't have any signs of dementia. He doesn't smoke or use any illicit drugs.","Males and females between the ages of 30-80.

        Carry the diagnosis of idiopathic Parkinson's disease based on the presence of a
        characteristic clinical history and neurologic findings.

        Patients with relatively advanced disease (Hohen and Yahr stage II-IV in the off state).

        Patients with Parkinson's disease who have been treated with levodopa for at least one
        year.

        Patients with Parkinson's disease who require levodopa/carbidopa dosing at qid or more
        frequent intervals.

        Will have been receiving a stable regimen of treatment for Parkinson's disease for at least
        4 weeks prior to study admission.

        Patients with Parkinson's disease who have associated motor response complications,
        including wearing-off fluctuations and peak-dose dyskinesias.

        Must be able to provide written informed consent.

        Patients with non-idiopathic parkinsonism or parkinsonian variants (e.g. juvenile
        Parkinson's disease; atypical parkinsonism; secondary parkinsonism; progressive
        supra-nuclear palsy; Shy-Drager syndrome; olivopontocerebellar atrophy will be excluded.

        Patients with a clinically significant illness of any organ system, including hepatic,
        renal, pancreatic, cardiovascular, endrocrinologic, gastrointestinal, respiratory, and
        neurologic system (except for those with Parkinson's disease) who may require a change in
        the treatment of that illness during the trial, or that may compromise the safety of the
        patient volunteer during the trial, or that may affect the ability of the volunteer to
        complete the trial will be excluded.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risk, including cancer (except basal cell carcinoma or
        surgically excised carcinoma in situ of the cervix) as well as liver or pancreatic enzyme
        test results above the upper limit of normal.

        Patients who have had bilateral intracranial neurosurgical procedures such as nuclear
        ablation, stimulator implantation or tissue transplantation will be excluded.

        Patients with a history of seizures, including one or more infantile febrile seizures, or
        with a history of neuroepileptic malignant syndrome will be excluded.

        Patients who, for any reason, are judged by the investigator to be inappropriate for the
        study (including volunteers who are unable to communicate or to cooperate with the
        investigator) will be excluded.

        Patients with significant dementia (MMSE 25 or less), major psychotic illness, history of
        drug or alcohol abuse within past two years, and those who require drug therapy for a
        DSM-IV major depressive episode will be excluded.

        Patients who satisfy DSM-IV criteria for alcohol or other drug abuse or dependence within
        two years of being exposed to KW-6002 will be excluded.

        Patients who have been treated with a centrally acting dopamine antagonist drug, including
        neuroleptic agents, metoclopramide and buspirone within three months (within six months for
        depot formulations) because of the potential liability for extrapyramidal side effects will
        be excluded.

        Patients taking nonselective monoamine oxidase inhibitors (phenelzine, isocarboxazid,
        tranylcypromine) will be excluded.

        Patients who have taken terfenadine, astemizole, cisapride, simvastatin, lovastatin,
        felodipine, or nifedipine within seven days before being exposed to KW-6002 will be
        excluded.

        Patients who have previously been exposed to KW-6002 or who have been treated with any
        other investigational agents within 12 weeks (or within five half-lives for investigational
        agents with a half-life of longer than 2 weeks) of being exposed to KW-6002 will be
        excluded.

        Patients with unacceptable prior/concomitant medications as will patients who have taken an
        investigational drug within the 2 months prior to randomization will be excluded.

        Pregnant will be excluded.

        Females who are of childbearing potential must be using a reliable method of contraception
        at the time they agree to study participation and must agree to continue using a reliable
        method of contraception include hormonal products (e.g. approved oral contraceptives or
        long-term injectable or implantable contraceptives), double barrier methods (e.g. condom
        plus diaphragm; condom plus spermicidal foam; condom plus spermicidal sponge). an
        intra-uterine device or tubal ligation.

        All female volunteers of child-bearing potential must have a negative urine pregnancy test
        on the day before first exposure to KW-6002.

        No patients taking any medications listed in Section 6.2, Forbidden Medications.",KW-6002 to Treat Parkinson's Disease,1
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","Inclusion Criteria:

        M/F ages 21-45 with a history of smoked cocaine use at least twice a week for the past six
        months, including 0.5 g of cocaine in a 24hr period on at least one occasion. In good
        health as evidenced by physical exam and complete blood count, chest X-ray and electrolyte
        and liver function tests, with a normal resting 12-lead electrocardiograph (ECG) and blood
        pressure of less than 140/90 mmHg. Using an acceptable method of birth control. Having a
        urine toxicology screen positive for cocaine metabolites.

        Exclusion Criteria:

        Any DSM-IV Axis I disorder other than cocaine abuse or dependence, or dependence or daily
        use of psychoactive drugs other than nicotine or caffeine. A history of violence and/or
        currently on probation, parole or awaiting trial. Pregnant as determined by serum pregnancy
        screen, lactating or having delivered a child in the past 12 months. Seropositive tests for
        the human immunodeficiency virus (HIV) or hepatitis B. History of seizure disorder.",Acute Withdrawal From Smoked Cocaine - 9,0
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","Inclusion Criteria

        Volunteers must have:

          -  Normal history and physical exam.

          -  HIV negativity.

          -  Absolute CD4 count >= 400 cells/mm3.

          -  Normal urine dipstick with esterase and nitrite.

          -  Lower risk sexual behavior.

        Exclusion Criteria

        Co-existing Condition:

        Subjects with the following symptoms or conditions are excluded:

          -  Positive hepatitis B surface antigen.

          -  Medical or psychiatric condition (such as recent suicidal ideation or present
             psychosis) that precludes compliance.

          -  Active syphilis. NOTE: Subjects with serology documented to be a false positive or due
             to a remote (> 6 months) treated infection are eligible.

          -  Active tuberculosis. NOTE: Subjects with a positive PPD and a normal chest x-ray
             showing no evidence of TB and not requiring isoniazid therapy are eligible.

        Subjects with the following prior conditions are excluded:

          -  History of immunodeficiency, chronic illness, autoimmune disease, or use of
             immunosuppressive medications.

          -  History of anaphylaxis or other serious adverse reactions to vaccines.

          -  History of serious allergic reaction to any substance, requiring hospitalization or
             emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension).

          -  Prior psychiatric condition (such as history of suicide attempts or past psychosis)
             that precludes compliance.

          -  History of cancer unless there has been surgical excision that is considered to have
             achieved cure.

        Prior Medication:

        Excluded:

          -  Live attenuated vaccines within 60 days prior to study entry. NOTE: Medically
             indicated killed or subunit vaccines (e.g., influenza, pneumococcal) do not exclude if
             administered at least 2 weeks from HIV immunizations.

          -  Experimental agents within 30 days prior to study entry.

          -  Prior HIV vaccines.

        Prior Treatment:

        Excluded:

          -  Blood products or immunoglobulin within the past 6 months.

        Identifiable high-risk behavior for HIV infection, including:

          -  History of injection drug use within past 12 months.

          -  Higher risk sexual behavior.","A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers",0
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Confirmed diagnosis of hereditary angioedema (HAE) based upon C4 antigenic level,
             positive family history, and C1 inhibitor (C1INH) antigenic level (Type I HAE) or
             functional level (Type II HAE)

          -  Functional C1 within normal levels if diagnosis of acquired C1INH is possible

          -  Negative family history will not exclude as long as patient meets all other criteria,
             has normal C1 level, and has no evidence of acquired C1INH deficiency

          -  History of symptoms of HAE including episodic swelling, abdominal pain, and/or
             respiratory difficulty

          -  Experiencing a minimum of 1-2 HAE episodes within 6 weeks

        --Prior/Concurrent Therapy--

          -  Endocrine therapy: Anabolic steroids allowed as long as dose has not been changed in
             at least 30 days

          -  Other: No concurrent and at least 1 week since prior aspirin, nonsteroidal
             antiinflammatory agents, dipyridamole, Coumadin-like drugs, or any other medication
             having an effect on coagulation or platelets

        --Patient Characteristics--

          -  Hematopoietic: No clinically significant history of hematologic disease

          -  Hepatic: No clinically significant history of hepatic disease

          -  Renal: No clinically significant history of renal disease

          -  Cardiovascular: No clinically significant history of cardiac disease or hypertension

          -  Pulmonary: No clinically significant history of pulmonary disease

          -  Other: No contraindication to the use of inhaled or subcutaneous heparin No drug
             allergy that would interfere with the study No clinically significant history of:
             Malignancy Diabetes mellitus Neurologic disease Immunologic disease Bleeding disorder
             Infirmity No history of drug abuse, alcoholism, psychosis, or other
             psychological/psychiatric disorder",Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations,0
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","Inclusion criteria for probands: Onset of hypertension by age 60 years and the presence of
        at least one additional hypertensive sibling who was willing to participate. Hypertension
        was defined according to systolic BP 140 or diastolic BP 90 in at least two different
        evaluations, or treatment for hypertension. Volunteers with type 1 diabetes or renal
        failure were excluded.

        Inclusion criteria for subsequent recruits: Criteria as indicated in Study Population
        Description (i.e., criteria based on familial relationships, hypertension and
        antihypertensive medication status).",Family Blood Pressure Program - HyperGEN,0
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","Diagnosis of ITP, based on the history, physical examination, complete blood count, and
        examination of the peripheral smear, which should exclude other causes of thrombocytopenia.
        These criteria for ITP are based on the American Society of Hematology practice guideline
        for ITP.

        Subjects 5 years of age or older.

        Before the study specific procedure, the subject or legally acceptable representative must
        give written informed consent(s) for participation in the study.

        No subjects with documented history of Human Immunodeficiency Virus (HIV) or Hepatitis.

        No subjects with known underlying causes of thrombocytopenia such as lupus erythematosus,
        autoimmune thyroid disorders, drug-induced thrombocytopenia, bone marrow disorders, and
        liver disease.

        No psychiatric or addictive disorders that compromise the subject's ability to give truly
        informed consent for participation in the study.","An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers",0
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","Confirmed diagnosis of sickle cell trait.

        Greater than age 17.

        No active systemic infection or history of recurrent infections requiring intravenous
        antibiotic treatment .

        Normal renal function: creatinine less than 2X normal, or proteinuria less than 1+.

        Normal liver function: bilirubin less than 2X normal, transaminases within normal limits.

        Normal blood count: WBC 3,000-10,000/mm3, granulocytes greater than 1,500/mm3, platelets
        greater than 150,000/mm3, hemoglobin greater than 12.5g/dL, MCV and MCHC within normal
        limits.

        Female volunteers of childbearing age should have a negative serum pregnancy test within
        one week of beginning G-CSF administration.

        Eligible for normal blood donation (i.e. tested negative for syphilis (RPR), hepatitis B
        and C (Hasbro, Anti-Hubcap, Anti-HCV), HIV, and HTLV-1.

        Subject must give informed consent to participate in the protocol.

        No history of sickle cell crises.

        Children less than 18 years of age are excluded as is per routine for normal volunteer
        protocols.

        No active systemic viral, bacterial, fungal, or parasitic infection.

        No female volunteers with positive pregnancy test or who are lactating.

        No history of autoimmune disease, such as rheumatoid arthritis and systemic lupus
        erythematosus.

        No history of cancer excluding squamous or basal cell carcinoma of the skin.

        No history of any malignant hematologic disorders.

        No history of cardiovascular disease or related symptoms such as chest pain and shortness
        of breath..

        No allergy to G-CSF or bacterial E. coli products.

        No history of G-CSF administration or leukapheresis.",Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait,0
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","-  INCLUSION CRITERIA:

        A. Women with normal ovarian function:

        Age 18 to 55.

        Normal body mass index (18-30 kg/m(2)).

        Normal menstrual cycles (between 25-35 days in length).

        Ovulatory serum progesterone concentrations (in excess of 6 ng/mL in the menstrual cycle
        just preceding the study cycle).

        B. Postmenopausal women (to serve as negative controls):

        Greater than or equal to 60 years of age.

        Proven fertility (as evidenced by a history of pregnancy regardless of outcome).

        Normal body mass index (18-30 kg/m(2)).

        Naturally menopausal: amenorrhea for at least one year; serum FSH greater than 40 IU/mL.

        C. Women carriers of FMR1 premutations:

        Age 18 to 40.

        50 to 200 CGG repeats.

        Normal menstrual cycles (between 25-35 days in length).

        Have previously had genetic counseling regarding their FMR1 status.

        EXCLUSION CRITERIA:

        History of infertility or infertility in a first degree relative.

        Acute or chronic disease.

        Menopause due to surgery, radiation, or chemotherapy.

        Current use of oral contraceptives or hormone replacement therapy, or use of these agents
        within the previous 3 months.

        Use within the previous three months of any medication known to affect the
        hypothalamic-pituitary-ovarian axis (including over-the-counter and alternative medicines).

        History of excessive exercise (greater than 10 hours a week).

        Girls will be excluded because there are no data regarding FSH use in children.

        Smokers.

        Pregnant.

        Breast feeding.

        Persistent ovarian masses.

        History of tumors of the ovary, breast, uterus, hypothalamus, or pituitary.

        History of breast or endometrial cancer.

        History of hypersensitivity to recombinant FSH or any one of its excipients.",Feasibility Study for Development of an Early Test for Ovarian Failure,0
"19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain.
She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first visit when she was at 6 weeks of gestational age. She is getting weight normally during her pregnancies.","Inclusion Criteria:

          -  Healthy individuals

          -  Insensate individuals

        Exclusion Criteria:

          -  History or physical findings of any trunk, back or lower extremity orthopedic or
             neurologic abnormalities

          -  Inability to walk

          -  Inability to follow verbal directions",How Shoes With Rocker Soles Affect Walking,0
"The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time).
The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.","Inclusion Criteria:

          -  Have dementia or Parkinson's disease and are found to aspirate on thin liquid during a
             set of qualifying swallows.

        Exclusion Criteria:

          -  Have smoked more than a pack of cigarettes per day in the last year.

          -  Drink more than 3 alcoholic beverages per day on a regular basis.

          -  Have had any head and neck cancer treatment.

          -  Have any head and neck anatomic deformities.

          -  Have a history of 20 years or longer of insulin-dependent diabetes.

          -  Have other exclusionary neurologic diagnoses.

          -  Have had pneumonia within 6 weeks of screening.

          -  Currently have a nasogastric tube.

          -  Currently have a tracheotomy.

          -  Are a resident in non-participating nursing home or assisted living environment.

          -  Live alone.

          -  Have no regular care provider present at meals.

          -  Have no Speech-Language Pathologist to provide a 3-month follow-up.",Randomized Study of Two Interventions for Liquid Aspiration: Short-Term and Long-Term Effects,1
"The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time).
The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.","Inclusion Criteria

        Patients must have:

          -  ARC or AIDS by CDC criteria.

          -  Uncontrolled diarrhea unresponsive to high-dose, nonspecific antidiarrheal therapy.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Known idiopathic ulcerative colitis or Crohn colitis.

          -  Acute stool-culture-positive bacterial colitis.

          -  Acute amoebic colitis.

          -  Pseudomembranous colitis with Clostridium difficile toxin positivity.

          -  Short-gut syndrome.

          -  Chronic pancreatitis.

          -  Ischemic bowel disease.

          -  Enteroenteric fistulae.

          -  Other gastrointestinal tract disorders known to cause diarrhea.

          -  Underlying evidence of immunosuppression other than that related to HIV infection.

          -  Unable or unwilling to have subcutaneous injections.

          -  Clinically significant CNS, hepatic, or renal disease.

        Concurrent Medication:

        Excluded:

          -  Other experimental antidiarrheal drugs.

          -  Antibiotic therapy.

        Prior Medication:

        Excluded:

          -  Other experimental drugs within 1 month prior to study entry.

        Required:

          -  At least 2 weeks of prior high-dose, nonspecific antidiarrheal therapy (i.e.,
             loperamide, diphenoxylate hydrochloride-atropine sulfate, or opiates) at maximally
             tolerable doses.",Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea,0
"The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time).
The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.","DISEASE CHARACTERISTICS: Leukemia, lymphoma, or Hodgkin's disease OR Stem cell
        transplantation or bone marrow transplantation (allogenic or autologous) for a neoplastic
        disease Absolute granulocyte count no greater than 1,000/mm3 anticipated to fall below
        500/mm3 within 24-48 hours, and expected to last for longer than 7 days from onset of fever
        Fever (i.e., oral or axillary temperature at least 38.5 degrees C or 101.3 degrees F once,
        or at least 38 degrees C or 100.4 degrees F on two or more occasions separated at least by
        1 hour during a 12 hour period) Presumed infection

        PATIENT CHARACTERISTICS: Age: 2 and over Performance status: Not moribund or comatose for
        any reason with little hope of recovery Life expectancy: At least 48 hours Hematopoietic:
        See Disease Characteristics Hepatic: No hepatic stupor or coma Renal: Adults: No renal
        failure requiring hemodialysis or peritoneal dialysis OR Creatinine no greater than 2.25
        mg/dL OR Creatinine clearance at least 40 mL/min Children: No renal impairment (i.e.,
        creatinine greater than upper limit of normal) Pulmonary: No lung infiltrate Other: No
        known allergy to piperacillin, tazobactam, or vancomycin No history of immediate or
        accelerated reaction to beta-lactam antibiotics No prior inclusion in this study No
        catheter related infection No known HIV infection Not pregnant or nursing

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not
        specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
        specified Other: At least 4 days since prior intravenous antibacterial agents Oral
        antibiotics for prophylaxis of bacterial infection allowed At least 30 days since prior
        treatment with any other investigational antibiotic No other concurrent antibiotics except
        trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia",Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count,0
"The patient is a 14-year-old boy complaining of scoliosis and back pain. He has no other medical condition. He used to be able to play routine activities such as basketball and soccer, however, he recently has problem doing them. The pain is in his leg and back and aggravated by physical activities. He prefer lying down most of the time. He is not happy with his body gesture and complaints of shoulder imbalance and shifting his head to right. Patient is a well-dressed and well-nourished adolescent who is alert and cooperative. The left shoulder is slightly higher than the right shoulder. The scoliotic curve is measured as 45 degree. The patients is candidate for scoliosis surgery according to perioperative MEP monitoring","DISEASE CHARACTERISTICS:

        Histologically confirmed adult T-cell leukemia/lymphoma (ATL) or cutaneous T-cell lymphoma
        (CTCL).

        Reactivity of at least 10% of peripheral blood, lymph node, or dermal malignant cells with
        anti-Tac as determined by immunofluorescent staining or soluble IL-2 receptor level greater
        than 1,500 U required.

        All stages of Tac-expressing T-cell leukemia and lymphoma eligible except Stage I CTCL.

        All forms of ATL eligible, including the ""smoldering"" type as well as aggressive disease.

        No symptomatic CNS disease other than tropical spastic paraparesis.

        Asymptomatic CNS disease with demonstrable malignant cells in the CSF allowed (such
        patients receive CNS therapy, e.g., intrathecal methotrexate and/or CNS irradiation, as
        appropriate).

        PRIOR/CONCURRENT THERAPY:

        Biologic Therapy: Not specified.

        Chemotherapy:

        CTCL must have failed initial chemotherapy.

        ATL may or may not have had prior chemotherapy.

        At least 4 weeks since prior cytotoxic chemotherapy.

        Endocrine Therapy: Not specified.

        Radiotherapy: At least 4 weeks since prior radiotherapy.

        Surgery: Not specified.

        PATIENT CHARACTERISTICS:

        Age: 18 and over.

        Performance status: Not specified.

        Life expectancy: Greater than 1 month.

        Hematopoietic: WBC at least 3,000, Platelets at least 75,000.

        Hepatic: Not specified.

        Renal: Not specified.

        Other:

        No pregnant women.

        Negative pregnancy test required of fertile women.",Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac,0
"The patient is a 14-year-old boy complaining of scoliosis and back pain. He has no other medical condition. He used to be able to play routine activities such as basketball and soccer, however, he recently has problem doing them. The pain is in his leg and back and aggravated by physical activities. He prefer lying down most of the time. He is not happy with his body gesture and complaints of shoulder imbalance and shifting his head to right. Patient is a well-dressed and well-nourished adolescent who is alert and cooperative. The left shoulder is slightly higher than the right shoulder. The scoliotic curve is measured as 45 degree. The patients is candidate for scoliosis surgery according to perioperative MEP monitoring","DISEASE CHARACTERISTICS:

          -  Histologically or cytologically proven newly diagnosed, stage IIIA (T1-3, N2)
             non-small cell lung cancer

               -  Eligible subtypes:

                    -  Adenocarcinoma

                    -  Large cell carcinoma

                    -  Squamous cell carcinoma

                    -  Nonlobar and nondiffuse bronchoalveolar cell carcinoma

          -  Measurable or evaluable disease on chest x-ray and/or contrast CT scan

               -  Contrast thoracic CT required to complete staging

          -  Single primary bronchogenic tumor (no more than 1 parenchymal lung lesion)

          -  Pleural effusions allowed if 1 of the following conditions is met:

               -  Negative cytology on thoracentesis if effusions present before mediastinoscopy or
                  exploratory thoracotomy

               -  Effusion seen on CT scan but not on chest x-ray and deemed too small to tap under
                  CT or ultrasound guidance

          -  Positive ipsilateral mediastinal node(s) with or without positive ipsilateral hilar
             nodes

               -  Mediastinal nodes separate from primary lesion on CT scan or surgical exploration

               -  Histologic or cytologic proof of N2 disease by thoracotomy, mediastinoscopy,
                  mediastinotomy, Chamberlain procedure, Wang needle, or fine needle aspiration
                  under bronchoscopic or CT guidance

               -  Nodal biopsy or aspiration waived if all of the following conditions are met:

                    -  Paralyzed left true vocal cord documented by bronchoscopy or indirect
                       laryngoscopy

                    -  Nodes visible in Level 5 region on CT scan

                    -  Distinct primary lesion separate from nodes on CT scan

               -  All mediastinal nodal involvement mapped (positive or negative)

          -  No positive nodes in contralateral mediastinum (supraclavicular areas and higher) and
             neck

               -  Mediastinoscopy, mediastinotomy, Chamberlain procedure, or thoracotomy required
                  for nodes larger than 1 cm on contrast CT scan

               -  Surgery waived if nodes negative or no larger than 1 cm on CT scan

          -  Lymphadenopathy allowed if biopsy proof of a benign cause

          -  No metastases by contrast CT or MRI scan of the brain, bone scan, CT scan of the lungs
             to exclude other ipsilateral or contralateral parenchymal lesions, and contrast CT
             scan of the upper abdomen including entire liver and adrenals

          -  No hepatomegaly or splenomegaly by physical examination or CT scan unless
             documentation of a benign cause

          -  No pericardial effusion

          -  No superior vena cava syndrome

          -  No prior diagnosis of lung cancer

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 90-100% (70-80% allowed if albumin at least 0.85 times lower limit of normal
             and weight loss no greater than 10% within 3 months before diagnosis)

        Hematopoietic:

          -  White blood cell count (WBC) at least 4,000/mm^3 OR

          -  Granulocyte count at least 2,000/mm^3

          -  Platelet count normal

          -  Hemoglobin at least 10.0 g/dL (less than 8.5 g/dL allowed if no marrow involvement
             with tumor)

        Hepatic:

          -  See Performance status

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)*

          -  Serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate
             transaminase (SGPT) no greater than 1.5 times ULN* NOTE: * Unless documentation of a
             benign cause

        Renal:

          -  Creatinine clearance at least 50 mL/min

        Cardiovascular:

          -  No myocardial infarction within the past 3 months

          -  No active angina

          -  No unstable arrhythmia

          -  No congestive heart failure

        Pulmonary:

          -  Forced expiratory volume at one second (FEV1) at least 2.0 liters OR

          -  Predicted postresection FEV1 at least 800 mL based on quantitative V/Q scan

          -  Diffusion capacity of lung for carbon monoxide (DLCO) at least 50% predicted
             (corrected for hemoglobin) if pneumonectomy planned or likely after induction
             chemotherapy

        Other:

          -  No clinically significant hearing loss unless willing to accept the potential of
             further loss

          -  No symptomatic peripheral neuropathy

          -  No peptic ulcer disease under active treatment

          -  No other medical illness not controllable by appropriate medical therapy

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or ductal or lobular
             carcinoma in situ of the breast

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent colony-stimulating factors

        Chemotherapy:

          -  No prior chemotherapy for lung cancer

          -  No concurrent chemotherapy for another condition (such as arthritis)

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy for lung cancer

        Surgery:

          -  See Disease Characteristics

          -  No prior resection of primary tumor",Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer,0
"The patient is a 14-year-old boy complaining of scoliosis and back pain. He has no other medical condition. He used to be able to play routine activities such as basketball and soccer, however, he recently has problem doing them. The pain is in his leg and back and aggravated by physical activities. He prefer lying down most of the time. He is not happy with his body gesture and complaints of shoulder imbalance and shifting his head to right. Patient is a well-dressed and well-nourished adolescent who is alert and cooperative. The left shoulder is slightly higher than the right shoulder. The scoliotic curve is measured as 45 degree. The patients is candidate for scoliosis surgery according to perioperative MEP monitoring","DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma or adenocarcinoma
        of the upper, middle, or lower third esophagus Stage I, II, or III disease Measurable
        disease No distant metastases Negative liver biopsy Negative bone scan unless due to benign
        disease No tracheobronchial involvement No vocal cord paralysis No phrenic nerve
        involvement No celiac axis lymph node involvement unless due to primary cancer at
        gastroesophageal junction No evidence of disseminated cancer

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
        least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL
        SGOT/SGPT no greater than 2 times upper limit of normal (ULN) Alkaline phosphatase no
        greater than 2 times ULN Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance
        at least 60 mL/min Cardiovascular: No uncontrolled or severe cardiovascular disease No
        congestive heart failure No myocardial infarction within the past 6 months No severe or
        uncontrolled hypertension (systolic greater than 150 mmHg and diastolic greater than 100
        mmHg) Pulmonary: FEV1/FVC at least 75% predicted Arterial blood saturation at least 92%
        Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective
        contraception No other malignancy except curatively treated nonmelanoma skin cancer or
        carcinoma in situ of the cervix No other serious medical illness that would limit survival
        to fewer than 2 years No active uncontrolled bacterial, viral, or fungal infection No
        active uncontrolled duodenal ulcer No psychiatric disorder that would preclude study

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior chest radiotherapy
        Surgery: No prior surgical resection of tumor Other: No prior therapy for esophageal cancer","Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer",0
"The patient is a 14-year-old boy complaining of scoliosis and back pain. He has no other medical condition. He used to be able to play routine activities such as basketball and soccer, however, he recently has problem doing them. The pain is in his leg and back and aggravated by physical activities. He prefer lying down most of the time. He is not happy with his body gesture and complaints of shoulder imbalance and shifting his head to right. Patient is a well-dressed and well-nourished adolescent who is alert and cooperative. The left shoulder is slightly higher than the right shoulder. The scoliotic curve is measured as 45 degree. The patients is candidate for scoliosis surgery according to perioperative MEP monitoring","-  INCLUSION CRITERIA:

        All patients greater than or equal to 12 months of age with tumors of the CNS of interest
        to the NOB, who may be candidates for another NOB trial at some point in the future.

        Patients with tumors of the CNS that are of particular interest to members of the NOB
        because they pose important clinical and/or scientific questions and/or shed light on
        important aspects of the disease.

        Patients with tumors of the CNS who offer an important educational benefit to
        neuro-oncology trainees and staff.

        Ability of subject or Legally Authorized Representative (LAR) to understand and the
        willingness to sign a written informed consent document. Availability of a parent or legal
        guardian to give informed consent for children.

        EXCLUSION CRITERIA:

        Patients less than 12 months of age.",Natural History of Patients With Brain and Spinal Cord Tumors,0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Men and women, ages 18 to 50, who had at least three emergency room visits or
        hospitalizations for sickle cell anemia during the year prior to recruitment. Patients with
        greater than 20 crises per year were included. A total of 295 patients had Hb ss and four
        had Hb SB thalassemia.",Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH),2
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Oral antiemetics.

        Patients must have the following for inclusion:

          -  HIV positive by ELISA, p24 antigen or culture.

          -  Pneumocystis carinii pneumonia (PCP).

          -  Patients must have an (A-a) DO2 < 40 mmHg on room air.

          -  Willingness to sign an informed consent.

        Prior Medication:

        Allowed:

        - Prophylaxis for Pneumocystis carinii pneumonia (PCP) with agents other than clindamycin
        and primaquine.

        Exclusion Criteria

        Concurrent Medication:

        Excluded:

          -  Hematotoxic therapy, including zidovudine (AZT) or ganciclovir.

        Patients with the following are excluded:

          -  History of allergy to clindamycin, lincomycin, or related drugs; or to primaquine or
             related drugs.

          -  Positive screen for G6PD deficiency, known NAD methemoglobin reductase deficiency,
             and/or known hemoglobin M abnormality.

          -  Concomitant conditions defined in Patient Exclusion Co-Existing Conditions.

          -  Any medical or social situation which, in the opinion of the investigator, would
             adversely affect participation in the study.

          -  Note:

        Patients may be enrolled while G6PD screen is pending, but must be withdrawn if results are
        not known within 5 days after entry.

        Prior Medication:

        Excluded within 14 days of study entry:

          -  Systemic steroids at doses exceeding physiologic replacement or other investigational
             agents.

          -  Excluded within 6 weeks of study entry:

          -  Prior institution of any antiprotozoal therapy for the current episode of Pneumocystis
             carinii pneumonia or prophylaxis.

        Patients must not have any of the following symptoms or diseases:

          -  History of allergy to clindamycin, lincomycin, or related drugs; or to primaquine or
             related drugs.

          -  Positive screen for G6PD deficiency, known NAD methemoglobin reductase deficiency,
             and/or known hemoglobin M abnormality.

          -  Diarrhea, defined as = or > 3 watery stools per day.

          -  Severe nausea and vomiting or other medical condition, such as ileus, that precludes
             oral therapy.

          -  Ventilator dependence or (A-a) DO2 = > 30 mm Hg.

          -  Any medical or social situation which, in the opinion of the investigator, would
             adversely affect participation in the study.

          -  Note:

        Patients may be enrolled while G6PD screen is pending, but must be withdrawn if results are
        not known within 5 days after entry.",The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS,0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Inclusion Criteria

        Patients must have:

          -  HIV infection.

          -  CD4 count <= 200 cells/mm3 OR a history of prior PCP.

          -  No active pneumocystosis. Patients or their guardians must sign informed consent.
             Pregnant patients are eligible at the clinician's discretion. Patients who do not meet
             required laboratory values may be eligible at the discretion of the clinician.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

          -  Known treatment-limiting reaction to sulfonamides or trimethoprim.

        Concurrent Medication:

        Excluded:

          -  Other PCP prophylaxis or medication with anti-PCP activity.","A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients",0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Inclusion Criteria

        Concurrent Medication: Strongly recommended:

          -  Pyrimethamine (50 mg) and folinic acid (15 mg) weekly in patients receiving dapsone
             who have CD4 count < 100 cells/mm3 and are toxoplasmosis seropositive.

        Patients must have:

          -  Working diagnosis of HIV infection.

          -  CD4 count <= 200 cells/mm3 or <= 15 percent of total lymphocyte count at any time in
             the past OR a history of PCP.

          -  History of intolerance of trimethoprim and/or sulfonamides that required permanent
             discontinuation.

        NOTE:

          -  Pregnant patients are eligible at the clinician's discretion.

        Prior Medication:

        Allowed:

          -  Prior PCP prophylaxis.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Active pneumocystosis.

        Concurrent Medication:

        Excluded:

          -  PCP prophylaxis (other than study drug) or any medication with potential anti-PCP
             activity.

        Patients with the following prior conditions are excluded:

          -  Known treatment-limiting reaction to dapsone or atovaquone.","A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides",0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Inclusion Criteria

        Patient must:

          -  Have Pneumocystis carinii pneumonia (PCP) that has not been treated for current
             episode. PCP must be documented by observation of > 1 cluster of organisms in sputum,
             bronchial secretion, or lung tissue.

          -  Have clinical symptoms of respiratory disease or radiologic abnormalities.

        Exclusion Criteria

          -  Patient cannot have significant emotional disorder.

        Concurrent Medication: Excluded:

          -  Drugs likely to be bone marrow toxic.

          -  Investigational drugs.

        Prior Medication: Excluded:

          -  Three patients in each group cannot have had zidovudine (AZT) for at least 2 months
             prior to administration of trimetrexate.",A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP,0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Acetaminophen:

          -  650 mg prescribed as necessary for temperature > 38.7 degrees C. Acetaminophen should
             not be prescribed as a standing order for more than 48 hours.

        Prior Medication:

        Allowed:

          -  Zidovudine (AZT) as long as such therapy is suspended prior to randomization and not
             reinstituted until therapy for the acute episode is completed and the patient's white
             blood cell count is acceptable.

          -  Other myelosuppressive therapies which may be handled in the same manner as AZT.

          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP).

          -  Unequivocal diagnosis of Pneumocystis carinii pneumonia (PCP) by morphologic
             confirmation of three or more typical P. carinii organisms in sputum, bronchoalveolar
             lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3
             days before or after randomization. If morphologic confirmation is not possible prior
             to therapy, patients may be randomized if the investigator believes there is a high
             suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be
             established within 6 days of randomization, the patient will be withdrawn from study
             therapy. Resting (A-a) DO2 < 30 torr on room air. Patient, parent, guardian, or person
             with power of attorney gives informed consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients will be excluded for the following reasons:

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reaction secondary to antibiotics
             containing sulfa, trimethoprim, or trimetrexate.

          -  History of life-threatening pentamidine toxicity.

        Concurrent Medication:

        Excluded:

          -  Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia
             (PCP).

          -  Disalcid.

          -  Aspirin.

          -  Acetaminophen q4h as a standing order for more than 48 hours.

        Prior Medication:

        Excluded within 14 days of study entry:

          -  Systemic steroids exceeding physiological replacement.

          -  Other investigational drugs including ganciclovir.

          -  Excluded within 6 weeks of study entry:

          -  Another antiprotozoal regimen for this episode for therapy of active Pneumocystis
             carinii pneumonia (PCP).

          -  Patients who are unable to have arterial blood gas analysis (ABG's) on room air.

          -  Patients for whom a liter of intravenous fluid (5 percent dextrose in water) per 24
             hours, which is required to maintain blinding, would be medically inadvisable.",Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Acetaminophen 650 mg prescribed as necessary for temperature > 38.7 degrees C.
             Acetaminophen q4h should not be prescribed as a standing order for more than 48 hours.

        Prior Medication:

        Allowed:

          -  Zidovudine as long as such therapy is suspended prior to randomization and not
             reinstituted until therapy for the acute episode is completed.

          -  Prophylaxis for Pneumocystis carinii pneumonia (PCP).

          -  Unequivocal diagnosis of Pneumocystis carinii pneumonia (PCP) by morphologic
             confirmation of three or more typical P. carinii organisms in sputum, bronchoalveolar
             lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3
             days before or after randomization. If morphologic confirmation is not possible prior
             to therapy, patients may be randomized if the investigator believes there is a high
             suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be
             established within 6 days of randomization, the patient will be withdrawn from study
             therapy.

          -  Resting alveolar-arterial oxygen differences = or > 30 mm Hg on room air.

        Exclusion Criteria

        Patients with the following are excluded:

          -  Inability to have alveolar blood gas analysis on room air.

          -  Medically unable to receive a liter of intravenous fluid (5 percent dextrose in water)
             per 24 hours. This procedure is required in order to maintain blinding.

        Prior Medication:

        Excluded within 14 days of study entry:

          -  Systemic steroids exceeding physiological replacement.

          -  Other investigational drugs.

          -  Excluded within 6 weeks of study entry:

          -  Antiprotozoal regimen for this episode consisting of pentamidine, eflornithine, DFMO,
             or dapsone, for therapy of active Pneumocystis carinii pneumonia (PCP)

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reaction secondary to antibiotics
             containing sulfa, trimethoprim, or trimetrexate.

          -  History of life-threatening pentamidine toxicity.

          -  Requirement for treatment with agents that are known to be myelosuppressive or
             nephrotoxic during the period of acute Pneumocystis carinii pneumonia (PCP) therapy.

          -  Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia
             (PCP); disulcid; aspirin; acetaminophen q4h for more than 48 hours.",Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS,0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Inclusion Criteria

        Patients must have:

          -  HIV infection.

          -  CD4 count <= 200 cells/mm3 or <= 15 percent of total lymphocytes OR a history of prior
             PCP.

          -  History of intolerance to trimethoprim and/or sulfonamides.

          -  No active pneumocystosis. Patient or guardian must sign informed consent. Pregnant
             patients are eligible at the clinician's discretion. Patients who do not meet required
             laboratory values may be eligible at the discretion of the clinician.

        Exclusion Criteria

        Concurrent Medication:

        Excluded:

          -  Any medication with potential anti-PCP activity.

        Patients with the following prior conditions are excluded:

          -  Treatment-limiting reaction to pentamidine or dapsone.",A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides,0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","-  INCLUSION CRITERIA:

        A total of fifty severely affected patients with homozygous sickle cell disease or other
        sickling disorders (e.g., B negative or B positive Thalassemia/Sickle) who are greater than
        18 years of age will be eligible for treatment. Such patients must be able to tolerate an
        extensive period without blood transfusion and have relatively well preserved renal and
        hepatic function (creatinine less than 1.5 mg/dl and normal liver function test with
        exception of a mild elevation in transaminase). Evidence of severe sickle cell anemia will
        include recurrent pain crisis, chronic bone pain, evidence of aseptic necrosis with
        symptoms, and intractable leg ulcers, etc.

        EXCLUSION CRITERIA:

        Patients who are found to be HIV positive will be excluded from the study.",Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia,2
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","INCLUSION CRITERIA:

        Males or females 18 to 65 years of age.

        Diagnosis of sickle cell disease (electrophoretic documentation of SS homozygosity is
        required) or identification as a normal volunteer.

        Hematocrit greater than 18% (with an absolute reticulocyte count greater than 100,000/ml).

        Hematocrit 18-21% (with an absolute reticulocyte count greater than 100,000/ml): Only 100
        ml of blood may be drawn. The study subject may be re-entered in the study after four weeks
        (with repeat full screening labs).

        EXCLUSION CRITERIA:

        Clinically unstable sickle cell anemia defined by the following:

        Having greater than two acute pain crises in the last two months; on hydroxyurea or
        butyrate therapy any time in the last 12 months; or blood transfusion within last three
        months, or % hemoglobin A greater than 20%.

        Age less than 18 years or greater than 65 years.

        Current pregnancy or lactation.

        Inability to exercise the anterior tibialis muscle.

        Active cigarette smoker-defined as the inhalation of smoke from any tobacco product in the
        last one month.

        Medical conditions: diabetes mellitus; coronary artery disease; peripheral vascular
        disease; migraine headaches in the last 12 months; history of previous CVA or stroke; or
        creatinine greater than 1.0 mg/dL.

        MRI Exclusions: cardiac pacemaker or implantable defibrillator; aneurysm clip; neural
        stimulator (e.g. TENS-Unit); any type of ear implant; or metal in the eye (e.g. from
        machining); any implanted device (e.g. insulin pump, drug infusion device); or any metallic
        foreign body, shrapnel, or bullet.

        Hematocrit less than or equal to 18 percent: will not be eligible for the study; may return
        for evaluation at a later date.

        No aspirin or non-steroidal anti-inflammatory drugs (no NSAIDS and caffeine the day of the
        study.) Patients on opiates and acetaminophen will not be excluded.

        Patients taking Viagra will be excluded from the study.",Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia,2
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Sickle cell syndromes characterized by vaso-occlusive crises
        sufficiently severe to require prophylactic therapy Three or more crises per year
        sufficiently severe to require hospitalization Stable dose of hydroxyurea for at least 4
        months required --Prior/Concurrent Therapy-- No treatment with any other antisickling
        agents within the past 4 months Biologic therapy: No transfusion within 90 days No
        concurrent chronic transfusions allowed (defined as more than one transfusion per month for
        2 or more months) Chemotherapy: See Disease Characteristics Endocrine therapy: Not
        specified Radiotherapy: Not specified Surgery: Not specified Other: No chronic medications
        that alter neurologic, renal, or hepatic functions

          -  Patient Characteristics-- Performance status: Karnofsky 70-100% Hematopoietic: WBC
             within normal limits Platelet count within normal limits Hepatic: No history of
             chronic liver disease Bilirubin less than 2 times normal SGOT and SGPT less than 2.5
             times normal No severe hepatic damage Renal: Creatinine within normal limits No severe
             renal damage Neurologic: No severe neurologic impairment No recent or progressive
             neurologic impairment Other: Not pregnant Fertile patients must use effective
             contraception No allergies to hydroxyurea or clotrimazole",Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes,2
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Sickle cell disease confirmed by electrophoresis or high pressure liquid
             chromatography

          -  At least one prior documented painful crisis episode but no greater than 10 crises per
             year for the last two years

          -  Sudden onset of acute pain lasting 4-12 hours and involving at least one site

          -  Severe crisis pain that requires parenteral analgesics and hospitalization, but not
             within the preceding 2 weeks

        --Prior/Concurrent Therapy--

          -  Surgery: At least 2 weeks since prior major surgery No concurrent surgery

          -  Other: At least 2 weeks since prior puncture of noncompressible vessels No prior
             therapy using poloxamer 188 No concurrent investigational drug No concurrent use of
             nonsteroidal anti-inflammatory drugs

        --Patient Characteristics--

          -  Hematopoietic: No significant bleeding or bleeding disorder

          -  Hepatic: ALT no greater than 2 times normal

          -  Renal: No active renal disease Creatinine no greater than 1.0 mg/dL OR Creatinine
             clearance greater than 50 mL/min Protein less than 300 mg/dL

          -  Cardiovascular: No evidence of acute myocardial ischemia or infarction

          -  Neurologic: At least 6 months since prior cerebrovascular accident or seizure

          -  Other: Not pregnant Fertile patients must use effective contraception during and for
             at least 30 days after treatment No history of chronic bacterial osteomyelitis No
             history of drug or alcohol abuse At least 6 months since prior use of illicit drug
             Have adequate IV access No crisis with life-threatening complications such as: Hepatic
             or splenic sequestration Acute chest syndrome Aplastic crisis No known infection or
             infection with encapsulated organism No evidence of septic shock Not concurrently
             hospitalized for other conditions Not concurrently on hypertransfusion program",Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease,2
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of sickle cell anemia with clinically severe disease manifestations defined by:
        Recurrent painful events (at least 2 painful events in past year) which cannot be explained
        by other causes Pain lasts at least 4 hours Requires treatment with parenteral narcotics,
        equianalgesic dose of oral narcotics, or parenteral nonsteroidal antiinflammatory drugs
        Acute chest syndrome (ACS) with at least 2 episodes within past 2 years that required
        hospitalization, oxygen, and RBC transfusion Any combination of painful events and ACS
        episodes that total 2 events within the past year Abnormal cerebral MRI, abnormal
        angiography (MR or conventional), and abnormal neuropsychologic testing performance

        No stage III or IV sickle cell lung disease

        Genotypically HLA identical sibling donor available

        --Prior/Concurrent Therapy--

        No prior transfusions with greater than 5 units RBC

        --Patient Characteristics--

        Performance status: Karnofsky 70-100%

        Hepatic:

          -  No active hepatitis

          -  No moderate/severe portal fibrosis

        Renal: Glomerular filtration rate at least 30% predicted for age

        Neurologic:

          -  No severe residual functional neurologic impairment

          -  Hemiplegia alone allowed

        Other:

          -  HIV negative

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception",Bone Marrow Transplantation in Treating Children With Sickle Cell Disease,1
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of sickle cell anemia confirmed by hemoglobin electrophoresis

        Received hydroxyurea for at least 6 months On a stable dose for at least 3 months
        Tolerating dose of at least 5 mg/kg/day

        --Prior/Concurrent Therapy--

        Chemotherapy:

          -  No other concurrent antisickling agent

        Other: No concurrent drug that may interact with or influence the metabolism of hydroxyurea
        or clotrimazole

        --Patient Characteristics--

        Hematopoietic: WBC at least 4000/mm3 Platelet count at least 150,000/mm3 Hemoglobin less
        than 11 g/dL

        Hepatic: AST/ALT no greater than 100 units/L

        Renal: Creatinine no greater than 1.5 mg/dL

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No prior adverse reaction to hydroxyurea or clotrimazole

          -  No recent or progressive neurologic dysfunction",Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia,2
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Confirmed diagnosis of sickle cell trait.

        Greater than age 17.

        No active systemic infection or history of recurrent infections requiring intravenous
        antibiotic treatment .

        Normal renal function: creatinine less than 2X normal, or proteinuria less than 1+.

        Normal liver function: bilirubin less than 2X normal, transaminases within normal limits.

        Normal blood count: WBC 3,000-10,000/mm3, granulocytes greater than 1,500/mm3, platelets
        greater than 150,000/mm3, hemoglobin greater than 12.5g/dL, MCV and MCHC within normal
        limits.

        Female volunteers of childbearing age should have a negative serum pregnancy test within
        one week of beginning G-CSF administration.

        Eligible for normal blood donation (i.e. tested negative for syphilis (RPR), hepatitis B
        and C (Hasbro, Anti-Hubcap, Anti-HCV), HIV, and HTLV-1.

        Subject must give informed consent to participate in the protocol.

        No history of sickle cell crises.

        Children less than 18 years of age are excluded as is per routine for normal volunteer
        protocols.

        No active systemic viral, bacterial, fungal, or parasitic infection.

        No female volunteers with positive pregnancy test or who are lactating.

        No history of autoimmune disease, such as rheumatoid arthritis and systemic lupus
        erythematosus.

        No history of cancer excluding squamous or basal cell carcinoma of the skin.

        No history of any malignant hematologic disorders.

        No history of cardiovascular disease or related symptoms such as chest pain and shortness
        of breath..

        No allergy to G-CSF or bacterial E. coli products.

        No history of G-CSF administration or leukapheresis.",Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait,1
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","INCLUSION CRITERIA:

        Patients with Hb SS, Sbeta-thal, SD, or SO-Arab

        Age greater than or equal to 18 years.

        Patient must have had a previous neurologic event (either symptomatic or found by imaging
        alone).

        More than one painful crises per year for the last 2 years, each requiring hospitalization.

        A previous acute chest syndrome.

        Evidence of renal damage but with a creatinine clearance of greater than 50 percent of
        normal.

        Red cell alloimmunization.

        Bilateral retinopathy.

        Osteonecrosis of multiple bones.

        Unilateral or bilateral leg ulcers.

        Patients who have failed a course of hydroxyurea or who have declined to take hydroxyurea.

        Able to give informed consent.

        No active sickle cell crises or acute chest syndrome.

        No active uncontrolled infection.

        No hydroxyurea, erythropoietin, and/or arginine butyrate therapy in the previous month.

        No patients receiving hypertransfusion therapy.

        No current treatment (or within 2 weeks) with hematopoietic growth factors.

        No allergy to E. coli derived products.

        No history of seasonal or recurrent asthma within the 5 preceding years.

        No asthmatic symptoms (e.g. wheezing) related to a current respiratory tract infection.

        No other significant IgE-mediated hypersensitivities (including but not limited to allergic
        rhinitis, allergic eczema, anaphylactic reactions, congenital or acquired angioedema, and
        urticaria,). An isolated episode of urticaria occurring within the 5 years is not a
        contraindication. Patients with drug allergies manifested solely by rash are not excluded.

        No concurrent use of beta-adrenergic blocking agents.

        No concurrent use of monoamine oxidase inhibitors.

        No significant comorbid conditions including uncontrolled hypertension, congestive heart
        failure(greater NY class II), poorly controlled diabetes mellitus, and significant coronary
        artery disease with recent myocardial infarction or angioplasty (within the previous 6
        months).

        No pregnancy, breast feeding, and unwillingness to use contraception.

        No concurrent use of other investigational products.",A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders,2
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Severe hemoglobinopathy including, but not limited to the following:

        Homozygous beta thalassemia Other beta chain mutation as demonstrated by hemoglobin
        electrophoresis Sickle cell anemia (age 16 to 50 years) Evidence of one or more the
        following prior complications: Stage I-II sickle cell lung disease Sickle cell nephropathy
        (moderate to severe proteinuria or glomerular filtration rate of 30-50% predicted normal
        for age) Acute chest syndrome requiring blood transfusions More than 3 debilitating pain
        episodes per year for 3 years lasting more than 4 hours each Any combination of episodes of
        acute chest syndrome and painful episodes adding up to 3 episodes per year for 3
        consecutive years Requirement for chronic transfusions with alloimmunization (more than 2
        antibodies) Sickle cell anemia (age under 16 years) Evidence of one or more the following
        prior complications: Prior stroke or hemorrhage Any neurologic event lasting more than 24
        hours Abnormal cerebral MRI and cerebral arteriogram MRI angiographic impaired
        neuropsychologic testing Stage I-II sickle cell lung disease Sickle cell nephropathy
        (moderate to severe proteinuria or glomerular filtration rate of 30-50% predicted normal
        for age) Significant visual impairment in at least one eye with bilateral proliferative
        retinopathy Acute chest syndrome with history of recurrent hospitalizations or exchange
        transfusions Osteonecrosis of multiple joints with destructive changes More than 3
        debilitating pain episodes per year or priapism Requirement for chronic transfusions with
        alloimmunization

        OR

        Bone marrow failure syndrome unresponsive to therapy, including but not limited to the
        following: Congenital pure red cell aplasia (Diamond Blackfan anemia) Confirmed by bone
        marrow aspirate More than 6 transfusions per year despite steroid therapy Kostmann's
        neutropenia Confirmed by bone marrow aspirate Unable to maintain absolute neutrophil count
        greater than 750/mm3 or recurrent life threatening infections or more than 4
        hospitalizations per year despite therapy with filgrastim (G-CSF) No myelodysplasia or
        aplastic anemia

        Must have a related donor with at least a 5 out of 6 HLA antigen match

        --Patient Characteristics--

        Age: Sickle cell anemia patients 0 to 50; All other patients under 18

        Performance status: Karnofsky 70-100%

        Hepatic: Bilirubin no greater than 3.0 mg/dL with a direct fraction no greater than 2.0
        mg/dL ALT no greater than 150 U/L No moderate or severe portal fibrosis No active hepatitis

        Renal: Glomerular filtration rate at least 30% predicted (except with sickle cell anemia)
        No renal dysfunction

        Cardiovascular: Left ejection fraction at least 50% No cardiac compromise

        Other: No severe, stable neurologic impairment HIV negative","Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders",0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","Autoimmune thrombocytopenia purpura: platelet count less than 20,000/mm3 Adequate or
        increased marrow megakaryocytes Presence of detectable platelet associated immunoglobulins
        not due to alloreactive antibodies or posttransfusion purpura Prior response to
        immunosuppressive therapy Platelet count chronically less than 20,000/mm3 with petechial
        bleeding or less than 50,000/mm3 with other bleeding OR Any history of life threatening
        hemorrhage Refractory to conventional therapy for at least 21 days Splenectomy At least 1
        additional immunosuppressive therapy applied after splenectomy OR Controlled on
        conventional therapy but at price of unacceptable toxicity: Serious steroid related
        toxicity Absolute neutrophil count less than 500/mm3 25% of time, pure red blood cell
        transfusion dependent or other toxicities (e.g., hemorrhagic cystitis) that are a
        consequence of chronic or cytotoxic therapy Unable to wean from chronic daily or
        intermittent cytotoxic therapy

        Autoimmune hemolytic anemia or pure red cell aplasia, AIHA: Hemolytic anemia Hemoglobin
        less than 10.0 g/dL without transfusion Hemolysis as evidenced by both: Sustained
        reticulocytosis (greater than 125,000/mm3) without evidence of active bleeding or
        increasing hemoglobin Laboratory evidence of hemolysis Positive direct antiglobulin test or
        equivalent immune adherence test No evidence for paroxysmal nocturnal hemoglobinuria
        Negative Ham's test and sucrose hemolysis. For PRCA: Anemia due to selective decrease in
        marrow erythroid precursors Hemoglobin less than 10.0 g/dL without transfusion Severe
        reticulocytopenia (less than 20,000/mm3 despite anemia) Severely decreased marrow erythroid
        precursors Positive marrow coculture with serum or cells or response to immunosuppression
        No evidence for PNH Negative Ham's test and sucrose hemolysis Severe disease: Chronic
        (i.e., greater than 1 year) Transfusion dependent or untransfused hemoglobin less than 8.0
        g/dL Ferritin greater than 2,000 or evidence of organ dysfunction due to iron overload
        Refractory to conventional therapy after all 3 of the following: High dose steroids (at
        least 1 mg/kg) for at least 21 days Splenectomy (except cold reactive antibodies) 1
        additional immunosuppressive therapy OR Controlled on conventional therapy but at price of
        unacceptable toxicity

        Rheumatoid arthritis: Morning stiffness for at least 6 weeks Arthritis of 3 or more joint
        areas Arthritis of hand joints Symmetric arthritis Rheumatoid nodules Serum rheumatoid
        factor Radiographic changes Active rheumatoid disease as evidenced by all of the following:
        Elevated Westergren erythrocyte sedimentation rate Minimum of 16 swollen or tender joints
        using the 28 joint count method Must be at high risk for developing deforming joint disease
        as defined by at least 2 of the following: High titer IgM-IgG rheumatoid factor
        Radiographic evidence of erosive arthritis developing within the first 24 months of
        clinical disease Functional class II or III Refractory to conventional therapy after 12
        months of: Methotrexate used in combination with cyclosporine, hydroxychloroquine, or
        sulfasalazine OR Intramuscular gold therapy (total dose greater than 1.0 g and duration at
        least 6 months) OR Controlled on conventional therapy but at price of unacceptable toxicity

        Juvenile rheumatoid arthritis: Under 16 years of age at onset Arthritis in 1 or more joints
        as defined by swelling or effusion, or presence of 2 or more of the following: Limitation
        of range of motion Tenderness or pain on motion Increased heat Duration of disease 6 weeks
        or longer Onset type defined by type of disease in first 6 months: Polyarthritis (i.e., 5
        or more inflamed joints) Oligoarthritis (i.e., less than 5 inflamed joints) Systemic (i.e.,
        arthritis with characteristic fever) Exclusion of other forms of juvenile arthritis Active
        disease evidenced by 1 of the following: Minimum of 2 swollen or tender joints using the 71
        joint count method Endocardial or myocardial disease, or serositis Anemia or thrombocytosis
        of chronic disease High risk for developing deforming joint disease or evidence of
        potential life threatening involvement for at least 1 internal organ system Radiographic
        evidence of erosive arthritis developing within first 24 months of clinical disease
        Functional class II or III Endocardial, myocardial, pericardial, and/or pleural disease
        Hemoglobin less than 10.0 g/dL or platelet count greater than 600,000/mm3 Refractory to
        conventional therapy after 12 months of methotrexate used in combination with
        hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, or cyclophosphamide OR
        Controlled on conventional therapy but at price of unacceptable toxicity

        Systemic lupus erythematosus: Malar rash Discoid rash Photosensitivity Oral ulcers
        Arthritis Serositis Renal disorder Neurologic disorder Hematologic disorder Immunologic
        disorder Antinuclear antibody Must have at least 4 of 7 variables on the lupus activity
        scale measured Evidence of potential life threatening involvement of at least 1 internal
        organ system Endocardial and/or myocardial disease Central nervous system disease Pulmonary
        parenchymal disease Renal disease defined as WHO III, IV or V and a high activity and low
        chronicity index Immune mediated cytopenias Refractory to conventional therapy after
        attempts to control disease with at least 2 drugs, including prednisone and 1 of the
        following: Azathioprine Cyclophosphamide (greater than 500 mg/m2 monthly for 6 months)
        Cyclosporine OR Controlled on conventional therapy but at price of unacceptable toxicity

        Vasculitis Definitive diagnosis of 1 of the following forms: Churg-Strauss syndrome Giant
        cell arteritis Henoch-Schonlein purpura Hypersensitivity vasculitis Polyarteritis nodosa
        Takayasu arteritis Wegener's granulomatosis Evidence of active disease defined as
        reversible manifestations of the underlying inflammatory process Must have 1 or more of the
        following: Elevated Westergren erythrocyte sedimentation rate Elevated C reactive protein
        Decrease serum complement levels Evidence of potential life threatening involvement of at
        least 1 internal organ system Endocardial and/or myocardial disease Central nervous system
        disease Pulmonary parenchymal disease Renal disease defined as WHO III, IV or V and a high
        activity and low chronicity index Immune mediated cytopenias Refractory to conventional
        therapy (i.e., failed or relapsed within 6 months) after attempts to control disease with
        at least 2 drugs, including prednisone and 1 of the following: Methotrexate Azathioprine
        Cyclophosphamide Cyclosporine OR Controlled on conventional therapy but at price of
        unacceptable toxicity

        Performance status: ECOG 0-1 ECOG 2 allowed provided symptoms directly related to
        autoimmune disease Hepatic: No history of severe, prior or ongoing chronic liver disease
        Bilirubin less than 2.0 mg/dL AST less than 2 times upper limit of normal (ULN) Alkaline
        phosphatase less than 2 times ULN Renal: Creatinine less than 2.5 mg/dL OR Creatinine no
        greater than 2 times normal baseline for age in pediatric patients Cardiovascular: No
        symptoms of cardiac disease No active ischemic heart disease Ejection fraction greater than
        45% by MUGA No uncontrolled hypertension Pulmonary: FEV1/FVC at least 60% OR Resting PO2 at
        least 80 mm Hg DLCO greater than 50% predicted O2 saturations greater than 94% in children
        unable to perform PFTs Neurologic: No active or ongoing ischemic or degenerative CNS
        disease not attributable to underlying disease Other: Not pregnant No poorly controlled
        diabetes HIV negative",Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases,0
"The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow:
Hgb: 8 g/dl
WBC: 10000 /mm3
Plt: 300000 /ml
MCV: 106 fL
Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2
AST: 22 U/L
ALT: 43 U/L
Alk P: 53 U/L
Ferritin: 1200 ng/ml","-  INCLUSION CRITERIA:

        In this study chronic lumbar radicular signs and symptoms are defined as pain located in
        the lower lumbar spine corresponding to L1 and below for at least 3 months with radicular
        characteristics, i.e. pain described as sharp, burning, with numbness and/or tingling.

        Ability to understand the study measures and mentally capable of give consent to
        participate in the study (based on an 8th grade education level)

        Willingness to refrain from taking opioids other than their study medication.

        Patients with failed back syndrome who satisfy the criteria outlined in Appendix II.

        Patients with a pain level of 4/10 or greater on a scale of 0 to 10.

        EXCLUSION CRITERIA:

        Major coexisting medical condition such as cancer, chronic obstructive pulmonary disease
        and severe hepatic and renal dysfunction.

        Prostatic disease requiring usage of urological medications.

        Pregnancy or lactation.

        Unwillingness to discontinue pain medication(s) at study onset as follows: narcotic pain
        medications, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors
        (SSRIs) and monoamine oxidase inhibitors (MAOIs).

        Presence of pain of greater intensity in any other location than the low back or leg.

        Current major depression requiring usage of antidepressants.

        History of narcotic abuse at any time in the past and/or drug or alcohol abuse in the past
        year.

        History of narrow angle glaucoma.

        History of epilepsy.

        Current symptoms of coronary artery disease.

        History of fibromyalgia as described by Wolfe F et al., (1990) (a minimum of 12 out of 19
        points of tenderness must be present to satisfy criteria for fibromyalgia).

        History of spinal unstability (based on an MRI finding of grade II spondylolisthesis or
        greater).

        Cognitive impairment such that the individual is unable to give informed consent, complete
        study data collection tools or required study visits.

        Unwillingness to use adequate contraception (such as birth control pills or barrier methods
        with spermicide simultaneously).

        Presence of other medical condition presenting with numbness and pain in lower extremities,
        such as diabetic polyneuropathy and peripheral vascular disease.

        Allergy to any of the medications used in the study.

        Age 18 years or less due to rarity of sciatica in this age group.",Pain Treatment for Sciatica,0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Zidovudine (AZT) and didanosine (ddI). Dideoxycytidine (ddC), EPO, and other
             experimental therapies granted Treatment IND or Expanded Access status, with the
             exception of rifabutin.

          -  Concurrent therapies (acute and maintenance) for opportunistic infections not
             specifically prohibited.

        Concurrent Treatment:

        Allowed:

          -  Interferon-alfa.

        Patients must have the following:

          -  HIV infections or diagnosis of AIDS as per CDC classification.

          -  Mycobacterium avium isolated from blood.

          -  Capability of signing an informed consent, or consent of guardian if < 18 years of
             age.

          -  Ability and willingness to participate in all components of the study and receive all
             study therapies.

        Prior Medication:

        Allowed:

          -  Interferon-alfa.

          -  Single drug prophylaxis for Mycobacterium avium or M. tuberculosis within the previous
             4 weeks.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

        Treatment Phase:

          -  Known or suspected allergy to any of the study medications. Severe hearing loss.

        Maintenance Phase:

          -  Severe hearing loss. Hypersensitivity to macrolides. Intolerance to ethambutol and
             clofazimine.

        Concurrent Medication:

        Excluded:

          -  Acute therapy for other opportunistic infections at time of study entry.

          -  Nephrotoxic agents such as amphotericin B, intravenous vancomycin, or foscarnet during
             the first 4 weeks of study therapy without specific exemption from one of the protocol
             chairs. Antacids within 2 hours of ingestion of study drugs.

          -  Immunomodulators (except interferon-alfa) and other antimycobacterial drugs (including
             quinolones and aminoglycosides).

          -  All experimental therapies (except ddI, ddC, and other experimental agents granted
             ""Treatment IND"" or ""expanded access"" status) will be prohibited (specific exemptions
             must be obtained from one of the protocol chairs).

        Patients with the following are excluded:

          -  Known or suspected allergy to any of the study medications. Cannot take drugs orally.

          -  Severe hearing loss, at the discretion of the investigator.

        Prior Medication:

        Excluded:

          -  Antimycobacterial drugs (including azithromycin, clarithromycin, rifamycins,
             quinolones, and aminoglycosides) or immunomodulators (except interferon-alfa) within 4
             weeks prior to entry, except single-drug prophylaxis specifically allowed.

        History of unreliable drug intake.

          -  Inability to cooperate in the testing procedures.","A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.",0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Patients must meet the following criteria:

          -  CPCRA patients with confirmed pulmonary or extrapulmonary TB. Confirmed clinical TB
             requires a positive culture for Mycobacterium tuberculosis.

        NOTE:

          -  There is no requirement that patients have HIV infection.",A Registry of Tuberculosis Cases in the CPCRA,2
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Inclusion Criteria

        Patients must have:

          -  Working diagnosis of HIV infection.

          -  Working diagnosis of pulmonary TB.

        Per 08/02/94 amendment, patients with confirmed MDRTB or known susceptibilities for the
        current episode at baseline are not eligible for the epidemiologic study only.

        FOR TREATMENT PILOT:

          -  Positive sputum AFB smear (or a positive sputum culture for TB within 6 months prior
             to study entry).

          -  Assessment of suspect primary, suspect acquired, AND/OR confirmed MDRTB.

          -  Life expectancy of at least 2 weeks.

          -  Age >= 18 years for suspect MDRTB. Age >= 13 years for confirmed MDRTB.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Known hypersensitivity or resistance to quinolones.

          -  Other disorders or conditions for which the study drugs are contraindicated.

        Prior Medication:

        Excluded:

          -  More than 6 weeks total therapy within 3 months prior to study entry using three or
             more drugs effective against the isolates. (Per 08/02/94 amendment, patients from
             protocol ACTG 222/CPCRA 019 who have MDRTB are eligible for rollover to this study
             regardless of treatment duration on ACTG 222/CPCRA 019.)",A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.,0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Inclusion Criteria

        Patients must have:

          -  Positive AFB smear and/or culture for Mycobacterium tuberculosis, M. avium, or other
             mycobacterial infection, with or without documented HIV infection. NOTE:

          -  HIV-positive patients must have CD4 count < 500 cells/mm3 and be on antiretroviral
             therapy.

          -  One of the following manifestations:

          -  Temperature over 38 C on at least two occasions in the week prior to study entry.

          -  Recent weight loss of more than 5 kilograms.

          -  Pulmonary involvement of one or more lobes or involvement of other tissues due to
             tuberculosis or other mycobacterial infections, or symptomatic infections related to
             HIV status.

          -  Night sweats on two or more occasions in the week prior to study entry.

        NOTE:

          -  Patients must be hospitalized men aged 18-65 and postmenopausal women to age 65.
             Anticipated requirement for hospitalization must be at least 10 days.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Neuropathy or other disorders with risk of neuropathy.

        Required for HIV-positive patients if CD4 count < 500 cells/mm3:

          -  Antiretroviral therapy.",Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV,2
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Inclusion Criteria

        Patients must have:

          -  HIV seropositivity.

          -  Disseminated MAC.

          -  No MAC therapy between time of last positive blood culture draw and study entry
             (single-agent prophylaxis allowed).

          -  Life expectancy of at least 2 months.

          -  Consent of parent or guardian if below legal age of consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Known hypersensitivity to macrolide antibiotics (erythromycin, azithromycin, or
             clarithromycin) or ethambutol.

          -  Inability to take oral medications.

          -  Condition likely to interfere with drug absorption (e.g., gastrectomy, malabsorption
             syndromes).

        Concurrent Medication:

        Excluded:

          -  Another investigational drug started in the week prior to study entry.

        Prior Medication:

        Excluded:

          -  MAC therapy between time of last positive blood culture draw and study entry (although
             single-agent prophylaxis is allowed).","A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients",0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Inclusion Criteria

        Patients must have:

          -  History of HIV seropositivity.

          -  Disseminated MAC.

          -  Positive blood culture for MAC within 4 weeks prior to study entry.

          -  Consent of parent or guardian if less than 18 years of age.

          -  Ability to complete the study.

        NOTE:

          -  Patients with active opportunistic infections other than dMAC are permitted if dosage
             and clinical parameters have been stable for 4 weeks prior to enrollment.

        Exclusion Criteria

        Concurrent Medication:

        Excluded:

          -  Active therapy with carbamazepine or theophylline, unless investigator agrees to
             carefully monitor blood levels.

          -  Active therapy with investigational drugs other than treatment for HIV disease, except
             with approval of the sponsor.

          -  Concomitant terfenadine (Seldane or Seldane-D) or astemizole (Hismanal).

          -  Amikacin.

          -  Azithromycin.

          -  Capreomycin.

          -  Ciprofloxacin.

          -  Cycloserine.

          -  Ethionamide.

          -  Gentamicin.

          -  Kanamycin.

          -  Levofloxacin.

          -  Lomefloxacin.

          -  Ofloxacin.

          -  Rifampin.

          -  Rifabutin.

          -  Sparfloxacin.

          -  Streptomycin.

          -  Any other aminoglycosides, quinolones, and macrolides.

        Patients with the following prior conditions are excluded:

        History of allergy or hypersensitivity to macrolides, ethambutol, or clofazimine.

        Prior Medication:

        Excluded:

          -  Other antimycobacterials, including aminoglycosides, ansamycin (rifabutin), other
             macrolides (such as clindamycin), quinolones, and rifampin, between screening and
             study entry.

          -  Clarithromycin or azithromycin as prophylaxis or treatment (for any cause) for more
             than 14 days cumulative within the past 2 months.",The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS,0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Inclusion Criteria

        Concurrent Medication:

        Required:

          -  AZT, d4T, ddI, or ddC.

          -  Antipneumocystis prophylaxis.

        Allowed:

          -  Short course (< 14 days) of ciprofloxacin for acute infections.

        Patients must have:

          -  AIDS.

          -  CD4 count <= 100 cells/mm3.

          -  NO prior or current MAC infection.

        Prior Medication:

        Required:

          -  Antipneumocystis prophylaxis for at least 4 weeks prior to study entry.

        Allowed:

          -  Prior rifabutin.

          -  Prior ethambutol.

          -  Prior clarithromycin.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Positive tuberculin skin test (PPD > 5 mm).

          -  Active M. tuberculosis.

          -  Perceived as unreliable or unavailable for frequent monitoring.

        Concurrent Medication:

        Excluded:

          -  Other antiretrovirals not specifically allowed.

          -  All investigational drugs.

          -  Other antimycobacterial therapy, such as clarithromycin, azithromycin, rifampin,
             clofazimine, amikacin, streptomycin, isoniazid, cycloserine, ethionamide, and
             ciprofloxacin (>= 14 days).

        Patients with the following prior conditions are excluded:

        Known hypersensitivity to rifabutin, rifampin, or other rifamycins and/or ethambutol.

        Prior Medication:

        Excluded within 4 weeks prior to study entry:

          -  Rifampin.

          -  Isoniazid.

          -  Clofazimine.

          -  Cycloserine.

          -  Ethionamide.

          -  Amikacin.

          -  Ciprofloxacin.","A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS",0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Human immunodeficiency virus (HIV) or mycobacterial infection that requires at least 10
        days of inpatient antitubercular treatment

        Mycobacterial infection confirmed by positive acid-fast bacilli smear or culture for
        Mycobacterium tuberculosis

        At least 1 of the following signs and symptoms required:

          -  Temperature over 38 degrees C on at least 2 occasions within 1 week prior to treatment

          -  Weight loss greater than 5 kg

          -  Pulmonary involvement in at least 1 lobe on x-ray

        Night sweats on at least 2 occasions within 1 week prior to treatment

        --Prior/Concurrent Therapy--

        Concurrent rifampicin, isoniazid, pyrazinamide, and ethambutol for tuberculosis allowed

        --Patient Characteristics--

          -  No neuropathy and not at risk for neuropathy

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 4 weeks after study",Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections,2
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","PROTOCOL ENTRY CRITERIA:

        Patients over age 10 with cystic fibrosis documented as follows:

          -  Pilocarpine sweat chloride test at least 60 mEq/L OR

          -  Genotyping or transepithelial potential difference AND

          -  Clinical symptoms of suppurative respiratory disease or pancreatic insufficiency

        Able to produce at least 3 sputum samples

          -  Bronchoscopy specimens acceptable

          -  Throat/nasal specimens not acceptable

        No Pseudomonas cepacia colonization",Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients,0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Progressive pulmonary disease due to Mycobacterium avium complex (MAC) as defined by:
             Three of more sputum culture(s) positive for MAC Change in serial chest roentgenograms
             consistent with active mycobacterial disease over a 12 week period No other obvious
             cause of pulmonary disease

          -  Patients must have organisms that are: Susceptible to amithiozone AND Susceptible or
             moderately susceptible to the combination of rifampin and ethambutol, and to
             clarithromycin and streptomycin

        --Prior/Concurrent Therapy--

          -  No likelihood of resectional thoracic surgery within 24 weeks of evaluation

        --Patient Characteristics--

          -  Age: 18 and over

          -  Performance status: Not specified

          -  Hematopoietic: Not specified

          -  Hepatic: Bilirubin less than 3 times normal SGOT/SGPT less than 3 times normal
             Alkaline phosphatase less than 3 times normal

          -  Renal: Creatinine clearance at least 30 mL/min

          -  Cardiovascular: No New York Heart Association class III or IV heart failure

          -  Other: No optic disease that precludes the use of ethambutol No hypersensitivity to
             rifampin, ethambutol, clarithromycin, streptomycin, or amithiozone HIV negative Not
             pregnant or nursing",Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease,0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","PROTOCOL ENTRY CRITERIA:

        Population Characteristics

          -  Positive purified protein derivative (PPD) tuberculin skin test, with induration as
             follows: 10 mm or greater if HIV seronegative 5 mm or greater if HIV seropositive or
             status unknown

          -  No active tuberculosis (TB) on chest x-ray

          -  Candidate for isoniazid prophylaxis through Baltimore City Health Department

          -  Active or treated injection drug user, i.e.: Injected illicit drugs within the last 3
             months OR Previously injected drugs and is in drug treatment

          -  Injection use documented by: Subject self report Medical and referral records from
             drug treatment programs Physical exam for stigmata of injection drug use

        Prior/Concurrent Therapy

          -  No more than 6 months of prior TB preventive therapy for HIV

        Subject Characteristics

          -  Hepatic: ALT no greater than 3 x ULN

          -  Renal: Not specified

          -  Other: No prior serious adverse reaction to isoniazid No requirement for HIV therapy
             other than Pneumocystis prophylaxis or antiretrovirals",Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users,0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Documented cystic fibrosis with Pseudomonas aeruginosa present in a sputum or throat
        culture within 6 months prior to screening

        Sweat chloride at least 60 mEq/L

        --Prior/Concurrent Therapy--

        At least 14 days since prior intravenous or aerosolized tobramycin or other antipseudomonal
        antibiotic

        At least 4 weeks since prior administration of any investigational drug

        No concurrent antibiotics by aerosol

        --Patient Characteristics--

        Renal:

          -  Creatinine less than 2 mg/dL

          -  BUN less than 40 mg/dL

          -  No proteinuria of 2+ or greater

        Pulmonary:

          -  FEV1 at least 75% and at least 25% of predicted

          -  Room air oximetry at least 88% saturation

          -  Able to perform pulmonary function tests

          -  No hemoptysis of 60 mL or greater within 30 days prior to study

          -  No abnormal chest X-ray

        Other:

          -  Not pregnant

          -  Fertile females must use effective contraception

          -  No history of positive culture with Burkholderia cepacia

          -  No history of glucose-6-phosphate dehydrogenase deficiency

          -  No known local or systemic hypersensitivity to aminoglycosides, albuterol, or other
             beta-2 agonists",Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis,0
"Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow:
Hgb: 13 g/dl
WBC: 14000 /mm3
Plt: 300000 /ml
AST: 13 U/L
ALT: 15 U/L
Alk P: 53 U/L
Bill total: 0.6 mg/dl
Na: 137 mEq/l
K: 4 mEq/l
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
ESR: 120 mm/hr","Inclusion Criteria:

        -Patients with suspected and confirmed TB

        Exclusion Criteria:

        -Patients that are not a part of the therapy program established at Harlem Hospital, New
        York City",Behavioral Interventions for Control of TB,2
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","When the Physicians Health Study was established in the early 1980s by the NHLBI to collect
        data on a stable population at risk for heart attack, only male physicians were studied
        because males were thought to be at higher risk than females for ischemic heart problems.
        The study population consists of 22,071 male U.S. physicians who were aged 40 to 84 years
        in 1982. The subjects have no history of myocardial infarction, cancer, kidney disease,
        renal disease, or any other contraindication to the use of aspirin or beta-carotene,
        including regular use of corticosteroids.",Randomized Trial of Beta-Carotene and Macular Degeneration,0
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.",No eligibility criteria,Stress Reduction and Atherosclerotic CVD in Blacks,0
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","Men and women patients with known or suspected sites of serious infection if core
        temperature was 38.3 degrees Celsius, heart rate 90 in the absence of beta-blockers,
        respiratory rate 20 or minute ventilation 10 liters per minute. In addition, one o",Ibuprofen in Sepsis Study,0
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","Patient must be over 18 years of age requiring diagnostic cardiac catheterization will
        participate.

        Women on chronic estrogen therapy are eligible for the study.

        Patients investigated for chest pain syndrome with normal coronary arteries with and
        without risk factors for atherosclerosis, patients with coronary artery disease, and
        patients with heart failure.

        No patients with unstable angina; significant left main disease (greater than 50%
        stenosis); Recent myocardial infarction (less than 1 month); Pregnancy, lactation; Allergy
        to losartan; Renal failure (creatinine greater than 2.5 mg/dl); Inability to withdraw ACE
        inhibitors.",The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function,0
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","Inclusion Criteria:

          -  African Americans are eligible if they had a non-cardioembolic ischemic stroke at
             lease 7 days, but no more than 90 days before entering the trial.

          -  African American

          -  29-85 years of age

          -  Non-cardioembolic cerebral infarct

          -  Onset of entry stroke at least 7 days but no more than 90 days

          -  CT or MRI following entry stroke and consistent with occurrence of entry stroke (i.e.,
             shows entry infarct, shows old infarct, or shows no infarct) Measurable neurologic
             deficit that correlates with onset of entry stroke.

          -  Informed consent

          -  Able to follow outpatient treatment program

        Exclusion Criteria:

          -  Volunteers with transient ischemic attack (TIA) as the potentially qualifying event,
             intracranial hemorrhage, nonatherosclerotic stroke, sensitivity or major allergy to
             the study drugs, Modified Barthel Index < 10 or childbearing potential are not
             eligible.

          -  Non-qualifying entry events: TIA, subarachnoid hemorrhage, cardiac embolism,
             iatrogenic stroke, postoperative stroke within 30 days of operation, and carotid
             endarterectomy as preventive treatment of entry stroke.

          -  Mean arterial blood pressure > 130mmHg on 3 consecutive days

          -  Modified Barthel Index < 10

          -  History of dementia or neurodegenerative disease

          -  Severe comorbid condition such as cancer that would limit survival during 2 year
             follow-up period

          -  Concurrent enrollment in another clinical trial

          -  Sensitivity or allergy to aspirin or ticlopidine

          -  Women of childbearing potential

          -  Peptic ulcer disease, active bleeding diathesis, lower gastrointestinal bleeding,
             platelet or other hematologic abnormality currently active or clinically active in the
             past year, hematuria, positive stool guaiac, prolonged PT or PTT, BUN > 40mg%, serum
             creatinine > 2.0mg%, thrombocytopenia or neutropenia as defined by the lower limit of
             normal for the platelet count or white blood cell count, respectively (absolute
             neutrophil count of > 1800/mm3 required for participation), or > 2 times the upper
             range of normal on liver function tests (SGOT, SGPT, total bilirubin)",Antiplatelet Therapy to Prevent Stroke in African Americans,2
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Long standing ophthalmoparesis and fatiguable weakness of the limbs

          -  Mild ataxia and no central nervous system involvement

          -  History of mitochondrial DNA deletion and a measurable biochemical defect of the
             respiratory chain

          -  Steady deterioration in skeletal muscle mass and power over 5 years

        --Prior/Concurrent Therapy--

          -  Previous participation in studies of muscle disease natural history (CRC Protocol
             183A)",Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy,0
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","INCLUSION CRITERIA:

        Healthy volunteers between the ages of 18-65 years.

        Patients will be eligible for this study if the two mandibular molars are classified as
        partial or full bony impactions.

        EXCLUSION CRITERIA:

        Patients who are allergic to sulfa-drugs.

        Patients who have had asthma, hives or an allergic reaction to aspirin, ibuprofen or any
        similar drugs.

        Patients with gastrointestinal ulcers or a history of gastrointestinal bleeding.

        Patients who are pregnant or nursing.

        Patients of infection or inflammation [pericoronitis] at either extraction site.

        Patients with severe kidney disease.

        Patients who are taking any of the following drugs: anti-depressants, diuretics, aspirin on
        a near daily basis, coumadin or other blood thinners.

        Patients who are taking drugs known to inhibit P450 2C9 and drugs metabolized by P450 2D6.",Celebrex for Pain Relief After Oral Surgery,0
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","INCLUSION CRITERIA:

        Male or female volunteers referred for mandibular third molar extraction with a minimal
        difficulty rating score of 3-4; the rating will be verified by the oral surgeon at time of
        surgery.

        Age between 16-40.

        ASA status 1 or 2, deemed in good general health (able to tolerate outpatient conscious
        sedation safely).

        Willing to return at 24 hours for extraction of 1 tooth and be willing to wait up to 6
        hours for post op observation following tooth extraction.

        Willing to return another 48 hours later for final sensory testing.

        EXCLUSION CRITERIA:

        ASA status 3-5 and Emergency operation (E) that do not get a physician clearance; i.e.
        systemic disturbances that limits the patient's activity.

        Pregnant or breast-feeding mothers.

        Allergy to investigational drugs or to red chili peppers.

        Chronically use of analgesics (not limited to, but including: non-steroidal
        anti-inflammatory medications, steroids, anti-depressants, anti-convulsants).

        Presence of chronic disease (e.g. cardiovascular disease, liver disease, kidney disease,
        diabetes, etc.)",Capsaicin to Control Pain Following Third Molar Extraction,0
"A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.","-  INCLUSION CRITERIA:

               1. Age greater than 18

        EXCLUSION CRITERIA:

          1. Patient is less than 18 years of age.

          2. Subjects with contraindication to MRI scanning will be excluded from any testing which
             involves the use of MRI. These contraindications include subjects with the following
             devices or conditions:

               1. Central nervous system aneurysm clips;

               2. Implanted neural stimulator;

               3. Implanted cardiac pacemaker or defibrillator;

               4. Cochlear implant;

               5. Ocular foreign body (e.g. metal shavings);

               6. Insulin pump;

               7. Metal shrapnel or bullet;

               8. Any implanted device that is incompatible with MRI.

             Subjects with a condition precluding entry into the scanner (e.g. morbid obesity,
             claustrophobia, etc.) will not be included in the MRI portion of this study. Pregnant
             women will be excluded from testing which involves the use of MRI.

          3. Subjects will be excluded from 7T imaging if they are at risk of aspiration or have
             any condition that may require precipitous removal from the scanner.",Natural History of Stroke: Cause and Development,2
"Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.",No steroid sulfatase deficiency.,Study of Scaling Disorders and Other Inherited Skin Diseases,0
"Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.","Diagnosis of Polymyositis or Dermatomyositis.

        Baseline muscle weakness score of less than or equal to 139 out of 160 on manual testing
        (MMT).

        Baseline functional assessment score of less than or equal to 82 out of 91.

        Ability to provide informed consent to all aspects of the study after full information is
        provided.

        Age equal to or older than 18.

        A diagnosis of classic or definite polymyositis or dermatomyositis (Critieria A and B plus
        at least one of the three other criteria):

          1. Symmetrical proximal muscle weakness;

          2. Muscle biopsy abnormalities at some time during their disease:

        i. degeneration and regeneration of muscle fibers

        ii. necrosis

        iii. phagocytosis

        iv. interstitial mononuclear infiltration;

        c. Elevation of serum creatinine phosphokinase (CPK), transaminases, lactic dehydrogenase
        (LDH) or aldolase activity;

        d. Electromyography (EMG) triad of changes

        i. small amplitude, short duration polyphasic motor unit potentials

        ii. fibrillations, positive sharp waves, increased insertional irritability

        iii. spontaneous bizarre high frequency discharges;

        e. Typical skin rash of DM.

        Willingness to undergo 2 muscle biopsies.

        Evidence of active disease as measured by weakness, and an elevated CK or an active MRI.

        Must be tapered to a stable dose of steroid equal to or less than 0.50 mg/kg/day equivalent
        of prednisone for one month prior to the study.

        If on additional immunosuppressive drugs, the drugs must be maintained at a stable dose for
        1 month prior to the initiation of therapy and will be maintained throughout the trial.

        Women of childbearing potential and men whose partners are of childbearing potential must
        practice an acceptable form of contraception. No pregnant females or nursing mothers.

        No history of hepatitis or abnormal liver function tests.

        No history of prior thyroid disease.

        No active acute or chronic infections requiring antimicrobial therapy, or serious viral or
        fungal infections.

        No preexisting or coexisting malignancy other than basal cell and localized squamous cell
        carcinoma of the skin.

        No history of cerebrovascular accidents, seizure disorder, aseptic meningitis, transverse
        myelitis or central nervous system disease.

        No history of documented coronary artery disease, cardiomyopathy, greater than first-degree
        heart block, or dysrhythmia requiring therapy.

        No confounding medical illness that in the judgement of the investigators would pose added
        risk for study participants.

        No anemia requiring maintenance blood transfusions; leukoplakia with WBC less than 3,000
        micrograms or absolute neutrophil count less than 2,000 micrograms; and platelet count less
        than 100,000 micrograms on at least two different occasions.

        No history of (or current) autoimmune hemolytic anemia.

        No current anticoagulant therapy.",Methimazole to Treat Polymyositis and Dermatomyositis,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","Inclusion Criteria:

          -  Pubertal stage II

          -  Calcium intake below a threshold level

          -  Caucasian

          -  Normal health

        Exclusion Criteria:

          -  Medications affecting calcium and bone metabolism

          -  Chronic diseases

          -  Metabolic bone disease

          -  Abnormality in calcium metabolism",Calcium and Bone Mass in Young Females,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","INCLUSION CRITERIA:

        Patients are girls aged 1-8 years (on entry to the study) with gonadotropin-independent
        precocious puberty. All ethnic groups are included.

        EXCLUSION CRITERIA:

        Males are excluded, as are patients with clinically-significant hepatic and/or renal
        impairment (testolactone is metabolized via the liver and kidneys).",Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","Patients with extreme short stature will qualify for inclusion under this protocol if they
        meet the following criteria:

        Age 9 through 15.99 years at the start of treatment.

        Tanner II-V pubertal development.

        Height at least 2.25 S.D. below the median for chronologic age at the time of pubertal
        onset, or a predicted adult height at least 2.25 S.D. below median adult height.

        The height criterion must be met before study entry, but not necessarily on the actual date
        the patient starts to take the protocol injections because advancing puberty may cause an
        increase in height velocity that temporarily increases height standard deviation score.

        Unfused carpal and phalangeal epiphyses by bone age x-ray.",Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","-  INCLUSION CRITERIA:

        Fasting cholesterol greater than 500 mg/dl, low density lipoprotein cholesterol greater
        than 400 mg/dl, and triglycerides less than mg/dl.

        Family history of hypercholesterolemia and/or cardiovascular disease before the age of 60
        years.

        Tendinous and tuberous xanthomas.

        Arcus corneae before the age of 30.",Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","INCLUSION CRITERIA

        All subjects will be outpatients.

        Patients must be females with Turner's syndrome diagnosed by leukocyte karyotype

        Chronologic age greater than or equal to 5 years.

        Prepubertal Tanner I status. If breast development is Tanner II or III, demonstration of
        castrate status through measurement of serum FSH (greater than 12 MIU/ML).

        All patients must be below the 10th percentile for chronologic age.

        Patients must have at least 6 months accurate, growth measurements available for
        calculation of pre-study growth velocity. Pretreatment measurements must be obtained during
        a time when the patient is not receiving a potential growth-promoting agent.

        Patients judged to be thyroxine deficient must have replacement which has resulted in
        normal thyroid function tests over the three-month period prior to enrollment (T4, T3,
        Thyroid Stimulating Hormone).

        Patients and/or parents or legal guardians of patients must sign an informed consent
        statement. Assent should be obtained from all patients competent to understand the
        protocol. Local IRB requirements apply.

        EXCLUSION CRITERIA

        Patients who have received any form of human growth hormone within the past 3 months, or
        who have received a cumulative course of therapy totaling greater than one year.

        Patients who have received treatment with estrogen or androgen in the past three months or
        who have received a cumulative course of therapy totaling greater than one year.

        Patients who have any Y component in their chromosome analysis.

        Patients with a chronologic age greater than 12 years.

        Patients with a bone age greater than 12 years.

        Patients who have clinically significant cardiac, pulmonary, gastrointestinal, hepatic or
        renal disease or who have had any malignancy.

        Patients who have significant hematuria or proteinuria in pretherapy evaluation.

        Patients who have diabetes mellitus.

        Patients who have any active chronic infection (tuberculosis).

        Patients who are taking amphetamines or any other drugs known to interfere with growth
        hormone secretion or actions.

        Patients who are poor medical, psychological, or psychiatric risks for whom, in the opinion
        of the principal investigator, the investigational drug would be unwise.

        Patients whose parents are substance abusers, nor those who come from homes in which
        appropriate emotional development may be limited.

        Patients who cannot be seen on the schedule required by the protocol.",Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome,1
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","-  INCLUSION CRITERIA FOR HEALTHY CONTROLS:

        Subjects consenting to participation in the study

        -Over 3 years of age with no upper limit for age at time of enrollment.

        INCLUSION CRITERIA FOR MRI SCANNER CALIBRATION PROJECT:

        Participants will meet protocol criteria for adult healthy volunteers

        INCLUSION CRITERIA FOR PATIENT POPULATIONS:

          -  Male and female subjects over 3 years of age with no upper limit for age (with the
             exception of the Down syndrome group see below). Currently meet criteria for at least
             one of the following:

               -  DSM-IV (or other approved) criteria for one of the following clinical diagnoses:
                  Multi-Dimensionally Impaired, Obsessive Compulsive Disorder, Childhood Onset
                  Schizophrenia, Turner Syndrome, Autism Spectrum Disorder, Asperger Syndrome, High
                  Functioning Autism, Pervasive Development Disorder

               -  Sex chromosome aneuploidy as determined by karyotype (including XXX, XXXX, XXXXX,
                  XXY, XXYY, XXXY, XXXXY, XYY).

               -  ICD-10 criteria for Congenital Adrenal Hyperplasia, Cushings Syndrome, Kallmann
                  Syndrome, normosmic hypogonadotropic hypogonadism, Androgen Insensitivity
                  Syndrome

               -  ADHD

               -  Down s Syndrome

          -  Newly enrolled adults and minors once they become adults over age 18 who cannot give
             consent due to limited capacity may have a surrogate, i.e., a legally responsible
             representative (LAR), sign the consent. LARs include DPA holders, court-appointed
             legal guardians, or parents or siblings over 18 years of age. We will consult with the
             Human Subjects Protection Unit as necessary.

        ADDITIONAL INCLUSION CRITERIA FOR ADHD PARTICIPANTS:

        Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) defined
        ADHD. The DSM-IV diagnosis of ADHD will be based on the Parent Diagnostic Interview for
        Children and Adolescents.

        -Conners Teacher Hyperactivity rating greater than 2 SD above age- and sex-specific means.

        ADDITIONAL INCLUSION CRITERIA FOR DOWN SYNDROME PARTICIPANTS:

          -  Confirmed chromosomal diagnosis of Down syndrome.

          -  Age at entry into the study is 30 years or under. This upper age limit at study entry
             is being implemented for the Down syndrome group for several reasons. First, much of
             the research using magnetic resonance imaging with this population is focused on
             (older) adult populations and in particular the transition to early onset Alzheimer s
             disease. Because most (if not all) individuals with Down syndrome demonstrate some
             brain pathology consistent with Alzheimer s disease by age 30 (e.g., plaques and
             tangles; Mann & Esiri, 1989), we would like to enroll participants who are 30 years of
             age and under. Second, studying children and young adults with Down syndrome fills a
             significant gap in the literature, as there are very few structural magnetic resonance
             imaging studies of children and young adults with Down syndrome reported in the
             literature to date, and the majority of these studies are characterized by small
             samples of convenience (i.e., clinic populations). Thus, there is still a need to
             describe the developmental course of this disorder from early childhood to young
             adulthood. Such developmental research may help shed light on the causes of
             intellectual disability in Down syndrome and also identify individuals with the
             syndrome who are most at risk for experiencing the cognitive decline that is reported
             in the literature for some individuals after the age of 30 (Oliver et al., 1998).

        ADDITIONAL INCLUSION CRITERIA FOR PARTICIPANTS WITH AUTISM SPECTRUM DISORDERS:

          -  Meeting DSM-IV criteria for one of the pervasive developmental disorders (i.e.,
             autistic disorder, Asperger disorder, or pervasive developmental disorder-not
             otherwise specified).

          -  Having a minimum IQ of 70.

        EXCLUSION CRITERIA:

        NIMH staff and their immediate family are excluded from participation.

        EXCLUSION CRITERIA FOR HEALTHY CONTROLS:

          -  Presence of severe psychiatric disorder (as diagnosed prior to subject study
             enrollment) in the subject, sibling, or other first-degree relative. For these
             purposes, exclusionary severe psychiatric disorder include schizophrenia and bipolar
             affective disorder

          -  Presence or history of medical conditions known to affect cerebral anatomy.

          -  Dental braces.

          -  Contraindications for MRI scanning according to the NMR Center MRI Safety Screening
             Questionnaire and guidelines.

          -  For females who have reached menarche: Pregnancy or inability or unwillingness to
             undergo pregnancy testing.

        EXCLUSION CRITERIA FOR ALL PATIENT POPULATIONS:

          -  Dental braces.

          -  Contraindications for MRI scanning according to the NMR Center MRI Safety Screening
             Questionnaire and guidelines.

          -  For females who have reached menarche: Pregnancy or inability or unwillingness to
             undergo pregnancy testing.

          -  Evidence of another medical condition or traumatic event known to affect cerebral
             anatomy.

          -  A known genetic disorder (other than the condition under investigation) that would be
             expected to significantly impact findings from cognitive testing and/or neuroimaging.

        ADDITIONAL EXCLUSION CRITERIA FOR ADHD PARTICIPANTS:

          -  A full-scale IQ of less than 80.

          -  Birth before 34 weeks of gestation.

          -  Other axis I psychiatric disorder requiring treatment with medication at study entry
             (with the exception of oppositional-defiant disorder).","Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers",0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","INCLUSION CRITERIA:

        Patients will include girls and women ages 5-50 yr with the diagnosis of Turner syndrome
        based on absence of all or part of one of the X chromosomes.

        Control subjects must be within +/- 2SD for height and weight and have normal intelligence
        and educational achievement.

        Biological parents (both male and female) of TS subjects may be included in this study, but
        only to have blood drawn for genetic testing in order to determine the origin of the
        X-chromosome of their daughters.

        EXCLUSION CRITERIA:

        Those with severe physical or neurocognitive impairment, preventing accurate completion of
        the cognitive tasks, will be excluded.

        Normal subjects who have qualified for or participated in gifted and talented or remedial
        education programs.",The Effects of Estrogen on Cognition in Girls With Turner Syndrome,2
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","-  INCLUSION CRITERIA:

        Girls with Turner syndrome will qualify to participate in this study if they meet the
        following criteria:

        Karyotype diagnosis compatible with Turner syndrome.

        No treatment with estrogen, androgen or growth hormone exceeding twelve months, and no
        treatment with either of these agents in the preceding 3 months.

        Chronological age of 10.0 to 14.9 years.

        Bone age less than or equal to 12 years.

        EXCLUSION CRITERIA:

        Prior treatment with estrogen, androgen, or growth hormone for more than twelve months.

        Y component in peripheral karyotype.",The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome,2
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","Inclusion Criteria:

          -  Patients must have documentation of neurosensory hearing loss and retinitis pigmentosa
             and fulfill the clinical characteristics (Table) as accepted for USH 1 and USH 2.

          -  The minimal test battery will identify all patients with USH 1 and USH 2 as well as
             possible subtypes.

          -  Candidates will be recruited from lists of patients willing to participate in research
             studies compiled by the R.P. Foundation, and by referral from their private
             physicians.

          -  On occasion additional family members will be studied after an initial individual is
             ascertained as above.

          -  No patients with intrauterine and childhood infections, and intrauterine and birth
             complications can result in trauma to both the auditory or visual system and a
             positive history for these conditions will necessitate exclusion from the study.","Study of Usher Syndromes, Type 1 and Type 2",0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","-  INCLUSION CRITERIA:

        Subjects will be boys with bone ages 2 to 13 years and girls with bone ages 2 to 11 years
        with classic 21-hydroxylase.

        Subjects must either not yet have undergone pubertal activation of the
        hypothalamic-pituitary-gonadal axis, or, if pubertal activation has occurred, must be
        receiving an LHRH agonist to suppress secondary central precocious puberty.

        Children with a bone age of 1 to 2 years may enroll in the protocol for optimization of
        conventional therapy, but will not be randomized to a study arm until the bone age reaches
        2.

        EXCLUSION CRITERIA:

        Children who have concurrent illnesses requiring glucocorticoid treatment (such as severe
        asthma), or requiring drugs that markedly alter hydrocortisone metabolism (such as
        anticonvulsants), and children who cannot be brought into reasonable control with
        conventional treatment (an unusual occurrence).",Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","Physical anomalies or developmental anomalies.

        Karyotype showing derivative chromosome abnormality that is not fully characterized.

        No abnormal parental karyotype.

        No prenatal specimens.

        Probands of all ages, genders, and ethnic origin are eligible.

        The proband must have a non-mosaic abnormal G-banded chromosome analysis of good quality
        that shows one or more derivative chromosomes whose foreign component cannot be determined
        by standard G-banding techniques.

        The parents should also have G-banded chromosome analysis prior to eligibility for consent
        2. If this has not been done by the referring physician, it may be done as part of the
        protocol.

        The proband with the abnormal karyotype should have one or more of the following features:
        dysmorphic features; developmental delay or mental retardation; growth retardation,
        microephaly, short stature or failure to thrive; behavioral disorder

        Biological parents must be willing to supply a blood specimen. If they have any of the
        features listed above, they must attend the clinic if the proband is to be eligible.

        The proband must be evaluated by the NCHGR clinical genetics service by the PI, a
        co-investigator, or his associates.

        Mothers will be queried about potential non-paternity. If non-paternity is possible, the
        family will need to undergo clinical paternity evaluation before they are enrolled in the
        study.",Evaluation of Patients With Unresolved Chromosome Abnormalities,1
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","Patients greater than or equal to 18 years of age, with well-differentiated, non-medullary
        thyroid cancer, including papillary (including follicular-variant), follicular, and Hurthle
        cell.

        Patients who recently have undergone a total or near-total thyroidectomy and are scheduled
        to undergo initial 131I diagnostic studies and ablation.

        Patients must have evidence of residual thyroid tissue after thyroid surgery confirmed by
        ultrasound or other imaging technique (e.g., a technetium [Tc 99] pertechnetate or thallium
        scan).

        Patients who have undergone thyroidectomy or other thyroid surgery at least 6 weeks prior
        to enrollment.

        All patients who have been sustained on maintenance THST for at least 4 weeks, but not
        longer than 12 weeks after thyroidectomy.

        All patients who have confirmed serum TSH levels less than or equal to 0.5 mU per liter
        within 7 days prior to the first Thyrogen dose, and prior to randomization.

        Female patients of childbearing age must have a negative serum human chorionic gonadotropin
        (HCG) pregnancy test prior to entering the study and within 5 days of any 131I
        administration and must be following an approved method of contraception.

        Patients who are committed to following the protocol requirements as evidenced by providing
        written informed consent.

        Patients for whom a 131I scan is currently contraindicated because withdrawal from THST is
        not an option due to pituitary dysfunction or other compelling medical reasons are
        excluded.

        Patients should not have a concurrent major medical disorder (e.g., documented cardiac
        disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver
        disease or advanced pulmonary disease) who may be too ill to adequately comply with the
        requirements of this study.

        Patients with non-thyroidal conditions known to effect 131I uptake (e.g., congestive heart
        failure, renal failure) are excluded.

        Patients should not have undergone any intravenous water soluble radiographic contrast
        administration within the previous 4 weeks.

        Patients should not have received intrathecal or cholecystographic iodinated contrast agent
        administration within 3 months prior to enrollment.

        Patients should not be taking drugs that affect thyroid or renal function (e.g., renal
        drugs, lithium, or corticosteroids).

        Patients should not be participating in another investigational drug study or in such a
        study within 30 days of their enrollment in this study.

        No patients with a recent history of alcoholism or drug abuse, severe emotional behavioral
        or psychiatric problems who, in the opinion of the investigator, would not be able to
        comply with the requirements of this study.",Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","Patients with known or suspected skeletal dysplasias or short stature and their family
        members of any age will be recruited worldwide from diverse medical communities including
        genetics, orthopedics, ophthalmology, and pediatrics.

        DISEASE CATEGORY I:

        Individuals and family members with a suspected or an established diagnosis of any FGFR3
        disorder, type II collagen disorder, Schmid metaphyseal dysplasia, pyknodysostosis,
        proximal symphalangism, or brachydactyly type C.

        DISEASE CATEGORY II:

        Individuals and family members with a suspected or an established diagnosis of a skeletal
        dysplasia in which the disease gene is not yet known, including: Ellis van Crevald,
        brachydactyly types B and E, and cartilage-hair hypoplasia.

        DISEASE CATEGORY III:

        Individuals and family members who have previously uncharacterized systemic manifestations
        suggestive of a skeletal dysplasias, with clinical findings of: disproportionate or
        proportionate short stature; and/or cleft palate; and/or detached retina; and/or history of
        loose joints or frequent joint dislocation; and/or history of, or family history of,
        premature arthritis.

        Short Stature Category I: Individuals with generalized short stature and their family
        members. This includes adults with abnormal stature as statistically defined from
        standardized growth charts.

        Must be able to give informed consent, older children (greater than or equal to 7 years
        old) who do not give assent, or persons who are wards of the state will be excluded from
        the study.",Study of Skeletal Disorders and Short Stature,2
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","DISEASE CHARACTERISTICS: Histologically proven stage III or IV breast, ovarian, or nonsmall
        cell lung cancer (NSCLC): Adenocarcinoma No progressive disease May have comlpeted at least
        1 standard chemotherapy regimen Confirmed HER-2/neu protein overexpression in tumor (either
        primary tumor or metastasis)

        PATIENT CHARACTERISTICS: Age: Pre or postmenopausal Performance status: Not specified Life
        expectancy: At least 12 months Hematopoietic: WBC greater than 3,500/mm3 Platelet count
        greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine less than
        1.5 mg/dL Creatinine clearance greater than 60 mL/min Other: No anergy (positive delayed
        type hypersensitivity response required to two or more common recall antigens) Female
        patients must be nonfertile Male patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics At least 1 month since cytotoxic chemotherapy Endocrine therapy: At least 1
        month since corticosteroid therapy Concurrent hormone therapy allowed Radiotherapy:
        Concurrent radiation therapy for local control of disease allowed (except as initial
        therapy for NSCLC) Surgery: Not specified","HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer",0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","DISEASE CHARACTERISTICS: Histologically confirmed primary myelodysplastic syndrome (MDS)
        with greater than 10% bone marrow blasts Refractory anemia with excess blasts (RAEB) OR
        RAEB in transformation No chronic myelomonocytic leukemia No secondary MDS after prior
        chemotherapy except if treatment was for acute myeloid leukemia No allogeneic bone marrow
        transplantation planned

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At
        least 3 months Hematopoietic: Hemoglobin no greater than 10 g/dL OR transfusion requirement
        of at least 3 packs of RBCs per month OR Platelet count less than 50,000/mm3 OR Absolute
        neutrophil count less than 1,000/mm3 No disseminated intravascular coagulation defined as
        fibrinogen less than 100 mg/dL AND prolonged PT, PTT, or thrombin time AND platelet count
        less than 25,000/mm3 without transfusion Hepatic: Bilirubin no greater than 2.0 mg/dL
        Alkaline phosphatase no greater than 4 times upper limit of normal (ULN) (unless due to
        underlying disease or Gilbert's syndrome) SGPT and SGOT no greater than 4 times ULN (unless
        due to underlying disease or Gilbert's syndrome) Renal: Creatinine no greater than 2.0
        mg/dL Cardiovascular: No uncontrolled hypertension No congestive heart failure, cardiac
        arrhythmia, or angina pectoris No history of myocardial infarction within the past 6 months
        No other significant cardiovascular disease LVEF within normal range by MUGA or
        echocardiogram No active ischemia Pulmonary: No pulmonary dysfunction Other: No central or
        peripheral neuropathy No uncontrolled or unstable diabetes No other significant organ
        system dysfunction HIV negative No prior malignancy except basal cell carcinoma or
        carcinoma in situ of the uterus No active, uncontrolled infection Not pregnant or nursing
        Fertile patients must use effective contraception during and for 3 months after study

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 2 months
        since prior biologic therapy (e.g., hematopoietic growth factors or biological response
        modifiers) Chemotherapy: See Disease Characteristics At least 2 months since prior
        chemotherapy Endocrine therapy: At least 2 months since prior endocrine therapy
        Radiotherapy: At least 2 months since prior radiotherapy Concurrent radiotherapy allowed
        Surgery: At least 2 months since prior surgery Other: No other concurrent investigational
        drugs",Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","PROTOCOL ENTRY CRITERIA:

          -  Girls aged 8 and 12 years with Turner's syndrome-compatible karyotype

          -  Age-matched girls without Turner's syndrome entered as controls

          -  Concurrent registration on Thomas Jefferson University growth study required of
             subjects with Turner's syndrome",Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome,2
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","PROTOCOL ENTRY CRITERIA:

        Turner's syndrome-compatible karyotype No Y material in peripheral karyotype Bone age no
        greater than 11 years --Prior/Concurrent Therapy-- No more than 12 months of prior
        estrogen, androgen, or growth hormone",Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome,2
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","-  Familial Dwarfism of Sindh

          -  Severe short stature but proportionate without dysmorphic features

          -  Normal body size and weight at birth

          -  Bone age is severely delayed

          -  Puberty is somewhat delayed (age 15-16)

          -  Fertility present in at least 3 dwarfs",Study of Pituitary Size and Function in Familial Dwarfism of Sindh,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","-  Short stature and/or constitutional growth delay

          -  No epilepsy or risk of epilepsy",Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children,2
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","Inclusion Criteria:

          -  CF patients ages 5-12 who are less than the 25th percentile for age and sex normal
             values for height and/or weight",Growth Hormone Use in Cystic Fibrosis - a Multicenter Study,0
"A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.","-  INCLUSION CRITERIA - for TS Subjects:

        Phenotypic females greater than or equal to 10 years of age

        Evidence of X-chromosomal abnormality

        Those with a karyotype of 45X/46XX must have at least 80% 45X lymphocytes.

        EXCLUSION CRITERIA - for TS Subjects:

        Co-existing autosomal defects

        Pregnancy

        INCLUSION CRITERIA - for the Parents of TS Subjects (for DNA only):

        Biological parent of a TS subject

        Willingness to participate

        EXCLUSION CRITERIA - for the Parents of TS Subjects (for DNA only):

        None",Turner Syndrome: Genotype and Phenotype,2
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Boy and girl infants, birth to 3 years, born to mothers who were hepatitis B surface
        antigen carriers.",Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Inclusion Criteria

        A child may be eligible for this study if he/she:

          -  Is 0 - 18 years old.

          -  Is HIV-negative and is born to an HIV-negative mother.

          -  Is healthy (no serious infection or disease).

          -  Has signed informed consent of a parent or legal guardian if under 18.

        Exclusion Criteria

        A child will not be eligible for this study if he/she:

          -  Is pregnant or breast-feeding.

          -  Has already completed this study once before.

          -  Is taking prescription medications other than prescription vitamins.",A Blood Test to Look at Cells of the Immune System in Healthy Children,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Participants must have a gestational age at birth between 36-42 weeks and birth weight
        greater than or equal to 2500 gms.

        Participants must have normal growth and development as assessed by general pediatric
        examination and growth charts, obtained historically from family and/or pediatrician.

        Participants must have a normal visual system by ophthalmic examination.

        Participants must be between the post-conceptual ages of 40 weeks and 70 weeks of age
        inclusive.

        Participants must be able to undergo a complete opthalmic evaluation.

        Participants must be able to undergo standard eye movement recording.

        Participants must not have any eye diseases.

        Participants must not have any neurologic disease, developmental delay, congenital genetic
        syndromes, congenital organ malformations, malformation syndromes or metabolic diseases.

        Participants must not be on any systemic or ocular medications.",Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Patients with extreme short stature will qualify for inclusion under this protocol if they
        meet the following criteria:

        Age 9 through 15.99 years at the start of treatment.

        Tanner II-V pubertal development.

        Height at least 2.25 S.D. below the median for chronologic age at the time of pubertal
        onset, or a predicted adult height at least 2.25 S.D. below median adult height.

        The height criterion must be met before study entry, but not necessarily on the actual date
        the patient starts to take the protocol injections because advancing puberty may cause an
        increase in height velocity that temporarily increases height standard deviation score.

        Unfused carpal and phalangeal epiphyses by bone age x-ray.",Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"A history of pathologically documented (clinical documentation may be acceptable at
        relapse):

        Breast cancer: metastatic or locally advanced (Stage III/IV) with stable minimal (less than
        or equal to 2 cm) residual disease after 2 cycles of appropriate combination chemotherapy
        may start BMT.

        Non-Hodgkin's lymphomas: all stages of relapsed or induction failure (FSC, FM, FL, DSC, DL,
        DM, DIDL, IBL, LBL, SNC) after appropriate chemotherapy.

        Hodgkin's lymphomas: all stages of chemotherapy induction failures, first relapse less than
        or equal to 1 year from chemotherapy induced remission, first relapse greater than 1 year
        from chemotherapy induced remission if there is extranodal involvement at relapse, greater
        than or equal to 2 relapses (one may be after radiation) following appropriate combination
        chemotherapy, or relapse at any time from radiation therapy with stage IIB, IIIB, IV A/B.

        Testicular cancer: all stages of relapsed or induction failure following appropriate
        combination chemotherapy.

        No evidence of central nervous system cancer.

        Patients must be between 18 and 65 years old.

        Normal cardiac function: no history of angina pectoris, myocardial infarction, congestive
        heart failure or ejection fraction less than 40 percent.

        Creatinine clearance greater than or equal to 45 cc/min/m(2), bilirubin less than or equal
        to 1.5, SGOT less than or equal to 2x normal, and normal PT, PTT and calcium.

        Negative HIV serology and hepatitis B surface antigen.

        Adequate pulmonary function (PFTs are only obtained in patients with clinical evidence of
        pulmonary dysfunction): DLCO greater than 50 percent, compensated for Hgb, FEV 1 greater
        than 55 percent and PO2 greater than 60.

        Negative bilateral bone marrow biopsies prior to bone marrow harvest.

        No evidence of metastatic disease to the pelvis on plain film or bone scan.

        Karnofsky performance status greater than or equal to 70 and a life expectancy greater than
        or equal to 60 days.

        No evidence of pregnancy or risk of pregnancy at the time of transplantation in women.

        Ability to give informed consent.

        Good psychiatric and medical risk.","Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma",0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Children between the ages of 3 months and 18 years.

        Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC)
        Definition. Children and adolescents with vertically, transfusion or sexually acquired
        HIV-1 infection are eligible.

        Availability of a parent or guardian to provide Informed Consent.

        ARM A:

        Children and adolescents with vertically, transfusion or sexually acquired HIV-1 infection.

        No or moderate immune suppression at the time of study entry as defined by the CDC
        Classification System, Immune Categories 1 and 2.

        No history of or indication for antiretroviral intervention at time of enrollment or not
        receiving antiretroviral treatment because: (a) the patient has elected to decline
        treatment or (b) in the opinion of the patient's health care provider, antiretroviral
        treatment is not currently recommended because of the patient's inability to adhere to
        therapy, promoting the development of viral resistance.

        Children younger than 24 months of age must not have had plasma HIV-1 RNA levels greater
        than 8 X 10(4) copies/ml previously and at the time of initial evaluation, confirmed at
        least at two different time points 2 to 4 weeks apart, showing no sign of increase
        (increment less than 0.5 log(10). If the child has had plasma HIV-1 RNA levels greater than
        8 X 10(4) copies/ml at some point prior to the initial evaluation, he/she will have to be
        placed on antiretroviral treatment and must meet all the criteria for Arm B.

        ARM B:

        Children and adolescents with vertically, transfusion, or sexually acquired HIV-1
        infection, who are on or have received antiretroviral treatment of longer than 7 weeks.

        No or moderate immune suppression at the time of study entry as defined by CDC
        Classification System, Immune Categories 1 and 2.

        Children younger than 24 months or age, who meet all the inclusion criteria for army B must
        have plasma HIV-1 RNA levels less than 5 X 10(4) copies/ml while receiving optimal
        antiretroviral therapy, confirmed at least two different time points 2 to 4 weeks apart,
        showing no sign of increase (increment less than 0.5 log(10). If the child has been
        previously treated with antiretroviral drugs for more than 7 weeks (therefore not eligible
        for arm A) and is currently off drugs, he/she will have to be placed on optimal
        antiretroviral agents and will have to maintain viral RNA levels below 5 X 10(4) copies/ml
        prior to the entry.

        Each child enrolled in arm B has to be on constant regimen of antiretroviral treatment for
        at least 6 weeks-prior to the first inoculation. Children in immune categories 1 and 2 at
        the time of study entry will be allowed to enroll.

        Not critically ill or clinically unstable or no presence of active infection requiring
        on-going (or induction) therapy.

        No evidence of severe immune suppression at the time of study entry as defined by CDC
        classification system, Immune Category 3.

        For children younger than 24 months of age, no plasma HIV-1 RNA levels greater than or
        equal to 5 x 10(4) copies/ml despite appropriate antiretroviral treatment, confirmed at
        least at two different time points 2 to 4 weeks apart.

        No use of tube feeding or intravenous hyperalimentation itself will be allowed as long as
        it is a stable regimen.

        No administration of chemotherapeutic agents, or use of immunomodulating agents such as
        corticosteroids, interferons, G-CSF, EPO, growth hormone (GH) or IVIG within one month of
        enrollment.

        No abnormalities of laboratory findings within one month of enrollment including the
        following: SGPT or SGOT greater than 5 times the normal value; Total bilirubin greater than
        3 times normal; BUN or creatinine greater than 2 times normal; Total WBC greater than
        150/mm(3) or ANC greater than 750/mm(3); Hemoglobin greater than 8.0 g/dl (transfusions are
        allowed); Platelet count greater than 100,000/mm(3).

        Not pregnant or not planning to become pregnant.

        No active substance abuse.

        Able to comply with the study requirements for scheduled evaluations such as periodic
        clinic visits or blood sampling.",Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Diagnosis of HNPCC patient or HNPCC carrier status defined by:

        HNPCC patient is an individual with a personal history of RER plus HNPCC related malignancy
        AND; meets the Amsterdam criteria or modified Amsterdam criteria (an HNPCC associated
        extracolonic cancer may be substituted for one of the three colorectal cases in one family
        otherwise required by these criteria) OR; having a definite mutation of one of the HNPCC -
        related genes identified by gene sequencing or other method of reliability. This includes
        gene status determined through segregation analysis in cases in which ""direct"" testing
        yields no alteration.

        HNPCC carrier is a relative of an individual meeting the criteria of an ""HNPCC patient"" as
        described above and having a mutation of one of the HNPCC-related genes identified by gene
        sequencing or other method of equivalent reliability (this includes gene status determined
        through segregation analysis in cases in which direct testing yields no alterations, as
        above) OR; having an RER plus adenoma.

        Age greater than or equal to 18 years.

        Voluntary consent documented by a signed and witnessed informed consent.

        Willingness to abstain from use of NSAID's (including aspirin), oral adrenocorticosteroids,
        and other nonsterodial OTC products for the duration of the study.

        If patient is female and of childbearing potential, she must meet all of the following
        conditions:

        Have been using adequate contraception (e.g., abstinence, condom, IUD, birth control pill,
        diaphragm and spermicide gel combination) since her last menses AND;

        Be willing to use adequate contraception (as above) during the study AND;

        Not be breastfeeding AND;

        Have a negative serum pregnancy test within 14 days prior to study drug administration.

        Though an individual with prior colorectal surgery is allowed, the subject must have
        greater than or equal to 50 percent of the colorectum with documentation describing the
        post-surgical anatomy (e.g., operative report).

        No use of investigational agent within the last 3 months, or at the discretion of the
        medical monitor.

        The subject will be allowed to proceed to baseline colonoscopy so long as all of the
        following laboratory criteria are met on baseline evaluation: Hgb greater than 10.0 gm/dl,
        platelet count greater than 100,000/ul; WBC greater than 3,000/ul; ALT less than 1.5 x
        upper limit of normal; AST less than 1.5 x upper limit of normal, alkaline phosphatase less
        than 1.5 x upper limit of normal, total bilirubin less than 1.2 x upper limit of normal,
        creatinine less than 1.5 x upper limit of normal, negative pregnancy test. For tests not
        mentioned specifically, there must be no clinically significant abnormalities which in the
        opinion of the PI would preclude a subject's safe participation.

        To proceed to randomization, the subject must have all of the following:

        An assessable colon or colonic segment (greater than or equal to 50 percent) which was
        endoscopically evaluated in its entirety following an adequate preparative procedure AND;

        An assessment of aberrant crypt foci via ""enhanced"" endoscopy 10 cm distal to the ileocecal
        valve or 10 cm distal to the anastamosis and at the distal most 10 cm from the rectum AND;

        All polyps must have been removed with the exception of small polyps (less than or equal to
        0.6 cm in maximal diameter) amenable to serial endoscopic surveillance AND;

        Mucosal sampling via pinch biopsies must have been obtained from normal-appearing mucosa in
        standardized areas of the right and left colon (or surrogate regions in the case of prior
        surgical resections) and from any areas that are clearly neoplastic or suspicious for
        neoplastic pathologies (ACF, adenomas, carcinomas) of interest.

        No anticipated colectomy within eighteen months of randomization.

        No history of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAID's or salicylates.

        No use of NSAID's (including aspirin) or oral adrenocorticosteroids, at any dose at a
        frequency averaging greater than 3 times per week during the six months prior to study
        entry. Use of such NSAID's or oral adrenocorticosteroids at the above frequency will
        require a six-month washout period prior to eligibility, beginning with the time of the
        patient's last dose. Use of any dose of NSAID's or oral adrenocorticosteroids, at an
        average frequency of 1-3 times per week during the six months prior to study entry will
        require a three-month washout period beginning with the time of last dose.

        No history in the past year of discrete gastric or duodenal ulcer of size greater than 5
        mm, except that patients with a history of Helicobacter pylori-related peptic ulcer disease
        may become eligible for study upon successfully completing antibiotic treatment of
        Helicobacter pylori.

        Ability to participate in the scheduled follow-up tests.

        No significant medical or psychiatric problems which would make the patient a poor protocol
        candidate, in the opinion of the principal investigator.

        No ""unacceptable clinical risk"" to proceed (based upon the subclinical discoveries made via
        baseline colonoscopy and biopsies) including a previously-unknown bleeding diathesis, a new
        diagnosis of carcinoma, suspicion that the subject may require colectomy (complete or
        partial) within eighteen months of randomization.

        Patient must not have undergone a colectomy within the past 6 months.

        Patient must not have undergone chemotherapy within the past 6 months.

        Patient must not have received pelvic radiation.",Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Subjects must be between the ages of 11 and 21 years.

        Subjects must be diagnosed with HIV for at least one year (to ensure sufficient opportunity
        to experience living with a chronic condition such that adherence level is unlikely to be
        the result of skill or knowledge deficits).

        Subjects must be prescribed oral medications (e.g., pills, liquids, inhaler) to be taken on
        a daily basis.

        Subjects must be living with same female caregiver for at least one year.

        Subjects must have a telephone number where he/she can be contacted during the two weeks
        after recruitment.

        The adolescent and mother must be able to provide informed consent.

        Adolescents must not have mental retardation or developmental delay that would prevent the
        adolescent from reading and comprehending the questionnaire.",A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Cystic fibrosis-associated liver disease, defined by at least one of the following
             criteria: (1) Documented increase in serum concentrations of any of the liver enzymes
             (at least once in the preceding year) ALT at least twice normal AST at least 1.5 times
             normal Alkaline phosphatase at least 1.5 times normal GGT at least 1.5 times normal
             (2) Persistent hepatomegaly of more than 6 months duration defined by percussed liver
             span greater than 1 SEM for age (3) Splenomegaly, defined as a palpable spleen greater
             than 2.0 cm below the left costal margin (4) Abnormalities of ultrasound scan
             (increased size, dishomogeneous echogenicity, nodular liver, irregular margins,
             splenomegaly) within 6 months prior to study entry

          -  Patients enrolled in the first part of the study (objective I) are eligible to
             participate in the second part (objective II)

        --Prior/Concurrent Therapy--

          -  At least 3 months since prior ursodiol

          -  At least 3 months since treatment with drug with choleretic properties or effects that
             influence bile acid metabolism

        --Patient Characteristics--

          -  Hepatic: No decompensated cirrhosis No hepatic neoplasm or cholelithiasis

          -  Pulmonary: No significantly impaired pulmonary function with FEV1 less than 50%

          -  Other: At least 15 kg body weight No severely compromised clinical or nutritional
             state",Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"INCLUSION CRITERIA:

        Only mothers with singleton or twin pregnancies will be included in the pilot study.

        All parents will sign both the NIH and teh NNMC/Georgetown consent forms at the beginning
        of the study.",Study of Fetal Swallowing,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"INCLUSION CRITERIA:

        Members of families meeting the following criteria are eligible to participate:

        Have two left-handed siblings.

        Have at least one right-handed parent with no other known left-handed first degree
        relatives.

        EXCLUSION CRITERIA:

        All members of a family may be excluded if the right-handed parents or the left-handed
        siblings will not participate.

        Individuals in families whose left-handed siblings are under the age of eight are not
        eligible to participate.",Genetic Component of Handedness,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"Inclusion Criteria

        Mothers may be eligible for this study if they:

          -  Receive prenatal care at King Edward VIII Hospital, Durban, or St. Mary's Hospital,
             Marianhill, South Africa; or polyclinics in Chitungwiza District, Zimbabwe.

          -  Are pregnant for at least 30 weeks before giving birth.

          -  Are at least 18 years of age.

          -  Are HIV-positive by 2 ELISA tests.

          -  Have no serious current or previous problems in pregnancy (e.g., seizures).

          -  Have a fixed home and/or work address.

          -  Plan to deliver the baby at a hospital or clinic where the study is based.

          -  Plan to breast-feed their babies.

          -  Infants may be eligible for this study if they:

          -  Are born to women participating in this study.

          -  Weigh at least 2.5 kg at birth.

          -  Begin breast-feeding by 48 hours.

        Exclusion Criteria

        Mothers will not be eligible for this study if they:

          -  Have AIDS or any other serious illness.

          -  Are using illegal drugs or have been using alcohol for a long time.

          -  Are sensitive to NVP.

          -  Have taken any nonnucleoside reverse transcriptase inhibitors in the past.

          -  Are using rifampin, rifabutin, ketoconazole, macrolides, or cimetidine.

          -  Infants will not be eligible for this study if they:

          -  Have jaundice (yellowing of the skin and whites of eyes) that requires a blood
             transfusion.

          -  Have any serious or life-threatening condition(s).",The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months,0
A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.,"-  Infants inborn at NRN centers

          -  <27 weeks gestational age

          -  Infants enrolled in one or more additional NICHD NRN Follow-up studies. For infants
             that do not meet the inclusion criteria above, inclusion and exclusion criteria are
             determined by the criteria for the additional trial(s). In these cases, infants that
             are larger than 1,000 grams and/or older than 27 weeks may be included in the FU
             Study.

        Note: These inclusion criteria were changed as of 1/1/2008. Prior to this date, infants
        with birth weights between 401 and 1500 grams who were admitted to NRN NICUs within 14 days
        of birth were included in the database.",Follow-up Visit of High Risk Infants,0
"The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7C, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/L.","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Antihypertensive agents.

        Concurrent Treatment:

        Allowed:

          -  Blood products.

          -  Ventilatory support.

        Prior Medication:

        Required:

          -  At least 7 days trimethoprim / sulfamethoxazole or parenteral pentamidine.

          -  Allowed:

          -  Myelosuppressive or nephrotoxic agents including zidovudine, but must be discontinued
             during trial.

        No improvement in ventilatory status, defined as no change or a decrease in arterial or
        alveolar difference ((A-a) DO2) in the 72 hours prior to entry. (A-a) DO2 should be
        determined on room air, or receiving an FiO2 of 100 percent for 10 minutes via a tightly
        fitting non-rebreathing mask, or at an FiO2 of 100 percent for 10 minutes if the patient is
        being ventilated. Intolerance to TMP / SMX is defined as one or more of the following:

          -  Platelets < 50000 platelets/mm3 or absolute neutrophil count (polys + bands) = or <
             500 cells/mm3 on at least two occasions = or > 12 hours apart.

          -  Blistering rash, mucosal involvement, generalized maculopapular eruption or
             intolerable pruritus.

          -  Transaminase > 5 x ULN or = or > 300 IU if baseline abnormal.

          -  Daily temperature = or > 103 degrees F beginning after the 5th day of treatment and
             persisting for at least 3 days and not responsive to antipyretic therapy, with no
             other discernible cause.

          -  Any other severe or life-threatening adverse reaction to TMP / SMX that, in the
             investigator's opinion, makes continued or recurrent treatment with TMP / SMX
             inadvisable (approved on a case-by-case basis by the NIAID clinical monitor).

          -  Intolerance to pentamidine is defined as one or more of the following:

          -  Platelets < 50000 platelets/mm3 or absolute neutrophil count (polys + bands) < 550
             cells/mm3 on at least two occasions = or > 12 hours apart.

          -  Serum creatinine > 3.0 mg/dl.

          -  Systolic blood pressure < 90 mm requiring supportive therapy.

          -  Symptomatic hypoglycemia with blood glucose = or < 40 or hyperglycemia requiring
             therapy.

          -  Pancreatitis with laboratory confirmation (abnormal amylase and/or lipase).

          -  Any other severe or life-threatening adverse reaction to pentamidine that, in the
             investigator's opinion, makes continued or recurrent treatment with pentamidine
             inadvisable (approved on a case-by-case basis by the NIAID clinical monitor).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reactions due to trimetrexate.

          -  Patients with less severe adverse reactions may be enrolled if, in the opinion of the
             investigator, they do not prohibit rechallenge with the drug.

        Concurrent Medication:

        Excluded:

          -  Myelosuppressive or nephrotoxic agents.

          -  Other investigational drugs including high-dose steroids (exceeding physiologic
             replacement doses).

        Patients with the following are excluded:

          -  History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
             exfoliative dermatitis, or other life-threatening reactions due to trimetrexate.

          -  Patients with less severe adverse reactions may be enrolled if, in the opinion of the
             investigator, they do not prohibit rechallenge with the drug.",A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia,0
"The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7C, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/L.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7C, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/L.","-  INCLUSION CRITERIA:

        Age 3 or over.

        Access to a primary medical care provider outside of the NIH.

        Ability to give written informed consent (for adults) and parental consent (for those under
        18).

        Clinical evidence suggestive of a parasitic infection.

        EXCLUSION CRITERIA:

        Less than 3 years of age.

        No evidence suggestive of a parasitic infection.

        Although pregnant or nursing women can be enrolled, they will be

        excluded from receiving treatment while pregnant or breastfeeding","Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection",0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative","Children in grades 5 through 8 whose systolic blood pressure was greater than or equal to
        120 mm Hg on two visits.",Sodium-Potassium Blood Pressure Trial in Children,0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative","Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Medication for grades 1 and 2 oral toxicity. Antiemetic agents, except steroids, for
             gastrointestinal toxicity. Toxicity grades according to NIAID Recommendations for
             Grading of Acute and Subacute Toxic Effects (Adults).

        Patients must demonstrate any of the following clinical and laboratory findings:

          -  25 or more mucocutaneous lesions with or without lymphedema.

          -  Progressive Kaposi's sarcoma (KS) with 10 or more new lesions in the month prior to
             study entry or visceral involvement.

          -  Oral mucosal lesion(s) requiring therapy.

          -  Prior history of Pneumocystis carinii pneumonia (PCP) or Mycobacterium avium
             intracellulare.

        Patients with any of the following constitutional symptoms with no etiology established may
        be included:

          -  Temperature > 38 degrees C and/or drenching night sweats for more than 1 month.

          -  Watery diarrhea (= or > 3 stools/day) for 2 or more weeks.

          -  Weight loss > 10 percent of normal. Patients with carcinoma in situ of the cervix or
             localized squamous or basal cell carcinoma of the skin may be included.

        Active alcohol or drug abuse sufficient to prevent adequate compliance with study therapy.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions will be excluded:

          -  Peripheral sensory or motor neuropathy.

          -  Opportunistic infections requiring therapy.

          -  Significant pulmonary (exertional dyspnea with minimal exercise) or cardiac
             insufficiency (New York Heart Association, status > 2).

          -  Serious neuropsychiatric illness which would prevent informed consent of intensive
             treatment.

        Concurrent Medication:

        Excluded:

          -  Any drugs causing anemia, neutropenia, or significant risk of nephrotoxicity. Patients
             with a history of other systemic malignancies or lymphomas, except carcinoma in situ
             of the cervix or localized squamous or basal cell carcinoma of the skin, will be
             excluded from the study.

        Prior Medication:

        Excluded:

          -  Systemic antineoplastic chemotherapy.

          -  Excluded within 30 days of study entry:

          -  Any other investigational therapy.

          -  Antiretroviral agents (zidovudine, ribavirin).

          -  Immunomodulating agents (steroids, interferons, naltrexone, isoprinosine, and
             interleukin-2).",A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS,0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative","Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV-positive.

          -  Have a CD4 cell count below 150 cells/mm3.

          -  Have been on stable anti-HIV therapy that includes at least 2 nucleoside analogues for
             at least 4 weeks.

          -  Have chronic diarrhea (3 bowel movements a day that are loose or watery, for 5 days
             per week over 3 weeks).

          -  Test positively for Cryptosporidium.

          -  Are at least 18 years old.

          -  Agree to use effective methods of birth control.

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Have any other active opportunistic (AIDS-related) infection.

          -  Require intravenous (IV) fluids.

          -  Have a history of an allergy to certain medications, such as colony-stimulating
             factors (G-CSF or GM-CSF) or a type of antibiotic.

          -  Are pregnant.",Treatment of Chronic Cryptosporidiosis in AIDS Patients,0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative","-  INCLUSION CRITERIA:

               1. Patients with a verifiable diagnosis of Crohn s disease, ulcerative colitis, or
                  IBD known to be associated with a co-existing condition and which is supported by
                  characteristic clinical features, radiographic or endoscopic findings, or
                  consistent histopathologic mucosal

                  changes OR

               2. Patients with clinical features consistent with an unclassified inflammatory
                  bowel disease and histologic evidence of inflammation of the intestine OR

               3. Patients with any clinical features consistent with inflammatory bowel disease
                  (intestinal inflammation), including but not limited to abdominal pain, fistulae,
                  weight loss, diarrhea, hematochezia or melena or suggestive extra-intestinal
                  symptoms (pyoderma, erythema

                  nodosum, axial and articular arthralgias, uveitis, fatigue, fever), in which a
                  diagnosis has not been verified. OR

               4. Patients who have a defined genetic syndrome linked to inflammatory bowel disease
                  risk with or without symptoms or findings consistent with IBD

               5. All subjects to be enrolled will be between ages 0-75 (Participants coming to the
                  NIH Clinical Center must meet age and weight requirements of the clinical center,
                  but > 18 must years old for patients without IBD and may be as young as 0-2 years
                  old for mail-in

                  samples).

               6. To participate in the research biopsies during endoscopy, subjects must have the
                  following lab values within two weeks of the procedure:

                    -  Hematocrit greater than or equal to 30%

                    -  Platelet count greater than 100,000

                    -  PT INR less than or equal to 1.3 or PTT prolonged by less than or equal to 3
                       seconds

               7. Ability to consent to the protocol on their own.

        INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

          1. Must be willing to undergo blood draw and/or upper endoscopy and colonoscopy with
             biopsy to obtain material for research purposes.

          2. Must be greater than or equal to 18 years old.

          3. Must be willing to submit samples for storage.

        INCLUSION OF EMPLOYEES IN THE NIH INTRAMURAL STUDIES:

        NIH employees and members of their immediate families may participate in this protocol. We
        will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will
        give each employee a copy of the NIH information sheet on Employee Research Participation.

        For NIH employees:

          1. Neither participation nor refusal to participate will have an effect, either
             beneficial or adverse, on the participant s employment or work situation.

          2. The NIH information sheet regarding NIH employee research participation will be
             distributed to all potential subjects who are NIH employees.

          3. The employee subject s privacy and confidentiality will be preserved in accordance
             with NIH Clinical Center and NIAID policies, which define the scope and limitations of
             the protections.

          4. For NIH employee subjects, consent will be obtained by an individual independent of
             the employee s team. Those in a supervisory position to any employee and co-workers of
             the employee will not obtain consent. The protocol study staff will be trained
             annually on obtaining potentially sensitive and private information from co-workers or
             subordinates. This training will be reinforced as needed, at weekly team meetings.

        EXCLUSION CRITERIA:

          1. Failure to meet the inclusion criteria.

          2. Any medical, psychiatric, or social conditions which, in the opinion of the
             investigators, would make participation in this protocol not in the best interest of
             the subject.

        EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

          1. History of inflammatory bowel disease.

          2. Acute systemic or intestinal infection requiring antibiotics

          3. Any condition that, in the investigator s opinion, places the patient at undue risk by
             participating in the study.",Immune Regulation in Ulcerative Colitis or Crohn s Disease,0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative","DISEASE CHARACTERISTICS: Histologically confirmed colorectal carcinoma At least grade 2
        diarrhea as a consequence of chemotherapy

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:
        Concurrent enrollment into SWOG-9420 protocol allowed No sensitivity to octreotide acetate
        or loperamide hydrochloride Eligible if less than 24 hours since prior loperamide or
        octreotide and no resolution of diarrhea Not pregnant or lactating Effective contraception
        required of fertile patients Not HIV positive No idiopathic ulcerative colitis or Crohn's
        disease, acute stool culture positive bacterial colitis, pseudomembranous colitis, short
        bowel syndrome, enteroenteric fistulae, chronic pancreatitis, ischemic bowel disease, or
        gastrointestinal disorders known to cause diarrhea Absence of definitive culture results
        required

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy
        with a fluoropyrimidine alone or in combination with an accepted modulating agent
        (leucovorin, levamisole, methotrexate, interferon, PALA, or hydroxyurea) required Prior
        chemotherapy with uracil mustard and tegafur (UFT) allowed No concurrent chemotherapy
        allowed during study Endocrine therapy: Not specified Radiotherapy: No whole pelvic or
        abdominal radiation therapy allowed Surgery: No colectomy, coloanal anastamosis,
        abdominoperineal resection, or colostomy allowed Other: No antidiarrheal agents (e.g.,
        diphenoxylate hydrochloride, elixir paregoric, opium tincture or tincture of belladonna, or
        kaolin) during study No cyclosporine allowed",Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer,0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative","Inclusion Criteria:

          -  Patients must have a histologically proven Her2 overexpressing malignancy as
             determined by any standardized assay currently in clinical use

          -  Patients must have measurable or evaluable disease

          -  The patient must have failed standard curative and/or palliative therapies for their
             disease

          -  Life expectancy of at least 6 months

          -  No concurrent malignancy other than non-melanoma skin carcinoma

          -  Adequate hematopoietic, cardiac, renal, and hepatic function

          -  Calculated creatinine clearance will be used to assess renal function

          -  Karnofsky Performance Status index >= 70%

          -  Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control) prior to study entry and for the
             duration of study participation; a woman of childbearing potential is defined as a
             female who is biologically capable of becoming pregnant

          -  Normal cardiac ejection fraction by echocardiogram or MUGA (i.e., greater than OSU
             lower limit of normal)

          -  Written signed informed consent; the patient must be aware that his/her disease is
             neoplastic in nature and willingly consent after being informed of the procedure to be
             followed, the experimental nature of the therapy, alternatives, potential benefits,
             side-effects, risks, and discomforts

        Exclusion Criteria:

          -  History of significant peripheral neuropathy or significant central nervous system
             disease

          -  Brain or central nervous system metastasis at entry

          -  Active or unstable cardiovascular disease or cardiac disease requiring drug or device
             intervention; history of coronary artery disease or congestive heart failure

          -  Pregnant or nursing women

          -  Surgery, radiotherapy, chemotherapy, or hormonal therapy during the three weeks prior
             to the initiation of therapy

          -  Exposure to any investigational drug within three weeks prior to the start of dosing

          -  Concurrent use of systemic corticosteroids

          -  Known seropositive for hepatitis B surface antigen

          -  Known seropositive for HIV antibody

          -  Serious concurrent infection requiring intravenous antibiotic therapy

          -  Clinically significant autoimmune disease (e.g., rheumatoid arthritis)

          -  Clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer disease

          -  History of inflammatory bowel disease

          -  Any other major illness which, in the investigator's judgment, will substantially
             increase the risk associated with the patient's participation in this study

          -  Prior therapy with Herceptin",Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative",No eligibility criteria,Minneapolis Children's Blood Pressure Study,0
"A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow:
Sodium                           137 meq/L
Potassium                      2 meq/L
Chloride                         94meq/L
CO2                                 15 meq/L
Fecal leukocytes           None seen
Fecal occult blood        Negative",- BMI 25-40 kg/m2 inclusive,Effectiveness of Atkins Diet for Weight Loss,0
"Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)","Inclusion Criteria:

          -  Bone density of the spine or femoral neck two standard deviations below the mean of
             young adult men

          -  Normal renal and liver function tests, normal serum testosterone level, normal vitamin
             D and PTH levels

        Exclusion Criteria:

          -  Significant cardiac, renal, hepatic, or malignant disease.

          -  Disorders (e.g., Paget's disease, hyperthyroidism, hyperparathyroidism) or drugs
             (e.g., steroids, anticonvulsants, lithium, bisphosphonates, calcitonin, fluoride)
             known to affect bone metabolism

          -  Active peptic ulcer disease or severe reflux",Effects of Parathyroid Hormone in Men With Osteoporosis,0
"Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)","-  INCLUSION CRITERIA:

        This study will include patients (ages 17-69) with biochemically confirmed
        hypoparathyroidism.

        EXCLUSION CRITERIA

        Women who are pregnant will be excluded.",Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34,0
"Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)","INCLUSION CRITERIA:

        Patients over the age of 2 who are enrolled in 91-DK-0085, ""Studies of Hyperparathyroidism
        and Related Disorders"", or patients who are undergoing parathyroid localization as part of
        routine patient care while enrolled in other Clinical protocols will be considered for the
        study.

        EXCLUSION CRITERIA:

        Patients will be excluded if:

        There is any contraindication to arteriography.

        The Patient is pregnant.",Using X-Ray Dye to Locate Hidden Parathyroid Tumors,0
"Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)","-  INCLUSION CRITERIA:

        Screening FOR SUSPECTED PTLDS:

        Age greater than or equal to 13 years old, suspect of suffering from Lyme disease

        Post-Treatment Lyme Disease Syndrome (PTLDS): For the purposes of this study, PTLDS is
        defined as occurring in male or female patients age 13 and above who have been diagnosed
        with confirmed or probable Lyme disease per CDC definition
        (https://wwwn.cdc.gov/nndss/conditions/lyme-disease/case-definition/2017/). Studyphysician
        will review history to confirm probable cases. They have received recommended antibiotic
        therapy and have persistent or relapsing symptoms and/or signs for at least six months
        after therapy. They also should have no other documented explanation for their signs and
        symptoms.

        Lyme arthritis controls: For the purposes of this study, Lyme arthritis is defined as
        occurring in an otherwise healthy male or female aged 18 and above who have intermittent
        episodes of arthritis involving one or few joint, without any other cause being documented,
        and have positive serum antibodies to B.burgdorferi confirmed by Western blot according to
        the CDC criteria.

        Recovered Controls: For the purposes of this study, a recovered control is defined as an
        otherwise healthy male or female aged 18 and above who has had Lyme disease, fulfilling the
        CDC Lyme Disease National Surveillance Case Definition and who had received accepted
        antibiotic treatment for Lyme disease (at least 3 months since the end of antibiotic
        therapy before protocol evaluation) and who are currently asymptomatic.

        Seropositive Controls: For the purposes of this study, a serpositive control is defined as
        an otherwise healthy male or female aged 18 and above who has positive serum IgG antibody
        to B.burgdorferi by Western blot according to the CDC criteria and are asymptomatic and who
        recall no episodes of disease compatible with Lyme infection and have not received
        antibiotic therapy for Lyme disease.

        OspA vaccinated control: For the purposes of this study, a OspA vaccinated control is
        defined as an otherwise healthy male or female aged 18 and above who has received at least
        two doses of the OspA vaccine for Lyme disease (Lymerix [R]). These controls may have a
        positive ELISA for B.burgdorferi but a negative (or unreadable) IgG western blot.

        Multiple sclerosis controls: For the purposes of this study, a multiple sclerosis control
        is defined as an otherwise healthy male or female aged 18 and above with
        relapsing-remitting or progressive multiple sclerosis as defined by the Clinical Trial
        Committee of the National Multiple Sclerosis Society and no evidence of prior exposure to
        B.burgdorferi as indicate by negative history for Lyme disease and negative Western blot
        for B.burgdorferi in the serum by the CDC criteria. Patients should have a Kurtzke or
        Expanded Disability Status Scale (EDSS) between 1 to 5.

        Healthy Volunteers: For the purpose of this study, a healthy volunteer is defined as
        healthy male or female, age 18 and above, with no history compatible with Lyme disease and
        negative serological testing to B.burgdorferi by the CDC criteria.

        All study participants must agree to allow their samples to be used for future research.

        EXCLUSION CRITERIA:

        General exclusion criteria:

        Age less than 18 (less than 13 for patients with PTLDS).

        Weight less than 70 Lb (35 kg).

        Pregnancy or lactation.

        Women with childbearing potential who are sexually active with a male partner and unwilling
        to use effective contraception during the evaluation and treatment phases of the protocol.

        Clinically significant laboratory abnormalities including positive test for syphilis (RPR),
        HBsAg, anti-HCV, anti-HIV.

        Chronic medication use will be evaluated in a case-by-case basis.

        Not able to understand all of the requirements of the study or unable to give informed
        consent and/or comply with all aspects of the evaluation.

        EXCLUSION CRITERIA FOR PTLDS PATIENTS AND LYME ARTHRITIS CONTROLS:

        In addition to the general exclusion criteria, these individuals will be excluded for:

          1. Use of immunosuppressive drugs such as systemic (but not topical or inhalant) steroids
             and cytotoxic agents.

          2. History of any recognized autoimmune disease such as rheumatoid arthritis, vasculitis,
             systemic erythematous lupus, etc.

          3. Serious pre-existing or concurrent chronic medical or psychiatric illnesses other than
             Lyme disease.

          4. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness that might produce neurologic deficit (such as
             cerebrovascular disease).

          5. Use of systemic antibiotics in the previous month.

          6. Use of immunomodulators such as interferons.

          7. Chronic medication use will be evaluated in a case-by-case basis.

          8. Patients will be excluded from this protocol if they are judged by the principal
             investigator as having a significant impairment in their capacity for judgment and
             reasoning that compromise their ability to make decisions in their best interest.

        EXCLUSION CRITERIA FOR RECOVERED, SEROPOSITIVE, OSPA VACCINATED AND HEALTHY VOLUNTEERS
        CONTROLS:

        In addition to the above applicable exclusion criteria (general exclusion criteria and
        exclusion criteria for PTLDS patients and Lyme arthritis controls), these individuals will
        be excluded for:

        1. Pre-existing or concurrent serious chronic medical or psychiatric illness.

        EXCLUSION CRITERIA FOR MULTIPLE SCLEROSIS CONTROLS:

        In addition to the above general exclusion criteria, these individuals will be excluded
        for:

          1. Pre-existing or concurrent serious psychiatric or chronic medical illness besides
             Multiple Sclerosis.

          2. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness, besides Multiple Sclerosis, that might produce
             neurologic deficit (such as cerebrovascular disease).

          3. Previously received total lymphoid irradiation (TLI) or cladribine.

          4. Has used of immunoactive medications (excluding beta-interferon) in the three months
             preceding the study.

          5. In the three months prior to the study initiation, was given such investigational
             treatments as plasmapheresis, hyperbaric oxygen, gangliosides, Copolymer 1, etc.

        ELIGIBILITY OF SPECIAL POPULATIONS:

        Children: Children 13 years and older are eligible to participate in the PTLDS cohort
        because the condition under study can affect children. T, and this age was selected as
        appropriate for the children to provide assent to and comply with the study procedures.
        Children younger than 13 will be excluded from the PTLDS cohort, and no children will be
        enrolled in the other study cohorts.

        Pregnant and lactating women: Pregnant and lactating women are excluded from study
        participation. An enrolled participant who becomes pregnant during the study will be
        withdrawn

        Adults who lack capacity to consent: Adults who lack decision-making capacity to provide
        informed consent are excluded at screening, and enrolled adult participants who permanently
        lose the ability to consent during study participation will be withdrawn.

        NIH staff members: NIH staff may be enrolled if they meet eligibility criteria. Neither
        participation nor refusal to participate as a subject in the research will have an effect,
        either beneficial or adverse, on the participant s employment or position at NIH. Every
        effort will be made to protect participant information, but such information may be
        available in medical records and may be available to authorized users outside of the study
        team in both an identifiable and unidentifiable manner.","A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations",0
"Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)","DISEASE CHARACTERISTICS: Primary or therapy-related myelodysplastic syndrome: Refractory
        anemia with excess blasts Refractory anemia with excess blasts in transformation Chronic
        myelomonocytic leukemia Refractory anemia, refractory anemia with ringed sideroblasts, or
        refractory cytopenia with multilineage dysplasia These patients must also have one of the
        following criteria: Greater than 4 units of RBCs transfused within the past 3 months OR
        Platelet count less than 50,000/mm3 OR Neutrophil count less than 1,000/mm3 AND a recent
        infection requiring antibiotics

        PATIENT CHARACTERISTICS: Age: Over 15 Performance status: 0-2 Life expectancy: Not
        specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater than 1.5
        mg/dL SGOT no greater than 2 times upper limit of normal Renal: Creatinine no greater than
        1.5 mg/dL Other: Not pregnant or nursing Fertile patients must use effective contraception
        Free of any evidence of prior cancer for at least 12 months

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior interferon No
        prior hematopoietic growth factors or cytokines except epoetin alfa No concurrent epoetin
        alfa Chemotherapy: No prior topotecan No prior chemotherapy for this disease At least 12
        months since prior chemotherapy for another disease No other concurrent chemotherapy
        Endocrine therapy: At least 1 month since prior corticosteroids No concurrent hormonal
        therapy for disease-related conditions Concurrent steroids for adrenal failure allowed No
        concurrent dexamethasone and other steroidal antiemetics Radiotherapy: No prior
        radiotherapy for this disease At least 12 months since prior radiotherapy for another
        disease Surgery: Not specified Other: No prior cytotoxic therapy (including low-dose
        antimetabolites) for this disease At least 1 month since prior retinoids",Topotecan in Treating Patients With Myelodysplastic Syndrome,0
"Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)","DISEASE CHARACTERISTICS: Cytologically confirmed myelodysplastic syndrome (MDS) Increased
        blasts (i.e., greater than 1 to 30% peripheral blood blasts and/or 5 to 30% bone marrow
        blasts) AND International Prognostic Score intermediate 1, intermediate 2, or high risk
        Refractory anemia with excess blasts OR Refractory anemia with excess blasts in
        transformation (no presence of auer rods as sole criteria) OR Chronic myelomonocytic
        leukemia Greater than 1% blasts in the peripheral blood and/or at least 5% blasts in the
        bone marrow OR MDS related acute myeloid leukemia Arising after documented MDS of at least
        60 days Absolute peripheral blast count no greater than 5,000/mm3 Must have genotypically
        HLA identical sibling donor Must also be enrolled on SWOG-S9910 and SWOG-9007

        PATIENT CHARACTERISTICS: Age: 16 to 55 Performance status: Zubrod 0-2 Life expectancy: Not
        specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not
        specified Other: No prior malignancy within past 5 years except: Adequately treated basal
        cell or squamous cell skin cancer Carcinoma in situ of the cervix Adequately treated stage
        I or II cancer in complete remission HIV negative Not pregnant or nursing Fertile patients
        must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: No autologous peripheral stem cell
        transplantation prior to diagnosis of myelodysplastic syndrome (MDS) or MDS related acute
        myeloid leukemia Chemotherapy: No prior chemotherapy for MDS or MDS related acute myeloid
        leukemia except oral chemotherapy to control leukocytosis or thrombocytosis (e.g.,
        hydroxyurea or etoposide) Endocrine therapy: Not specified Radiotherapy: No radiotherapy
        prior to diagnosis of MDS or MDS related acute myeloid leukemia Surgery: Not specified",S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia,0
"Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)","-  INCLUSION CRITERIA - DEPRESSED WOMEN:

        The patient is a woman 21 to 45 years old on the date of the initial screening.

        The patient is not postmenopausal.

        She must be willing to practice an acceptable method of birth control, as appropriate (IUD,
        oral contraceptives, diaphragm, condoms, hormonal implants/injection, with the exception of
        subdermal levonorgestrel, sterilization) and have a negative serum pregnancy test at
        screening.

        Women currently on estrogen/progestin contraceptive therapy must have been on a stable
        regimen of estrogen/progestin for at least 6 months prior to enter the study.

        The patient understands the procedures and the risks of the study and has been informed
        that, alternatively, she may freely elect to be treated with the currently available
        treatments by her physician.

        The patient voluntarily agrees to participate in the study.

        INCLUSION CRITERIA RELATED TO THE PSYCHIATRIC STATUS:

        The patient had at least one episode of major depression within the last 3 years (DSM-IV).
        In addition, the subject has a past history (prior to the last 3 years) of at least one
        major depressive episode lasting more than 2 weeks.

        With the exception of depression, the patient is in good health, based on medical history,
        physical examination, and laboratory screening evaluation.

        The patient has a physician; either a family doctor, a psychiatrist, a psychotherapist, or
        another qualified health care professional who can provide medical treatment for
        depression. If the subject is not receiving any medical care for depression, a member of
        the NIH team will help the patient identify one and will work closely with this
        professional during the study.

        The patient can be on pharmacological antidepressant therapy, as medically indicated and
        prescribed by her primary physician or health professional. It is not a requirement of this
        study for subjects to stop antidepressant treatment, unless it is medically indicated for
        reasons such as the medication is ineffective, not well tolerated, or the patient no longer
        needs such treatment. This decision will be based upon their physician's evaluation.

        Patients starting a new antidepressant medication(s) should be on this treatment for 4-6
        weeks prior to enrollment.

        Carbamazepine, valproic acid or thyroid hormones used as adjunctive therapy for treatment
        of depression are allowed.

        Women with a current or recent (within the past 3 years) history of alcohol or drug abuse
        are eligible if, in the opinion of the principal investigator, this condition is not likely
        to impair patient compliance or if the participation in the study does not pose additional
        risks to the subject.

        INCLUSION CRITERIA RELATED TO THE BONE STATUS:

        The patient has spinal anatomy suitable for dual-energy x-ray absorptiometry (DEXA)
        densitometry of the lumbar spine, with no evidence of vertebral fractures in at least three
        vertebrae. Significant scoliosis, bony trauma, osteoarthritis, and sequelae of orthopedic
        procedures that result in anatomy unsuitable for accurate bone densitometry, must be absent
        from the lumbar spine.

        The patient has osteopenia or osteoporosis, as indicated by a bone mineral density at the
        spine that is between 1.5 and 5 standard deviations below peak bone mass, or history of an
        osteoporotic vertebral or hip fracture. Patients whose eligibility is based only on a
        prevalent vertebral fracture will have the fracture confirmed by a radiologist.

        EXCLUSION CRITERIA - DEPRESSED WOMEN:

        GENERAL EXCLUSION CRITERIA:

        The patient is, in the opinion of the investigator, mentally or legally incapacitated such
        that informed consent cannot be obtained.

        Pregnancy or breast-feeding.

        Menopause.

        The patient plans to move within the next 12 months to a location which could impair a
        continued follow-up.

        The patient has a history of or evidence for an illness or has significant abnormalities on
        prestudy clinical or laboratory evaluations, which, in the opinion of the principal
        investigator, might complicate the interpretation of the data or pose additional risk to
        the subject.

        The patient has any of the following medical conditions: any malabsorption syndrome,
        significant genitourinary, renal (serum creatinine greater than or equal to 1.6 mg/dL),
        hepatic, or pulmonary disease; uncontrolled hypertension; uncontrolled diabetes mellitus;
        decompensated heart failure; clinically significant arrhythmias; unstable angina, any
        immunodeficiency syndrome including AIDS.

        The patient has received any drug of investigation within 30 days of the start of the
        study.

        The use of subdermal levonorgestrel and similar preparations.

        EXCLUSION CRITERIA RELATED TO THE PSYCHIATRIC STATUS:

        The patient does not have an outside care provider for treatment of depression.

        The patient is judged to be at suicidal risk, as clinically evident or indicated by a score
        of 4 at the Hamilton Scale, question 3 (suicide), or by reports of suicidal intent during
        SCID-IV interview.

        The patient has a history suggesting potential for self-harm or violence towards others.

        The patient currently has psychotic depression (e.g. hallucinations, delusions).

        The patient has schizoaffective disorder.

        Patients with a diagnosis of active anorexia nervosa, bulimia or any other eating disorder
        are not eligible.

        Patients with a diagnosis of bipolar disorders type 1 or type 2 or any psychotic disorder
        other than psychotic depression are not eligible.

        Women with a current or recent (within the past 3 years) history of alcohol or drug
        dependence are not eligible.

        EXCLUSION CRITERIA RELATED TO THE BONE STATUS OR THE USE OF ALENDRONATE:

        The patient is affected by severe osteoporosis, as indicated by a history of recurrent
        non-traumatic fractures and/or a BMD value which is below 4 SD the peak bone mass at the
        spine and/or the hip.

        The patient has a history of recent major upper gastrointestinal (GI) (esophagus, stomach,
        duodenum) mucosal erosive disease. As defined by (1) significant upper GI bleeding within
        the last year resulting in hospitalization and/or transfusion. (2) Recurrent ulcer disease
        documented by radiographic or endoscopic means (two episodes in the last two years, or any
        documented ulcer in the preceeding 3 months). (3) Uncontrolled dyspepsia currently treated
        on a daily basis. (4) Esophageal or gastric variceal disease or (5) esophageal stricture,
        achalasia, or severe esophageal motor dysfunction. (This only applies to Group C and D)

        The patient has a history of cancer with the following exceptions: (1) superficial basal or
        squamous cell carcinoma of the skin that was treated, and (2) other malignancies treated at
        least 10 years ago without any evidence of recurrence.

        The patient has a history of, or evidence for, metabolic bone disease (other than low bone
        mineral density) including, but not limited to uncontrolled hyper- or hypocalcemia, hyper-
        or hypoparathyroidism, Paget's disease of bone, osteomalacia, or osteogenesis imperfecta.
        Patients with surgically cured hyperparathyrodism due to parathyroid adenoma (at least one
        year prior to randomization) are eligible for inclusion in the trial. Patients with
        well-controlled hyper- or hypothyrodism, as indicated by clinical evaluation and normal
        plasma TSH level are eligible for inclusion in the trial.

        The patient has received treatment prior to enrollment in the study that might have
        influenced bone turnover including:

        Beginning a regimen (for more than 2 consecutive weeks) within the last 6 months, of any
        estrogen preparation including mixed estrogen agonist/antagonist, (e.g., tamoxifen or
        raloxifene) or progestins.

        Having used within the last 6 months any of the following: anabolic steroids (including
        DHEA and other weaker analogs), calcitonin, calcitriol, alfacalcidol, excess vitamin A
        (greater than 10,000 units/day) or vitamin D (greater than 1,000 units/day), cyclosporine,
        or anticonvulsivants.

        The patient is on a thyroid hormone for treatment of a thyroid condition, unless the
        patient has received a stable dose for the last 6 weeks prior to study enrollment, and is
        euthyroid, as documented by an ultrasensitive TSH serum assay.

        The patient is on fluoride at a dose greater than 1 mg/day any time (fluoride taken greater
        than 3 months ago for less than 1 week is acceptable).

        The patient has a history of glucocorticoid treatment for more than 1 month, within 6
        months prior to study start (patients who received therapeutic glucocorticoids in the past
        must be considered unlikely to need glucocorticoid treatment during the course of the
        study).

        Any previous treatment with bisphophonates for more than 2 weeks.

        The patient's screening 25-hydroxyvitamin D level is less than 15 ng/mL unless 24-h urine
        calcium and serum PTH, calcium, and alkaline phosphatase are all within the normal range.

        The patient is not able to stand or sit upright for at least 30 minutes.

        The patient has a body weight greater than 137 kg, due to limitations in the accuracy of
        DEXA measurements above this body weight.

        EXCLUSION CRITERIA RELATED TO THE EXERCISE (COOPER) TEST:

        Subjects on beta-blockers will not be eligible to participate in the 12-min test.

        INCLUSION CRITERIA - HEALTHY CONTROL WOMEN:

        Healthy control women must be of good physical health; specifically, no history of any
        DSM-IV diagnoses, including but not limited to depression and anorexia nervosa.

        They also must have normal bone density, no history of osteoporotic fractures, and be
        willing to be on a valid contraceptive method.

        EXCLUSION CRITERIA - HEALTHY CONTROL WOMEN:

        Control women should not have any of the risk factors for bone loss such as smoking,
        alcohol abuse, dietary imbalances unless the risk factor is present only to a mild extent.",Bone Loss in Premenopausal Women With Depression,0
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","Patients greater than 1 year of age with the clinical and pathological diagnosis of WG
        whose illness presents a risk of permanent disability or death. Examples of processes that
        impart risk of permanent disability or death include: peripheral and central nervous system
        disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal
        organs.

        No women who are pregnant or intend to become pregnant.

        No patients who have known malignancies.

        Patients must be HIV negative.",Treatment of Wegener's Granulomatosis With Cyclophosphamide,1
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","INCLUSION CRITERIA:

        Diagnosis: Wegener's granulomatosis.

        Age: 10-80 years.

        Qualifications to eligibility:

        Prior documentation of vasculitis based on clinical characteristics and histopathological
        and/or angiographic evidence of vasculitis. Patients will be eligible for this study
        regardless of whether they are currently receiving immunosuppressive therapies. Failure to
        respond to prior therapy with other cytotoxic agents or toxicity from such agents, in the
        setting of persistent disease, will constitute one reason for eligibility for this study.

        In the absence of histopathological and/or angiographic evidence of vasculitis, patients
        with the following criteria will also be eligible:

        A. Positive C-ANCA (done at the NIH), and

        B. Glomerulonephritis as evidenced by the presence of red blood cell casts and proteinuria
        or renal biopsy showing necrotizing glomerulonephritis in the absence of positive
        immunofluorescence for immunoglobulin and complement, and

        C. One or more of the following:

        Inflammatory sinusitis with histopathological evidence of granulomatous inflammation and
        negative special stains for mycobacteria and fungi. Sinusitis must be present for at least
        3 months and have failed to respond to at least 2 weeks of antibiotic therapy directed
        against likely pathogens (H. influenza, S. pneumonia, and upper respiratory tract anaerobic
        bacteria);

        Pulmonary nodule or infiltrates in a patient in the absence of infection.

        Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater
        than or equal to 3 (Appendix I) or if begun on immunosuppressive therapy at an outside
        institution, a history of a Vasculitis Disease Activity Index greater than or equal to 3
        during the past 6 months.

        EXCLUSION CRITERIA:

        Evidence of infection by gram stain and/or culture specimens. In those instances in which
        infection cannot be ruled out by gram stain and culture of secretions or collections of
        fluid in involved organs, it may be necessary to obtain a biopsy of the affected tissue for
        microbiological and histopathological studies.

        Recent (within four weeks) increase in GC or cytotoxic drug therapy.

        Patients who are pregnant or nursing infants will not be eligible. Fertile women should
        have a negative pregnancy test within one week prior to study entry and should be using
        effective means of birth control.

        Processes that would predispose to enhanced risk of MTX toxicity: acute or chronic liver
        disease, alcohol abuse (greater than 14 oz of 100 proof liquor or equivalent per week),
        active peptic ulcer disease, and inability to comply with study guidelines.

        Serological evidence of infection with human immunodeficiency virus (a serological
        determination will be performed within two weeks of study entry).",Steroids and Methotrexate to Treat Systemic Vasculitis,2
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","-  INCLUSION CRITERIA - BLOOD DRAW/ASTHMA:

        Age 18-65.

        Asthma of greater than one year duration.

        Willingness to adhere to effective contraception in women of child bearing age.

        Negative HIV test.

        EXCLUSION CRITERIA - BLOOD DRAW/ASTHMA:

        For blood draws of greater than 100 ml, a hemoglobin of less than 12.5 g/dl. For blood
        draws of 100 ml or less, performed less frequently than every 56 days, a hemoglobin of less
        than 10.0 g/dl.

        Current pregnancy.

        Medical history suggesting lung diseases other than asthma.

        History of immunodeficiency or HIV infection.

        INCLUSION CRITERIA - BLOOD DRAW/NORMAL CONTROL:

        Age 18-65.

        Willingness to adhere to effective contraception in women of child bearing age.

        Negative HIV test.

        EXCLUSION CRITERIA - BLOOD DRAW/NORMAL CONTROL:

        For blood draws of greater than 100 ml, a hemoglobin of less than 12.5 g/dl. For blood
        draws of 100 ml or less, performed less frequently than every 56 days, a hemoglobin of less
        than 10.0 g/dl.

        Current pregnancy.

        Positive skin test to one or more allergens in the battery tested.

        History of asthma or other allergic diseases, such as hay fever.

        Medical history suggesting lung diseases other than asthma.

        History of immunodeficiency or HIV infection.

        INCLUSION CRITERIA - EXHALED BREATH CONDENSATE/ASTHMA:

        Age 18-65.

        Asthma as diagnosed by a physician or use of medications consistent with the treatment of
        asthma.

        Subjects must have a doctor outside NIH and they will provide routine and emergency care.

        EXCLUSION CRITERIA - EXHALED BREATH CONDENSATE/ASTHMA:

        History of immunodeficiency or HIV infection.

        History of allergy to latex.

        INCLUSION CRITERIA - EXHALED BREATH CONDENSATE/HEALTHY CONTROL:

        Age 18 - 65.

        EXCLUSION CRITERIA - EXHALED BREATH CONDENSATE/HEALTHY CONTROL:

        History of asthma or other allergic diseases, such as allergic rhinitis.

        Medical history suggesting lung diseases other than asthma.

        History of allergy to latex.

        History of immunodeficiency or HIV infection.",Role of T-Cells in Asthma,0
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","INCLUSION CRITERIA:

        Documentation of WG based on clinical characteristics and histopathological evidence of
        vasculitis. Patients with a positive C- or P-ANCA and glomerulonephritis as evidence by the
        presence of red blood cell casts and proteinuria or renal biopsy showing necrotizing
        glomerulonephritis in the absence of positive immunofluorescence for immunoglobulin and
        complement will also be eligible.

        Age 10-80 years.

        Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater
        than or equal to 3 or if begun on CTX and glucocorticoid at an outside institution, a
        history of a Vasculitis Disease Activity Index greater than or equal to 3 at the time of
        therapy initiation.

        EXCLUSION CRITERIA:

        Evidence of active systemic infection which, in the judgement of the investigator, is of
        greater danger to the patient than the underlying vasculitis. In those instances in which
        infection cannot be ruled out by gram stain and culture of secretions or collections of
        fluid in involved organs, it may be necessary to obtain a biopsy of the affected tissue for
        microbiological and histopathological studies.

        Patients who are pregnant or who are nursing infants will not be eligible. Fertile women
        must have a negative pregnancy test within one week prior to study entry and must be using
        an effective means of birth control.

        Processes associated with an increased risk of MTX toxicity: acute or chronic liver
        disease, past history of alcohol abuse (greater than 14 oz. of 100 proof liquor or
        equivalent per week), ongoing alcohol use of any volume that cannot be discontinued upon
        entry into the study.

        Serological evidence of infection with human immunodeficiency virus, hepatitis C, or a
        positive hepatitis B surface antigen. A serological determination will be performed within
        two weeks of beginning study participation.

        Inability to comply with study guidelines.",Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides,2
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","-  INCLUSION CRITERIA:

        Screening FOR SUSPECTED PTLDS:

        Age greater than or equal to 13 years old, suspect of suffering from Lyme disease

        Post-Treatment Lyme Disease Syndrome (PTLDS): For the purposes of this study, PTLDS is
        defined as occurring in male or female patients age 13 and above who have been diagnosed
        with confirmed or probable Lyme disease per CDC definition
        (https://wwwn.cdc.gov/nndss/conditions/lyme-disease/case-definition/2017/). Studyphysician
        will review history to confirm probable cases. They have received recommended antibiotic
        therapy and have persistent or relapsing symptoms and/or signs for at least six months
        after therapy. They also should have no other documented explanation for their signs and
        symptoms.

        Lyme arthritis controls: For the purposes of this study, Lyme arthritis is defined as
        occurring in an otherwise healthy male or female aged 18 and above who have intermittent
        episodes of arthritis involving one or few joint, without any other cause being documented,
        and have positive serum antibodies to B.burgdorferi confirmed by Western blot according to
        the CDC criteria.

        Recovered Controls: For the purposes of this study, a recovered control is defined as an
        otherwise healthy male or female aged 18 and above who has had Lyme disease, fulfilling the
        CDC Lyme Disease National Surveillance Case Definition and who had received accepted
        antibiotic treatment for Lyme disease (at least 3 months since the end of antibiotic
        therapy before protocol evaluation) and who are currently asymptomatic.

        Seropositive Controls: For the purposes of this study, a serpositive control is defined as
        an otherwise healthy male or female aged 18 and above who has positive serum IgG antibody
        to B.burgdorferi by Western blot according to the CDC criteria and are asymptomatic and who
        recall no episodes of disease compatible with Lyme infection and have not received
        antibiotic therapy for Lyme disease.

        OspA vaccinated control: For the purposes of this study, a OspA vaccinated control is
        defined as an otherwise healthy male or female aged 18 and above who has received at least
        two doses of the OspA vaccine for Lyme disease (Lymerix [R]). These controls may have a
        positive ELISA for B.burgdorferi but a negative (or unreadable) IgG western blot.

        Multiple sclerosis controls: For the purposes of this study, a multiple sclerosis control
        is defined as an otherwise healthy male or female aged 18 and above with
        relapsing-remitting or progressive multiple sclerosis as defined by the Clinical Trial
        Committee of the National Multiple Sclerosis Society and no evidence of prior exposure to
        B.burgdorferi as indicate by negative history for Lyme disease and negative Western blot
        for B.burgdorferi in the serum by the CDC criteria. Patients should have a Kurtzke or
        Expanded Disability Status Scale (EDSS) between 1 to 5.

        Healthy Volunteers: For the purpose of this study, a healthy volunteer is defined as
        healthy male or female, age 18 and above, with no history compatible with Lyme disease and
        negative serological testing to B.burgdorferi by the CDC criteria.

        All study participants must agree to allow their samples to be used for future research.

        EXCLUSION CRITERIA:

        General exclusion criteria:

        Age less than 18 (less than 13 for patients with PTLDS).

        Weight less than 70 Lb (35 kg).

        Pregnancy or lactation.

        Women with childbearing potential who are sexually active with a male partner and unwilling
        to use effective contraception during the evaluation and treatment phases of the protocol.

        Clinically significant laboratory abnormalities including positive test for syphilis (RPR),
        HBsAg, anti-HCV, anti-HIV.

        Chronic medication use will be evaluated in a case-by-case basis.

        Not able to understand all of the requirements of the study or unable to give informed
        consent and/or comply with all aspects of the evaluation.

        EXCLUSION CRITERIA FOR PTLDS PATIENTS AND LYME ARTHRITIS CONTROLS:

        In addition to the general exclusion criteria, these individuals will be excluded for:

          1. Use of immunosuppressive drugs such as systemic (but not topical or inhalant) steroids
             and cytotoxic agents.

          2. History of any recognized autoimmune disease such as rheumatoid arthritis, vasculitis,
             systemic erythematous lupus, etc.

          3. Serious pre-existing or concurrent chronic medical or psychiatric illnesses other than
             Lyme disease.

          4. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness that might produce neurologic deficit (such as
             cerebrovascular disease).

          5. Use of systemic antibiotics in the previous month.

          6. Use of immunomodulators such as interferons.

          7. Chronic medication use will be evaluated in a case-by-case basis.

          8. Patients will be excluded from this protocol if they are judged by the principal
             investigator as having a significant impairment in their capacity for judgment and
             reasoning that compromise their ability to make decisions in their best interest.

        EXCLUSION CRITERIA FOR RECOVERED, SEROPOSITIVE, OSPA VACCINATED AND HEALTHY VOLUNTEERS
        CONTROLS:

        In addition to the above applicable exclusion criteria (general exclusion criteria and
        exclusion criteria for PTLDS patients and Lyme arthritis controls), these individuals will
        be excluded for:

        1. Pre-existing or concurrent serious chronic medical or psychiatric illness.

        EXCLUSION CRITERIA FOR MULTIPLE SCLEROSIS CONTROLS:

        In addition to the above general exclusion criteria, these individuals will be excluded
        for:

          1. Pre-existing or concurrent serious psychiatric or chronic medical illness besides
             Multiple Sclerosis.

          2. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness, besides Multiple Sclerosis, that might produce
             neurologic deficit (such as cerebrovascular disease).

          3. Previously received total lymphoid irradiation (TLI) or cladribine.

          4. Has used of immunoactive medications (excluding beta-interferon) in the three months
             preceding the study.

          5. In the three months prior to the study initiation, was given such investigational
             treatments as plasmapheresis, hyperbaric oxygen, gangliosides, Copolymer 1, etc.

        ELIGIBILITY OF SPECIAL POPULATIONS:

        Children: Children 13 years and older are eligible to participate in the PTLDS cohort
        because the condition under study can affect children. T, and this age was selected as
        appropriate for the children to provide assent to and comply with the study procedures.
        Children younger than 13 will be excluded from the PTLDS cohort, and no children will be
        enrolled in the other study cohorts.

        Pregnant and lactating women: Pregnant and lactating women are excluded from study
        participation. An enrolled participant who becomes pregnant during the study will be
        withdrawn

        Adults who lack capacity to consent: Adults who lack decision-making capacity to provide
        informed consent are excluded at screening, and enrolled adult participants who permanently
        lose the ability to consent during study participation will be withdrawn.

        NIH staff members: NIH staff may be enrolled if they meet eligibility criteria. Neither
        participation nor refusal to participate as a subject in the research will have an effect,
        either beneficial or adverse, on the participant s employment or position at NIH. Every
        effort will be made to protect participant information, but such information may be
        available in medical records and may be available to authorized users outside of the study
        team in both an identifiable and unidentifiable manner.","A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations",0
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","INCLUSION CRITERIA:

        Diagnosis of Wegener's granulomatosis based on clinical and histological characteristics.

        Age between 18-75 years.

        Bronchoscopy is required as part of their standard medical care.

        FEV1 is greater than 55 percent of FVC.

        O2 saturation is greater than 90 percent.

        EXCLUSION CRITERIA:

        FEV1 is less than 55% of FVC.

        O2 saturation is less than 90%.

        Abnormal PT, PTT, or platelet count less than 50.

        History of adverse reaction to lidocaine or other local anesthetics.

        Pregnancy.",Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis,1
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","Diagnosis of Wegener's granulomatosis based on clinical characteristics and
        histopathological and/or angiographic evidence of vasculitis or the presence of
        glomerulonephritis and a positive assay for anti-neutrophil cytoplasmic autoantibodies
        (ANCA).

        Age between 18 to 65 years.

        No change in immunosuppressive drug therapy during the prior 4 weeks and one of the
        following:

        Persistent disease activity (""Vasculitis Activity Index"" score of greater than or equal to
        3) despite optimal therapy;

        Persistent or recurrent disease activity in a patient who cannot tolerate optimal therapy;

        Patients not on maximal immunosuppressive therapy but with persistent or recurrent disease
        activity that is not, in the judgment of investigators, immediately threatening the
        function of a major organ system;

        No evidence of active infection.

        Patients may not be pregnant or nursing infants. Fertile women must have a negative
        pregnancy test within one week prior to study entry and all participants must be using
        effective means of birth control.

        Serum creatinine is less than 3.5 mg/dL.

        Hemocytopenia (platelet count is greater than 100,000/mm(3), leukocyte count is greater
        than 3,500/mm(s), hemoglobin is greater than 9 mg/dL).

        Liver function test abnormalities is less than 3x upper limits of normal (either serum GOT,
        GPT, alkaline phosphatase, and/or bilirubin).

        Patients cannot be anti-HIV, anti-HCV, or anti-Hepatitis B surface antigen (HBsAG)
        positive.

        Weight greater less than 104 Kg (because of SCH 52000 concentration and volume limitations
        for subcutaneous injection).

        No treatment with any investigational drug within 30 days.

        No pre-existing malignancy.

        No known allergy to E. coli protein or IL-10.

        No history of psychiatric illness that in the opinion of the principal investigator would
        preclude entrance into the study.",Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis,2
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","INCLUSION CRITERIA:

        Documentation of Wegener's Granulomatosis (WG) based on clinical characteristics and
        histopathological evidence of vasculitis.

        Patient with a positive C- or P-ANCA and glomerulonephritis as evidenced by the presence of
        red blood cell casts and proteinuria or renal biopsy showing necrotizing glomerulonephritis
        in the absence of positive immunofluorescence for immunoglobulin and complement will also
        be eligible.

        Patients must be of the ages of 18-80 years.

        Patients on the CYC to MTX protocol (#95-I-0091) who experience a relapse of disease while
        on MTX maintenance therapy. Relapse is defined by a Vasculitis Disease Activity Index of
        greater than or equal to 3. Patients from outside the NIH will also be eligible if they
        have been treated with a CYC to MTX regimen identical to that used in #95-I-0091 and
        experience a relapse of disease while on MTX maintenance therapy. If treatment for this
        relapse has already been commenced at the outside institution with daily CYC and
        glucocorticoid, patients will still be eligible if there is a history of a Vasculitis
        Disease Activity Index greater than or equal to 3 at the time of CYC and glucocorticoid
        initiation. Patients who experience a relapse of disease after MTX has been stopped or
        while tapering the MTX dose (following 2 years of maintenance therapy) will not be
        eligible.

        Patients with active disease who have a contraindication to MTX therapy will be eligible.
        Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater
        than or equal to 3.

        Patients with inactive disease who have a contraindication to CYC and. Evidence of active
        disease as defined by a Vasculitis Disease Activity Index of greater than or equal to 3.

        Patients with inactive disease on MTX while on the CYC to MTX protocol (95-I-0091) or the
        MTX protocol (90-I-0086) who develop an contraindication necessitating discontinuation of
        MTX. Patients from outside the NIH will also be eligible if they similarly develop a
        contraindication to MTX while on treatment.

        Patients with inactive disease on the CYC protocol (#76-I-0041 or 76-I-0042) who develop a
        contraindication necessitating CYC discontinuation and also have a contraindication to
        receiving MTX. Patients from outside the NIH will also be eligible if they similarly
        develop a contraindication to CYC while on treatment and cannot receive MTX.

        Patients with inactive disease who are receiving treatment with CYC and prednisone in a
        manner similar to #76-I-0042 will be eligible if they have a contraindication to receiving
        MTX and have been in remission for less 3 months.

        EXCLUSION CRITERIA:

        Evidence of active infection which, in the judgment of the investigator, is of greater
        danger to the patient than the underlying vasculitis. In those instances in which infection
        cannot be ruled out by gram stain and culture of secretions or collections of fluid in
        involved organs, it may be necessary to obtain a biopsy of the affected tissue for
        microbiological and histopathological studies.

        Patients who are pregnant or who are nursing infants will not be eligible. Fertile women
        must have a negative pregnancy test within one week prior to study entry and must be using
        an effective means of birth control.

        Patients with active disease who are eligible for the CYC to MTX protocol (#95-I-0091) or
        the MTX protocol (#90-I-0086).

        Active peptic ulcer disease.

        Serological evidence of infection with human immunodeficiency virus. A serological
        determination will be performed within two weeks of beginning study participation.

        Inability to comply with study guidelines.

        Creatinine clearance less than 25ml/min.",Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions,1
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","INCLUSION CRITERIA:

        Documentation of Wegener's granulomatosis based on clinical characteristics and
        histopathologic and/or angiographic evidence of vasculitis. In the absence of
        histopathologic and/or angiographic evidence of vasculitis, patients who meet one of the
        following criteria and in whom infectious and autoimmune diseases that may mimic Wegener's
        granulomatosis or a related systemic vasculitides have been excluded will also be eligible:
        a) a positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and the
        presence of glomerulonephritis defined by red blood cell casts and proteinuria or renal
        biopsy showing necrotizing glomerulonephritis in the absence of immune deposits; b) a
        positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and the
        presence of granulomatous inflammation on biopsy plus abnormal chest radiograph (defined as
        the presence of nodules, fixed infiltrates, or cavities) plus nasal/oral inflammation on
        clinical examination.

        Subjects must be between the ages of 10 - 70 years.

        Subject must have evidence of active major organ disease.

        Patients who have never been previously seen at the NIH will be eligible if the above
        conditions are met and they either: are not receiving treatment; have been receiving
        prednisone at induction doses and MTX for less than 3 weeks; have been receiving prednisone
        at induction doses and CYC for less than 3 weeks but did not have severe disease.

        EXCLUSION CRITERIA:

        Patients with evidence of bacterial sepsis.

        Patients with evidence of other active systemic infection which in the judgment of the
        investigator, is of greater danger to the patient than the underlying vasculitis.

        Pregnant or subjects who are nursing infants.

        Fertile women must have a negative pregnancy test within one week prior to study entry and
        all participants must be using effective means of birth control.

        Patients with one or more of the following: serum creatinine greater than 2.5 mg/dl or
        creatinine clearance less than 35 ml/min; pulmonary disease resulting in a pO(2) less than
        70 mmHg, or FVC, FEV(1) or DLCO less than 70% of predicted; any Wegener's
        granulomatosis-related disease manifestation that, in the judgment of the investigators, is
        immediately life-threatening.

        Hemocytopenia: platelet count less than 80,000/mm(3), leukocyte count less than
        3,000/mm(3), hematocrit less than 20% (in the absence of gastrointestinal bleeding or
        hemolytic anemia).

        Liver function test abnormalities greater than three times upper limits of normal (either
        serum GOT, GPT, alkaline phosphatase, and/or bilirubin).

        Processes associated with an increased risk of MTX toxicity: acute or chronic liver
        disease, past history of alcohol abuse (greater than 14 oz. of 100 proof liquor or
        equivalent per week), ongoing alcohol use of any volume that cannot be discontinued upon
        entry into the study.

        Serological evidence of infection with human immunodeficiency virus, hepatitis C, or a
        positive hepatitis B surface antigen. A serological determination will be performed within
        two weeks of beginning study participation.

        Treatment with any investigational drug within 30 days.

        Known allergy to TNFR:Fc.

        Individuals with a history of psychiatric illness that in the opinion of the principal
        investigator (PI) would preclude entrance into the study.

        History of multiple sclerosis or other demyelinating disease.",Etanercept to Treat Wegener's Granulomatosis,1
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","Exclusion Criteria

        Co-existing Condition:

        Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal
        dysfunction, or gastric ulceration are excluded.

        Concurrent Medication:

        Excluded:

          -  Systemic corticosteroids.

          -  Cytotoxic immunosuppressive agents.

          -  Radiotherapy.

        Critically ill patients or those with CDC-defined AIDS are excluded.

        Prior Medication:

        Excluded within 1 month of study entry:

          -  Immunotherapy.

        Patients with persistent generalized lymphadenopathy (PGL).",A Study of Isoprinosine in Patients With Lymph Node Disease,0
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","INCLUSION CRITERIA:

          1. Documentation of Wegener's granulomatosis (WG) or a related systemic vasculitis based
             on clinical characteristics and histopathologic and/or angiographic evidence of
             vasculitis. In the absence of histopathologic and/or angiographic evidence of
             vasculitis, patients who meet one of the following criteria and in whom infectious and
             autoimmune diseases that may mimic WG or a related systemic vasculitides have been
             excluded will also be eligible:

             A. A positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and
             the presence of glomerulonephritis defined by red blood cell casts and proteinuria or
             renal biopsy showing necrotizing glomerulonephritis in the absence of immune deposits.

             B. A positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and
             the presence of granulomatous inflammation on biopsy plus abnormal chest radiograph
             (defined as the presence of nodules, fixed infiltrates, or cavities) plus nasal/oral
             inflammation on clinical examination.

          2. Age 10-80 years.

          3. Evidence of active disease as defined by a Vasculitis Disease Activity Index of
             greater than or equal to 3 or if begun on CYC and glucocorticoid at an outside
             institution, a history of a Vasculitis Disease Activity Index greater than or equal to
             3 at the time of therapy initiation.

        EXCLUSION CRITERIA:

          1. Evidence of active infection which, in the judgment of the investigator, is of greater
             danger to the patient than the underlying vasculitis. In those instances in which
             infection cannot be ruled out by gram stain and culture of secretions or collections
             of fluid in involved organs, it may be necessary to obtain a biopsy of the affected
             tissue for microbiological and histopathological studies.

          2. Patients who are pregnant or who are nursing infants will not be eligible. Fertile
             women must have a negative pregnancy test within one week prior to study entry and
             must be using an effective means of birth control.

          3. Serological evidence of infection with human immunodeficiency virus, hepatitis C, or a
             positive hepatitis B surface antigen. A serological determination will be performed
             within two weeks of beginning study participation.

          4. Acute or chronic liver disease, past history of alcohol abuse (greater than 14 oz of
             100 proof liquor or equivalent per week), ongoing alcohol use of any volume that
             cannot be discontinued upon entry into the study.

          5. History of CYC- or methotrexate- induced pneumonitis with past treatment.

          6. Hypersensitivity to CYC, MPM, or methotrexate.

          7. Transitional cell carcinoma of the bladder.

          8. Inability to comply with study guidelines.

          9. Hemocytopenia: platelet count less than 80,000/mm(3), leukocyte count less than
             3,000/mm(3), hematocrit less than 20% (in the absence of gastrointestinal bleeding or
             hemolytic anemia).",Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes,2
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of giant cell arteritis (GCA) by at least one of the following:

          -  Temporal artery biopsy confirming GCA Symptoms of GCA (including new onset (within 6
             months) symptoms of headaches, tenderness of the scalp or the temporal arteries,
             visual loss due to retinal ischemic optic neuropathy or otherwise unexplained tongue
             or jaw pain) and an aortic angiogram that revealed stenotic and/or aneurysmal disease
             of the aorta and its principal branches

          -  Symptoms of polymyalgia rheumatica plus ischemic optic neuropathy, newly identified
             tenderness over a temporal artery, or new onset of tongue or jaw pain

        Westergren erythrocyte sedimentation rate of at least 40 nm in one hour

        --Prior/Concurrent Therapy--

        Endocrine therapy: No greater than 20 days since initiation of prednisone therapy

        Other: No concurrent sulfa drugs or nonsteroidal antiinflammatory drugs

        --Patient Characteristics--

        Hematopoietic:

          -  WBC at least 4,000/mm3

          -  Platelet count at least 120,000/mm3

          -  No acute or chronic liver disease

        Hepatic:

          -  Alkaline phosphatase no greater than 2 times upper limit of normal

          -  No other reproducible abnormal liver function test

        Renal: Creatinine less than 2.0 mg/dL

        Other:

          -  HIV negative

          -  No symptomatic peptic ulcer disease within the last 3 months

          -  Hepatitis B or C antigen negative

          -  No alcohol use in excess of 2 ounces of 100 proof liquor or 1 beer or its equivalent
             per week

          -  No insulin dependent diabetes mellitus plus morbid obesity (greater than 33% over
             ideal body weight)

          -  No recently (less than 6 months) diagnosed malignancy

          -  Not pregnant or nursing

          -  Adequate contraception required of all fertile patients",Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis,0
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","Inclusion Criteria:

          -  Minimum weight of 40 kg.

          -  Diagnosis of WG, excluding infections, malignancies, systemic autoimmune disorders,
             and other forms of vasculitis that may mimic WG.

          -  At least two of the five modified American College of Rheumatology (ACR) criteria for
             a diagnosis of WG. The modified ACR criteria are: (1) nasal or oral inflammation,
             defined as the development of painful or painless oral ulcers or purulent or bloody
             nasal discharge; (2) abnormal chest radiograph, defined as the presence of nodules,
             fixed infiltrates, or cavities; (3) active urinary sediment, defined as microscopic
             hematuria (> 5 red blood cells per high-power field) or red blood cell casts; (4)
             granulomatous inflammation on biopsy, defined as histologic changes showing
             granulomatous inflammation within the wall of an artery or in the perivascular or
             extravascular area (artery or arteriole); and (5) positive serum ELISA for ANCAs
             (anti-neutrophil cytoplasmic antibodies) directed at PR-3.

          -  Birmingham Vasculitis Activity Score (BVAS) score 3 or greater within 28 days of
             randomization. This may include either the presence of one or more major items (3
             points each) or the presence of three or more minor items (1 point each).

          -  Willingness and ability, with the assistance of a caregiver if necessary, to comply
             with treatment and followup procedures.

          -  Willingness of men and women of childbearing potential to practice an adequate method
             of birth control during the study and for 3 months afterwards.

          -  Willingness to limit alcohol consumption to one alcoholic drink per week while taking
             methotrexate.

          -  Willingness to refrain from breast-feeding during the study and for 3 months
             afterwards.

          -  Collection of all baseline data within 14 days prior to randomization.

          -  Signed consent statement.

        Exclusion Criteria:

          -  Presence of an active systemic infection.

          -  White blood cell count less than 4,000/mm cubed or a platelet count less than
             120,000/mm cubed.

          -  Creatinine greater than 2.0 mg/dL secondary to non-WG causes (e.g., hypertensive
             nephropathy) for a patient with limited disease.

          -  Known acute or chronic liver disease.

          -  History of multiple sclerosis or other neurological symptoms suggesting a
             demyelinating syndrome.

          -  Current evidence of malignancy or malignancy diagnosed within 5 years of study entry.
             Patients with squamous or basal cell carcinomas of the skin may be enrolled if they
             have received curative surgical treatment.

          -  Positive serum pregnancy test for women of childbearing potential.

          -  Previous treatment with specific therapies directed against tumor necrosis factor,
             e.g., etanercept or infliximab.",Etanercept for Wegener's Granulomatosis,2
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","DISEASE CHARACTERISTICS: Histologically proven newly diagnosed glioblastoma multiforme
        Measurable residual tumor by MRI after biopsy or craniotomy

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 70-100% Life
        expectancy: More than 8 weeks Hematopoietic: Not specified Hepatic: Not specified Renal:
        Not specified Pulmonary: No severe pulmonary disease (e.g., emphysema with carbon dioxide
        retention) No untreated pneumothorax Other: Not pregnant or nursing Negative pregnancy test
        Fertile patients must use effective contraception No other malignancy within the past 5
        years except epithelial skin cancer No psychological, familial, sociological, or
        geographical conditions that would preclude study No intractable seizure disorder

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior or
        concurrent bleomycin Endocrine therapy: Not specified Radiotherapy: No prior cranial
        radiotherapy Surgery: See Disease Characteristics Other: No other prior therapy, including
        adjuvant therapy, for glioblastoma multiforme",Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,0
"A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow:
A wellbeing, well-nourished man, non-icteric, cooperative and alert
Weight: 73 kg
Height: 177
BP: 120/80
HR: 90/min
RR: 22/min
Hgb: 13 g/dl
WBC: 8000 /mm3 (Neutrophil: 2700/mm3)
Plt: 300000 /ml
AST: 40 U/L
ALT: 56 U/L
Alk P: 147 U/L
Bill total: 1.2 mg/dl
ESR: 120 mm/hr
MPO-ANCA: 153 EU","DISEASE CHARACTERISTICS:

          -  Histologically proven supratentorial malignant glioblastoma multiforme

               -  Clear evidence of disease progression by MRI

               -  Unresectable tumor that has spherical, spheroid, or ovoid shape (not multicentric
                  or multilobulated)

               -  Central necrosis and/or central cystic areas allowed in the presence of enhancing
                  rim thickness greater than 5 mm

               -  No brainstem (pons or medulla) or midbrain (mesencephalon) involvement

               -  No involvement of primary sensorimotor cortex in the dominant hemisphere or
                  within 1.5 cm of the optic chiasm, either optic nerve, or any other cranial nerve

               -  No tumor extension into the ventricular system

               -  Tumor volume no greater than 33.4 cm3

          -  At least one prior radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 75

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  No evidence of bleeding diathesis

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  SGOT/SGPT no greater than 2.5 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL OR

          -  Creatinine clearance at least 40 mL/min

          -  BUN no greater than 30 mg/dL

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active uncontrolled infection

          -  Afebrile unless fever due to presence of tumor

          -  No other concurrent serious medical or psychiatric illness that would preclude study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin
             including Gliadel wafer therapy) and recovered

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy and recovered

          -  No prior intracranial brachytherapy

        Surgery:

          -  Recovered from any prior surgery

        Other:

          -  No prior anticoagulants

          -  No other concurrent investigational agents",Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","Males and females age 10 years or older with two to four quadrants of corneal stroma
        vascularization or a history of allograft rejection in the eye considered for surgery were
        eligible for both studies in the CCTS.

        Patients must have been willing to participate in 3 years of followup. No one was eligible
        for the CCTS who had a condition that would greatly increase the risk of nonrejection graft
        failure, such as xerophthalmia or severe exposure keratopathy. Also excluded were patients
        with systemic diseases or with medication usage that might alter their immune response.",Collaborative Corneal Transplantation Studies (CCTS),0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","Patients with keratoconus were eligible if they were at least 12 years old; had an
        irregular cornea as determined by keratometry, retinoscopy, or direct ophthalmoscopy in at
        least one eye; had Vogt's striae, Fleischer's ring, or corneal scarring characteristic of
        keratoconus in at least one eye; and planned to stay in the area for at least 3 years. They
        were ineligible if they had bilateral corneal transplants or bilateral nonkeratoconic eye
        disease (cataract, intraocular lenses, macular disease, or optic nerve disease other than
        glaucoma).",The Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","Inclusion Criteria

          -  Are HIV-positive.

          -  Have levels of CD4 cells (immune cells that fight infection) less than 200 cells/mm3
             and viral loads (level of HIV in the blood) greater than 2,000 copies/ml or viral
             loads greater than 50,000 copies/ml and any CD4 cell levels.

          -  Are either: 1) starting a new potent antiretroviral therapy for HIV; 2) enrolling in a
             potent antiretroviral trial; or 3) currently participating in an ongoing
             antiretroviral trial or in clinical care and will be changing treatment due to
             treatment failure. The entry visit for ACTG 736 must occur before starting the
             treatment or before changing to the new treatment. (This study has been changed to
             include patients who have changed treatment due to treatment failure and those who are
             starting a new anti-HIV regimen.)

        Exclusion Criteria

          -  Have an infection or cancer in the brain or certain diseases of the brain or nervous
             system.

          -  Have a serious psychiatric illness (such as schizophrenia or severe depression).

          -  Have completed treatment for a significant infection within 4 weeks of beginning the
             study (but certain drugs that fight infection are allowed on this study).

          -  Are taking drugs to prevent or dissolve blood clots.

          -  Abuse drugs or alcohol.",HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","-  INCLUSION CRITERIA:

        Newborn infants in whom Menkes disease is confirmed on biochemical or molecular grounds and
        in whom no neurological symptoms are present are eligible for enrollment in this study.

        EXCLUSION CRITERIA:

        Newly identified patients classified as symptomatic at the time of diagnosis, and affected
        individuals with mild phenotypes are not currently eligible for this clinical trial.",Copper Histidine Therapy for Menkes Diseases,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","-  INCLUSION AND EXCLUSION CRITERIA, BY GROUP:

               1. African-descent with FSGS: renal biopsy showing FSGS or collapsing
                  glomerulopathy, including HIV-associated collapsing glomerulopathy
                  (HIV-associated nephropathy). We will include adult and pediatric patients. We
                  will exclude patients with hyperfiltration FSGS.

               2. Other patients with FSGS (similar inclusion and exclusion criteria as in group
                  1).

               3. African descent with HIV and without kidney disease (controls). We will include
                  adult patients who have had serologically confirmed HIV-1 infection for at least
                  8 years and lack clinical renal disease, as evidenced by normal creatinine and
                  urine protein/creatinine ratio <0.5 or 24 hour urine protein excretion <500 mg/d.

               4. African descent (controls). We will include adults only. Exclusions will include
                  HIV-1 infection, cardiovascular disease, and renal disease.

               5. European and Asian descent (controls). These samples represent DNA already
                  obtained by Dr. Winkler s group under IRB approved protocols and these patients
                  will not be recruited as part of the present study.<TAB>

               6. Relatives of patients with FSGS. In selected families (in which a patient has
                  been found to have a mutation in an FSGS risk gene whose pathologic role has not
                  been established), we will obtain individual histories of renal disease
                  (hematuria, proteinuria, hypertension, nephrolithiasis) and will measure serum
                  creatinine and urine protein excretion. We will include adults with and without
                  renal disease and children with renal disease. We will evaluate children <18
                  years by obtaining a urine sample; if urinalysis and urine protein excretion are
                  normal, we will not request a blood sample unless blood is being obtained for a
                  clinical indication.

               7. Kidney donors. We will include NIH kidney donors only. We will obtain individual
                  histories that provide information as to age, sex, race, surgical and medical
                  histories, and family history. Our purpose is to examine whether particular
                  genetic variants, including those in MYH9, influence the ability of the kidney to
                  undergo hypertrophy following renal donation or the propensity to manifest
                  albuminuria as a sign of glomerular stress. These findings have the potential to
                  extend our understanding of the biology of MYH9 and might have clinical relevance
                  for selecting kidney donors.

               8. Tamil population. We will recruit from a Tamil population. A Tamil will be
                  defined as anyone that identifies themselves, their parents and their
                  grandparents as Tamilian. We will ask these patients about their family history.
                  We will exclude subjects under 18 and multiple subjects within the same family.
                  We will draw blood for genetic testing. Our purpose is to determine whether
                  particular genetic variants, including those in MYH9, are prevalent in a Tamilian
                  population. If prevalence is indicated, we hope to study how these variants
                  influence the progression of kidney disease in this population.

               9. Women who are pregnant will be excluded from participating in the apheresis
                  component of this protocol.",Genetic Markers for Focal Segmental Glomerulosclerosis,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","Patients with PD.

        No epilepsy.

        No seizures.

        No metal in the head.",Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","INCLUSION CRITERIA:

        A total of 20 subjects will be enrolled in the study. 10 normal subjects will be enrolled
        in the study. All will have an 8-12 Hz component of physiologic tremor as determined by
        neurophysiologic studies. Patients will have a prominent 8-12 Hz spike on accelerometry
        recordings that is associated with an EMG spike at the same frequency.

        5 patients with essential palatal tremor and 5 patients with symptomatic palatal tremor
        will be included.

        All participants must be a minimum of 21 years of age.

        EXCLUSION CRITERIA:

        The presence of any medical condition, such as liver disease, history or family history of
        alcoholism, that can reasonably be expected to subject the patient to unwarranted risk or
        compromise the value of the data.

        Any patient with pathologic tremor, such as parkinsonian rest tremor, essential tremor, or
        tremor secondary to medications or structural brain lesions.

        Any clinically significant laboratory abnormalities.

        Lack of effective contraception.

        Patients who are pregnant.

        Inability to understand the nature of the study or its procedures.

        Persons under the age of 21, who are not of legal age to consume alcohol in Maryland.

        Patients taking any psychoactive medications including certain cough or cold medicine
        preparations.

        No one will be excluded or discriminated against based on the grounds of race, creed,
        gender, color, or national origin. Every attempt will be made to include women and
        minorities in the study population.",Effect of Alcohol on Tremors,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","Study subjects will satisfy NINCDS-ADRDA criteria for probable AD. Dementia severity will
        be in the mild to moderate range, as evidenced by a Mini-Mental State Examination total
        score of 12-25 which is roughly equivalent to Alzheimer's Disease Assessment Scale
        Cognitive (ADAS-Cog) scores of 30 to 11, will include deficits in at least 2 areas of
        cognition, will have been present at least 1 year, and will have progressed gradually since
        onset. Patients must be between the ages of 50-90 with onset of dementia after age 40. The
        modified Hachinski Ischemia Score must be less than 4 and the brain MRI within 2 years of
        enrollment must be consistent with the diagnosis of AD.

        Patients must have had a brain MRI since the onset of dementia symptoms that is consistent
        with the diagnosis of AD.

        Patients must have an acceptable nutritional status (i.e., body weight within 20% of
        desirable weight for height).

        Patients must be surgically sterile.

        Patients must be post-menopausal or practicing adequate contraception.

        Physical and laboratory exams must be normal, or the abnormalities must be attributed to
        the dementing illness or judged clinically unimportant to the safe conduct of this trial.

        Chest X-ray within 1 year of enrollment must show no active disease.

        No history or clinical diagnosis of stroke within 1 year before or concurrent with onset of
        dementia; hydrocephalus, subdural hematoma, or mass lesion on screening MRI; current
        seizure disorder; head trauma with loss of consciousness and hospitalization within 1 year
        before or concurrent with onset of dementia; dementia onset within 1 year following cardiac
        arrest or surgery; Parkinson's disease (onset prior to or concurrent with dementia),
        Wilson's, Huntington's, Creutzfeldt-Jakob disease, Pick's disease, or Wernicke's
        encephalopathy; chronic CNS infection (positive RPR and/or FTA-ABS acceptable if luetic
        brain disease excluded by documented studies and/or treatment).

        No COPD or asthma requiring hospital treatment within 1 year before enrollment (treatment
        of acute respiratory infections is acceptable).

        No acute systemic infection.

        No hypothyroidism (TSH greater than 6.0 mclU/ml).

        No folic acid (less than 0.9 ng/ml) or B12 deficiency (less than 100 pg/ml) within 1 year
        before study enrollment.

        No recent or acute HAV or HBV infection, or chronic HBV infection by immuno-assays.

        No insulin dependent diabetes or poorly controlled non-insulin dependent diabetes.

        No history of leukopenia, neutropenia, or thrombocytopenia, cancer (except treated,
        non-recurrent skin cancer) within 2 years before enrollment.

        No severe renal insufficiency (Clcr less than 25 ml/min, BUN greater than 30 mg/dl, or
        creatinine greater than 2.0 mg/dl), hepatic insufficiency (as indicated by: ASAT (SGOT) 3 x
        ULN, ALAT (SGPT) 3 x ULN, or total bilirubin greater than 2.0 mg/dl).

        No homocysteinemia (greater than 14 micromol/L).

        No past history of schizophrenia.

        No substance use disorder within 1 year of dementia onset.

        No depression requiring medical treatment within the past 30 days.

        No administration of tacrine (Cognex) or donezepil (Aricept), investigational drugs, or
        nutritional supplements used as neurotransmitter precursors for cognitive enhancement
        within 30 days before enrollment.

        No use of anticonvulsants, psychostimulants, centrally acting anticholinergics and agents
        known to inhibit or be metabolized by CYP 3A4 (e.g., erythromycin, chlarythromycin,
        troleandomycin, fluconazole, miconazole, ketoconazole, itraconazole and grapefruit juice)
        within 2 weeks prior to enrollment.

        No hepatic, cardiovascular, gastrointestinal, or hematological illness which could
        interfere with drug absorption, distribution, metabolism, or excretion.

        No medical condition that contraindicates cholinergics.

        No known hypersensitivity to nefiracetam.

        Must be able to swallow/retain tablets.

        No history of medical noncompliance.

        Must have significant other person or caregiver to assure compliance.

        No uncorrectable loss of hearing or eyesight that precludes psychometric testing.

        Ability to comprehend instructions or respond to test items of the ADAS and Repeatable
        Battery for the Assessment of Neuropsychological Status (RBANS) during baseline
        administration.

        No male patients interested in conceiving children given the potential adverse effects on
        spermatogenesis.",Nefiracetam in the Treatment of Alzheimer's Disease,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","Patients with essential tremor affecting the upper limbs who are 21 years of age or older.

        Patients who are not taking medications for essential tremor or any other medical condition
        for at least 2 weeks.

        Patients who have not consumed alcohol or cold medications containing alcohol for at least
        24 hours prior to the day of the study.

        Women must not be pregnant or lactating. Women of childbearing age must use birth control
        while participating in this study.

        Patients must not have any neurological disease other than tremor (e.g., Parkinson's
        disease).

        Patients must not have evidence of thyroid, liver, kidney or chronic lung disease.",1-Octanol to Treat Essential Tremor,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","Inclusion Criteria

        You may be eligible for this study if you:

          -  Are HIV-positive.

          -  Have been on a stable HAART regimen consisting of at least 3 antiretroviral drugs for
             at least 16 weeks prior to study entry.

          -  Have a CD4 count of 50 cells/mm3 or more.

          -  Have a viral load greater than 50 and less than or equal to 400 copies/ml within 14
             days prior to study entry.

          -  Have had at least 1 additional viral load in the past that was less than or equal to
             400 copies/ml while on your current stable HAART regimen.",A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","DISEASE CHARACTERISTICS: Histologically proven stage III/IV ovarian or non-small cell lung
        cancer

        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-2 Life Expectancy: Not
        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
        least 100,000/mm3 Hepatic: Bilirubin no greater than 3.0 mg/dL Renal: Creatinine no greater
        than 2 mg/dL Other: Not pregnant or nursing No history of platinum, paclitaxel or
        amifostine hypersensitivity Prior myelosuppressive events allowed No clinically significant
        ascites

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy within 1 month of study Endocrine therapy: Not specified Radiotherapy: No
        prior radiation therapy within 1 month of study Surgery: Not specified",Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","1. Any other serious illnesses which would limit survival to <2 years, or psychiatric
             condition which would prevent compliance with treatment or informed consent.

          2. Uncontrolled or severe cardiovascular disease.

          3. History of pancreatitis or overt coagulopathy (prior cerebrovascular accident or
             hemorrhage, transient ischemic attack or deep venous thrombosis).

          4. Elevations in bilirubin, creatinine, or amylase that may suggest impaired hepatic,
             renal, or pancreatic function must be considered as potentially serious obstacles for
             safe tolerance of the therapy prescribed in this protocol.

          5. Prior use of the agents administered in this protocol for other non-malignant disease
             may reduce the likelihood of beneficial outcome, and should also be considered prior
             to enrolling patients.

          6. Treatment under this protocol would expose an unborn child to significant risks.

             Women and men of reproductive potential should agree to use an effective means of
             birth control.

          7. Unequivocal histologic diagnosis of Acute Lymphoblastic leukemia (ALL), FAB L1-or L2
             or Acute Undifferentiated Leukemia (AUL).

          8. Age  15 years

          9. Prior Treatment: No prior treatment for leukemia, with three permissible exceptions:

             i. emergency leukapheresis; ii. emergency treatment for hyperleukocytosis with
             hydroxyurea; iii. cranial RT for CNS leukostasis (one dose only).",Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","DISEASE CHARACTERISTICS: Histologically proven unresectable primary or metastatic
        hepatocellular carcinoma Measurable disease by CT or MRI scan No tense ascites Brain
        metastases allowed with proper treatment

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Zubrod
        0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count at least
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL
        Albumin at least 3 g/dL Alkaline phosphatase no greater than 3 times upper limit of normal
        Renal: Creatinine no greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients
        must use effective contraception No significant infection Peripheral neurologic toxicity
        limited to paresthesia and decreased vibratory sense without motor weakness allowed
        Constipation managed with laxatives without evidence of bowel obstruction allowed No
        psychological disorders including delirium, confusion, suicidal ideation, or untreated
        depression

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: Prior palliative radiotherapy
        allowed At least 3 weeks since prior radiotherapy and recovered Surgery: Recovered from any
        prior surgery",Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer,0
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","PROTOCOL ENTRY CRITERIA: Wilson disease Presymptomatic, pregnant, and children 16 years or
        younger patients eligible Patient age: Any age, including children",Study of Zinc for Wilson Disease,1
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Wilson disease presenting with neurologic or psychiatric symptoms

          -  No concurrent seizure activity

          -  No white matter lesions on brain magnetic resonance imaging

        --Prior/Concurrent Therapy--

          -  No more than 2 weeks of prior therapy

          -  No penicillamine or trientine for longer than 2 weeks

        --Patient Characteristics--

          -  Hepatic: No severe hepatic failure

          -  Other: No psychiatric or medical contraindication to protocol therapy

          -  Not pregnant",Study of Tetrathiomolybdate in Patients With Wilson Disease,2
"A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 g/24 h). Wilson disease was confirmed by high liver copper concentration (305 g/g dry weight of liver).","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Clinical or biochemical evidence of liver disease, unexplained fat-soluble vitamin
        malabsorption, or peroxisomal dysfunction that compromises bile acid biosynthesis

        Inclusion criteria for enrollment were:

          -  Infants < age 3 months

          -  Children presenting for evaluation of cholestasis defined as a conjugated bilirubin >
             2mg/dl or increased serum bile acids

          -  Older subjects of any age with cholestatic liver disease if urine screens suggested
             that they had inborn errors of bile acid metabolism

          -  Confirmation of a diagnosis of an inborn error of bile acid synthesis based upon urine
             analysis by FAB-MS to determine whether specific abnormalities in bile acid synthesis
             are indicated

          -  The patient and/or parent/legal guardian must have signed the written informed consent
             document before study start.

          -  The patient must be willing and able to comply with all study assessments and
             procedures.",Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid,0
The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.,"-  INCLUSION CRITERIA:

        Patient Selection:

        Patients with IgG or IgA multiple myeloma who attain at least a PR before transplantation
        are eligible for thsi protocol.

        Patients may only have received 3-4 courses of VAD, high dose cyclophosphamide and one
        autologous transplant before entering the study.

        All previous therapy must be completed at least 2 weeks prior to study entry.

        Patients should have recovered from all hematologic and non-hematologic toxicity of
        previous therapy.

        Steroid must be discontinued at least two weeks prior to vaccination.

        Only patients less than 60 years are eligible for this protocol.

        Patients must meet the following criteria:

        A. Karnofsky performance status greater than or equal to 70 percent.

        B. Life expectancy greater than 8 weeks and absence of co-existing medical problems which
        would significantly increase the risk of the transplant procedure in the judgment of the
        bone marrow transplant attending physicians (e.g., the MUGA left ventricular ejection
        fraction has to be greater than 50% and DLCO greater thant 50% of the expected value when
        corrected for Hb).

        Creatinine less than 2x normal and not rising for at least 2-4 weeks before
        transplantation. If creatinine is elevated, then creatinine clearance must be greater than
        40 ml/min.

        Direct bilirubin less than 2 mg/dl, SGOT less than 4x top normal, and none of these
        parameters increasing, for at least 2-4 weeks before transplantation.

        Patients must be HIV-negative, HBsAg-, and Hepatitis C antibody Negative.

        Not pregnant or lactating. Patients of childbearing potential must use an effective method
        of contraception.

        M-protein concentration in the harvested plasma must be greater than 90 percent of the
        total Ig of the corresponding isotype.

        Patients must be greater than or equal to 18 years old.

        Donor criteria:

        Any consenting healthy individual who fulfills the donor criteria will be considered for
        the marrow donation.

        HLA-identical sibling donors.

        HLA, A and B and DR phenotypically identical family donors.

        HIV, hepatitis B or C seropositive.

        Complete blood count, platelets, and PT, PTT within normal limits.",Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation,0
The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.,"INCLUSION CRITERIA:

        Male or female patients, 18 years of age or older.

        Newly diagnosed patients with acromegaly, or previously untreated.

        Presence of a pituitary tumor greater than 10 mm at greatest diameter (macroadenoma).

        Lack of suppression of GH to less than 2.0 ng/mL using a regular GH RIA, or less than one
        ng/mL using a two-site immunoradiometric or chemiluminescent GH assay, after oral
        administration of 100 g of glucose.

        IGF-1 levels above the upper limits of normal (adjusted for age and gender).

        Demonstrated tolerance to a test dose of s.c. Sandostatin Injection.

        Demonstrated responsiveness to a 100 ug s.c. Sandostatin Injection test dose, as evidenced
        by suppression of mean 4HR GH to less than 5 ng/mL, or to greater than 50 % of the baseline
        value.

        Patients who are able to provide written informed consent.

        EXCLUSION CRITERIA:

        Patients demonstrating intolerance to a s.c. Sandostatin (octreotide acetate) test dose.

        Patients who have received any prior treatment for their acromegaly, including
        radiotherapy, octreotide, bromocriptine, lanreotide, or prior surgery.

        Female patients who are pregnant or lactating, or are of childbearing potential and not
        practicing a medically acceptable method of birth control.

        Patients with compression of the optic chiasm significant enough to cause visual field
        defects on automated testing.

        Patients who require surgery for relief of any neurologic signs or symptoms associated with
        their tumor.

        Patients with symptomatic cholelithiasis.

        Patients who have congestive heart failure (NYHA Class III and IV), unstable angina,
        sustained ventricular tachycardia, ventricular fibrillation, or a history of acute
        myocardial infarction within the three months preceding study entry.

        Patients with liver disease such as cirrhosis, chronic active hepatitis or chronic
        persistent hepatitis, or persistent ALT, AST, or alkaline phosphatase 2X greater than upper
        limit of normal; or direct bilirubin more than 10% greater than upper limit of normal.

        Patients with abnormal clinical laboratory values considered by the Investigator or the
        Sponsor's Medical Monitor to be clinically significant and which could affect the
        interpretation of the study results.

        Patients who have any current or prior medical condition that may interfere with the
        conduct of the study or of the evaluation of its result in the opinion of the Investigator
        or Sponsor's Medical Monitor.

        Patients who have a history of alcohol or drug abuse in the six month period prior to Visit
        1.

        Patients who have received any investigational drug within one month prior to Visit 1, or
        who plan to take an investigational drug during the study.

        Patients with any mental impairment limiting their ability to comply with all study
        requirements.

        Patients who, for any reason, will be unable to complete the entire study.",Sandostatin LAR Depot vs. Surgery for Treating Acromegaly,1
The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.,"-  INCLUSION CRITERIA:

        Patients will be enrolled who are 18 years of age or over who are referred for care.",The Treatment and Natural History of Acromegaly,2
The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.,"DISEASE CHARACTERISTICS:

          -  Histologically proven neuroblastoma or maturing ganglioneuroma that is judged to be
             intermediate risk by one of the following criteria:

               -  International Neuroblastoma Staging System (INSS) stage III

                    -  Under 1 year old, MYCN oncogene nonamplified, and any ploidy

                    -  1 to 20 years old, MYCN nonamplified, favorable Shimada histology

               -  INSS stage IV

                    -  Under 1 year old, MYCN nonamplified, any ploidy

               -  INSS stage IVS

                    -  Under 1 year old, MYCN nonamplified, unfavorable Shimada histology and any
                       ploidy OR favorable Shimada histology and diploidy

          -  All patients must be registered on the companion neuroblastoma biology study
             (COG-ANBL00B1)

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 21

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No abnormal organ function that would prohibit chemotherapy unless due to
             neuroblastoma

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Prior chemotherapy for patients with intradural extension and emergent paresis allowed
             provided biopsy was performed within 96 hours after treatment

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No other prior therapy",Combination Chemotherapy in Treating Children With Neuroblastoma,0
The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.,"PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of acromegaly and treated with transsphenoidal surgery

        Biochemically and histologically confirmed growth hormone secreting tumor

        OR

        Healthy volunteers

        --Prior/Concurrent Therapy--

        Surgery:

          -  See Disease Characteristics

          -  Greater than 6 months since prior surgery

        Other: At least 1 month since prior bromocriptine or octreotide

        --Patient Characteristics--

        Performance status: Ambulatory

        Hepatic: No active hepatic disease

        Renal: No active renal disease

        Other:

          -  No diabetes mellitus

          -  No glucose intolerance

          -  Hypopituitarism allowed if on stable doses of replacement therapy",Measurement of Outcome of Surgical Treatment in Patients With Acromegaly,1
"The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.","Patients must be in good general health. Patients with chronic stable complications of Type
        2 diabetes or stable obesity related comorbid conditions will not be excluded.

        Obesity: Defined as subjects having a body mass index greater than 30 kg/m(2). Weight must
        be less than 300 lb (136 kg) because of limits related to the DXA and CT scanners.

        Patients with Type 2 Diabetes, impaired glucose tolerance, or hyperinsulinemia are
        eligible.

        Patients' age must be greater than or equal to 18 years at the start of the study.

        Patients must be planning to undergo large volume liposuction.

        Premenopausal women participating in the study must have a negative pregnancy test at the
        start of the study and will be required to remain on some form of effective contraception
        for the duration of the study.

        Patients recruited for the pilot study will be required to have all four grandparents and
        both parents to be either all non-Hispanic Caucasians or non-Hispanic African-American.

        Volunteers with the presence of significant, unstable or evolving renal disease are not
        eligible. Subjects must not have calculated (age and weight corrected) creatinine
        clearances below 50 ml/min or significant worsening of serum creatinine levels during the
        course of the study (greater than 30% increase from baseline).

        Volunteers with the presence of significant, unstable or evolving hepatic disease
        associated with SGOT and/or SGPT greater than 2.5 times normal are not eligible.

        Volunteers with the presence of significant, evolving or unstable cardiac disease are not
        eligible. Subjects with NYHA stage 3 or 4 disease will be excluded from the study.

        Volunteers with the presence of significant, evolving or unstable pulmonary disease
        including uncontrolled bronchial asthma and/or chronic bronchitis are not eligible.

        Volunteers with the presence of other uncontrolled or unstable medical conditions including
        uncontrolled thyroid disease, Cushing's syndrome, autoimmune or gastrointestinal disease
        are not eligible.

        Volunteers who are pregnant are not eligible.

        Volunteers must not have uncontrolled Type 2 diabetes as evidenced by recent coma or
        pre-coma states, frequent episodes of hypoglycemia, predominantly severe hyperglycemia
        (plasma glucose greater than 400 mg/dl) in the past three months prior to study
        commencement, a glycosylated hemoglobin (HBA1C) value greater than 10 in the past three
        months prior to the study commencement, and frequent or recurrent episodes of ketosis
        (ketonuria and/or ketonemia).

        Volunteers with uncontrolled, significant or evolving psychiatric/psychological syndromes
        which in the opinion of the investigators would place the patient at increased risk during
        the course of the study or would impede competence and/or ability to complete the study are
        not eligible.

        Volunteers with current history of illicit substance abuse and/or alcoholism based on
        reported history and the CAGE questionnaire are not eligible.

        Volunteers must not have a recent use (within the preceding 6 months) of anorexiant
        medications or medications that would affect nutrient absorption such as orlistat or
        acarbose.

        Volunteers must not be receiving treatment with an insulin-sensitizing medication such as
        metformin or the thiazolidinediones. Use of insulin, meglitides or the sulphonylureas will
        not constitute an exclusion.

        Volunteers with an absence of spontaneous menses for greater than 1 year are not eligible.","Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes",1
"The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.","All patients greater than 18 years old who have had a prior resection of colorectal cancer
        and are suspected of having recurrent disease.

        Rising serum CEA levels greater than 6 on two successive tests.

        Resectable residual or recurrent disease. Patients in the occult arm (Arm 1) must have no
        visible residual disease in the abdomen at the time of the last surgical exploration. In
        addition, there must be no imageable definitive site of recurrent disease using
        conventional imaging modalities including; CT scan of chest/ abdomen/ pelvis with contrast,
        MRI scan, and chest x-ray. Patients in arm 2 may have a single site of recurrent or
        metastatic disease which is resectable but in whom additional sites of disease are not
        known and no imageable disease other than a solitary site of potentially resectable disease
        is identified.

        Patients must have an ECOG performance status of 0-1.

        Patients must be willing to return to NIH for follow-up.

        Patients must be able to provide informed consent as demonstrated by the signed consent.

        Patients must be 2 or more months from abdominal or thoracic surgery.

        No patients with medical contraindication to abdominal exploration.

        No patients with recurrent disease detected by conventional imaging studies as outlined
        above. Metastatic disease localized outside of the abdominal cavity by conventional imaging
        studies as outlined above. Patients must weigh less than 136 kgs. which is the weight limit
        for the scanner tables.

        No patients with previous injection of murine monoclonal antibodies: Human anti-mouse assay
        (HAMA) will be performed in patients with prior history of receiving murine monoclonal
        antibodies.

        No patients that are pregnant or breast feeding.

        Patients who are HIV + will be excluded.",Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities,0
"The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.","DISEASE CHARACTERISTICS: Histologically or cytologically proven non-small cell lung cancer
        Squamous cell lung cancer Large cell lung cancer Adenocarcinoma lung cancer Mixture of
        above Locally advanced disease for which the patient declined aggressive treatment or that
        is unsuitable for aggressive curative treatment due to at least one of the following:
        Performance status of ECOG 2 or 3 Otherwise unexplained weight loss greater than 10% in the
        last 6 months Bulky disease that cannot be irradiated safely to high doses Inability to
        tolerate chemotherapy Cytologically positive pleural effusion OR Clinically or
        radiologically proven metastatic disease for which palliative chemotherapy is not planned
        in the first 38 days after radiotherapy No more than one brain metastasis allowed One of
        the following symptoms identified as the index symptom: Loss of appetite Nausea Vomiting
        Cough Coughing up blood Chest pain Shortness of breath Difficulty swallowing Fatigue Must
        have symptoms related to intrathoracic lung cancer that are amenable to radiation
        palliation

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-3 Life expectancy:
        Greater than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: Fluent in English or French No loss of sight or other inability to
        complete questionnaires or diary Not pregnant No concurrent terminal illness No other
        active malignancy that is causing symptoms or is expected to progress in the next 3 months

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 30 days
        since prior chemotherapy and failed No planned chemotherapy within 38 days after study
        treatment Endocrine therapy: Not specified Radiotherapy: No planned laser therapy within 38
        days after study treatment Surgery: At least 30 days since prior surgery and failed Other:
        No planned photodynamic therapy or sclerotherapy within 38 days after study treatment",Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer,0
"The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.","Patients must have regionally confined histologically or cytologically proven
        adenocarcinoma of the pancreas or Ampulla of Vater. Tumors must overexpress HER2 as
        demonstrated by greater than or equal to 2+ immunohistochemical staining of the biopsy
        specimen.

        Patients must sign an informed consent.

        Patients must have an ECOG performance status of less than or equal to 2.

        Patients should have a serum creatinine less than 1.5 mg/dl or creatinine clearance greater
        than 60 ml/hr; SGOT and SGPT less than 4 times the upper limit of normal.

        Patients must have an ANC greater than 2000/mm(3) and platelets greater than 100,000/mm(3).

        Patients must be at least 18 years of age.

        Patients of all racial and gender groups will be included.

        Patients must not have received any prior gemcitabine, radiotherapy, or Herceptin therapy
        for pancreatic cancer.

        Patients cannot receive concurrent hormonal or immunotherapy treatment for pancreatic
        cancer.

        Patients cannot receive any anti-tumor therapy within 30 days of protocol eligibility and
        must have recovered from any prior treatment related toxicity.

        Patients must not have evidence of distant metastases (e.g., peritoneal, carcinomatosis,
        liver metastases).

        No concurrent second malignancy other than non-melanoma skin cancer or cervical carcinoma
        in situ.

        Must not have medical conditions that preclude undergoing surgery or receiving therapy or
        follow up, or have psychiatric disease which would prevent adequate informed consent or
        render receiving this therapy unsafe.

        No patients with an LV ejection fraction less than the lower limit of normal as determined
        at the Clinical Center, NIH.

        Women must not be pregnant or nursing due to the unknown effects of this therapy on the
        unborn or nursing child.

        Must not have received prior abdominal or pelvic radiation.

        Must not have recent myocardial infarction (less than 6 months prior), unstable angina, or
        congestive heart failure (NYHA class III or IV).

        Must not have active diseases which make the patient more susceptible to infection,
        including but not limited to AIDS, hepatitis, history of autoimmune disorders, because the
        experimental treatment being evaluated in this protocol may be unsafe in the absence of an
        intact immune system.","Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas",0
"The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.","Participants must have a gestational age at birth between 36-42 weeks and birth weight
        greater than or equal to 2500 gms.

        Participants must have normal growth and development as assessed by general pediatric
        examination and growth charts, obtained historically from family and/or pediatrician.

        Participants must have a normal visual system by ophthalmic examination.

        Participants must be between the post-conceptual ages of 40 weeks and 70 weeks of age
        inclusive.

        Participants must be able to undergo a complete opthalmic evaluation.

        Participants must be able to undergo standard eye movement recording.

        Participants must not have any eye diseases.

        Participants must not have any neurologic disease, developmental delay, congenital genetic
        syndromes, congenital organ malformations, malformation syndromes or metabolic diseases.

        Participants must not be on any systemic or ocular medications.",Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye,0
"The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.","Any alpha 1 antitrypsin-deficient individuals.

        18-65 years old.

        FEV1 greater than 1 equal to 50 percent of predicted (forced expiratory volume).

        Study participation is required for one year.

        A total of four bronchoscopies will be performed over a year period.

        Methacholine challenge test will be performed at the beginning and end of the study to
        assess the degree of reactive airways disease.

        Pneumococcal and annual influenza vaccine will be given.

        No prolastin within one year prior to start of the study.

        No oral systemic corticosteroids within 30 days prior to start of study.

        No allergy to topical or local anesthetic (i.e., lidocaine).

        No pregnancy.

        No HIV positive patients.

        No Hepatitis B/C virus positive patients.

        No patients with any condition associated with immunodeficiency.

        No patients with presence of significant cardiac diseases.

        No patients with presence of uncorrected blood-clotting disorders.

        No patients with any oxygen at home on a regular basis.

        No adverse reactions to methacholine.",Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals,0
"The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.","Subjects must be between the ages of 11 and 21 years.

        Subjects must be diagnosed with HIV for at least one year (to ensure sufficient opportunity
        to experience living with a chronic condition such that adherence level is unlikely to be
        the result of skill or knowledge deficits).

        Subjects must be prescribed oral medications (e.g., pills, liquids, inhaler) to be taken on
        a daily basis.

        Subjects must be living with same female caregiver for at least one year.

        Subjects must have a telephone number where he/she can be contacted during the two weeks
        after recruitment.

        The adolescent and mother must be able to provide informed consent.

        Adolescents must not have mental retardation or developmental delay that would prevent the
        adolescent from reading and comprehending the questionnaire.",A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers,0
"The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.","ASTHMATICS:

        Must be between 18 and 65 years of age, male or female, and must be at least 5 feet in
        height.

        The diagnosis of asthma requires a history of intermittent, reversible expiratory flow
        limitation. Patients will have mild-to-moderately severe asthma as defined by a baseline
        forced expiratory flow in one second (FEV(1)) greater than 70% of predicted (at least 6
        hours after bronchodilator use) and therapy limited to inhaled beta-agonists.

        Positive skin prick-puncture test to one or more common aeroallergens.

        A positive inhaled methacholine challenge as defined by a decrease in FEV(1) of at least
        20% (PC(20)) in response to inhalation of less than 25 mg/ml of methacholine.

        A decrease in FEV(1) of at least 20% in response to inhalation of up to 10,000
        bioequivalency allergy units (BAU) or allergy units (AU) per ml of a selected common
        aeroallergen (house dust mite, cat hair or grasses) or up to 150 Antigen E units per ml of
        short ragweed. Asthmatic patients must also demonstrate a late asthmatic response (defined
        as a 20% fall from the baseline established following completion of the early asthmatic
        response).

        Normal complete blood count, PT, PTT, and serum electrolytes, mineral and hepatic panels
        (less than 30 ml of blood will be drawn), normal EKG and chest radiograph without acute
        pulmonary infiltrates.

        Women of childbearing potential must have a negative pregnancy test within 2 weeks prior to
        study and willingness to adhere to reliable birth control methods during the study.

        Must not have a diagnosis of a pulmonary disorder other than asthma (e.g., chronic
        bronchitis, cystic fibrosis, bronchiectasis, HIV-related lymphocytic airway inflammation).

        Must not have a baseline FEV(1) of less than 70% predicted.

        Must not have respiratory tract infection or asthma exacerbation within 4 weeks of
        screening.

        Must not use theophylline, oral or inhaled corticosteroids, nedocromil sodium, cromolyn
        sodium, zilueton, leukotriene receptor antagonists (e.g., zafirlukast or montelukast), or
        anti-cholinergic agents within the prior 3 months. In addition, patients requiring ongoing
        therapy with anti-histamines, hydroxyzine, and tricyclic anti-depressants will be excluded.
        Research subjects can continue therapy with inhaled beta-agonists during the study.

        No history of anaphylaxis or severe allergic response.

        No history of adverse reactions to lidocaine or other local anesthetics.

        No history of active inhaled or intravenous drug abuse or alcohol abuse.

        Must not have an abnormal EKG or evidence of coronary artery disease.

        Must not require chronic anti-coagulant therapy.

        Must not use aspirin within 2 weeks of the bronchoscopic study or non-steroidal
        anti-inflammatory agents within 2 days of the bronchoscopic study.

        No history of cigarette smoking within the past 3 years.

        No history of allergy immunotherapy within the past year.

        Not allergic to methacholine.

        PT or PTT must not be prolonged 2 seconds greater than normal range.

        Platelet count must be greater than or equal to 150,000/mm(3).

        Must not test positive for human immunodeficiency virus.

        RESEARCH VOLUNTEERS:

        Must be between 18 and 65 years of age, male or female, and must be at least 5 feet in
        height.

        A negative inhaled methacholine challenge as defined by the absence of a decrease in FEV(1)
        by 20% (PC(20)) in response to inhalation of 25 mg/ml of methacholine.

        A negative skin test to a panel of common aeroallergens.

        Normal complete blood count, PT, PTT, and serum electrolytes, mineral and hepatic panels
        (less than 30 ml of blood will be drawn). Negative hepatitis serology. Normal EKG and chest
        radiograph without acute pulmonary infiltrates.

        Women of childbearing potential must have a negative pregnancy test within 2 weeks prior to
        study and willingness to adhere to reliable birth control methods during the study.

        No history of asthma, allergic rhinitis, or atopic dermatitis.

        Must not have a diagnosis of a pulmonary disorder other than asthma (e.g., chronic
        bronchitis, cystic fibrosis, bronchiectasis, HIV-related lymphocytic airway inflammation).

        Must not have a baseline FEV(1) of less than 70% predicted.

        Must not have respiratory tract infection or asthma exacerbation within 4 weeks of
        screening.

        Must not use theophylline, oral or inhaled corticosteroids, nedocromil sodium, cromolyn
        sodium, zilueton, leukotriene receptor antagonists (e.g., zafirlukast or montelukast), or
        anti-cholinergic agents within the prior 3 months. In addition, patients requiring ongoing
        therapy with anti-histamines, hydroxyzine, and tricyclic anti-depressants will be excluded.
        Research subjects can continue therapy with inhaled beta-agonists during the study.

        No history of anaphylaxis or severe allergic response.

        No history of adverse reactions to lidocaine or other local anesthetics.

        No history of active inhaled or intravenous drug abuse or alcohol abuse.

        Must not have an abnormal EKG or evidence of coronary artery disease.

        Must not require chronic anti-coagulant therapy.

        Must not use aspirin within 2 weeks of the bronchoscopic study or non-steroidal
        anti-inflammatory agents within 2 days of the bronchoscopic study.

        No history of cigarette smoking within the past 3 years.

        No history of allergy immunotherapy within the past year.

        Not allergic to methacholine.

        PT or PTT must not be prolonged 2 seconds greater than normal range.

        Platelet count must be greater than or equal to 150,000/mm(3).

        Must not test positive for human immunodeficiency virus.",Factors Involved in Asthma and Airway Inflammation,1
"The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.","Male or nonpregnant, non-breastfeeding females age 12-85 years.

        Diagnosis of persistent asthma for greater than 1 year and currently being treated with
        short acting beta-2 agonist only.

        FEV1 50-80% of predicted (must be demonstrated at Day 10 and Day 0). Patients will be
        stratified into 50-70% or 71-80% cohort at Day 10.

        Increase of greater than or equal to 15% over baseline FEV1 approximately 15-20 minutes
        after beta-2 agonist inhalation (2-4 puffs of albuterol via MDI or the nebulized
        equivalent) documented at baseline.

        Positive prick skin test to at least two allergens (defined as wheal 3 mm greater than
        control and erythema greater than control).

        History of asthma symptoms (wheezing, shortness of breath, cough, chest tightness, or
        nighttime awakening) on least 3 of the last 7 days.

        Fulfillment of washout criteria by not using any of the medications listed below for the
        specified times prior to Day 0 of the study drug treatment:

        Parenteral corticosteroids for 4 weeks;

        Oral corticosteroids for 4 weeks;

        Inhaled corticosteroids for 4 weeks;

        Cromolyn sodium (Intal), nedocromil (Tilade) for 4 weeks;

        Theophylline, zileuton (Zyflo), zafirlukast (Accolate), or montelukast (Singulair) for 4
        weeks;

        Astemizole (Hismanal) for 12 weeks;

        Terfenadine (Seldane), or fexofenadine (Allegra) for 6 days;

        Cetirizine (Zyrtec) for 6 days;

        Hydroxyzine (Atarax, Vistaril) for 6 days;

        Azelastine (Astelin) nasal spray for 6 days; and

        Salmeterol (Serevent) for 9 days.

        No clinically significant abnormality in chemistry, hematology, urinalysis: serum
        creatinine less than or equal to 1.7 mg/dL; total bilirubin less than or equal to 1.5
        mg/dL; AST (SGOT), ALT (SGPT) less than or equal to 2 times laboratory's upper limit of
        normal.

        No clinically significant abnormality in EKG within 1 month prior to enrollment.

        No clinically significant abnormality in CXR (other than changes consistent with asthma)
        within 1 year prior to enrollment.

        Nonsmoker, for at least 2 years with a smoking history of no more than 10 pack years (e.g.,
        one pack per day for 10 years).

        Agreement to use medically accepted contraception throughout the study, if sexually active,
        except females who are postmenopausal for greater than or equal to 2 years.

        Agreement not to donate blood or blood products throughout the study.

        Demonstrated ability to follow proper technique in the use of the AERx system.

        A written, signed, and witnessed consent form.

        No desensitization therapy within 3 months prior to Day 0 of study drug treatment.

        No use of any investigational or non-approved drug therapy within 30 days prior to Day 0 of
        study drug treatment.

        No occurrence of acute asthma exacerbation requiring emergency room treatment within 6
        weeks of Day 0 of study drug treatment.

        No occurrence of acute asthma exacerbation requiring hospitalization within 12 months of
        Day 0 of study drug treatment.

        No occurrence of respiratory infection which affects asthma within 4 weeks prior to Day 0
        of study drug treatment.

        No history of endotracheal intubation for asthma-related exacerbation within 15 years prior
        to Day 0 of study drug treatment.

        No presence of significant medical conditions (including obesity affecting respiratory
        function, congestive heart failure, myocardial infarction, unstable angina, uncontrolled
        hypertension, severe pulmonary disease, history of cancer [other than resected cutaneous
        basal or squamous cell carcinoma], insulin-dependent diabetes, autoimmune disease, or known
        HIV infection).

        No previous enrollment in a study of soluble IL-4 receptor.

        No history of alcohol abuse, drug abuse, or psychiatric illness that would interfere with
        ability to comply with protocol requirements or give informed consent.

        No patients experiencing hypersensitivity to soluble IL-4R.",Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma,2
"The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.",No eligibility criteria,Family Heart Study (FHS),0
"The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.",No eligibility criteria,Impact of Adult Asthma,2
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","POPULATION CHARACTERISTICS:

        Regional advanced postradiation fibrosis of the neck, chest wall, pelvis, or extremities
        causing measurable impairment of specific function, i.e.: Decreased range of motion,
        Weakness, Sensory deficit, Pain requiring narcotics, Significantly altered activities of
        daily living.

        None of these conditions present either before or during radiotherapy or attributed to
        surgery or chemotherapy.

        Patients with prostate cancer allowed if prostate-specific antigen (PSA) is less than 4.0
        ng/mL and the last 3 PSA values were stable or decreasing. Abnormal bone scan or film
        acceptable if consistent with degenerative disease.

        No recurrent or metastatic cancer.

        No concurrent second cancer.

        PRIOR/CONCURRENT THERAPY: At least 3 months since pentoxifylline.

        PATIENT CHARACTERISTICS:

        Age: 18 and over.

        Performance status: Karnofsky 70%-100% (unrelated to postradiation fibrosis).

        CARDIOVASCULAR:

        No symptomatic coronary artery disease with frequent anginal episodes necessitating any of
        the following during past 6 months: Coronary artery bypass, Angioplasty, Pacemaker
        placement, Thrombolytic treatment.

        No chronic cardiac failure with persistent hemodynamic abnormality and ejection fraction
        less than 40%.

        No coagulation, platelet, or vascular disorder that threatens to cause bleeding.

        OTHER:

        No intolerance to pentoxifylline or other xanthines (e.g., caffeine, theophylline,
        theobromine).

        No seizure disorder.

        No peptic ulcer disease.

        Willing to undergo serial evaluations (excluding biopsies, laser Doppler, MRI) by NCI
        rehabilitation specialist for documentation and grading of functional disability.

        No pregnant or nursing women.

        Adequate contraception encouraged in fertile women.",Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis,0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS:

          -  Histologically proven locally advanced adenocarcinoma of the prostate, defined as 1 of
             the following:

               -  T3-4, N0 or NX, M0

               -  T2, PSA greater than 40 g/L

               -  T2, PSA greater than 20 g/L AND Gleason score at least 8

          -  Diagnosis made within the past 6 months

          -  Gleason score and PSA known

          -  Pelvic lymph nodes must be clinically negative

               -  Lymph nodes no more than 1.5 cm in greatest diameter by CT scan or MRI of the
                  pelvis

               -  Negative needle aspirate required for any lymph node more than 1.5 cm

               -  If a lymph node dissection was performed, it must be histologically negative

          -  No small cell or transitional cell carcinoma by biopsy

          -  No bony metastases by bone scan

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 80

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  At least 5 years excluding malignancy

        Hematopoietic:

          -  Hemoglobin at least 10.0 g/dL

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  SGOT and SGPT less than 2 times ULN

          -  Alkaline phosphatase less than 2 times ULN

          -  No history of chronic liver disease

        Renal:

          -  Creatinine less than 2 times ULN

        Other:

          -  No contraindication to wide-field pelvic irradiation (e.g., inflammatory bowel disease
             or severe bladder irritability)

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Prior hormonal therapy within the past 12 weeks allowed provided the following
             conditions are met:

               -  Negative bone scan before beginning any hormonal therapy

               -  Extracapsular extension remains palpable on rectal re-exam

               -  Baseline PSA known before beginning any hormonal therapy

          -  At least 4-6 weeks since prior 5-alpha-reductase inhibitor (e.g., finasteride) for
             benign prostatic hypertrophy

        Radiotherapy:

          -  No prior pelvic irradiation

        Surgery:

          -  No prior radical prostatectomy

          -  Prior transurethral resection of the prostate allowed

        Other:

          -  No prior cytotoxic anticancer therapy

          -  No other prior treatment for prostate cancer

          -  No other concurrent anticancer therapy unless documented disease progression",Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer,0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS:

          -  Histologically proven localized adenocarcinoma of the prostate

               -  Prostate specific antigen (PSA) greater than 4 or Gleason score at least 8 if PSA
                  is no greater than 4

               -  CT, MRI, or pelvic lymphadenectomy negative for metastases, if PSA is no greater
                  than 50

               -  Negative pelvic lymphadenectomy, if PSA is greater than 50

               -  Bone scan negative for metastases or PSA no greater than 20

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance Status:

          -  Not specified

        Life Expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm3

          -  Platelet count at least 70,000/mm3

          -  Hemoglobin at least 10 g/dL

          -  Patients on anticoagulant therapy must have a baseline PT test

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  ALT or AST less than 1.5 times ULN

          -  Alkaline phosphatase less than 1.5 times ULN

        Renal:

          -  Creatinine less than 1.5 times ULN

        Cardiovascular:

          -  No history of collagen vascular disease

        Other:

          -  No acute infection requiring antibiotics

          -  No history of hypersensitivity to flutamide

          -  No history of hypersensitivity to leuprolide acetate

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified",Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer,0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage II or III organ confined prostate cancer

               -  Resectable disease (candidate for retropubic prostatectomy)

          -  Gleason score at least 6

          -  Prostate specific antigen value (PSA) at least 5 ng/mL

          -  No significant central nervous system (CNS) disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 80-100%

          -  Eastern Cooperative Oncology Group (ECOG) 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  White blood cell count (WBC) greater than 3,000/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin greater than 9.0 g/dL

        Hepatic

          -  Bilirubin normal; serum glutamic oxaloacetic transaminase (SGOT), serum
             glutamic-pyruvic transaminase (SGPT) less than 3 times upper limit of normal

          -  Prothrombin time (PT)/partial thromboplastin time (PTT) normal

          -  Albumin greater than 3.0 g/dL

          -  Hepatitis B surface antigen negative

        Renal

          -  Creatinine normal

        Cardiovascular

          -  No uncontrolled hypertension

          -  No significant cardiovascular disease

          -  No history of ventricular dysfunction or arrhythmia

          -  No congestive heart failure

          -  No symptoms of coronary artery disease

          -  No prior myocardial infarction

        Other

          -  No active autoimmune disease

          -  No active infection requiring parenteral antibiotics

          -  HIV negative

          -  No significant psychiatric disorder that would preclude compliance

          -  No other malignancy within the past 5 years except curatively treated basal or
             squamous cell skin cancer

          -  No diabetes mellitus

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for prostate cancer

          -  At least 5 years since other prior chemotherapy

        Endocrine therapy

          -  No prior glucocorticoids for prostate cancer

          -  At least 5 years since other prior glucocorticoids

        Radiotherapy

          -  No prior radiotherapy for prostate cancer

          -  At least 5 years since other prior radiotherapy

        Surgery

          -  See Disease Characteristics

          -  At least 4 weeks since prior intrathoracic or intrabdominal surgery

          -  At least 2 weeks since other major surgery

        Other

          -  At least 10 days since prior anticoagulants or nonsteroidal antiinflammatory agents

          -  No other neoadjuvant or concurrent anticancer drugs

          -  No concurrent immunosuppressive drugs

          -  No other concurrent experimental therapy

          -  No concurrent parenteral antibiotics",Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer,0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS:

          -  Histologically proven prostate cancer at high risk for relapse as determined by either
             of the following:

               -  Prostate-specific antigen (PSA) 20-100 ng/mL and Gleason score at least 7 (any T
                  stage)

               -  Clinical stage at least T2, Gleason score at least 8, and PSA no greater than 100
                  ng/mL

          -  Negative lymph nodes

          -  No metastatic disease

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  Zubrod 0 or 1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  White blood cell (WBC) count of at least 3,000/mm^3

          -  Platelet count at least 130,000/mm^3

          -  Hemoglobin at least 11.4 g/dL

        Hepatic:

          -  Aspartate aminotransferase (AST) no greater than 2 times upper limit of normal

        Renal:

          -  Creatinine no greater than 2.5 mg/dL

        Other:

          -  No other invasive cancer within the past 5 years except superficial nonmelanomatous
             skin cancer

          -  No major medical or psychiatric illness that would preclude study participation

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 5 years since prior chemotherapy

        Endocrine therapy:

          -  At least 60 days since prior finasteride for prostatic hypertrophy

          -  At least 90 days since prior testosterone

          -  No more than 30 days since initiation of prior pharmacologic androgen ablation for
             prostate cancer

        Radiotherapy:

          -  No prior pelvic radiotherapy

          -  No concurrent intensity-modulated radiotherapy

        Surgery:

          -  No prior radical prostatectomy

          -  No prior cryosurgery for prostate cancer

          -  No prior orchiectomy",Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer,0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the prostate with evidence of metastatic
             disease including any of the following:

               -  Lymph node positive and prostate-specific antigen (PSA) at least 10 ng/mL

               -  Bone scan positive and PSA at least 10 ng/mL

               -  Prior radical prostatectomy with rising PSA and PSA at least 2 ng/mL

               -  Prior radiotherapy and PSA at least 10 ng/mL

               -  Prior cryosurgery and PSA at least 10 ng/mL

                    -  PSA criteria does not apply to patients who are assigned to group B of this
                       study and were previously treated on vaccine trial DFCI-96079

          -  No symptomatic metastatic disease (no bony pain)

          -  Complete HLA typing required

          -  Performance status - ECOG 0 or 1

          -  WBC greater than 2,000/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Bilirubin less than 2.0 mg/dL

          -  SGPT less than 4 times upper limit of normal

          -  Creatinine less than 4.0 mg/dL

          -  No altered immune function such as eczema

          -  No autoimmune diseases such as the following:

               -  Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia

               -  Systemic lupus erythematosus, Sjgren's syndrome, or scleroderma

               -  Myasthenia gravis

               -  Goodpasture's syndrome

               -  Addison's disease, Hashimoto's thyroiditis, or active Graves' disease

          -  HIV negative

          -  No allergy or untoward reaction to prior vaccinia (smallpox) vaccination

          -  No hypersensitivity to eggs

          -  No prior or concurrent extensive eczema or skin disorders (e.g., extensive psoriasis,
             burns, impetigo, or disseminated zoster)

          -  No other concurrent serious illness

          -  No active infection requiring antibiotics until infection has cleared and antibiotics
             have been stopped for at least 3 days

          -  Fertile patients must use effective contraception

          -  No close contact or household contact with the following high-risk individuals for at
             least 2 weeks after each vaccination:

               -  Children under age 5

               -  Pregnant or nursing women

               -  Individuals with prior or concurrent extensive eczema or other eczematoid skin
                  disorders

               -  Individuals with other acute, chronic, or exfoliative skin conditions (e.g.,
                  atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open
                  rashes or wounds)

               -  Immunodeficient or immunosuppressed individuals (by disease or therapy) such as
                  those with HIV infection

          -  See Disease Characteristics

          -  See Endocrine therapy

          -  Prior vaccinia (smallpox) immunization required

          -  No other concurrent biologic therapy (e.g., interferon or interleukin) for cancer

          -  No prior chemotherapy for metastatic disease

          -  No concurrent anticancer chemotherapy

          -  No prior hormonal therapy for metastatic disease

          -  Prior neoadjuvant hormonal therapy followed by prostatectomy or radiotherapy allowed

          -  Patients previously treated with recombinant vaccinia-PSA vaccine may have hormonal
             therapy since discontinuing that treatment (Group B)

          -  No concurrent hormonal therapy or steroids

          -  See Disease Characteristics

          -  See Endocrine therapy

          -  No concurrent radiotherapy

          -  See Disease Characteristics

          -  See Endocrine therapy

          -  No prior splenectomy

          -  At least 3 days since prior antibiotics

          -  No concurrent immunosuppressive treatment (e.g., after organ transplantation)",Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer),0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS: Histologically proven locally recurrent organ-confined prostate
        cancer after external beam radiotherapy, radiation seed implants, or cryosurgery. Gleason
        score of at least 6. Prostate specific antigen values (PSA) of at least 1.0 ng/mL with 2
        consecutive rises in PSA at least 2 weeks apart, of which the second increase is greater
        than the first, after achieving a nadir. Must have at least 3 recorded PSA values over a
        minimum of the last 3 months to determine the slope. Patients must have declined additional
        conventional treatment or be ineligible for conventional treatment of their prostate
        cancer. No metastasis by bone scan. No significant central nervous system (CNS) disease.

        PATIENT CHARACTERISTICS: Age: 18 and over. Performance status: Karnofsky 80-100% OR Eastern
        Cooperative Oncology Group (ECOG) 0 or 1. Life expectancy: Not specified. Hematopoietic:
        White blood cell count (WBC) greater than 3,000/mm3. Platelet count greater than
        100,000/mm3. Hemoglobin greater than 9.0 g/dL. Hepatic: Bilirubin normal. Serum glutamic
        oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) less than 3
        times upper limit of normal. Albumin greater than 3 g/dL. Prothrombin time (PT) and partial
        thromboplastin time (PTT) normal. Hepatitis B surface antigen negative. Renal: Creatinine
        normal. Cardiovascular: No uncontrolled hypertension. No significant cardiovascular
        disease, e.g.: History of ventricular dysfunction; Congestive heart failure; Symptoms of
        coronary artery disease; History of any ventricular arrhythmia; Prior myocardial
        infarction. Other: HIV negative. Fertile patients must use effective double-barrier
        contraception during and for 3 months after study participation. No active autoimmune
        disease. No active infection requiring IV antibiotics. No uncontrolled diabetes mellitus.
        No significant psychiatric disorder that would preclude study. No other malignancy within
        the past 5 years except adequately treated basal cell or squamous cell skin cancer.

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior Leuvectin. Chemotherapy: At least 3
        weeks since prior chemotherapy (6 weeks for mitomycin or hydroxyurea). Endocrine therapy:
        No prior hormonal therapy for prostate cancer. Radiotherapy: See Disease Characteristics.
        At least 3 weeks since prior radiotherapy. Surgery: At least 1 month since prior
        intrathoracic or intra-abdominal surgery. At least 2 weeks since other prior major surgery.
        Other: At least 10 days since prior anticoagulants or non-steroidal anti-inflammatory
        agents. No neoadjuvant or other concurrent anticancer drug therapy. No concurrent
        immunosuppressive drugs. No other concurrent experimental therapy.",Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer,0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS: Histologically proven stage I or II prostate cancer Organ confined
        (T1 or T2) At least 1 current positive biopsy Failed prior external beam radiotherapy for
        T1-T2 prostate cancer within last 18 months (with no worsening of the cancer in the first
        12 months after radiotherapy) PSA nadir less than 4 ng/mL after external beam radiotherapy
        If prior hormonal therapy, PSA must be greater than 1.0 ng/mL and testosterone level normal
        after therapy Prostate volume no greater than 35 g, or 35-50 g if maximum anterior
        posterior diameter no greater than 2.5 cm Kattan Nomogram at least .50 60-month
        recurrence-free probability prior to external beam radiotherapy ASA Classification 1-3 No
        lymph node involvement by CT scan No metastases No prostate seroma, prostate abscess, or
        active prostatitis Must meet the following conditions: No artificial sphincter, penile
        prosthesis, or intraprostatic implant such as stent or catheter Normal rectal anatomy and
        rectal mucosa Rectal wall measurement no greater than 6 mm with treatment probe in place No
        calcification inducing a shadow in the prostate that would preclude study No significant
        rectal or bladder morbidity after radiotherapy (RTOG/EORTC rectal or bladder scores at
        least 2) No rectal fibrosis, stenosis, fistula, disease, or other rectal anomalies that
        would make rectal probe insertion difficult

        PATIENT CHARACTERISTICS: Age: 50 and over Performance status: Not specified Life
        expectancy: At least 5 years Hematopoietic: Not specified Hepatic: Not specified Renal:
        Creatinine greater than 1.8 mg/dL No prior superficial bladder cancer, urethral stricture,
        or bladder neck contracture No active urinary tract infection No upper urinary tract
        disease No compromised renal function No urinary tract fistula No urethral stenosis Other:
        No inflammatory bowel disease No interest in future fertility No prior HIV infection, AIDS,
        or other immunosuppression No known latex hypersensitivity Mentally coherent and capable of
        completing symptom and quality of life questionnaires No prior or concurrent illness or
        surgery that would preclude study or follow-up

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: See Disease Characteristics At least 6 months since prior hormonal
        therapy Radiotherapy: See Disease Characteristics No more than 10 permanent radioactive
        seed implants Less than 1 cm from prostate apex or less than 1.2 cm from rectal wall
        Surgery: At least 6 weeks since prior transurethral resection of the prostate or other
        prostate surgery No prior rectal surgery except hemorrhoidectomy Other: No definitive local
        treatment for prostate cancer since completion of external beam radiotherapy At least 2
        months since prior finasteride or other agents that affect PSA (e.g., saw palmetto) At
        least 3 months since prior benign prostatic hypertrophy thermotherapy or hyperthermia
        treatment At least 30 days since prior investigational drug or device No concurrent
        participation in another clinical trial",Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer,0
"The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed:
Post-void residual: 71 mL
Prostate volume (TRUS): 63 mL
Prostate-specific antigen (PSA) level: 3.5 ng/mL
His recent blood chemistry (3 days ago) was normal: 
Hgb: 13.6 g/dl
WBC: 133000 /mm3
Plt: 370000 /ml
PT: 12 second
PTT: 34 second
INR: 0.9
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
U/A:
Color: yellow
Appearance: cloudy
PH: 5.3
Specific gravity: 1.010
Glc: 100
Nitrite: negative
Ketone: none
Leukocyte esterase: negative
RBC: negative
WBC: 2 WBCs/hpf
U/C: negative","DISEASE CHARACTERISTICS: Asymptomatic smokers who either refuse to or cannot stop smoking
        Urinary cotinine levels greater than 100 ng/mL Willing to adhere to certain dietary
        restrictions limiting intake of cruciferous vegetables (watercress, broccoli, radishes,
        mustard, brussels sprouts) while on study

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin less than 1.6 mg/dL Transaminases less than 2 times normal
        Renal: Creatinine less than 1.6 mg/dL Urinary RBC levels 0-2 Urinary WBC levels at least
        0-2 Pulmonary: No dyspnea at rest Other: No concurrent illness, condition, or symptom that
        would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must
        use effective contraception

        PRIOR CONCURRENT THERAPY: Not specified",Phenethyl Isothiocyanate in Preventing Lung Cancer in People Who Smoke,0
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"INCLUSION CRITERIA

        Women of any age with clinical stage II breast cancer who met the following criteria:

        Patients with stage II breast cancer will include primary tumor less than or equal to 5 cm
        in size with axillary lymph nodes which are clinically ([N0 or N1] [T1N1, T2N0, T2N1]).

        Patients will be staged according to the 1986 AJCC TMM classification.

        Patients with bilateral breast cancer will be eligible provided at least one tumor is
        invasive and classified as stage I or II, and neither breast is stage III.

        Histologic sections of the breast tumor must be classified as an invasive primary breast
        neoplasm of epithelial origin.

        Patients must be geographically accessible for follow-up and willing to return for the
        follow-up at the NCI.

        Patients must be mentally competent to understand and give informed consent for the
        protocol.

        Estrogen receptor (ER) status can include ER positive, negative, or unknown.

        Patients with prior cancers may be eligible as long as they have received curative therapy
        and have had no evidence of recurrence for greater than or equal to 10 years.

        EXCLUSION CRITERIA

        Patients will be excluded from this protocol for the following reasons:

        Advanced local disease or distant metastases (stage III or IV).

        Previous therapy to the breast other than excisional biopsy.

        Pregnancy.

        Unwillingness to use birth control during chemotherapy.

        Chronic disease such as heart, lung, liver, kidney, blood or metabolic disorders which may
        render the patient a poor risk for surgery or chemotherapy. Specifically, liver function -
        SGOT, SGPT, alkaline phosphatase and total bilirubin should be less than 1.5 x the upper
        limits of normal. Renal function - creatinine should be less than 1.7 and/or creatinine
        clearance should be greater than 45 ml/min. If there is any history of cardiac disease,
        patients must have a normal ejection fraction on MUGA scan and no angina.",Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial,0
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"DISEASE CHARACTERISTICS: Histologically confirmed nonlobular invasive breast cancer of one
        of the following histologies: Ductal Papillary Medullary Colloid (mucinous) Tubular Stage
        I/II (T1-2 N0-1 M0) tumor no greater than 3 cm Prior tylectomy and axillary lymph node
        dissection required No more than 3 positive axillary lymph nodes and no extracapsular
        extension At least 6 lymph nodes sampled OR Negative sentinal node Surgical clips in place
        delineating margins of tylectomy cavity Negative, or close but negative, inked histologic
        margins of tylectomy or re-excision specimen Negative margins defined as no tumor at least
        2 mm away from the inked margins Close but negative margins defined as tumor within 2 mm of
        inked margin Positive margins defined as invasive or noninvasive tumor at inked resection
        margins Negative post-tylectomy or post-reexcision mammogram required if disease presented
        with malignancy-associated microcalcifications No remaining suspicious microcalcifications
        If catheters are placed at time of reexcision, the crieria may not be feasible but a post
        brachytherapy mammogram should be obtained as soon as possible No extensive intraductal
        carcinoma by the Harvard definition, i.e.: More than 25% of tumor is ductal carcinoma in
        situ (DCIS) and there is DCIS in adjacent breast tissue OR Intraductal carcinoma with
        microinvasion No proven multicentric carcinoma, i.e.: Tumor in different quadrants of the
        breast OR Tumor separated by at least 4 cm The following exclude: Skin or chest wall
        invasion Matted or fixed axillary adenopathy Metastatic internal mammary or supraclavicular
        nodes Paget's disease of the nipple Previously treated contralateral breast carcinoma or
        synchronous bilateral breast carcinoma Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: Any age Sex: Female Menopausal status: Not specified
        Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified
        Renal: Not specified Other: No collagen vascular disease with a c-reactive protein level
        above normal or with an active skin rash (e.g., systemic lupus erythematosus, scleroderma,
        or dermatomyositis) No coexisting medical condition that reduces life expectancy to less
        than 2 years No second malignancy within 5 years except nonmelanomatous skin cancer Not
        pregnant or nursing Negative pregnancy test

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy for breast cancer Planned chemotherapy may begin at least 2 weeks after
        removal of brachytherapy catheters Endocrine therapy: Concurrent tamoxifen permitted
        Radiotherapy: No prior radiotherapy for breast cancer Surgery: See Disease Characteristics",Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer,0
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"DISEASE CHARACTERISTICS:

          -  One of the following histologically proven diagnoses:

               -  Primary invasive adenocarcinoma of the unilateral or bilateral breast

                    -  Stage I, IIA, or IIB (T1-3, N0-1, M0)

                    -  No recurrent invasive breast cancer

               -  Ductal carcinoma in situ (DCIS)

               -  Lobular carcinoma in situ (LCIS) with microinvasion

               -  Paget's disease of the nipple

          -  No sarcoma, lymphoma, or apocrine, adenocystic, or squamous cell cancer of the breast

          -  Currently free of breast cancer (no evidence of disease)

               -  No evidence of distant disease on chest x-ray or chest CT scan and mammogram of
                  the opposite breast within the past year

          -  Prior definitive local treatment of primary lesion (mastectomy or breast-sparing
             procedure with radiotherapy) and either axillary node or sentinel node biopsy

               -  Surgical margins clear of both infiltrating carcinoma (any type) and DCIS

                    -  No gross or microscopically positive margins except:

                         -  Invasive cancer or DCIS at the focal margin treated with definitive
                            radiotherapy

                         -  Gross or LCIS at the final margin

               -  Biopsy requirement waived for DCIS or LCIS with minimal microinvasion

          -  Patients with breast-sparing procedure must have received or be planning to receive
             radiotherapy at start of tamoxifen treatment

          -  No endometrial simple or cystic hyperplasia, proliferative changes, complex
             (adenomatous) or atypical hyperplasia, or carcinoma

          -  Patients must be planning one of the following:

               -  Starting adjuvant tamoxifen for five years OR

               -  Started tamoxifen within 28 days prior to study and planning to receive adjuvant
                  tamoxifen for five years

          -  Hormone receptor status:

               -  Candidate for adjuvant tamoxifen therapy

        PATIENT CHARACTERISTICS:

        Age:

          -  Adult

        Sex:

          -  Female

        Menopausal status:

          -  Postmenopausal defined as:

               -  At least 1 year since last menstrual period

               -  At least 2 months since bilateral oophorectomy prior to breast cancer diagnosis

               -  4-12 months since last menstrual period and FSH elevated to postmenopausal range

               -  Postmenopausal estrogen therapy and 55 years of age or older

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  Fertile patients must use effective contraception during and for at least 2 months
             after study

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer
             currently in complete remission

          -  No concurrent nonmalignant-related illness that would preclude study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Adjuvant chemotherapy allowed

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  See Disease Characteristics

          -  No prior hormonal treatment for breast cancer (except tamoxifen)

          -  No concurrent postmenopausal estrogen therapy

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  See Disease Characteristics

          -  No prior or concurrent hysterectomy

        Other:

          -  No prior or current participation in an adjuvant intergroup trial","S9630, Medroxyprogesterone in Treating Women With Breast Cancer",0
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"DISEASE CHARACTERISTICS: Histologically confirmed resectable adenocarcinoma of the breast
        Histologically positive lymph nodes (1 to 3) OR Lymph node negative and high risk disease
        Tumor greater than 1.0 cm diameter May have undergone an axillary dissection with at least
        6 nodes removed and examined or a sentinel node biopsy Patients who are positive by
        sentinel node biopsy will receive an axillary dissection No locally advanced or
        inflammatory or metastatic breast cancer Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified
        Performance status: Not specified Life expectancy: Not specified Hematopoietic: Neutrophil
        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Adequate hepatic
        function Bilirubin no greater than upper limit of normal Renal: Adequate renal function
        Cardiovascular: Adequate cardiac function Normal MUGA or echocardiogram Other: Not pregnant
        or nursing Fertile patients must use effective barrier method contraception At least 5
        years since prior invasive malignancies, except basal cell or squamous cell carcinoma of
        the skin or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy for this malignancy Endocrine therapy: No concurrent tamoxifen Up to 4 weeks
        of tamoxifen treatment for this malignancy allowed Radiotherapy: No prior radiotherapy for
        this malignancy Prior radiotherapy to the breast for ductal carcinoma in situ allowed
        Surgery: Tumor should be removed by either a modified radical mastectomy and/or a segmental
        mastectomy plus axillary lymph node dissection or sentinel node biopsy before beginning
        treatment on protocol No greater than 84 days since last surgical procedure that
        constitutes or completes definitive surgical therapy (mastectomy; axillary
        dissection/sentinel node biopsy; or resection of primary site to obtain a negative margin",Combination Chemotherapy in Treating Women With Breast Cancer,1
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"DISEASE CHARACTERISTICS: Histologically or cytologically proven stage I or IIA invasive
        breast cancer T0, T1, or T2 (no greater than 3 cm), N0 Noninflammatory Nonmetastatic No
        ductal carcinoma in situ Eligible for breast-conserving surgery Hormone receptor status:
        Positive or negative

        PATIENT CHARACTERISTICS: Age: Any age Sex: Female Menopausal status: Pre- and
        postmenopausal Performance status: Not specified Life expectancy: Not specified
        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not
        pregnant No allergy or sensitivity to radiopharmaceuticals or patent blue V dye

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No
        prior neoadjuvant chemotherapy Endocrine therapy: No prior endocrine therapy Radiotherapy:
        No prior neoadjuvant radiotherapy Surgery: No prior breast surgical biopsy or axillary
        surgery",Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer,0
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"DISEASE CHARACTERISTICS:

          -  Resectable invasive adenocarcinoma of the breast, confirmed by 1 of the following:

               -  Histologically confirmed by core or open biopsy

               -  Confirmed by fine needle aspiration cytology AND positive clinical breast
                  examination and ultrasound or mammography

          -  Clinically negative lymph nodes

               -  No positive ipsilateral axillary lymph nodes

               -  No prior removal of ipsilateral axillary lymph nodes

               -  No suspicious palpable nodes in the contralateral axilla or palpable
                  supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy

          -  No ulceration, erythema, infiltration of the skin or underlying chest wall (complete
             fixation), peau d'orange, or skin edema of any magnitude

               -  Tethering or dimpling of the skin or nipple inversion allowed

          -  No bilateral malignancy or mass in the opposite breast that is suspicious for
             malignancy, unless proven nonmalignant by biopsy

          -  No diffuse tumors or multiple malignant tumors in different quadrants of the breast

          -  No other prior breast malignancy except lobular carcinoma in situ

          -  No prior or concurrent breast implants

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  18 years and older

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 10 years (excluding diagnosis of cancer)

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No hepatic systemic disease

        Renal:

          -  No renal systemic disease

        Cardiovascular:

          -  No cardiovascular systemic disease

        Other:

          -  No prior malignancy within past 5 years except:

               -  Effectively treated squamous cell or basal cell skin cancer

               -  Surgically treated carcinoma in situ of the cervix

               -  Surgically treated lobular carcinoma in situ of the ipsilateral or contralateral
                  breast

          -  No concurrent psychiatric or addictive disorder

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for this cancer

        Chemotherapy:

          -  No prior chemotherapy for this cancer, including neoadjuvant chemotherapy

        Endocrine therapy:

          -  No prior hormonal therapy for this cancer

        Radiotherapy:

          -  No prior radiotherapy for this cancer

        Surgery:

          -  See Disease Characteristics

          -  No prior breast reduction surgery

          -  Prior excisional biopsy or lumpectomy allowed",Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer,0
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"DISEASE CHARACTERISTICS:

          -  Histologically confirmed resectable adenocarcinoma of the breast

               -  pT1, pT2, pT3, or minimal dermal involvement on pathology only

               -  pN0, pN1, pN2, or M0

                    -  Negative nodal status

                         -  At least 8 nodes are negative

                    -  Unknown nodal status

                         -  Less than 8 nodes examined and no pathological finding

                    -  Positive nodal status

                         -  Any positive finding independent of the number of nodes examined

               -  Negative sentinel node or no prior nodal dissection allowed if all other criteria
                  met

          -  Must have had total mastectomy, lumpectomy, or quadrantectomy

               -  Should have prior chest wall radiotherapy after segmental mastectomy or
                  histopathologic T4 dermal involvement

          -  Stage I, II, or IIIa allowed if the tumor is completely removed macroscopically and
             margins of the resected tumor are microscopically free of tumor

          -  Must undergo chest wall radiotherapy or second resection if microscopic disease at the
             mastectomy margins

          -  No bilateral disease except in situ disease, either ductal or lobular of the
             contralateral breast

          -  Postmenopausal

               -  Regardless of prior hormonal replacement therapy (HRT) or hysterectomy:

                    -  Bilateral oophorectomy and any age

                    -  Radiologic castration and amenorrheic for at least 3 months and any age

                    -  Not postmenopausal at the start of adjuvant chemotherapy AND and completed
                       at least 6 courses of prior cyclophosphamide, methotrexate, and fluorouracil
                       (CMF) or at least 4 courses of prior anthracycline-cyclophosphamide
                       continuation therapy and at least age 45 with follicle stimulating hormone
                       (FSH), luteinizing hormone (LH), and estradiol (E2) postmenopausal levels

               -  No prior HRT:

                    -  Prior hysterectomy and less than age 55 with FSH/LH/E2 postmenopausal levels

                    -  Prior hysterectomy and at least age 55

               -  No prior HRT or hysterectomy:

                    -  Amenorrhea more than 1 year and less than age 50

                    -  Amenorrhea more than 6 months and at least age 50

               -  Prior HRT regardless of hysterectomy:

                    -  At least 1 month since prior HRT and less than age 55 with FSH/LH/E2
                       postmenopausal levels

                    -  At least 1 month since prior HRT and at least age 55

               -  FSH/LH/E2 postmenopausal levels and uncategorized

          -  No distant metastases, including bone scans showing hot spots unconfirmed as benign
             disease or skeletal pain of unknown cause

          -  At least 10% hormone receptor-positive tumor cells

          -  Hormone receptor status:

               -  Estrogen receptor positive AND/OR

               -  Progesterone receptor positive

        PATIENT CHARACTERISTICS:

        Age:

          -  30 and over

        Sex:

          -  Female

        Menopausal status:

          -  Postmenopausal

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin greater than 10 g/dL

        Hepatic:

          -  Bilirubin less than 3.0 mg/dL

          -  SGOT or SGPT less than 1.5 times upper limit of normal

          -  No hepatic disease that would preclude study

        Renal:

          -  Creatinine less than 1.8 mg/dL

          -  No renal disease that would preclude study

        Cardiovascular:

          -  No cardiovascular disease that would preclude study

          -  Prior deep vein thrombosis allowed if medically stable

        Pulmonary:

          -  No lung embolism

        Other:

          -  No other prior or concurrent malignancy within the past 5 years except adequately
             treated basal or squamous cell skin cancer or carcinoma in situ of the cervix

          -  No prior noncompliance to medical regimens

          -  No other nonmalignant systemic diseases that would preclude follow-up

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Prior immunotherapy or biological response modifiers (e.g., interferon) allowed

        Chemotherapy:

          -  See Disease Characteristics

          -  Prior adjuvant or neoadjuvant chemotherapy allowed

          -  Concurrent adjuvant chemotherapy allowed

        Endocrine therapy:

          -  See Disease Characteristics

          -  Prior neoadjuvant hormonal therapy allowed (e.g., antiestrogens, progestins, or
             aromatase inhibitors) if no more than 4 months duration and no disease progression

          -  Prior corticosteroids allowed

          -  At least 4 weeks since prior HRT

          -  Prior adjuvant antiestrogen therapy allowed if less than 1 month duration and
             immediately after surgery, radiotherapy, and/or chemotherapy

          -  Prior antiestrogens for chemoprevention allowed if at least 18 months between
             completion of chemoprevention and diagnosis

          -  No other concurrent antiestrogens or aromatase inhibitors

          -  No concurrent raloxifene

          -  No concurrent systemic HRT with or without progestins of more than 3 months duration

        Radiotherapy:

          -  See Disease Characteristics

          -  Concurrent radiotherapy allowed

        Surgery:

          -  See Disease Characteristics

        Other:

          -  At least 30 days since prior systemic investigational drugs

          -  At least 7 days since prior topical investigational drugs

          -  Concurrent bisphosphonates allowed",Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer,0
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"DISEASE CHARACTERISTICS: HER2 overexpressing (3+) metastatic breast cancer by
        immunohistochemistry, or amplified by fluorescent in situ hybridization (FISH) No prior
        chemotherapy for breast cancer metastases No bilateral disease Bidimensionally measurable
        disease At least 1 target lesion greater than 1 cm2 No significant lymphedema in the arm
        ipsilateral to mastectomy site, unless patient has an indwelling catheter for the purpose
        of chemotherapy infusion No CNS metastases Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified
        Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic:
        Hemoglobin at least 9.0 g/dL WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
        Granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper
        limit of normal (ULN) ALT, AST, and alkaline phosphatase no greater than 2.5 times ULN (no
        greater than 4.0 times ULN with liver or bone metastases) Renal: Creatinine no greater than
        1.5 times ULN Cardiovascular: No clinically significant cardiovascular disease (e.g.,
        uncontrolled hypertension, myocardial infarction, unstable angina, intractable arrhythmia,
        congestive heart failure, or New York Heart Association class II-IV heart disease) Left
        ventricular ejection fraction at least 50% or above lower limit of normal, whichever is
        lower Other: No severe hypersensitivity to products containing Cremophor EL (e.g.,
        cyclosporine or teniposide for injection concentrate) No other serious medical condition
        that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients
        must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 14 days since prior immunotherapy No
        prior trastuzumab (Herceptin) No other concurrent immunotherapy Chemotherapy: See Disease
        Characteristics Prior cytotoxic chemotherapy allowed in adjuvant setting Prior cumulative
        doxorubicin exposure no greater than 300 mg/m2 At least 1 year since prior taxane therapy
        No other concurrent chemotherapy Endocrine therapy: At least 14 days since prior hormonal
        therapy No concurrent hormonal therapy (e.g., tamoxifen, megestrol acetate,
        fluoxymesterone, or aminoglutethimide) Radiotherapy: At least 14 days since prior
        radiotherapy No concurrent radiotherapy to target lesions Surgery: Not specified Other: At
        least 30 days since other prior investigational agent or procedure No other concurrent
        investigational agents",Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2,2
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"Inclusion Criteria:

          -  Required tumor parameters for node positive disease: NOTE: This study will continue to
             use the American Joint Committee on Cancer (AJCC) 5th edition for TNM classification
             and staging

               -  Operable, histologically confirmed adenocarcinoma of the female breast and
                  positive lymph nodes

                    -  Node positivity may be determined by either an axillary node dissection or a
                       positive sentinel node finding by hematoxylin and eosin (H&E)

                         -  NOTE: Positive nodes refers to H&E visible nodal metastases;
                            immunohistochemistry (IHC) positive only cells in lymph nodes will not
                            be considered positive nodes

                    -  One or more positive lymph nodes whose tumors are T1-3, pN1-2, M0 are
                       eligible

                    -  cN2 disease is not eligible

                    -  pN2 disease is eligible

                    -  One positive lymph node by sentinel node biopsy or at least 6 axillary nodes
                       must be examined on axillary node dissection with at least one positive
                       lymph node

                    -  Metaplastic carcinoma is eligible

               -  ER/PgR determination

               -  HER-2 positive (pre-entry requirement for registration)

                    -  FISH must show gene amplification OR

                    -  IHC assay must show a strong positive (3+) staining score

                         -  NOTE: ductal carcinoma in situ (DCIS) components should not be counted
                            in the determination of degree of IHC staining or FISH amplification

          -  Required tumor parameters for high-risk node-negative disease; NOTE: This study will
             continue to use the AJCC 5th edition for TNM classification and staging

               -  Operable, histologically confirmed adenocarcinoma of the female breast and
                  negative lymph nodes

                    -  Node status may be determined by either axillary node dissection or sentinel
                       node biopsy with H&E staining; to be considered node negative, either of the
                       following must be true: 1) negative sentinel node biopsy or 2) no positive
                       lymph nodes found among at least 6 axillary nodes examined on axillary node
                       dissection

                    -  NOTE: IHC positive only cells in lymph nodes will not be considered positive
                       nodes

                    -  Tumors > 2.0 cm (irrespective of hormonal receptor status) or > 1.0 cm if
                       ER-negative and PR-negative disease

               -  ER/PgR determination

               -  HER-2 positive (pre-entry requirement for registration)

                    -  FISH must show gene amplification OR

                    -  IHC assay must show a strong positive (3+) staining score

                         -  NOTE: DCIS components should not be counted in the determination of
                            degree of IHC staining or FISH amplification

          -  =< 84 days from mastectomy or =< 84 days from axillary dissection or sentinel node
             detection if the patient's most extensive breast surgery was a breast sparing
             procedure; (This timing is per a decision by the Breast Intergroup)

          -  Surgical resection margins. All tumor should be removed by either a modified radical
             mastectomy or a segmental mastectomy with axillary node dissection

               -  Mastectomy: There will be no evidence of gross or microscopic tumor (invasive or
                  DCIS) at the surgical resection margins noted in the final surgery or pathology
                  reports; patients with close margins are eligible

               -  Segmental mastectomy (lumpectomy): Margins must be clear of invasive cancer and
                  DCIS

               -  Axillary dissection or sentinel node dissection: There will be no gross residual
                  adenopathy

          -  TAM therapy

               -  May have received up to four weeks of TAM therapy, or any other hormonal agent,
                  for this malignancy

               -  May have received TAM or raloxifene for purposes of chemoprevention (e.g., Breast
                  Cancer Prevention Trial) or for other indications (including previous breast
                  cancer if lobular carcinoma in situ [LCIS]) but must be discontinued before
                  registration on this study

               -  May never have received TAM, raloxifene, or any other hormonal agent

          -  Absolute neutrophil count (ANC) >= 1500/mm^3

          -  Platelets (PLT) >= 100,000/mm^3

          -  Total bilirubin =< 1.5 x upper normal limit (UNL)

          -  Aspartate aminotransferase (AST) =< 2.0 x UNL

          -  Left ventricular ejection fraction (LVEF) within institutional normal range; if LVEF
             is > 75%, the investigator should consider performing a second review of the
             multigated acquisition (MUGA)/echocardiogram or performing a repeat
             MUGA/echocardiogram prior to registration; such re-reviews or repeat
             MUGA/echocardiogram are not permitted after registration

          -  Willingness to discontinue sex hormonal therapy, e.g., birth control pills, ovarian
             hormonal replacement therapy, etc., prior to registration and while on study

          -  Willingness to discontinue any hormonal agent such as raloxifene (Evista) prior to
             registration and while on study

          -  Non-breast malignancies that have not recurred within the last 5 years and are deemed
             to be at low risk for recurrence

        EXCEPTIONS: These non-breast malignancies are eligible even if diagnosed =< 5 years prior
        to registration:

          -  Squamous or basal cell carcinoma of the skin that has been effectively treated

          -  Carcinoma in situ of the cervix that has been treated by surgery only

          -  Lobular carcinoma in situ (LCIS) of the ipsilateral or contralateral breast treated by
             surgery and/or tamoxifen only

               -  Patients undergoing breast conservation therapy (i.e., lumpectomy and axillary
                  dissection) must have plans to receive radiation therapy to the breast +/-
                  regional lymphatics following completion of the chemotherapy; for patients
                  treated with mastectomy, the use of radiation therapy is required for 4 or more
                  positive lymph nodes and must be started after completion of chemotherapy; the
                  use of radiation therapy is at the discretion of the investigator for 0-3
                  positive lymph nodes but, if used, must be started after the completion of
                  chemotherapy

               -  Prior to registration, the physician must designate if it is planned for the
                  patient to receive radiation therapy (for adjuvant radiation therapy
                  post-mastectomy or, less commonly, post-conservative therapy but not primary
                  breast radiation as part of breast conserving treatment)

               -  Willing and able to sign an informed consent

               -  Gene amplified by FISH or strong positivity (3+) by HercepTest on central review;
                  Note: The patient registers based on community HER-2 testing using FISH or IHC,
                  AC chemotherapy is initiated; the tumor block or slides must be received =< 2
                  weeks from time of registration to the North Central Cancer Treatment Group
                  (NCCTG) Operations Office for central HER-2 testing

        Exclusion Criteria:

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Women of childbearing potential or their sexual partners who are unwilling to
                  employ adequate contraception (condoms, diaphragm, intrauterine device [IUD],
                  surgical sterilization, or abstinence, etc.); hormonal birth control methods are
                  not permitted

          -  Locally advanced tumors (classification T4) at diagnosis including tumors fixed to
             chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes
             (diffuse brawny cutaneous induration with an erysipeloid edge)

          -  Prior history of breast cancer, except LCIS

          -  Bilateral invasive carcinoma, either metachronous or synchronous (EXCEPTION: Patients
             diagnosed with unilateral invasive carcinoma and metachronous or synchronous DCIS of
             the contralateral breast treated with mastectomy are eligible)

          -  Prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer

          -  Active, unresolved infection

          -  Active cardiac disease

               -  Any prior myocardial infarction

               -  History of documented congestive heart failure (CHF)

               -  Current use of digitalis or beta-blockers for CHF

               -  Any prior history of arrhythmia or cardiac valvular disease requiring medications
                  or clinically significant

               -  Current use of medications for treatment of arrhythmias or angina pectoris

               -  Current uncontrolled hypertension (diastolic > 100 mmHg or systolic > 200 mmHg)

               -  Clinically significant pericardial effusion

          -  Prior anthracycline or taxane therapy for any malignancy

          -  Sensitivity to benzyl alcohol

          -  Neurology/Neuropathy-Sensory >= grade 2 per the National Cancer Institute's (NCI's)
             Common Toxicity Criteria Version 2.0; EXCEPTION: Any chronic neurologic disorder will
             be looked at on a case-by-case basis by the study chair","Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer",2
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"Inclusion Criteria

          -  Histologically confirmed stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV
             primary carcinoma of the breast

               -  Fine needle aspiration, core needle biopsy, or incisional biopsy allowed

               -  No excisional biopsy

               -  Any of the following:

                    -  Tumor size 2, Nodes 1 (T2N1) or tumor size 3 nodes 0 (T3N0)

                    -  Any T with N2 (including axillary lymph nodes matted to one another) or N3

                    -  Any T4, including inflammatory breast cancer

                    -  Adjuvant patients with at least 4 positive lymph nodes and HER-2
                       overexpressing tumor

                    -  Supraclavicular or infraclavicular positive lymph nodes without distant
                       metastases

                    -  Distant metastases with measurable disease in breast or lymph nodes

          -  Synchronous bilateral primary breast cancer allowed if the more serious cancer meets
             entry criteria

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

        Age: Not specified

        Sex: Female

        Menopausal status: Not specified

        Performance status: Not specified

        Life expectancy: Not specified

        Hematopoietic:

        White cell count > 3000 / mm3 Platelet count > 100,000 / mm3

        Hemoglobin > 9 mg / dl Bilirubin < 1.5 x normal Creatinine < 1.5 x normal left ventricular
        ejection fraction (LVEF) normal by resting nuclear ventriculogram Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception

        Exclusions

        Prior malignancies except:

        Effectively treated squamous cell or basal cell skin cancer Carcinoma in situ of the cervix
        that has been curatively treated by surgery alone Nonbreast malignancy from which patient
        has been disease-free for 5 years and is at low risk of recurrence","Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer",2
The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.,"-  ELIGIBILITY CRITERIA:

        Inclusion Criteria - Menstrual Cycle Study:

        To participate in the Menstrual Cycle Pilot Study, a woman must:

        Must be at least 25 years of age (or 5 years younger than the age at diagnosis of the
        youngest family member with a tumor associated with the Breast-Ovarian Cancer Syndrome) and
        less than 46 years of age.

        Must be premenopausal as determined by menstrual history (no change in menstrual pattern in
        prior 6 months) and an FSH level less than 15 mIU/ml obtained on the third day of the
        menstrual cycle.

        Have undergone genetic counseling and risk assessment.

        Must be a known mutation carrier or be a first- or second-degree relative of an individual
        with a tumor associated with the Breast-Ovarian Cancer Syndrome in a family with a known
        BRCA mutation.

        Agree to release of genetic test result for stratification purposes, whether or not she has
        chosen to receive individual test results for clinical decision-making.

        Be willing to use non-hormonal methods of contraception until completion of the 3 month
        follow-up studies.

        Have an ECOG performance status of 0-1.

        Be able to provide informed consent.

        Exclusion Criteria - Menstrual Cycle Study:

        Any of the following will result in exclusion from the Menstrual Cycle Pilot Study:

        A history of menstrual cycle irregularities over the previous 6 months, including history
        of cycles less than 26 days or more than 35 days.

        Steroid therapy, use of selective estrogen receptor modulators (SERMs) or hormonal agents
        (including tamoxifen, raloxifene, estrogen, DHEA, anabolic steroids, oral contraceptives,
        depoprovera, progestin IUD, oral progestins, norplant, or drugs to induce ovulation) within
        6 months prior to study entry and must agree not to use these compounds until completion of
        the three-month follow-up study.

        Pregnancy or lactation within 12 months of enrollment.

        History of infertility with a suspected ovarian etiology or persistent ovarian cyst.

        Abnormal CA-125 level.

        History of invasive cancer except for non-melanoma skin cancer or cervical carcinoma in
        situ.

        Creatinine greater than 2.

        Previous bilateral mastectomy, bilateral radiation therapy to the breast, or oophorectomy.

        History of DCIS or LCIS .

        Weight over 136 kilograms.

        Allergy to gadolinium.

        Allergy to lidocaine or Marcaine (bupivacaine) (excluded from breast duct lavage only).

        Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would
        preclude informed consent or ability to participate in clinical research.

        Inclusion Criteria - Training Cohort:

        To participate in the Training Cohort a volunteer must:

          -  Be female and at least 18 years and less than 51 years of age.

          -  Have at least one breast considered eligible for study.

          -  Provide evidence (either films or radiologist's report) of a mammogram done within the
             12 months prior to enrollment showing low or no suspicion of carcinoma in at least one
             breast. (Mammograms will not be provided to participants as part of the training
             cohort.)

          -  Have a physical examination of the breast to be studied consistent with low or no
             suspicion of carcinoma at the time of enrollment.

          -  Provide the name of a primary care physician to whom the results of breast duct lavage
             cytologies can be sent.

          -  Have signed the informed consent for breast duct lavage.

        Exclusion Criteria - Training Cohort:

        Any of the following will exclude a potential participant from the Training Cohort:

          -  Pregnancy or lactation within the past 12 prior to enrollment.

          -  Subareolar or other surgery of the breast to be studied (papilloma resection, biopsy
             or fine needle aspirations which might disrupt the ductal systems within 2 cm of the
             nipple. (Biopsies of fine needle aspirations of the breast greater than or equal to 2
             cm from the nipple are acceptable.)

          -  A breast implant or prior silicone injections in the breast to be studied.

          -  Radiation therapy to a breast to be studied.

          -  Active infections or inflammation in a breast to be studied.

          -  Chemotherapy or a selective estrogen receptor modifier (e.g., tamoxifen or raloxifen)
             taken within 12 months prior to enrollment.

          -  A known allergy to lidocaine, prilocaine or Marcaine (bupivacaine).",Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study,0
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.","Men and women, normocholesterolemic, with 30 percent or greater narrowing of a coronary
        artery lumen as revealed by angiography. (Cholesterol-Lowering Agent Trial).

        Men and women with angiographically-documented coronary heart disease (Fish Oil Tr",Harvard Atherosclerosis Reversibility Project (HARP),1
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.","Inclusion Criteria:

          -  Diagnosed with type 2 diabetes mellitus, as determined by the new American Diabetes
             Association guidelines, which include a fasting plasma glucose level greater than 126
             mg/dl (7.0 mmol/l), or a 2-hour postload value in the oral glucose tolerance test of
             greater than 200 mg/dl, with confirmation by a retest

          -  For participants aged 40 years or older, history of CVD (heart attack, stroke, history
             of coronary revascularization, history of peripheral or carotid revascularization, or
             demonstrated angina)

          -  For participants aged 55 years or older, a history of CVD is not required, but
             participant must be considered to be at high risk for experiencing a CVD event due to
             existing CVD, subclinical disease, or 2+ CVD risk factors

          -  HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs)",Action to Control Cardiovascular Risk in Diabetes (ACCORD),1
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.","Patient must be over 18 years of age requiring diagnostic cardiac catheterization will
        participate.

        Women on chronic estrogen therapy are eligible for the study.

        Patients investigated for chest pain syndrome with normal coronary arteries with and
        without risk factors for atherosclerosis, patients with coronary artery disease, and
        patients with heart failure.

        No patients with unstable angina; significant left main disease (greater than 50%
        stenosis); Recent myocardial infarction (less than 1 month); Pregnancy, lactation; Allergy
        to losartan; Renal failure (creatinine greater than 2.5 mg/dl); Inability to withdraw ACE
        inhibitors.",The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function,0
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.","Ability to comprehend or unwillingness to sign the consent form.

        No use of estrogen therapy within 2 months of this study.

        No history of breast cancer, uterine cancer, or estrogen-dependent tumor.

        No history of deep vein thrombosis or pulmonary embolus.

        No cigarette smokers (within 2 years).

        No diabetes mellitus (FBS greater than 120 mg/dL).

        Triglycerides less than 400 mg/dL.

        Blood pressure less than 160/90 without antihypertensive therapy.

        No history of coronary artery disease.

        No history of carotid artery disease or stroke.

        No history of pancreatitis.

        No history of claustrophobia.

        No history of involuntary motion disorder.

        Specific MRI exclusion criteria (i.e., no pacemaker, no cochlear implants, no AICD, no
        internal infusion pump, no metal implants or clips in field of view).

        No systemic inflammatory disorder (e.g., rheumatoid arthritis, periarteritis nodosa,
        systemic lupus erythromatosus, temporal arteritis).

        Must not have a need for chronic aspirin or NSAID therapy.",Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls,0
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.","Inclusion Criteria:

          -  No history of the following: hypertension, diabetes mellitus, smoking, and coronary
             artery disease",Effect of Pravastatin on Endothelial Dysfunction Following a Single High Fat Meal,1
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",No eligibility criteria,Carotid Atherosclerosis Follow-up Study,2
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",No eligibility criteria,Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia,2
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",No eligibility criteria,Intimal Thickening and Antioxidants in Hispanics and Anglos (Los Angeles Atherosclerosis Study),2
"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158mg/dL, resp.) were within normal limits.
The patient reported no use of lipid-lowering medications.
Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5cm/s and 54.5cm/s, respectively; RICA PSV was 91.72cm/s and RICA EDV was 37.37cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",No eligibility criteria,Molecular & Clinical Evaluation of Low HDL Syndromes,2
"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.","DISEASE CHARACTERISTICS: Histologically or cytologically proven non-small cell lung cancer
        Squamous cell lung cancer Large cell lung cancer Adenocarcinoma lung cancer Mixture of
        above Locally advanced disease for which the patient declined aggressive treatment or that
        is unsuitable for aggressive curative treatment due to at least one of the following:
        Performance status of ECOG 2 or 3 Otherwise unexplained weight loss greater than 10% in the
        last 6 months Bulky disease that cannot be irradiated safely to high doses Inability to
        tolerate chemotherapy Cytologically positive pleural effusion OR Clinically or
        radiologically proven metastatic disease for which palliative chemotherapy is not planned
        in the first 38 days after radiotherapy No more than one brain metastasis allowed One of
        the following symptoms identified as the index symptom: Loss of appetite Nausea Vomiting
        Cough Coughing up blood Chest pain Shortness of breath Difficulty swallowing Fatigue Must
        have symptoms related to intrathoracic lung cancer that are amenable to radiation
        palliation

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-3 Life expectancy:
        Greater than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: Fluent in English or French No loss of sight or other inability to
        complete questionnaires or diary Not pregnant No concurrent terminal illness No other
        active malignancy that is causing symptoms or is expected to progress in the next 3 months

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 30 days
        since prior chemotherapy and failed No planned chemotherapy within 38 days after study
        treatment Endocrine therapy: Not specified Radiotherapy: No planned laser therapy within 38
        days after study treatment Surgery: At least 30 days since prior surgery and failed Other:
        No planned photodynamic therapy or sclerotherapy within 38 days after study treatment",Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer,0
"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Cystic fibrosis (CF), i.e.: Sweat chloride greater than 60
        mEq/L Clinical manifestations of CF Homozygous delta F508 mutation preferred Compound
        heterozygotes for F508 mutation with pancreatic insufficiency eligible FEV1 greater than
        40% of predicted PO2 at least 60 mm Hg on room air No acute or recurrent sinusitis No
        obstructive nasal polyposis No pneumothorax or hemoptysis, e.g., more than 250 mL blood
        within 24-hour period, within past year No unstable lung disease with worsening pulmonary
        symptoms, arterial blood gas, or pulmonary function tests within 2 weeks prior to entry No
        pulmonary exacerbation within 4 weeks prior to entry --Prior/Concurrent Therapy-- At least
        2 months since participation in any other clinical study At least 2 months since DNase At
        least 4 months since corticosteroids --Patient Characteristics-- Cardiac: No severe cardiac
        disease Other: No other severe organ system disease, e.g., juvenile-type diabetes mellitus
        No pregnant women",Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis,0
"The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","INCLUSION CRITERIA

        Age 18 years or above, male or female.

        Known presence of HBsAg in serum for at least 6 months.

        Liver biopsy histology showing chronic hepatitis with or without cirrhosis.

        Previous therapy with alpha interferon without a lasting effect or intolerance to alpha
        interferon, due to side effects.

        Written informed consent.

        Group A: For patients with chronic hepatitis B with atypical serology: absence of HBeAg
        from serum despite elevations in serum aminotransferases, such as that the average levels
        are greater than 55 U/L (approximately 1.3 times the upper limit of the normal range) based
        upon two determinations taken at least one month apart during the 6 months before entry.

        Group B: For patients with glomerulonephritis: proteinuria of greater than 1 gm per 24
        hours. For patients with polyarteritis, radiological proof of arteritis and involvement of
        at least on organ system outside of the liver.

        Group C: For patients with chronic delta hepatitis: anti-HDV in serum and HDV antigen in
        liver biopsy or HDV RNA in serum and elevations in serum aminotransferases, such that the
        average levels are greater than 55 U/L based upon two determinations taken at least one
        month apart during the 6 months before entry.

        Group D: For patients with chronic hepatitis B and typical serology: HBeAg and HBV DNA in
        serum but ineligibility to enter the multicenter trial of lamivudine either because of
        previous receipt of interferon and intolerable side effects, refusal to receive interferon
        again, because of normal serum aminotransferases, or lack of availability of the trial.

        EXCLUSION CRITERIA

        Pregnant or if capable of bearing or fathering children must practice adequate
        contraception.

        Significant systemic illnesses other than liver diseases, including congestive heart
        failure, renal failure, chronic pancreatitis, diabetes mellitus with poor control.

        Pre-existing bone marrow compromise: hematocrit must be greater than 30%, white blood cell
        count must be greater than 2000 mm(3), platelets must be greater than 70,000 mm(3).

        Creatinine clearance must be greater than 50 cc/min.

        A history of clinically apparent pancreatitis or evidence of subclinically pancreatitis as
        shown by serum amylase values twice the upper limits of the normal range and abnormalities
        of the pancreas on computerized tomography or other imaging studies of the abdomen.

        Irreversibly severe cirrhosis as defined by Child's stage C.

        Presence of anti-HIV or anti-HCV with HCV RNA in serum.

        Immunosuppressive therapy requiring use of more than 10 mg of prednisone (or its
        equivalent) per day.

        Other antiviral therapy for chronic hepatitis B within the previous 3 months.

        Sensory or motor neuropathy apparent from medical history and physical examination.",Lamivudine for Chronic Hepatitis B,1
"The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","INCLUSION CRITERIA:

        Age above 18 years, male or female.

        Serum alanine or asparate aminotransferase activities that are above the upper limit of
        normal (ALT greater than 41 or AST greater than 31 U/L) on an average of three
        determinations taken during the previous 6 months. The mean of the three determinations
        will be defined as ""baseline"" levels.

        Presence of anti-HCV and HCV RNA in serum tested at least once during the previous six
        months.

        Evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a
        histology activity index of at least 6 (out of a maximum of 22).

        Written informed consent.

        EXCLUSION CRITERIA:

        If previously treated with interferon or ribavirin, must not have a lack of sustained
        virological response as shown by the presence of HCV RNA in serum six months after stopping
        therapy. Patients must not have received the combination of alpha interferon and ribavirin
        in the past.

        Decompensated liver disease, as marked by bilirubin greater than 4 mg%, albumin less than
        3.0 gm%, prothrombin time greater than 2 sec prolonged, or history of bleeding esophageal
        varices, ascites or hepatic encephalopathy. Patients with ALT levels greater than 1000 U/L
        (greater than 25 times ULN) will not be enrolled but may be followed until three
        determinations are below this level.

        Pregnancy or, in women of child-bearing potential or spouses of such women, inability to
        practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or
        use of condoms and spermacide, or birth control pills, or an intrauterine device.

        Significant systemic or major illnesses other than liver disease, including congestive
        heart failure, renal failure (creatinine clearance less than 50 ml/min), organ
        transplantation, serious psychiatric disease or depression, and angina pectoris.

        Pre-existing anemia (hematocrit less than 36% for men and less than 34% for women) or known
        history of hemolytic anemia.

        Antiviral or immunosuppressive therapy within the last 6 months.

        Evidence of another form of liver disease in addition to viral hepatitis (e.g., autoimmune
        liver disease, Wilson's disease, alcoholic liver disease, hemochromatosis,
        alpha-1-antitrypsin deficiency).

        Any evidence of coronary artery disease or cerebral vascular disease, including
        abnormalities on exercise stress testing in patients with defined risk factors who will be
        screened for evidence of underlying coronary artery disease.

        Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one
        year.

        Evidence of hepatocellular carcinoma; either alphafetoprotein (AFP) levels greater than 50
        ng/ml (normal is less than 9 ng/ml) and /or ultrasound (or other imaging study)
        demonstrating a mass suggestive of liver cancer.

        Clinical gout.",Combination Drug Therapy for Patients With Hepatitis C,1
"The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","Patients with chronic hepatitis C.

        Age 18 to 70 years, male or female.

        HCV infection indicated by the presence of anti-HCV (by ELISA and recombinant immunoblot
        assay [RIBA]).

        Written informed consent.

        Women must not be pregnant.

        Patients must not have significant systemic illnesses other than liver disease, including
        congestive heart failure, renal failure, uncontrolled diabetes mellitus.

        Patients must not have antiviral or immunosuppressive therapy within the last 6 months.

        Patients must not have HIV infection.

        Patients must not have contraindications to liver biopsy (mainly clotting abnormality
        (coumadin therapy, platelet count less than 50,000/cubic millimeter, prothrombin time more
        than 4 seconds beyond control)).",History of Hepatitis C in Volunteer Blood Donors,2
"The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Pathologically confirmed primary sclerosing cholangitis (PSC) meeting the following
        criteria:

          -  Chronic cholestatic disease for at least 6 months

          -  Liver biopsy within the past 6 months compatible with the diagnosis of PSC Intra
             and/or extrahepatic biliary duct obstruction, beading, or narrowing

        OR

        Pathologically confirmed primary biliary cirrhosis (PBC) that is experiencing suboptimal
        response to ursodeoxycholic acid and meeting the following criteria:

          -  Chronic cholestatic liver disease for at least 6 months

          -  Positive antimitochondrial antibody

          -  No biliary obstruction by ultrasound, CT, or cholangiography

          -  Prior liver biopsy compatible with diagnosis of PBC

          -  Received ursodeoxycholic acid for at least 6 months

        --Prior/Concurrent Therapy--

        Biologic therapy:

          -  At least 3 months since prior D-penicillamine

          -  No planned transplantation for at least 1 year

        Chemotherapy:

          -  At least 3 months (6 months for PBC) since prior cyclosporin, colchicine,
             azathioprine, or methotrexate

          -  At least 6 months since prior chlorambucil (PBC only)

        Endocrine therapy: At least 3 months (6 months for PBC) since prior corticosteroids

        Surgery: No prior intraductal stones or operations on the biliary tree except
        cholecystectomy (PSC only)

        Other:

          -  At least 3 months since prior pentoxifylline, ursodeoxycholic acid, or nicotine (PSC
             only)

          -  At least 6 months since prior chenodeoxycholic acid (PBC only)

        --Patient Characteristics--

        Life expectancy: At least 3 years

        Hematopoietic: Not specified

        Hepatic:

          -  Alkaline phosphatase at least 2 times upper limits of normal

          -  No chronic hepatitis B infection

          -  No hepatitis C infection

          -  No autoimmune hepatitis

          -  Bilirubin no greater than 4 mg/dL (PBC only)

        Cardiovascular: No severe cardiopulmonary disease

        Other:

          -  No concurrent advanced malignancy

          -  At least 3 months since prior inflammatory bowel disease requiring specific treatment
             except maintenance therapy (PSC only)

          -  No anticipated need for transplantation within 1 year

          -  Not pregnant

          -  No liver disease of other etiology such as:

        Chronic alcoholic liver disease

        Hemochromatosis

        Wilson's disease

        Congenital biliary disease

        Cholangiocarcinoma

        No recurrent ascending cholangitis requiring hospitalization more than 2 times per year
        (PSC only)

        At least 1 year since prior active peptic ulcer

        No recurrent variceal bleeds

        No spontaneous encephalopathy

        No diuretic-resistant ascites",Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis,0
"The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.",Persistent infection with mild hepatitis that is non-progressive.,Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies,2
"The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.","-  INCLUSION CRITERIA:

        Patients who have recovered from past HCV exposure (positive anti-HCV but negative HCV
        viremia and absent liver disease).

        Patients with asymptomatic HCV infection (positive anti-HCV and HCV viremia, but
        persistently normal or minimally elevated ALT and normal or mild disease on liver biopsy).

        Patients with active liver disease (positive anti-HCV and HCV viremia, persistently
        elevated ALT and/or moderate disease on liver biopsy).

        Patients with active extrahepatic manifestations of HCV infection (cryoglobulinemia,
        glomerulonephritis, vasculitis, etc.).

        Patients with rapidly progressive, severe liver disease and/or hepatocellular carcinoma.

        Patients who have undergone or are undergoing treatment.

        Patients from a single-source outbreak of HCV infections (in which the viral factors should
        be identical and the patients are often from a homogeneous population with less genetic
        variability).

        HCV infected family members and twins.

        Patients with other forms of liver disease including HBV infection, primary biliary
        cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, hemochromatosis, and
        Wilson's Disease, as well as normal volunteers.

        EXCLUSION CRITERIA:

        Adult subjects with a Hct of less than 30 or pediatric subjects less than 25 will be
        excluded.

        Children with HCV infection younger than 2 years of age will be excluded.

        Unaffected healthy volunteers who are minors are not eligible for this study.",Genetics of Hepatitis C Virus Infection,1
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl","Men with with LDL-cholesterol of 125-189 mg/dL and HDL-cholesterol below or equal to 44
        mg/dL, and postmenopausal women, age 45 to 64, with LDL-cholesterol of 125 to 209 mg/dL and
        HDL-cholesterol below or equal to 59 mg/dL.",Diet and Exercise for Elevated Risk (DEER),1
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl","INCLUSION CRITERIA:

        Patients must have a histologic diagnosis of carcinoma of the prostate and must not have
        had a trial of hormonal therapy or chemotherapy.

        Patients must be 18 years of age and an SGOT/SGPT within 2 times of normal.

        Patients must have stage D2 prostate carcinoma or State D1 disease with a Gleason grade 7
        or above (poorly differentiated).

        No other malignancy except curatively treated basal cell cancer of the skin.

        Performance status ECOG of 0-3.

        Ability to give informed consent.

        No history of bleeding diathesis. Patients with a history of peptic ulcer disease will be
        eligible if the ulcer is shown to be resolved by a barium study.

        No history of cerebrovascular event, either thrombotic or hemorrhagic.

        No current clinical signs of congestive heart failure, angina pectoris or myocardial
        infarction. Patient cannot be on calcium channel blockers such as Nifedipine, Diltiazem, or
        Verapamil.

        No clinical or radiographic evidence of brain metastases.

        Patients with extensive liver replacement (greater than 50%) by tumor will be ineligible.

        Patients must have a creatinine lest than or equal 2.5 mg/dl or creatinine clearance of
        greater than or equal to 40 ml/min.

        Patients must have adequate hepatic function (bilirubin less than 1.5mg%).

        If the patient has white cells in his urinalysis or other evidence of a urinary tract
        infection, this must be evaluated and appropriate therapy initiation prior to the
        initiation of therapy.

        Patients must not have received chemotherapy.

        An absolute granulocyte count greater than 1,500; platelet count greater than 100,000;
        Fibrinogen greater than 200 mg/dl; Hgb greater than or equal to 9 gm/dl.

        Reliability of the patient to take oral medication, go home and return for follow-up and
        treatment.",A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma,0
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl","Left ventricular ejection fraction by radionuclide angiography of less than or equal to
        40%.

        New York Heart Association class II, III or IV symptoms on standard heart failure
        medications which my include digoxin, diuretics and angiotensin converting enzyme
        inhibitors for at least one month prior to enrollment.

        Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major
        vessel.

        Dilated cardiomyopathy-if no coronary disease.

        No pregnant or lactating women.

        No women of child-bearing age not on proven birth control.

        No severe hepatic or renal disease.

        No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl.

        No primary valvular heart disease.

        No PTCA or CABG within 3 months of enrollment.

        No history of myocardial infarction or unstable angina within past 2 months.

        No resting heart rate less than 60 bpm.

        No A-V block greater than 1 degree block without pacemaker.

        No severe ETOH abuse within 6 months of enrollment.

        No severe bronchospasm.",PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers,1
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl","INCLUSION CRITERIA

        HCM of either gender, aged 20-55 years.

        Non-dilated LV (LVIDd less than 60 mm) with LV wall thickness of greater than or equal to
        16 mm measured in any LV segment by NMR.

        Non-obstructive HCM: A LV outflow gradient of less than or equal to 30 mm Hg gradient at
        rest and less than or equal to 55 mm Hg following isoproterenol infusion to a heart rate of
        greater than or equal to 120 beats per minute at cardiac catheterization.

        New York Heart Association functional class I-III.

        Patients who have participated in the previous toxicity study may be recruited for this
        study, if they wish.

        Patients who have previously taken an ACE inhibitor or losartan could only be included in
        this study, if they have been off these drugs for a period of 6 months or longer.

        EXCLUSION CRITERIA

        Severe cardiac symptoms at rest (NYHA IV).

        LV outflow tract gradient of greater than 30 mm Hg at rest or greater than 55 mm Hg
        following isoproterenol infusion to a heart rate of greater than or equal to 120 beats per
        minute at cardiac catheterization.

        Systemic diseases (respiratory, neurologic, or locomotor) that prevent exercise testing,
        echocardiography or NMR, MUGA, thallium studies, and cardiac catheterization.

        Coronary artery disease (greater than 50% arterial luminal narrowing of a major epicardial
        vessel) or congenital cardiovascular abnormalities (e.g. ASD, VSD, coronary anomalies).

        Chronic atrial fibrillation.

        Bleeding disorder (PTT greater than 35 sec, pro time greater than 14.7 sec, platelet count
        less than 154 k/mm3).

        Anemia (Hb less than 12.7 g/dl in males and less than 11.0 g/dl in females); renal
        impairment (BUN greater than 22 mg/dl and serum creatinine greater than 1.4 mg/dl); K+ less
        than 3.3 mmol/l or greater than 5.1 mmol/l.

        Hypertension: basal systolic and diastolic pressures of greater than 160 mm Hg or greater
        than 95 mm Hg, respectively on two occasions separated by one hour of rest.

        Hypotension: basal sitting systolic arterial pressure less than 100 mm Hg confirmed 30
        minutes later.

        Must have ability to estimate LV wall thickness.

        Radiographic evidence of overt cardiac failure (pulmonary edema on chest X-ray).

        Negative urine pregnancy test.

        Pregnant or lactating female patients.

        Diminished LV systolic function (resting or exercise LV ejection fractions estimated by
        radionuclide angiography less than 50%).

        Dependence on other cardioactive drugs such as diuretics, verapamil, B-blockers, or
        antiarrhythmic drugs to control symptoms and arrhythmias.

        Negative HIV test.

        Sensitivity to ACE inhibitor e.g. angioedema.

        Must have ability to set up an outpatient monitoring system.",Long Term Effects of Enalapril and Losartan on Genetic Heart Disease,0
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl","INCLUSION CRITERIA

        HCM subjects 5 years or older, with distinct sarcomeric gene mutations and LV wall
        thickness greater than 15 mm in subjects older than 18 years, and greater than 2 SDs in
        subjects 18 years of age or younger, as assessed by MRI.

        Age- and gender-matched blood relatives with sarcomeric gene mutations but without LVH.

        Age- and gender-matched blood relatives without sarcomeric gene mutations.

        EXCLUSION CRITERIA

        History of hypertension (basal systolic and diastolic pressures above 170 mm Hg and 95 mm
        Hg, respectively) or another systemic or cardiac disease that may cause cardiac
        hypertrophy.

        History of recent acute illness or other chronic illness that might affect plasma levels of
        IGF-I and IGFBP3.

        History of thyrotoxicosis, diabetes mellitus or abnormally elevated fasting blood sugar.

        Any conditions which would exclude patients from undergoing MRI scan.",Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts,0
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl",Individuals with cardiomyopathy referred for evaluation to the NIH.,Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease,0
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl","PROTOCOL ENTRY CRITERIA:

          -  Mild cystic fibrosis

          -  Not pregnant or nursing Negative pregnancy test",Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis,0
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl","Inclusion Criteria:

          -  Newly diagnosed type 1 diabetes (within one month of diagnosis).

          -  IDDM patients: Prepubescent, adolescent, or early adult patients.

        Exclusion Criteria:

          -  Patients below the age of 3 or over 25.

          -  Patients will not be eligible if they are on immunosuppressive or immunostimulatory
             medications such as azathioprine, oral nicotinamide, superoxide
             dismutase-desferroxamine, vitamin E, aminoguanidine, oral insulin or other
             experimental therapies at any time.

          -  Patients with a history of alcoholism, renal, cardiac, or pulmonary disease or in whom
             intellectual functioning is impaired sufficiently to interfere with the understanding
             of the protocol, or participation in the treatment and evaluation program

          -  Patients who are pregnant or nursing, or those who are not willing to practice an
             acceptable birth control method

          -  Patients with abnormal pre-treatment values on WBC or who are receiving potentially
             hepatotoxic medications","Ingested Interferon Alpha: Prolongation or Permanence of the ""Honeymoon"" Phase in Newly Diagnosed Type 1 Diabetes Mellitus",0
"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:
FBS: 100 mg/dl
HbA1c: 6.5%
Cholesterol: 190 mg/dl
TG: 140 mg/dl
LDL: 125 mg/dl
HDL: 40 mg/dl",No eligibility criteria,Coronary Artery Calcification in Type 1 Diabetes,2
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Inclusion Criteria:

          -  Healthy women

          -  No previous history of cardiovascular disease or cancer

          -  No contraindications to aspirin or vitamin E",Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","-  INCLUSION CRITERIA:

        The categories of subjects eligible to participate in this study include:

          1. Patients with known or suspected thyroid abnormalities (e.g. hypothyroidism,
             hyperthyroidism, extreme iodine deficiency, and inherited forms of hypothyroidism
             resulting from abnormalities in the expression of genes coding for the TSH- beta
             subunit, Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS.

          2. Patients with thyroid function test (TFT) abnormalities due to:

               -  Non-thyroidal illness

               -  Abnormalities of serum TH binding proteins leading to euthyroid hyperthyroxinemia
                  or hypotriiodothyronemia.

               -  Genetic deficiency of thyroxine-binding globulin (TBG).

               -  Antibodies to mouse immunoglobulins leading to an artifactual elevation in the
                  TSH ultrasensitive (""3rd generation"") assay which may mimic ""inappropriate""
                  secretion of TSH.

        Inclusion and exclusion criteria for each group of subjects are given below.

        Patients with known or suspected thyroid abnormalities will be eligible to p rticipate if
        the individual meets all of the following criteria:

          1. Stated willingness to comply with all study procedures and availability for the
             duration of the study.

          2. Male or female, aged 6 months+.

        Hyperthyroid states include but are not restricted to:

          1. Graves' disease (GD) thought to result from thyroid-stimulating immunoglobulins
             (TSIg's), a subclass of which also stimulate eye muscle and fatty tissue producing
             exophthalmos (Graves' ophthalmopathy), as well as the skin in the pretibial area
             causing pretibial myxedema (Graves' dermopathy);

          2. Subacute thyroiditis (SAT), a painful inflammation thought to result from viral
             infection with Coxsackie, as well as other viruses;

          3. Silent thyroiditis, a painless inflammation thought to result from autoimmune attack
             of thyrocytes by antimicrosomal antibodies directed against thyroid peroxidase (TPO),
             as well as antithyroglobulin(anti-Tg) antibodies;

          4. Single or multiple hyperfunctioning thyroid nodules of unknown etiology, probably
             resulting from the activation of certain thyroid oncogenes and/or growth factors, such
             as the thyrotropin (TSH) receptor (TSHR) and the a-subunit of the G protein (Ga);

          5. Iodide-induced hyperthyroidism of unknown etiology;

          6. Surreptitious administration of thyroid hormone (TH), usually present in patients with
             underlying psychiatric disease or occasionally related to patients with obesity and
             other eating disorders

          7. Trophoblastic neoplasms, thought to result from high levels of hCG secretion, which,
             because of its structural similarity to TSH, causes ""spillover"" of action at the TSHR
             level;

          8. ""Inappropriate"" secretion of TSH, which may be present either in patients with TSH-
             producing pituitary tumors (TSHomas) or from a non-neoplastic cause, i.e. pituitary
             resistance to the action of thyroid hormone (3,4).

        Hypothyroid states include but are not restricted to:

          1. Primary (or thyroidal) hypothyroidism, usually resulting from auto-antibodies to
             thyroid proteins, such as antimicrosomal antibodies to TPO usually associated with
             lymphocytic (Hashimoto's) thyroiditis (HT) or atrophic thyroiditis, or blocking
             antibodies to the TSHR, usually in the context of non-goitrous hypothyroidism;

          2. Secondary (or pituitary) hypothyroidism, usually resulting from tumors of the
             pituitary of non-thyrotropic origin such, as growth hormone (GH)-secreting tumors or
             prolactinomas;

          3. Tertiary (or hypothalamic) hypothyroidism, usually resulting from a deficiency in the
             hypothalamic hormone thyrotropin-releasing hormone (TRH), either of unknown etiology
             or secondary to a pituitary tumor;

          4. Bio-inactive TSH, either relating to an endogenous abnormality of hypothalamic
             hormones or secondary to pituitary tumors (and usually related to abnormal
             glycosylation patterns of the TSH molecule);

          5. Generalized resistance to thyroid hormone (RTH), a disease which has been shown to be
             due to abnormalities in the TH receptor, c-erbA-beta (or TR- beta).

        The above are the principal disorders under study, but we may also investigate other
        abnormalities, such as extreme iodine deficiency, and inherited forms of hypothyroidism
        resulting from abnormalities in the expression of genes coding for the TSH- beta subunit,
        Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS (among others).

        EXCLUSION CRITERIA:

        There are no exclusion criteria for subjects with known or suspected thyroid abnormalities.",Evaluation of Patients With Thyroid Disorders,2
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","INCLUSION CRITERIA:

        Selected patients should have PM, IBM or DM.

        Specifically they should have a) proximal muscle weakness; b) no evidence of clinical,
        histological or family history of another neuromuscular illness; c) elevation of muscle
        enzymes during the course of the disease; d) typical skin rash in case of DM; and e)
        diagnostic muscle biopsy.

        Suitable candidates for IVIg should be patients with active, bonefide disease who:

          1. have been treated with steroids but had: a) no response or incomplete response (as
             defined by continued muscle weakness) to high-dose therapy or b) a good response to
             steroids but inability to taper the dose without a flare of disease activity or c)
             unacceptable steroid side effects such as gastrointestinal hemorrhages, osteonecrosis,
             hyperglycemia, extreme weight gain etc., and

          2. have been treated with one immunosuppressive drug (such as azathioprine, Methotrexate,
             Cyclophosphamide, Cyclosporine) but without benefit or with unacceptable side effects.

        EXCLUSION CRITERIA:

        Pregnant or nursing women (confirmed by a screening pregnancy test).

        Critically ill patients such as those requiring intravenous pressors for maintenance of
        cardiac output due to severe cardiomyopathy, patients with respiratory insufficiency and
        patients with severe muscle weakness requiring help for basic self care.

        Children below age 18.

        Patients with severe renal or hepatic disease, severe COPD or coronary artery disease or
        other systemic medical problems often seen when PM or DM is associated with severe cases of
        lupus, rheumatoid arthritis or scleroderma.

        Patients with known allergic reaction to IVIg.

        Serum IgA less than 11mg/dl.",Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","The patient must fall into one of the following diagnostic categories:

        Ewing's sarcoma family of tumors (ESF): Includes Ewing's sarcoma (classic, atypical,
        extra-osseous), primitive sarcoma of bone, ectomesenchymoma, or peripheral primitive
        neuroectodermal tumor (peripheral neuroepithelioma).

        Rhabdomyosarcoma: The patient must have either

        High-risk arm: Metastatic disease at diagnosis (any site, any histology);

        OR

        Moderate-risk arm: Incompletely resected ( Clinical Group III) Stage II tumors and ALL
        stage III tumors (regardless of degree of surgical resection).

        Neuroblastoma: Any patient with metastatic disease at diagnosis (POG stage D or Evans'
        stage IV); or, patients with loco-regional metastatic disease (POG stage C) or tumor
        infiltrating across the midline (Evans' stage III) IF they have an elevated serum ferritin
        (greater than 142 ng/ml), an amplified N-myc copy number (greater than 10 copies on
        Southern analysis), or a DNA index of greater than 1.1.

        The patient must not have been previously treated with chemotherapy or radiation therapy.

        Patients must be greater than or equal to 1 year of age but less than or equal to 25 years
        of age. Patients weight must be greater than or equal to 15 kg.

        The patient (or his/her guardian if less than 18 years of age) must sign a document
        indicating that he/she is aware of the investigational nature of this treatment protocol
        and the potential risks and benefits that may be expected.

        Potentially fertile female patients must have a documented negative urine or serum
        pregnancy test.

        Patients must have a documented negative HIV serologic evaluation (Western Blot and/or
        ELISA).

        Patients must not have abnormal cardiac function (left ventricular ejection fraction less
        than 45% as measured by gated equilibrium radionuclide angiography [MUGA scan] and
        confirmed by echocardiography).

        Patients must not have impaired renal function (serum creatinine greater than or equal to
        twice the upper limit of normal for age).

        Patients with a total bilirubin of greater than 4.0 mg/dl (or a direct bilirubin of greater
        than 2.0 mg/dl) or SGOT/SGPT greater than five times the upper limits of normal (NOT on the
        basis of hepatic involvement by tumor) will be excluded.

        Patients with a second malignancy following previous therapy will be excluded.

        Patients previously treated with chemotherapy or radiation therapy (other than limited,
        emergency radiation therapy) will be excluded.

        Patients who are HIV-infected will be excluced.","New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma",0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Children between the ages of 3 months and 18 years.

        Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC)
        Definition. Children and adolescents with vertically, transfusion or sexually acquired
        HIV-1 infection are eligible.

        Availability of a parent or guardian to provide Informed Consent.

        ARM A:

        Children and adolescents with vertically, transfusion or sexually acquired HIV-1 infection.

        No or moderate immune suppression at the time of study entry as defined by the CDC
        Classification System, Immune Categories 1 and 2.

        No history of or indication for antiretroviral intervention at time of enrollment or not
        receiving antiretroviral treatment because: (a) the patient has elected to decline
        treatment or (b) in the opinion of the patient's health care provider, antiretroviral
        treatment is not currently recommended because of the patient's inability to adhere to
        therapy, promoting the development of viral resistance.

        Children younger than 24 months of age must not have had plasma HIV-1 RNA levels greater
        than 8 X 10(4) copies/ml previously and at the time of initial evaluation, confirmed at
        least at two different time points 2 to 4 weeks apart, showing no sign of increase
        (increment less than 0.5 log(10). If the child has had plasma HIV-1 RNA levels greater than
        8 X 10(4) copies/ml at some point prior to the initial evaluation, he/she will have to be
        placed on antiretroviral treatment and must meet all the criteria for Arm B.

        ARM B:

        Children and adolescents with vertically, transfusion, or sexually acquired HIV-1
        infection, who are on or have received antiretroviral treatment of longer than 7 weeks.

        No or moderate immune suppression at the time of study entry as defined by CDC
        Classification System, Immune Categories 1 and 2.

        Children younger than 24 months or age, who meet all the inclusion criteria for army B must
        have plasma HIV-1 RNA levels less than 5 X 10(4) copies/ml while receiving optimal
        antiretroviral therapy, confirmed at least two different time points 2 to 4 weeks apart,
        showing no sign of increase (increment less than 0.5 log(10). If the child has been
        previously treated with antiretroviral drugs for more than 7 weeks (therefore not eligible
        for arm A) and is currently off drugs, he/she will have to be placed on optimal
        antiretroviral agents and will have to maintain viral RNA levels below 5 X 10(4) copies/ml
        prior to the entry.

        Each child enrolled in arm B has to be on constant regimen of antiretroviral treatment for
        at least 6 weeks-prior to the first inoculation. Children in immune categories 1 and 2 at
        the time of study entry will be allowed to enroll.

        Not critically ill or clinically unstable or no presence of active infection requiring
        on-going (or induction) therapy.

        No evidence of severe immune suppression at the time of study entry as defined by CDC
        classification system, Immune Category 3.

        For children younger than 24 months of age, no plasma HIV-1 RNA levels greater than or
        equal to 5 x 10(4) copies/ml despite appropriate antiretroviral treatment, confirmed at
        least at two different time points 2 to 4 weeks apart.

        No use of tube feeding or intravenous hyperalimentation itself will be allowed as long as
        it is a stable regimen.

        No administration of chemotherapeutic agents, or use of immunomodulating agents such as
        corticosteroids, interferons, G-CSF, EPO, growth hormone (GH) or IVIG within one month of
        enrollment.

        No abnormalities of laboratory findings within one month of enrollment including the
        following: SGPT or SGOT greater than 5 times the normal value; Total bilirubin greater than
        3 times normal; BUN or creatinine greater than 2 times normal; Total WBC greater than
        150/mm(3) or ANC greater than 750/mm(3); Hemoglobin greater than 8.0 g/dl (transfusions are
        allowed); Platelet count greater than 100,000/mm(3).

        Not pregnant or not planning to become pregnant.

        No active substance abuse.

        Able to comply with the study requirements for scheduled evaluations such as periodic
        clinic visits or blood sampling.",Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","-  INCLUSION CRITERIA:

        Volunteers will qualify for inclusion under this protocol if they meet the following
        criteria:

          1. Good general health. Individuals with renal, hepatic, most endocrinologic (e.g.
             hypothyroidism, or Cushing syndrome), or pulmonary disorders (other than mild asthma
             not requiring chronic medication) will be excluded.

          2. For obese subjects, body mass index for age above the 85th percentile (determined by
             NHANES I age-, sex-, and race-special data). For normal weight subjects of obese
             parents, body mass index (determined by NHANES I age-, sex-, and race- specific data)
             between the 5th and 85th percentile and both parents' current body mass index above 25
             kg/m(2), or a history of a body mass index above 25 kg/m(2).

          3. No significant psychiatric illness.

          4. At initial visit, Tanner I (prepubertal) or Tanner II (early pubertal) pubic hair and
             breast stage of development for girls, and Tanner I or Tanner II pubic hair and testes
             size (6ml) for boys.

          5. Subjects must be able to undergo MRI. Volunteers with metal in their bodies that are
             contraindications for MRI will be excluded. These include cardiac pacemakers, neural
             pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants,
             non-detachable electronic or electromechanical devices (such as infusion pumps, nerve
             stimulators, bone growth stimulators, etc.).

          6. Age 6 to12 years at the start of the study.

          7. For girls who have been followed to an age when they are menstruating (or are of an
             age when pregnancy is a possibility), a negative pregnancy test.

          8. Race of all 4 grandparents self-identified either as all Caucasian or all African
             American.",Metabolic Differences of Overweight Children and Children of Overweight Parents,1
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Depressed patients must have a history of past major depression of at least four months
        duration, or a history of two or more briefer episodes. Must be overweight.

        Must not need a hospital admission as part of their treatment.

        Overweight normal volunteers.

        No subjects on chronic medication which cannot be washed out for one month.

        No subjects with any serious medical illness.

        No women who are pregnant, trying to become pregnant, or sexually active and not using
        effective contraception.

        No patients with HIV infection.

        No subjects who cannot discontinue use of alcohol/tobacco.",Dynamics of Leptin and Endocrine Function,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Patients must be 18 years of age or older and able to provide informed consent.

        Patients must have at least 4 criteria for SLE as defined by the American Rheumatism
        Association (ARA).

        Active glomerulonephritis with:

        Renal biopsy within 1 year with class III or class IV active lupus nephritis, AND;

        Abnormal urine analysis:

        Greater than 10 RBC/hpf and cellular (RBC, WBC or mixed) casts, OR;

        Greater than 10 RBC/hpf and proteinuria greater than 2 g/day, OR;

        Proteinuria greater than 3.5 g/day.

        No patients with severe proliferative lupus nephritis: a. very active renal histology with
        crescents or necrosis in more than 25% of glomeruli; or b. rapidly progressive
        glomerulonephritis (doubling of serum creatinine in less than or equal to 3 months); or c.
        severe impairment of renal function Cr greater than 2.5 mg/dL or GFR less than 50 mL/min
        measured by inulin clearance.

        Patient has not had previous immunosuppressive therapy:

        Patients must not be receiving azathioprine, cyclosporine, methotrexate. Patients receiving
        these drugs will be eligible only if these drugs are discontinued and after a waiting
        period of greater than or equal to 4 weeks;

        Patients must not be receiving cyclophosphamide:

        Greater than 3 pulses (maximum 1 g/m(2)/pulse) within the last 12 months or since last
        renal biopsy showing active disease; OR

        greater than 6 pulses ever.

        Patients must not have had pulse therapy with glucocorticoids or any experimental therapy
        during the 4 weeks before study entry.

        Patients who need at study entry oral corticosteroids in dosages greater than 0.5 mg/kg/day
        of predisone to control extrarenal disease are not eligible.

        Patients with active or chronic infection are not eligible.

        Patients who are pregnant, breast-feeding or using inadequate birth control are not
        eligible.

        Patients who have poorly controlled diabetes mellitus or with evidence of end-organ damage
        are not eligible.

        No history of cerebrovascular accident, seizures within the last 5 years or chronic
        neurologic disease.

        No history of malignancy other than squamous cell and/or basal carcinoma of the skin.

        No confounding medical illness that in the judgment of investigators would pose added risk
        for study participants such as:

        Unstable coronary artery disease, cardiomyopathy or dysrhythmia requiring therapy;

        Pulmonary disease (PFTs less 70% of predicted value or DLCO less than 60%), or;

        Hematologic disease (Hb less than 8 mg/dL, platelets less than 100,000 micro liters or WBC
        less than 2,500/micro liters.",Cyclophosphamide and Fludarabine to Treat Lupus Nephritis,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Patients greater than or equal to 18 years of age, with well-differentiated, non-medullary
        thyroid cancer, including papillary (including follicular-variant), follicular, and Hurthle
        cell.

        Patients who recently have undergone a total or near-total thyroidectomy and are scheduled
        to undergo initial 131I diagnostic studies and ablation.

        Patients must have evidence of residual thyroid tissue after thyroid surgery confirmed by
        ultrasound or other imaging technique (e.g., a technetium [Tc 99] pertechnetate or thallium
        scan).

        Patients who have undergone thyroidectomy or other thyroid surgery at least 6 weeks prior
        to enrollment.

        All patients who have been sustained on maintenance THST for at least 4 weeks, but not
        longer than 12 weeks after thyroidectomy.

        All patients who have confirmed serum TSH levels less than or equal to 0.5 mU per liter
        within 7 days prior to the first Thyrogen dose, and prior to randomization.

        Female patients of childbearing age must have a negative serum human chorionic gonadotropin
        (HCG) pregnancy test prior to entering the study and within 5 days of any 131I
        administration and must be following an approved method of contraception.

        Patients who are committed to following the protocol requirements as evidenced by providing
        written informed consent.

        Patients for whom a 131I scan is currently contraindicated because withdrawal from THST is
        not an option due to pituitary dysfunction or other compelling medical reasons are
        excluded.

        Patients should not have a concurrent major medical disorder (e.g., documented cardiac
        disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver
        disease or advanced pulmonary disease) who may be too ill to adequately comply with the
        requirements of this study.

        Patients with non-thyroidal conditions known to effect 131I uptake (e.g., congestive heart
        failure, renal failure) are excluded.

        Patients should not have undergone any intravenous water soluble radiographic contrast
        administration within the previous 4 weeks.

        Patients should not have received intrathecal or cholecystographic iodinated contrast agent
        administration within 3 months prior to enrollment.

        Patients should not be taking drugs that affect thyroid or renal function (e.g., renal
        drugs, lithium, or corticosteroids).

        Patients should not be participating in another investigational drug study or in such a
        study within 30 days of their enrollment in this study.

        No patients with a recent history of alcoholism or drug abuse, severe emotional behavioral
        or psychiatric problems who, in the opinion of the investigator, would not be able to
        comply with the requirements of this study.",Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Inclusion Criteria

          -  Clinical diagnosis of VOD defined by:

               -  Jaundice (bilirubin  2 mg/dL) and 2 or more of the following: ascites, weight
                  gain > 5% above baseline weight (see Section 5.2), hepatomegaly, RUQ pain

                    -  Patients with jaundice and reversal of flow on Doppler examination of the
                       portal vein will be eligible with one of the following: ascites, weight gain
                       > 5% above baseline weight, hepatomegaly, RUQ pain

                    -  Patients with pre-existing hepatomegaly must have documentation by physical
                       exam or imaging that liver size is increased over baseline at admission

               -  Patients who do not meet the criteria in Section 3.1.1 (ie. have two of the major
                  criteria but not three) and have biopsy proven VOD are eligible in the presence
                  of characteristics consistent with severe disease (see below).

               -  Patients with concurrent, confounding causes of liver dysfunction clinically
                  evident or evident on ultrasound or other radiographic imaging (such as evidence
                  of biliary ductal dilatation or focal tissue defects) may require biopsy-proven
                  VOD and/or elevated wedged trans-hepatic venous pressure gradient measurement (
                  10 mm mercury) to be considered eligible. Best medical judgment and further
                  imaging studies can be used to clarify the diagnosis and determine confounding
                  causes of liver dysfunction.

          -  Severity of VOD defined by:

               -  For patients addressed by the Bearman model (i.e. within 16 days of SCT and
                  conditioned with either BU/CY, CY/TBI or CBV), there must be a 30% or greater
                  risk of severe VOD (see Appendix B).

               -  For all other patients who are not addressed by the Bearman model (ie. beyond 16
                  days of SCT and/or not conditioned with either BU/CY,

               -  CY/TBI or CBV), there must be concomitant multi-organ failure defined as presence
                  of one or more of the following :

                    -  renal dysfunction: a) creatinine 2x value on the date of admission day to
                       the BMT unit for conditioning or 2x lowest value during conditioning (use
                       the lowest value for calculation), or b) creatinine clearance or GFR 50% of
                       admission value, or c) dialysis dependence""

                    -  pulmonary dysfunction: documentation of oxygenation saturation  90% on room
                       air; requirement for positive pressure/ventilator dependence

                       ----pulmonary dysfunction must not be attributable to another cause (e.g.
                       documented infectious pneumonia)

                    -  central nervous dysfunction: documentation of confusion, lethargy, and/or
                       delirium ---- central nervous dysfunction must not be attributable to
                       another cause (e.g. documented cyclosporin toxicity)

               -  Patients or their parents/guardians or designated proxy must have the ability to
                  give voluntary informed consent to the protocol. Where possible, patient assent
                  will also be obtained

               -  Patients must be  12 hours after cessation of heparin

               -  Patient must have an eligible diagnosis of VOD by Day 35 post transplant

          -  Exclusion Criteria

               -  Patients receiving concomitant heparin or other anticoagulants unless being used
                  for routine CVL management, fibrinolytic instillation for CVL occlusion,
                  intermittent dialysis or ultrafiltration are excluded. Patients who have received
                  systemic t-PA (concomitant or prior) are excluded.

               -  Patients with significant uncontrolled acute bleeding, defined as hemorrhage
                  requiring > 15 cc/kg of packed red blood cells (ie. a pediatric patient weighing
                  20 kg and requiring > 300cc of packed red blood cells /24 hours or an adult
                  patient weighing 70 kg and requiring >3 units of packed red blood cells/24 hours)
                  to replace blood loss are excluded. These parameters must be reviewed prior to
                  enrollment by the PI or his/her designate.

               -  Patients with hemodynamic instability as defined below:

                    -  Hemodynamic stability is defined as having no requirement for pressor
                       support OR being able to maintain mean arterial pressure within 1 SD of
                       age-adjusted levels with pressor support (see Appendix D)

                    -  Patients requiring renal dose dopamine alone (2-5 mcg/kg/min) are eligible
                       without measurement of mean arterial pressure

               -  Patients with Grade B-D GVHD, graded according to the IBMTR Severity Index (see
                  Appendix G). Please note patients with Grade B skin only are eligible.

               -  Patients intubated for documented intrinsic lung disease

                  --- Patients intubated secondary to a mechanical barrier to ventilation,
                  e.g.pulmonary edema or ascites, will be eligible as long as the PaO2/FiO2 ratio
                  is  300 and/or the oxygen index (OI={MAP x FiO2} PaO2 x 100) is  25% at the
                  time of enrollment

               -  Patients who meet Grade IV common toxicity criteria for neurotoxicity (other than
                  Grade IV confusion and/or delirium), i.e. coma, seizures, toxic psychosis

               -  Patients who are currently receiving treatment with another experimental agent.

               -  Please note that an experimental agent in this setting is defined as any drug or
                  device used under an IND designation which is associated with systemic effects
                  that could influence the outcome in a patient with severe VOD. If the continued
                  use of an experimental agent is considered both necessary and appropriate, this
                  must be reviewed and approved on a case by case basis by the Overall Study PI,
                  Dr. Paul Richardson, or his designate, who will approve the entry of patients
                  being concurrently treated with another experimental agent only if there is no
                  evidence for a potential adverse pharmacokinetic interaction or overlapping
                  toxicity.",Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation,0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage I, II, or III primary breast cancer undergoing breast
             surgery

               -  Invasive disease (e.g., lobular or ductal)

               -  No bilateral disease

          -  No distant metastases

          -  Premenopausal

               -  Regular menses (no amenorrhea of more than 90 days) without hormone replacement

               -  Documented last menstrual period

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  Premenopausal

        Sex:

          -  Female

        Menopausal status:

          -  See Disease Characteristics

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No other prior malignancies

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No preoperative chemotherapy

        Endocrine therapy:

          -  No concurrent hormonal replacement therapy

          -  No concurrent interruptive oral contraceptive use of less than 3 months

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics

          -  No prior hysterectomy and/or bilateral oophorectomy","Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer",0
"A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.","Patients must be in good general health. Patients with chronic stable complications of Type
        2 diabetes or stable obesity related comorbid conditions will not be excluded.

        Obesity: Defined as subjects having a body mass index greater than 30 kg/m(2). Weight must
        be less than 300 lb (136 kg) because of limits related to the DXA and CT scanners.

        Patients with Type 2 Diabetes, impaired glucose tolerance, or hyperinsulinemia are
        eligible.

        Patients' age must be greater than or equal to 18 years at the start of the study.

        Patients must be planning to undergo large volume liposuction.

        Premenopausal women participating in the study must have a negative pregnancy test at the
        start of the study and will be required to remain on some form of effective contraception
        for the duration of the study.

        Patients recruited for the pilot study will be required to have all four grandparents and
        both parents to be either all non-Hispanic Caucasians or non-Hispanic African-American.

        Volunteers with the presence of significant, unstable or evolving renal disease are not
        eligible. Subjects must not have calculated (age and weight corrected) creatinine
        clearances below 50 ml/min or significant worsening of serum creatinine levels during the
        course of the study (greater than 30% increase from baseline).

        Volunteers with the presence of significant, unstable or evolving hepatic disease
        associated with SGOT and/or SGPT greater than 2.5 times normal are not eligible.

        Volunteers with the presence of significant, evolving or unstable cardiac disease are not
        eligible. Subjects with NYHA stage 3 or 4 disease will be excluded from the study.

        Volunteers with the presence of significant, evolving or unstable pulmonary disease
        including uncontrolled bronchial asthma and/or chronic bronchitis are not eligible.

        Volunteers with the presence of other uncontrolled or unstable medical conditions including
        uncontrolled thyroid disease, Cushing's syndrome, autoimmune or gastrointestinal disease
        are not eligible.

        Volunteers who are pregnant are not eligible.

        Volunteers must not have uncontrolled Type 2 diabetes as evidenced by recent coma or
        pre-coma states, frequent episodes of hypoglycemia, predominantly severe hyperglycemia
        (plasma glucose greater than 400 mg/dl) in the past three months prior to study
        commencement, a glycosylated hemoglobin (HBA1C) value greater than 10 in the past three
        months prior to the study commencement, and frequent or recurrent episodes of ketosis
        (ketonuria and/or ketonemia).

        Volunteers with uncontrolled, significant or evolving psychiatric/psychological syndromes
        which in the opinion of the investigators would place the patient at increased risk during
        the course of the study or would impede competence and/or ability to complete the study are
        not eligible.

        Volunteers with current history of illicit substance abuse and/or alcoholism based on
        reported history and the CAGE questionnaire are not eligible.

        Volunteers must not have a recent use (within the preceding 6 months) of anorexiant
        medications or medications that would affect nutrient absorption such as orlistat or
        acarbose.

        Volunteers must not be receiving treatment with an insulin-sensitizing medication such as
        metformin or the thiazolidinediones. Use of insulin, meglitides or the sulphonylureas will
        not constitute an exclusion.

        Volunteers with an absence of spontaneous menses for greater than 1 year are not eligible.","Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes",0
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"Inclusion Criteria:

          -  Meets criteria for alcohol dependence and nicotine dependence.

          -  Expresses a desire to cut down or stop drinking and smoking.

        Exclusion Criteria:

          -  Currently meets criteria for dependence on substances other than alcohol and nicotine.

          -  Any history of opiate dependence or evidence of current opiate use.

          -  Significant medical disorders that will increase potential risk or interfere with
             study participation.

          -  Liver function tests more than 3 times normal or elevated bilirubin.

          -  Females who are pregnant, nursing, or not using a reliable method of birth control.

          -  Meets criteria for a major psychiatric disorder and is in need of or currently
             undergoing drug therapy.

          -  Inability to understand and/or comply with the provisions of the protocol and consent
             form.

          -  Treatment with an investigational drug during the previous month.

          -  Chronic treatment with any narcotic-containing medications during the previous month.

          -  Sensitivity to drug as evidenced by adverse drug experiences especially with narcotic-
             containing analgesics or opioid antagonists.

          -  Current treatment with disulfiram (Antabuse) or nicotine replacement therapy.

          -  More than 6 weeks of abstinence.",Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone),0
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"-  INCLUSION CRITERIA:

        Family or personal medical history of neoplasia of an unusual type, pattern, or number.

        Known or suspected factor(s) predisposing to neoplasia, such as environmental exposure
        (particularly immunological or virological), genetic or congenital factors (Mendelian
        traits predisposing to neoplasia, birth defects, and chromosomal anomalies), or unusual
        demographic features.","Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers",0
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"Inclusion Criteria:

          -  Cytologically confirmed atypical glandular cells of undetermined significance (AGUS)

          -  Must be scheduled to undergo complete histologic examination of the cervix by cone
             biopsy using loop electrosurgical excision procedure with an endocervical curettage,
             excisional cone biopsy with or without endocervical curettage, or hysterectomy within
             6 months of the initial cytologic diagnosis of AGUS

          -  No history of endometrial hyperplasia

          -  No history of cancer of the endometrium, vagina, or cervix

          -  HIV negative

          -  No pregnant patients who are at high risk for excessive bleeding or preterm labor if a
             cone biopsy is performed

          -  No prior cytotoxic chemotherapy for vaginal and/or cervical cancer

          -  No prior radiotherapy to the vagina or cervix

          -  No concurrent radiotherapy to the vagina or cervix

          -  No prior hysterectomy",Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer,2
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"DISEASE CHARACTERISTICS: Diagnosis of abnormal Pap test, as indicated by one of the
        following: Atypical squamous cells of undetermined significance (ASCUS) Low grade squamous
        intraepithelial lesion (LGSIL) High grade squamous intraepithelial lesion (HGSIL) Visible
        lesion on cervix by colposcopy

        PATIENT CHARACTERISTICS: Age: Any age Performance status: ECOG 0-4 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:
        Pregnant or nursing women allowed

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: Not specified Radiotherapy: No prior pelvic irradiation Surgery: No
        prior total hysterectomy",Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results,2
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"Inclusion Criteria:

          -  Cervical intraepithelial neoplasia (CIN) grade II or III

          -  No cytologic, colposcopic, or histologic evidence of invasive squamous cell carcinoma

          -  No evidence of glandular atypia on Pap smear, endocervical curettage, or biopsy

          -  No inadequate colposcopy (i.e., entire transformation zone cannot be visualized and/or
             upper limit of a colposcopically abnormal lesion cannot be visualized fully)

          -  HIV positive but not currently on antiviral therapy

          -  Performance status - 0-2

          -  WBC greater than 4,000/mm^3

          -  Absolute neutrophil count greater than 2,000/mm^3

          -  Platelet count normal

          -  Liver enzymes normal

          -  No liver impairment

          -  BUN normal

          -  Creatinine normal

          -  No renal insufficiency

          -  No coronary artery disease

          -  No cardiac arrhythmia

          -  No congestive heart failure

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for at least 1 month
             after study

          -  No other serious medical illness (e.g., non-insulin and insulin-dependent diabetes or
             connective tissue disorders)

          -  No other prior or concurrent malignancy

          -  No known G6PD deficiency

          -  No porphyria

          -  No history of 2 prior ablative/excisional therapies (i.e., cryotherapy, laser
             ablation, loop electrical excision procedure, or cold knife cone biopsy)

          -  No concurrent non-steroidal anti-inflammatory drugs (NSAIDS)

          -  No other concurrent significant medication/therapy such as:

          -  Anti-hypertensives, anti-arrhythmics, or inotropic agents for cardiopulmonary disease

          -  Diuretics for renal insufficiency

          -  Steroids or NSAIDs for connective tissue disorders",Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia,1
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed advanced or metastatic adenocarcinoma

          -  Expression of +1 to 3+ HER2/neu on immunohistochemical or immunocytochemistry staining

          -  No brain metastases unless all of the following is true:

               -  Previously treated

               -  Asymptomatic

               -  Stable dose of decadron

          -  No evidence of edema

        PATIENT CHARACTERISTICS:

          -  Age: 18 and over

          -  Performance status: ECOG 0-2

          -  Life expectancy: At least 12 weeks

          -  Absolute granulocyte count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

          -  Hemoglobin at least 9.0 g/dL

          -  Bilirubin no greater than 1.5 mg/dL

          -  AST/ALT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times
             ULN in case of liver involvement)

          -  Creatinine no greater than 1.5 mg/dL

          -  LVEF at least 50% by RVG or MUGA

          -  No uncontrolled unstable angina

          -  No history of congestive heart failure or cardiac ischemia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No concurrent active infection or serious systemic disorder that would preclude study

          -  No allergies to imidazole compounds

        PRIOR CONCURRENT THERAPY:

          -  No prior trastuzumab (Herceptin) No other concurrent immunotherapy

          -  At least 4 weeks since prior chemotherapy (6 weeks since mitomycin or nitrosoureas)
             and recovered

          -  No other concurrent chemotherapy

          -  No concurrent hormonal cancer therapy except LHRH agonists for prostate cancer

          -  No concurrent radiotherapy

          -  No other concurrent experimental medications",Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer,0
A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.,"Inclusion Criteria

        Women may be eligible for this study if they:

          -  Are HIV-positive.

          -  Are at least 13 years of age and menstruating.

          -  Are willing to enroll in another drug study.

          -  Have written consent of a parent or guardian if under 18 years.

          -  This study has been changed to increase enrollment. Women who are starting HAART-based
             therapy prescribed by a personal physician or participating in an antiretroviral trial
             are all eligible.

          -  Intend to start antiretroviral therapy within 14 days of study entry.

        Exclusion Criteria

        Women will not be eligible for this study if they:

          -  Have been on anti-HIV treatment for more than 14 days.

          -  Are abusing drugs or alcohol.

          -  Are receiving medication that affects the immune system, fights HPV, or is
             investigational, except for anti-HIV drugs provided by coenrolling in a Phase II or
             III trial with approval of a study chair within 30 days of study entry, including but
             not limited to systemic interferons and interleukins, thalidomide, systemic cidofovir,
             and HPV vaccines. This study has been changed. The following medications are no longer
             excluded: thymopentin, hydroxyurea, granulocyte colony-stimulating factor (G-CSF and
             filgrastim), and GM-CSF (sargramostim).

          -  Have cervical cancer or a history of cervical cancer.

          -  Have had a hysterectomy (removal of the uterus).

          -  Participated in HPV trials at any time.

          -  Use imiquimod inside the vagina.

          -  Are taking corticosteroid treatment in large doses.",The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria:

          -  Knee osteoarthritis

          -  Moderate radiographic evidence by Kellgren and Lawrence grade 2-4

          -  Knee pain > 20 on VAS pain scale

        Exclusion Criteria:

          -  Bilateral knee replacements

          -  Unwillingness to take acetaminophen for pain relief",Toward Better Outcomes in Osteoarthritis,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria

        Subjects must have:

          -  Normal history and physical exam.

          -  Negative ELISA for HIV.

          -  Normal cell-mediated immune responses using Merieux skin test.

          -  Normal urinalysis.

        Exclusion Criteria

        Co-existing Condition:

        Subjects with the following conditions are excluded:

          -  Evidence of psychological or psychiatric problems that may lead to noncompliance with
             study requirements.

          -  Positive syphilis serology. If serology is documented as a false positive or is due to
             a remote (> 6 months) treated infection, subject is eligible.

          -  Circulating hepatitis B surface antigen.

        Subjects with the following prior conditions are excluded:

          -  History of immunodeficiency, chronic illness, autoimmune disease, or use of
             immunosuppressive medications.

          -  History of anaphylaxis or other adverse reactions to vaccines.

        Prior Medication:

        Excluded:

          -  Prior HIV vaccines.

          -  Immunoglobulins or vaccines within the past 3 months.

          -  Experimental agents within the past 30 days.

        Prior Treatment:

        Excluded:

          -  Blood transfusions or cryoprecipitates within the past 3 months.

        Identifiable high-risk behavior for HIV infection, including:

          -  Any history of intravenous (IV) drug use within the past year.

          -  Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia
             or pelvic inflammatory disease) in the past 6 months.

          -  More than two sexual partners, or sexual contact with a high-risk partner, in the past
             6 months.","A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months",0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria

        Patients must have:

          -  HIV infection.

          -  Stable weight.

          -  CD4+ cell count <200 cells/mm3.

          -  Life expectancy of at least 6 months.

          -  Parent or legal guardian to sign written, informed consent for patients < 18 years
             old.

        Exclusion Criteria

        Co-existing Condition:

        Patients with any of the following symptoms or conditions are excluded:

          -  Active opportunistic infection, requiring acute treatment.

          -  Malignancy (other than stable cutaneous Kaposi's sarcoma that does not require
             systemic chemotherapy).

          -  Diabetes mellitus or other conditions requiring special dietary restrictions.

          -  Body mass index (BMI) >= 29.0 kg/m2.

          -  Disorders or conditions that, in the treating clinician's opinion, may prevent
             adequate compliance with protocol requirements.

        Concurrent Medication:

        Excluded:

          -  Growth hormone.

          -  Megestrol acetate (Megace).

          -  Cyproheptadine (Periactin).

          -  Dronabinol (Marinol).

          -  Thalidomide.

          -  Anabolic steroids (e.g., nandrolone decanoate)(Deca-durabolin).

          -  Pharmacologic-dose corticosteroids (e.g., > 15 mg/day prednisone equivalent)

        NOTE:

          -  Men requiring testosterone replacement therapy for documented hypogonadism may be
             enrolled.

          -  Caloric nutritional supplements deemed by the clinician to promote weight gain or
             maintenance.

        Patients with the following prior condition are excluded:

          -  History of phenylketonuria.

        Prior Medication:

        Excluded within the past 2 weeks:

          -  Use of caloric nutritional supplements for more than 5 days deemed by the clinician to
             promote weight gain or maintenance.

        Excluded within the past 30 days:

          -  Growth hormone.

          -  Megestrol acetate (Megace).

          -  Cyproheptadine (Periactin).

          -  Dronabinol (Marinol).

          -  Thalidomide.

          -  Anabolic steroids (e.g., nandrolone decanoate)(Deca-durabolin)

          -  Pharmacologic-dose corticosteroids (e.g., > 15 mg/day prednisone equivalent).

        NOTE:

          -  Men requiring testosterone replacement therapy for documented hypogonadism may be
             enrolled.",A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria

        Patients may be eligible for the main study if they:

          -  Became infected with HIV within the last 120 days.

          -  Are at least age 16 and have written consent of a parent or guardian if under 18.

          -  Are willing to practice abstinence or use barrier methods of birth control, such as
             condoms.

          -  Are available for at least 72 weeks.

          -  Patients may be eligible for 1 of the 2 substudies if they:

          -  Are at least age 16 and have written consent of a parent or guardian if under 18.

          -  Have had HIV infection for more than 1 year and have a CD4 cell count greater than 500
             cells/mm3, or do not have HIV infection but are at risk of getting HIV because of
             their lifestyle, such as sexual activity or injection drug use.

          -  Have never had hepatitis B infection or a hepatitis B vaccine and they are available
             for 28 weeks (hepatitis B vaccine substudy only).

          -  Have not received a tetanus shot in the past 5 years, have never had an allergic
             reaction to a tetanus shot, and are available for 8 weeks (tetanus shot substudy
             only).

        Exclusion Criteria

        Patients will not be eligible for the main study if they:

          -  Have taken anti-HIV drugs for more than 7 days for the treatment of HIV. However,
             anti-HIV drugs taken to help prevent HIV are acceptable.

          -  Have certain types of cancer.

          -  Are receiving an experimental treatment.

          -  Are pregnant or breast-feeding.

          -  Are allergic to study drugs.

          -  Have taken certain medications that may interfere with the study.

          -  Patients will not be eligible for 1 of the 2 substudies if they:

          -  Are receiving an experimental treatment.

          -  Are pregnant or breast-feeding.",Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria:

        Your child may be eligible for this study if he/she:

          -  Is between the ages of 18 months and 18 years, with consent of parent or guardian.

          -  Is a resident of the Temple-Belton, Texas area.

        Exclusion Criteria:

        Your child will not be eligible for this study if he/she:

          -  Has had a fever within 3 days before vaccination.

          -  Has symptoms of a weakened immune system.

          -  Has had a wheezing episode within the past 2 weeks.

          -  Has moderate to severe asthma.

          -  Is allergic to eggs.

          -  Needs to take aspirin on a regular basis.

          -  Has received another vaccine or study drug in the past month.",Study of a Flu Vaccine in Children,1
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria

        Your child may be eligible for this study if he/she:

          -  Is 3 months to 16 years old.

          -  Is HIV-positive.

          -  Has never taken protease inhibitors or has previously taken ritonavir (RTV),
             saquinavir (SQV), or indinavir (IDV) and is willing to stop the medication at study
             entry.

          -  Is taking an anti-HIV drug combination that will not change during at least the 2
             weeks prior to study entry.

          -  Agrees to use effective barrier methods of birth control, such as condoms, during the
             study.

          -  Has consent of parent or guardian.

        Exclusion Criteria

        Your child will not be eligible for this study if he/she:

          -  Has ever taken NFV.

          -  Has a history of opportunistic (AIDS-related) infection.

          -  Has any disease or illness that would prevent him/her from completing the study,
             including cancer.

          -  Has taken certain medications, including protease inhibitors at study entry.

          -  Is receiving an HIV vaccine at study entry.

          -  Is pregnant.",Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"DISEASE CHARACTERISTICS: Histologically confirmed stage 0 and I (Ta, T1 or Tis) resected
        transitional cell carcinoma of the bladder No advanced disease or muscle invasion No
        history of transitional cell carcinoma of the prostate

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
        expectancy: Greater than 3 years Hematopoietic: WBC at least 3500/mm3 Platelet count at
        least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 times
        upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN SGOT no
        greater than 3 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: Not
        pregnant or nursing Fertile patients must use effective contraception At least 5 years
        since prior malignancy except nonmetastatic squamous cell or basal cell carcinoma of the
        skin No history of drug interactions which could affect therapy No immunodeficiency

        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior intravesical BCG required (if T1 or Tis
        pathology and negative cytology PAB) Chemotherapy: Not specified Endocrine therapy: Not
        specified Radiotherapy: No prior radiotherapy to the pelvis Surgery: Not specified Other:
        Intravesical therapy within 30 days allowed At least 30 days since greater than 2
        multivitamins daily",High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV-positive.

          -  Are receiving an anti-HIV drug combination that contains three drugs from at least two
             classes of anti-HIV drugs (such as protease inhibitors). Patients must have been
             receiving this drug combination for at least 6 months before study entry. Before
             beginning this drug combination, patients must have taken either no anti-HIV drugs or
             only one or two nucleoside analogues (NRTIs).

          -  Had a viral load between 5,000 and 100,000 copies/ml before beginning their current
             anti-HIV therapy.

          -  Have a viral load below 50 copies/ml while on their current anti-HIV therapy within 2
             weeks before study entry.

          -  Have a CD4 count greater than 350 cells/mm3 at the time of study entry.

          -  Are at least 13 years old (consent of parent or guardian required if under 18).",Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune),0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"Inclusion Criteria:

          -  Postmenopausal

          -  Non-smoker

          -  BMI <30

          -  Healthy

          -  Without surgically-induced menopause

          -  Not on HRT or >1 year post HRT

          -  Normal mammogram within last year

          -  No cardiovascular disease other than mild hypertension",Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women,0
A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.,"HEALTHY VOLUNTEERS:

        Male or female subjects who are at least 18 years of age, but no older than 60 years of
        age.

        Received complete hepatitis B and/or tetanus/diphtheria vaccination series.

        If female, have a negative urine or serum pregnancy test within two weeks prior to entry
        into this study, and agree to avoid pregnancy during entire participation through the use
        of effective birth control or abstinence.

        Volunteers reporting good general health and denying any illness that can adversely affect
        an immune response to a vaccine.

        No history of a serious adverse event associated with any previous vaccination.

        Not participating in another experimental vaccine study.

        Serum hemoglobin greater than or equal to 11 g/dL.

        No history of hepatitis B.

        Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months.

        HSCT VOLUNTEERS:

        Male or female subjects who are at least 5 years of age, but no older than 60 years of age.

        Be enrolled in a HSCT protocol at NIH.

        Be greater than or equal to 3 months post-HSCT.

        Received tetanus/diphtheria vaccination series.

        If female, have a negative urine or serum pregnancy test within two weeks prior to entry
        into this study, and agree to avoid pregnancy during entire participation through the use
        of effective birth control or abstinence.

        No history of a serious adverse event associated with any previous vaccination.

        Not participating in another experimental vaccine study.

        Serum hemoglobin greater than or equal to 9 g/dL.

        No history of hepatitis B.

        Not receiving any more than replacement glucocorticoid therapy.

        Not receiving any dose of cyclosporine.

        No acute graft-versus-host disease grade II or higher, at time of consideration for study.

        No chronic graft-versus-host disease more involved than localized skin lesions and/or liver
        dysfunction, at time of consideration for study.

        Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months.",Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers,0
"A 46-year-old Asian woman  with MDD  complains of persistent feelings of sadness and loss of interest in daily activities. She states that her mood is still depressed most of the days. She complains of loss of energy and feelings of worthlessness nearly every day. She is on anti-depressants for the past 6 months, but the symptoms are still present. She does not drink alcohol or smoke. She used to exercise every day for at least 30 min., but she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was diagnosed with colon cancer a year ago and is undergoing chemotherapy. Her past medical history is unremarkable. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Inclusion Criteria:

          -  Patient must be ambulatory and relatively good health. Even if unable to work at least
             able to partially care care for self and not demented.

          -  May have been alcoholic or drug abuser 6 months previous.

          -  Unspecified

          -  CD4 Unspecified.

        Exclusion Criteria:

          -  Non ambulatory patients or those requiring extensive help in self care are excluded.

          -  Non ambulatory patients or those requiring extensive help in self care are excluded.

          -  Current alcohol or drug abuse.

          -  Unspecified",Antidepressant Treatment of AIDS Related Depression.,1
"A 46-year-old Asian woman  with MDD  complains of persistent feelings of sadness and loss of interest in daily activities. She states that her mood is still depressed most of the days. She complains of loss of energy and feelings of worthlessness nearly every day. She is on anti-depressants for the past 6 months, but the symptoms are still present. She does not drink alcohol or smoke. She used to exercise every day for at least 30 min., but she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was diagnosed with colon cancer a year ago and is undergoing chemotherapy. Her past medical history is unremarkable. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"A 46-year-old Asian woman  with MDD  complains of persistent feelings of sadness and loss of interest in daily activities. She states that her mood is still depressed most of the days. She complains of loss of energy and feelings of worthlessness nearly every day. She is on anti-depressants for the past 6 months, but the symptoms are still present. She does not drink alcohol or smoke. She used to exercise every day for at least 30 min., but she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was diagnosed with colon cancer a year ago and is undergoing chemotherapy. Her past medical history is unremarkable. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","-  INCLUSION CRITERIA:

        The subjects of this study will be women who meet the following criteria:

          -  history within the last two years of at least six months with menstrually-related mood
             or behavioral disturbances of at least moderate severity - that is, disturbances that
             are distinct in appearance and associated with a notable degree of subjective
             distress;

          -  a 30% increase in mean negative mood ratings (relative to the range of the scale
             employed) in the premenstrual week compared with the week following the end of menses
             in at least two of three cycles;

          -  age 18 to 50;

          -  not pregnant and in good medical health;

          -  regular menses.

        For subjects with recurrent brief depression:

          -  dysphoric mood or loss of interest or pleasure;

          -  duration less than two weeks;

          -  four of the following symptoms: poor appetite or significant weight loss (when not
             dieting) or increased appetite or significant weight gain; insomnia or hypersomnia;
             psychomotor agitation or retardation; loss of interest or pleasure in usual
             activities, or decrease in sexual drive; loss of energy; fatigue; feelings of
             worthlessness, self-reproach, or excessive or inappropriate guilt; diminished ability
             to think or concentrate, slowed thinking, or indecisiveness;

          -  impairment in usual occupational activities;

          -  at least one-two episodes per month over one year.

        Age-matched women without mood and behavioral disorders will be recruited.

        EXCLUSION CRITERIA for all study participants:

          -  Subjects should have no general medical illness that is primary (i.e., appears to be
             causing the mood disorder);

          -  Current antidepressant therapy (since this is a screening protocol for subsequent
             treatment and physiologic evaluation studies in which participants must be untreated).
             Antidepressants will not be withheld from participants who need or want them;

          -  Current alcohol or substance use or dependence (excluding nicotine) of sufficient
             magnitude to require independent, concurrent treatment intervention (e.g., antabuse or
             opiate treatment, but not including self-help groups).

          -  Pregnant or lactating women

          -  Subjects who are unable to provide informed consent

          -  NIMH employees/staff and their immediate family members will be excluded from the
             study per NIMH policy.",Study of Premenstrual Syndrome and Premenstrual Dysphoria,1
"A 46-year-old Asian woman  with MDD  complains of persistent feelings of sadness and loss of interest in daily activities. She states that her mood is still depressed most of the days. She complains of loss of energy and feelings of worthlessness nearly every day. She is on anti-depressants for the past 6 months, but the symptoms are still present. She does not drink alcohol or smoke. She used to exercise every day for at least 30 min., but she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was diagnosed with colon cancer a year ago and is undergoing chemotherapy. Her past medical history is unremarkable. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","INCLUSION CRITERIA:

        Patients over the age of 2 who are enrolled in 91-DK-0085, ""Studies of Hyperparathyroidism
        and Related Disorders"", or patients who are undergoing parathyroid localization as part of
        routine patient care while enrolled in other Clinical protocols will be considered for the
        study.

        EXCLUSION CRITERIA:

        Patients will be excluded if:

        There is any contraindication to arteriography.

        The Patient is pregnant.",Using X-Ray Dye to Locate Hidden Parathyroid Tumors,0
"A 46-year-old Asian woman  with MDD  complains of persistent feelings of sadness and loss of interest in daily activities. She states that her mood is still depressed most of the days. She complains of loss of energy and feelings of worthlessness nearly every day. She is on anti-depressants for the past 6 months, but the symptoms are still present. She does not drink alcohol or smoke. She used to exercise every day for at least 30 min., but she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was diagnosed with colon cancer a year ago and is undergoing chemotherapy. Her past medical history is unremarkable. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","-INCLUSION CRITERIA:

        i. Normal Language Development, Hearing and Cognition

        ii. The following screening tests previously published with norms were found to have a good
        distribution for determining normal functioning in adolescents and adults as all subjects
        did not hit ceiling and all had scores greater than or equal to the 80th percentile. These
        tests are being used to ensure that subjects affected with stuttering or FPPD do not have
        other disorders such as hearing loss, language delay, or mental retardation.

        Peabody Picture Vocabulary Test III (PPVT-III)

        Expressive Vocabulary Test (EVT)

        Oral Speech Mechanism Screening Examination

        Revised Token Test; Token test for Children

        Test of Non verbal intelligence (TONI-2)

        Digit Span subtest of the WICS-R

        Audiometric Screening

        Goldman Fristoe Test of Articulation

        WUG Test of Morphological Encoding

        Test of Auditory Comprehension of Language (TACL)

        Khan-Lewis Phonological Analysis

        INCLUSION CRITERIA FOR IDENTIFYING AND QUANTIFYING STUTTERING:

        The Stuttering Severity Index -3 (Riley, 1981) has been found to be accurate for
        identifying and assessing the severity of stuttering during conversational speech. For the
        inclusion of a stuttering subject we require:

        i. A total overall score of 11 or greater between 3 and 17 years,

        ii. A total overall score of 18 or greater from age 18 and above.

        INCLUSION CRITERIA FOR IDENTIFYING FPPD:

        i. A family history of an autosomal dominant pattern of inheritance of the speech disorder
        over several generations with persistence into adulthood in some cases,

        ii. Speech symptoms during conversational speech include: deletion of final consonants;
        syllable reduction and syllable deletion; deletion of grammatical markers such as copulas,
        auxiliaries, prepositions, connectives; poor ability to self-correct; poor awareness of
        errors; and consonant cluster reduction.

        iii. Greater than 9% discourse errors during analysis of a sample of 300 syllables.

        iv. A discrepancy of 30 points (1 and 1/2 Standard Deviations) between receptive (the
        higher score) and expressive percentile score on the PPVT III and Expressive Vocabulary
        Test.

        v. For subjects greater than 7 years of age, a phonological process rating of 3 or more for
        any phonological process on the Khan-Lewis Phonological Analysis. For subjects less than 7
        years of age, a phonological process rating of 3 or more on 2 phonological processes on the
        Khan-Lewis Phonological Analysis. Finally, any subjects with a non developmental
        phonological process error will be identified as potentially having FPPD.

        EXCLUSION CRITERIA:

        i. Anyone with a hearing loss will be excluded from participation during the diagnostic
        testing.

        ii. Children with delayed language, more than 1 year delay from norms on receptive and
        expression language testing will be excluded.

        iii. Language impairment: scores more than 2 standard deviations below the age appropriate
        score on the standardized language tests listed under the inclusion criteria.

        iv. Cognitive impairment: scores more than 2 standard deviations below the age appropriate
        score on the standardized cognitive tests listed under the inclusion criteria.

        v. Bilingual non-native English speakers - Studies have demonstrated that brain
        organization for speech and language may differ in bilingual persons. It is hypothesized
        that this may alter speech motor learning and thus kinematic data from non-native English
        speakers would differ from native English speakers. Therefore, only native-American English
        speakers, with only one language spoken in the home, will be included.",Characteristics of Idiopathic Familial Speech Disorders,0
"A 46-year-old Asian woman  with MDD  complains of persistent feelings of sadness and loss of interest in daily activities. She states that her mood is still depressed most of the days. She complains of loss of energy and feelings of worthlessness nearly every day. She is on anti-depressants for the past 6 months, but the symptoms are still present. She does not drink alcohol or smoke. She used to exercise every day for at least 30 min., but she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was diagnosed with colon cancer a year ago and is undergoing chemotherapy. Her past medical history is unremarkable. Her family history is negative for any psychologic problems. Her HAM-D score is 20.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"A 46-year-old Asian woman  with MDD  complains of persistent feelings of sadness and loss of interest in daily activities. She states that her mood is still depressed most of the days. She complains of loss of energy and feelings of worthlessness nearly every day. She is on anti-depressants for the past 6 months, but the symptoms are still present. She does not drink alcohol or smoke. She used to exercise every day for at least 30 min., but she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was diagnosed with colon cancer a year ago and is undergoing chemotherapy. Her past medical history is unremarkable. Her family history is negative for any psychologic problems. Her HAM-D score is 20.",People over the age of 50 who have lost their spouse within the last three months.,Consequences of Conjugal Bereavement in Adults,0
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.",Stratified random sample based on risk severity obtained during phone interview,Prevalence of Sleep Apnea in Women,2
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Obese women with chronic anovulation due to polycystic ovary syndrome (PCOS)

        Must have oligoamenorrhea and hyperandrogenemia

        --Prior/Concurrent Therapy--

        At least 2 months since prior standard therapy (including over the counter drugs) At least
        2 months since prior investigational agents

        --Patient Characteristics--

        Hematopoietic: Hematocrit greater than 38%

        Hepatic: Liver function normal No clinically significant hepatic disease

        Renal: No clinically significant renal disease Creatinine less than 1.4 mg/dL No
        proteinuria

        Cardiovascular: No clinically significant cardiac disease

        Pulmonary: No clinically significant pulmonary disease

        Hormonal: Thyroid function normal Prolactin normal Fasting 17 alpha-hydroxy progesterone
        less than 200 mg/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency

        Other: Not pregnant Negative pregnancy test Fertile patients must use effective
        contraception No diabetes mellitus No clinically significant neurologic, psychiatric,
        infectious, neoplastic, or metabolic disease No clinically significant malignant disease
        except nonmelanomatous skin cancer At least 1 year since any prior drug abuse or alcoholism",Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome,2
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.","INCLUSION CRITERIA:

        All ethnic groups

        Males and females

        Age greater than 14 years

        Clinically-significant lipodystrophy, identified by the study physician during the physical
        examination as an absence of fat outside the range of normal variation and/or identified as
        a disfiguring factor by the patient.

        Circulating leptin levels less than 4.0 ng/ml in females and less than 3.0 ng/ml in males
        as measured by Linco assay on at least 2 occasions.

        Presence of at least one of the following metabolic abnormalities:

        Presence of diabetes as defined by the 1997 ADA criteria: a) fasting plasma glucose greater
        than or equal to 126 mg/dL, or b) 2 hour plasma glucose greater than or equal to 200 mg/dL
        following a 75 gram oral glucose load, or c) diabetic symptoms with a random plasma glucose
        greater than or equal to 200 mg/dL.

        Fasting insulin greater than 30 micrograms/ml;

        Fasting hypertriglyceridemia greater than 200 mg/dl.

        EXCLUSION

        General: Pregnant women, women in their reproductive years who do not use an effective
        method of birth control, women currently nursing or lactating within 6 weeks of having
        completed nursing, and persons who are unable to provide informed consent will be excluded
        from the study.

        Exclusions for underlying disease likely to increase side effects or to hinder objective
        data collection:

        Known liver disease due to causes other than non-alcoholic steatohepatitis

        Current alcohol or substance abuse

        Psychiatric disorder impeding competence or compliance

        Active tuberculosis

        Use of anorexiogenic drugs

        Other condition which in the opinion of the clinical investigators would impede completion
        of the study

        Subjects who have a known hypersensitivity to E. Coli derived proteins",Leptin to Treat Lipodystrophy,0
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.",- BMI 25-40 kg/m2 inclusive,Effectiveness of Atkins Diet for Weight Loss,1
"The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5).  In the past, she unsuccessfully used  antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete  the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results:
FBS: 98 mg/dl
TG: 150 mg/dl
Cholesterol: 180 mg/dl
LDL: 90 mg/dl
HDL: 35 mg/dl
She is considering a laparoscopic gastric bypass.","-  INCLUSION CRITERIA:

        Based on the Inclusion Criteria outlined below, patients will accrue to one of the cohorts
        of the trial.

        Cohort- chemotherapy regimens allowed. Cohort Status

        Cohort 1

        Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome)-2 or fewer. Closed to
        accrual

        Cohort 2

        Peripheral T-cell Lymphoma, unspecified, or Anaplastic large cell lymphoma (T and null
        cell) Primary Cutaneous Type -2 or fewer. Open and accruing

        Cohort 3

        Cutaneous T-cell Lymphomas or Peripheral T-cell Lymphoma-More than 2. Closed to accrual

        Cohort 4

        Other Mature T cell Lymphomas-Any number. Open and accruing

        Cohort 5

        Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome)-2 or fewer-Cohort 5 is a
        replicate cohort, identical to #1

        Cohort 6

        Peripheral T-cell Lymphoma (PTCL), unspecified, or Anaplastic large cell lymphoma (T and
        null cell) Primary Cutaneous Type-More than 2. Patients with PTCL in cohort 3 migrated to
        this cohort

        Cohort 7

        Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome) Prior vorinostat
        required-Any number

        Patients with cutaneous T-cell lymphoma [CTCL (mycosis fungoides or Sezary syndrome) stage
        IB to IVB are eligible. Patients with stage IB and IIA should be refractory to, intolerant
        to, or have reached a six-month or longer response plateau on at least two prior therapies
        from the following list: psoralen plus ultraviolet A irradiation (PUVA), ultraviolet B
        (UVB), electron beam therapy (EBT), photophoresis, interferon, systemic cytotoxic
        chemotherapy, topical nitrogen mustard, or topical carmustine (BCNU). One qualifying prior
        treatment must have been topical nitrogen mustard, topical carmustine or a phototherapy
        (UVB, PUVA or EBT). Topical steroids, systemic retinoids or biologicals do not qualify.
        Patients with stage IB or IIA who are not candidates for topical nitrogen mustard, topical
        carmustine or phototherapy (UVB, PUVA or EBT) are eligible for enrollment. Patients may not
        have received more than two systemic cytotoxic chemotherapy regimens. Steroids, retinoids,
        and biologic agents, will not be considered as systemic cytotoxic chemotherapy.
        Radiolabeled monoclonal antibody therapy is considered equivalent to a systemic cytotoxic
        chemotherapy regimen and must be counted toward the two prior systemic cytotoxic regimens.
        Patients with stage IIB-IVB who have had no more than 2 prior systemic cytotoxic
        chemotherapeutic regimens are eligible. There is no restriction regarding number of prior
        topical therapies, skin irradiation, or non-cytotoxic systemic therapies (i.e. PUVA,
        retinoids or biologic, with the exception of radiolabeled monoclonal antibody therapy) in
        this patient group. After 24 patients were enrolled in this arm, the arm was closed, and a
        replicate arm constituted of this same patient population was opened (Cohort 5).

        Patients with peripheral T-cell lymphoma (PTCL), unspecified, or anaplastic large cell
        lymphoma, T and null cell, primary cutaneous type, as defined by the Revised European
        American Lymphoma (REAL)/World Health Organization (WHO) classification (16-18), who have
        experienced disease progression after receiving prior standard treatment and who have had
        no more than 2 prior systemic cytotoxic chemotherapeutic regimens are eligible.

        Patients with cutaneous T cell lymphoma (Mycosis fungoides or Sezary Syndrome) or
        peripheral T cell lymphoma as defined above who have received more than 2 prior systemic
        therapies and who have experienced disease progression will be included in a third and
        independent arm. This arm of the protocol was closed to accrual for CTCL with Amendment H.

        Patients with mature T cell lymphomas not included above will be enrolled in a fourth arm.
        These include but are not exclusively limited to: Enteropathy-type T cell lymphoma;
        Hepatosplenic T-cell lymphoma; Subcutaneous panniculitis-like T cell lymphoma;
        Angioimmunoblastic T-cell lymphoma; Anaplastic large cell lymphoma. Patients must have
        experienced disease progression after receiving prior standard treatment. There will be no
        limit on the number of prior regimens. Primitive T cell neoplasms and T cell leukemias will
        not be enrolled.

        Patients with peripheral T-cell lymphoma, unspecified, or anaplastic large cell lymphoma, T
        and null cell, primary cutaneous type, as defined by the REAL/WHO classification (16-18),
        who have experienced disease progression after receiving prior standard treatment and who
        have had more than 2 prior systemic cytotoxic chemotherapeutic regimens are eligible for
        enrollment to a sixth arm of the trial.

        Patients with cutaneous T cell lymphoma (Mycosis fungoides or Sezary Syndrome) or
        peripheral T cell lymphoma as defined in #1 who have received any number of prior systemic
        therapies and who have previously been treated with vorinostat will be included in a third
        and independent arm. Patients can be enrolled in this arm if they received prior vorinostat
        and experienced disease progression, subsequent relapse, or had to discontinue to agent due
        to toxicity.

        Disease that is measurable by radiographic imaging, assessing skin lesions, or by
        quantitating Sezary cell count.

        Patients must:

        be age greater than or equal to 18 years

        have a performance status of Eastern Cooperative Oncology Group (ECOG) 0-2

        have no serious or intercurrent illness and have a life expectancy of greater than 12 weeks

        give written informed consent

        female patients of childbearing potential must have a negative pregnancy test within 4
        weeks and must use effective contraception

        sexually active males must use effective contraception

        Laboratory values (performed less than or equal to 14 days prior to registration):

        absolute neutrophil count greater than or equal to 1000/microliter, platelets greater than
        or equal to l00,000/microliter, bilirubin (total and direct) less than or equal to 1.5x
        upper limit of normal, and aspartate aminotransferase (AST) less than or equal to 3x upper
        limit of normal, unless impairment is due to organ involvement by lymphoma, creatinine less
        than or equal to 1.5x upper limit of normal, or documented creatinine clearance of greater
        than or equal to 60mL/min

        Cardiac studies (performed within 4 weeks of registration):

        Ejection fraction of greater than 50% by Echocardiogram or Cardiac magnetic resonance
        imaging (MRI), or greater than or equal to 45% by multi-gated acquisition scan (MUGA) Scan.

        A stable dose (greater than 1 month) of corticosteroids administered for symptom management
        will not preclude enrollment. Tapering will be initiated following administration of
        depsipeptide.

        EXCLUSION CRITERIA:

        Patients with unconfirmed diagnosis, or with B-cell lymphomas will be excluded.

        Prior or concurrent malignancies that have not been curatively treated.

        Known central nervous system (CNS) lymphoma.

        Chemotherapy within 4 weeks, 6 weeks for nitrosoureas or mitomycin C.

        Biologics, Immunotherapy within 2 weeks.

        Human Immunodeficiency virus (HIV) seropositivity.

        Pregnant or breast-feeding patients.

        Major surgery within 21 days.

        Uncontrolled infection or uncontrolled medical illness.

        Patients having received prior histone deacetylase (HDAC) inhibitor therapy for T cell
        lymphoma will be excluded except for patients eligible to enroll in cohort 7.

        Patients with the following cardiac risk factors will be excluded from the study:

        Patients with known cardiac abnormalities such as:

        Congenital long QT syndrome

        Corrected QT interval (QTc) interval greater than 480 milliseconds

        Patients who have had a myocardial infarction within 12 months of study entry.

        Patients who have active coronary artery disease as, e.g. angina as defined by Canadian
        Class II-IV

        Patients with an electrocardiography (ECG) recorded at screening showing evidence of
        cardiac ischemia (ST depression of greater than or equal to 2 mm).

        Any patient in whom coronary artery disease is suspected should be referred for a
        cardiology consultation and if active myocardial ischemia is demonstrated the patient
        should be excluded. If a noninvasive imaging study is equivocal, it may be necessary to
        proceed to coronary angiography.

        Patients with congestive heart failure that meets New York Heart Association (NYHA) Class
        II to IV definitions and/or ejection fraction less than 45% by MUGA scan or less than 50%
        by echocardiogram and/or MRI.

        Patients with a history of sustained ventricular tachycardia (VT), ventricular fibrillation
        (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic
        implantable cardioverter defibrillator (AICD). Patients with a history of arrhythmia should
        have Holter monitoring and evaluation by cardiology.

        Patients with dilated, hypertrophic, or restrictive cardiomyopathy from prior treatment or
        other causes (in doubt, see ejection fraction criteria above). Patients with left
        ventricular hypertrophy should be discussed with the Principal Investigator or Study
        Chairman.

        Patients with uncontrolled hypertension, i.e., systolic blood pressure (SBP) greater than
        or equal to 160 mm Hg or diastolic blood pressure (DBP) greater than or equal to 95 mm Hg.

        Patients with cardiac arrhythmia requiring anti-arrhythmic medication other than beta
        blocker or calcium channel blocker. Patients in whom digitalis cannot be discontinued are
        excluded from study.

        Patients with Mobitz II second degree heart block who do not have a pacemaker. Patients
        with first degree or Mobitz I second degree heart block, bradyarrhythmias or sick sinus
        syndrome require Holter monitoring and evaluation by cardiology.

        Patients with other cardiac disease may be excluded at the discretion of the principal
        investigator (PI) following consultation with cardiology.",Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Postmenopausal women, up to age 86, with angiographically documented coronary artery
        disease of at least 15 percent, but no more than 75 percent occlusion.",Women's Angiographic Vitamin and Estrogen Trial (WAVE),0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Postmenopausal women with angiographically-documented coronary disease. Approximately 70
        percent minority",Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART),0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Inclusion Criteria

        A woman may be eligible for this study if:

          -  She is HIV-positive.

          -  She is at least 34 weeks pregnant.

          -  She has a history of at least 4 weeks of continuous oral ZDV during her current
             pregnancy and tolerated it well.

          -  She has given consent for her newborn to participate in this study. (The father must
             also give consent if he is available after reasonable attempts to contact him. A woman
             under 18 needs the consent of a parent or legal guardian for her and her infant to
             participate.)

        Exclusion Criteria

        A woman will not be eligible for this study if:

          -  She is taking part in another study of HIV treatment during pregnancy.

          -  Her infant has a life-threatening illness indicated in an ultrasound.

          -  Her infant does not appear to be growing normally in the womb.

          -  She has a cesarean section.

          -  She has abnormal blood test results.

          -  She has severe nausea, vomiting, or other problems of the stomach and intestines at
             the time of study entry.

          -  She has an active opportunistic (AIDS-related) infection or other serious infection at
             the time of study entry.

          -  The study staff cannot find a usable vein.

          -  The study doctor feels that she cannot take drugs by mouth.",A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Inclusion Criteria

        A patient may be eligible for this study if she:

          -  Is an HIV-positive woman.

          -  Is receiving care at a study site during the study period or her infant is receiving
             care at a study site and whose delivery information is available.

          -  Had a baby on or after January 1, 1998.",A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Inclusion Criteria

        Concurrent Medication:

        Recommended:

          -  PCP prophylaxis.

        Allowed:

          -  Any antiretroviral therapies available by prescription or through expanded access or
             Treatment IND programs, including combination or sequential use.

          -  Chemotherapy for Kaposi's sarcoma, lymphoma, or other malignancies IF patient is
             hematologically stable for at least 30 days prior to study entry.

          -  Discrete courses of oral or parenteral acyclovir for VZV or HSV infection, not to
             exceed 21 days per episode (may co-enroll on ACTG 169). For recurrent episodes,
             open-label acyclovir for a total of 60 days over a 12-month period is allowed. Study
             drug is interrupted.

          -  Supportive therapies available by prescription, expanded access, or Treatment IND
             programs, such as G-CSF, GM-CSF, and erythropoietin.

          -  Other medications necessary for the patient's welfare, at the discretion of the
             investigator.

        Patients must have:

          -  HIV infection or AIDS-defining conditions.

          -  CD4+ count < 100 cells/mm3.

          -  IgG antibodies to CMV.

          -  No active CMV disease or history of CMV end-organ disease.

          -  Consent of parent or guardian if less than 18 years of age.

          -  Ability to comply with protocol.

        NOTE:

          -  Patients may be co-enrolled in ACTG primary infection Phase II/III studies, ACTG
             opportunistic infection protocols, or treatment protocols or similar studies sponsored
             by other research networks as long as those studies do not violate the restrictions
             placed on concomitant therapies and toxicity management.

        Prior Medication:

        Allowed:

          -  PCP prophylaxis.

          -  Any antiretroviral therapies available by prescription or through expanded access or
             Treatment IND programs, including combination or sequential use.

          -  Chemotherapy for Kaposi's sarcoma, lymphoma, or other malignancies.

          -  Acyclovir.

          -  Supportive therapies available by prescription, expanded access, or Treatment IND
             programs, such as G-CSF, GM-CSF, and erythropoietin.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

          -  Nausea or vomiting that precludes oral dosing.

          -  Ocular media opacities that preclude adequate visualization of fundi.

          -  Pregnancy.

          -  Known hypersensitivity to acyclovir.

          -  Known lactose intolerance.

        Concurrent Medication:

        Excluded:

          -  Systemic interferons and immunomodulators (including CMV hyperimmune serum/globulin
             and chronic corticosteroids at doses in excess of physiologic replacement).

          -  Probenecid.

          -  Investigational or marketed agents with potential activity against CMV, herpes
             simplex, and/or Varicella zoster, EXCEPT as specifically allowed.

        Patients with the following prior condition are excluded:

          -  Pre-existing necrotizing retinopathy that may interfere with a subsequent diagnosis of
             CMV retinitis.

        Prior Medication:

        Excluded:

          -  Prior ganciclovir, foscarnet, or any investigational anti-CMV agent including use of
             foscarnet for acyclovir-resistant herpes.

          -  Interferons, immunomodulators (other than colony stimulating factors), or CMV
             hyperimmune globulin within 30 days prior to study entry.",A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","-  INCLUSION CRITERIA:

          -  Enrolled on another LPD protocol.

          -  Weight greater than or equal to 25 kg

          -  Willingness to participate

        EXCLUSION CRITERIA:

          -  Age less than 7 years

          -  Weight less than 25 kg

          -  Cardiovascular instability

          -  Hct less than 30

          -  Inadequate venous access

          -  PTT or PT greater than 1.5 normal

          -  Pregnancy

          -  Women who are actively breastfeeding

          -  Other condition which the attending physician or Apheresis Unit staff considers a
             contraindication to the procedure

          -  For Hetastarch procedure

               -  Hypertension

               -  Evidence of fluid retention",Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Children between the ages of 3 months and 18 years.

        Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC)
        Definition. Children and adolescents with vertically, transfusion or sexually acquired
        HIV-1 infection are eligible.

        Availability of a parent or guardian to provide Informed Consent.

        ARM A:

        Children and adolescents with vertically, transfusion or sexually acquired HIV-1 infection.

        No or moderate immune suppression at the time of study entry as defined by the CDC
        Classification System, Immune Categories 1 and 2.

        No history of or indication for antiretroviral intervention at time of enrollment or not
        receiving antiretroviral treatment because: (a) the patient has elected to decline
        treatment or (b) in the opinion of the patient's health care provider, antiretroviral
        treatment is not currently recommended because of the patient's inability to adhere to
        therapy, promoting the development of viral resistance.

        Children younger than 24 months of age must not have had plasma HIV-1 RNA levels greater
        than 8 X 10(4) copies/ml previously and at the time of initial evaluation, confirmed at
        least at two different time points 2 to 4 weeks apart, showing no sign of increase
        (increment less than 0.5 log(10). If the child has had plasma HIV-1 RNA levels greater than
        8 X 10(4) copies/ml at some point prior to the initial evaluation, he/she will have to be
        placed on antiretroviral treatment and must meet all the criteria for Arm B.

        ARM B:

        Children and adolescents with vertically, transfusion, or sexually acquired HIV-1
        infection, who are on or have received antiretroviral treatment of longer than 7 weeks.

        No or moderate immune suppression at the time of study entry as defined by CDC
        Classification System, Immune Categories 1 and 2.

        Children younger than 24 months or age, who meet all the inclusion criteria for army B must
        have plasma HIV-1 RNA levels less than 5 X 10(4) copies/ml while receiving optimal
        antiretroviral therapy, confirmed at least two different time points 2 to 4 weeks apart,
        showing no sign of increase (increment less than 0.5 log(10). If the child has been
        previously treated with antiretroviral drugs for more than 7 weeks (therefore not eligible
        for arm A) and is currently off drugs, he/she will have to be placed on optimal
        antiretroviral agents and will have to maintain viral RNA levels below 5 X 10(4) copies/ml
        prior to the entry.

        Each child enrolled in arm B has to be on constant regimen of antiretroviral treatment for
        at least 6 weeks-prior to the first inoculation. Children in immune categories 1 and 2 at
        the time of study entry will be allowed to enroll.

        Not critically ill or clinically unstable or no presence of active infection requiring
        on-going (or induction) therapy.

        No evidence of severe immune suppression at the time of study entry as defined by CDC
        classification system, Immune Category 3.

        For children younger than 24 months of age, no plasma HIV-1 RNA levels greater than or
        equal to 5 x 10(4) copies/ml despite appropriate antiretroviral treatment, confirmed at
        least at two different time points 2 to 4 weeks apart.

        No use of tube feeding or intravenous hyperalimentation itself will be allowed as long as
        it is a stable regimen.

        No administration of chemotherapeutic agents, or use of immunomodulating agents such as
        corticosteroids, interferons, G-CSF, EPO, growth hormone (GH) or IVIG within one month of
        enrollment.

        No abnormalities of laboratory findings within one month of enrollment including the
        following: SGPT or SGOT greater than 5 times the normal value; Total bilirubin greater than
        3 times normal; BUN or creatinine greater than 2 times normal; Total WBC greater than
        150/mm(3) or ANC greater than 750/mm(3); Hemoglobin greater than 8.0 g/dl (transfusions are
        allowed); Platelet count greater than 100,000/mm(3).

        Not pregnant or not planning to become pregnant.

        No active substance abuse.

        Able to comply with the study requirements for scheduled evaluations such as periodic
        clinic visits or blood sampling.",Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","American Society of Anethesiology Class I-III adult patients undergoing elective surgery
        requiring neuromuscular blockage for endotracheal intubation.

        No pre-existing renal or hepatic disease, Myasthenia-Gravis, Eaton-Lambert Disease,
        pregnancy, concurrent anticonvulsant therapy, history of hypersensitivity to rocuronium,
        neostigmine, or glycopyrrolate.",The Early Reversibility of Rocuronium After Different Doses of Neostigmine,1
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","18 to 60 years of age, HIV-1 negative by HIV-1 ELISA, HIV PCR and Western Blot analysis.

        Subjects in good health with no evidence of underlying disease based on history, physical
        exam and laboratory analysis.

        Must have normal organ function as characterized by the following:

        Hematopoietic: absolute granulocyte count of at least 1500/mm(3); platelet count of at
        least 150, 000/mm(3); hematocrit within normal range.

        Renal: BUN less than 23 mg/dl; creatine less than 1.6 mg/dl.

        Hepatic: serum total bilirubin less than 1.5 mg%.

        Metabolic: ALT less than or equal to 1.5 x upper limit of normal range; serum calcium
        within normal range; serum lactate within normal range; total serum CPK within normal
        range.

        Endocrine: serum glucose -- within normal range.

        Immunologic: CD4 count greater than or equal to 500 cells/mm(3); total serum immunoglobulin
        (IgM, IgG and IgA) levels within normal ranges.

        No other clinically significant laboratory abnormalities.

        All subjects must understand the basis of transmission of HIV and other common sexual and
        blood borne infections and agree to practice abstinence or clinically accepted methods of
        prevention, including barrier protection during intercourse for the duration of the study.

        Female subjects of child bearing potential must have a negative pregnancy test.

        Must be available for active follow-up.

        Able to give informed consent by signing the Institutional Review Board (IRB)-approved
        consent form(s).

        Must not have previous immunization with any experimental vaccine directed against HIV or
        receipt of any experimental agent within 30 days prior to enrollment.

        Must not receive any blood product or immunoglobulin within 6 months prior to enrollment.

        Must not be exposed to potentially infective HIV fluids within the prior 6 months or tested
        positive for HIV at any time.

        No history of any prior disease or therapy which would affect immune function including:

        Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma of the
        skin or carcinoma in situ of the cervix;

        Radiation therapy or cytotoxic/cancer chemotherapy;

        immunodeficiency or auto-immune disease;

        Acute infection or a recent (within 6 months) history of chronic infection.

        Female subjects must not be nursing a child.

        Must not be taking any medication which may affect immune function, with the following
        exceptions: subjects may be taking low doses of nonprescription strength NSAIDS (e.g.
        ibuprofen or aspirin) or acetaminophen.

        No known hypersensitivity to bupivacaine or any amide-type local anesthetic (such as
        lidocaine, dibucaine, mepivacaine, and prilocaine) or a history of anaphylaxis or of any
        serious adverse reactions to vaccines.

        No evidence of active drug or alcohol abuse or uncontrolled (unstable) psychiatric
        disorders which would interfere with study participation.

        Must not be engaging in HIV-related high-risk behavior such as unprotected sex, sex with
        multiple partners, or intravenous drug use.

        No evidence of infection with HBV, HIV-1, HCV or HTLV-1 using standard testing procedures.

        Must not have any positive result for anti-DNA antibodies as measured by standard testing
        procedures (anti-DNA antibody and anti-nuclear antibody (ANA) assays. This study does
        permit enrollment of volunteers with a low positive ANA (less than or equal to 1:160)
        titers, if there is no clinical evidence of underlying disorders that are associated with a
        positive ANA, if no first degree relative has an autoimmune disease, and if anti-DNA and
        ENA are negative.","Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers",0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","-  INCLUSION CRITERIA:

        Screening FOR SUSPECTED PTLDS:

        Age greater than or equal to 13 years old, suspect of suffering from Lyme disease

        Post-Treatment Lyme Disease Syndrome (PTLDS): For the purposes of this study, PTLDS is
        defined as occurring in male or female patients age 13 and above who have been diagnosed
        with confirmed or probable Lyme disease per CDC definition
        (https://wwwn.cdc.gov/nndss/conditions/lyme-disease/case-definition/2017/). Studyphysician
        will review history to confirm probable cases. They have received recommended antibiotic
        therapy and have persistent or relapsing symptoms and/or signs for at least six months
        after therapy. They also should have no other documented explanation for their signs and
        symptoms.

        Lyme arthritis controls: For the purposes of this study, Lyme arthritis is defined as
        occurring in an otherwise healthy male or female aged 18 and above who have intermittent
        episodes of arthritis involving one or few joint, without any other cause being documented,
        and have positive serum antibodies to B.burgdorferi confirmed by Western blot according to
        the CDC criteria.

        Recovered Controls: For the purposes of this study, a recovered control is defined as an
        otherwise healthy male or female aged 18 and above who has had Lyme disease, fulfilling the
        CDC Lyme Disease National Surveillance Case Definition and who had received accepted
        antibiotic treatment for Lyme disease (at least 3 months since the end of antibiotic
        therapy before protocol evaluation) and who are currently asymptomatic.

        Seropositive Controls: For the purposes of this study, a serpositive control is defined as
        an otherwise healthy male or female aged 18 and above who has positive serum IgG antibody
        to B.burgdorferi by Western blot according to the CDC criteria and are asymptomatic and who
        recall no episodes of disease compatible with Lyme infection and have not received
        antibiotic therapy for Lyme disease.

        OspA vaccinated control: For the purposes of this study, a OspA vaccinated control is
        defined as an otherwise healthy male or female aged 18 and above who has received at least
        two doses of the OspA vaccine for Lyme disease (Lymerix [R]). These controls may have a
        positive ELISA for B.burgdorferi but a negative (or unreadable) IgG western blot.

        Multiple sclerosis controls: For the purposes of this study, a multiple sclerosis control
        is defined as an otherwise healthy male or female aged 18 and above with
        relapsing-remitting or progressive multiple sclerosis as defined by the Clinical Trial
        Committee of the National Multiple Sclerosis Society and no evidence of prior exposure to
        B.burgdorferi as indicate by negative history for Lyme disease and negative Western blot
        for B.burgdorferi in the serum by the CDC criteria. Patients should have a Kurtzke or
        Expanded Disability Status Scale (EDSS) between 1 to 5.

        Healthy Volunteers: For the purpose of this study, a healthy volunteer is defined as
        healthy male or female, age 18 and above, with no history compatible with Lyme disease and
        negative serological testing to B.burgdorferi by the CDC criteria.

        All study participants must agree to allow their samples to be used for future research.

        EXCLUSION CRITERIA:

        General exclusion criteria:

        Age less than 18 (less than 13 for patients with PTLDS).

        Weight less than 70 Lb (35 kg).

        Pregnancy or lactation.

        Women with childbearing potential who are sexually active with a male partner and unwilling
        to use effective contraception during the evaluation and treatment phases of the protocol.

        Clinically significant laboratory abnormalities including positive test for syphilis (RPR),
        HBsAg, anti-HCV, anti-HIV.

        Chronic medication use will be evaluated in a case-by-case basis.

        Not able to understand all of the requirements of the study or unable to give informed
        consent and/or comply with all aspects of the evaluation.

        EXCLUSION CRITERIA FOR PTLDS PATIENTS AND LYME ARTHRITIS CONTROLS:

        In addition to the general exclusion criteria, these individuals will be excluded for:

          1. Use of immunosuppressive drugs such as systemic (but not topical or inhalant) steroids
             and cytotoxic agents.

          2. History of any recognized autoimmune disease such as rheumatoid arthritis, vasculitis,
             systemic erythematous lupus, etc.

          3. Serious pre-existing or concurrent chronic medical or psychiatric illnesses other than
             Lyme disease.

          4. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness that might produce neurologic deficit (such as
             cerebrovascular disease).

          5. Use of systemic antibiotics in the previous month.

          6. Use of immunomodulators such as interferons.

          7. Chronic medication use will be evaluated in a case-by-case basis.

          8. Patients will be excluded from this protocol if they are judged by the principal
             investigator as having a significant impairment in their capacity for judgment and
             reasoning that compromise their ability to make decisions in their best interest.

        EXCLUSION CRITERIA FOR RECOVERED, SEROPOSITIVE, OSPA VACCINATED AND HEALTHY VOLUNTEERS
        CONTROLS:

        In addition to the above applicable exclusion criteria (general exclusion criteria and
        exclusion criteria for PTLDS patients and Lyme arthritis controls), these individuals will
        be excluded for:

        1. Pre-existing or concurrent serious chronic medical or psychiatric illness.

        EXCLUSION CRITERIA FOR MULTIPLE SCLEROSIS CONTROLS:

        In addition to the above general exclusion criteria, these individuals will be excluded
        for:

          1. Pre-existing or concurrent serious psychiatric or chronic medical illness besides
             Multiple Sclerosis.

          2. Past history of significant head trauma, alcohol or substance abuse in the past 5
             years or other medical illness, besides Multiple Sclerosis, that might produce
             neurologic deficit (such as cerebrovascular disease).

          3. Previously received total lymphoid irradiation (TLI) or cladribine.

          4. Has used of immunoactive medications (excluding beta-interferon) in the three months
             preceding the study.

          5. In the three months prior to the study initiation, was given such investigational
             treatments as plasmapheresis, hyperbaric oxygen, gangliosides, Copolymer 1, etc.

        ELIGIBILITY OF SPECIAL POPULATIONS:

        Children: Children 13 years and older are eligible to participate in the PTLDS cohort
        because the condition under study can affect children. T, and this age was selected as
        appropriate for the children to provide assent to and comply with the study procedures.
        Children younger than 13 will be excluded from the PTLDS cohort, and no children will be
        enrolled in the other study cohorts.

        Pregnant and lactating women: Pregnant and lactating women are excluded from study
        participation. An enrolled participant who becomes pregnant during the study will be
        withdrawn

        Adults who lack capacity to consent: Adults who lack decision-making capacity to provide
        informed consent are excluded at screening, and enrolled adult participants who permanently
        lose the ability to consent during study participation will be withdrawn.

        NIH staff members: NIH staff may be enrolled if they meet eligibility criteria. Neither
        participation nor refusal to participate as a subject in the research will have an effect,
        either beneficial or adverse, on the participant s employment or position at NIH. Every
        effort will be made to protect participant information, but such information may be
        available in medical records and may be available to authorized users outside of the study
        team in both an identifiable and unidentifiable manner.","A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations",0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","-  INCLUSION CRITERIA:

        Patients 8 years old and older with signs or symptoms of pulmonary disease of medical
        interest to the professional staff of CPB will be eligible for participation in this
        protocol. Only standard diagnostic procedures and conventional therapy will be performed.
        Patients will not be subjected to any research procedures. This protocol does not commit
        the NIH to medical or surgical treatment of protocol participants after discharge. Patients
        will be discharged to the referring physician.

        Consenting to pregnancy testing in minors of childbearing age:

        We will inform the minor during the assent process that for safety, we need to do a
        pregnancy test. She will also be told that if it is positive, we will counsel her and help
        her tell her parents. If the minor does not want to proceed she will be advised not to sign
        assent and her enrollment on this training protocol will end.

        EXCLUSION CRITERIA:

        Patients without symptoms of pulmonary disease will be excluded from this protocol.",Evaluation and Treatment of Patients With Lung Disease Not Participating in Research,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Documented HIV infection (ELISA and Western blot positive).

        18 years or older.

        Clinically stable enough to travel to NIH and meet protocol schedule requirements.

        Negative urine or serum pregnancy test within 14 days prior to study entry (for women of
        childbearing potential).

        Patients should be receiving a combination of FDA approved antiretroviral drugs or expanded
        access antiretroviral therapy for at least two weeks prior to study entry. The exception
        would be that, in the opinion of the primary treating physician, this therapy would not
        likely provide benefit.

        Greater than or equal to 1 positive blood culture or 1 positive culture from a normally
        sterile site (e.g. lymph node, bone marrow, etc.) for MAC within 6 weeks of study. The
        initial screening blood culture at the NIH must be positive.

        The following lab values must be present at study entry:

        Transaminases, alkaline phosphatase, total bilirubin less than or equal to 5x upper limit
        of normal range.

        Serum creatinine less than or equal to 2.0 mg/ml.

        Proteinuria less than or equal to positive 1.

        Normal PT/PTT.

        Granulocyte count greater than or equal to 750/cubic millimeter.

        Hemoglobin greater than or equal to 8 gm/dL and platelet count greater than or equal to
        75,000.

        Fasting Blood glucose 1.25x upper normal limit (126 g/dl). (In persons with no history of
        diabetes.)

        No malignancy other than Kaposi sarcoma. Patients with Kaposi sarcoma are eligible, but
        must not have received systemic therapy for KS.

        No current life threatening AIDS related opportunistic infection other than disseminated
        MAC.

        No evidence of active substance abuse according to the standard 8th floor clinic substance
        abuse assessment, which allows enrollment at the discretion of the principal investigator.

        No patients exhibiting psychiatric disturbance or illness, which in the assessment of the
        protocol team may affect patient safety or compliance.

        No significant cardiac, gastrointestinal, pulmonary, autoimmune, renal, or CNS disease
        which could interfere with patient safety.

        No hypertension requiring anti-hypertensive therapy.

        No pregnant or lactating patients, or any patient with an inability or unwillingness to use
        effective contraception.

        Willingness to comply with current NIH Clinical Center guidelines concerning appropriate
        notification by an individual of current or ongoing sexual partners and/or needle-sharing
        partners regarding his or her HIV seropositivity and the risk of transmission of HIV
        infection.",Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","INCLUSION CRITERIA

        Right handed normal volunteers (18-65 years old).

        Patients with Parkinson's disease off medication.

        Patients with cerebellar deficits.

        Patients with frontal lobe lesions.

        Patients with frontal lobe dementia.

        EXCLUSION CRITERIA

        Subjects with personal or family history of seizures or other neurological disorders.

        Pregnant women.

        Volunteers or patients with severe coronary artery disease.

        Metal in the cranium except mouth.

        Intracardiac lines.

        Increased intracranial pressure as evaluated by clinical means.

        Cardiac pacemakers.

        Intake of neuroleptics.",Effects of Brain Stimulation on Learning and Reasoning,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Female gender only, ages 18 to 75.

        Patients should have documented primary Sjogren's syndrome as determined by protocol
        84-D-0056. The diagnosis of primary Sjogren's syndrome will be based on the presence of all
        three of the following:

        Salivary gland abnormalities;

        Lacrimal gland abnormalities;

        Serologic abnormalities.

        Controls should have no signs or symptoms of Sjogren's syndrome, and negative serologic
        testing reconfirmed within 2 weeks of the OGTT.

        Willingness to: a) participate in phase I and II of the protocol; b) follow the guidelines
        set to prepare for the OGTT; and c) modify current medical therapy if necessary.

        Must be able to comply with protocol procedures.

        No patients with ""incomplete"" Sjogren's syndrome, i.e., with less than three positive
        findings as described above.

        No presence of physical or mental conditions that may interfere with the protocol. These
        include the following diseases and conditions:

        (Present at time of phase I/II): significant disruption of sleep-wake pattern (i.e., less
        than 4 hours of continuous sleep, on the night before the OGTT only), BMI less than 18 or
        equal to/greater than 30, anemia with Hgb less than 10 gm/dl, use of tobacco or alcohol;

        (Within the past 6 weeks): acute weight change (greater than 5%), use of contraceptives
        -BCP-, Depoprovera or Norplant), irregular menstrual cycle, lactation, blood drawing in
        excess of 50 ml, use of recreational drugs, modification of estrogen replacement therapy;

        (Within the past 6 months): chronic pattern of weight change (greater than 10%), eating
        disorders, uncontrolled hypo/hyperthyroidism, breast cancer, lymphoma or other malignancy,
        pregnancy, treatment for depression, insulinoma, VIPoma, pheochromocytoma, atrophic
        gastritis, active tuberculosis or treatment for it;

        (A history of): HIV+, sarcoidosis, secondary Sjogren's syndrome, bleeding diathesis, organ
        transplant, severe neuroendocrine, renal, cardiovascular, pulmonary or gastrointestinal
        disease (e.g., renal insufficiency, unstable angina, heart failure, severe emphysema,
        Crohn's disease), diabetes mellitus, acromegaly and mental retardation.

        No contraindications to OGTT. These include:

        Hospital inpatient status, acute illness, immobilization, starvation, severe emotional
        distress within one week of the OGTT;

        Low carbohydrate diet (less than 150 g/day) for 3 days preceding the OGTT;

        Pregnancy;

        Therapy which impairs glucose tolerance: e.g., niacin, thiazide diuretics, phenytoin,
        excess thyroxine or psychotropic drugs within 1 month of phase I, oral contraceptives
        within 6 weeks of phase I, glucocorticoid treatment within the past 6 months (or one year
        if treatment lasted over 2 weeks), Beta blockers/agonists (e.g., terbutaline) within 2 days
        of phase I;

        Diabetes mellitus;

        Glucose intolerance.

        Subjects may not take medications that can affect somatostatin levels, such as
        antidepressants, benzodiazepines, neuromodulators (e.g., cholinergic, alpha/beta
        adrenergic), oral contraceptives (BCP), steroid hormones (with the exception of estrogen
        replacement therapy -ERT-, for which subjects will be matched), immunomodulators,
        anticonvulsants (e.g., carbamazepine), cimetidine -Tagamet (Registered Trademark)-, herbal
        remedies (because of their variable substance content). Subjects may not take drugs
        affecting gastrin secretion: antacids (e.g., Maalox (Registered Trademark), Mylanta
        (Registered Trademark), H(2) receptor antagonists (e.g., famotidine -Pepcid (Registered
        Trademark)-, ranitidine -Zantac (Registered Trademark)-), cathecolamines, atropine,
        haloperidol. To become eligible, subjects should be able to safely discontinue these
        medications at least one month prior to phase I. Antacids, H(2) antagonists and
        neuromodulators (e.g., Salagen) may be discontinued 2 days prior to phase I.

        Patients cannot have take experimental drugs within 1 month of the beginning of the
        protocol.",The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Adults (greater than 18 years) infected with HIV-1.

        Plasma viral burden greater than 8,000 and less than 60,000 RNA copies per ml. by bDNA
        method at screening.

        CD4 cell count above 200 cells per microliter at screen.

        No prior treatment with any anti-retroviral agent.

        Laboratory values at screen: hemoglobin greater than 9 g per dl; granulocyte count greater
        than 900 cells per microliter; platelet count greater than 80,000 cells per microliter; AST
        (SGOT) less than 151 U/L; creatinine less than 2 mg/dL.

        Must not be pregnant or breast-feeding and willing to avoid pregnancy by the use of
        non-hormonal methods of birth control during study participation. Pregnancy test (blood or
        urine) must be negative within two weeks prior to dosing with study medications.

        Willing and able to provide written informed consent.

        No history suggestive of malabsorption.

        No chronic diarrhea.

        Must not have had treatment with systemic corticosteroids at greater than physiologic
        replacement doses, interleukins, interferons, radiation therapy or cytotoxic
        chemotherapeutic agents within 30 days of study drug administration or an anticipated need
        for radiation or chemotherapy treatment within the next 48 weeks (with the exception of
        local treatment of Kaposi's sarcoma).

        Must not have current or anticipated therapy with other agents with documented activity
        against HIV-1 in vitro.

        Must not have active, untreated opportunistic infection or other major illness that would,
        in the opinion of the investigator, increase the risk that adverse events might pose to the
        patient or might render the patient too ill to return for study visits.

        Must not have significant substance abuse or psychiatric illness that might interfere with
        assessment or compliance.

        Must not have current or anticipated future need for any of the following drugs which are
        contraindicated with an amprenavir-ritonavir regimen because of drug-drug interactions:
        Terfenadine (Seldane), Astemizole (Hismanal), Cisapride (Propulsid), Triazolam (Halcion),
        Bepridil (Vascor), Medazolam (Versed), Rifampin (Rifadin, Rifamate, Rifater),
        Ergotamine/Dihydroergotamine containing regimens (Ergomar, Wygraine, Ercaf, DHE, Migranal),
        Amiodarone (Cordarone), Flecanaide (Tambocor), Propafenone (Rythmol), Quinidine
        (Quinaglute, Cardioquin), and Pimozide (Orap).

        Must not have current or anticipated future need for the following anticonvulsants:
        phenobarbital, phenytoin, carbamazepine.",Once-Daily Drug Regimen for HIV-Infected Patients,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","Male or female patients that are 10 years of age or older up to 80 years of age are
        included.

        Patients must be enrolled in a protocol at the NIH Clinical Center that will result in the
        patient receiving an allogeneic stem cell transplant (A-HSCT).

        Patients who have not yet received a pre-transplant chemotherapy and radiation therapy
        conditioning regimen are eligible.

        Patients must not have a negative IgG serologic test for CMV and whose hematopoietic stem
        cell donor also has a negative IgG serologic test as reported by the Bone Marrow Transplant
        staff.

        Patients must not have documentation of prior cytomegalovirus antigenemia or disease prior
        to starting the conditioning regimen.",Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","DISEASE CHARACTERISTICS: Pathological stage III/IV endometrial carcinoma of any histology
        (including clear cell and serous papillary carcinomas) The following extent of disease
        eligible: Positive adnexa Tumor invading the serosa Positive pelvic nodes Positive
        para-aortic nodes Involvement of the bowel mucosa Intra-abdominal metastases Positive
        pelvic washings Vaginal involvement within the radiotherapy field Hysterectomy and
        bilateral salpingo-oophorectomy (BSO) required with residual tumor not greater than 2 cm at
        any site Selective pelvic and para-aortic lymph node sampling optional for patients with
        stage III/IV disease by other criteria If para-aortic nodes are positive, scalene nodes
        must be negative on biopsy and chest CT must be negative for intrathoracic disease The
        following disease conditions exclude: Parenchymal liver metastasis Lung metastasis Positive
        inguinal nodes Positive scalene nodes Recurrent disease Protocol therapy must begin within
        8 weeks after surgery

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-3 Hematopoietic: WBC
        at least 3,000/mm3 Absolute granulocyte count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal AST no greater than 3 times
        normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: Left ventricular
        ejection fraction normal Other: No past or concomitant malignancy other than
        nonmelanomatous skin cancer

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No
        prior chemotherapy Endocrine therapy: Prior progestational agents allowed No other prior
        endocrine therapy Radiotherapy: No prior pelvic or abdominal radiotherapy Surgery:
        Hysterectomy and BSO required Pelvic and para-aortic lymph node sampling optional (see
        Disease Characteristics)",Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","DISEASE CHARACTERISTICS:

          -  Histologically diagnosed malignant melanoma with regional lymph node metastases

          -  Undergone complete lymph node dissection and free of any residual tumor

          -  No greater than 90 days from diagnosis of regional lymph nodes metastases

          -  No distant or resected in-transit metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  10 to 66

          -  66 to 70 if in excellent physical condition

        Performance status:

          -  0-2

        Life expectancy:

          -  At least 12 months

        Hematopoietic:

          -  Hemoglobin greater than 10 g/dL

          -  WBC greater than 3,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.2 mg/dL

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Other:

          -  No serious intercurrent illness that would compromise tolerance of therapy and long
             term survival

          -  Must be able to participate in follow up for minimum of 5 years

          -  No second malignancy except:

               -  In situ cervical cancer

               -  Basal or squamous skin cancer

          -  Must be able to physically and emotionally tolerate biochemotherapy

          -  No history of pulmonary or cardiac dysfunction, e.g., cardiac rhythm disturbance,
             congestive heart failure, coronary bypass, or impaired cardiac ejection fraction

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy with interferon or IL-2

          -  No concurrent immunomodulators

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No concurrent steroids

        Radiotherapy:

          -  Prior adjuvant local radiotherapy allowed for head and neck

        Surgery:

          -  No greater than 8 weeks after definitive surgery for lymph node metastases

        Other:

          -  No concurrent nonsteroid anti-inflammatory drugs, or other prostaglandin synthetase
             inhibitors",Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","DISEASE CHARACTERISTICS: Histologically proven stage IIB, IIIA, IIIB, and IVA squamous cell
        carcinoma of the cervix Bidimensionally measurable disease No bilateral hydronefrosis

        PATIENT CHARACTERISTICS: Age: Any age Performance status: WHO 0-2 Life expectancy: At least
        12 weeks Hematopoietic: Hemoglobin at least 10 g/dL Leukocytes at least 4,000/mm3 Platelet
        count at least 75,000/mm3 Hepatic: Bilirubin less than 1.25 times upper limit of normal
        (ULN) AST less than 1.25 times ULN Renal: BUN less than 30 mg/dL AND Creatinine less than
        1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: No prior or other concurrent
        malignancies, other than properly treated basal cell skin cancer

        PRIOR CONCURRENT THERAPY: Not specified",Docetaxel in Treating Patients With Advanced Cancer of the Cervix,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","DISEASE CHARACTERISTICS:

          -  Histologically confirmed cancer of the head and neck that is unlikely to respond to
             existing therapy and for which no curative therapy exists

               -  Metastatic disease OR incurable with surgery or radiation

          -  Measurable disease by CT scan or MRI

               -  Tumor must be at least 2 cm for the lymph nodes located in the head, neck,
                  axillary, inguinal or femoral areas and at least 0.5 cm for other areas

        PATIENT CHARACTERISTICS:

        Age:

          -  16 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 50,000/mm^3

        Hepatic:

          -  No hepatic insufficiency

          -  Bilirubin no greater than 2.5 mg/dL

          -  SGOT and SGPT no greater than 2.5 mg/dL

        Renal:

          -  No renal insufficiency

          -  Creatinine no greater than 2.5 mg/dL

          -  No renal conditions that contraindicate high dosages of sodium

        Cardiovascular:

          -  No chronic heart failure

          -  No uncontrolled hypertension

          -  No history of congestive heart failure

          -  No other cardiovascular conditions that contraindicate high dosages of sodium

        Pulmonary:

          -  No serious lung disease (e.g., severe chronic obstructive pulmonary disease)

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 4 weeks after study
             participation

          -  No other serious medical or psychiatric conditions

          -  No active infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy and recovered

          -  No concurrent immunomodulatory agents

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No concurrent antineoplastic therapy

        Endocrine therapy:

          -  Concurrent corticosteroids allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 8 weeks since prior radiotherapy (unless multiple tumors) and recovered

        Surgery:

          -  See Disease Characteristics

        Other:

          -  Prior cytodifferentiating agents allowed",Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer,0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","INCLUSION CRITERIA:

        Adult patients with weakness or motor dysfunction: 8/year.

        Normal volunteers, adults: 2/year.

        EXCLUSION CRITERIA:

        Anticoagulation or uncorrected bleeding disorder.

        Children are not optimal subjects for fellows undergoing training in these techniques and
        will be excluded.",Electromyography to Diagnose Neuromuscular Disorders,2
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Mild or moderate generalized myasthenia gravis Grade 2 or 3
        myasthenia gravis according to a modified Osserman groups system Ocular myasthenia gravis
        alone or myasthenia gravis in crisis not eligible Must have elevated acetylcholine receptor
        antibody titer No evidence of thymoma on chest CT or MRI No immunoglobulin-A deficiency
        less than 5 mg/dL Group 1: Patients who have not received other immunosuppressive therapy
        in the past, including intravenous immunoglobulin Group 2: Patients considered
        steroid-dependent

        Considered steroid-dependent if demonstrated improvement following initiation of
        corticosteroid therapy but continue to have generalized weakness on examination despite
        receiving 20 mg of prednisone (or equivalent) every other day and experience unacceptable
        symptoms on lower doses Prednisone and other immunosuppressive drug doses must not have
        changed within last 4 weeks May have had other immunosuppressive medication (azathioprine,
        cyclosporine, cyclophosphamide) or have received plasma exchange if these treatments were
        not initiated in the 2 months prior to study enrollment Must be receiving immunosuppressive
        medication for at least 3 months prior to study

        --Prior/Concurrent Therapy-- Endocrine therapy: Corticosteroid must be maintained at a
        constant dose during study Surgery: No thymectomy in the last 3 months Other: No
        plasmapheresis in the last 2 months --Patient Characteristics-- Age: 15 and over Weight: No
        greater than 80% above ideal body weight Hepatic: SGOT, SGPT, and alkaline phosphatase no
        greater than 1.5 times upper limit of normal (ULN) Renal: BUN no greater than ULN
        Creatinine no great than ULN Neurology: No history of relevant chronic degenerative,
        psychiatric, or neurologic disorder, other than myasthenia gravis, that can produce
        weakness or fatigue No altered consciousness, dementia, or abnormal mental status
        Pulmonary: Forced vital capacity at least 50% of predicted Not at high risk for aspiration
        Other: No active thyroid gland dysfunction as manifested by abnormal thyroid function tests
        or the need for current thyroid replacement Normal thyroid function tests required No other
        major relevant chronic or debilitating illnesses within 6 months of study Not pregnant or
        nursing Adequate contraception required of all fertile patients",Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis,2
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage I, II, III, or IVA squamous cell carcinoma of the vulva
             amenable to curative treatment with surgery, radiotherapy, or both

               -  At least 1 positive inguinal and/or femoral lymph node

               -  No inoperable (fixed or ulcerating) groin nodes

               -  Must not require resection of urethra or anal sphincter to achieve negative
                  margins

          -  Must have undergone vulvar biopsy and bilateral inguinal/femoral lymph node dissection
             within 8 weeks of randomization

          -  No metastatic disease

        PATIENT CHARACTERISTICS:

        Age:

          -  Any age

        Performance status:

          -  GOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Granulocyte count at least 1,500/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 times normal

          -  SGOT no greater than 3 times normal

          -  Alkaline phosphatase no greater than 3 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other prior invasive malignancy within the past 5 years except nonmelanoma skin
             cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy

        Surgery:

          -  See Disease Characteristics

          -  No more than 8 weeks since prior surgery

        Other:

          -  No prior therapy for another malignancy that would preclude study","Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva",0
"The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities.
BP: 110/75
Hgb: 11 g/dl
WBC: 8000 /mm3
Plt: 300000 /ml
Creatinine: 0.5 mg/dl
BUN: 10 mg/dl
Beta hcg: negative for pregnancy","-  INCLUSION CRITERIA:

               1. Patients with idiopathic focal segmental glomerulosclerosis on renal biopsy,
                  including the following categories:

                  A) Untreated FSGS

                  B) Steroid-dependent FSGS

                  C) Steroid resistant FSGS

                  D) Recurrent FSGS, with functioning allograft

                  E) FSGS in ESRD, receiving hemodialysis

               2. Adults greater than or equal to18 will be eligible for all studies.

               3. Children greater than 20 kilograms, will be eligible for all branches of the
                  study except for treatment of steroid resistant FSGS with pirfenidone, as
                  pirfenidone has not previously been administered to pediatric patients in any
                  setting. Children less than 20 kilograms will be excluded from the study for the
                  following reason: plasma exchange in patients less than 20 kilograms requires a
                  red blood cell transfusion, which significantly increases the risk of the
                  procedure by exposing the patient to the risk of transfusion associated
                  infections, and the safety of an aggressive course of plasma exchange has not
                  been established in this population.

        EXCLUSION CRITERIA:

          1. Secondary FSGS: HIV-associated FSGS or hyperfiltration FSGS, including FSGS associated
             with congenital renal abnormalities, renal mass reduction, reflux nephropathy,
             interstitial nephritis, and sickle cell anemia are excluded.

          2. Patients with disease associated with immunosuppression, other than chronic renal
             failure.

          3. The presence of malignancy or the history of other serious, complicating illness such
             as myocardial infarction or cerebrovascular accident in the past six months, at the
             discretion of the investigators.

          4. For plasma exchange: A Department of Transfusion Medicine consultant will evaluate all
             potential plasma exchange patients. Those with prolonged PT, PTT, platelet count less
             than 100,000 or receiving anticoagulant therapy will undergo plasma exchange only if
             the consultant considers this to be safe.

          5. For prednisone: uncontrolled diabetes mellitus (requiring greater than 100 units of
             insulin/day with the concurrence of the Endocrinology consultant), active infection
             including hepatitis B or C (if that is the advice of the Hepatology consultant),
             infection with HIV (as these patients are at increased risk of avascular necrosis),
             other active infection (if that is the advice of the Infectious Disease consultant),
             history of avascular necrosis or bone densitometry indicating bone mass less than 2SD
             below normal, active ulcer disease, history of steroid-induced psychosis, morbid
             obesity, positive PPD or history of past positive PPD without adequate treatment are
             excluded.

          6. For Cyclophosphamide:

        A) Allergy or hypersensitivity to cyclophosphamide

        B) Leukocyte less than 3000 cells/microliter or ANC less than 1500 cells/microliter or
        evidence of bone marrow compromise

        C) Prior irradiation to the heart or therapy with doxorubicin or other cardiotoxic
        medication (may increase the risk for cardiotoxicity)

        D) Peritoneal dialysis, as there is no published evidence that cyclophosphamide metabolites
        can be safely removed.

        E) Certain drugs will be used with caution or avoided. Barbiturates and phenytoin induce
        the hepatic enzymes that metabolize cyclophosphamide and therefore if these medications are
        required, cyclophosphamide doses may need to be increased to achieve a comparable
        immunosuppressive effect. Drugs that inhibit cyclophosphamide metabolism include
        allopurinol, imipramine, and phenothiazines, chloramphenicol and chlorpromazine; these
        drugs will be avoided. NSAID increase the risk of hyponatremia; these drugs will be
        avoided.",Permeability Factor in Focal Segmental Glomerulosclerosis,0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","DISEASE CHARACTERISTICS:

        Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous
        Ewing's sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma,
        primitive sarcoma of bone, and ectomesenchymoma.

        Confirmed presence of tumor-specific infusion protein by documented RT-PCR which
        corresponds to one of the tumor specific peptides available for vaccination.

        Measurable tumor.

        No prior or current CNS metastases.

        PRIOR/CONCURRENT THERAPY:

        ARM A PATIENTS:

        May be enrolled on the protocol for the first phase in the absence of RT PCR documentation
        of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides
        available for vaccination. However, RT PCR documentation at the time of tumor recurrence
        must occur prior to administration of immunotherapy. At time of initial tumor diagnosis,
        prior to any cytoreductive therapy.

        ARM B PATIENTS:

        Tumor recurrence occurring during or after receiving at least first line cytoreductive
        therapy for ESFT and AR. No more than two post-recurrence salvage regimens unless
        peripheral CD4+T cell number is greater than 400 cells per millimeter cubed.

        At least 6 weeks since any treatments and recovered from all acute toxic effects from time
        in which immunotherapy will be started for this study.

        No concurrent estrogen therapy during immunotherapy section of study.

        PATIENT CHARACTERISTICS:

        Age: 2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).

        Weight: Greater than 15 kg (at time of apheresis).

        Performance status: ECOG 0-2.

        Life expectancy: At least 8 weeks.

        Hematopoietic:

        ANC greater than 100,000/mm(3).

        Hemoglobin greater than 9.0 g/dL.

        Platelet count greater than 50,000/mm(3).

        Hepatic:

        Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).

        Transaminases less than 3 times normal (unless related to involvement by tumor).

        Renal:

        Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.

        Cardiovascular:

        No major disorder of cardiovascular system.

        Cardiac ejection fraction greater than 40%.

        Pulmonary:

        No major disorder of pulmonary system.

        OTHER:

        Not pregnant or nursing.

        HIV negative.

        Hepatitis B or C negative.

        No patients requiring daily oral corticosteroid therapy.

        If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre
        syndrome, ineligible to receive influenza vaccine.","A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer",0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","Children between ages of 4 years and 18 years.

        Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC)
        Definition.

        Availability of a parent or guardian to provide Informed Consent.

        Child is not critically ill or clinically unstable.

        No CDC categories N1 and A1 (1994 revised classification for HIV infection in children less
        than 13 years of age) and the CDC 1993 revised HIV classification and expanded AIDS
        surveillance definition for adolescents and adults.

        Non-presence of an active opportunistic infection requiring acute intervention at the time
        of entry (e.g. CMV, aspergillosis, cryptococcosis, Candida, etc.). Patients receiving
        treatment for an infection that requires prolonged treatment must have been stable on
        therapy for at least 30 days prior to study entry.

        No administration of chemotherapeutic agents, investigational agents or use of
        immunomodulating agents such as IVIG, corticosteroids, interferons, pentoxifylline,
        G-CSF/GM-CSF, erythropoeitin, growth hormone and other growth factors within one month of
        enrollment.

        None of the following laboratory abnormalities within 2 weeks of study entry:

        Total WBC count less than 1500/mm(3) or an absolute neutrophil count less than 750/mm(3);

        Hemoglobin less than 8.0 g/dl;

        Platelet count less than 75,000/mm(3);

        Creatinine greater than 2.0 x normal;

        Creatinine clearance less than or equal to 50 mL/min/m(2);

        Total bilirubin greater than 2 x normal;

        SGOT/SGPT greater than 5 x normal;

        Serum amylase pancreatic isoenzyme greater than 90 U/L (2 x upper limit of normal for
        adult). Serum amylase pancreatic isoenzyme should be obtained only if total serum amylase
        is greater than 180 U/L.

        No history of clinical pancreatitis and/or elevation in serum amylase pancreatic isoenzyme
        of greater than 180 U/L.

        No history of peripheral neuropathy of Grade II or greater severity.

        No previous treatment with ritonavir, indinavir, nelfinavir, nevirapine or stavudine.
        Patients may have received treatment with ritonavir, indinavir, nelfinavir for less than 4
        weeks.

        Ability to swallow tablets.

        No child for whom the volume of research blood required for study evaluation exceeds the
        maximum volume of research blood allowable (3 ml/kg in a single blood withdrawal and 7
        ml/kg in a 6-week period). This would be applicable to a child less than 16.5 kg.

        No patients who refuse or cannot have leukapheresis done.

        Sexually active post-menarchal females must be willing to use a barrier method of
        contraception or be willing to remain sexually abstinent.","A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine",0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","Must be 18 years old or greater.

        ECOG performance status of 0-1.

        Individuals without a history of cancer are eligible, as are those with a history of
        cancer. Individuals with a history of cancer (excluding non-melanomatous skin cancer ) will
        need to submit their pathology slides for review in the Laboratory of Pathology, NCI.

        Must be able to understand and give informed consent.

        Life expectancy greater than 6 months.

        Hgb greater than or equal to 8.0gm/dl, platelets greater than or equal to
        100,000/microliters, ANC greater than or equal to 1000/microliters, creatinine less than or
        equal to 2.0/mg/dl, SGPT and SGOT less than or equal to 147 and 168 U/L, total bilirubin
        less than or equal to 2 mg/dl (patients with a higher level of bilirubin due to a familial
        defect in bilirubin metabolism will be considered on an individual basis).

        No history of breast cancer.

        No pregnant or breast feeding subjects.

        Must not be HIV positive.

        No history of venous thrombosis within the past year.

        No medical conditions, which, in the opinion of the investigators would jeopardize either
        the patient or the integrity of the data obtained.

        No patients who are currently receiving active therapy for neoplastic disorders. However,
        patients with prostate cancer who are on an LHRH agonist (e.g., Lupron or Zoladex), or who
        have undergone surgical castration, are eligible for study.

        No patients who are on estrogen therapy.

        No patients taking hormonal forms of contraception.

        No patients with a known soy intolerance.","A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor",0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","Inclusion Criteria

          -  Clinical diagnosis of VOD defined by:

               -  Jaundice (bilirubin  2 mg/dL) and 2 or more of the following: ascites, weight
                  gain > 5% above baseline weight (see Section 5.2), hepatomegaly, RUQ pain

                    -  Patients with jaundice and reversal of flow on Doppler examination of the
                       portal vein will be eligible with one of the following: ascites, weight gain
                       > 5% above baseline weight, hepatomegaly, RUQ pain

                    -  Patients with pre-existing hepatomegaly must have documentation by physical
                       exam or imaging that liver size is increased over baseline at admission

               -  Patients who do not meet the criteria in Section 3.1.1 (ie. have two of the major
                  criteria but not three) and have biopsy proven VOD are eligible in the presence
                  of characteristics consistent with severe disease (see below).

               -  Patients with concurrent, confounding causes of liver dysfunction clinically
                  evident or evident on ultrasound or other radiographic imaging (such as evidence
                  of biliary ductal dilatation or focal tissue defects) may require biopsy-proven
                  VOD and/or elevated wedged trans-hepatic venous pressure gradient measurement (
                  10 mm mercury) to be considered eligible. Best medical judgment and further
                  imaging studies can be used to clarify the diagnosis and determine confounding
                  causes of liver dysfunction.

          -  Severity of VOD defined by:

               -  For patients addressed by the Bearman model (i.e. within 16 days of SCT and
                  conditioned with either BU/CY, CY/TBI or CBV), there must be a 30% or greater
                  risk of severe VOD (see Appendix B).

               -  For all other patients who are not addressed by the Bearman model (ie. beyond 16
                  days of SCT and/or not conditioned with either BU/CY,

               -  CY/TBI or CBV), there must be concomitant multi-organ failure defined as presence
                  of one or more of the following :

                    -  renal dysfunction: a) creatinine 2x value on the date of admission day to
                       the BMT unit for conditioning or 2x lowest value during conditioning (use
                       the lowest value for calculation), or b) creatinine clearance or GFR 50% of
                       admission value, or c) dialysis dependence""

                    -  pulmonary dysfunction: documentation of oxygenation saturation  90% on room
                       air; requirement for positive pressure/ventilator dependence

                       ----pulmonary dysfunction must not be attributable to another cause (e.g.
                       documented infectious pneumonia)

                    -  central nervous dysfunction: documentation of confusion, lethargy, and/or
                       delirium ---- central nervous dysfunction must not be attributable to
                       another cause (e.g. documented cyclosporin toxicity)

               -  Patients or their parents/guardians or designated proxy must have the ability to
                  give voluntary informed consent to the protocol. Where possible, patient assent
                  will also be obtained

               -  Patients must be  12 hours after cessation of heparin

               -  Patient must have an eligible diagnosis of VOD by Day 35 post transplant

          -  Exclusion Criteria

               -  Patients receiving concomitant heparin or other anticoagulants unless being used
                  for routine CVL management, fibrinolytic instillation for CVL occlusion,
                  intermittent dialysis or ultrafiltration are excluded. Patients who have received
                  systemic t-PA (concomitant or prior) are excluded.

               -  Patients with significant uncontrolled acute bleeding, defined as hemorrhage
                  requiring > 15 cc/kg of packed red blood cells (ie. a pediatric patient weighing
                  20 kg and requiring > 300cc of packed red blood cells /24 hours or an adult
                  patient weighing 70 kg and requiring >3 units of packed red blood cells/24 hours)
                  to replace blood loss are excluded. These parameters must be reviewed prior to
                  enrollment by the PI or his/her designate.

               -  Patients with hemodynamic instability as defined below:

                    -  Hemodynamic stability is defined as having no requirement for pressor
                       support OR being able to maintain mean arterial pressure within 1 SD of
                       age-adjusted levels with pressor support (see Appendix D)

                    -  Patients requiring renal dose dopamine alone (2-5 mcg/kg/min) are eligible
                       without measurement of mean arterial pressure

               -  Patients with Grade B-D GVHD, graded according to the IBMTR Severity Index (see
                  Appendix G). Please note patients with Grade B skin only are eligible.

               -  Patients intubated for documented intrinsic lung disease

                  --- Patients intubated secondary to a mechanical barrier to ventilation,
                  e.g.pulmonary edema or ascites, will be eligible as long as the PaO2/FiO2 ratio
                  is  300 and/or the oxygen index (OI={MAP x FiO2} PaO2 x 100) is  25% at the
                  time of enrollment

               -  Patients who meet Grade IV common toxicity criteria for neurotoxicity (other than
                  Grade IV confusion and/or delirium), i.e. coma, seizures, toxic psychosis

               -  Patients who are currently receiving treatment with another experimental agent.

               -  Please note that an experimental agent in this setting is defined as any drug or
                  device used under an IND designation which is associated with systemic effects
                  that could influence the outcome in a patient with severe VOD. If the continued
                  use of an experimental agent is considered both necessary and appropriate, this
                  must be reviewed and approved on a case by case basis by the Overall Study PI,
                  Dr. Paul Richardson, or his designate, who will approve the entry of patients
                  being concurrently treated with another experimental agent only if there is no
                  evidence for a potential adverse pharmacokinetic interaction or overlapping
                  toxicity.",Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation,0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Severely premature neonates (less than 1000 g at birth and
        estimated gestational age of no greater than 28 weeks) that require greater than 50% of
        caloric requirements by parenteral means within 7 days of birth OR Neonates with one or
        more of the following surgical conditions: Necrotizing enterocolitis Gastroschisis Severe
        jejunal-ileal atresia within 7 days of diagnosis --Prior/Concurrent Therapy-- Biologic
        therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified
        Radiotherapy: Not specified Surgery: See Disease Characteristics No other cardiovascular
        (thoracotomy) or major gastrointestinal surgery (laparotomy) during the newborn period
        Other: No prior or concurrent ursodeoxycholic acid No concurrent use of extracorporeal life
        support --Patient Characteristics-- Performance status: Not specified Hematopoietic: Not
        specified Hepatic: Conjugated bilirubin no greater than 1.0 mg/dL No primary or secondary
        liver disease No hepatic insufficiency as documented by either a biopsy with cirrhosis or
        elevated prothrombin time without evidence of systemic coagulopathy and no administration
        of an anticoagulant Renal: No renal failure as indicated by a progressive increase in
        creatinine levels Other: No hemodynamic instability No documented communicable infection
        (including infectious hepatitis or HIV) No metabolic pathway defect that is associated with
        liver dysfunction in the neonatal period including hereditary fructose intolerance,
        galactosemia due to transferase deficiency, and neonatal tyrosinemia",Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis,0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Cystic fibrosis-associated liver disease, defined by at least one of the following
             criteria: (1) Documented increase in serum concentrations of any of the liver enzymes
             (at least once in the preceding year) ALT at least twice normal AST at least 1.5 times
             normal Alkaline phosphatase at least 1.5 times normal GGT at least 1.5 times normal
             (2) Persistent hepatomegaly of more than 6 months duration defined by percussed liver
             span greater than 1 SEM for age (3) Splenomegaly, defined as a palpable spleen greater
             than 2.0 cm below the left costal margin (4) Abnormalities of ultrasound scan
             (increased size, dishomogeneous echogenicity, nodular liver, irregular margins,
             splenomegaly) within 6 months prior to study entry

          -  Patients enrolled in the first part of the study (objective I) are eligible to
             participate in the second part (objective II)

        --Prior/Concurrent Therapy--

          -  At least 3 months since prior ursodiol

          -  At least 3 months since treatment with drug with choleretic properties or effects that
             influence bile acid metabolism

        --Patient Characteristics--

          -  Hepatic: No decompensated cirrhosis No hepatic neoplasm or cholelithiasis

          -  Pulmonary: No significantly impaired pulmonary function with FEV1 less than 50%

          -  Other: At least 15 kg body weight No severely compromised clinical or nutritional
             state",Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis,0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","Inclusion Criteria:

          -  At least 36 weeks gestation

          -  Any blood gas (cord, postnatal) done within the first 60 minutes had a pH less than or
             equal to 7.0

          -  Any blood gas (cord postnatal) done within the first 60 minutes had a base deficit
             greater than or equal to 16 mEq/L

          -  All infants must have seizures or signs of moderate to severe encephalopathy before
             randomization

        Exclusion Criteria:

          -  Inability to randomize by 6 hours of age

          -  Presence of known chromosomal anomaly or major congenital anomaly

          -  Severe intrauterine growth restriction (weight less than 1800g)

          -  All blood gases done within the first 60 minutes had a pH less than 7.15 and a base
             deficit less than 10 mEq/L

          -  Infants in extremis for whom no additional intensive therapy will be offered by
             attending neonatologist

          -  Parents refuse consent

          -  Attending neonatologist refuses consent",Whole-Body Cooling for Birth Asphyxia in Term Infants,0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Infants diagnosed with herpes simplex virus infection involving the central nervous
             system with or without evidence of viral dissemination to other organs (i.e., skin,
             liver, or lungs) HSV-1 or HSV-2 isolated from cutaneous lesions from any site (skin,
             oropharynx, cerebrospinal fluid (CSF), urine, etc.) OR Must have positive CSF
             polymerase chain reaction (PCR) if no cutaneous skin lesions are present and viral
             cultures are negative No infection limited to skin, eyes, or mouth Evidence of CNS
             involvement includes one or more of the following: Abnormal CSF indices for term
             infants (WBC greater than 22/mm3 and protein greater than 115 mg/dL) Abnormal CSF
             indices for preterm infants (WBC greater than 25/mm3 and protein greater than 220
             mg/dL) Abnormal neuroimaging study (CT with contrast, MRI with gadolinium, or head
             ultrasound) Disseminated disease is defined as one or more of the following: SGPT at
             least 2.5 times upper limit of normal Pneumonia/pneumonitis Necrotizing enterocolitis
             Disseminated intravascular coagulopathy

          -  Birth weight at least 800 grams

        --Prior/Concurrent Therapy--

          -  No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or
             famciclovir for longer than 120 hours or 5 days

        --Patient Characteristics--

          -  Renal: Creatinine no greater than 1.5 mg/dL

          -  Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage

          -  Other: No infants known to be born to HIV positive women",Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System,0
"The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation.
Laboratory results are as follows: 
Serum total bilirubin: 21.02 mg/dL
Direct bilirubin of 2.04 mg/dL
AST: 37 U/L
ALT: 20 U/L
GGT: 745 U/L
Alkaline phosphatase: 531 U/L
Creatinine: 0.3 mg/dL
Urea: 29 mg/dL
Na: 147 mEq/L
K: 4.5 mEq/L
CRP: 3 mg/L
Complete blood cell count within the normal range.
She is diagnosed with neonatal jaundice that may require phototherapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Infants diagnosed with herpes simplex virus infection limited to skin, eyes, and mouth;
        HSV-1 or HSV-2 isolated from cutaneous lesions, conjunctivae, or oropharynx (presence of
        skin lesions not required); normal CSF indices: WBC less than 22/mm3 and protein less than
        115 mg/dL for term infants OR WBC less than 25/mm3 and protein less than 220 mg/dL for
        preterm infants; no evidence of CNS involvement by CT with contrast, MRI with gadolinium,
        or head ultrasound; no visceral dissemination (normal liver function tests, normal chest
        x-ray, etc.); negative CSF PCR result

        Birth weight at least 800 grams

        --Prior/Concurrent Therapy--

        No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or
        famciclovir for longer than 120 hours or 5 days; no prior prophylactic acyclovir for risk
        of herpes simplex virus infection

        --Patient Characteristics--

        Renal: Creatinine no greater than 1.5 mg/dL

        Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage

        Other: No infants known to be born to HIV-positive women","Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth",0
"The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty   chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination.  Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems.  She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Low bone mass (T score less than -2.0) with no secondary cause on routine exam

          -  Premenopausal

        OR

          -  Perimenopausal

        --Prior/Concurrent Therapy--

          -  Chemotherapy: No prior or concurrent chemotherapeutic agents

          -  Endocrine therapy: No prior or concurrent glucocorticoids or suppressive doses of
             thyroid hormone

          -  Other: No prior or concurrent anticonvulsants

        --Patient Characteristics--

          -  Hematopoietic: No multiple myeloma

          -  Other: No hyperparathyroidism No thyrotoxicosis No anorexia nervosa No Paget's disease
             of bone No rheumatoid arthritis No Cushing's syndrome No malabsorption syndrome No
             type I diabetes mellitus",Study of Low Bone Mass in Premenopausal or Perimenopausal Women,0
"The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty   chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination.  Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems.  She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.","INCLUSION CRITERIA

        Male or female volunteers referred for extraction of third molars willing to undergo two
        surgical appointments for the extraction of unilateral third molars.

        Between the ages of 16 to 35 years (based upon eruption patterns and age-related
        complications associated with surgical extraction of third molars).

        In good general health - ASA status 1 or 2 (healthy subjects based upon criteria for safe
        outpatient conscious sedation).

        Willing to undergo observation period for four hours postoperatively.

        Willing to return at 48 hours for measurement of pain, swelling, and tissue biopsy.

        Willing to return for a total of four visits beyond the screening visit.

        EXCLUSION CRITERIA

        Pregnant or lactating females.

        Current mental disorder or substance abuse.

        Allergy to aspirin or NSAIDs.

        Chronic use of medications confounding assessment of the inflammatory response or analgesia
        (antihistamines, NSAIDs, steroids, antidepressants).

        Presence of chronic debilitating disease (such as diabetes, rheumatoid arthritis, liver
        disease, etc).

        Presence of symptomatic tooth suggesting infection or inflammation.

        Unusual surgical difficulty encountered during the surgical procedure.",Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction,0
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","-  Any volunteer of any age from birth to old age who is deemed medically fit to
             participate and is willing to provide their informed consent will be included in the
             study.",Human Movement Database,0
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","-  INCLUSION CRITERIA:

        Individuals age 18 or over from families in which an autosomal dominant form of Parkinson's
        disease is apparently being inherited.

        The diagnosis must be supported by accepted clinical criteria: tremor, bradykinesia, and
        responsiveness to L-DOPA.

        Unaffected family members will also be enrolled.

        Subjects must give consent.

        Parkinson's disease may be associated with dementia.

        Decisionally-impaired individuals will be enrolled.",Genetic Analysis of Parkinson's Disease,1
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","-  INCLUSION CRITERIA:

        Individuals over the age of 18 from families in which there are three or more individuals
        affected with Parkinson's disease (within three generations) and the proband was the only
        affected person available or willing to participate in the study

        The diagnosis must be supported by accepted clinical criteria: tremor, bradykinesia, and
        responsiveness to L-DOPA.

        PD may be associated with dementia. The study will lose power if individuals with mental
        impairment and PD are excluded. For this reason, decisionally-impaired individuals will be
        enrolled.

        EXCLUSION CRITERIA:

        No one under 18 will be enrolled because, with the exception of the rare autosomal
        recessive PD due to parkin mutations, PD does not affect minors. Study design does not
        involve testing fetuses.",Gene Analysis of Parkinson's Disease,1
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","INCLUSION CRITERIA

        Right handed normal volunteers (18-65 years old).

        Patients with Parkinson's disease off medication.

        Patients with cerebellar deficits.

        Patients with frontal lobe lesions.

        Patients with frontal lobe dementia.

        EXCLUSION CRITERIA

        Subjects with personal or family history of seizures or other neurological disorders.

        Pregnant women.

        Volunteers or patients with severe coronary artery disease.

        Metal in the cranium except mouth.

        Intracardiac lines.

        Increased intracranial pressure as evaluated by clinical means.

        Cardiac pacemakers.

        Intake of neuroleptics.",Effects of Brain Stimulation on Learning and Reasoning,2
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","INCLUSION CRITERIA:

        A total of 20 subjects will be enrolled in the study. 10 normal subjects will be enrolled
        in the study. All will have an 8-12 Hz component of physiologic tremor as determined by
        neurophysiologic studies. Patients will have a prominent 8-12 Hz spike on accelerometry
        recordings that is associated with an EMG spike at the same frequency.

        5 patients with essential palatal tremor and 5 patients with symptomatic palatal tremor
        will be included.

        All participants must be a minimum of 21 years of age.

        EXCLUSION CRITERIA:

        The presence of any medical condition, such as liver disease, history or family history of
        alcoholism, that can reasonably be expected to subject the patient to unwarranted risk or
        compromise the value of the data.

        Any patient with pathologic tremor, such as parkinsonian rest tremor, essential tremor, or
        tremor secondary to medications or structural brain lesions.

        Any clinically significant laboratory abnormalities.

        Lack of effective contraception.

        Patients who are pregnant.

        Inability to understand the nature of the study or its procedures.

        Persons under the age of 21, who are not of legal age to consume alcohol in Maryland.

        Patients taking any psychoactive medications including certain cough or cold medicine
        preparations.

        No one will be excluded or discriminated against based on the grounds of race, creed,
        gender, color, or national origin. Every attempt will be made to include women and
        minorities in the study population.",Effect of Alcohol on Tremors,1
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","All patients will have parkinsonism of undetermined etiology.

        Males and females between the ages of 18 and 85 are eligible for the study.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risks, specifically those who have the following: a history of
        convulsive, hepatic, or renal disorders; currently receiving treatment for myocardial
        infarction, arrhythmia or cardiac failure; and pregnant women or anyone not practicing an
        effective means of birth control.",Intravenous Levodopa for the Diagnosis of Parkinson's Disease,2
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","All patients will carry a diagnosis of idiopathic Parkinson's Disease based on the presence
        of a characteristic clinical history and neurologic findings. Most will have relatively
        advanced disease with associated motor response complications.

        Males and females between the ages of 18-75.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risk.

        No patients with baseline QTc prolongation (greater than 440 msec).

        No pregnant women nor those not practicing effective means of birth control.",Treatment of Parkinson's Disease With Eliprodil,2
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","All patients will carry a diagnosis of Parkinson's Disease based on the presence of a
        characteristic clinical history and neurological findings. Symptom severity will range from
        Hoehn & Yahr stage II-IV.

        Males and females between the ages 30-76 are eligible for the study.

        Initial emphasis will be on patients who are taking few or no other medications than
        levodopa for their Parkinson's disease.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risk.

        No patients with a history of significant cardiac (myocardial infarction within 12 months
        prior to study, dysrhythmia; QTc intervals greater than 440 msec).

        No patients who are convulsive, hepatic, or with renal disorders (exceeding the upper limit
        of normal values for LFT's and creatinine respectively).

        No patients with evidence of other serious medical illness, a history of alcohol or drug
        abuse, those who have participated in an investigational trial within 28 days prior to
        study, and pregnant or nursing women or anyone not practicing effective means of birth
        control.",Treatment of Parkinson's Disease With a Transdermal Skin Patch,1
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Advanced Parkinson's disease Hoehn-Yahr stage IV or worse
        during ""off"" periods Hoehn-Yahr stage III or better during ""on"" periods Predictable motor
        fluctuations with at least 20% of waking day in the ""off"" stage No atypical parkinsonism or
        secondary parkinsonism --Prior/Concurrent Therapy-- Biologic therapy: Not specified
        Chemotherapy: Stable doses of levodopa/carbidopa or any other antiparkinson therapy for 2
        months prior to study Surgery: No previous intracranial/neurosurgical procedures --Patient
        Characteristics-- Renal: Creatinine clearance at least 70 mL/min or creatinine no greater
        than 1.8 mg/dL Protein no greater than 300 mg/dL Other: Not pregnant or nursing Adequate
        contraception required of fertile patients Prior history of good response to levodopa No
        sensitivity to cyclosporine Not HIV positive (e.g., HIV I or II) No human T-cell
        leukemia/lymphoma virus (HTLV-1) No tremors interfering with stereotactic surgery No
        clinically significant medical, neoplastic or infectious disease No clinically significant
        laboratory abnormality No dementia that precludes signing informed consent or score of less
        than 24 on Mini-Mental status examination",Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease,1
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","Males and females between the ages of 30 and 75 are eligible for the study. All will carry
        the diagnosis of idiopathic Parkinson's disease based on the presence of a characteristic
        clinical history and neurological findings. All will have relatively advanced disease
        (Hoehn and Yahr Stages II to IV) with levodopa-associated motor response complications,
        including wearing-off fluctuations and peak-dose dyskinesias.

        No presence or history of any medical condition that can reasonably be expected to subject
        the patient to unwarranted risk.

        No clinically significant laboratory abnormalities including liver enzyme elevations more
        than three times the upper limit of normal, or neutropenia (WBC less than 4000).

        No parkinson's disease patients exhibiting diphasic or end-of-dose dyskinesias or disabling
        dystonia.

        Since LY300164 is an inhibitor of CP4503A4, patients receiving certain drugs metabolized by
        that pathway will not be included.

        No patients who are unable to be treated with levodopa/carbidopa alone or a single,
        relatively short-acting dopamine agonist.

        No patients who require additional treatment with amantadine or other concomitant
        medications.

        No pregnant women or those not practicing effective means of birth control since the
        influence of any investigational compound on the unborn child and reproductive organs is
        unknown.",Study of LY300164 for the Treatment of Parkinson's Disease,1
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","Inclusion Criteria:

          -  The subjects must have the three cardinal features of PD: slowness of movement,
             resting tremor and rigidity. The signs of PD must be greater on one side.

        Exclusion Criteria:

          -  Disorders that mimic PD.

          -  Other serious medical problems.",Parkinson's Disease Treatment With Coenzyme Q10,2
"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife.  They have three children.  He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in.  His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.","Inclusion Criteria:

          -  Early, mild PD, not requiring medications

          -  Age 30 or older

          -  Duration from time of diagnosis of PD: less than 2 years

          -  Hoehn & Yahr Stage 1 or 2

          -  Exposure to levodopa or dopamine agonist of 14 days or less",Timing of Levodopa Treatment in Parkinson's Disease,1
